<SEC-DOCUMENT>0001104659-13-084191.txt : 20131113
<SEC-HEADER>0001104659-13-084191.hdr.sgml : 20131113
<ACCEPTANCE-DATETIME>20131113161049
ACCESSION NUMBER:		0001104659-13-084191
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131113
DATE AS OF CHANGE:		20131113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		131214720

	BUSINESS ADDRESS:	
		STREET 1:		3535 GENERAL ATOMICS COURT
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		3535 GENERAL ATOMICS COURT
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a13-22691_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font></b><b>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended September&nbsp;30, 2013</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b>TRANSITION REPORT UNDER SECTION&nbsp;13 OF 15(d)&nbsp;OR THE EXCHANGE ACT OF 1934</b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">From the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number 001-36067</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FATE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">65-1311552</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or   other jurisdiction</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS   Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification   No.)</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3535 General Atomics   Court, Suite&nbsp;200, San Diego, CA</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">92121</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of   principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:<b> (858) 875-1800</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large&nbsp;accelerated&nbsp;filer</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="14%" valign="bottom" style="padding:0in 0in 0in 0in;width:14.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated&nbsp;filer</font></p>    </td>
<td width="1%" valign="top" style="padding:0in 0in 0in 0in;width:1.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="62%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" valign="bottom" style="padding:0in 0in 0in 0in;width:14.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="23%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:23.16%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="17%" valign="top" style="padding:0in 0in 0in 0in;width:17.64%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></p>    </td>
<td width="14%" valign="bottom" style="padding:0in 0in 0in 0in;width:14.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="21%" valign="top" style="padding:0in 0in 0in 0in;width:21.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller&nbsp;reporting&nbsp;company</font></p>    </td>
<td width="1%" valign="top" style="padding:0in 0in 0in 0in;width:1.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November 11, 2013, there were 20,357,158 shares of the registrant&#146;s common stock, par value $0.001 per share, outstanding.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-ba.htm',USER='107902',CD='Nov 12 07:21 2013' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FATE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><a name="TableOfContents"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="93%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.48%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Parti_FinancialInformation_105709" title="Click to goto ">PART&nbsp;I.   FINANCIAL INFORMATION</a></font></p>    </td>
<td width="6%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_105701">Item 1.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_105701">Financial Statements</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedBalanceSheet_105656" title="Click to goto ">Condensed Consolidated Balance Sheets as of   September&nbsp;30, 2013 (unaudited) and December&nbsp;31, 2012</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedStatementsOf_110014" title="Click to goto ">Condensed Consolidated Statements of Operations and   Comprehensive Loss for the three and nine months ended September&nbsp;30,   2013 and 2012 (unaudited) and the period from April&nbsp;27, 2007 (inception)   through September&nbsp;30, 2013 (unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedStatementsOf_110010" title="Click to goto ">Condensed Consolidated Statements of Cash Flows for   the nine months ended September&nbsp;30, 2013 and 2012 (unaudited) and the   period from April&nbsp;27, 2007 (inception) through September&nbsp;30, 2013   (unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NotesToCondensedConsolidatedFinan_111539" title="Click to goto ">Notes to Condensed Consolidated Financial Statements   (unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_111754">Item 2.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_111754">Management&#146;s   Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_112903">Item 3.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_112903">Quantitative   and Qualitative Disclosures About Market Risk</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_112904">Item 4.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_112904">Controls and   Procedures</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Partii_OtherInformation_113237" title="Click to goto ">PART&nbsp;II.   OTHER INFORMATION</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_113239">Item 1.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_113239">Legal Proceedings</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_113241">Item 1A.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_113241">Risk Factors</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_114802">Item 2.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_114802">Unregistered   Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_114919">Item 3.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_114919">Defaults Upon   Senior Securities</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_114921">Item 4.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_114921">Mine Safety   Disclosures</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_114922">Item 5.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_114922">Other Information</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.84%;">
<p style="margin:0in 0in .0001pt 12.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_114923">Item 6.</a></font></p>    </td>
<td width="82%" valign="top" style="padding:0in 0in 0in 0in;width:82.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_114923">Exhibits</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Signatures_115527" title="Click to goto ">SIGNATURES</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.48%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_105509_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-bg.htm',USER='107913',CD='Nov  9 12:12 2013' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I. FINANCIAL INFORMATION</font></b><a name="Parti_FinancialInformation_105709"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160;&#160; Financial Statements</font></b><a name="Item1_FinancialStatements_105701"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(A Development Stage Company)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></b><a name="CondensedConsolidatedBalanceSheet_105656"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except share and per share data)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September<br>   30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December<br>   31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,082</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,087</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses   and other current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">304</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">706</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,386</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,793</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Property and   equipment, net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">789</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,161</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,743</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted cash</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">122</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">122</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,040</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,076</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities,   convertible preferred stock and stockholders&#146; deficit</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current   liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable   and accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,725</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,268</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of   deferred revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of   deferred rent</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">251</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible notes,   net of discount</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,481</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Repurchase   liability for unvested equity awards</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">143</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock   warrant liability</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">184</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt,   current portion</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,971</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,941</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current   liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,491</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,850</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">153</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">132</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">137</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchangeable share   liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">551</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt,   less current portion</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">250</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,732</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term   convertible notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments and   contingencies</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock, $0.001 par value; authorized shares &#151; 68,360,186 at   September&nbsp;30, 2013 and 62,200,000 at December&nbsp;31, 2012; issued and   outstanding shares &#151; 44,967,690 at September&nbsp;30, 2013 and   December&nbsp;31, 2012; liquidation preference of $58,518 at   September&nbsp;30, 2013 and December&nbsp;31, 2012</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56,526</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56,526</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders&#146;   deficit:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock,   $0.001 par value; authorized shares &#151; 110,000,000 at September&nbsp;30, 2013   and 100,000,000 at December&nbsp;31, 2012; issued and outstanding shares &#151;   1,377,659 at September&nbsp;30, 2013 and 1,334,115 at December&nbsp;31, 2012</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in   capital</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,367</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,789</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deficit   accumulated during the development stage</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(80,770</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(65,615</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   stockholders&#146; deficit</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(66,402</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(52,825</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities,   convertible preferred stock and stockholders&#146; deficit</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,040</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,076</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_105645_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-fa.htm',USER='107913',CD='Nov  9 12:36 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(A Development Stage Company)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></b><a name="CondensedConsolidatedStatementsOf_110014"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except share and per share data)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="22%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:22.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period<br>   From&nbsp;April<br>   27,&nbsp;2007<br>   (inception)<br>   to<br>   September<br>   30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" colspan="11" valign="bottom" style="padding:0in 0in 0in 0in;width:47.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenues:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration   revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">208</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">626</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,075</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,927</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">320</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">345</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">952</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,084</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">528</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">971</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,027</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,011</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,378</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,315</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,976</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,596</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53,955</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,979</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">863</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,768</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,944</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28,839</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,357</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,178</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13,744</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,540</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82,794</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from   operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,148</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,650</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12,773</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9,513</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(77,783</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income   (expense), net</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(925</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(463</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,382</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(571</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,987</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss and   comprehensive loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,073</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,113</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,155</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10,084</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(80,770</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per   common share, basic and diluted</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4.81</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3.51</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12.24</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9.52</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average   shares used to compute basic and diluted net loss per share</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,262,546</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,171,012</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,238,567</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,059,113</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_105856_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-fa.htm',USER='107913',CD='Nov  9 12:36 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(A Development Stage Company)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></b><a name="CondensedConsolidatedStatementsOf_110010"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September<br>   30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Period&nbsp;From<br>   April&nbsp;27,&nbsp;2007<br>   (inception)&nbsp;to<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating   activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consolidated net   loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(15,155</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10,084</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(80,770</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to   reconcile net loss to net cash used in operating activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and   amortization</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">442</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">430</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,379</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuances of   common stock for technology</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based   compensation</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,169</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,938</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of   discounts</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">129</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">271</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Noncash interest   expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">134</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">97</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,156</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(185</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(138</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">198</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(63</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(63</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Initial fair value   and change in fair value of exchangeable shares</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,334</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair   value of preferred stock warrants</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(35</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(64</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss on disposal   of assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">135</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss on   extinguishment of debt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">323</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">332</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in   operating assets and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses   and other current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(960</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(204</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,666</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable   and accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,350</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(363</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,618</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   operating activities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10,795</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9,880</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(69,531</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of   property and equipment</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(94</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(414</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,511</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from sale   of property and equipment</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">208</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted cash</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(122</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   investing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(88</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(414</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,425</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financing   activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of common   stock, net of repurchases</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">205</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">287</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Costs paid in   connection with initial public offering</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,381</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,381</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   convertible promissory notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,736</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32,236</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from   long-term debt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,400</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payments on   long-term debt</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,500</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,150</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of   convertible preferred stock, net of offering costs</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,166</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,646</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided   by financing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,878</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,371</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">92,038</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net change in cash   and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,995</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(923</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,082</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents at beginning of the period</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,087</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,387</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents at end of the period</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,082</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,464</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,082</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_110023_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-fa.htm',USER='107913',CD='Nov  9 12:36 2013' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(A Development Stage Company)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></b><a name="NotesToCondensedConsolidatedFinan_111539"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Unaudited)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</font></b></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Organization</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on April&nbsp;27, 2007 and conducts its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells.&nbsp;Based on the Company&#146;s understanding of key biological mechanisms that guide the fate of adult stem cells, the Company has built two platforms that optimize the activity and enhance the therapeutic potential of adult stem cells: its hematopoietic stem cell, or HSC, modulation platform and its muscle satellite stem cell, or SSC, modulation platform.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Principles of Consolidation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics (Canada) Inc. (&#147;Fate Canada&#148;), Fate Therapeutics Ltd., incorporated in the United Kingdom, and Destin Therapeutics Inc., incorporated in Canada. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Reverse Stock Split</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;12, 2013, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a one-for-6.5 reverse stock split of the Company&#146;s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company&#146;s consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Unaudited Interim Financial Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (&#147;GAAP&#148;) and following the requirements of the United States Securities and Exchange Commission (&#147;SEC&#148;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&#160; In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&#146;s financial statements and accompanying notes for the fiscal year ended December&nbsp;31, 2012, contained in the Company&#146;s final prospectus dated September&nbsp;30, 2013 filed by the Company with the SEC on October&nbsp;1, 2013 pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), in connection with the Company&#146;s initial public offering (&#147;IPO&#148;). The results for the three and nine months ended September&nbsp;30, 2013 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#146;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#146;s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company&#146;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_110148_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other Assets</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets consist of the Company&#146;s deferred IPO costs. These costs represent legal, accounting and other direct costs related to the Company&#146;s efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Preferred Stock Warrant Liability</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. The fair value of these warrants is classified as a current liability in the accompanying consolidated balance sheets since the underlying convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets instead of in stockholders&#146; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that are outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock can cause its redemption. The warrants are recorded at fair value using the Black-Scholes option pricing model with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The warrant liability will continue to be remeasured at fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revenue Recognition</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes revenues when all four of the following criteria are met: (i)&nbsp;persuasive evidence that an agreement exists; (ii)&nbsp;delivery of the products and/or services has occurred; (iii)&nbsp;the selling price is fixed or determinable; and (iv)&nbsp;collectibility is reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#146;s control.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beginning in 2011, revenue is allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#147;VSOE&#148;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#147;TPE&#148;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&nbsp;the consideration being earned should be commensurate with either the Company&#146;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_110221_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s performance to achieve the milestone; (ii)&nbsp;the consideration being earned should relate solely to past performance; (iii)&nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#146;s revenue recognition criteria are recorded as deferred revenue on the Company&#146;s consolidated balance sheets.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award. The receivable for reimbursable amounts that have not been collected is reflected in prepaid and other current assets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock-Based Compensation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice based model.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition has been achieved.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net Loss Per Share</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 102,998 shares and 166,252 shares for the three months ended September&nbsp;30, 2013 and 2012, respectively, and 111,614 shares and 184,517 shares for the nine months ended September&nbsp;30, 2013 and 2012, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, warrants for the purchase of convertible preferred stock, exchangeable shares and common stock options outstanding under the Company&#146;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#146;s net loss position.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="66%" style="border-collapse:collapse;margin-left:1.25in;width:66.68%;">
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="39%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.78%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;and&nbsp;Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.04%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" style="padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="18%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock outstanding</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,229,590</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,065,934</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants for   convertible preferred stock</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,074</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,074</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchangeable   shares</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">480,763</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">403,841</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="top" style="padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock   options</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,710,517</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">721,539</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="55%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:55.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,456,944</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:18.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,227,388</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_110241_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition to the potentially dilutive securities noted above, the Company has an aggregate of approximately $23.7 million of outstanding principal as of September&nbsp;30, 2013 under convertible promissory notes, issued in June&nbsp;2013, July&nbsp;2013 and August&nbsp;2013, that are convertible into convertible preferred stock or common stock upon the occurrence of various future events at prices that are not determinable until the occurrence of those future events. As such, the Company has excluded these convertible notes payable from the table above.&#160; A portion of the convertible notes were repaid in cash and the balance of the notes converted into common stock in connection with the closing of the Company&#146;s IPO in October&nbsp;2013 (see Note 6).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Asset Acquisition of Verio Therapeutics Inc.</font></b></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;7, 2010, the Company acquired Verio Therapeutics Inc. (&#147;Verio&#148;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &#147;Exchangeable Shares&#148;) that were initially exchangeable into 138,462 shares of our common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, may be exchangeable for up to 884,605 shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Exchangeable Shares will be automatically redeemed and exchanged for shares of the Company&#146;s common stock upon the earliest of: (i)&nbsp;April&nbsp;13, 2017, (ii)&nbsp;the date immediately prior to an IPO of the Company&#146;s common stock pursuant to a registration statement filed with and declared effective by the SEC, (iii)&nbsp;the effective date of certain change of control events, (iv)&nbsp;the date upon which holders of at least a majority of the then outstanding Exchangeable Shares approve the redemption and exchange of all of the outstanding Exchangeable Shares, (v)&nbsp;the date upon which there are less than 450,000 Exchangeable Shares outstanding or (vi)&nbsp;the date that the holders of the Exchangeable Shares can exchange for shares of the Company&#146;s common stock on a tax-deferred basis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the Exchangeable Shares were exchangeable into 480,763 shares and 403,841 shares, respectively, of the Company&#146;s common stock. As of September&nbsp;30, 2013, the number of shares of the Company&#146;s common stock to be issued upon exchange of the Exchangeable Shares is subject to further increase as follows: (i)&nbsp;76,922 shares for the achievement of certain pre-clinical milestones, (ii)&nbsp;211,539 shares for the achievement of certain clinical milestones and (iii)&nbsp;115,381 shares for the achievement of certain commercialization milestones.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the date of an increase in the number of shares of the Company&#146;s common stock issuable upon any exchange of the Exchangeable Shares due to the achievement of a milestone as described above, the fair value of these additional shares of common stock is charged to research and development expense. At the end of each reporting period, any changes in the fair value of Exchangeable Shares resulting from changes in the fair value of the underlying common stock of the Company are recorded as a component of other income (expense).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2013, the changes in the number of shares of the Company&#146;s common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares are summarized as follows (in thousands, except share and per share amounts):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exchangeable<br>   Shares</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value&nbsp;Per<br>   Share&nbsp;of<br>   Underlying<br>   Common&nbsp;Stock</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Initial&nbsp;Fair<br>   Value&nbsp;of<br>   Exchangeable<br>   Shares</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;2010</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">138,462</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.69</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">234</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March&nbsp;2011</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">92,308</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.69</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">156</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">May&nbsp;2011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">115,380</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.69</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">195</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;2012</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57,691</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.37</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">July&nbsp;2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">76,922</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.49</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">346</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">480,763</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,009</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="316" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="90" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_110343_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Fair Value Measurements</font></b></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 1: Observable inputs such as quoted prices in active markets;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#146;s cash equivalents. As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the carrying amount of cash equivalents was $0.3 million and $1.3&nbsp;million, respectively, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial liabilities that are measured at fair value on a recurring basis include the preferred stock warrant liability and exchangeable shares (see Note 2). None of the Company&#146;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities measured at fair value on a recurring basis are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.25in;width:93.34%;">
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="43%" colspan="8" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value&nbsp;Measurements&nbsp;at<br>   Reporting&nbsp;Date&nbsp;Using</font></b></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices<br>   in&nbsp;Active<br>   Markets&nbsp;for<br>   Identical<br>   Assets<br>   (Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   Other<br>   Observable<br>   Inputs<br>   (Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   Unobservable<br>   Inputs<br>   (Level&nbsp;3)</font></b></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of   September&nbsp;30, 2013:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant liability</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchangeable share   liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,048</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,048</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of   December&nbsp;31, 2012:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrant liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">184</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">184</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchangeable share   liability</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">551</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">551</font></p>    </td>
<td width="0%" valign="bottom" style="padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.04%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">735</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">735</font></p>    </td>
<td width="0%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The preferred stock warrant liability was recorded at fair value using the Black-Scholes option pricing model and the exchangeable share liability was recorded at fair value based on the fair value of the underlying common stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_110646_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following assumptions were used in the Black-Scholes option pricing model to determine the fair value of the preferred stock warrant liability:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;width:73.34%;">
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September<br>   30,&nbsp;2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December<br>   31,&nbsp;2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest   rate</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected   volatility</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85.9</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remaining   contractual term (in years)</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.56</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.31</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="top" style="padding:0in 0in 0in 0in;width:59.1%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend   yield</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="16%" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="73%" style="border-collapse:collapse;margin-left:1.0in;width:73.34%;">
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Warrant<br>   Liability</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exchangeable<br>   Share<br>   Liability</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   December&nbsp;31, 2011</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">221</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">563</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of   exchangeable shares</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">78</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair   value</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(37</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(90</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   December&nbsp;31, 2012</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">184</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">551</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of   exchangeable shares</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">346</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" style="padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Change in fair   value</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,988</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="59%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:59.14%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   September&nbsp;30, 2013</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" style="font-size:10.0pt;">The preferred stock warrant liability and the exchangeable share liability were each reclassified into additional paid-in capital at their fair value in connection with the Company&#146;s IPO on October&nbsp;4, 2013 (see Note 6).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Long-Term Debt, Commitments and Contingencies</font></b></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Long-Term Debt</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt and unamortized discount balances (excluding convertible debt) are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September<br>   30,&nbsp;2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December<br>   31,&nbsp;2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,750</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less debt   discount, net of current portion</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt,   net of debt discount</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,732</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less current   portion of long-term debt</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt,   net of current portion</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">250</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,732</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of   long-term debt</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of   debt discount</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(29</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(59</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of   long-term debt, net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,971</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,941</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" style="font-size:10.0pt;font-weight:bold;">June&nbsp;and July&nbsp;2013 Convertible Note Financing</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In June&nbsp;and July&nbsp;2013, the Company issued convertible promissory notes in an aggregate principal amount of $3.7 million to certain existing stockholders. The notes accrue interest at 2% per year and are due on June&nbsp;24, 2014, if not earlier repaid or converted in full. In connection with the issuance of the convertible notes, the Company recorded a debt discount of $0.3 million related to a beneficial conversion feature that was recorded as a result of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_111120_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">gross fair value of the shares of Series&nbsp;C convertible preferred stock into which the debt could convert being greater than the proceeds allocated to the debt instrument. The debt discount is amortized as interest expense utilizing the effective interest method over the one year term of the debt. During the three and nine months ended September&nbsp;30, 2013, the Company recorded debt discount amortization of $0.1 million.&nbsp;As of September&nbsp;30, 2013, an aggregate of $3.7 million of principal, $0.3 million of unamortized debt discount and $0.1 million of accrued interest were outstanding under the promissory notes. The notes converted into common stock in connection with the Company&#146;s IPO in October&nbsp;2013 (see Note 6).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">August&nbsp;2013 Convertible Note Financing</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August&nbsp;2013, the Company issued convertible promissory notes in an aggregate principal amount of $20.0 million to certain new investors. The notes accrue interest at 2% per year and are due on August&nbsp;8, 2016, if not earlier repaid or converted in full. As of September&nbsp;30, 2013, an aggregate of $20.0 million of principal and $0.1 million of accrued interest were outstanding under the promissory notes. A portion of the notes were repaid in cash and the balance of the notes converted into common stock in connection with the Company&#146;s IPO in October&nbsp;2013 (see Note 6).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Facility Lease</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;26, 2013, the Company exercised its option to extend for two years the lease on its office and laboratory space in San Diego, California until June&nbsp;2016. As a result of the lease extension, the Company added an additional $0.5 million, $0.9 million and $0.5 million, respectively, of non-cancelable operating lease commitments for the years ending December&nbsp;31, 2014, 2015 and 2016.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Stockholders&#146; Deficit</font></b></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2007 Equity Incentive Plan</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;12, 2013, the Company&#146;s board of directors approved an increase in the number of shares of common stock authorized for issuance under the Company&#146;s 2007 Equity Incentive Plan (the &#147;Plan&#148;) to 2,423,072&nbsp;shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock option activity under the Plan is summarized as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Options</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   Average&nbsp;Price</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   December&nbsp;31, 2012</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,432,369</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.43</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">331,860</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.60</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canceled</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(17,860</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.56</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(35,852</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.65</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at   September&nbsp;30, 2013</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,710,517</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.26</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="374" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="90" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="80" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" style="font-size:10.0pt;">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">581</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">686</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" style="padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">401</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">483</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="31%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:31.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">982</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,169</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">106</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_111328_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2013, the outstanding options included 340,121 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at September&nbsp;30, 2013 was $1.8 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2013, the outstanding options included 220,496 options with both performance-based milestones and market conditions that were determined not to be probable of achievement. The aggregate grant date fair value of these unvested options at September&nbsp;30, 2013 was $0.2 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2013, the unrecognized compensation cost related to outstanding options (excluding those with performance-based and/or market conditions) was $0.6 million and is expected to be recognized as expense over approximately 3.5 years.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest   rate</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.6</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected   volatility</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90.2</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term (in   years)</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.07</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.06</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend   yield</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="80%" style="border-collapse:collapse;margin-left:.75in;width:80.0%;">
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="33%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="bottom" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest   rate</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected   volatility</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90.3</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">93.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remaining   contractual term (in years)</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.27</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.23</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="62%" valign="top" style="padding:0in 0in 0in 0in;width:62.52%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend   yield</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2013 Stock Option and Incentive Plan</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On August&nbsp;28, 2013, the Company&#146;s board of directors and stockholders approved and adopted the 2013 Stock Option and Incentive Plan (the &#147;2013 Plan&#148;). The 2013 Plan became effective immediately prior to the Company&#146;s IPO. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, directors or consultants of the Company or its subsidiaries. A total of 1,020,000 shares of common stock were initially reserved for issuance under the 2013 Plan. In addition, the number of shares of stock available for issuance under the 2013 Plan will be automatically increased each January&nbsp;1, beginning on January&nbsp;1, 2014, by 4% of the outstanding number of shares of the Company&#146;s common stock on the immediately preceding December&nbsp;31 or such lesser number as determined by the compensation committee of the Company&#146;s board of directors.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_111521_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fn.htm',USER='107902',CD='Nov 12 08:00 2013' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Employee Stock Purchase Plan</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;13, 2013, the Company&#146;s board of directors approved and adopted the 2013 Employee Stock Purchase Plan (the &#147;ESPP&#148;). The ESPP became effective immediately prior to the Company&#146;s IPO. A total of 729,000 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of stock available for issuance under the ESPP will be automatically increased each January&nbsp;1, beginning on January&nbsp;1, 2015, by the lesser of (i)&nbsp;2% of the outstanding number of shares of the Company&#146;s common stock on the immediately preceding December&nbsp;31, (ii)&nbsp;450,000 shares, or (iii)&nbsp;such lesser number as determined by the compensation committee of the Company&#146;s board of directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Subsequent Events</font></b></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Initial Public Offering and Related Transactions</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;4, 2013, the Company completed its IPO whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Estimated net proceeds from the IPO were determined as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="89%" style="border-collapse:collapse;margin-left:.4in;width:89.34%;">
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gross proceeds   (including over-allotment)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Underwriting   discounts and commissions</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,695</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated total   offering costs (including costs paid as of September&nbsp;30, 2013)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,900</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Offering costs   paid as of September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,381</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated net   proceeds to be received subsequent to September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41,786</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partial repayment   of August&nbsp;2013 Notes subsequent to September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,741</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.7%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated net cash   impact of IPO and related transactions</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.8%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.12%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40,045</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.1%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, each of the following occurred in connection with the completion of our IPO on October&nbsp;4, 2013:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of all outstanding shares of convertible preferred stock into 7,229,590 shares of the Company&#146;s common stock;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of $22.1 million of outstanding principal and accrued interest on convertible notes into 3,679,401 shares of common stock, the write-off of $0.3 million of unamortized debt discount and the related cash repayment of $1.7 million of outstanding principal and accrued interest on convertible notes and accrued interest outstanding as of September&nbsp;30, 2013;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">480,763 shares of the Company&#146;s common stock became issuable pursuant to the redemption of an aggregate of 900,000 exchangeable shares of Fate Canada and the resultant reclassification of the exchangeable share liability to additional paid-in capital;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of warrants to purchase 230,000 shares of convertible preferred stock into warrants to purchase 36,074 shares of the Company&#146;s common stock and the resultant reclassification of the warrant liability to additional paid-in capital; and</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an amended and restated certificate of incorporation was filed on October&nbsp;3, 2013, authorizing 150,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_111714_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company&#146;s IPO noted above, as of September&nbsp;30, 2013 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September<br>   30,&nbsp;2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Pro&nbsp;Forma<br>   September<br>   30,&nbsp;2013</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash   equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,082</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">59,127</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,743</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable   and accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,725</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,344</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term accrued   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">137</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">79</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible notes,   net of discount</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23,481</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock   warrant liability</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">163</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchangeable share   liability</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,885</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   preferred stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">56,526</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in   capital</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,367</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">136,398</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deficit   accumulated during the development stage</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(80,770</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(81,024</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   stockholders&#146; (deficit) equity</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(66,402</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,394</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="424" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" style="font-size:10.0pt;">In connection with the closing of its IPO on October&nbsp;4, 2013, the Company recorded an additional aggregate non-cash charge of $0.5 million in other income (expense) related to the final fair value adjustment of the exchangeable share liability and the preferred stock warrant liability. This final fair value adjustment </font><font size="2" style="font-size:10.0pt;">is excluded from the table above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_111752_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.&#160; Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</font></b><a name="Item2_ManagementsDiscussionAndAna_111754"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form&nbsp;10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December&nbsp;31, 2012 and the related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our final prospectus dated September&nbsp;30, 2013, filed with the Securities and Exchange Commission on October&nbsp;1, 2013 pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), in connection with our initial public offering.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This Quarterly Report on Form&nbsp;10-Q contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Such forward looking statements, which represent our intent, belief, or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;believe,&#148; &#147;should&#148; and similar expressions. Factors that could cause or contribute to differences in results include, but are not limited to, those set forth under &#147;Risk Factors&#148; under Item&nbsp;1A of Part&nbsp;II below, and elsewhere in this Quarterly Report on Form&nbsp;10-Q. Except as required by law we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Our novel approaches utilize established pharmacologic modalities, including small molecules and therapeutic proteins, and target well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells. Based on our deep understanding of key biological mechanisms that guide the fate of adult stem cells, we have built two platforms that optimize the activity of adult stem cells using both <i>ex vivo</i> and <i>in vivo</i> techniques: our hematopoietic stem cell, or HSC, modulation platform and muscle satellite stem cell, or SSC, modulation platform. We believe that the product candidates generated by our platforms have significant potential as life-changing or curative therapeutics across a broad range of orphan indications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our HSC modulation platform focuses on the <i>ex vivo</i> pharmacologic optimization of hematopoietic stem cells, or HSCs. Our lead product candidate from this platform, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. We have established human proof-of-concept for ProHema in a Phase 1b clinical trial by demonstrating enhanced engraftment. We are presently advancing ProHema in Phase 2 clinical development for hematologic malignancies.&nbsp;Our SSC modulation platform focuses on the <i>in vivo</i> pharmacologic activation of satellite stem cells, or SSCs.&nbsp;We have identified Wnt7a as a natural promoter of SSCs to drive muscle regeneration, and we have demonstrated proof-of-concept of Wnt7a analogs as potential therapeutics for muscular dystrophy in preclinical animal studies.&nbsp;We are presently advancing our Wnt7a analogs in preclinical development with the goal of filing an Investigational New Drug application, or IND, in 2014.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception in 2007, we have devoted substantially all of our resources to the development of our stem cell modulation platforms, the clinical and preclinical advancement of our product candidates, the creation, licensing and protection of related intellectual property and the provision of general and administrative support for these operations. We have generated revenues from collaboration activities and grants, but have not generated any revenues from therapeutic product sales. We have funded our operations primarily through the private placement of preferred stock and convertible notes, through commercial bank debt and through the public offering of common stock. We continue to be classified as a development stage company for financial reporting purposes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never been profitable and have incurred net losses in each year since inception. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our expenses will increase substantially in connection with our ongoing activities as we:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conduct clinical trials of our initial product candidates;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">continue our research and development efforts;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_111811_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">manufacture preclinical study and clinical trial materials;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, expand and protect our intellectual property portfolio;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">seek regulatory approvals for our product candidates that successfully complete clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire additional clinical, quality control and technical personnel to conduct our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire additional scientific personnel to support our product development efforts;</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">implement operational, financial and management systems; and</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">add general and administrative personnel to operate as a public company.</font></p>
<p style="margin:0in 0in .0001pt 59.0pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not expect to generate any revenues from therapeutic product sales until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will seek to fund our operations through public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and ability to develop our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Recent Developments</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;4, 2013, we completed our initial public offering (&#147;IPO&#148;) whereby we sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Estimated net proceeds from our IPO were determined as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gross proceeds   (including over-allotment)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Underwriting   discounts and commissions</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,695</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated total   offering costs (including costs paid as of September&nbsp;30, 2013)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,900</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Offering costs   paid as of September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,381</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated net   proceeds to be received subsequent to September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41,786</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" style="padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Partial repayment   of August&nbsp;2013 Notes subsequent to September&nbsp;30, 2013</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,741</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="82%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:82.12%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Estimated net cash   impact of IPO and related transactions</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40,045</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, each of the following occurred in the fourth quarter of 2013 in connection with the completion of our IPO on October&nbsp;4, 2013:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of all outstanding shares of convertible preferred stock into 7,229,590 shares of our common stock;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of $22.1 million of outstanding principal and accrued interest on convertible notes into 3,679,401 shares of common stock, the write-off of $0.3 million of unamortized debt discount and the related repayment of $1.7 million of outstanding principal and accrued interest on convertible notes and accrued interest outstanding as of September&nbsp;30, 2013;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">480,763 shares of our common stock became issuable pursuant to the redemption of an aggregate of 900,000 exchangeable shares of Fate Canada and the resultant reclassification of the $3.3 million exchangeable share liability to additional paid-in capital, of which $2.9 million was recorded as of September&nbsp;30, 2013;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the conversion of warrants to purchase 230,000 shares of convertible preferred stock into warrants to purchase 36,074 shares of our common stock and the resultant reclassification of the $0.2 million warrant liability to additional paid-in capital; and</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 58.3pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an amended and restated certificate of incorporation was filed on October&nbsp;3, 2013 to authorize 150,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_111850_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial Operations Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We conduct substantially all of our activities through Fate Therapeutics,&nbsp;Inc., a Delaware corporation, at our facility in San Diego, California. Fate Therapeutics,&nbsp;Inc. owns 100% of the voting shares of Fate Canada that were outstanding at September&nbsp;30, 2013 and directs all of its operational activities, which are insignificant as compared to the operations of Fate Therapeutics,&nbsp;Inc. The following information is presented on a consolidated basis to include the accounts of Fate Therapeutics,&nbsp;Inc. and Fate Canada. All intercompany transactions and balances are eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenues from therapeutic product sales. Our revenues have been derived from collaboration activities and grant revenues.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration revenues are generated exclusively from our collaboration arrangement with Becton, Dickinson and Company, or BD. In September&nbsp;2010, we entered into a worldwide exclusive license and collaboration agreement with BD for the joint development and worldwide commercialization of certain induced pluripotent stem cell, or iPSC, tools and technologies for use in drug discovery and development. The license and collaboration agreement was assigned by BD to Corning Incorporated in October&nbsp;2012. In connection with the agreement, we received an upfront, non-refundable license payment, and are entitled to receive research funding for the conduct of joint development activities for a period of three years ending in September&nbsp;2013. In addition, we are eligible to receive certain commercialization milestones and royalties on the sale of iPSC reagent products. In connection with the arrangement with BD, we recognized $0.2 million, $0.2 million, $0.6 million and $1.1 million for the three months ended September&nbsp;30, 2013 and 2012 and the nine months ended September&nbsp;30, 2013 and 2012, respectively, as collaboration revenue in our consolidated statements of operations. Our three-year joint development period under our license and collaboration agreement with BD concluded in September&nbsp;2013. We do not currently anticipate generating any significant revenues associated with iPSC tools and technologies thereafter.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue is primarily generated through research and development grant programs offered by the U.S. government and its agencies. In April&nbsp;2011, we were awarded a $2.1 million grant from the U.S. Army Telemedicine&nbsp;&amp; Advanced Technology Research Center, or TATRC, to identify and develop regenerative medicines for acute sound-inducing hearing loss. All funding under the TATRC grant was expended in full as of May&nbsp;2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist of development costs associated with our platforms and programs. These costs are expensed as incurred and include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">compensation and employee-related costs;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs associated with conducting our preclinical, clinical and regulatory activities, including fees paid to third-party professional consultants and service providers;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs incurred under clinical trial agreements with investigative sites;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs for laboratory supplies;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs to acquire, develop and manufacture preclinical study and clinical trial materials;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">charges associated with the achievement of certain preclinical and financial milestones pursuant to our asset acquisition of Verio Therapeutics Inc., or Verio, that was completed in April&nbsp;2010; and</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities.</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From inception through September&nbsp;30, 2013, we incurred $54.0 million in research and development expenses. We plan to increase our current level of research and development expenses for the foreseeable future as we continue the development of our stem cell modulation platforms and our initial therapeutic product candidates. Our current planned research and development activities include the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">advancing ProHema in a Phase 2 clinical trial in the setting of adult patients with orphan hematologic malignancies in 2014 to examine its safety and its curative potential in allogeneic hematopoietic stem cell transplant, or HSCT;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">initiating in 2014 a clinical trial of a pharmacologically-modulated HSC product candidate in pediatric patients with lysosomal storage disorders, or LSDs, to evaluate its safety and its curative potential in allogeneic HSCT; and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conducting IND-enabling studies, filing an IND in 2014 and initiating a clinical trial of a Wnt7a protein analog product candidate to evaluate its safety and its potential to promote muscle regeneration.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_111910_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot determine with certainty the timing of initiation, the duration and the completion costs of current or future preclinical studies and clinical trials of our therapeutic product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our programs, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in the continued development of our product candidates, including ProHema. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our research and development expenses by major programs for the periods indicated (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">HSC modulation   platform</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">977</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,807</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,491</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,099</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other preclinical   programs and technologies</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,128</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">832</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,879</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,664</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total direct   research and development expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,105</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,639</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,370</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,763</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unallocated   expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,273</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">676</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,606</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,833</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and   development expenses</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,378</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,315</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,976</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,596</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" style="font-size:10.0pt;">We do not allocate general equipment and supply costs, or facilities, depreciation and other miscellaneous expenses to specific programs as these expenses are deployed across all of our programs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation and travel expenses for our employees in executive, operational, finance and human resource functions. Other general and administrative expenses include facility-related costs and professional fees for directors, accounting and legal services and expenses associated with obtaining and maintaining patents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with being a public company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expense), net consists primarily of interest income earned on cash and cash equivalents; interest expense on convertible notes and on amounts outstanding under our credit facility; changes in fair value of the exchangeable share liability relating to the total exchangeable shares held by the prior stockholders of Verio; and changes in fair value of the warrant liability relating to our outstanding preferred stock warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_112035_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity in our final prospectus dated September&nbsp;30, 2013 filed with the SEC on October&nbsp;1, 2013 pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act in connection with our IPO. There have been no material changes to our critical accounting policies and estimates as disclosed in our final prospectus.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended September&nbsp;30, 2013 and 2012</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the results of our operations for the three months ended September&nbsp;30, 2013 and 2012 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Increase&nbsp;/</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Decrease)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration   revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">209</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.58%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">208</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">320</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(320</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,378</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,315</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">63</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative   expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,979</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">863</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,116</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.62%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other income   (expense), net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(925</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.88%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(463</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(462</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr height="0">
<td width="315" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="82" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><i><font size="2" style="font-size:10.0pt;font-style:italic;">Revenue.<b>&nbsp;</b></font></i><font size="2" style="font-size:10.0pt;"> Total revenue was $0.2 million for the three months ended September&nbsp;30, 2013, compared to $0.5 million for the three months ended September&nbsp;30, 2012. The decrease of $0.3 million was due to the completion of our TATRC grant in May&nbsp;2013.&#160; Our three-year joint development period under our license and collaboration agreement with BD concluded in September&nbsp;2013, and we do not expect to generate any significant revenue under this agreement thereafter.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and development expenses.<b>&nbsp;</b></font></i><font size="2" style="font-size:10.0pt;"> Research and development expenses were $3.4 million for the three&nbsp;months ended September&nbsp;30, 2013, compared to $3.3 million for the three months ended September&nbsp;30, 2012.&#160; The $0.1 million increase in research and development expenses primarily reflects the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.2 million increase in employee compensation and benefits expense to support the clinical development of ProHema and the preclinical development of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.6 million increase in non-employee stock-based compensation expense;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million non-cash charge relating to an increase in the number of shares of our common stock issuable upon the exchange of the exchangeable shares;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.7 million decrease in third-party professional consultant and service provider expenses relating to the initiation of our ProHema-03 trial in December&nbsp;2012, including expenses to support regulatory filing and other clinical start-up activities; and</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million decrease in expenditures for laboratory equipment and supplies relating to the initiation and support of our ProHema-03 trial.</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">General and administrative expenses.&nbsp;</font></i><font size="2" style="font-size:10.0pt;">&nbsp;General and administrative expenses were $2.0 million for the three&nbsp;months ended September&nbsp;30, 2013, compared to $0.9 million for the three months ended September&nbsp;30, 2012.&#160; The $1.1 million increase in general and administrative expenses primarily reflects the following:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.2 million increase in employee compensation and benefits expense associated with the expansion of our executive management team;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.4 million increase in non-employee stock-based compensation expense;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million increase in intellectual property related expenses; and</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.2 million increase in third-party professional consultant and service provider expenses to support our financial and legal preparedness as a public company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_112151_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fp.htm',USER='107902',CD='Nov 12 07:35 2013' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other income (expense), net.</font></i><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;Other income (expense), net was $(0.9) million for the three months ended September&nbsp;30, 2013, compared to $(0.5) million for the three months ended September&nbsp;30, 2012.&#160; The increase in other expense was primarily due to an increase in the fair value of the exchangeable share liability relating to the total exchangeable shares held by the former stockholders of Verio.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Nine Months Ended September&nbsp;30, 2013 and 2012</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the results of our operations for the nine months ended September&nbsp;30, 2013 and 2012 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.68%;">
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Increase&nbsp;/</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Decrease)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration   revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">626</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,075</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(449</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">345</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">952</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(607</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and   development expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,976</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,596</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">380</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" style="padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and   administrative expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,768</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,944</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,824</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:48.64%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other income   (expense), net</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2,382</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(571</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,811</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr height="0">
<td width="315" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="82" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><i><font size="2" style="font-size:10.0pt;font-style:italic;">Revenue.<b>&nbsp;</b></font></i><font size="2" style="font-size:10.0pt;"> Total revenue was $1.0 million for the nine months ended September&nbsp;30, 2013, compared to $2.0 million for the nine months ended September&nbsp;30, 2012. The decrease of $1.0 million was due to the completion of our TATRC grant in May&nbsp;2013 and the receipt of a $0.5 million commercialization milestone payment in 2012 that did not recur in 2013 under our license and collaboration agreement with BD.&#160; Our three-year joint development period under our agreement with BD concluded in September&nbsp;2013, and we do not expect to generate any significant revenue under this agreement thereafter.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and development expenses.<b>&nbsp;</b></font></i><font size="2" style="font-size:10.0pt;"> Research and development expenses were $9.0 million for the nine&nbsp;months ended September&nbsp;30, 2013, compared to $8.6 million for the nine months ended September&nbsp;30, 2012.&#160; The $0.4 million increase in research and development expenses primarily reflects the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$1.0 million increase in employee compensation and benefits expense to support the clinical development of ProHema and the preclinical development of our other product candidates;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.6 million increase in non-employee stock-based compensation expense;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million non-cash charge relating to an increase in the number of shares of our common stock issuable upon the exchange of the exchangeable shares;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.8 million decrease in third-party professional consultant and service provider expenses relating to the conduct of our ProHema-02 trial during the first half of 2012 and the initiation of our ProHema-03 trial in December&nbsp;2012, including expenses to support clinical trial conduct, regulatory filing and other clinical start-up activities; and</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.7 million decrease in expenditures for laboratory equipment and supplies relating to the initiation and support of our ProHema-03 trial and the conduct of our preclinical programs.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">General and administrative expenses.</font></i><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;General and administrative expenses were $4.8 million for the nine&nbsp;months ended September&nbsp;30, 2013, compared to $2.9 million for the nine months ended September&nbsp;30, 2012.&#160; The $1.8 million increase in general and administrative expenses primarily reflects the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.6 million increase in employee compensation and benefits expense associated with the expansion of our executive management team;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.4 million increase in non-employee stock-based compensation expense;</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million increase in intellectual property related expenses; and</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.5 million increase in third-party professional consultant and service provider expenses, and other general expenses, to support our financial and legal preparedness as a public company.</font></p>
<p style="margin:0in 0in .0001pt 41.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other income (expense), net.</font></i><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;Other income (expense), net was $(2.4) million for the nine months ended September&nbsp;30, 2013, compared to $(0.6) million for the nine months ended September&nbsp;30, 2012. The increase in other expense was primarily due to an increase in the fair value of the exchangeable share liability relating to the total exchangeable shares held by the former stockholders of Verio.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_112617_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fr.htm',USER='107902',CD='Nov 12 07:50 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred losses and negative cash flows from operations since inception. As of September&nbsp;30, 2013, we had an accumulated deficit of $80.8 million and anticipate that we will continue to incur net losses for the foreseeable future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From our inception through September&nbsp;30, 2013, we have funded our consolidated operations primarily through the private placement of preferred stock and convertible notes, commercial bank debt and revenues from collaboration activities and grants. As of September&nbsp;30, 2013, we had cash and cash equivalents of approximately $19.1&nbsp;million. As discussed above, our IPO and related transactions resulted in net proceeds of $40.0 million subsequent to September&nbsp;30, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In 2009, we entered into a $3.0 million loan and security agreement collateralized by substantially all of our assets, excluding certain intellectual property. We drew the full $3.0 million available under the loan and security agreement in 2009. In August&nbsp;2011, the loan and security agreement was amended to: (i)&nbsp;increase the available credit under the loan and security agreement to $4.0 million, (ii)&nbsp;add an additional payment upon maturity equal to 5% of the maximum loan amount and (iii)&nbsp;repay the remaining $0.6 million of outstanding principal related to the original $3.0 million loan. We accessed the full $4.0 million of available credit under the amended loan and security agreement by taking a term advance of $2.0 million in August&nbsp;2011 and a term advance of $2.0 million in December&nbsp;2011, each of which are scheduled to be fully paid by August&nbsp;2014 and December&nbsp;2014, respectively. The term advances require interest-only payments during the first 12 months from access and equal monthly principal and interest payments during the final 24 months from access. The interest rate on the term advances is fixed at 7.0%&nbsp;per annum for their entire 36-month term of the debt. As of September&nbsp;30, 2013, the aggregate outstanding principal was $2.3 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="30%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended<br>   September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   operating activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10,795</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9,880</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in   investing activities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(88</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(414</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided   by financing activities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,878</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.86%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,371</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net change in cash   and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,995</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.48%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.38%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(923</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 2.25pt 0in;width:1.12%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Operating Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash used in operating activities increased $0.9 million from $9.9 million for the nine months ended September&nbsp;30, 2012 to $10.8 million for the nine months ended September&nbsp;30, 2013. The primary driver of operating cash requirements was our net loss in each period. During the nine months ended September&nbsp;30, 2012, we used cash from operating activities of $9.9 million while our net loss was $10.1 million. The difference was a result of $0.6 million net change in our operating assets and liabilities, offset by $0.8 million of non-cash charges and deferrals, including depreciation expense and stock-based compensation. During the nine months ended September&nbsp;30, 2013, we used cash from operating activities of $10.8 million while our net loss was $15.2 million. The difference was a result of $0.4&nbsp;million net change in our operating assets and liabilities and $4.0 million of non-cash charges and deferrals, including $0.4 million of depreciation expense, $1.2 million of stock-based compensation and $2.3 million related to the change in fair value of exchangeable shares.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Investing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the nine months ended September&nbsp;30, 2012 and 2013, investing activities used cash of $0.4 million and $0.1 million, respectively, for the purchase of property and equipment.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_112705_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fr.htm',USER='107902',CD='Nov 12 07:50 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Financing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financing activities provided cash of $9.4 million for the nine months ended September&nbsp;30, 2012 and provided cash of $20.9 million for the nine months ended September&nbsp;30, 2013. During the nine months ended September&nbsp;30, 2012, we received $9.2 million in net proceeds from the sale of Series&nbsp;C preferred stock. During the nine months ended September&nbsp;30, 2013, we paid down principal of $1.5 million on our outstanding long-term debt. No principal amounts were paid down in 2012 as the debt was still in its interest-only period. In addition, we received $23.7 million of proceeds from the sale of convertible notes and paid $1.4 million for initial public offering costs during the nine months ended September&nbsp;30, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Operating Capital Requirements</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenues from therapeutic product sales. We do not know when, or if, we will generate any revenue from therapeutic product sales. We do not expect to generate significant revenue from therapeutic product sales unless and until we obtain regulatory approval of and commercialize one of our current or future product candidates. We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to all of the risks incident in the development of new therapeutic products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We expect to incur additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that the net proceeds from our IPO and our existing cash and cash equivalents will be sufficient to fund our projected operating requirements through at least the end of 2014. However, we may require additional capital for the further development of our existing product candidates and may also need to raise additional funds sooner to pursue other development activities related to additional product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Until we can generate a sufficient amount of revenue from our therapeutic products, if ever, we expect to finance future cash needs through public or private equity or debt offerings. In any event, we do not expect to achieve significant revenue from therapeutic product sales prior to the use of the net proceeds from our IPO. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the design, initiation, progress, size, timing, costs and results of preclinical studies and clinical trials for our product candidates;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than those that we currently expect;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and costs associated with manufacturing our product candidates for clinical trials, preclinical studies and, if approved, for commercial sale;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number and characteristics of product candidates that we pursue;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_112729_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fr.htm',USER='107902',CD='Nov 12 07:50 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our need to expand our research and development activities, including our need and ability to hire additional employees;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our need to implement additional infrastructure and internal systems and hire additional employees as we operate as a public company;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effect of competing technological and market developments; and</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of establishing sales, marketing and distribution capabilities for any products for which we may receive regulatory approval.</font></p>
<p style="margin:0in 0in .0001pt 59.05pt;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual Obligations and Commitments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our contractual obligations and commitments as of December&nbsp;31, 2012 that will affect our future liquidity (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Less&nbsp;than<br>   1&nbsp;year</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">1-3&nbsp;years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">3-5&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">More<br>   than&nbsp;5<br>   Years</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt   (including interest)</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,212</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,201</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,011</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="top" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating lease   obligation (1)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,331</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">883</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">448</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,543</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,084</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,459</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .3in;text-indent:-.3in;"><font size="2" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">On December&nbsp;3, 2009, we entered into a multi-year building lease for our facility in San Diego, California. The operating lease is non-cancelable and was scheduled to expire on June&nbsp;30, 2014. In September&nbsp;2013, we exercised an option to extend this lease by an additional two years. As a result of the lease extension, we will incur an additional $0.5 million, $0.9 million and $0.5 million, respectively, of non-cancelable operating lease commitments for the years ending December&nbsp;31, 2014, 2015 and 2016. The table above excludes these additional amounts.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The table above excludes convertible promissory notes we issued to certain existing stockholders in June&nbsp;and July&nbsp;2013 for an aggregate principal amount of $3.7 million.&nbsp;These notes accrued interest at 2% per year and had a maturity date of June&nbsp;24, 2014, if not earlier repaid or converted in full.&nbsp;The table above also excludes convertible promissory notes we issued to certain new investors in August&nbsp;2013 for an aggregate principal amount of $20.0 million.&nbsp;These notes accrued interest at 2% per year and had a maturity date of August&nbsp;8, 2016, if not earlier repaid or converted in full.&nbsp;</font><font size="2" style="font-size:10.0pt;">Upon the closing of our IPO, $22.1 million of outstanding principal and accrued interest on these convertible notes converted into 3,679,401 shares of common stock and we repaid $1.7 million of outstanding principal and accrued interest.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&nbsp;and regulations of the SEC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_112854_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fr.htm',USER='107902',CD='Nov 12 07:50 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3.&#160; Quantitative and Qualitative Disclosures about Market Risk</font></b><a name="Item3_QuantitativeAndQualitativeD_112903"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest Rate Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our cash and cash equivalents as of September&nbsp;30, 2013 consisted of cash and money market mutual funds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S.&nbsp;interest rates. However, because of the short-term nature of the instruments in our portfolio, a 10% change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our debt bears interest at a fixed rate and therefore has minimal exposure to changes in interest rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4.&#160; Controls and Procedures</font></b><a name="Item4_ControlsAndProcedures_112904"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Disclosure Controls and Procedures</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Exchange Act as of the end of the period covered by this Quarterly Report on Form&nbsp;10-Q. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September&nbsp;30, 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_112912_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\107902\13-22691-1\task6363702\22691-1-fr.htm',USER='107902',CD='Nov 12 07:50 2013' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;II. OTHER INFORMATION</font></b><a name="Partii_OtherInformation_113237"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160; Legal Proceedings</font></b><a name="Item1_LegalProceedings_113239"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are currently not a party to any material legal proceedings, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations or financial condition. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A.&#160; Risk Factors</font></b><a name="Item1a_RiskFactors_113241"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">You should carefully consider the following risk factors, as well as the other information in this report, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Financial Position</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a clinical-stage biopharmaceutical discovery and development company, formed in 2007, with a limited operating history. Since inception, we have devoted substantially all of our resources to the development of our stem cell modulation platforms, the clinical and preclinical advancement of our product candidates, the creation, licensing and protection of related intellectual property rights and the provision of general and administrative support for these operations. We have not yet obtained regulatory approval for any product candidates or generated any revenues from therapeutic product sales. If ProHema or any of our other product candidates fails in clinical trials or preclinical development, or does not gain regulatory approval, or if our product candidates do not achieve market acceptance, we may never become profitable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred net losses in each year since our inception, including net losses of approximately $13.4&nbsp;million and $14.2&nbsp;million for the years ended December&nbsp;31, 2011 and 2012, respectively, and approximately $10.1 million and $15.2 million for the nine months ended September&nbsp;30, 2012 and 2013, respectively. As of September&nbsp;30, 2013, we had an accumulated deficit of approximately $80.8&nbsp;million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approval for, our product candidates. In addition, if we receive approval to market any of our product candidates, we will incur additional losses as we build an internal sales and marketing organization to commercialize any approved products. We also expect our expenditures to increase as we add infrastructure and personnel to support our operations as a public company. We anticipate that our net losses for the next several years could be significant as we conduct our planned operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because of the numerous risks and uncertainties associated with pharmaceutical and biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates. The amount of our future net losses will depend, in part, on the rate of increase in our expenses, our ability to generate revenues and our ability to raise additional capital. These net losses have had, and will continue to have, an adverse effect on our stockholders&#146; equity and working capital.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back or cease our product development activities and operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are currently advancing ProHema through clinical development and our Wnt7a analogs through preclinical development. Developing biological products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional capital in order to complete the clinical development of, and to commercialize, ProHema, and to conduct the research and development and clinical and regulatory activities necessary to bring other product candidates to market. If the FDA or comparable foreign regulatory authorities require that we perform additional preclinical studies or clinical trials at any point, our expenses would further increase beyond what we currently expect, and the anticipated timing of any future clinical development activities and potential regulatory approvals would likely be delayed. Raising funds in the current economic environment may be difficult and additional funding may not be available on acceptable terms, or at all.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_113249_9862"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The amount and timing of our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the timing of, and our ability to incorporate, the use of our nutrient rich media formulation, or NRM, formulation in our clinical development activities for ProHema, including our Phase 2 clinical trial in adults with hematologic malignancies;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the agreement by the FDA and any foreign regulatory authorities to accept our protocols for clinical trials of ProHema, our Wnt7a analogs or any other product candidates that we may develop;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the progress, costs, results and timing of our Phase 2 clinical trial and planned Phase 1b clinical trial of ProHema and our planned additional preclinical studies and Phase 1 clinical trial of our Wnt7a analogs;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to initiate, and the size, outcome, costs and timing of additional future clinical trials, including Phase 3 clinical trial costs for ProHema, that will be necessary to support any application for regulatory approval of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our need to expand our research and development activities, including the hiring of additional employees;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the costs of acquiring, licensing or investing in complementary businesses, products, product candidates and technologies;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the effect of competing technological and market developments;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our need to maintain the requisite internal systems and infrastructure, including financial and reporting systems, as a public company;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the costs associated with securing and establishing commercialization and manufacturing capabilities;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">market acceptance of any products for which we receive approval; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some of these factors are outside of our control. Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operations at least through the end of 2014. This period could be shortened if there are any significant or unanticipated increases in spending on development programs. In addition, the net proceeds from our IPO will not be sufficient to complete the advanced clinical development, including Phase 3 clinical trials, of ProHema or clinical trials of our Wnt analogs that would be necessary to support an application for regulatory approval. Accordingly, we will continue to require substantial additional capital. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our products under development.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are required to secure additional financing, such additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or curtail our operations, which will have a material adverse effect on our business, operating results and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding and other collaborations, strategic alliances and licensing arrangements. These financing activities may have an adverse impact on our stockholders&#146; rights as well as on our operations. Any equity financing, or any issuance of securities that may be converted, exercised or exchanged for shares of our capital stock, will result in dilution to our stockholders and may cause the market price of our stock to decline, and any debt</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_113249_9111"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">financing may impose restrictive covenants on our operations or otherwise adversely affect the holdings or the rights of our stockholders. In addition, if we seek funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Discovery, Development and Regulation of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to complete preclinical development and clinical trials, obtain regulatory approval, or successfully commercialize our product candidates from our HSC and SSC modulation platforms, our business would be significantly harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not completed clinical development for any of our product candidates and will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities in well-designed and conducted clinical trials that the product candidate is safe, pure and potent, and effective, and otherwise meets the appropriate standards required for approval for a particular indication. Clinical trials are lengthy, complex and extremely expensive processes with uncertain results. A failure of one or more clinical trials may occur at any stage.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never obtained marketing approval from the FDA or any comparable foreign regulatory authority for any product candidate. Our ability to obtain regulatory approval of our product candidates depends on, among other things, completion of additional preclinical studies and clinical trials, whether our clinical trials demonstrate statistically significant efficacy with safety issues that do not potentially outweigh the therapeutic benefit of the product candidates, and whether the regulatory agencies agree that the data from our future clinical trials are sufficient to support approval for any of our product candidates. The final results of our current and future clinical trials may not meet the FDA&#146;s or other regulatory agencies&#146; requirements to approve a product candidate for marketing, and the regulatory agencies may otherwise determine that our manufacturing processes or facilities are insufficient to support approval. We may need to conduct more clinical trials than we currently anticipate. Even if we do receive FDA or other regulatory agency approval, we may not be successful in commercializing approved product candidates. If any of these events occur, our business could be materially harmed and the value of our common stock would likely decline.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because our product candidates are based on novel technologies, it is difficult to predict the time and cost of development and our ability to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product candidates are based on our novel HSC and SSC modulation platforms, and unexpected problems related to this new technology may arise that can cause us to delay, suspend or terminate our development efforts. Regulatory approval of novel product candidates such as ours can be more expensive and take longer than for other more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#146; lack of experience with them.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stem cell therapies represent a relatively new therapeutic area, and the FDA has cautioned consumers about potential safety risks associated with these therapies. To date, there are relatively few approved stem cell products. In addition, there are currently no approved products in any major territory throughout the world with a label designation that supports the use of a product to improve multi-lineage engraftment or survival in patients undergoing HSCT, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for ProHema or any of our other modulated HSC product candidates in the United States and elsewhere. Furthermore, the requirement that ProHema is manufactured at cell processing facilities in close proximity to transplant centers within a short period of time before transplantation may present unprecedented additional complexities associated with ensuring consistent manufacture across all sites, the degree of qualification testing necessary for cell-based therapies both pre- and post-administration, and ProHema&#146;s rapid release nature, all of which contribute to regulatory uncertainty.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory requirements governing cell therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In addition, adverse developments in clinical trials of potential stem cell therapies conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates. These regulatory authorities and advisory groups and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with the FDA and other regulatory authorities, and our products will likely be reviewed</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_113249_2270"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by the FDA&#146;s advisory committee. We also must comply with applicable requirements, and if we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could impair our ability to generate sufficient product revenues to maintain our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our clinical development of ProHema could be substantially delayed if the FDA requires us to conduct additional studies or trials or imposes other requirements or restrictions.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We initiated a Phase 2 clinical trial of ProHema, which we refer to as our ProHema-03 trial, in December&nbsp;2012 and notified the FDA in May&nbsp;2013 of our election to pause enrollment in our ProHema-03 trial to incorporate the use of our improved NRM formulation in the manufacture of ProHema for the trial. In August&nbsp;2013, we submitted to the FDA preclinical and product development data to qualify the use of our NRM formulation in our ProHema manufacturing process&nbsp;and support that the use of the NRM formulation should not result in&nbsp;additional safety risks. In addition, we submitted an amended&nbsp;protocol&nbsp;for our ProHema-03 trial that defines how we will resume enrollment with ProHema as manufactured using our NRM formulation. Based on our communications with the FDA, we expect to resume enrollment in our ProHema-03 trial in the first half of 2014, with the goal of generating full data in the primary and major secondary endpoints in mid-2015. Before resuming enrollment in our ProHema-03 trial, we will need to generate, and provide the FDA with, product data for ProHema as manufactured using our NRM formulation with materials intended for clinical use. The&nbsp;FDA may also require us to generate additional&nbsp;preclinical or clinical data to support the use of our NRM formulation in our ProHema-03 trial or any&nbsp;subsequent&nbsp;clinical trials for ProHema that we may plan to conduct. Additionally, the FDA may impose other requirements on the protocol for our ProHema-03 trial or our other clinical trial protocols. These additional requirements may cause further delays in our ProHema-03 trial or other clinical development activities for ProHema, which could require us to incur additional development costs, seek funding for these increased costs or delay or cease our clinical development activities for ProHema. Any inability to advance ProHema or any other product candidate through clinical development would have a material adverse effect on our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be required to file new INDs to initiate clinical trials of ProHema for the treatment of hematologic malignancies and LSDs in pediatric patients.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We plan to conduct clinical trials of ProHema for hematopoietic reconstitution in both hematologic malignancies and LSDs in pediatric patients. We believe we can conduct these trials under our current IND for ProHema, and thus we may be able to file the appropriate amendments in order to commence these planned clinical trials. Although we currently believe that these amendments will suffice, we will need to submit clinical development plans to the FDA before we can commence these trials. The FDA may disagree with our plans and require us to file new INDs for the clinical evaluation of ProHema for the treatment of pediatric patients with hematologic malignancies and LSDs. If we are required to do so, this will delay our timeline, require additional resources and data and create uncertainty and additional complexity in our ability to obtain regulatory approval for these indications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our Wnt7a analogs are still in preclinical development, which may not be successful. If we are unable to successfully complete preclinical studies and clinical trials of our Wnt7a analogs, our business will be harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our Wnt7a analogs are still in preclinical development. To our knowledge, there are no Wnt proteins currently undergoing clinical development, primarily due to certain molecular characteristics that prevent their effective development as biologic therapeutics. Although we believe we are the first company to produce an analog of a Wnt protein that is amenable to manufacture, formulation and administration for <i>in vivo</i> therapeutic use, we may later encounter difficulties in manufacturing, formulating or administering of our Wnt7a analogs, or we may otherwise observe undesirable safety or efficacy profiles in these product candidates as our development activities progress. Subject to our selection of a lead candidate, the completion of IND-enabling studies and our pre-IND meeting with the FDA, we plan to file an IND with the FDA and initiate a Phase 1 clinical trial of a Wnt7a analog. If the results of our ongoing or future preclinical studies or clinical trials are not positive, or the FDA does not allow us to proceed with clinical development for any reason, we may delay or cancel our planned clinical development activities for our Wnt7a analogs, which could materially harm our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may face delays in completing our clinical trials, and we may not be able to complete them at all.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not completed the clinical trials necessary to support an application for approval to market any of our product candidates. Our current and future clinical trials of ProHema and our other product candidates may be delayed, unsuccessful or terminated as a result of many factors, including:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_113249_6952"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">delays in our ability to resume enrollment in our ProHema-03 trial;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the introduction of our NRM formulation into our ProHema-03 trial may not produce the benefits that we currently anticipate or may result in unanticipated adverse effects;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">delays in designing appropriate clinical trial protocols and reaching agreement on trial design with investigators and regulatory authorities;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">delays or failure in reaching agreement on acceptable clinical trial contracts or protocols with prospective sites;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">governmental or regulatory delays, failure to obtain regulatory approval or changes in regulatory requirements, policy or guidelines;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">reaching agreement on acceptable terms with third-party service providers to manage various aspects of our clinical trials, the terms of which can be subject to extensive negotiation and may vary significantly among different service providers and trial sites;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the actual performance of third-party service providers and clinical trial sites in ensuring the proper and timely conduct of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ability of clinical trial sites to manufacture ProHema consistently under the correct conditions at their on-site cell processing facilities for use in our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ability of third-party manufacturers to manufacture to the appropriate specifications the critical reagents necessary for the manufacture of ProHema;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="2" style="font-size:10.0pt;"> the commercial availability of other materials necessary for the manufacture of ProHema;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">delays in achieving study endpoints and completing data analysis for a trial;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">regulators or institutional review boards, or IRBs, may not authorize us to commence or recommence a clinical trial;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">data safety monitoring committees may recommend suspension, termination or a clinical hold for various reasons, including concerns about patient safety;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">regulators or IRBs may suspend or terminate the trial or impose a clinical hold for various reasons, including noncompliance with regulatory requirements or concerns about patient safety;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">patients with serious, life-threatening diseases included in our clinical trials may die or suffer other adverse medical events for reasons that may not be related to our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">participating patients may be subject to unacceptable health risks;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">patients may not complete clinical trials due to safety issues, side effects, or other reasons;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our product candidates may demonstrate a lack of safety or efficacy during clinical trials; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">changes in regulatory requirements and guidance may occur, which require us to amend clinical trial protocols to reflect these changes.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA has indicated that we will need to standardize the process for manufacturing ProHema across the multiple cell processing facilities at the clinical sites participating in our trials, and any delays in, or inability to, establish manufacturing protocols acceptable to the FDA will result in further delays to our clinical development plans. Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Moreover, our development costs will increase because we will be required to complete additional or larger clinical trials for product candidates from our HSC and SSC modulation platforms prior to FDA or other regulatory approval. We may not have adequate capital or other resources to commence or complete these additional or larger trials. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed. In addition, any delays in commencing or completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any of these occurrences may significantly harm our business, financial condition and prospects.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_113330_9801"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will be required to identify and enroll a sufficient number of patients with the disease under investigation for each of our ongoing and planned clinical trials of our product candidates. Each indication for which we plan to evaluate our current product candidates represents a rare disease or condition with limited patient populations from which to draw participants in clinical trials. Due to our focus on the development of product candidates for the treatment of orphan hematologic malignancies, rare genetic diseases and muscular dystrophies, we may not be able to identify and enroll a sufficient number of patients, or those with required or desired characteristics and criteria, in a timely manner. In addition, there are currently only a limited number of specialized transplant centers that perform HSCTs, and among physicians who perform HSCTs, some may not choose to perform these procedures under conditions that fall within our protocols, which would have an adverse effect on our development of ProHema. Our ability to enroll patients in our clinical trials is affected by factors including:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">severity of the disease under investigation;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">design of the trial protocol;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the relatively small size and nature of the patient population;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">eligibility criteria for the trial in question;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">perceived risks and benefits of the product candidate under study;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">availability of competing therapies and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">efforts to facilitate timely enrollment in clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the availability of time and resources at the limited number of institutions at which clinical trials are and will be conducted;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ability to identify, solicit and recruit a sufficient number of patients;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ability to monitor patients adequately during and after treatment; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the proximity and availability of clinical trial sites for prospective patients.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Results from preclinical studies and earlier clinical trials do not ensure that future clinical trials will be successful.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of our product candidates are still in an early stage of development, and we cannot be assured that these trials will ultimately be successful. For example, although the results of our Phase 1b clinical trial of ProHema in adults with hematologic malignancies undergoing double umbilical cord blood transplant demonstrated human proof-of-concept, we may not achieve or duplicate these results in our ProHema-03 trial or planned additional clinical trials of ProHema for a variety of reasons, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the anticipated use of our NRM formulation may not produce the potency and efficacy benefits observed in preclinical studies, or may result in unanticipated side effects in comparison to the standard processing media used in our Phase 1b clinical trial;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the increase in the number of patients enrolled in later-stage trials may not produce the same or similar results as earlier trials with fewer patients;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the expansion in the number of participating clinical centers and the variabilities among the centers may result in complexities in conducting clinical trials, which we may be unable to manage adequately;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">we may be unable to ensure the consistent manufacture of ProHema, which is required to be manufactured at cell processing facilities at each clinical center, across all participating clinical centers once we resume our ProHema-03 trial or in any future clinical trials that we may conduct;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">differences in the design of the Phase 2 clinical trial, such as additional conditioning regimens, expanded eligibility criteria, potential patient population changes based on additional clinical centers that are more geographically dispersed, the addition of a concurrent control arm and our efforts to standardize and automate our ProHema manufacturing process to make it acceptable to FDA for entry into Phase 2 clinical trials may make it less effective than the product manufactured during our Phase 1b trial or otherwise adversely affect ProHema; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">we have not previously evaluated ProHema in pediatric patients, and pediatric patients may experience side effects or other adverse events not observed in adult patients.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:28.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, because our Wnt7a analogs are still in preclinical development, we cannot assure you that any product candidates selected from our SSC modulation platform will demonstrate the safety, purity and potency profile necessary to support further clinical development or regulatory approval.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_113403_2440"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stages of development. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily predict final results. Even if early stage clinical trials are successful, we may need to conduct additional clinical trials for product candidates in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to demonstrate the required characteristics to support marketing approval for our product candidates in our planned and future clinical trials would substantially harm our business and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our planned clinical development activities for ProHema present operational, technical and timing issues related to pediatric clinical trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many clinical centers that could potentially participate in our pediatric clinical trials of ProHema are distinct and separate from the centers participating in our adult trials, and finding sufficient, capable centers that would be interested in participating in our pediatric trials may take additional time. There will be fewer eligible patients with hematologic malignancies and rare genetic disorders for our planned clinical trials in pediatric patients because the total number of pediatric patients with such diseases and disorders is lower than it is in adults. This may increase the time to enroll our planned pediatric clinical trials in hematologic malignancies and rare genetic disorders and could also further limit our ability to enroll patients in our planned Phase 1 clinical trial of ProHema in pediatric patients.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As we have not previously evaluated ProHema in pediatric patients, we will have to modify the current formulation of ProHema to one that is suitable for children, due to their smaller size and requirement for smaller infusion volume. Such a modification will require an amendment to our current IND or the filing of a new IND and may present technical challenges and may cause further delays in our planned clinical trial. In addition, any such IND amendment or new IND will require FDA review and approval of our modified formulation of ProHema for children. The FDA will need to review and approve our specific clinical plans in pediatric hematologic malignancies and rare genetic disorders, and may present additional requirements, including additional data in adult patients, before we can proceed with our planned pediatric clinical trials. Any delays in our planned clinical development activities for pediatric patients could have an adverse effect on our business operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to rely heavily on orphan drug status to develop and commercialize our product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected commercial benefits.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to rely heavily on orphan drug exclusivity for our product candidates, including ProHema. Orphan drug status confers seven years of marketing exclusivity under the Federal Food, Drug, and Cosmetic Act, and up to ten years of marketing exclusivity in Europe for a particular product in a specified indication. We have been granted orphan drug designation in the United States for human allogeneic HSCs <i>ex vivo</i> modulated with FT1050 for the enhancement of stem cell engraftment and in the European Union for ProHema for the treatment of acute myelogenous leukemia through the <i>ex vivo</i> modulation of allogeneic umbilical cord blood cells. While we have been granted these orphan designations, we will not be able to rely on these designations to exclude other companies from manufacturing or selling biological products using the same principal molecular structural features for the same indication beyond these timeframes. Furthermore, the marketing exclusivity in Europe can be reduced from ten years to six years if the initial designation criteria have significantly changed since the market authorization of the orphan product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For any product candidate for which we have been granted orphan drug designation in a particular indication, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#146;s period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to the orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, qualification testing, post-approval clinical data, labeling and promotional activities for such product, will be subject to continual and additional requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information, reports, registration and listing requirements, good</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_113454_5340"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manufacturing practices, or GMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical and biological products to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved labeling.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, later discovery of previously unknown problems with our products, manufacturing processes, or failure to comply with regulatory requirements, may lead to various adverse results, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on such products, manufacturers or manufacturing processes;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on the labeling or marketing of a product;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">restrictions on product distribution or use;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">requirements to conduct post-marketing clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">requirements to institute a risk evaluation and mitigation strategy, or REMS, to monitor safety of the product post-approval;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">requirements to individually license clinical cell processing facilities for the manufacture of ProHema;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">warning letters issued by the FDA or other regulatory authorities;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">withdrawal of the products from the market;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">recall of products, fines, restitution or disgorgement of profits or revenue;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">suspension, revocation or withdrawal of marketing approvals;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">refusal to permit the import or export of our products; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">injunctions or the imposition of civil or criminal penalties.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to certain regulations, including federal and state healthcare fraud and abuse laws and health information privacy and security laws. Any failure to comply with these regulations could have a material adverse effect on our business and financial condition.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal anti-kickback statute. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_113528_9995"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to product candidates granted breakthrough therapy or fast track designation by the FDA.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are evaluating the possibility of seeking breakthrough therapy or fast track designation for some of our product candidates, although we may elect not to do so. A breakthrough therapy program is for a product candidate intended to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement on a clinically significant endpoint(s)&nbsp;over available therapies. In contrast, a fast track program is for a product candidate that treats a serious or life-threatening condition, and nonclinical or clinical data demonstrate the potential to address an unmet medical need. Although we believe some of our product candidates may qualify under either or both of the breakthrough therapy and fast track programs, we may elect not to pursue either of these programs, and the FDA has broad discretion whether or not to grant these designations. Accordingly, even if we believe a particular product candidate is eligible for breakthrough therapy or fast track designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive breakthrough therapy or fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw breakthrough therapy or fast track designation if it believes that the product no longer meets the qualifying criteria. In addition, the breakthrough therapy program is a relatively new program. As a result, we cannot be certain whether any of our product candidates can or will qualify for breakthrough therapy designation. Our business may be harmed if we are unable to avail ourselves of these or any other expedited development and regulatory pathways.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:4.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on third-party suppliers for various components of our improved NRM formulation for the manufacture of ProHema and do not have supply arrangements for certain of these components to complete clinical development.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently rely, and expect to continue to rely, on third-party suppliers for components that enable us to develop and use our NRM formulation for the manufacture of ProHema in our Phase&nbsp;2 clinical trial and any subsequent clinical trials. We have not entered into supply agreements for certain of the components necessary to produce our NRM formulation and may not be able to obtain clinical supply agreements that provide for an adequate and reliable supply of these components to complete our planned clinical development of ProHema through to commercialization. Even if we are able to secure such clinical supply agreements, we may be limited to a sole manufacturer for certain of the components required in our NRM formulation. Accordingly, we cannot guarantee that we will have an adequate supply of NRM to complete our planned clinical development of ProHema, including our Phase&nbsp;3 clinical trial or any other future clinical trials. In addition, if we are unable to secure adequate quantities of these components from our preferred suppliers, we may be required to identify alternate suppliers of these components, or to modify our NRM formulation. If we are required to change suppliers of our components, or modify our NRM formulation, the efficacy and potency of ProHema may be adversely affected. We also may be required to make further changes to our trial protocol or provide additional data to the FDA regarding the use of alternative components for our NRM formulation or a modified NRM formulation, which could delay our clinical development plans for ProHema and increase the costs required to complete our planned clinical development of ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on a single third-party supplier for the FT1050 starting material required for the manufacture of ProHema and depend on third-party suppliers for other components necessary for the manufacture of ProHema.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have obtained our supplies of 16, 16-dimethyl prostaglandin E2, which we refer to as FT1050, for the manufacture of ProHema in our preclinical studies and clinical trials from a single third-party manufacturer. This manufacturer supplies FT1050 to us for our clinical trials on a purchase order basis under a clinical supply manufacturing agreement, and we do not have any current contractual relationships for the commercial manufacture and supply of bulk FT1050 substance for manufacturing ProHema. Additionally, to date, we have acquired or our clinical cell processing facilities have acquired other equipment, materials and disposables necessary for the manufacture of ProHema from third parties.&#160; These materials include but are not limited to automated cell washing devices, automated cell warming units, commercially available media, cord blood transfer and wash sets, and other disposables. We do not have any current contractual relationships for the commercial supply of these materials for manufacturing ProHema and rely on their general commercial availability.&#160;&#160; Although we believe that we have alternate suppliers for FT1050 and the other components necessary for the manufacture of ProHema should our current third-party manufacturers or suppliers become unavailable to us for any reason, we may incur delays associated with identifying and qualifying replacement suppliers and negotiating the terms of any supply contracts with the replacement suppliers. These delays could adversely impact our clinical development plans and harm our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_113536_6763"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face a variety of challenges and uncertainties associated with our dependence on the availability of human umbilical cord blood units, or CBUs, at cord blood banks for the manufacture of ProHema.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CBUs are one of the raw materials for the manufacture of ProHema. The CBUs currently used in the manufacture of ProHema are procured directly by the clinical cell processing facilities from cord blood banks. The availability of CBUs for the manufacture of ProHema depends on a number of regulatory, political, economic and technical factors outside of our control, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">government policies relating to the regulation of CBUs for clinical use;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the availability of government funding for cord blood banks;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">individual cord blood bank policies and practices relating to CBU acquisition and banking;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the pricing of CBUs;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the methods used in searching for and matching CBUs to patients, which involve emerging technology related to current and future CBU parameters that guide the selection of an appropriate CBU for transplantation; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">methods for the procurement and shipment of CBUs and their handling and storage at clinical sites.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, we do not have control over the supply, availability, price or types of CBUs that these third parties use in the manufacture of ProHema. We rely heavily on these clinical cell processing facilities to procure CBUs from cord blood banks that are compliant with government regulations and within the current standard of care. In addition, we may identify specific characteristics of CBUs, such as their volume and red blood cell content, that may limit their ability to be used to manufacture ProHema even though these CBUs may otherwise be suitable for use in allogeneic transplant. As a result, the requirement for CBUs to meet our specifications may limit the potential inventory of CBUs eligible for use in the manufacture of ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States, cord blood banks are required to file a biologics license application, or BLA, and to meet certain continued regulatory requirements, in order to bank and provide CBUs for transplantation. CBUs from a cord blood bank that maintains a BLA are considered to be licensed and have a product label describing their intended use. While the FDA currently allows unlicensed CBUs to be used for transplantation and we have only used unlicensed CBUs in the manufacture of ProHema for our clinical trials, the FDA may later prohibit the use of unlicensed CBUs for transplantation. Additionally, although CBUs from foreign cord blood banks, which are generally unlicensed, are currently available in the United States for use in transplantation and we have used CBUs from foreign cord blood banks in our clinical trials, changes in U.S. and foreign regulations may prohibit or limit the future use of foreign CBUs in the United States. Any inability to procure adequate supplies of CBUs will adversely impact our ability to develop and commercialize ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on facilities operated by transplant centers for the manufacture of ProHema under specific conditions. Any failure by these facilities to manufacture ProHema consistently and under the proper conditions may result in delays to our clinical development plans and impair our ability to commercialize ProHema, if approved.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ProHema is currently manufactured at clinical cell processing facilities operated by or affiliated with our clinical sites and is required to be manufactured in close proximity to the treatment site on the same day as product administration. The FDA has stated that we will be required to standardize the manufacture of ProHema to maximize consistency across the multiple clinical cell processing facilities, including our oversight for facility and raw material and vendor qualification through to final product analytical testing and release. Although we are responsible for ensuring compliance with GMPs and for overseeing all aspects of product manufacture and release prior to applying for marketing approval, we do not control the activities of these third-party cell processing facilities. The clinical cell processing facilities at which ProHema is manufactured must be approved by applicable regulatory authorities, including the FDA, pursuant to inspections that will be conducted after a BLA, or comparable foreign regulatory marketing application is submitted. We do not control the manufacturing process for ProHema and are completely dependent on third parties for compliance with the FDA&#146;s requirements and proper execution of the protocol for the manufacture of ProHema. Because of the requirement that ProHema be manufactured in close proximity to the transplant center within a short period of time before transplant, if the applicable clinical cell processing facilities are unable to manufacture ProHema in a manner that conforms to our specifications and the FDA&#146;s strict regulatory requirements, we will not be able to secure backup manufacturing capabilities. For example, to comply with GMPs and other regulatory requirements and our manufacturing protocols, the clinical cell processing facility may be required to possess or obtain certain equipment necessary for the manufacture of ProHema including but not limited to biosafety cabinets, warming devices, cell washing devices, freezers or other materials; or to modify aspects of its operations, including its physical facility or layout, environmental systems, monitoring systems, quality systems or training procedures, for the compliant manufacture of ProHema. Clinical cell</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_113545_158"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\107907\13-22691-1\task6364320\22691-1-ga.htm',USER='107907',CD='Nov 12 12:19 2013' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">processing facilities may be unwilling or unable to comply with these requirements, which could restrict or prohibit a given clinical center from manufacturing ProHema and making it available for administration to patients within the required timeframes. Any failure by these clinical cell processing facilities to properly manufacture ProHema will have an adverse impact on our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will be substantially dependent on third parties for the manufacture of our clinical supplies of our Wnt7a analogs.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to rely on third-party manufacturers for clinical supplies of our Wnt7a analogs and other product candidates that we may develop. These third-party manufacturers will be required to comply with current GMPs and other applicable laws and regulations. We will have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of these third parties for the manufacture of our other product candidates or any products that we may successfully develop, or if it withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all. In addition, Wnt proteins have specific molecular characteristics that make their manufacture for therapeutic application difficult, and it is possible that any third-party manufacturers that we engage may experience difficulties in such manufacture. Any of these factors would significantly impact our ability to develop, obtain regulatory approval for or market our Wnt7a analogs and adversely affect our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We currently rely on third parties to support the conduct of our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have relied upon and expect to continue to rely upon third parties to monitor and manage data for our ongoing and planned clinical programs. We rely on these parties for execution of our clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and our third-party service providers are required to comply with good clinical practices, or GCP, which are regulations and guidelines enforced by the FDA, as well as comparable foreign regulations and guidelines, for all of our product candidates in clinical development. Regulatory authorities enforce these GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party service providers or clinical trial sites fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under applicable GMP requirements. We also rely on third parties to assist in conducting our preclinical studies, including IND-enabling studies, in accordance with good laboratory practices, or GLP.&#160; Failure by our third-party services providers to comply with applicable legal, regulatory or scientific standards in our clinical trials or our preclinical studies may require us to repeat nonclinical and clinical trials or preclinical studies, which would delay the regulatory approval process.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our third-party service providers are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical and nonclinical programs. If third-party service providers do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party service providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_113655_5753"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">affected. Although we carefully manage our relationships with our third-party service providers, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we lose our relationships with our third-party service providers, our product development efforts could be&nbsp;delayed.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on third-party service providers for clinical trials related to our product development efforts. Switching or adding additional third-party service providers involves additional cost and timing considerations and requires management time and focus. Some of our third-party service providers have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our third-party service providers have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. In addition, there is a natural transition period when a new service provider commences work and the new provider may not provide the same type or level of services as the original provider. If any of our relationships with our third-party service providers terminate, we may not be able to enter into arrangements with alternative service providers or to do so on commercially reasonable terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates, the processes used to manufacture them and the methods for using them, as well as successfully defending these patents against third-party challenges. We are currently the owner of record of 14 patent applications pending in the United States and in certain foreign jurisdictions relating to ProHema and other therapeutic compositions of stem cells that have been pharmacologically modulated to enhance their therapeutic properties, and methods of manufacturing the cellular compositions. In addition, we currently own ten patent applications pending in the United States and in certain foreign jurisdictions relating to our Wnt analogs, covering compositions of matter, processes for preparing such Wnt proteins and formulations, and the modulation of SSCs. To date, no patents have been issued to us specifically covering our product candidates, and we cannot be certain that any patents will issue with claims that cover our ProHema and Wnt product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in foreign jurisdictions outside of the United States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents that may be issued from the applications we currently or may in the future own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">others may be able to develop a platform similar to, or better than, ours in a way that is not covered by the claims of our patents;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">others may be able to make therapeutics or compounds that are similar to our product candidates, but that are not covered by the claims of our patents;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_113725_1002"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">we might not have been the first to make the inventions covered by our pending patent applications;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">we might not have been the first to file patent applications for these inventions;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our pending patent applications may not result in issued patents;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the claims of our issued patents or patent applications when issued may not cover our products or product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">any patents that we obtain may not provide us with any competitive advantages;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">any granted patents may be held invalid or unenforceable as a result of legal challenges by third parties;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">we may not develop additional proprietary technologies that are patentable; or</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the patents of others may have an adverse effect on our business.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on our licensors to prosecute and maintain patents and patent applications that are material to our business. Any failure by our licensors to effectively protect these intellectual property rights could adversely impact our business and operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are currently the exclusive licensee of 45 issued or pending U.S. and non-U.S. patents or patent applications relating to ProHema and other therapeutic compositions of stem cells that have been pharmacologically modulated to enhance their therapeutic properties, methods of manufacturing the cellular compositions, and methods of promoting hematopoietic reconstitution, expansion and self-renewal using modulators that increase prostaglandin signaling activity.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have exclusive licenses to 18 patents and patent applications relating to our Wnt analogs, covering compositions of matter, processes for preparing such Wnt proteins and formulations, and the modulation of SSCs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a licensee of third parties, we rely on these third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Due to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of our product candidates or methods involving these candidates in the parent patent application.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us. For example, under our exclusive license agreements with various universities and research institutions, we are required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products, and must satisfy specified milestone and royalty payment obligations. If we fail to comply with our obligations under our agreements with any of these licensors, we may be subject to termination of the license agreement in whole or in part, increased financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop or commercialize products covered by the license agreement will be impaired. Additionally, we may be subject to royalty obligations to multiple licensors with respect to the same product.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_113753_1031"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our diligence obligations under the license agreement and what activities satisfy those obligations;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">if a third party expresses interest in an area under a license that we are not pursuing, under the terms of certain of our license agreements, we may be required to sublicense rights in that area to a third party, and that sublicense could harm our business; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule&nbsp;that such patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#146;s activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by the U.S. Patent and Trademark Office, or USPTO, in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We cannot guarantee that our products, or manufacture or use of our product candidates, will not infringe third-party patents. Furthermore, a third party may claim that we are using inventions covered by the third party&#146;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third party&#146;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of the relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#146;s patents. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_113819_2846"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">some patent applications in the United States may be maintained in secrecy until the patents are issued;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">patent applications in the United States are typically not published until 18 months after the priority date; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">publications in the scientific literature often lag behind actual discoveries.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours that claims priority to an application filed prior to March&nbsp;16, 2013, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. In addition, changes enacted on March&nbsp;15, 2013 to the U.S. patent laws resulted in the United States changing from a &#147;first to invent&#148; country to a &#147;first to file&#148; country. As a result, we may lose the ability to obtain issued patent if a third party files with the patent office first. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Furthermore, some of our license agreements require us to notify, and in some cases license back to the licensor, certain additional proprietary information or intellectual property that we developed using the rights licensed to us under these agreements. Any such licenses back to the licensor could allow our licensors to use that proprietary information or intellectual property in a manner that could harm our business. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_113828_457"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Commercialization of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have no experience selling and marketing any products. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. If any of our initial product candidates are approved for marketing, we intend to build an internal sales and marketing organization to commercialize these products in highly specialized target markets, where patient and physician communities are concentrated and product adoption is driven by key opinion leaders. However, we may not have adequate financial resources or expertise to build an effective sales and marketing organization.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may selectively seek to enter into partnerships with other entities to utilize their marketing and distribution capabilities in larger target markets, but we may be unable to enter into these arrangements on favorable terms, if at all. If we are unable to develop adequate marketing capabilities on our own or effectively partner with third parties, we will be unable to generate revenues from our approved products. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The commercial success of any current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ethical, social and legal concerns about stem cell therapies could result in additional regulations restricting or prohibiting the use of our product candidates. Even with the requisite approvals, the commercial success of our product candidates will depend in part on the medical community, patients and third-party payers accepting stem cell therapies in general, and our product candidates in particular, as medically useful, cost-effective and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payers and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the potential efficacy and other advantages over alternative treatments;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#146;s approved labeling;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the prevalence and severity of any side effects resulting from the chemotherapy and myeloablative treatments associated with the procedure by which ProHema or any other HSC therapeutics that we may develop are administered;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">relative convenience and ease of administration;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the willingness of the target patient population to try new therapeutics and of physicians to prescribe these therapeutics;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the strength of marketing and distribution support and timing of market introduction of competitive products;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">publicity concerning our products or competing products and treatments; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">sufficient third-party insurance coverage or reimbursement.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payers on the benefits of our product candidates may require significant resources and may never be successful. Any failure to achieve market acceptance for our product candidates will harm our business, results and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If any of our product candidates are approved for commercialization, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">different regulatory requirements for approval of drugs and biologics in foreign countries;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">reduced or uncertain protection for our intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_113846_2959"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">complexity and difficulty in coordinating the communications and operations of our business; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to face uncertainty regarding the pricing of ProHema and any other product candidates that we may develop. If pricing policies for our product candidates are unfavorable, our commercial success will be impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Due to the targeted indication of HSCT procedures in general and our HSC product candidates in particular, we face significant uncertainty as to the pricing of any such products for which we may receive marketing approval. While we anticipate that pricing for these candidates will be relatively high due to their anticipated use in a one-time, potentially life-saving procedure with curative intent, the biopharmaceutical industry has recently experienced significant pricing pressures, including in the area of orphan drug products. Additionally, because our target patient populations are relatively small, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. In addition, there are currently no approved products for the treatment of muscular dystrophies, and it is difficult to predict the level of reimbursement, if any, that would be available for any product candidates that we may develop in these indications. If pricing is set at unsatisfactory levels, our ability to successfully market and sell our product candidates will be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly in the area of orphan drug products, has become very intense. These pricing pressures have imposed significant barriers to the entry of new products.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates, which may adversely affect our ability to generate profit from the sales of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new products could limit our ability to market any product that we may develop and decrease our ability to generate revenue.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments, such as stem cell transplants. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In particular, there is no body of established practices and precedents for reimbursement of modulated stem cell products, and it is difficult to predict what the regulatory authority or private payer will decide with respect to reimbursement levels for novel products such as ours. Our products may not qualify for coverage or direct reimbursement and may be subject to limited reimbursement. Stem cell transplant procedures are typically covered by one-time reimbursement, generally available for a limited number of days after transplant. If reimbursement or insurance coverage is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be sufficient to allow us to establish or maintain pricing to generate income.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_113855_3821"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, reimbursement agencies in foreign jurisdictions may be more conservative than those in the United States. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Failure to obtain or maintain adequate reimbursement for any products for which we receive marketing approval will adversely impact our ability to achieve commercial success.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If the market opportunities for our product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer. Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and capture a significant market share to achieve and maintain profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We focus our research and product development on treatments for orphan hematologic malignancies, rare genetic disorders and muscular dystrophies. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Additionally, because our target patient populations are small, we will be required to capture a significant market share to achieve and maintain profitability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Business and Industry</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The success of our HSC and SSC modulation platforms and our product candidates is substantially dependent on developments within the emerging field of stem cell therapies, some of which are beyond our control.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our HSC and SSC modulation platforms and our product candidates are designed to optimize the biological activity of adult stem cells, which represents a novel development within the field of stem cell therapeutics. Stem cell therapies in turn represent a relatively new therapeutic area that presents a number of scientific, clinical, regulatory and ethical challenges. Any adverse developments in the field of stem cell therapeutics generally, and in the practice of HSCT in particular, will negatively impact our ability to develop and commercialize our product candidates. In particular, we currently anticipate that ProHema and any additional product candidates that we develop from our HSC modulation platform would be adopted into the current standard of care for HSCT procedures. If the market for HSCT procedures declines or fails to grow at anticipated levels for any reason, or if the development and commercialization of therapies targeted at the underlying cause of diseases addressed by ProHema obviate the need for patients to undergo HSCT procedures, our business prospects will be significantly harmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:25.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We face competition from major multinational pharmaceutical companies, established and early-stage biotechnology companies, and universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection or FDA approval or discovering, developing and commercializing treatments in the rare disease indications that we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There are several clinical-stage development programs that seek to improve human umbilical cord blood transplantation through the use of <i>ex vivo</i> expansion technologies to increase the quantity of HSCs for use in HSCT or the use of <i>ex vivo</i> differentiation technologies to increase the quantity of hematopoietic progenitor cells for use in HSCT. Although there are currently no approved pharmaceutical products specifically for the treatment of muscular dystrophies, we are aware of several other companies with product candidates in various stages of development for the treatment of muscular dystrophies. In addition, many universities and private and public research institutes may develop technologies of interest to us, but license them to our competitors. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products that are more effective or less costly than ProHema or any other product candidates that we are currently developing or that we may develop, which could render our products obsolete and noncompetitive.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_113918_3011"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe that our ability to successfully compete will depend on, among other things:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the results of our preclinical studies and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to recruit and enroll patients for our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the efficacy, safety and reliability of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the speed at which we develop our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to design and successfully execute appropriate clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to protect and develop intellectual property rights related to our products;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain a good relationship with regulatory authorities;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the timing and scope of regulatory approvals, if any;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to commercialize and market any of our product candidates that receive regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">market perception and acceptance of stem cell therapeutics;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">acceptance of our product candidates by physicians and institutions that perform HSCTs;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the price of our products;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">our ability to manufacture and sell commercial quantities of any approved products to the market.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If our competitors market products that are more effective, safer or less expensive than our future products, if any, or that reach the market sooner than our future products, if any, we may not achieve commercial success. Any inability to successfully compete effectively will adversely impact our business and financial prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As we increase the number of ongoing product development programs and advance our product candidates through preclinical studies and clinical trials, we will need to increase our product development, scientific and administrative headcount to manage these programs. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-align:justify;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">successfully attract and recruit new employees or consultants with the requisite expertise and experience;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-align:justify;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">manage our clinical programs effectively;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">if we receive regulatory approval for any product candidate, develop a marketing and sales infrastructure; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">continue to improve our operational, financial and management controls, reporting systems and procedures, including those related to being a public company.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of Christian Weyer, our President and Chief Executive Officer; J. Scott Wolchko, our Chief Financial Officer and Chief Operating Officer; Pratik&nbsp;S. Multani, our Chief Medical Officer; Daniel D. Shoemaker, our Chief Technology Officer; and Peter Flynn, our Senior Vice President, Early Program Development. If we lose one or more of our executive officers or key consultants, our ability to implement our business strategy successfully could be seriously</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_114537_9487"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">harmed. While we have entered into employment contracts with each of our executive officers, any of them could leave our employment at any time, as all of our employees are at-will employees. Replacing key personnel and consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We rely on our scientific founders and other scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. In particular, if we are unable to maintain consulting relationships with our scientific founders or if they provide services to our competitors, our development and commercialization efforts will be impaired and our business will be significantly harmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of disclosure controls and procedures and internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, we are required to comply with the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, and the related rules&nbsp;and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot assure that we will not have material weaknesses or significant deficiencies in our internal control over financial reporting. If we are unable to successfully remediate any material weakness or significant deficiency in our internal control over financial reporting, or identify any material weaknesses or significant deficiencies that may exist, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have begun implementing our system of internal controls over financial reporting and preparing the documentation necessary to perform the evaluation needed to comply with Section&nbsp;404(a)&nbsp;of the Sarbanes-Oxley Act. However, we will need to retain additional finance capabilities and build our financial infrastructure as we begin operating as a public company, including complying with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and continuing to improve our financial infrastructure with the retention of additional financial and accounting capabilities, the enhancement of internal controls and additional training for our financial and accounting staff. Management oversight will be required as part of the process and as a result, management&#146;s attention may be diverted from other business concerns, which could harm our business and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, products liability and directors&#146; and officers&#146; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time we have considered, and we will continue to consider in the future, strategic business initiatives intended to further the expansion and development of our business. These initiatives may include acquiring businesses, technologies or products or entering into a business combination with another company. If we pursue such a strategy, we could, among other things:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">issue equity securities that would dilute our current stockholders&#146; percentage ownership;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">incur substantial debt that may place strains on our operations;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">spend substantial operational, financial and management resources to integrate new businesses, technologies and products;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45<a name="PB_45_114553_9799"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='45',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-gc.htm',USER='107993',CD='Nov 12 07:41 2013' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">assume substantial actual or contingent liabilities;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">reprioritize our development programs and even cease development and commercialization of our product candidates; or</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company on terms that certain of our stockholders may not deem desirable.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements or understandings with respect to any acquisition, reorganization or business combination at this time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face potential product liability and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by participants in clinical trials, consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates and any products for which we obtain marketing approval. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">impairment of our business reputation;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">withdrawal of clinical trial participants;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">costs due to related litigation;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">distraction of management&#146;s attention from our primary business;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">substantial monetary awards to patients or other claimants;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the inability to commercialize our product candidates; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">decreased demand for our product candidates, if approved for commercial sale.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We carry product liability insurance of $5.0 million per occurrence and $5.0 million aggregate limit. We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. In addition, under some of our agreements with clinical trial sites, we are required to indemnify the sites and their personnel against product liability and other claims. A successful product liability claim or series of claims brought against us or any third parties whom we are required to indemnify could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our development and commercialization efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46<a name="PB_46_114649_4015"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='46',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We use hazardous chemicals, biological materials and infectious agents in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our research and development and manufacturing processes involve the controlled use of hazardous materials, including chemicals, biological materials and infectious disease agents. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research, development and production efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our business is subject to the risks of earthquakes, fire, power outages, floods and other catastrophic events, and to interruption by manmade problems such as terrorism.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A significant natural disaster, such as an earthquake, fire or a flood, or a significant power outage could have a material adverse impact on our business, operating results and financial condition. Our corporate headquarters are located in San Diego, California, a region known for seismic activity. In addition, natural disasters could affect our third-party service providers&#146; ability to perform services for us on a timely basis. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for, and to commercialize, our product candidates may be delayed or prevented. In addition, if a catastrophe such as an earthquake, fire, flood or power loss should affect one of the third parties on which we rely, our business prospects could be harmed. For example, if a central laboratory holding all of our clinical study samples were to suffer a catastrophic loss of their facility, we would lose all of our samples and would have to repeat our studies. In addition, acts of terrorism could cause disruptions in our business or the business of our third-party service providers, partners, customers or the economy as a whole.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA or foreign regulators, provide accurate information to the FDA or foreign regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47<a name="PB_47_114706_1605"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='47',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Market volatility may affect our stock price and the value of your investment.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market price of shares of our common stock could be subject to wide fluctuations as a result of many risks listed in this section, and others beyond our control, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the timing of the initiation or completion of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the results of our clinical trials and preclinical studies;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the results of clinical trials of our competitors&#146; product candidates or of other stem cell therapeutics in general;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">developments concerning our owned or licensed intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">changes in laws or regulations applicable to stem cell therapeutics generally or our product candidates in particular, including but not limited to clinical trial requirements for approvals;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">changes in the markets for HSCT products and in the field of stem cell therapeutics, or changes in the markets for the treatment of muscular dystrophies and other diseases targeted by our product candidates;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">actual or anticipated fluctuations in our financial condition and operating results;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">actual or anticipated changes in our growth rate relative to our competitors;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">competition from existing products or new products that may emerge;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">issuance of new or updated research or reports by securities analysts;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">additions or departures of key management or scientific personnel;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">announcements or expectations of additional debt or equity financing efforts;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">sales of our common stock by us, our insiders or our other stockholders; and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-5.75pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">general economic and market conditions.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general, and The NASDAQ Global Market and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our principal stockholders exercise significant control over our company.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on shares outstanding as of September&nbsp;30, 2013, and after giving effect to our initial public offering on October&nbsp;4, 2013, our executive officers, directors and entities affiliated with our five percent stockholders beneficially own, in the aggregate, shares representing approximately 62% of our outstanding voting stock. Although we are not aware of any voting arrangements in place among these stockholders, if these stockholders were to choose to act together, as a result of their stock ownership, they would be able to influence our management and affairs and control all matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our common stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">48<a name="PB_48_114724_1629"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='48',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause our stock price to decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Approximately 12.4 million shares will be eligible for sale by our shareholders in the public market upon the expiration of lock-up agreements in March&nbsp;2014, although a portion of such shares held by our affiliates will be subject to volume limitations and other conditions pursuant to Rule&nbsp;144 of the Securities Act. In addition, the shares subject to outstanding options under our equity incentive plans and the shares reserved for future issuance under our equity incentive plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. Moreover, after March&nbsp;2014, certain holders of our common stock will have the right to require us to register these shares under the Securities Act pursuant to an investor rights agreement. If our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We will have broad discretion in how we use our existing cash, including the proceeds from our IPO. We may not use our existing cash effectively, which could affect our results of operations and cause our stock price to decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will have considerable discretion in the application of our existing cash, including the net proceeds from our IPO.&#160; We expect to use our existing cash to fund research and development activities and for working capital and general corporate purposes, including funding the costs of operating as a public company.&#160; We may use these proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest our cash resources in a manner that does not produce income or that loses value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Being a public company will increase our expenses and administrative burden.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, we will incur significant legal, insurance, accounting and other expenses that we did not incur as a private company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, laws, regulations and standards applicable to public companies relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and related regulations implemented by the SEC and The NASDAQ Stock Market, are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, and could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from product development activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. Further, it will be more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Provisions of Delaware law or our charter documents could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for you to change management.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws, which will be effective upon the completion of this offering, may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or delay attempts by stockholders to replace or remove our current management or members of our board of directors. These provisions include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">a classified board of directors with limitations on the removal of directors;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">advance notice requirements for stockholder proposals and nominations;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the inability of stockholders to act by written consent or to call special meetings;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the ability of our board of directors to make, alter or repeal our amended and restated bylaws: and</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine.</font></p>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-6.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The affirmative vote of the holders of at least 75% of our shares of capital stock entitled to vote, and not less than 75% of the outstanding shares of each class entitled to vote thereon as a class, is generally necessary to amend or repeal the above provisions that are contained in our amended and restated certificate of incorporation. In addition, absent approval of our board of directors, our amended and restated bylaws may only be amended or repealed by the affirmative vote of the holders of at least 75% of our shares of capital stock entitled to vote.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49<a name="PB_49_114747_4102"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='49',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which limits business combination transactions with stockholders of 15% or more of our outstanding voting stock that our board of directors has not approved. These provisions and other similar provisions make it more difficult for stockholders or potential acquirers to acquire us without negotiation. These provisions may apply even if some stockholders may consider the transaction beneficial to them.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a result, these provisions could limit the price that investors are willing to pay in the future for shares of our common stock. These provisions might also discourage a potential acquisition proposal or tender offer, even if the acquisition proposal or tender offer is at a premium over the then-current market price for our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are an &#147;emerging growth company&#148; and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an &#147;emerging growth company&#148; until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (ii)&nbsp;December&nbsp;31, 2018; (iii)&nbsp;the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules&nbsp;of the SEC. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The trading market for our common stock will rely in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common stock could decline significantly if one or more equity analysts downgrade our common stock or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We currently do not intend to pay dividends on our common stock and, consequently, an investor&#146;s only opportunity to achieve a return on the investment is if the price of our common stock appreciates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently do not plan to declare dividends on shares of our common stock in the foreseeable future. Consequently, an investor&#146;s only opportunity to achieve a return on the investment in us will be if the market price of our common stock appreciates and the investor sells shares at a profit. There is no guarantee that the price of our common stock in the market will ever exceed the price that an investor paid.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards may be subject to limitation and may result in increased future tax liability to us.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Generally, a change of more than 50% in the ownership of a corporation&#146;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit a company&#146;s ability to use its net operating loss carryforwards attributable to the period prior to such change. We have not performed a detailed analysis to determine whether an ownership change under Section&nbsp;382 of the Internal Revenue Code has occurred after each of our previous private placements of preferred stock or after the issuance of shares of common stock in connection with our initial public offering. In the event we have undergone an ownership change under Section&nbsp;382, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50<a name="PB_50_114759_4129"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='50',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</font></b><a name="Item2_UnregisteredSalesOfEquitySe_114802"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Unregistered Sales of Equity Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From July&nbsp;1, 2013 to September&nbsp;30, 2013, we issued and sold the equity securities described below:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In July&nbsp;2013, we issued and sold an aggregate of approximately $0.7 million in principal amount of convertible promissory notes to five existing investors.&#160; The sale of these notes was deemed to be exempt from registration pursuant to Section&nbsp;4(2)&nbsp;of the Securities Act as a transaction by an issuer not involving a public offering. These notes converted into common stock in connection with our IPO.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In August&nbsp;2013, we issued and sold an aggregate of $20.0 million in principal amount of convertible promissory notes to three new investors.&#160; We have filed a Form&nbsp;D to ensure that all securities issued in this transaction fall within the safe harbor provided pursuant to Rule&nbsp;506 of Regulation D promulgated under the Securities Act. We repaid a portion of these notes in cash, and the balance of the notes converted into common stock in connection with our IPO.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">We issued to employees, directors and consultants an aggregate of 20,469 shares of common stock upon the exercise of options under the 2007 Equity Incentive Plan, with exercise prices ranging from $0.08 to $1.69 per share, for an aggregate exercise price of approximately $22,000.&#160; The issuances of these securities were deemed to be exempt from registration pursuant to Rule&nbsp;701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans.</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of the securities issued and sold as described above are deemed to be restricted securities for purposes of the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Proceeds</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;30, 2013, the SEC declared effective the registration statement on Form&nbsp;S-1 (File No.&nbsp;333-190608) for our initial public offering of our common stock.&#160; Pursuant to the registration statement, we registered the offer and sale of 7,666,667 shares of our common stock (including 1,000,000 shares of our common stock pursuant to the underwriters&#146; over-allotment option).&#160; On October&nbsp;4, 2013, we sold 7,666,667 shares of our common stock (including 1,000,000 shares of our common stock pursuant to the underwriters&#146; over-allotment option) at a public offering price of $6.00 per share. The offering has terminated. The joint book-running managing underwriters of the offering were Cowen and Company, LLC and BMO Capital Markets Corp. After deducting underwriting discounts, commissions and estimated offering costs paid or payable by us of approximately $5.6 million, the net proceeds from the offering were approximately $40.4 million. No offering expenses were paid or are payable directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The net proceeds from the offering have been invested in highly-liquid money market funds. There has been no material change in the expected use of the net proceeds from our initial public offering as described in the final prospectus filed with the SEC pursuant to Rule&nbsp;424(b).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Defaults Upon Senior Securities</font></b><a name="Item3_DefaultsUponSeniorSecuritie_114919"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Mine Safety Disclosure</font></b><a name="Item4_MineSafetyDisclosure_114921"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other Information</font></b><a name="Item5_OtherInformation_114922"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:39.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Exhibits</font></b><a name="Item6_Exhibits_114923"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See Exhibit&nbsp;Index.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51<a name="PB_51_114844_3263"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='51',FILE='C:\JMS\107993\13-22691-1\task6363712\22691-1-ge.htm',USER='107993',CD='Nov 12 07:42 2013' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name="Signatures_115527"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.74%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics, Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:&nbsp;&nbsp;   November 13, 2013</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian Weyer</font><font size="2" style="font-size:10.0pt;">  </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief Executive Officer</font><font size="2" style="font-size:10.0pt;">  </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal Executive Officer)</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer and Chief Operating   Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal Financial and Accounting Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">52<a name="PB_52_115326_2077"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='52',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-gg.htm',USER='107913',CD='Nov  9 11:55 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Index to Exhibits</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="84%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:84.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Document</font></b></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated Certificate of   Incorporation (filed as Exhibit 3.2 to the registrant&#146;s Registration   Statement on Form S-1/A (File No. 333-190608) filed with the SEC on August   29, 2013 and incorporated herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended and Restated Bylaws (filed as   Exhibit 3.4 to the registrant&#146;s Registration Statement on Form S-1/A (File   No. 333-190608) filed with the SEC on August 29, 2013 and incorporated herein   by reference).</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen Common Stock Certificate (filed as   Exhibit 4.1 to the registrant&#146;s Registration Statement on Form S-1/A (File   No. 333-190608) filed with the SEC on August 29, 2013 and incorporated herein   by reference).</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Principal Executive Officer   pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities   Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Principal Financial Officer   pursuant to Rules 13a-14 and 15-d-14 promulgated pursuant to the Securities   Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Principal Executive Officer   pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification of Principal Financial Officer   pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the   Sarbanes-Oxley Act of 2002</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.INS*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Instance Document</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.SCH*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension Schema Document</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.CAL*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension Calculation Linkbase   Document</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.DEF*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension Definition Linkbase   Document</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.LAB*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension Label Linkbase   Document</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="13%" valign="top" style="padding:0in 0in 0in 0in;width:13.28%;">
<p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.PRE*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="84%" valign="top" style="padding:0in 0in 0in 0in;width:84.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL Taxonomy Extension Presentation   Linkbase Document</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .05pt;text-indent:-.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt .05pt;text-indent:-.05pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">53<a name="PB_53_115505_1861"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='53',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-gg.htm',USER='107913',CD='Nov  9 11:55 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a13-22691_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PURSUANT TO RULE 13a-14(a)&nbsp;AND 15d-14(a)&nbsp;OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Christian Weyer, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1. I have reviewed this quarterly report on Form&nbsp;10-Q of Fate Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: November&nbsp;13, 2013</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal Executive Officer)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-ma.htm',USER='107913',CD='Nov  9 11:57 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a13-22691_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PURSUANT TO RULE 13a-14(a)&nbsp;AND 15d-14(a)&nbsp;OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, J. Scott Wolchko, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1. I have reviewed this quarterly report on Form&nbsp;10-Q of Fate Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: November&nbsp;13, 2013</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer and Chief Operating   Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal Financial Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-mc.htm',USER='107913',CD='Nov  9 11:58 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a13-22691_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AS ADOPTED PURSUANT TO</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended September&nbsp;30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, Christian Weyer, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: November&nbsp;13, 2013</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&nbsp;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-me.htm',USER='107913',CD='Nov  9 11:59 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a13-22691_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.2</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AS ADOPTED PURSUANT TO</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended September&nbsp;30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, J. Scott Wolchko, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: November&nbsp;13, 2013</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J. Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer and Chief Operating   Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&nbsp;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107913\13-22691-1\task6360699\22691-1-mg.htm',USER='107913',CD='Nov  9 12:01 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>fate-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS Proton Version 4.0.2.6-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:fate="http://www.fatetherapeutics.com/20130930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="fate-20130930.xsd" />
  <xbrli:context id="I2013Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3ITD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2007-04-27</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_M0912">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-11</xbrli:startDate>
      <xbrli:endDate>2013-09-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_ExchangeableShareLiabilityMember_FV">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EquityUnitPurchaseAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityUnitPurchaseAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_EquityUnitPurchaseAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityUnitPurchaseAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EquityUnitPurchaseAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0731_ConvertiblePromissoryNotesDueOn24June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn24June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0831_ConvertiblePromissoryNotesDueOn8August2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn8August2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2010Q2_M0407_VerioTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-04-06</xbrli:startDate>
      <xbrli:endDate>2010-04-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_VerioTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2010Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">fate:PeriodOfApril2010Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMarch2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">fate:PeriodOfMarch2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMay2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">fate:PeriodOfMay2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">fate:PeriodOfApril2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn24June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfJuly2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">fate:PeriodOfJuly2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_ConvertiblePromissoryNotesDueOn8August2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn8August2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsNonrecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member_CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member_CarryingReportedAmountFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_PreferredStockWarrantLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_ExchangeableShareLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">fate:ExchangeableShareLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_2M_ConvertiblePromissoryNotesDueOn24June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn24June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>
      <xbrli:endDate>2013-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn24June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_ConvertiblePromissoryNotesDueOn24June2014Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn24June2014Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0812_EquityIncentivePlan2007Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0828_StockOptionAndIncentivePlan2013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:StockOptionAndIncentivePlan2013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_M0913_EmployeeStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_M0913_EmployeeStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-11</xbrli:startDate>
      <xbrli:endDate>2013-09-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q4_M1004_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-10-03</xbrli:startDate>
      <xbrli:endDate>2013-10-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q4_M1004_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q4_M1004_ConvertiblePromissoryNotesDueOn8August2016Member_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn8August2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-10-03</xbrli:startDate>
      <xbrli:endDate>2013-10-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_NonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:NonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_EquityIncentivePlan2007Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_EquityIncentivePlan2007Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityIncentivePlan2007Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:NonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:NonEmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fate:EquityIncentivePlan2007Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013Q3_ProFormaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_M0926">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-25</xbrli:startDate>
      <xbrli:endDate>2013-09-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2013Q3_M0831_ConvertiblePromissoryNotesDueOn8August2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001434316</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:ConvertiblePromissoryNotesDueOn8August2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-08-08</xbrli:startDate>
      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>fate:item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag1" decimals="-3" contextRef="I2013Q3" unitRef="USD">19082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag2" decimals="-3" contextRef="I2013Q3" unitRef="USD">304000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag3" decimals="-3" contextRef="I2013Q3" unitRef="USD">19386000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag4" decimals="-3" contextRef="I2013Q3" unitRef="USD">789000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag5" decimals="-3" contextRef="I2013Q3" unitRef="USD">2743000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Tag6" decimals="-3" contextRef="I2013Q3" unitRef="USD">122000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:Assets id="Tag7" decimals="-3" contextRef="I2013Q3" unitRef="USD">23040000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag8" decimals="-3" contextRef="I2012" unitRef="USD">9087000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag9" decimals="-3" contextRef="I2012" unitRef="USD">706000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag10" decimals="-3" contextRef="I2012" unitRef="USD">9793000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag11" decimals="-3" contextRef="I2012" unitRef="USD">1161000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="Tag12" decimals="-3" contextRef="I2012" unitRef="USD">122000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="Tag13" decimals="-3" contextRef="I2013Q3" unitRef="USD">3725000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditCurrent id="Tag14" decimals="-3" contextRef="I2013Q3" unitRef="USD">45000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent id="Tag15" decimals="-3" contextRef="I2013Q3" unitRef="USD">3481000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:WarrantsAndRightsOutstanding id="Tag16" decimals="-3" contextRef="I2013Q3" unitRef="USD">163000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:LongTermDebtCurrent id="Tag17" decimals="-3" contextRef="I2013Q3" unitRef="USD">1971000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag18" decimals="-3" contextRef="I2013Q3" unitRef="USD">9491000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="Tag19" decimals="-3" contextRef="I2013Q3" unitRef="USD">153000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent id="Tag20" decimals="-3" contextRef="I2013Q3" unitRef="USD">137000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
  <fate:ExchangeableShareLiabilityNoncurrent id="Tag21" decimals="-3" contextRef="I2013Q3" unitRef="USD">2885000</fate:ExchangeableShareLiabilityNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag22" decimals="-3" contextRef="I2013Q3" unitRef="USD">250000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:CommitmentsAndContingencies id="Tag23" xsi:nil="true" contextRef="I2013Q3" unitRef="USD" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag24" decimals="-3" contextRef="I2013Q3" unitRef="USD">56526000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="Tag25" decimals="-3" contextRef="I2012" unitRef="USD">2268000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="Tag26" decimals="-3" contextRef="I2012" unitRef="USD">63000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditCurrent id="Tag27" decimals="-3" contextRef="I2012" unitRef="USD">251000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:WarrantsAndRightsOutstanding id="Tag28" decimals="-3" contextRef="I2012" unitRef="USD">184000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:LongTermDebtCurrent id="Tag29" decimals="-3" contextRef="I2012" unitRef="USD">1941000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag30" decimals="-3" contextRef="I2012" unitRef="USD">4850000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="Tag31" decimals="-3" contextRef="I2012" unitRef="USD">132000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent id="Tag32" decimals="-3" contextRef="I2012" unitRef="USD">110000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
  <fate:ExchangeableShareLiabilityNoncurrent id="Tag33" decimals="-3" contextRef="I2012" unitRef="USD">551000</fate:ExchangeableShareLiabilityNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag34" decimals="-3" contextRef="I2012" unitRef="USD">1732000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:CommitmentsAndContingencies id="Tag35" xsi:nil="true" contextRef="I2012" unitRef="USD" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="Tag36" decimals="-3" contextRef="I2012" unitRef="USD">56526000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockValue id="Tag37" decimals="-3" contextRef="I2013Q3" unitRef="USD">1000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag38" decimals="-3" contextRef="I2013Q3" unitRef="USD">14367000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag39" decimals="-3" contextRef="I2013Q3" unitRef="USD">80770000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag40" decimals="-3" contextRef="I2013Q3" unitRef="USD">-66402000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag41" decimals="-3" contextRef="I2013Q3" unitRef="USD">23040000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital id="Tag42" decimals="-3" contextRef="I2012" unitRef="USD">12789000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag43" decimals="-3" contextRef="I2012" unitRef="USD">65615000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag44" decimals="-3" contextRef="I2012" unitRef="USD">-52825000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag45" decimals="-3" contextRef="I2012" unitRef="USD">11076000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:Assets id="Tag46" decimals="-3" contextRef="I2012" unitRef="USD">11076000</us-gaap:Assets>
  <us-gaap:CommonStockValue id="Tag47" decimals="-3" contextRef="I2012" unitRef="USD">1000</us-gaap:CommonStockValue>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag48" decimals="INF" contextRef="I2013Q3" unitRef="USDPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="Tag49" decimals="INF" contextRef="I2012" unitRef="USDPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag50" decimals="INF" contextRef="I2013Q3" unitRef="Shares">68360186</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="Tag51" decimals="INF" contextRef="I2012" unitRef="Shares">62200000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="Tag52" decimals="INF" contextRef="I2013Q3" unitRef="Shares">44967690</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="Tag53" decimals="INF" contextRef="I2012" unitRef="Shares">44967690</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag54" decimals="INF" contextRef="I2013Q3" unitRef="Shares">44967690</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="Tag55" decimals="INF" contextRef="I2012" unitRef="Shares">44967690</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="Tag56" decimals="-3" contextRef="I2013Q3" unitRef="USD">58518000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference id="Tag57" decimals="-3" contextRef="I2012" unitRef="USD">58518000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag58" decimals="INF" contextRef="I2013Q3" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag59" decimals="INF" contextRef="I2012" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag60" decimals="INF" contextRef="I2013Q3" unitRef="Shares">110000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Tag61" decimals="INF" contextRef="I2012" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag62" decimals="INF" contextRef="I2013Q3" unitRef="Shares">1377659</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag63" decimals="INF" contextRef="I2013Q3" unitRef="Shares">1377659</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued id="Tag64" decimals="INF" contextRef="I2012" unitRef="Shares">1334115</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag65" decimals="INF" contextRef="I2012" unitRef="Shares">1334115</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ContractsRevenue id="Tag66" decimals="-3" contextRef="D2013Q3" unitRef="USD">209000</us-gaap:ContractsRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodFactors id="Tag67" contextRef="D2013Q3YTD">(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured</us-gaap:RevenueRecognitionMilestoneMethodFactors>
  <us-gaap:SalesRevenueNet id="Tag68" decimals="-3" contextRef="D2013Q3" unitRef="USD">209000</us-gaap:SalesRevenueNet>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag69" decimals="-3" contextRef="D2013Q3" unitRef="USD">3378000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag70" decimals="-3" contextRef="D2013Q3" unitRef="USD">1979000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag71" decimals="-3" contextRef="D2013Q3" unitRef="USD">5357000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag72" decimals="-3" contextRef="D2013Q3" unitRef="USD">-5148000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag73" decimals="-3" contextRef="D2013Q3" unitRef="USD">-925000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag74" decimals="-3" contextRef="D2013Q3" unitRef="USD">-6073000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag75" decimals="2" contextRef="D2013Q3" unitRef="USDPerShare">-4.81</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag76" decimals="0" contextRef="D2013Q3" unitRef="Shares">1262546</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ContractsRevenue id="Tag77" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">626000</us-gaap:ContractsRevenue>
  <us-gaap:RevenueFromGrants id="Tag78" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">345000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueNet id="Tag79" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">971000</us-gaap:SalesRevenueNet>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag80" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">8976000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag81" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">4768000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag82" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">13744000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag83" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-12773000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag84" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-2382000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag85" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-15155000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag86" decimals="2" contextRef="D2013Q3YTD" unitRef="USDPerShare">-12.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag87" decimals="0" contextRef="D2013Q3YTD" unitRef="Shares">1238567</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ContractsRevenue id="Tag88" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">2927000</us-gaap:ContractsRevenue>
  <us-gaap:RevenueFromGrants id="Tag89" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">2084000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueNet id="Tag90" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">5011000</us-gaap:SalesRevenueNet>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag91" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">53955000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag92" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">28839000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag93" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">82794000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag94" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-77783000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag95" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-2987000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag96" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-80770000</us-gaap:NetIncomeLoss>
  <us-gaap:ContractsRevenue id="Tag97" decimals="-3" contextRef="D2012Q3" unitRef="USD">208000</us-gaap:ContractsRevenue>
  <us-gaap:RevenueFromGrants id="Tag98" decimals="-3" contextRef="D2012Q3" unitRef="USD">320000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueNet id="Tag99" decimals="-3" contextRef="D2012Q3" unitRef="USD">528000</us-gaap:SalesRevenueNet>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag100" decimals="-3" contextRef="D2012Q3" unitRef="USD">3315000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag101" decimals="-3" contextRef="D2012Q3" unitRef="USD">863000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag102" decimals="-3" contextRef="D2012Q3" unitRef="USD">4178000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag103" decimals="-3" contextRef="D2012Q3" unitRef="USD">-3650000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag104" decimals="-3" contextRef="D2012Q3" unitRef="USD">-463000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag105" decimals="-3" contextRef="D2012Q3" unitRef="USD">-4113000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag106" decimals="2" contextRef="D2012Q3" unitRef="USDPerShare">-3.51</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag107" decimals="0" contextRef="D2012Q3" unitRef="Shares">1171012</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ContractsRevenue id="Tag108" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">1075000</us-gaap:ContractsRevenue>
  <us-gaap:RevenueFromGrants id="Tag109" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">952000</us-gaap:RevenueFromGrants>
  <us-gaap:SalesRevenueNet id="Tag110" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">2027000</us-gaap:SalesRevenueNet>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag111" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">8596000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag112" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">2944000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag113" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">11540000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag114" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-9513000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag115" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-571000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="Tag116" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-10084000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag117" decimals="2" contextRef="D2012Q3YTD" unitRef="USDPerShare">-9.52</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag118" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares">1059113</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="Tag119" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;1.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Organization and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Organization&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Fate Therapeutics,&amp;#160;Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated in the state of Delaware on April&amp;#160;27, 2007 and conducts its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells.&amp;#160;Based on the Company&amp;#8217;s understanding of key biological mechanisms that guide the fate of adult stem cells, the Company has built two platforms that optimize the activity and enhance the therapeutic potential of adult stem cells: its hematopoietic stem cell, or HSC, modulation platform and its muscle satellite stem cell, or SSC, modulation platform.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Principles of Consolidation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics (Canada) Inc. (&amp;#8220;Fate Canada&amp;#8221;), Fate Therapeutics Ltd., incorporated in the United Kingdom, and Destin Therapeutics Inc., incorporated in Canada. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Reverse Stock Split&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On September&amp;#160;12, 2013, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a one-for-6.5 reverse stock split of the Company&amp;#8217;s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company&amp;#8217;s consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Unaudited Interim Financial Information&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) and following the requirements of the United States Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&amp;#160; In management&amp;#8217;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&amp;#8217;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&amp;#8217;s financial statements and accompanying notes for the fiscal year ended December&amp;#160;31, 2012, contained in the Company&amp;#8217;s final prospectus dated September&amp;#160;30, 2013 filed by the Company with the SEC on October&amp;#160;1, 2013 pursuant to Rule&amp;#160;424(b)&amp;#160;under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), in connection with the Company&amp;#8217;s initial public offering (&amp;#8220;IPO&amp;#8221;). The results for the three and nine months ended September&amp;#160;30, 2013 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company&amp;#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&amp;#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&amp;#8217;s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company&amp;#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Other Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other assets consist of the Company&amp;#8217;s deferred IPO costs. These costs represent legal, accounting and other direct costs related to the Company&amp;#8217;s efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Preferred Stock Warrant Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. The fair value of these warrants is classified as a current liability in the accompanying consolidated balance sheets since the underlying convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets instead of in stockholders&amp;#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that are outside of the Company&amp;#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock can cause its redemption. The warrants are recorded at fair value using the Black-Scholes option pricing model with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The warrant liability will continue to be remeasured at fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Revenue Recognition&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company recognizes revenues when all four of the following criteria are met: (i)&amp;#160;persuasive evidence that an agreement exists; (ii)&amp;#160;delivery of the products and/or services has occurred; (iii)&amp;#160;the selling price is fixed or determinable; and (iv)&amp;#160;collectibility is reasonably assured.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Beginning in 2011, revenue is allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&amp;#8220;TPE&amp;#8221;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&amp;#160;the consideration being earned should be commensurate with either the Company&amp;#8217;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&amp;#8217;s performance to achieve the milestone; (ii)&amp;#160;the consideration being earned should relate solely to past performance; (iii)&amp;#160;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&amp;#160;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&amp;#8217;s revenue recognition criteria are recorded as deferred revenue on the Company&amp;#8217;s consolidated balance sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award. The receivable for reimbursable amounts that have not been collected is reflected in prepaid and other current assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice based model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition has been achieved.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 102,998 shares and 166,252 shares for the three months ended September&amp;#160;30, 2013 and 2012, respectively, and 111,614 shares and 184,517 shares for the nine months ended September&amp;#160;30, 2013 and 2012, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, warrants for the purchase of convertible preferred stock, exchangeable shares and common stock options outstanding under the Company&amp;#8217;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#8217;s net loss position.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 66.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="66%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;and&amp;#160;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock outstanding&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,229,590&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6,065,934&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants for convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;480,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;403,841&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,710,517&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;721,539&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9,456,944&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,227,388&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In addition to the potentially dilutive securities noted above, the Company has an aggregate of approximately $23.7 million of outstanding principal as of September&amp;#160;30, 2013 under convertible promissory notes, issued in June&amp;#160;2013, July&amp;#160;2013 and August&amp;#160;2013, that are convertible into convertible preferred stock or common stock upon the occurrence of various future events at prices that are not determinable until the occurrence of those future events. As such, the Company has excluded these convertible notes payable from the table above.&amp;#160; A portion of the convertible notes were repaid in cash and the balance of the notes converted into common stock in connection with the closing of the Company&amp;#8217;s IPO in October&amp;#160;2013 (see Note 6).&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag120" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;3.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Fair Value Measurements&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Level 1: Observable inputs such as quoted prices in active markets;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 46.05pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&amp;#8217;s cash equivalents. As of September&amp;#160;30, 2013 and December&amp;#160;31, 2012, the carrying amount of cash equivalents was $0.3 million and $1.3&amp;#160;million, respectively, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of September&amp;#160;30, 2013 and December&amp;#160;31, 2012, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Financial liabilities that are measured at fair value on a recurring basis include the preferred stock warrant liability and exchangeable shares (see Note 2). None of the Company&amp;#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities measured at fair value on a recurring basis are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 93.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.25in;" border="0" cellspacing="0" cellpadding="0" width="93%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="8"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&lt;br /&gt;
Reporting&amp;#160;Date&amp;#160;Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&lt;br /&gt;
in&amp;#160;Active&lt;br /&gt;
Markets&amp;#160;for&lt;br /&gt;
Identical&lt;br /&gt;
Assets&lt;br /&gt;
(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs&lt;br /&gt;
(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&lt;br /&gt;
(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,048&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,048&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of December&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;735&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;735&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The preferred stock warrant liability was recorded at fair value using the Black-Scholes option pricing model and the exchangeable share liability was recorded at fair value based on the fair value of the underlying common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following assumptions were used in the Black-Scholes option pricing model to determine the fair value of the preferred stock warrant liability:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 73.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="73%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&lt;br /&gt;
31,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;85.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.56&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 73.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="73%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Warrant&lt;br /&gt;
Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exchangeable&lt;br /&gt;
Share&lt;br /&gt;
Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;221&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;563&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance of exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance of exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;346&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(21&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,988&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;The preferred stock warrant liability and the exchangeable share liability were each reclassified into additional paid-in capital at their fair value in connection with the Company&amp;#8217;s IPO on October&amp;#160;4, 2013 (see Note 6).&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:LongTermDebtTextBlock id="Tag121" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;4.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Long-Term Debt, Commitments and Contingencies&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Long-Term Debt&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt and unamortized discount balances (excluding convertible debt) are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&lt;br /&gt;
31,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Less debt discount, net of current portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt, net of debt discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Less current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt, net of current portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of debt discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(59&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,971&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,941&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;June&amp;#160;and July&amp;#160;2013 Convertible Note Financing&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In June&amp;#160;and July&amp;#160;2013, the Company issued convertible promissory notes in an aggregate principal amount of $3.7 million to certain existing stockholders. The notes accrue interest at 2% per year and are due on June&amp;#160;24, 2014, if not earlier repaid or converted in full. In connection with the issuance of the convertible notes, the Company recorded a debt discount of $0.3 million related to a beneficial conversion feature that was recorded as a result of the gross fair value of the shares of Series&amp;#160;C convertible preferred stock into which the debt could convert being greater than the proceeds allocated to the debt instrument. The debt discount is amortized as interest expense utilizing the effective interest method over the one year term of the debt. During the three and nine months ended September&amp;#160;30, 2013, the Company recorded debt discount amortization of $0.1 million.&amp;#160;As of September&amp;#160;30, 2013, an aggregate of $3.7 million of principal, $0.3 million of unamortized debt discount and $0.1 million of accrued interest were outstanding under the promissory notes. The notes converted into common stock in connection with the Company&amp;#8217;s IPO in October&amp;#160;2013 (see Note 6).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;August&amp;#160;2013 Convertible Note Financing&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In August&amp;#160;2013, the Company issued convertible promissory notes in an aggregate principal amount of $20.0 million to certain new investors. The notes accrue interest at 2% per year and are due on August&amp;#160;8, 2016, if not earlier repaid or converted in full. As of September&amp;#160;30, 2013, an aggregate of $20.0 million of principal and $0.1 million of accrued interest were outstanding under the promissory notes. A portion of the notes were repaid in cash and the balance of the notes converted into common stock in connection with the Company&amp;#8217;s IPO in October&amp;#160;2013 (see Note 6).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Facility Lease&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On September&amp;#160;26, 2013, the Company exercised its option to extend for two years the lease on its office and laboratory space in San Diego, California until June&amp;#160;2016. As a result of the lease extension, the Company added an additional $0.5 million, $0.9 million and $0.5 million, respectively, of non-cancelable operating lease commitments for the years ending December&amp;#160;31, 2014, 2015 and 2016.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag122" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;5.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stockholders&amp;#8217; Deficit&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2007 Equity Incentive Plan&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On August&amp;#160;12, 2013, the Company&amp;#8217;s board of directors approved an increase in the number of shares of common stock authorized for issuance under the Company&amp;#8217;s 2007 Equity Incentive Plan (the &amp;#8220;Plan&amp;#8221;) to 2,423,072&amp;#160;shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock option activity under the Plan is summarized as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;br /&gt;
Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted-&lt;br /&gt;
Average&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,432,369&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.43&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;331,860&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.60&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Canceled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(17,860&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.56&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(35,852&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.65&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,710,517&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.26&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="374"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.6%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;581&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;32&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;686&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;82&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;483&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;24&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;982&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;42&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,169&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;106&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013, the outstanding options included 340,121 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at September&amp;#160;30, 2013 was $1.8 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013, the outstanding options included 220,496 options with both performance-based milestones and market conditions that were determined not to be probable of achievement. The aggregate grant date fair value of these unvested options at September&amp;#160;30, 2013 was $0.2 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013, the unrecognized compensation cost related to outstanding options (excluding those with performance-based and/or market conditions) was $0.6 million and is expected to be recognized as expense over approximately 3.5 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.07&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.23&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2013 Stock Option and Incentive Plan&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On August&amp;#160;28, 2013, the Company&amp;#8217;s board of directors and stockholders approved and adopted the 2013 Stock Option and Incentive Plan (the &amp;#8220;2013 Plan&amp;#8221;). The 2013 Plan became effective immediately prior to the Company&amp;#8217;s IPO. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, directors or consultants of the Company or its subsidiaries. A total of 1,020,000 shares of common stock were initially reserved for issuance under the 2013 Plan. In addition, the number of shares of stock available for issuance under the 2013 Plan will be automatically increased each January&amp;#160;1, beginning on January&amp;#160;1, 2014, by 4% of the outstanding number of shares of the Company&amp;#8217;s common stock on the immediately preceding December&amp;#160;31 or such lesser number as determined by the compensation committee of the Company&amp;#8217;s board of directors.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On September&amp;#160;13, 2013, the Company&amp;#8217;s board of directors approved and adopted the 2013 Employee Stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;). The ESPP became effective immediately prior to the Company&amp;#8217;s IPO. A total of 729,000 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of stock available for issuance under the ESPP will be automatically increased each January&amp;#160;1, beginning on January&amp;#160;1, 2015, by the lesser of (i)&amp;#160;2% of the outstanding number of shares of the Company&amp;#8217;s common stock on the immediately preceding December&amp;#160;31, (ii)&amp;#160;450,000 shares, or (iii)&amp;#160;such lesser number as determined by the compensation committee of the Company&amp;#8217;s board of directors.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="Tag123" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;6.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Subsequent Events&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Initial Public Offering and Related Transactions&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On October&amp;#160;4, 2013, the Company completed its IPO whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Estimated net proceeds from the IPO were determined as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 89.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.4in;" border="0" cellspacing="0" cellpadding="0" width="89%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Gross proceeds (including over-allotment)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;46,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Underwriting discounts and commissions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,695&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated total offering costs (including costs paid as of September&amp;#160;30, 2013)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,900&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Offering costs paid as of September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,381&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated net proceeds to be received subsequent to September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;41,786&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Partial repayment of August&amp;#160;2013 Notes subsequent to September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(1,741&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated net cash impact of IPO and related transactions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;40,045&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In addition, each of the following occurred in connection with the completion of our IPO on October&amp;#160;4, 2013:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;the conversion of all outstanding shares of convertible preferred stock into 7,229,590 shares of the Company&amp;#8217;s common stock;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;the conversion of $22.1 million of outstanding principal and accrued interest on convertible notes into 3,679,401 shares of common stock, the write-off of $0.3 million of unamortized debt discount and the related cash repayment of $1.7 million of outstanding principal and accrued interest on convertible notes and accrued interest outstanding as of September&amp;#160;30, 2013;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;480,763 shares of the Company&amp;#8217;s common stock became issuable pursuant to the redemption of an aggregate of 900,000 exchangeable shares of Fate Canada and the resultant reclassification of the exchangeable share liability to additional paid-in capital;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;the conversion of warrants to purchase 230,000 shares of convertible preferred stock into warrants to purchase 36,074 shares of the Company&amp;#8217;s common stock and the resultant reclassification of the warrant liability to additional paid-in capital; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 3pt;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;an amended and restated certificate of incorporation was filed on October&amp;#160;3, 2013, authorizing 150,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company&amp;#8217;s IPO noted above, as of September&amp;#160;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Pro&amp;#160;Forma&lt;br /&gt;
September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19,082&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;59,127&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,743&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,725&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,344&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;137&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;79&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible notes, net of discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;23,481&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Preferred stock warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;56,526&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Additional paid-in capital&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14,367&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;136,398&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Deficit accumulated during the development stage&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(80,770&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(81,024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stockholders&amp;#8217; (deficit) equity&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(66,402&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;55,394&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="424"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;In connection with the closing of its IPO on October&amp;#160;4, 2013, the Company recorded an additional aggregate non-cash charge of $0.5 million in other income (expense) related to the final fair value adjustment of the exchangeable share liability and the preferred stock warrant liability. This final fair value adjustment&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt;" size="2"&gt;is excluded from the table above.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag124" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">430000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="Tag125" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">106000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Tag126" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">63000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:PaidInKindInterest id="Tag127" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">97000</us-gaap:PaidInKindInterest>
  <us-gaap:StraightLineRent id="Tag128" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">138000</us-gaap:StraightLineRent>
  <us-gaap:RecognitionOfDeferredRevenue id="Tag129" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">63000</us-gaap:RecognitionOfDeferredRevenue>
  <fate:FairValueAdjustmentOfExchangeableShares id="Tag130" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-12000</fate:FairValueAdjustmentOfExchangeableShares>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag131" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-35000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Tag132" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-323000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag133" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">204000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag134" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-363000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag135" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-9880000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag136" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">414000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag137" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-414000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromRepurchaseOfEquity id="Tag138" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">205000</us-gaap:ProceedsFromRepurchaseOfEquity>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="Tag139" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">9166000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag140" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">9371000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag141" decimals="-3" contextRef="D2012Q3YTD" unitRef="USD">-923000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag142" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">442000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Tag143" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">13000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:ShareBasedCompensation id="Tag144" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">1169000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Tag145" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">129000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:PaidInKindInterest id="Tag146" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">134000</us-gaap:PaidInKindInterest>
  <us-gaap:StraightLineRent id="Tag147" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">185000</us-gaap:StraightLineRent>
  <us-gaap:RecognitionOfDeferredRevenue id="Tag148" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">63000</us-gaap:RecognitionOfDeferredRevenue>
  <fate:FairValueAdjustmentOfExchangeableShares id="Tag149" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">2334000</fate:FairValueAdjustmentOfExchangeableShares>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag150" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-21000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GainLossOnDispositionOfAssets1 id="Tag151" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-18000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag152" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">960000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag153" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">1350000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag154" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-10795000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag155" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag156" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">6000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag157" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">-88000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromRepurchaseOfEquity id="Tag158" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">23000</us-gaap:ProceedsFromRepurchaseOfEquity>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Tag159" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">1381000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag160" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">23736000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="Tag161" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">1500000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag162" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">20878000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag163" decimals="-3" contextRef="D2013Q3YTD" unitRef="USD">9995000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag164" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">2379000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Tag165" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">57000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:ShareBasedCompensation id="Tag166" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">1938000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Tag167" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">271000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:PaidInKindInterest id="Tag168" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">1156000</us-gaap:PaidInKindInterest>
  <us-gaap:StraightLineRent id="Tag169" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-198000</us-gaap:StraightLineRent>
  <fate:FairValueAdjustmentOfExchangeableShares id="Tag170" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">2885000</fate:FairValueAdjustmentOfExchangeableShares>
  <us-gaap:FairValueAdjustmentOfWarrants id="Tag171" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-64000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:GainLossOnDispositionOfAssets1 id="Tag172" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-135000</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="Tag173" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-332000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag174" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">1666000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag175" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">3618000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag176" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-69531000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag177" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">3511000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag178" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">208000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="Tag179" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">122000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag180" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">-3425000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromRepurchaseOfEquity id="Tag181" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">287000</us-gaap:ProceedsFromRepurchaseOfEquity>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Tag182" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">1381000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag183" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">32236000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="Tag184" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">6400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="Tag185" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">4150000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="Tag186" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">58646000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag187" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">92038000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag188" decimals="-3" contextRef="D2013Q3ITD" unitRef="USD">19082000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ConsolidationPolicyTextBlock id="Tag189" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Principles of Consolidation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics (Canada) Inc. (&amp;#8220;Fate Canada&amp;#8221;), Fate Therapeutics Ltd., incorporated in the United Kingdom, and Destin Therapeutics Inc., incorporated in Canada. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="Tag190" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Use of Estimates&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company&amp;#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&amp;#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&amp;#8217;s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company&amp;#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Tag191" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Preferred Stock Warrant Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. The fair value of these warrants is classified as a current liability in the accompanying consolidated balance sheets since the underlying convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets instead of in stockholders&amp;#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that are outside of the Company&amp;#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock can cause its redemption. The warrants are recorded at fair value using the Black-Scholes option pricing model with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The warrant liability will continue to be remeasured at fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="Tag192" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Revenue Recognition&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company recognizes revenues when all four of the following criteria are met: (i)&amp;#160;persuasive evidence that an agreement exists; (ii)&amp;#160;delivery of the products and/or services has occurred; (iii)&amp;#160;the selling price is fixed or determinable; and (iv)&amp;#160;collectibility is reasonably assured.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&amp;#8217;s control.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Beginning in 2011, revenue is allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&amp;#8220;TPE&amp;#8221;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&amp;#160;the consideration being earned should be commensurate with either the Company&amp;#8217;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&amp;#8217;s performance to achieve the milestone; (ii)&amp;#160;the consideration being earned should relate solely to past performance; (iii)&amp;#160;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&amp;#160;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&amp;#8217;s revenue recognition criteria are recorded as deferred revenue on the Company&amp;#8217;s consolidated balance sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award. The receivable for reimbursable amounts that have not been collected is reflected in prepaid and other current assets.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Tag193" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice based model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition has been achieved.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag194" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Net Loss Per Share&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 102,998 shares and 166,252 shares for the three months ended September&amp;#160;30, 2013 and 2012, respectively, and 111,614 shares and 184,517 shares for the nine months ended September&amp;#160;30, 2013 and 2012, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, warrants for the purchase of convertible preferred stock, exchangeable shares and common stock options outstanding under the Company&amp;#8217;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#8217;s net loss position.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 66.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="66%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;and&amp;#160;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock outstanding&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,229,590&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6,065,934&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants for convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;480,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;403,841&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,710,517&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;721,539&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9,456,944&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,227,388&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In addition to the potentially dilutive securities noted above, the Company has an aggregate of approximately $23.7 million of outstanding principal as of September&amp;#160;30, 2013 under convertible promissory notes, issued in June&amp;#160;2013, July&amp;#160;2013 and August&amp;#160;2013, that are convertible into convertible preferred stock or common stock upon the occurrence of various future events at prices that are not determinable until the occurrence of those future events. As such, the Company has excluded these convertible notes payable from the table above.&amp;#160; A portion of the convertible notes were repaid in cash and the balance of the notes converted into common stock in connection with the closing of the Company&amp;#8217;s IPO in October&amp;#160;2013 (see Note 6).&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Tag195" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 646px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="646"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;and&amp;#160;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock outstanding&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,229,590&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6,065,934&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrants for convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;36,074&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;480,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;403,841&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock options&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,710,517&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;721,539&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;9,456,944&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7,227,388&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <fate:NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells id="Tag196" decimals="INF" contextRef="D2013Q3YTD" unitRef="Item">2</fate:NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="Tag197" decimals="3" contextRef="D2013Q3_M0912" unitRef="Pure">0.154</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="Tag198" decimals="-3" contextRef="D2013Q3YTD_ExchangeableShareLiabilityMember_FV" unitRef="USD">346000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding id="Tag199" decimals="INF" contextRef="D2012Q3" unitRef="Shares">166252</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding id="Tag200" decimals="INF" contextRef="D2012Q3YTD" unitRef="Shares">184517</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding id="Tag201" decimals="INF" contextRef="D2013Q3" unitRef="Shares">102998</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding id="Tag202" decimals="INF" contextRef="D2013Q3YTD" unitRef="Shares">111614</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag203" decimals="INF" contextRef="D2012Q3_ConvertiblePreferredStockMember" unitRef="Shares">6065934</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag204" decimals="INF" contextRef="D2012Q3YTD_ConvertiblePreferredStockMember" unitRef="Shares">6065934</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag205" decimals="INF" contextRef="D2013Q3_ConvertiblePreferredStockMember" unitRef="Shares">7229590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag206" decimals="INF" contextRef="D2013Q3YTD_ConvertiblePreferredStockMember" unitRef="Shares">7229590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag207" decimals="INF" contextRef="D2012Q3_WarrantMember" unitRef="Shares">36074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag208" decimals="INF" contextRef="D2012Q3YTD_WarrantMember" unitRef="Shares">36074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag209" decimals="INF" contextRef="D2013Q3_WarrantMember" unitRef="Shares">36074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag210" decimals="INF" contextRef="D2012Q3_EquityUnitPurchaseAgreementsMember" unitRef="Shares">403841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag211" decimals="INF" contextRef="D2012Q3YTD_EquityUnitPurchaseAgreementsMember" unitRef="Shares">403841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag212" decimals="INF" contextRef="D2013Q3YTD_WarrantMember" unitRef="Shares">36074</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag213" decimals="INF" contextRef="D2013Q3_EquityUnitPurchaseAgreementsMember" unitRef="Shares">480763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag214" decimals="INF" contextRef="D2013Q3YTD_EquityUnitPurchaseAgreementsMember" unitRef="Shares">480763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag215" decimals="INF" contextRef="D2012Q3_StockCompensationPlanMember" unitRef="Shares">721539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag216" decimals="INF" contextRef="D2012Q3YTD_StockCompensationPlanMember" unitRef="Shares">721539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag217" decimals="INF" contextRef="D2013Q3_StockCompensationPlanMember" unitRef="Shares">1710517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag218" decimals="INF" contextRef="D2012Q3" unitRef="Shares">7227388</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag219" decimals="INF" contextRef="D2012Q3YTD" unitRef="Shares">7227388</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag220" decimals="INF" contextRef="D2013Q3" unitRef="Shares">9456944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag221" decimals="INF" contextRef="D2013Q3YTD" unitRef="Shares">9456944</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag222" decimals="INF" contextRef="D2013Q3YTD_StockCompensationPlanMember" unitRef="Shares">1710517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:DebtInstrumentFaceAmount id="Tag223" decimals="-5" contextRef="I2013Q3_M0731_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">3700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag224" decimals="INF" contextRef="I2013Q3_M0831_ConvertiblePromissoryNotesDueOn8August2016Member" unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <fate:ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock id="Tag225" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013, the changes in the number of shares of the Company&amp;#8217;s common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares are summarized as follows (in thousands, except share and per share amounts):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 809px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="809"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exchangeable&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Per&lt;br /&gt;
Share&amp;#160;of&lt;br /&gt;
Underlying&lt;br /&gt;
Common&amp;#160;Stock&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Initial&amp;#160;Fair&lt;br /&gt;
Value&amp;#160;of&lt;br /&gt;
Exchangeable&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;April&amp;#160;2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;138,462&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;234&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;March&amp;#160;2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;92,308&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;May&amp;#160;2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;115,380&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;195&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;April&amp;#160;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;57,691&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;July&amp;#160;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;76,922&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;346&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;480,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="316"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fate:ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock>
  <fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions id="Tag226" decimals="INF" contextRef="D2010Q2_M0407_VerioTherapeuticsIncMember" unitRef="Shares">900000</fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag227" decimals="INF" contextRef="D2010Q2_M0407_VerioTherapeuticsIncMember" unitRef="Shares">138462</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <fate:BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares id="Tag228" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_MaximumMember" unitRef="Shares">450000</fate:BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag229" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember" unitRef="Shares">480763</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag230" decimals="INF" contextRef="D2012_VerioTherapeuticsIncMember" unitRef="Shares">403841</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones id="Tag231" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember" unitRef="Shares">76922</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag232" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_MaximumMember" unitRef="Shares">884605</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag233" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2010Member" unitRef="Shares">138462</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag234" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMarch2011Member" unitRef="Shares">92308</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag235" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMay2011Member" unitRef="Shares">115380</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag236" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2012Member" unitRef="Shares">57691</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:InterestPayableCurrent id="Tag237" decimals="-5" contextRef="I2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">100000</us-gaap:InterestPayableCurrent>
  <fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock id="Tag238" decimals="2" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2010Member" unitRef="USDPerShare">1.69</fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock>
  <fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock id="Tag239" decimals="2" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMarch2011Member" unitRef="USDPerShare">1.69</fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock>
  <fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock id="Tag240" decimals="2" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMay2011Member" unitRef="USDPerShare">1.69</fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock>
  <fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock id="Tag241" decimals="2" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2012Member" unitRef="USDPerShare">1.37</fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock>
  <fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock id="Tag242" decimals="2" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfJuly2013Member" unitRef="USDPerShare">4.49</fate:BusinessAcquisitionFairValueOfUnderlyingCommonStock>
  <us-gaap:ConvertibleLongTermNotesPayable id="Tag243" decimals="-5" contextRef="I2013Q3_ConvertiblePromissoryNotesDueOn8August2016Member" unitRef="USD">20000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock id="Tag244" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Liabilities measured at fair value on a recurring basis are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 856px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.25in;" border="0" cellspacing="0" cellpadding="0" width="856"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="8"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;at&lt;br /&gt;
Reporting&amp;#160;Date&amp;#160;Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Quoted&amp;#160;Prices&lt;br /&gt;
in&amp;#160;Active&lt;br /&gt;
Markets&amp;#160;for&lt;br /&gt;
Identical&lt;br /&gt;
Assets&lt;br /&gt;
(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs&lt;br /&gt;
(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&lt;br /&gt;
(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,048&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,048&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of December&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;735&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;735&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
  <us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock id="Tag245" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 682px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="682"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&lt;br /&gt;
31,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;85.9&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.56&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;8.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Tag246" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 715px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="715"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Warrant&lt;br /&gt;
Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exchangeable&lt;br /&gt;
Share&lt;br /&gt;
Liability&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;221&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;563&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance of exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(90&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;184&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;551&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Issuance of exchangeable shares&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;346&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Change in fair value&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(21&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,988&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:AssetsFairValueDisclosureNonrecurring id="Tag247" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsNonrecurringMember" unitRef="USD">0</us-gaap:AssetsFairValueDisclosureNonrecurring>
  <us-gaap:NonfinancialLiabilitiesFairValueDisclosure id="Tag248" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsNonrecurringMember" unitRef="USD">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="Tag249" decimals="-3" contextRef="I2013Q3" unitRef="USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="Tag250" decimals="-3" contextRef="I2013Q3" unitRef="USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="Tag251" decimals="-3" contextRef="I2013Q3" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="Tag252" decimals="-3" contextRef="I2013Q3" unitRef="USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="Tag253" decimals="-5" contextRef="I2013Q3_M0731_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag254" decimals="-5" contextRef="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member_CarryingReportedAmountFairValueDisclosureMember" unitRef="USD">1300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="Tag255" decimals="-5" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel1Member_CarryingReportedAmountFairValueDisclosureMember" unitRef="USD">300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag256" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_PreferredStockWarrantLiabilityMember" unitRef="USD">163000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag257" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_PreferredStockWarrantLiabilityMember" unitRef="USD">163000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag258" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ExchangeableShareLiabilityMember" unitRef="USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag259" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ExchangeableShareLiabilityMember" unitRef="USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag260" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD">3048000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag261" decimals="-3" contextRef="I2013Q3_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member" unitRef="USD">3048000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag262" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_PreferredStockWarrantLiabilityMember" unitRef="USD">184000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <dei:EntityCentralIndexKey id="Tag263" contextRef="D2013Q3YTD">0001434316</dei:EntityCentralIndexKey>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag264" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_PreferredStockWarrantLiabilityMember" unitRef="USD">184000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag265" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember_ExchangeableShareLiabilityMember" unitRef="USD">551000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag266" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ExchangeableShareLiabilityMember" unitRef="USD">551000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag267" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD">735000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure id="Tag268" decimals="-3" contextRef="I2012_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member" unitRef="USD">735000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag269" decimals="3" contextRef="D2013Q3YTD_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.021</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag270" decimals="3" contextRef="D2012_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.012</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag271" decimals="3" contextRef="D2013Q3YTD_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.859</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag272" decimals="3" contextRef="D2012_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.935</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="Tag273" decimals="3" contextRef="D2013Q3YTD_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate id="Tag274" decimals="3" contextRef="D2012_PreferredStockWarrantLiabilityMember" unitRef="Pure">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Tag275" contextRef="D2013Q3YTD_PreferredStockWarrantLiabilityMember">P7Y6M22D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedTerm id="Tag276" contextRef="D2012_PreferredStockWarrantLiabilityMember">P8Y3M22D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag277" decimals="-3" contextRef="I2011_PreferredStockWarrantLiabilityMember" unitRef="USD">221000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag278" decimals="-3" contextRef="I2012_PreferredStockWarrantLiabilityMember" unitRef="USD">184000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag279" decimals="-3" contextRef="I2013Q3_PreferredStockWarrantLiabilityMember" unitRef="USD">163000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag280" decimals="-3" contextRef="I2011_ExchangeableShareLiabilityMember" unitRef="USD">563000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag281" decimals="-3" contextRef="I2012_ExchangeableShareLiabilityMember" unitRef="USD">551000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="Tag282" decimals="-3" contextRef="I2013Q3_ExchangeableShareLiabilityMember" unitRef="USD">2885000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues id="Tag283" decimals="-3" contextRef="D2012_ExchangeableShareLiabilityMember" unitRef="USD">78000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Tag284" decimals="-3" contextRef="D2012_PreferredStockWarrantLiabilityMember" unitRef="USD">-37000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Tag285" decimals="-3" contextRef="D2013Q3YTD_PreferredStockWarrantLiabilityMember" unitRef="USD">-21000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Tag286" decimals="-3" contextRef="D2012_ExchangeableShareLiabilityMember" unitRef="USD">-90000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss id="Tag287" decimals="-3" contextRef="D2013Q3YTD_ExchangeableShareLiabilityMember_FV" unitRef="USD">1988000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock id="Tag288" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt and unamortized discount balances (excluding convertible debt) are as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 796px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="796"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;December&lt;br /&gt;
31,&amp;#160;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,750&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Less debt discount, net of current portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(18&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt, net of debt discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Less current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term debt, net of current portion&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;250&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,732&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of debt discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(29&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(59&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Current portion of long-term debt, net&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,971&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,941&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:ScheduleOfSubsequentEventsTextBlock id="Tag289" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated net proceeds from the IPO were determined as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 820px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.4in;" border="0" cellspacing="0" cellpadding="0" width="820"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Gross proceeds (including over-allotment)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;46,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Underwriting discounts and commissions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,695&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated total offering costs (including costs paid as of September&amp;#160;30, 2013)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(2,900&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Offering costs paid as of September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,381&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated net proceeds to be received subsequent to September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;41,786&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Partial repayment of August&amp;#160;2013 Notes subsequent to September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(1,741&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Estimated net cash impact of IPO and related transactions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;40,045&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSubsequentEventsTextBlock>
  <us-gaap:DebtInstrumentCarryingAmount id="Tag290" decimals="-3" contextRef="I2013Q3" unitRef="USD">2250000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:LongTermDebt id="Tag291" decimals="-3" contextRef="I2013Q3" unitRef="USD">2250000</us-gaap:LongTermDebt>
  <fate:LongTermDebtGrossCurrent id="Tag292" decimals="-3" contextRef="I2013Q3" unitRef="USD">2000000</fate:LongTermDebtGrossCurrent>
  <fate:DebtInstrumentDiscountCurrent id="Tag293" decimals="-3" contextRef="I2013Q3" unitRef="USD">29000</fate:DebtInstrumentDiscountCurrent>
  <us-gaap:DebtInstrumentCarryingAmount id="Tag294" decimals="-3" contextRef="I2012" unitRef="USD">3750000</us-gaap:DebtInstrumentCarryingAmount>
  <fate:DebtInstrumentDiscountNonCurrent id="Tag295" decimals="-3" contextRef="I2012" unitRef="USD">18000</fate:DebtInstrumentDiscountNonCurrent>
  <us-gaap:LongTermDebt id="Tag296" decimals="-3" contextRef="I2012" unitRef="USD">3732000</us-gaap:LongTermDebt>
  <fate:LongTermDebtGrossCurrent id="Tag297" decimals="-3" contextRef="I2012" unitRef="USD">2000000</fate:LongTermDebtGrossCurrent>
  <fate:DebtInstrumentDiscountCurrent id="Tag298" decimals="-3" contextRef="I2012" unitRef="USD">59000</fate:DebtInstrumentDiscountCurrent>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag299" decimals="INF" contextRef="I2013Q3_M0731_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="Pure">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentTerm id="Tag300" contextRef="D2013Q3_2M_ConvertiblePromissoryNotesDueOn24June2014Member">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Tag301" decimals="-5" contextRef="D2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium id="Tag302" decimals="-5" contextRef="D2013Q3YTD_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="Tag303" decimals="-5" contextRef="I2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentFaceAmount id="Tag304" decimals="-5" contextRef="I2013Q3_M0831_ConvertiblePromissoryNotesDueOn8August2016Member" unitRef="USD">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Tag305" decimals="INF" contextRef="I2013Q3_M0812_EquityIncentivePlan2007Member" unitRef="Shares">2423072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag306" decimals="INF" contextRef="I2013Q3_M0828_StockOptionAndIncentivePlan2013Member" unitRef="Shares">1020000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized id="Tag307" decimals="INF" contextRef="I2013Q3_M0828_StockOptionAndIncentivePlan2013Member" unitRef="Pure">0.04</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag308" decimals="INF" contextRef="I2013Q3_M0913_EmployeeStockMember" unitRef="Shares">729000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized id="Tag309" decimals="INF" contextRef="I2013Q3_M0913_EmployeeStockMember" unitRef="Pure">0.02</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="Tag310" decimals="INF" contextRef="D2013Q3_M0913_EmployeeStockMember" unitRef="Shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash id="Tag311" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">7666667</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>
  <us-gaap:EquityIssuancePerShareAmount id="Tag312" decimals="2" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USDPerShare">6.00</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Tag313" decimals="-3" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">46000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <fate:UnderwritingDiscountsAndCommissions id="Tag314" decimals="-3" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">2695000</fate:UnderwritingDiscountsAndCommissions>
  <us-gaap:OtherNoninterestExpense id="Tag315" decimals="-3" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">2900000</us-gaap:OtherNoninterestExpense>
  <fate:ProceedsReceivableFromIssuanceInitialPublicOffering id="Tag316" decimals="-3" contextRef="I2013Q4_M1004_SubsequentEventMember" unitRef="USD">41786000</fate:ProceedsReceivableFromIssuanceInitialPublicOffering>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="Tag317" decimals="INF" contextRef="I2013Q4_M1004_SubsequentEventMember" unitRef="Shares">7229590</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Tag318" decimals="-5" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">22100000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Tag319" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">3679401</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:RepaymentsOfConvertibleDebt id="Tag320" decimals="-3" contextRef="D2013Q4_M1004_ConvertiblePromissoryNotesDueOn8August2016Member_SubsequentEventMember" unitRef="USD">1741000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag321" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">480763</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <fate:ExchangeableSharesRedeemedDuringPeriodShares id="Tag322" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">900000</fate:ExchangeableSharesRedeemedDuringPeriodShares>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted id="Tag323" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">230000</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion id="Tag324" decimals="INF" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="Shares">36074</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion>
  <us-gaap:CommonStockSharesAuthorized id="Tag325" decimals="INF" contextRef="I2013Q4_M1004_SubsequentEventMember" unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="Tag326" decimals="INF" contextRef="I2013Q4_M1004_SubsequentEventMember" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ConvertibleNotesPayable id="Tag327" decimals="-5" contextRef="I2013Q3" unitRef="USD">23700000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="Tag328" decimals="-5" contextRef="I2013Q3" unitRef="USD">500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="Tag329" decimals="-5" contextRef="I2013Q3" unitRef="USD">900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="Tag330" decimals="-5" contextRef="I2013Q3" unitRef="USD">500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <dei:DocumentType id="Tag331" contextRef="D2013Q3YTD">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag332" contextRef="D2013Q3YTD">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag333" contextRef="D2013Q3YTD">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag334" contextRef="D2013Q3YTD">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag335" contextRef="D2013Q3YTD">No</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag336" contextRef="D2013Q3YTD">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus id="Tag337" contextRef="D2013Q3YTD">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag338" contextRef="D2013Q3YTD">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:EntityRegistrantName id="Tag339" contextRef="D2013Q3YTD">FATE THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:EntityCommonStockSharesOutstanding id="Tag340" decimals="INF" contextRef="I2013Q3SO" unitRef="Shares">20357158</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="Tag341" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfJuly2013Member" unitRef="Shares">76922</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:StockholdersEquityPolicyTextBlock id="Tag342" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Reverse Stock Split&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On September&amp;#160;12, 2013, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a one-for-6.5 reverse stock split of the Company&amp;#8217;s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company&amp;#8217;s consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag343" decimals="-3" contextRef="I2012Q3" unitRef="USD">5464000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag344" decimals="-3" contextRef="I2011" unitRef="USD">6387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent id="Tag345" decimals="-3" contextRef="I2012" unitRef="USD">143000</fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent>
  <fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent id="Tag346" decimals="-3" contextRef="I2013Q3" unitRef="USD">106000</fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable id="Tag347" decimals="-3" contextRef="I2013Q3" unitRef="USD">20000000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock id="Tag348" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 750px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="750"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Number&amp;#160;of&lt;br /&gt;
Options&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Weighted-&lt;br /&gt;
Average&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at December&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,432,369&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.43&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;331,860&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;5.60&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Canceled&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(17,860&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.56&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(35,852&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.65&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Balance at September&amp;#160;30, 2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,710,517&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.26&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="374"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag349" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-SIZE: 10pt;" size="2"&gt;The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 777px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="777"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.6%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Research and development&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;581&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;32&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;686&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;82&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;401&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;483&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;24&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;982&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;42&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,169&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;106&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Tag350" contextRef="D2013Q3YTD_EmployeeStockOptionMember">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 734px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="734"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2.1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90.3&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Remaining contractual term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.27&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;7.23&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="Tag351" contextRef="D2013Q3YTD_NonEmployeeStockOptionMember">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 730px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="730"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Nine&amp;#160;Months&amp;#160;Ended&lt;br /&gt;
September&amp;#160;30,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;90.2&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;93.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.07&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;6.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;0.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag352" decimals="INF" contextRef="I2012_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="Shares">1432369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag353" decimals="INF" contextRef="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="Shares">1710517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag354" decimals="INF" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="Shares">331860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Tag355" decimals="INF" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="Shares">17860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="Tag356" decimals="INF" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="Shares">35852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag357" decimals="2" contextRef="I2012_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USDPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag358" decimals="2" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USDPerShare">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Tag359" decimals="2" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USDPerShare">1.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="Tag360" decimals="2" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USDPerShare">0.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Tag361" decimals="2" contextRef="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USDPerShare">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag362" decimals="-3" contextRef="D2013Q3_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember" unitRef="USD">581000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag363" decimals="-3" contextRef="D2013Q3_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember" unitRef="USD">401000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag364" decimals="-3" contextRef="D2013Q3_EquityIncentivePlan2007Member" unitRef="USD">982000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag365" decimals="-3" contextRef="D2012Q3_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember" unitRef="USD">32000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag366" decimals="-3" contextRef="D2012Q3_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember" unitRef="USD">10000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag367" decimals="-3" contextRef="D2012Q3_EquityIncentivePlan2007Member" unitRef="USD">42000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag368" decimals="-3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember" unitRef="USD">686000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag369" decimals="-3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember" unitRef="USD">483000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag370" decimals="-3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member" unitRef="USD">1169000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag371" decimals="-3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_ResearchAndDevelopmentExpenseMember" unitRef="USD">82000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag372" decimals="-3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_GeneralAndAdministrativeExpenseMember" unitRef="USD">24000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag373" decimals="-3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member" unitRef="USD">106000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag374" decimals="INF" contextRef="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceMember" unitRef="Shares">340121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Tag375" decimals="INF" contextRef="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" unitRef="Shares">220496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag376" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag377" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag378" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Tag379" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag380" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag381" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag382" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Tag383" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag384" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="Tag385" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember">P6Y22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag386" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag387" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_EmployeeStockOptionMember" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Tag388" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Tag389" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember">P7Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag390" decimals="3" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Tag391" decimals="3" contextRef="D2012Q3YTD_EquityIncentivePlan2007Member_NonEmployeeStockOptionMember" unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue id="Tag392" decimals="-5" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceMember" unitRef="USD">1800000</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue>
  <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue id="Tag393" decimals="-5" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" unitRef="USD">200000</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Tag394" decimals="-5" contextRef="I2013Q3_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember" unitRef="USD">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Tag395" contextRef="D2013Q3YTD_EquityIncentivePlan2007Member_EmployeeAndNonEmployeeStockOptionMember">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <fate:EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions id="Tag396" decimals="-3" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">40045000</fate:EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions>
  <us-gaap:WriteOffOfDeferredDebtIssuanceCost id="Tag397" decimals="-5" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">300000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag398" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">59127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="Tag399" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">2344000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent id="Tag400" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">79000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
  <us-gaap:CommonStockValue id="Tag401" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">20000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="Tag402" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">136398000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag403" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">81024000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag404" decimals="-3" contextRef="I2013Q3_ProFormaMember" unitRef="USD">55394000</us-gaap:StockholdersEquity>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones id="Tag405" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember" unitRef="Shares">211539</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones id="Tag406" decimals="INF" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember" unitRef="Shares">115381</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones>
  <fate:LeaseTermExtended id="Tag407" contextRef="D2013Q3_M0926">P2Y</fate:LeaseTermExtended>
  <fate:NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability id="Tag408" decimals="-5" contextRef="D2013Q4_M1004_SubsequentEventMember" unitRef="USD">500000</fate:NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability>
  <fate:AssetAcquisitionTextBlock id="Tag409" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;2.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/b&gt; &lt;b&gt;&lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Asset Acquisition of Verio Therapeutics Inc.&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;On April&amp;#160;7, 2010, the Company acquired Verio Therapeutics Inc. (&amp;#8220;Verio&amp;#8221;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &amp;#8220;Exchangeable Shares&amp;#8221;) that were initially exchangeable into 138,462 shares of our common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, may be exchangeable for up to 884,605 shares of our common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The Exchangeable Shares will be automatically redeemed and exchanged for shares of the Company&amp;#8217;s common stock upon the earliest of: (i)&amp;#160;April&amp;#160;13, 2017, (ii)&amp;#160;the date immediately prior to an IPO of the Company&amp;#8217;s common stock pursuant to a registration statement filed with and declared effective by the SEC, (iii)&amp;#160;the effective date of certain change of control events, (iv)&amp;#160;the date upon which holders of at least a majority of the then outstanding Exchangeable Shares approve the redemption and exchange of all of the outstanding Exchangeable Shares, (v)&amp;#160;the date upon which there are less than 450,000 Exchangeable Shares outstanding or (vi)&amp;#160;the date that the holders of the Exchangeable Shares can exchange for shares of the Company&amp;#8217;s common stock on a tax-deferred basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013 and December&amp;#160;31, 2012, the Exchangeable Shares were exchangeable into 480,763 shares and 403,841 shares, respectively, of the Company&amp;#8217;s common stock. As of September&amp;#160;30, 2013, the number of shares of the Company&amp;#8217;s common stock to be issued upon exchange of the Exchangeable Shares is subject to further increase as follows: (i)&amp;#160;76,922 shares for the achievement of certain pre-clinical milestones, (ii)&amp;#160;211,539 shares for the achievement of certain clinical milestones and (iii)&amp;#160;115,381 shares for the achievement of certain commercialization milestones.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;At the date of an increase in the number of shares of the Company&amp;#8217;s common stock issuable upon any exchange of the Exchangeable Shares due to the achievement of a milestone as described above, the fair value of these additional shares of common stock is charged to research and development expense. At the end of each reporting period, any changes in the fair value of Exchangeable Shares resulting from changes in the fair value of the underlying common stock of the Company are recorded as a component of other income (expense).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;As of September&amp;#160;30, 2013, the changes in the number of shares of the Company&amp;#8217;s common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares are summarized as follows (in thousands, except share and per share amounts):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"&gt;

&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Exchangeable&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Fair&amp;#160;Value&amp;#160;Per&lt;br /&gt;
Share&amp;#160;of&lt;br /&gt;
Underlying&lt;br /&gt;
Common&amp;#160;Stock&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Initial&amp;#160;Fair&lt;br /&gt;
Value&amp;#160;of&lt;br /&gt;
Exchangeable&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;April&amp;#160;2010&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;138,462&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;234&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;March&amp;#160;2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;92,308&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;156&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;May&amp;#160;2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;115,380&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.69&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;195&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;April&amp;#160;2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;57,691&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1.37&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;78&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;July&amp;#160;2013&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;76,922&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;4.49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;346&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;480,763&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1,009&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="316"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;/div&gt;</fate:AssetAcquisitionTextBlock>
  <fate:OtherAssetsPolicy id="Tag410" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2"&gt;Other Assets&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other assets consist of the Company&amp;#8217;s deferred IPO costs. These costs represent legal, accounting and other direct costs related to the Company&amp;#8217;s efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</fate:OtherAssetsPolicy>
  <fate:ScheduleOfActualAndProformaBalanceSheetDetail id="Tag411" contextRef="D2013Q3YTD">&lt;div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"&gt;
&lt;p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company&amp;#8217;s IPO noted above, as of September&amp;#160;30, 2013 (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="text-align:left;TEXT-ALIGN: left; WIDTH: 797px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="797"&gt;

&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1"&gt;Pro&amp;#160;Forma&lt;br /&gt;
September&lt;br /&gt;
30,&amp;#160;2013&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;19,082&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;59,127&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Other assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,743&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Accounts payable and accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;3,725&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,344&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Long-term accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;137&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;79&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible notes, net of discount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;23,481&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Preferred stock warrant liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;163&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Exchangeable share liability&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;2,885&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Convertible preferred stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;56,526&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;1&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;20&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Additional paid-in capital&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;14,367&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;136,398&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Deficit accumulated during the development stage&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(80,770&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(81,024&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;Total stockholders&amp;#8217; (deficit) equity&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;(66,402&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2"&gt;55,394&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="424"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fate:ScheduleOfActualAndProformaBalanceSheetDetail>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag412" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2010Member" unitRef="USD">234000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag413" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMarch2011Member" unitRef="USD">156000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag414" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfMay2011Member" unitRef="USD">195000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag415" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfApril2012Member" unitRef="USD">78000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag416" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember" unitRef="USD">1009000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <fate:BusinessAcquisitionInitialFairValueOfExchangeableShares id="Tag417" decimals="-3" contextRef="D2013Q3YTD_VerioTherapeuticsIncMember_PeriodOfJuly2013Member" unitRef="USD">346000</fate:BusinessAcquisitionInitialFairValueOfExchangeableShares>
  <us-gaap:DebtInstrumentTerm id="Tag418" contextRef="D2013Q3_M0831_ConvertiblePromissoryNotesDueOn8August2016Member">P3Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:ConvertibleNotesPayable id="Tag419" decimals="-5" contextRef="I2013Q3_ConvertiblePromissoryNotesDueOn24June2014Member" unitRef="USD">3700000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="Tag420" decimals="-5" contextRef="I2013Q3_ConvertiblePromissoryNotesDueOn8August2016Member" unitRef="USD">100000</us-gaap:InterestPayableCurrentAndNoncurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fate-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<xsd:schema targetNamespace="http://www.fatetherapeutics.com/20130930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:fate="http://www.fatetherapeutics.com/20130930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20130930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20130930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20130930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20130930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/CashFlows" id="CashFlows">
        <link:definition>0030 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>1010 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc" id="DisclosureAssetAcquisitionOfVerioTherapeuticsInc">
        <link:definition>1020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1030 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingencies" id="DisclosureLongTermDebtCommitmentsAndContingencies">
        <link:definition>1040 - Disclosure - Long-Term Debt, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficit" id="DisclosureStockholdersDeficit">
        <link:definition>1050 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>1060 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2010 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>3010 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables" id="DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables">
        <link:definition>3020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>3030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesTables" id="DisclosureLongTermDebtCommitmentsAndContingenciesTables">
        <link:definition>3040 - Disclosure - Long-Term Debt, Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables" id="DisclosureStockholdersDeficitTables">
        <link:definition>3050 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsTables" id="DisclosureSubsequentEventsTables">
        <link:definition>3060 - Disclosure - Subsequent Events (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>4010 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>4011 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" id="DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails">
        <link:definition>4020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>4030 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" id="DisclosureFairValueMeasurementsDetails2">
        <link:definition>4031 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails" id="DisclosureLongTermDebtCommitmentsAndContingenciesDetails">
        <link:definition>4040 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails2" id="DisclosureLongTermDebtCommitmentsAndContingenciesDetails2">
        <link:definition>4041 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetailsCalc2" id="DisclosureLongTermDebtCommitmentsAndContingenciesDetailsCalc2">
        <link:definition>4042 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails" id="DisclosureStockholdersDeficitDetails">
        <link:definition>4050 - Disclosure - Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>4060 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2" id="DisclosureSubsequentEventsDetails2">
        <link:definition>4061 - Disclosure - Subsequent Events (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:element name="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" id="fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ActualAndProformaBalanceSheetDataAbstract" id="fate_ActualAndProformaBalanceSheetDataAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExchangeableShareLiabilityNoncurrent" id="fate_ExchangeableShareLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FairValueAdjustmentOfExchangeableShares" id="fate_FairValueAdjustmentOfExchangeableShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" id="fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" id="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExchangeableShareLiabilityMember" id="fate_ExchangeableShareLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" id="fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VerioTherapeuticsIncMember" id="fate_VerioTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockWarrantLiabilityMember" id="fate_PreferredStockWarrantLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfApril2010Member" id="fate_PeriodOfApril2010Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfMarch2011Member" id="fate_PeriodOfMarch2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfMay2011Member" id="fate_PeriodOfMay2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfApril2012Member" id="fate_PeriodOfApril2012Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" id="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" id="fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionFairValueOfUnderlyingCommonStock" id="fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock" type="num:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentDiscountNonCurrent" id="fate_DebtInstrumentDiscountNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LongTermDebtGrossCurrent" id="fate_LongTermDebtGrossCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentDiscountCurrent" id="fate_DebtInstrumentDiscountCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EquityIncentivePlan2007Member" id="fate_EquityIncentivePlan2007Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionAndIncentivePlan2013Member" id="fate_StockOptionAndIncentivePlan2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="UnderwritingDiscountsAndCommissions" id="fate_UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsReceivableFromIssuanceInitialPublicOffering" id="fate_ProceedsReceivableFromIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ExchangeableSharesRedeemedDuringPeriodShares" id="fate_ExchangeableSharesRedeemedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" id="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" id="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePromissoryNotesDueOn24June2014Member" id="fate_ConvertiblePromissoryNotesDueOn24June2014Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePromissoryNotesDueOn8August2016Member" id="fate_ConvertiblePromissoryNotesDueOn8August2016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="fate_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" id="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NonEmployeeStockOptionMember" id="fate_NonEmployeeStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonEmployeeStockOptionMember" id="fate_EmployeeAndNonEmployeeStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VestingBasedOnPerformanceMember" id="fate_VestingBasedOnPerformanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" id="fate_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodOfJuly2013Member" id="fate_PeriodOfJuly2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseTermExtended" id="fate_LeaseTermExtended" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" id="fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AssetAcquisitionAbstract" id="fate_AssetAcquisitionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetAcquisitionTextBlock" id="fate_AssetAcquisitionTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAssetsPolicy" id="fate_OtherAssetsPolicy" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfActualAndProformaBalanceSheetDetail" id="fate_ScheduleOfActualAndProformaBalanceSheetDetail" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionInitialFairValueOfExchangeableShares" id="fate_BusinessAcquisitionInitialFairValueOfExchangeableShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>fate-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="fate-20130930.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="fate-20130930.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="fate-20130930.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetailsCalc2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesDetailsCalc2" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LiabilitiesCurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LiabilitiesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRevenueCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRevenueCurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DeferredRentCreditCurrent" xlink:title="calculation: LiabilitiesCurrent to DeferredRentCreditCurrent" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to ConvertibleNotesPayableCurrent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="calculation: LiabilitiesCurrent to RepurchaseLiabilityForUnvestedEquityAwardsCurrent" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="WarrantsAndRightsOutstanding" xlink:title="calculation: LiabilitiesCurrent to WarrantsAndRightsOutstanding" use="optional" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtCurrent" use="optional" order="7.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="DeferredRentCreditNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to DeferredRentCreditNoncurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityNoncurrent" xlink:label="ExchangeableShareLiabilityNoncurrent" xlink:title="ExchangeableShareLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="ExchangeableShareLiabilityNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to ExchangeableShareLiabilityNoncurrent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="LongTermDebtNoncurrent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to LongTermDebtNoncurrent" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="calculation: LiabilitiesAndStockholdersEquity to ConvertibleLongTermNotesPayable" use="optional" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="calculation: LiabilitiesAndStockholdersEquity to TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="7.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" use="optional" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="calculation: StockholdersEquity to DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="calculation: Assets to RestrictedCashAndCashEquivalentsNoncurrent" use="optional" order="4.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLoss" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DepreciationDepletionAndAmortization" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to AmortizationOfDebtDiscountPremium" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to PaidInKindInterest" use="optional" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StraightLineRent" xlink:label="StraightLineRent" xlink:title="StraightLineRent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="StraightLineRent" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to StraightLineRent" use="optional" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="RecognitionOfDeferredRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to RecognitionOfDeferredRevenue" use="optional" order="8.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_FairValueAdjustmentOfExchangeableShares" xlink:label="FairValueAdjustmentOfExchangeableShares" xlink:title="FairValueAdjustmentOfExchangeableShares" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="FairValueAdjustmentOfExchangeableShares" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to FairValueAdjustmentOfExchangeableShares" use="optional" order="9.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to FairValueAdjustmentOfWarrants" use="optional" order="10.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnDispositionOfAssets1" use="optional" order="11.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainsLossesOnExtinguishmentOfDebt" use="optional" order="12.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="13.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="14.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="IncreaseDecreaseInRestrictedCash" xlink:title="IncreaseDecreaseInRestrictedCash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInRestrictedCash" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to IncreaseDecreaseInRestrictedCash" use="optional" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="ProceedsFromRepurchaseOfEquity" xlink:title="ProceedsFromRepurchaseOfEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromRepurchaseOfEquity" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromRepurchaseOfEquity" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to PaymentsOfStockIssuanceCosts" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromConvertibleDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromConvertibleDebt" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfLongTermDebt" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="RepaymentsOfLongTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to RepaymentsOfLongTermDebt" use="optional" order="5.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="6.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="SalesRevenueNet" xlink:title="calculation: OperatingIncomeLoss to SalesRevenueNet" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="ContractsRevenue" xlink:title="calculation: SalesRevenueNet to ContractsRevenue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SalesRevenueNet" xlink:to="RevenueFromGrants" xlink:title="calculation: SalesRevenueNet to RevenueFromGrants" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to OtherNonoperatingIncomeExpense" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LongTermDebtGrossCurrent" xlink:label="LongTermDebtGrossCurrent" xlink:title="LongTermDebtGrossCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebtCurrent" xlink:to="LongTermDebtGrossCurrent" xlink:title="calculation: LongTermDebtCurrent to LongTermDebtGrossCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="DebtInstrumentDiscountCurrent" xlink:title="DebtInstrumentDiscountCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebtCurrent" xlink:to="DebtInstrumentDiscountCurrent" xlink:title="calculation: LongTermDebtCurrent to DebtInstrumentDiscountCurrent" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentCarryingAmount" xlink:title="calculation: LongTermDebt to DebtInstrumentCarryingAmount" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="DebtInstrumentDiscountNonCurrent" xlink:title="DebtInstrumentDiscountNonCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentDiscountNonCurrent" xlink:title="calculation: LongTermDebt to DebtInstrumentDiscountNonCurrent" use="optional" order="2.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LongTermDebtGrossCurrent" xlink:label="LongTermDebtGrossCurrent" xlink:title="LongTermDebtGrossCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtGrossCurrent" xlink:title="calculation: LongTermDebt to LongTermDebtGrossCurrent" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtNoncurrent" xlink:title="calculation: LongTermDebt to LongTermDebtNoncurrent" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>fate-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureStockholdersDeficitTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureStockholdersDeficitDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEventsDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurementsDetails2" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="definition: AwardDateAxis to AwardDateDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain_2" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain_2" xlink:title="definition: AwardDateAxis to AwardDateDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AwardDateDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AwardDateDomain to EmployeeStockOptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NonEmployeeStockOptionMember" xlink:label="NonEmployeeStockOptionMember" xlink:title="NonEmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AwardDateDomain" xlink:to="NonEmployeeStockOptionMember" xlink:title="definition: AwardDateDomain to NonEmployeeStockOptionMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="ScheduleOfStockOptionsRollForwardTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfStockOptionsRollForwardTableTextBlock" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="definition: AwardDateAxis to AwardDateDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="EmployeeAndNonEmployeeStockOptionMember" xlink:title="EmployeeAndNonEmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AwardDateDomain" xlink:to="EmployeeAndNonEmployeeStockOptionMember" xlink:title="definition: AwardDateDomain to EmployeeAndNonEmployeeStockOptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="EmployeeStockOptionMember" xlink:title="definition: EmployeeAndNonEmployeeStockOptionMember to EmployeeStockOptionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NonEmployeeStockOptionMember" xlink:label="NonEmployeeStockOptionMember" xlink:title="NonEmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="NonEmployeeStockOptionMember" xlink:title="definition: EmployeeAndNonEmployeeStockOptionMember to NonEmployeeStockOptionMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EquityIncentivePlan2007Member" xlink:label="EquityIncentivePlan2007Member" xlink:title="EquityIncentivePlan2007Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2007Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2007Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="StockOptionAndIncentivePlan2013Member" xlink:title="StockOptionAndIncentivePlan2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="StockOptionAndIncentivePlan2013Member" xlink:title="definition: PlanNameDomain to StockOptionAndIncentivePlan2013Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EmployeeStockMember" xlink:title="definition: PlanNameDomain to EmployeeStockMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain_2" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain_2" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="VestingBasedOnPerformanceMember" xlink:title="VestingBasedOnPerformanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="VestingBasedOnPerformanceMember" xlink:title="definition: VestingDomain to VestingBasedOnPerformanceMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:label="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="definition: VestingDomain to VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" order="12.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn24June2014Member" xlink:label="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn24June2014Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:label="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn8August2016Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="DebtInstrumentDiscountNonCurrent" xlink:title="DebtInstrumentDiscountNonCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentDiscountNonCurrent" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentDiscountNonCurrent" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="definition: DebtInstrumentLineItems to LongTermDebt" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LongTermDebtGrossCurrent" xlink:label="LongTermDebtGrossCurrent" xlink:title="LongTermDebtGrossCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtGrossCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtGrossCurrent" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtNoncurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtNoncurrent" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="DebtInstrumentDiscountCurrent" xlink:title="DebtInstrumentDiscountCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentDiscountCurrent" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentDiscountCurrent" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtCurrent" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfDebtDiscountPremium" use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="ConvertibleNotesPayable" xlink:title="ConvertibleNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayable" xlink:title="definition: DebtInstrumentLineItems to ConvertibleNotesPayable" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="definition: DebtInstrumentLineItems to ConvertibleLongTermNotesPayable" use="optional" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" use="optional" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrent" xlink:title="definition: DebtInstrumentLineItems to InterestPayableCurrent" use="optional" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="definition: DebtInstrumentLineItems to InterestPayableCurrentAndNoncurrent" order="17.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:label="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="definition: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn8August2016Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: SubsequentEventTable to DebtInstrumentAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="StockIssuedDuringPeriodSharesIssuedForCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="definition: SubsequentEventLineItems to StockIssuedDuringPeriodSharesIssuedForCash" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="definition: SubsequentEventLineItems to EquityIssuancePerShareAmount" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceInitialPublicOffering" xlink:title="definition: SubsequentEventLineItems to ProceedsFromIssuanceInitialPublicOffering" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_UnderwritingDiscountsAndCommissions" xlink:label="UnderwritingDiscountsAndCommissions" xlink:title="UnderwritingDiscountsAndCommissions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="UnderwritingDiscountsAndCommissions" xlink:title="definition: SubsequentEventLineItems to UnderwritingDiscountsAndCommissions" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoninterestExpense" xlink:label="OtherNoninterestExpense" xlink:title="OtherNoninterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="OtherNoninterestExpense" xlink:title="definition: SubsequentEventLineItems to OtherNoninterestExpense" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: SubsequentEventLineItems to PaymentsOfStockIssuanceCosts" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:label="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="definition: SubsequentEventLineItems to ProceedsReceivableFromIssuanceInitialPublicOffering" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RepaymentsOfConvertibleDebt" xlink:title="definition: SubsequentEventLineItems to RepaymentsOfConvertibleDebt" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:label="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="definition: SubsequentEventLineItems to EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="definition: SubsequentEventLineItems to ConvertiblePreferredStockSharesIssuedUponConversion" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="definition: SubsequentEventLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: SubsequentEventLineItems to DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="WriteOffOfDeferredDebtIssuanceCost" xlink:title="WriteOffOfDeferredDebtIssuanceCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="WriteOffOfDeferredDebtIssuanceCost" xlink:title="definition: SubsequentEventLineItems to WriteOffOfDeferredDebtIssuanceCost" use="optional" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="definition: SubsequentEventLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableSharesRedeemedDuringPeriodShares" xlink:label="ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="definition: SubsequentEventLineItems to ExchangeableSharesRedeemedDuringPeriodShares" use="optional" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" use="optional" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" use="optional" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: SubsequentEventLineItems to CommonStockSharesAuthorized" use="optional" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: SubsequentEventLineItems to PreferredStockSharesAuthorized" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ActualAndProformaBalanceSheetDataAbstract" xlink:label="ActualAndProformaBalanceSheetDataAbstract" xlink:title="ActualAndProformaBalanceSheetDataAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ActualAndProformaBalanceSheetDataAbstract" xlink:title="definition: SubsequentEventLineItems to ActualAndProformaBalanceSheetDataAbstract" use="optional" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to OtherAssetsNoncurrent" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to ConvertibleNotesPayableCurrent" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to WarrantsAndRightsOutstanding" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityNoncurrent" xlink:label="ExchangeableShareLiabilityNoncurrent" xlink:title="ExchangeableShareLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="ExchangeableShareLiabilityNoncurrent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to ExchangeableShareLiabilityNoncurrent" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="StatementScenarioAxis" xlink:title="definition: SubsequentEventTable to StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProFormaMember" xlink:label="ProFormaMember" xlink:title="ProFormaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ProFormaMember" xlink:title="definition: ScenarioUnspecifiedDomain to ProFormaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ActualAndProformaBalanceSheetDataAbstract" xlink:label="ActualAndProformaBalanceSheetDataAbstract" xlink:title="ActualAndProformaBalanceSheetDataAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ActualAndProformaBalanceSheetDataAbstract" xlink:title="definition: SubsequentEventLineItems to ActualAndProformaBalanceSheetDataAbstract" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="CommonStockValue" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to CommonStockValue" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to AdditionalPaidInCapital" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="StockholdersEquity" xlink:title="definition: ActualAndProformaBalanceSheetDataAbstract to StockholdersEquity" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:label="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="definition: SubsequentEventLineItems to NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" use="optional" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="EquityUnitPurchaseAgreementsMember" xlink:title="EquityUnitPurchaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EquityUnitPurchaseAgreementsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EquityUnitPurchaseAgreementsMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="StockCompensationPlanMember" xlink:title="StockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockCompensationPlanMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockCompensationPlanMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VerioTherapeuticsIncMember" xlink:label="VerioTherapeuticsIncMember" xlink:title="VerioTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="VerioTherapeuticsIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to VerioTherapeuticsIncMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessCombinationSeparatelyRecognizedTransactionsAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsAxis to BusinessCombinationSeparatelyRecognizedTransactionsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsDomain_2" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="BusinessCombinationSeparatelyRecognizedTransactionsDomain_2" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsAxis to BusinessCombinationSeparatelyRecognizedTransactionsDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2010Member" xlink:label="PeriodOfApril2010Member" xlink:title="PeriodOfApril2010Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfApril2010Member" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfApril2010Member" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMarch2011Member" xlink:label="PeriodOfMarch2011Member" xlink:title="PeriodOfMarch2011Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfMarch2011Member" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfMarch2011Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMay2011Member" xlink:label="PeriodOfMay2011Member" xlink:title="PeriodOfMay2011Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfMay2011Member" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfMay2011Member" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2012Member" xlink:label="PeriodOfApril2012Member" xlink:title="PeriodOfApril2012Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfApril2012Member" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfApril2012Member" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfJuly2013Member" xlink:label="PeriodOfJuly2013Member" xlink:title="PeriodOfJuly2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfJuly2013Member" xlink:title="definition: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfJuly2013Member" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to ExchangeableStockIssuedDuringPeriodSharesAcquisitions" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:label="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:label="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionFairValueOfUnderlyingCommonStock" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:label="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="BusinessAcquisitionInitialFairValueOfExchangeableShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionInitialFairValueOfExchangeableShares" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementBasisAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementBasisAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="FairValueDisclosureItemAmountsDomain" xlink:title="definition: FairValueByMeasurementBasisAxis to FairValueDisclosureItemAmountsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain_2" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="FairValueDisclosureItemAmountsDomain_2" xlink:title="definition: FairValueByMeasurementBasisAxis to FairValueDisclosureItemAmountsDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="CarryingReportedAmountFairValueDisclosureMember" xlink:title="CarryingReportedAmountFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="CarryingReportedAmountFairValueDisclosureMember" xlink:title="definition: FairValueDisclosureItemAmountsDomain to CarryingReportedAmountFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="EstimateOfFairValueFairValueDisclosureMember" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PreferredStockWarrantLiabilityMember" xlink:label="PreferredStockWarrantLiabilityMember" xlink:title="PreferredStockWarrantLiabilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PreferredStockWarrantLiabilityMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PreferredStockWarrantLiabilityMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityMember" xlink:label="ExchangeableShareLiabilityMember" xlink:title="ExchangeableShareLiabilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ExchangeableShareLiabilityMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ExchangeableShareLiabilityMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="AssetsFairValueDisclosureNonrecurring" xlink:title="AssetsFairValueDisclosureNonrecurring" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureNonrecurring" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureNonrecurring" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="NonfinancialLiabilitiesFairValueDisclosure" xlink:title="NonfinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="NonfinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to NonfinancialLiabilitiesFairValueDisclosure" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialLiabilitiesFairValueDisclosure" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedVolatilityRate" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedTerm" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedTerm" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedDividendRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedDividendRate" use="optional" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PreferredStockWarrantLiabilityMember" xlink:label="PreferredStockWarrantLiabilityMember" xlink:title="PreferredStockWarrantLiabilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PreferredStockWarrantLiabilityMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PreferredStockWarrantLiabilityMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityMember" xlink:label="ExchangeableShareLiabilityMember" xlink:title="ExchangeableShareLiabilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ExchangeableShareLiabilityMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ExchangeableShareLiabilityMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByLiabilityClassAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="3.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>fate-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:label="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:label xlink:type="resource" xlink:label="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xml:lang="en-US" id="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions">Estimated Net Cash Impact of Initial Public Offering and Related Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:to="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="label: EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions to label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:label xlink:type="resource" xlink:label="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xml:lang="en-US" id="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_2">Estimated net cash impact of IPO and related transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:to="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_2" xlink:title="label: EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions to label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:label xlink:type="resource" xlink:label="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xml:lang="en-US" id="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_3">Represents the estimated, net cash impact of initial public offering (IPO) and related transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:to="label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions_3" xlink:title="label: EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions to label_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue">Represents the aggregate grant-date fair value of share-based compensation plan awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_2">Share Based Compensation Arrangement by Share Based Payment Award Total Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_3">Aggregate grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ActualAndProformaBalanceSheetDataAbstract" xlink:label="ActualAndProformaBalanceSheetDataAbstract" xlink:title="ActualAndProformaBalanceSheetDataAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ActualAndProformaBalanceSheetDataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ActualAndProformaBalanceSheetDataAbstract" xml:lang="en-US" id="label_ActualAndProformaBalanceSheetDataAbstract">Actual and Proforma Balance Sheet Data [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="label_ActualAndProformaBalanceSheetDataAbstract" xlink:title="label: ActualAndProformaBalanceSheetDataAbstract to label_ActualAndProformaBalanceSheetDataAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ActualAndProformaBalanceSheetDataAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ActualAndProformaBalanceSheetDataAbstract" xml:lang="en-US" id="label_ActualAndProformaBalanceSheetDataAbstract_2">Actual balance sheet data and pro forma balance sheet data</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="label_ActualAndProformaBalanceSheetDataAbstract_2" xlink:title="label: ActualAndProformaBalanceSheetDataAbstract to label_ActualAndProformaBalanceSheetDataAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityNoncurrent" xlink:label="ExchangeableShareLiabilityNoncurrent" xlink:title="ExchangeableShareLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExchangeableShareLiabilityNoncurrent" xml:lang="en-US" id="label_ExchangeableShareLiabilityNoncurrent">Exchangeable Share Liability Non current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityNoncurrent" xlink:to="label_ExchangeableShareLiabilityNoncurrent" xlink:title="label: ExchangeableShareLiabilityNoncurrent to label_ExchangeableShareLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExchangeableShareLiabilityNoncurrent" xml:lang="en-US" id="label_ExchangeableShareLiabilityNoncurrent_2">Exchangeable share liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityNoncurrent" xlink:to="label_ExchangeableShareLiabilityNoncurrent_2" xlink:title="label: ExchangeableShareLiabilityNoncurrent to label_ExchangeableShareLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityNoncurrent_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExchangeableShareLiabilityNoncurrent" xml:lang="en-US" id="label_ExchangeableShareLiabilityNoncurrent_3">Represents the carrying value as of the balance sheet date of exchangeable share liability, which is expected to be paid after one year (or the normal operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityNoncurrent" xlink:to="label_ExchangeableShareLiabilityNoncurrent_3" xlink:title="label: ExchangeableShareLiabilityNoncurrent to label_ExchangeableShareLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_FairValueAdjustmentOfExchangeableShares" xlink:label="FairValueAdjustmentOfExchangeableShares" xlink:title="FairValueAdjustmentOfExchangeableShares" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfExchangeableShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAdjustmentOfExchangeableShares" xml:lang="en-US" id="label_FairValueAdjustmentOfExchangeableShares">Fair Value Adjustment of Exchangeable Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfExchangeableShares" xlink:to="label_FairValueAdjustmentOfExchangeableShares" xlink:title="label: FairValueAdjustmentOfExchangeableShares to label_FairValueAdjustmentOfExchangeableShares" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfExchangeableShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAdjustmentOfExchangeableShares" xml:lang="en-US" id="label_FairValueAdjustmentOfExchangeableShares_2">Initial fair value and change in fair value of exchangeable shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfExchangeableShares" xlink:to="label_FairValueAdjustmentOfExchangeableShares_2" xlink:title="label: FairValueAdjustmentOfExchangeableShares to label_FairValueAdjustmentOfExchangeableShares" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfExchangeableShares_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FairValueAdjustmentOfExchangeableShares" xml:lang="en-US" id="label_FairValueAdjustmentOfExchangeableShares_3">Represents the initial fair value and change in fair value amounts of exchangeable shares during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfExchangeableShares" xlink:to="label_FairValueAdjustmentOfExchangeableShares_3" xlink:title="label: FairValueAdjustmentOfExchangeableShares to label_FairValueAdjustmentOfExchangeableShares" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:label="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:title="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xml:lang="en-US" id="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells">Number of Platforms to Enhance Therapeutic Potential of Adult Stem Cells</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:to="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:title="label: NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells to label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xml:lang="en-US" id="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_2">Number of platforms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:to="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_2" xlink:title="label: NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells to label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xml:lang="en-US" id="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_3">Represents the number of platforms that optimize the activity and enhance the therapeutic potential of adult stem cells.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:to="label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells_3" xlink:title="label: NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells to label_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:label="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:title="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xml:lang="en-US" id="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding">Shares Attributable to Share Based Payment Arrangements Excluded from Weighted Average Number of Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:to="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:title="label: SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding to label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xml:lang="en-US" id="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_2">Shares excluded from weighted average number of shares attributable to share based payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:to="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_2" xlink:title="label: SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding to label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xml:lang="en-US" id="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_3">Represents the shares excluded from the weighted-average number of shares outstanding attributable to share based payment arrangements including shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:to="label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_3" xlink:title="label: SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding to label_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityMember" xlink:label="ExchangeableShareLiabilityMember" xlink:title="ExchangeableShareLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExchangeableShareLiabilityMember" xml:lang="en-US" id="label_ExchangeableShareLiabilityMember">Exchangeable Share Liability [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityMember" xlink:to="label_ExchangeableShareLiabilityMember" xlink:title="label: ExchangeableShareLiabilityMember to label_ExchangeableShareLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExchangeableShareLiabilityMember" xml:lang="en-US" id="label_ExchangeableShareLiabilityMember_2">Exchangeable share liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityMember" xlink:to="label_ExchangeableShareLiabilityMember_2" xlink:title="label: ExchangeableShareLiabilityMember to label_ExchangeableShareLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableShareLiabilityMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExchangeableShareLiabilityMember" xml:lang="en-US" id="label_ExchangeableShareLiabilityMember_3">Represents information pertaining to exchangeable shares liability amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableShareLiabilityMember" xlink:to="label_ExchangeableShareLiabilityMember_3" xlink:title="label: ExchangeableShareLiabilityMember to label_ExchangeableShareLiabilityMember" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:label="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:title="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xml:lang="en-US" id="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock">Schedule of Changes in Shares Issued upon Exchange of Exchangeable Shares and Initial Fair Value [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:to="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:title="label: ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock to label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xml:lang="en-US" id="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_2">Summary of changes in the number of shares of the Company's common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:to="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_2" xlink:title="label: ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock to label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xml:lang="en-US" id="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_3">Tabular disclosure of changes in the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value of the shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:to="label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock_3" xlink:title="label: ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock to label_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VerioTherapeuticsIncMember" xlink:label="VerioTherapeuticsIncMember" xlink:title="VerioTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="label_VerioTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VerioTherapeuticsIncMember" xml:lang="en-US" id="label_VerioTherapeuticsIncMember">Verio Therapeutics Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VerioTherapeuticsIncMember" xlink:to="label_VerioTherapeuticsIncMember" xlink:title="label: VerioTherapeuticsIncMember to label_VerioTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="label_VerioTherapeuticsIncMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VerioTherapeuticsIncMember" xml:lang="en-US" id="label_VerioTherapeuticsIncMember_2">Verio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VerioTherapeuticsIncMember" xlink:to="label_VerioTherapeuticsIncMember_2" xlink:title="label: VerioTherapeuticsIncMember to label_VerioTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="label_VerioTherapeuticsIncMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_VerioTherapeuticsIncMember" xml:lang="en-US" id="label_VerioTherapeuticsIncMember_3">Represents information pertaining to Verio Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VerioTherapeuticsIncMember" xlink:to="label_VerioTherapeuticsIncMember_3" xlink:title="label: VerioTherapeuticsIncMember to label_VerioTherapeuticsIncMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label: AmendmentDescription to label_AmendmentDescription" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PreferredStockWarrantLiabilityMember" xlink:label="PreferredStockWarrantLiabilityMember" xlink:title="PreferredStockWarrantLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockWarrantLiabilityMember" xml:lang="en-US" id="label_PreferredStockWarrantLiabilityMember">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantLiabilityMember" xlink:to="label_PreferredStockWarrantLiabilityMember" xlink:title="label: PreferredStockWarrantLiabilityMember to label_PreferredStockWarrantLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantLiabilityMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PreferredStockWarrantLiabilityMember" xml:lang="en-US" id="label_PreferredStockWarrantLiabilityMember_2">Represents information pertaining to the preferred stock warrant liability amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantLiabilityMember" xlink:to="label_PreferredStockWarrantLiabilityMember_2" xlink:title="label: PreferredStockWarrantLiabilityMember to label_PreferredStockWarrantLiabilityMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockWarrantLiabilityMember_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockWarrantLiabilityMember" xml:lang="en-US" id="label_PreferredStockWarrantLiabilityMember_3">Preferred Stock Warrant Liability [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockWarrantLiabilityMember" xlink:to="label_PreferredStockWarrantLiabilityMember_3" xlink:title="label: PreferredStockWarrantLiabilityMember to label_PreferredStockWarrantLiabilityMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label: AmendmentFlag to label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Commercialization Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_2">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain commercialization milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_2" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_3">Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain commercialization milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_3" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Clinical Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_2">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain clinical milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_2" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_3">Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain clinical milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_3" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2010Member" xlink:label="PeriodOfApril2010Member" xlink:title="PeriodOfApril2010Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodOfApril2010Member" xml:lang="en-US" id="label_PeriodOfApril2010Member">Period of April 2010 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2010Member" xlink:to="label_PeriodOfApril2010Member" xlink:title="label: PeriodOfApril2010Member to label_PeriodOfApril2010Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2010Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodOfApril2010Member" xml:lang="en-US" id="label_PeriodOfApril2010Member_2">April 2010</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2010Member" xlink:to="label_PeriodOfApril2010Member_2" xlink:title="label: PeriodOfApril2010Member to label_PeriodOfApril2010Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2010Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodOfApril2010Member" xml:lang="en-US" id="label_PeriodOfApril2010Member_3">Represents the period of April 2010 where the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value are disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2010Member" xlink:to="label_PeriodOfApril2010Member_3" xlink:title="label: PeriodOfApril2010Member to label_PeriodOfApril2010Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMarch2011Member" xlink:label="PeriodOfMarch2011Member" xlink:title="PeriodOfMarch2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMarch2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodOfMarch2011Member" xml:lang="en-US" id="label_PeriodOfMarch2011Member">Period of March 2011 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMarch2011Member" xlink:to="label_PeriodOfMarch2011Member" xlink:title="label: PeriodOfMarch2011Member to label_PeriodOfMarch2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMarch2011Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodOfMarch2011Member" xml:lang="en-US" id="label_PeriodOfMarch2011Member_2">March 2011</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMarch2011Member" xlink:to="label_PeriodOfMarch2011Member_2" xlink:title="label: PeriodOfMarch2011Member to label_PeriodOfMarch2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMarch2011Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodOfMarch2011Member" xml:lang="en-US" id="label_PeriodOfMarch2011Member_3">Represents the period of March 2011 where the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value are disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMarch2011Member" xlink:to="label_PeriodOfMarch2011Member_3" xlink:title="label: PeriodOfMarch2011Member to label_PeriodOfMarch2011Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMay2011Member" xlink:label="PeriodOfMay2011Member" xlink:title="PeriodOfMay2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMay2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodOfMay2011Member" xml:lang="en-US" id="label_PeriodOfMay2011Member">Period of May 2011 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMay2011Member" xlink:to="label_PeriodOfMay2011Member" xlink:title="label: PeriodOfMay2011Member to label_PeriodOfMay2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMay2011Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodOfMay2011Member" xml:lang="en-US" id="label_PeriodOfMay2011Member_2">May 2011</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMay2011Member" xlink:to="label_PeriodOfMay2011Member_2" xlink:title="label: PeriodOfMay2011Member to label_PeriodOfMay2011Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfMay2011Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodOfMay2011Member" xml:lang="en-US" id="label_PeriodOfMay2011Member_3">Represents the period of May 2011 where the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value are disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfMay2011Member" xlink:to="label_PeriodOfMay2011Member_3" xlink:title="label: PeriodOfMay2011Member to label_PeriodOfMay2011Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2012Member" xlink:label="PeriodOfApril2012Member" xlink:title="PeriodOfApril2012Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodOfApril2012Member" xml:lang="en-US" id="label_PeriodOfApril2012Member">Represents the period of April 2012 where the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value are disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2012Member" xlink:to="label_PeriodOfApril2012Member" xlink:title="label: PeriodOfApril2012Member to label_PeriodOfApril2012Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2012Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodOfApril2012Member" xml:lang="en-US" id="label_PeriodOfApril2012Member_2">Period of April 2012 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2012Member" xlink:to="label_PeriodOfApril2012Member_2" xlink:title="label: PeriodOfApril2012Member to label_PeriodOfApril2012Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfApril2012Member_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodOfApril2012Member" xml:lang="en-US" id="label_PeriodOfApril2012Member_3">April 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfApril2012Member" xlink:to="label_PeriodOfApril2012Member_3" xlink:title="label: PeriodOfApril2012Member to label_PeriodOfApril2012Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions">Number of shares of exchangeable stock issued during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="label: ExchangeableStockIssuedDuringPeriodSharesAcquisitions to label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_2">Exchangeable Stock Issued during Period Shares Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_2" xlink:title="label: ExchangeableStockIssuedDuringPeriodSharesAcquisitions to label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_3">Exchangeable Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_3" xlink:title="label: ExchangeableStockIssuedDuringPeriodSharesAcquisitions to label_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:label="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xml:lang="en-US" id="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares">Represents the shares outstanding, as a condition for automatic redemption and exchange of shares in a business acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:to="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="label: BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares to label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xml:lang="en-US" id="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_2">Business Acquisition Shares Outstanding for Automatic Redemption and Exchange of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:to="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_2" xlink:title="label: BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares to label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xml:lang="en-US" id="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_3">Shares outstanding for automatic redemption and exchange of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:to="label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares_3" xlink:title="label: BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares to label_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain preclinical milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_2">Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain preclinical milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_2" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_3">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Preclinical Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:to="label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_3" xlink:title="label: BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones to label_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:label="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xml:lang="en-US" id="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock">Business Acquisition Fair Value of Underlying Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:to="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="label: BusinessAcquisitionFairValueOfUnderlyingCommonStock to label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xml:lang="en-US" id="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_2">Fair value per share of underlying common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:to="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_2" xlink:title="label: BusinessAcquisitionFairValueOfUnderlyingCommonStock to label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xml:lang="en-US" id="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_3">Represents the fair value per share of underlying common stock in a business acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:to="label_BusinessAcquisitionFairValueOfUnderlyingCommonStock_3" xlink:title="label: BusinessAcquisitionFairValueOfUnderlyingCommonStock to label_BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="DebtInstrumentDiscountNonCurrent" xlink:title="DebtInstrumentDiscountNonCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentDiscountNonCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountNonCurrent">Debt Instrument Discount, Non Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountNonCurrent" xlink:to="label_DebtInstrumentDiscountNonCurrent" xlink:title="label: DebtInstrumentDiscountNonCurrent to label_DebtInstrumentDiscountNonCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountNonCurrent_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DebtInstrumentDiscountNonCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountNonCurrent_2">Less debt discount, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountNonCurrent" xlink:to="label_DebtInstrumentDiscountNonCurrent_2" xlink:title="label: DebtInstrumentDiscountNonCurrent to label_DebtInstrumentDiscountNonCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountNonCurrent_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentDiscountNonCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountNonCurrent_3">Represents the non-current portion of discount recognized at the issuance of debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountNonCurrent" xlink:to="label_DebtInstrumentDiscountNonCurrent_3" xlink:title="label: DebtInstrumentDiscountNonCurrent to label_DebtInstrumentDiscountNonCurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LongTermDebtGrossCurrent" xlink:label="LongTermDebtGrossCurrent" xlink:title="LongTermDebtGrossCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtGrossCurrent" xml:lang="en-US" id="label_LongTermDebtGrossCurrent">Long Term Debt, Gross, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtGrossCurrent" xlink:to="label_LongTermDebtGrossCurrent" xlink:title="label: LongTermDebtGrossCurrent to label_LongTermDebtGrossCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtGrossCurrent_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_LongTermDebtGrossCurrent" xml:lang="en-US" id="label_LongTermDebtGrossCurrent_2">Less current portion of long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtGrossCurrent" xlink:to="label_LongTermDebtGrossCurrent_2" xlink:title="label: LongTermDebtGrossCurrent to label_LongTermDebtGrossCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtGrossCurrent_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LongTermDebtGrossCurrent" xml:lang="en-US" id="label_LongTermDebtGrossCurrent_3">Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtGrossCurrent" xlink:to="label_LongTermDebtGrossCurrent_3" xlink:title="label: LongTermDebtGrossCurrent to label_LongTermDebtGrossCurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="DebtInstrumentDiscountCurrent" xlink:title="DebtInstrumentDiscountCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentDiscountCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountCurrent">Debt Instrument Discount, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountCurrent" xlink:to="label_DebtInstrumentDiscountCurrent" xlink:title="label: DebtInstrumentDiscountCurrent to label_DebtInstrumentDiscountCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountCurrent_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DebtInstrumentDiscountCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountCurrent_2">Current portion of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountCurrent" xlink:to="label_DebtInstrumentDiscountCurrent_2" xlink:title="label: DebtInstrumentDiscountCurrent to label_DebtInstrumentDiscountCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentDiscountCurrent_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentDiscountCurrent" xml:lang="en-US" id="label_DebtInstrumentDiscountCurrent_3">Represents the current portion of discount recognized at the issuance of debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentDiscountCurrent" xlink:to="label_DebtInstrumentDiscountCurrent_3" xlink:title="label: DebtInstrumentDiscountCurrent to label_DebtInstrumentDiscountCurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EquityIncentivePlan2007Member" xlink:label="EquityIncentivePlan2007Member" xlink:title="EquityIncentivePlan2007Member" />
    <link:label xlink:type="resource" xlink:label="label_EquityIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIncentivePlan2007Member" xml:lang="en-US" id="label_EquityIncentivePlan2007Member">Equity Incentive Plan 2007 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2007Member" xlink:to="label_EquityIncentivePlan2007Member" xlink:title="label: EquityIncentivePlan2007Member to label_EquityIncentivePlan2007Member" />
    <link:label xlink:type="resource" xlink:label="label_EquityIncentivePlan2007Member_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityIncentivePlan2007Member" xml:lang="en-US" id="label_EquityIncentivePlan2007Member_2">Represents information pertaining to 2007 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2007Member" xlink:to="label_EquityIncentivePlan2007Member_2" xlink:title="label: EquityIncentivePlan2007Member to label_EquityIncentivePlan2007Member" />
    <link:label xlink:type="resource" xlink:label="label_EquityIncentivePlan2007Member_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityIncentivePlan2007Member" xml:lang="en-US" id="label_EquityIncentivePlan2007Member_3">Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2007Member" xlink:to="label_EquityIncentivePlan2007Member_3" xlink:title="label: EquityIncentivePlan2007Member to label_EquityIncentivePlan2007Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="StockOptionAndIncentivePlan2013Member" xlink:title="StockOptionAndIncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionAndIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockOptionAndIncentivePlan2013Member" xml:lang="en-US" id="label_StockOptionAndIncentivePlan2013Member">Represents information pertaining to 2013 Stock Option and Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionAndIncentivePlan2013Member" xlink:to="label_StockOptionAndIncentivePlan2013Member" xlink:title="label: StockOptionAndIncentivePlan2013Member to label_StockOptionAndIncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionAndIncentivePlan2013Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockOptionAndIncentivePlan2013Member" xml:lang="en-US" id="label_StockOptionAndIncentivePlan2013Member_2">Stock Option and Incentive Plan 2013 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionAndIncentivePlan2013Member" xlink:to="label_StockOptionAndIncentivePlan2013Member_2" xlink:title="label: StockOptionAndIncentivePlan2013Member to label_StockOptionAndIncentivePlan2013Member" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionAndIncentivePlan2013Member_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockOptionAndIncentivePlan2013Member" xml:lang="en-US" id="label_StockOptionAndIncentivePlan2013Member_3">2013 Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionAndIncentivePlan2013Member" xlink:to="label_StockOptionAndIncentivePlan2013Member_3" xlink:title="label: StockOptionAndIncentivePlan2013Member to label_StockOptionAndIncentivePlan2013Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized">Additional shares authorized (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_2">Represents the percentage of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_3">Share Based Compensation Arrangement by Share Based Payment Award Percentage of Additional Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_UnderwritingDiscountsAndCommissions" xlink:label="UnderwritingDiscountsAndCommissions" xlink:title="UnderwritingDiscountsAndCommissions" />
    <link:label xlink:type="resource" xlink:label="label_UnderwritingDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnderwritingDiscountsAndCommissions" xml:lang="en-US" id="label_UnderwritingDiscountsAndCommissions">Underwriting Discounts and Commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwritingDiscountsAndCommissions" xlink:to="label_UnderwritingDiscountsAndCommissions" xlink:title="label: UnderwritingDiscountsAndCommissions to label_UnderwritingDiscountsAndCommissions" />
    <link:label xlink:type="resource" xlink:label="label_UnderwritingDiscountsAndCommissions_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_UnderwritingDiscountsAndCommissions" xml:lang="en-US" id="label_UnderwritingDiscountsAndCommissions_2">Underwriting discounts and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwritingDiscountsAndCommissions" xlink:to="label_UnderwritingDiscountsAndCommissions_2" xlink:title="label: UnderwritingDiscountsAndCommissions to label_UnderwritingDiscountsAndCommissions" />
    <link:label xlink:type="resource" xlink:label="label_UnderwritingDiscountsAndCommissions_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_UnderwritingDiscountsAndCommissions" xml:lang="en-US" id="label_UnderwritingDiscountsAndCommissions_3">Represents the amount of underwriting discounts and commissions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnderwritingDiscountsAndCommissions" xlink:to="label_UnderwritingDiscountsAndCommissions_3" xlink:title="label: UnderwritingDiscountsAndCommissions to label_UnderwritingDiscountsAndCommissions" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardDateAxis" xml:lang="en-US" id="label_AwardDateAxis">Award Date [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateAxis" xlink:to="label_AwardDateAxis" xlink:title="label: AwardDateAxis to label_AwardDateAxis" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:label="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsReceivableFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsReceivableFromIssuanceInitialPublicOffering">Proceeds Receivable from Issuance Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="label: ProceedsReceivableFromIssuanceInitialPublicOffering to label_ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsReceivableFromIssuanceInitialPublicOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsReceivableFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsReceivableFromIssuanceInitialPublicOffering_2">Estimated net proceeds to be received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsReceivableFromIssuanceInitialPublicOffering_2" xlink:title="label: ProceedsReceivableFromIssuanceInitialPublicOffering to label_ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsReceivableFromIssuanceInitialPublicOffering_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsReceivableFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsReceivableFromIssuanceInitialPublicOffering_3">Represents the estimated net proceeds to be received from the entity's first offering of stock to the public.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsReceivableFromIssuanceInitialPublicOffering_3" xlink:title="label: ProceedsReceivableFromIssuanceInitialPublicOffering to label_ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:label xlink:type="resource" xlink:label="label_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardDateDomain" xml:lang="en-US" id="label_AwardDateDomain">Award Date [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateDomain" xlink:to="label_AwardDateDomain" xlink:title="label: AwardDateDomain to label_AwardDateDomain" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableSharesRedeemedDuringPeriodShares" xlink:label="ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableSharesRedeemedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExchangeableSharesRedeemedDuringPeriodShares" xml:lang="en-US" id="label_ExchangeableSharesRedeemedDuringPeriodShares">Exchangeable Shares Redeemed During Period, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableSharesRedeemedDuringPeriodShares" xlink:to="label_ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="label: ExchangeableSharesRedeemedDuringPeriodShares to label_ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableSharesRedeemedDuringPeriodShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExchangeableSharesRedeemedDuringPeriodShares" xml:lang="en-US" id="label_ExchangeableSharesRedeemedDuringPeriodShares_2">Exchangeable shares redeemed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableSharesRedeemedDuringPeriodShares" xlink:to="label_ExchangeableSharesRedeemedDuringPeriodShares_2" xlink:title="label: ExchangeableSharesRedeemedDuringPeriodShares to label_ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="label_ExchangeableSharesRedeemedDuringPeriodShares_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExchangeableSharesRedeemedDuringPeriodShares" xml:lang="en-US" id="label_ExchangeableSharesRedeemedDuringPeriodShares_3">Represents the number of exchangeable shares redeemed during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExchangeableSharesRedeemedDuringPeriodShares" xlink:to="label_ExchangeableSharesRedeemedDuringPeriodShares_3" xlink:title="label: ExchangeableSharesRedeemedDuringPeriodShares to label_ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted">Class of Warrant or Right Warrants Issued to Purchase Shares of Convertible Preferred Stock Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_2">Warrants to purchase shares of convertible preferred stock which are converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_2" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_3">Represents the warrant issued to purchase shares of convertible preferred stock, converted into new warrants to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted_3" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion">Class of Warrant or Right Warrants Issued to Purchase Shares of Common Stock on Conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_2">Warrants to purchase shares of common stock issued on conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_2" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xml:lang="en-US" id="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_3">Represents the warrant issued to purchase shares of common stock converted from old warrants to purchase convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:to="label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_3" xlink:title="label: ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion to label_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn24June2014Member" xlink:label="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn24June2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNotesDueOn24June2014Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn24June2014Member">Convertible Promissory Notes Due on 24 June 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:to="label_ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="label: ConvertiblePromissoryNotesDueOn24June2014Member to label_ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn24June2014Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNotesDueOn24June2014Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn24June2014Member_2">June and July 2013 Convertible Note Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:to="label_ConvertiblePromissoryNotesDueOn24June2014Member_2" xlink:title="label: ConvertiblePromissoryNotesDueOn24June2014Member to label_ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn24June2014Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNotesDueOn24June2014Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn24June2014Member_3">Represents information pertaining to the convertible promissory notes due on June 24, 2014 issued by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:to="label_ConvertiblePromissoryNotesDueOn24June2014Member_3" xlink:title="label: ConvertiblePromissoryNotesDueOn24June2014Member to label_ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:label="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePromissoryNotesDueOn8August2016Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn8August2016Member">Convertible Promissory Notes Due on 8 August 2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:to="label_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="label: ConvertiblePromissoryNotesDueOn8August2016Member to label_ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn8August2016Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePromissoryNotesDueOn8August2016Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn8August2016Member_2">August 2013 Convertible Note Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:to="label_ConvertiblePromissoryNotesDueOn8August2016Member_2" xlink:title="label: ConvertiblePromissoryNotesDueOn8August2016Member to label_ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn8August2016Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertiblePromissoryNotesDueOn8August2016Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn8August2016Member_3">Represents information pertaining to the convertible promissory notes due on August 8, 2016 issued by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:to="label_ConvertiblePromissoryNotesDueOn8August2016Member_3" xlink:title="label: ConvertiblePromissoryNotesDueOn8August2016Member to label_ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePromissoryNotesDueOn8August2016Member_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertiblePromissoryNotesDueOn8August2016Member" xml:lang="en-US" id="label_ConvertiblePromissoryNotesDueOn8August2016Member_4">August 2013 Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:to="label_ConvertiblePromissoryNotesDueOn8August2016Member_4" xlink:title="label: ConvertiblePromissoryNotesDueOn8August2016Member to label_ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label: DocumentAndEntityInformationAbstract to label_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xml:lang="en-US" id="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent">Represents the carrying value, as of the balance sheet date, of repurchase liability for unvested equity awards, which is expected to be paid within one year (or the operating cycle, if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:to="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="label: RepurchaseLiabilityForUnvestedEquityAwardsCurrent to label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xml:lang="en-US" id="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_2">Repurchase Liability for Unvested Equity Awards Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:to="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_2" xlink:title="label: RepurchaseLiabilityForUnvestedEquityAwardsCurrent to label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xml:lang="en-US" id="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_3">Repurchase liability for unvested equity awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:to="label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_3" xlink:title="label: RepurchaseLiabilityForUnvestedEquityAwardsCurrent to label_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NonEmployeeStockOptionMember" xlink:label="NonEmployeeStockOptionMember" xlink:title="NonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonEmployeeStockOptionMember" xml:lang="en-US" id="label_NonEmployeeStockOptionMember">Non Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionMember" xlink:to="label_NonEmployeeStockOptionMember" xlink:title="label: NonEmployeeStockOptionMember to label_NonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonEmployeeStockOptionMember" xml:lang="en-US" id="label_NonEmployeeStockOptionMember_2">Non-employee stock option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionMember" xlink:to="label_NonEmployeeStockOptionMember_2" xlink:title="label: NonEmployeeStockOptionMember to label_NonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_NonEmployeeStockOptionMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NonEmployeeStockOptionMember" xml:lang="en-US" id="label_NonEmployeeStockOptionMember_3">Represents an arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonEmployeeStockOptionMember" xlink:to="label_NonEmployeeStockOptionMember_3" xlink:title="label: NonEmployeeStockOptionMember to label_NonEmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="EmployeeAndNonEmployeeStockOptionMember" xlink:title="EmployeeAndNonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeAndNonEmployeeStockOptionMember">Employee and Non Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="label_EmployeeAndNonEmployeeStockOptionMember" xlink:title="label: EmployeeAndNonEmployeeStockOptionMember to label_EmployeeAndNonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonEmployeeStockOptionMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeAndNonEmployeeStockOptionMember_2">Stock option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="label_EmployeeAndNonEmployeeStockOptionMember_2" xlink:title="label: EmployeeAndNonEmployeeStockOptionMember to label_EmployeeAndNonEmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeAndNonEmployeeStockOptionMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EmployeeAndNonEmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeAndNonEmployeeStockOptionMember_3">Represents an arrangement whereby both an employee and a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="label_EmployeeAndNonEmployeeStockOptionMember_3" xlink:title="label: EmployeeAndNonEmployeeStockOptionMember to label_EmployeeAndNonEmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="VestingBasedOnPerformanceMember" xlink:title="VestingBasedOnPerformanceMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingBasedOnPerformanceMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceMember">Vesting Based on Performance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceMember" xlink:to="label_VestingBasedOnPerformanceMember" xlink:title="label: VestingBasedOnPerformanceMember to label_VestingBasedOnPerformanceMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VestingBasedOnPerformanceMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceMember_2">Performance-based</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceMember" xlink:to="label_VestingBasedOnPerformanceMember_2" xlink:title="label: VestingBasedOnPerformanceMember to label_VestingBasedOnPerformanceMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_VestingBasedOnPerformanceMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceMember_3">Represents the vesting based on performance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceMember" xlink:to="label_VestingBasedOnPerformanceMember_3" xlink:title="label: VestingBasedOnPerformanceMember to label_VestingBasedOnPerformanceMember" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:label="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember">Represents the vesting based on achievement of performance-based milestones and market conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:to="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="label: VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember to label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_2">Vesting Based on Performance Based Milestones and Market Conditions [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:to="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_2" xlink:title="label: VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember to label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:label xlink:type="resource" xlink:label="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xml:lang="en-US" id="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_3">Performance-based milestones and market conditions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:to="label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember_3" xlink:title="label: VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember to label_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfJuly2013Member" xlink:label="PeriodOfJuly2013Member" xlink:title="PeriodOfJuly2013Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfJuly2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodOfJuly2013Member" xml:lang="en-US" id="label_PeriodOfJuly2013Member">Period of July 2013 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfJuly2013Member" xlink:to="label_PeriodOfJuly2013Member" xlink:title="label: PeriodOfJuly2013Member to label_PeriodOfJuly2013Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfJuly2013Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodOfJuly2013Member" xml:lang="en-US" id="label_PeriodOfJuly2013Member_2">July 2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfJuly2013Member" xlink:to="label_PeriodOfJuly2013Member_2" xlink:title="label: PeriodOfJuly2013Member to label_PeriodOfJuly2013Member" />
    <link:label xlink:type="resource" xlink:label="label_PeriodOfJuly2013Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodOfJuly2013Member" xml:lang="en-US" id="label_PeriodOfJuly2013Member_3">Represents the period of July 2013 where the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value are disclosed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfJuly2013Member" xlink:to="label_PeriodOfJuly2013Member_3" xlink:title="label: PeriodOfJuly2013Member to label_PeriodOfJuly2013Member" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LeaseTermExtended" xlink:label="LeaseTermExtended" xlink:title="LeaseTermExtended" />
    <link:label xlink:type="resource" xlink:label="label_LeaseTermExtended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeaseTermExtended" xml:lang="en-US" id="label_LeaseTermExtended">Lease Term Extended</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseTermExtended" xlink:to="label_LeaseTermExtended" xlink:title="label: LeaseTermExtended to label_LeaseTermExtended" />
    <link:label xlink:type="resource" xlink:label="label_LeaseTermExtended_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeaseTermExtended" xml:lang="en-US" id="label_LeaseTermExtended_2">Lease period extended</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseTermExtended" xlink:to="label_LeaseTermExtended_2" xlink:title="label: LeaseTermExtended to label_LeaseTermExtended" />
    <link:label xlink:type="resource" xlink:label="label_LeaseTermExtended_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LeaseTermExtended" xml:lang="en-US" id="label_LeaseTermExtended_3">Represents the extended lease period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseTermExtended" xlink:to="label_LeaseTermExtended_3" xlink:title="label: LeaseTermExtended to label_LeaseTermExtended" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:label="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" />
    <link:label xlink:type="resource" xlink:label="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xml:lang="en-US" id="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability">Noncash Charge Related to Fair Value Adjustment of Exchangeable Shares and Preferred Stock Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:to="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="label: NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability to label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xml:lang="en-US" id="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_2">Aggregate non-cash charge related to the final fair value adjustment of the exchangeable share liability and the preferred stock warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:to="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_2" xlink:title="label: NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability to label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xml:lang="en-US" id="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_3">Represents the amount of non-cash charge related to the fair value adjustment of the exchangeable shares and the preferred stock warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:to="label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability_3" xlink:title="label: NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability to label_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" use="optional" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetAcquisitionAbstract" xml:lang="en-US" id="label_AssetAcquisitionAbstract">Asset Acquisition of Verio Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionAbstract" xlink:to="label_AssetAcquisitionAbstract" xlink:title="label: AssetAcquisitionAbstract to label_AssetAcquisitionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionTextBlock" xlink:label="AssetAcquisitionTextBlock" xlink:title="AssetAcquisitionTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetAcquisitionTextBlock" xml:lang="en-US" id="label_AssetAcquisitionTextBlock">Asset Acquisition [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTextBlock" xlink:to="label_AssetAcquisitionTextBlock" xlink:title="label: AssetAcquisitionTextBlock to label_AssetAcquisitionTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetAcquisitionTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AssetAcquisitionTextBlock" xml:lang="en-US" id="label_AssetAcquisitionTextBlock_2">The entire disclosure for an asset acquisition completed during the period, including background, timing, and recognized assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTextBlock" xlink:to="label_AssetAcquisitionTextBlock_2" xlink:title="label: AssetAcquisitionTextBlock to label_AssetAcquisitionTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetAcquisitionTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetAcquisitionTextBlock" xml:lang="en-US" id="label_AssetAcquisitionTextBlock_3">Asset Acquisition of Verio Therapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTextBlock" xlink:to="label_AssetAcquisitionTextBlock_3" xlink:title="label: AssetAcquisitionTextBlock to label_AssetAcquisitionTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_OtherAssetsPolicy" xlink:label="OtherAssetsPolicy" xlink:title="OtherAssetsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OtherAssetsPolicy" xml:lang="en-US" id="label_OtherAssetsPolicy">Accounting policy relating to other assets which can consist of the Company's deferred IPO costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsPolicy" xlink:to="label_OtherAssetsPolicy" xlink:title="label: OtherAssetsPolicy to label_OtherAssetsPolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsPolicy_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsPolicy" xml:lang="en-US" id="label_OtherAssetsPolicy_2">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsPolicy" xlink:to="label_OtherAssetsPolicy_2" xlink:title="label: OtherAssetsPolicy to label_OtherAssetsPolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsPolicy_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsPolicy" xml:lang="en-US" id="label_OtherAssetsPolicy_3">Other Assets Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsPolicy" xlink:to="label_OtherAssetsPolicy_3" xlink:title="label: OtherAssetsPolicy to label_OtherAssetsPolicy" use="optional" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ScheduleOfActualAndProformaBalanceSheetDetail" xlink:label="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:title="ScheduleOfActualAndProformaBalanceSheetDetail" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfActualAndProformaBalanceSheetDetail" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfActualAndProformaBalanceSheetDetail" xml:lang="en-US" id="label_ScheduleOfActualAndProformaBalanceSheetDetail">Schedule of Actual and Proforma Balance Sheet Detail [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:to="label_ScheduleOfActualAndProformaBalanceSheetDetail" xlink:title="label: ScheduleOfActualAndProformaBalanceSheetDetail to label_ScheduleOfActualAndProformaBalanceSheetDetail" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfActualAndProformaBalanceSheetDetail_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfActualAndProformaBalanceSheetDetail" xml:lang="en-US" id="label_ScheduleOfActualAndProformaBalanceSheetDetail_2">Tabular disclosure summary of the actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company's IPO.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:to="label_ScheduleOfActualAndProformaBalanceSheetDetail_2" xlink:title="label: ScheduleOfActualAndProformaBalanceSheetDetail to label_ScheduleOfActualAndProformaBalanceSheetDetail" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfActualAndProformaBalanceSheetDetail_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfActualAndProformaBalanceSheetDetail" xml:lang="en-US" id="label_ScheduleOfActualAndProformaBalanceSheetDetail_3">Summary of actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company's IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:to="label_ScheduleOfActualAndProformaBalanceSheetDetail_3" xlink:title="label: ScheduleOfActualAndProformaBalanceSheetDetail to label_ScheduleOfActualAndProformaBalanceSheetDetail" use="optional" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:label="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="BusinessAcquisitionInitialFairValueOfExchangeableShares" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionInitialFairValueOfExchangeableShares" xml:lang="en-US" id="label_BusinessAcquisitionInitialFairValueOfExchangeableShares">Business Acquisition Initial Fair Value of Exchangeable Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:to="label_BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="label: BusinessAcquisitionInitialFairValueOfExchangeableShares to label_BusinessAcquisitionInitialFairValueOfExchangeableShares" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessAcquisitionInitialFairValueOfExchangeableShares" xml:lang="en-US" id="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_2">Represents the initial fair value amount of exchangeable shares (in dollars).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:to="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_2" xlink:title="label: BusinessAcquisitionInitialFairValueOfExchangeableShares to label_BusinessAcquisitionInitialFairValueOfExchangeableShares" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionInitialFairValueOfExchangeableShares" xml:lang="en-US" id="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_3">Initial fair value of exchangeable shares (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:to="label_BusinessAcquisitionInitialFairValueOfExchangeableShares_3" xlink:title="label: BusinessAcquisitionInitialFairValueOfExchangeableShares to label_BusinessAcquisitionInitialFairValueOfExchangeableShares" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to label_EntityWellKnownSeasonedIssuer" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to label_EntityVoluntaryFilers" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to label_EntityCurrentReportingStatus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label: EntityFilerCategory to label_EntityFilerCategory" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label: EntityPublicFloat to label_EntityPublicFloat" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label: EntityRegistrantName to label_EntityRegistrantName" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to label_EntityCentralIndexKey" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to label_EntityCommonStockSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to label_DocumentFiscalYearFocus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to label_DocumentFiscalPeriodFocus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label: DocumentType to label_DocumentType" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesCurrent">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to label_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesCurrent_2">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesCurrent_2" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to label_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesNoncurrent">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="label: AccountsPayableAndAccruedLiabilitiesNoncurrent to label_AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_2">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_2" xlink:title="label: AccountsPayableAndAccruedLiabilitiesNoncurrent to label_AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesNoncurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_3">Long-term accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesNoncurrent_3" xlink:title="label: AccountsPayableAndAccruedLiabilitiesNoncurrent to label_AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to label_AdditionalPaidInCapital" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital_2">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital_2" xlink:title="label: AdditionalPaidInCapital to label_AdditionalPaidInCapital" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense">Allocated stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to label_AllocatedShareBasedCompensationExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_2">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_2" xlink:title="label: AllocatedShareBasedCompensationExpense to label_AllocatedShareBasedCompensationExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to label_AmortizationOfDebtDiscountPremium" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium_2">Amortization of discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium_2" xlink:title="label: AmortizationOfDebtDiscountPremium to label_AmortizationOfDebtDiscountPremium" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfDebtDiscountPremium_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="label_AmortizationOfDebtDiscountPremium_3">Debt discount amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="label_AmortizationOfDebtDiscountPremium_3" xlink:title="label: AmortizationOfDebtDiscountPremium to label_AmortizationOfDebtDiscountPremium" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="label_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to label_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Anti-dilutive securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Assets_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets_2">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_2" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract_2">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_2" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract_2">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_2" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent_2">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_2" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="AssetsFairValueDisclosureNonrecurring" xlink:title="AssetsFairValueDisclosureNonrecurring" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureNonrecurring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsFairValueDisclosureNonrecurring" xml:lang="en-US" id="label_AssetsFairValueDisclosureNonrecurring">Assets, Fair Value Disclosure, Nonrecurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureNonrecurring" xlink:to="label_AssetsFairValueDisclosureNonrecurring" xlink:title="label: AssetsFairValueDisclosureNonrecurring to label_AssetsFairValueDisclosureNonrecurring" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureNonrecurring_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsFairValueDisclosureNonrecurring" xml:lang="en-US" id="label_AssetsFairValueDisclosureNonrecurring_2">Non-financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureNonrecurring" xlink:to="label_AssetsFairValueDisclosureNonrecurring_2" xlink:title="label: AssetsFairValueDisclosureNonrecurring to label_AssetsFairValueDisclosureNonrecurring" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xml:lang="en-US" id="label_BusinessCombinationSeparatelyRecognizedTransactionsAxis">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="label_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="label: BusinessCombinationSeparatelyRecognizedTransactionsAxis to label_BusinessCombinationSeparatelyRecognizedTransactionsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAxis" xml:lang="en-US" id="label_BusinessAcquisitionAxis">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="label_BusinessAcquisitionAxis" xlink:title="label: BusinessAcquisitionAxis to label_BusinessAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionLineItems" xml:lang="en-US" id="label_BusinessAcquisitionLineItems">Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="label_BusinessAcquisitionLineItems" xlink:title="label: BusinessAcquisitionLineItems to label_BusinessAcquisitionLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionLineItems" xml:lang="en-US" id="label_BusinessAcquisitionLineItems_2">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="label_BusinessAcquisitionLineItems_2" xlink:title="label: BusinessAcquisitionLineItems to label_BusinessAcquisitionLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAcquireeDomain" xml:lang="en-US" id="label_BusinessAcquisitionAcquireeDomain">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="label_BusinessAcquisitionAcquireeDomain" xlink:title="label: BusinessAcquisitionAcquireeDomain to label_BusinessAcquisitionAcquireeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xml:lang="en-US" id="label_BusinessCombinationSeparatelyRecognizedTransactionsDomain">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="label_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="label: BusinessCombinationSeparatelyRecognizedTransactionsDomain to label_BusinessCombinationSeparatelyRecognizedTransactionsDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">Shares issuable on exchange of exchangeable shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US" id="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to label_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="CarryingReportedAmountFairValueDisclosureMember" xlink:title="CarryingReportedAmountFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US" id="label_CarryingReportedAmountFairValueDisclosureMember">Reported Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingReportedAmountFairValueDisclosureMember" xlink:to="label_CarryingReportedAmountFairValueDisclosureMember" xlink:title="label: CarryingReportedAmountFairValueDisclosureMember to label_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CarryingReportedAmountFairValueDisclosureMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US" id="label_CarryingReportedAmountFairValueDisclosureMember_2">Carrying amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CarryingReportedAmountFairValueDisclosureMember" xlink:to="label_CarryingReportedAmountFairValueDisclosureMember_2" xlink:title="label: CarryingReportedAmountFairValueDisclosureMember to label_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_CashAndCashEquivalentsPeriodIncreaseDecrease">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to label_CashAndCashEquivalentsPeriodIncreaseDecrease" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsPeriodIncreaseDecrease_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_CashAndCashEquivalentsPeriodIncreaseDecrease_2">Net change in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_CashAndCashEquivalentsPeriodIncreaseDecrease_2" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to label_CashAndCashEquivalentsPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">Cash and cash equivalents at beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_4">Cash and cash equivalents at end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to label_CashAndCashEquivalentsFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="label_CashAndCashEquivalentsFairValueDisclosure_2">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="label_CashAndCashEquivalentsFairValueDisclosure_2" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to label_CashAndCashEquivalentsFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies_2">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_2" xlink:title="label: CommitmentsAndContingencies to label_CommitmentsAndContingencies" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="label: CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common stock, $0.001 par value; authorized shares - 110,000,000 at September 30, 2013 and 100,000,000 at December 31, 2012; issued and outstanding shares - 1,377,659 at September 30, 2013 and 1,334,115 at December 31, 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="label: CommonStockValue to label_CommonStockValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue_2">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_2" xlink:title="label: CommonStockValue to label_CommonStockValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue_3">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_3" xlink:title="label: CommonStockValue to label_CommonStockValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_2">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_2" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="label: CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance">Shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to label_CommonStockCapitalSharesReservedForFutureIssuance" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockCapitalSharesReservedForFutureIssuance_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_CommonStockCapitalSharesReservedForFutureIssuance_2">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_CommonStockCapitalSharesReservedForFutureIssuance_2" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to label_CommonStockCapitalSharesReservedForFutureIssuance" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConsolidationPolicyTextBlock" xml:lang="en-US" id="label_ConsolidationPolicyTextBlock">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="label_ConsolidationPolicyTextBlock" xlink:title="label: ConsolidationPolicyTextBlock to label_ConsolidationPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConsolidationPolicyTextBlock" xml:lang="en-US" id="label_ConsolidationPolicyTextBlock_2">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="label_ConsolidationPolicyTextBlock_2" xlink:title="label: ConsolidationPolicyTextBlock to label_ConsolidationPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:label xlink:type="resource" xlink:label="label_ContractsRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ContractsRevenue" xml:lang="en-US" id="label_ContractsRevenue">Collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractsRevenue" xlink:to="label_ContractsRevenue" xlink:title="label: ContractsRevenue to label_ContractsRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ContractsRevenue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ContractsRevenue" xml:lang="en-US" id="label_ContractsRevenue_2">Contracts Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractsRevenue" xlink:to="label_ContractsRevenue_2" xlink:title="label: ContractsRevenue to label_ContractsRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="ConvertibleNotesPayable" xlink:title="ConvertibleNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotesPayable" xml:lang="en-US" id="label_ConvertibleNotesPayable">Convertible Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayable" xlink:to="label_ConvertibleNotesPayable" xlink:title="label: ConvertibleNotesPayable to label_ConvertibleNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotesPayable" xml:lang="en-US" id="label_ConvertibleNotesPayable_2">Outstanding principal under convertible promissory notes (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayable" xlink:to="label_ConvertibleNotesPayable_2" xlink:title="label: ConvertibleNotesPayable to label_ConvertibleNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayable_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertibleNotesPayable" xml:lang="en-US" id="label_ConvertibleNotesPayable_3">Outstanding debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayable" xlink:to="label_ConvertibleNotesPayable_3" xlink:title="label: ConvertibleNotesPayable to label_ConvertibleNotesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePreferredStockMember" xml:lang="en-US" id="label_ConvertiblePreferredStockMember">Convertible preferred stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="label_ConvertiblePreferredStockMember" xlink:title="label: ConvertiblePreferredStockMember to label_ConvertiblePreferredStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockMember" xml:lang="en-US" id="label_ConvertiblePreferredStockMember_2">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="label_ConvertiblePreferredStockMember_2" xlink:title="label: ConvertiblePreferredStockMember to label_ConvertiblePreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_ConvertibleLongTermNotesPayable">Convertible Notes Payable, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongTermNotesPayable" xlink:to="label_ConvertibleLongTermNotesPayable" xlink:title="label: ConvertibleLongTermNotesPayable to label_ConvertibleLongTermNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleLongTermNotesPayable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_ConvertibleLongTermNotesPayable_2">Long-term convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongTermNotesPayable" xlink:to="label_ConvertibleLongTermNotesPayable_2" xlink:title="label: ConvertibleLongTermNotesPayable to label_ConvertibleLongTermNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleLongTermNotesPayable_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_ConvertibleLongTermNotesPayable_3">Outstanding debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongTermNotesPayable" xlink:to="label_ConvertibleLongTermNotesPayable_3" xlink:title="label: ConvertibleLongTermNotesPayable to label_ConvertibleLongTermNotesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US" id="label_ConvertiblePreferredStockSharesIssuedUponConversion">Shares issued on conversion of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="label_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="label: ConvertiblePreferredStockSharesIssuedUponConversion to label_ConvertiblePreferredStockSharesIssuedUponConversion" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockSharesIssuedUponConversion_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US" id="label_ConvertiblePreferredStockSharesIssuedUponConversion_2">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="label_ConvertiblePreferredStockSharesIssuedUponConversion_2" xlink:title="label: ConvertiblePreferredStockSharesIssuedUponConversion to label_ConvertiblePreferredStockSharesIssuedUponConversion" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotesPayableCurrent" xml:lang="en-US" id="label_ConvertibleNotesPayableCurrent">Convertible notes, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableCurrent" xlink:to="label_ConvertibleNotesPayableCurrent" xlink:title="label: ConvertibleNotesPayableCurrent to label_ConvertibleNotesPayableCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotesPayableCurrent" xml:lang="en-US" id="label_ConvertibleNotesPayableCurrent_2">Convertible Notes Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableCurrent" xlink:to="label_ConvertibleNotesPayableCurrent_2" xlink:title="label: ConvertibleNotesPayableCurrent to label_ConvertibleNotesPayableCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to label_DebtInstrumentLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems_2">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems_2" xlink:title="label: DebtInstrumentLineItems to label_DebtInstrumentLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTable" xml:lang="en-US" id="label_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="label_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to label_DebtInstrumentTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1">Outstanding amount of convertible notes converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1" xlink:title="label: DebtConversionOriginalDebtAmount1 to label_DebtConversionOriginalDebtAmount1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_2">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_2" xlink:title="label: DebtConversionOriginalDebtAmount1 to label_DebtConversionOriginalDebtAmount1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1">Shares issued on conversion of convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1" xlink:title="label: DebtConversionConvertedInstrumentSharesIssued1 to label_DebtConversionConvertedInstrumentSharesIssued1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionConvertedInstrumentSharesIssued1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US" id="label_DebtConversionConvertedInstrumentSharesIssued1_2">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="label_DebtConversionConvertedInstrumentSharesIssued1_2" xlink:title="label: DebtConversionConvertedInstrumentSharesIssued1 to label_DebtConversionConvertedInstrumentSharesIssued1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount" xlink:title="label: DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_2">Debt issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_2" xlink:title="label: DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentCarryingAmount" xml:lang="en-US" id="label_DebtInstrumentCarryingAmount">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="label_DebtInstrumentCarryingAmount" xlink:title="label: DebtInstrumentCarryingAmount to label_DebtInstrumentCarryingAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentCarryingAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentCarryingAmount" xml:lang="en-US" id="label_DebtInstrumentCarryingAmount_2">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="label_DebtInstrumentCarryingAmount_2" xlink:title="label: DebtInstrumentCarryingAmount to label_DebtInstrumentCarryingAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentTerm" xml:lang="en-US" id="label_DebtInstrumentTerm">Term of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="label_DebtInstrumentTerm" xlink:title="label: DebtInstrumentTerm to label_DebtInstrumentTerm" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTerm" xml:lang="en-US" id="label_DebtInstrumentTerm_2">Debt Instrument, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="label_DebtInstrumentTerm_2" xlink:title="label: DebtInstrumentTerm to label_DebtInstrumentTerm" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentAxis" xml:lang="en-US" id="label_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="label_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to label_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentNameDomain" xml:lang="en-US" id="label_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to label_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="label_DebtInstrumentUnamortizedDiscount">Debt discount related to beneficial conversion feature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="label_DebtInstrumentUnamortizedDiscount" xlink:title="label: DebtInstrumentUnamortizedDiscount to label_DebtInstrumentUnamortizedDiscount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentUnamortizedDiscount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="label_DebtInstrumentUnamortizedDiscount_2">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="label_DebtInstrumentUnamortizedDiscount_2" xlink:title="label: DebtInstrumentUnamortizedDiscount to label_DebtInstrumentUnamortizedDiscount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_DebtInstrumentInterestRateStatedPercentage" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage_2">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage_2" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_DebtInstrumentInterestRateStatedPercentage" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRentCreditNoncurrent" xml:lang="en-US" id="label_DeferredRentCreditNoncurrent">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="label_DeferredRentCreditNoncurrent" xlink:title="label: DeferredRentCreditNoncurrent to label_DeferredRentCreditNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRentCreditNoncurrent" xml:lang="en-US" id="label_DeferredRentCreditNoncurrent_2">Deferred Rent Credit, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditNoncurrent" xlink:to="label_DeferredRentCreditNoncurrent_2" xlink:title="label: DeferredRentCreditNoncurrent to label_DeferredRentCreditNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRevenueCurrent" xml:lang="en-US" id="label_DeferredRevenueCurrent">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="label_DeferredRevenueCurrent" xlink:title="label: DeferredRevenueCurrent to label_DeferredRevenueCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRevenueCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRevenueCurrent" xml:lang="en-US" id="label_DeferredRevenueCurrent_2">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueCurrent" xlink:to="label_DeferredRevenueCurrent_2" xlink:title="label: DeferredRevenueCurrent to label_DeferredRevenueCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredRentCreditCurrent" xml:lang="en-US" id="label_DeferredRentCreditCurrent">Current portion of deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditCurrent" xlink:to="label_DeferredRentCreditCurrent" xlink:title="label: DeferredRentCreditCurrent to label_DeferredRentCreditCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DeferredRentCreditCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredRentCreditCurrent" xml:lang="en-US" id="label_DeferredRentCreditCurrent_2">Deferred Rent Credit, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCreditCurrent" xlink:to="label_DeferredRentCreditCurrent_2" xlink:title="label: DeferredRentCreditCurrent to label_DeferredRentCreditCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization_2">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization_2" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:label xlink:type="resource" xlink:label="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US" id="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">Deficit accumulated during the development stage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="label: DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage to label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US" id="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2">Development Stage Enterprise, Deficit Accumulated During Development Stage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_2" xlink:title="label: DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage to label_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stockholders' Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">Stockholders' Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">Net loss per common share, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to label_EarningsPerSharePolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock_2">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock_2" xlink:title="label: EarningsPerSharePolicyTextBlock to label_EarningsPerSharePolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeStockOptionMember">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to label_EmployeeStockOptionMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockOptionMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeStockOptionMember" xml:lang="en-US" id="label_EmployeeStockOptionMember_2">Employee stock option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="label_EmployeeStockOptionMember_2" xlink:title="label: EmployeeStockOptionMember to label_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeStockMember" xml:lang="en-US" id="label_EmployeeStockMember">ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="label_EmployeeStockMember" xlink:title="label: EmployeeStockMember to label_EmployeeStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeStockMember" xml:lang="en-US" id="label_EmployeeStockMember_2">Employee Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="label_EmployeeStockMember_2" xlink:title="label: EmployeeStockMember to label_EmployeeStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Expected recognition period of unrecognized compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unrecognized compensation cost related to outstanding options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to label_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_EquityIssuancePerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityIssuancePerShareAmount" xml:lang="en-US" id="label_EquityIssuancePerShareAmount">Public offering price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="label_EquityIssuancePerShareAmount" xlink:title="label: EquityIssuancePerShareAmount to label_EquityIssuancePerShareAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EquityIssuancePerShareAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityIssuancePerShareAmount" xml:lang="en-US" id="label_EquityIssuancePerShareAmount_2">Development Stage Entities, Equity Issuance, Per Share Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIssuancePerShareAmount" xlink:to="label_EquityIssuancePerShareAmount_2" xlink:title="label: EquityIssuancePerShareAmount to label_EquityIssuancePerShareAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="EquityUnitPurchaseAgreementsMember" xlink:title="EquityUnitPurchaseAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="label_EquityUnitPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityUnitPurchaseAgreementsMember" xml:lang="en-US" id="label_EquityUnitPurchaseAgreementsMember">Exchangeable shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityUnitPurchaseAgreementsMember" xlink:to="label_EquityUnitPurchaseAgreementsMember" xlink:title="label: EquityUnitPurchaseAgreementsMember to label_EquityUnitPurchaseAgreementsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EquityUnitPurchaseAgreementsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityUnitPurchaseAgreementsMember" xml:lang="en-US" id="label_EquityUnitPurchaseAgreementsMember_2">Equity Unit Purchase Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityUnitPurchaseAgreementsMember" xlink:to="label_EquityUnitPurchaseAgreementsMember_2" xlink:title="label: EquityUnitPurchaseAgreementsMember to label_EquityUnitPurchaseAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember" xlink:title="label: EstimateOfFairValueFairValueDisclosureMember to label_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember_2">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember_2" xlink:title="label: EstimateOfFairValueFairValueDisclosureMember to label_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="label: FairValueByMeasurementFrequencyAxis to label_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate">Expected volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to label_FairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate_2">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate_2" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to label_FairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss to label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_2">Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_2" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss to label_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to label_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByLiabilityClassAxis" xml:lang="en-US" id="label_FairValueByLiabilityClassAxis">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByLiabilityClassAxis" xlink:to="label_FairValueByLiabilityClassAxis" xlink:title="label: FairValueByLiabilityClassAxis to label_FairValueByLiabilityClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="label: FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_2">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_2" xlink:title="label: FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount">Transfer of assets from level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="label: FairValueAssetsLevel2ToLevel1TransfersAmount to label_FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel2ToLevel1TransfersAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel2ToLevel1TransfersAmount_2">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueAssetsLevel2ToLevel1TransfersAmount_2" xlink:title="label: FairValueAssetsLevel2ToLevel1TransfersAmount to label_FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="label: FairValueMeasurementFrequencyDomain to label_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to label_FairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate_2">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate_2" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to label_FairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">Transfer of liabilities from level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="label: FairValueLiabilitiesLevel1ToLevel2TransfersAmount to label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_2">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_2" xlink:title="label: FairValueLiabilitiesLevel1ToLevel2TransfersAmount to label_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants" xlink:title="label: FairValueAdjustmentOfWarrants to label_FairValueAdjustmentOfWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants_2">Change in fair value of preferred stock warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants_2" xlink:title="label: FairValueAdjustmentOfWarrants to label_FairValueAdjustmentOfWarrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedTerm" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm">Remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm" xlink:title="label: FairValueAssumptionsExpectedTerm to label_FairValueAssumptionsExpectedTerm" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedTerm" xml:lang="en-US" id="label_FairValueAssumptionsExpectedTerm_2">Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedTerm" xlink:to="label_FairValueAssumptionsExpectedTerm_2" xlink:title="label: FairValueAssumptionsExpectedTerm to label_FairValueAssumptionsExpectedTerm" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount">Transfer of assets from level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="label: FairValueAssetsLevel1ToLevel2TransfersAmount to label_FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsLevel1ToLevel2TransfersAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US" id="label_FairValueAssetsLevel1ToLevel2TransfersAmount_2">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="label_FairValueAssetsLevel1ToLevel2TransfersAmount_2" xlink:title="label: FairValueAssetsLevel1ToLevel2TransfersAmount to label_FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementBasisAxis" xml:lang="en-US" id="label_FairValueByMeasurementBasisAxis">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="label_FairValueByMeasurementBasisAxis" xlink:title="label: FairValueByMeasurementBasisAxis to label_FairValueByMeasurementBasisAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">Assumptions used to determine the fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="label: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2" xlink:title="label: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">Issuance of exchangeable shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues to label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues to label_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedDividendRate">Expected dividend yield (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedDividendRate" xlink:to="label_FairValueAssumptionsExpectedDividendRate" xlink:title="label: FairValueAssumptionsExpectedDividendRate to label_FairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedDividendRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedDividendRate_2">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedDividendRate" xlink:to="label_FairValueAssumptionsExpectedDividendRate_2" xlink:title="label: FairValueAssumptionsExpectedDividendRate to label_FairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">Balance at the beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2">Balance at the end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US" id="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to label_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">Transfer of liabilities from level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="label: FairValueLiabilitiesLevel2ToLevel1TransfersAmount to label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US" id="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_2">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_2" xlink:title="label: FairValueLiabilitiesLevel2ToLevel1TransfersAmount to label_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to label_FairValueDisclosuresAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsNonrecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsNonrecurringMember">Non-recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="label_FairValueMeasurementsNonrecurringMember" xlink:title="label: FairValueMeasurementsNonrecurringMember to label_FairValueMeasurementsNonrecurringMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsNonrecurringMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsNonrecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsNonrecurringMember_2">Fair Value, Measurements, Nonrecurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="label_FairValueMeasurementsNonrecurringMember_2" xlink:title="label: FairValueMeasurementsNonrecurringMember to label_FairValueMeasurementsNonrecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to label_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy">Preferred Stock Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to label_FairValueOfFinancialInstrumentsPolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy_2">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy_2" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to label_FairValueOfFinancialInstrumentsPolicy" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_2">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_2" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosureItemAmountsDomain" xml:lang="en-US" id="label_FairValueDisclosureItemAmountsDomain">Fair Value Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="label_FairValueDisclosureItemAmountsDomain" xlink:title="label: FairValueDisclosureItemAmountsDomain to label_FairValueDisclosureItemAmountsDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Schedule of reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member">Significant Unobservable Inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to label_FairValueInputsLevel3Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member_2">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_2" xlink:title="label: FairValueInputsLevel3Member to label_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">Reconciliation of liabilities measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to label_FairValueInputsLevel1Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member_2">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member_2" xlink:title="label: FairValueInputsLevel1Member to label_FairValueInputsLevel1Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to label_FairValueInputsLevel2Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member_2">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member_2" xlink:title="label: FairValueInputsLevel2Member to label_FairValueInputsLevel2Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">Schedule of liabilities measured at fair value on a recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_2">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_2" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_FinancialLiabilitiesFairValueDisclosure">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="label_FinancialLiabilitiesFairValueDisclosure" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to label_FinancialLiabilitiesFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FinancialLiabilitiesFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_FinancialLiabilitiesFairValueDisclosure_2">Financial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="label_FinancialLiabilitiesFairValueDisclosure_2" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to label_FinancialLiabilitiesFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnDispositionOfAssets1" xml:lang="en-US" id="label_GainLossOnDispositionOfAssets1">Gain (Loss) on Disposition of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="label_GainLossOnDispositionOfAssets1" xlink:title="label: GainLossOnDispositionOfAssets1 to label_GainLossOnDispositionOfAssets1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnDispositionOfAssets1_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnDispositionOfAssets1" xml:lang="en-US" id="label_GainLossOnDispositionOfAssets1_2">Loss on disposal of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="label_GainLossOnDispositionOfAssets1_2" xlink:title="label: GainLossOnDispositionOfAssets1 to label_GainLossOnDispositionOfAssets1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt">Gains (Losses) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to label_GainsLossesOnExtinguishmentOfDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainsLossesOnExtinguishmentOfDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="label_GainsLossesOnExtinguishmentOfDebt_2">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="label_GainsLossesOnExtinguishmentOfDebt_2" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to label_GainsLossesOnExtinguishmentOfDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_2">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_2" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to label_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember_2">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember_2" xlink:title="label: GeneralAndAdministrativeExpenseMember to label_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">Condensed Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to label_IncomeStatementAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationAxis" xml:lang="en-US" id="label_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="label_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to label_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationDomain" xml:lang="en-US" id="label_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to label_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_2">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="IncreaseDecreaseInRestrictedCash" xlink:title="IncreaseDecreaseInRestrictedCash" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInRestrictedCash" xml:lang="en-US" id="label_IncreaseDecreaseInRestrictedCash">Increase (Decrease) in Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRestrictedCash" xlink:to="label_IncreaseDecreaseInRestrictedCash" xlink:title="label: IncreaseDecreaseInRestrictedCash to label_IncreaseDecreaseInRestrictedCash" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInRestrictedCash_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInRestrictedCash" xml:lang="en-US" id="label_IncreaseDecreaseInRestrictedCash_2">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRestrictedCash" xlink:to="label_IncreaseDecreaseInRestrictedCash_2" xlink:title="label: IncreaseDecreaseInRestrictedCash to label_IncreaseDecreaseInRestrictedCash" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPayableCurrentAndNoncurrent" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent">Interest Payable Current And Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent" xlink:title="label: InterestPayableCurrentAndNoncurrent to label_InterestPayableCurrentAndNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPayableCurrentAndNoncurrent" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent_2">Accrued interest, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent_2" xlink:title="label: InterestPayableCurrentAndNoncurrent to label_InterestPayableCurrentAndNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPayableCurrent" xml:lang="en-US" id="label_InterestPayableCurrent">Accrued interest, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="label_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to label_InterestPayableCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPayableCurrent" xml:lang="en-US" id="label_InterestPayableCurrent_2">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="label_InterestPayableCurrent_2" xlink:title="label: InterestPayableCurrent to label_InterestPayableCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStockAndWarrantsForServicesOrClaims">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to label_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2">Issuances of common stock for technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to label_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent_2">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_2" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Total liabilities, convertible preferred stock and stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_2">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_2" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_2">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_2" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">Liabilities, convertible preferred stock and stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_2">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtAbstract" xml:lang="en-US" id="label_LongTermDebtAbstract">Long-Term Debt, Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAbstract" xlink:to="label_LongTermDebtAbstract" xlink:title="label: LongTermDebtAbstract to label_LongTermDebtAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt">Long-term debt, net of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt" xlink:title="label: LongTermDebt to label_LongTermDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt_2">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt_2" xlink:title="label: LongTermDebt to label_LongTermDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtTextBlock" xml:lang="en-US" id="label_LongTermDebtTextBlock">Long-Term Debt, Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="label_LongTermDebtTextBlock" xlink:title="label: LongTermDebtTextBlock to label_LongTermDebtTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtTextBlock" xml:lang="en-US" id="label_LongTermDebtTextBlock_2">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="label_LongTermDebtTextBlock_2" xlink:title="label: LongTermDebtTextBlock to label_LongTermDebtTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtCurrent" xml:lang="en-US" id="label_LongTermDebtCurrent">Long-term debt, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent" xlink:title="label: LongTermDebtCurrent to label_LongTermDebtCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtCurrent" xml:lang="en-US" id="label_LongTermDebtCurrent_2">Long-term Debt, Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent_2" xlink:title="label: LongTermDebtCurrent to label_LongTermDebtCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebtCurrent" xml:lang="en-US" id="label_LongTermDebtCurrent_3">Current portion of long-term debt, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent_3" xlink:title="label: LongTermDebtCurrent to label_LongTermDebtCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtNoncurrent" xml:lang="en-US" id="label_LongTermDebtNoncurrent">Long-term debt, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="label_LongTermDebtNoncurrent" xlink:title="label: LongTermDebtNoncurrent to label_LongTermDebtNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtNoncurrent" xml:lang="en-US" id="label_LongTermDebtNoncurrent_2">Long-term Debt, Excluding Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="label_LongTermDebtNoncurrent_2" xlink:title="label: LongTermDebtNoncurrent to label_LongTermDebtNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtNoncurrent_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebtNoncurrent" xml:lang="en-US" id="label_LongTermDebtNoncurrent_3">Long-term debt, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtNoncurrent" xlink:to="label_LongTermDebtNoncurrent_3" xlink:title="label: LongTermDebtNoncurrent to label_LongTermDebtNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember" xlink:title="label: MaximumMember to label_MaximumMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember_2">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_2" xlink:title="label: MaximumMember to label_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="NonfinancialLiabilitiesFairValueDisclosure" xlink:title="NonfinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_NonfinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonfinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_NonfinancialLiabilitiesFairValueDisclosure">Non-financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonfinancialLiabilitiesFairValueDisclosure" xlink:to="label_NonfinancialLiabilitiesFairValueDisclosure" xlink:title="label: NonfinancialLiabilitiesFairValueDisclosure to label_NonfinancialLiabilitiesFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NonfinancialLiabilitiesFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonfinancialLiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_NonfinancialLiabilitiesFairValueDisclosure_2">Nonfinancial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonfinancialLiabilitiesFairValueDisclosure" xlink:to="label_NonfinancialLiabilitiesFairValueDisclosure_2" xlink:title="label: NonfinancialLiabilitiesFairValueDisclosure to label_NonfinancialLiabilitiesFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss_2">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_2" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss_3">Consolidated net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_3" xlink:title="label: NetIncomeLoss to label_NetIncomeLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueAbstract">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueAbstract to label_OperatingLeasesFutureMinimumPaymentsDueAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to label_OperatingExpensesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract_2">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract_2" xlink:title="label: OperatingExpensesAbstract to label_OperatingExpensesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses" xlink:title="label: OperatingExpenses to label_OperatingExpenses" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses_2">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses_2" xlink:title="label: OperatingExpenses to label_OperatingExpenses" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">Non-cancellable operating lease commitments for 2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInThreeYears to label_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueCurrent">Non-cancellable operating lease commitments for 2014</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to label_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_2">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueCurrent_2" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueCurrent to label_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss_2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_2" xlink:title="label: OperatingIncomeLoss to label_OperatingIncomeLoss" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">Non-cancellable operating lease commitments for 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US" id="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2" xlink:title="label: OperatingLeasesFutureMinimumPaymentsDueInTwoYears to label_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Organization and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">Organization and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to label_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent" xlink:title="label: OtherAssetsNoncurrent to label_OtherAssetsNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent_2">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent_2" xlink:title="label: OtherAssetsNoncurrent to label_OtherAssetsNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoninterestExpense" xlink:label="OtherNoninterestExpense" xlink:title="OtherNoninterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoninterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNoninterestExpense" xml:lang="en-US" id="label_OtherNoninterestExpense">Other Noninterest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoninterestExpense" xlink:to="label_OtherNoninterestExpense" xlink:title="label: OtherNoninterestExpense to label_OtherNoninterestExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoninterestExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_OtherNoninterestExpense" xml:lang="en-US" id="label_OtherNoninterestExpense_2">Estimated total offering costs (including costs paid)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoninterestExpense" xlink:to="label_OtherNoninterestExpense_2" xlink:title="label: OtherNoninterestExpense to label_OtherNoninterestExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense" xlink:title="label: OtherNonoperatingIncomeExpense to label_OtherNonoperatingIncomeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense_2">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense_2" xlink:title="label: OtherNonoperatingIncomeExpense to label_OtherNonoperatingIncomeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="label_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaidInKindInterest" xml:lang="en-US" id="label_PaidInKindInterest">Paid-in-Kind Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="label_PaidInKindInterest" xlink:title="label: PaidInKindInterest to label_PaidInKindInterest" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaidInKindInterest_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaidInKindInterest" xml:lang="en-US" id="label_PaidInKindInterest_2">Noncash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="label_PaidInKindInterest_2" xlink:title="label: PaidInKindInterest to label_PaidInKindInterest" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_2">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts" xlink:title="label: PaymentsOfStockIssuanceCosts to label_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts_2">Costs paid in connection with initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts_2" xlink:title="label: PaymentsOfStockIssuanceCosts to label_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsOfStockIssuanceCosts_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="label_PaymentsOfStockIssuanceCosts_3">Offering costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="label_PaymentsOfStockIssuanceCosts_3" xlink:title="label: PaymentsOfStockIssuanceCosts to label_PaymentsOfStockIssuanceCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameDomain" xml:lang="en-US" id="label_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain" xlink:title="label: PlanNameDomain to label_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameAxis" xml:lang="en-US" id="label_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="label_PlanNameAxis" xlink:title="label: PlanNameAxis to label_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Undesignated preferred stock, authorized shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_2">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_2" xlink:title="label: PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProFormaMember" xlink:label="ProFormaMember" xlink:title="ProFormaMember" />
    <link:label xlink:type="resource" xlink:label="label_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProFormaMember" xml:lang="en-US" id="label_ProFormaMember">Pro Forma</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaMember" xlink:to="label_ProFormaMember" xlink:title="label: ProFormaMember to label_ProFormaMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProFormaMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProFormaMember" xml:lang="en-US" id="label_ProFormaMember_2">Pro Forma [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaMember" xlink:to="label_ProFormaMember_2" xlink:title="label: ProFormaMember to label_ProFormaMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="ProceedsFromRepurchaseOfEquity" xlink:title="ProceedsFromRepurchaseOfEquity" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromRepurchaseOfEquity" xml:lang="en-US" id="label_ProceedsFromRepurchaseOfEquity">Proceeds from (Repurchase of) Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRepurchaseOfEquity" xlink:to="label_ProceedsFromRepurchaseOfEquity" xlink:title="label: ProceedsFromRepurchaseOfEquity to label_ProceedsFromRepurchaseOfEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromRepurchaseOfEquity_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromRepurchaseOfEquity" xml:lang="en-US" id="label_ProceedsFromRepurchaseOfEquity_2">Issuance of common stock, net of repurchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromRepurchaseOfEquity" xlink:to="label_ProceedsFromRepurchaseOfEquity_2" xlink:title="label: ProceedsFromRepurchaseOfEquity to label_ProceedsFromRepurchaseOfEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_ProceedsFromConvertibleDebt">Proceeds from convertible promissory notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="label_ProceedsFromConvertibleDebt" xlink:title="label: ProceedsFromConvertibleDebt to label_ProceedsFromConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromConvertibleDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromConvertibleDebt" xml:lang="en-US" id="label_ProceedsFromConvertibleDebt_2">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="label_ProceedsFromConvertibleDebt_2" xlink:title="label: ProceedsFromConvertibleDebt to label_ProceedsFromConvertibleDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfConvertiblePreferredStock">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="label_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="label: ProceedsFromIssuanceOfConvertiblePreferredStock to label_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfConvertiblePreferredStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfConvertiblePreferredStock_2">Issuance of convertible preferred stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="label_ProceedsFromIssuanceOfConvertiblePreferredStock_2" xlink:title="label: ProceedsFromIssuanceOfConvertiblePreferredStock to label_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt">Proceeds from Issuance of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt" xlink:title="label: ProceedsFromIssuanceOfLongTermDebt to label_ProceedsFromIssuanceOfLongTermDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfLongTermDebt_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US" id="label_ProceedsFromIssuanceOfLongTermDebt_2">Proceeds from long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfLongTermDebt" xlink:to="label_ProceedsFromIssuanceOfLongTermDebt_2" xlink:title="label: ProceedsFromIssuanceOfLongTermDebt to label_ProceedsFromIssuanceOfLongTermDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering">Proceeds from Issuance Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering" xlink:title="label: ProceedsFromIssuanceInitialPublicOffering to label_ProceedsFromIssuanceInitialPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering_2">Gross proceeds (including over-allotment)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering_2" xlink:title="label: ProceedsFromIssuanceInitialPublicOffering to label_ProceedsFromIssuanceInitialPublicOffering" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2">Proceeds from sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_ProceedsFromSaleOfPropertyPlantAndEquipment_2" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to label_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="label: RangeAxis to label_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="label: RangeMember to label_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_RecognitionOfDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RecognitionOfDeferredRevenue" xml:lang="en-US" id="label_RecognitionOfDeferredRevenue">Recognition of Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="label_RecognitionOfDeferredRevenue" xlink:title="label: RecognitionOfDeferredRevenue to label_RecognitionOfDeferredRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RecognitionOfDeferredRevenue_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RecognitionOfDeferredRevenue" xml:lang="en-US" id="label_RecognitionOfDeferredRevenue_2">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RecognitionOfDeferredRevenue" xlink:to="label_RecognitionOfDeferredRevenue_2" xlink:title="label: RecognitionOfDeferredRevenue to label_RecognitionOfDeferredRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfLongTermDebt" xml:lang="en-US" id="label_RepaymentsOfLongTermDebt">Repayments of Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="label_RepaymentsOfLongTermDebt" xlink:title="label: RepaymentsOfLongTermDebt to label_RepaymentsOfLongTermDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfLongTermDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfLongTermDebt" xml:lang="en-US" id="label_RepaymentsOfLongTermDebt_2">Payments on long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebt" xlink:to="label_RepaymentsOfLongTermDebt_2" xlink:title="label: RepaymentsOfLongTermDebt to label_RepaymentsOfLongTermDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfConvertibleDebt">Partial repayment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfConvertibleDebt" xlink:to="label_RepaymentsOfConvertibleDebt" xlink:title="label: RepaymentsOfConvertibleDebt to label_RepaymentsOfConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfConvertibleDebt_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfConvertibleDebt_2">Repayments of Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfConvertibleDebt" xlink:to="label_RepaymentsOfConvertibleDebt_2" xlink:title="label: RepaymentsOfConvertibleDebt to label_RepaymentsOfConvertibleDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_2">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_2" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to label_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember_2">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember_2" xlink:title="label: ResearchAndDevelopmentExpenseMember to label_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsNoncurrent">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="label_RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="label: RestrictedCashAndCashEquivalentsNoncurrent to label_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedCashAndCashEquivalentsNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedCashAndCashEquivalentsNoncurrent" xml:lang="en-US" id="label_RestrictedCashAndCashEquivalentsNoncurrent_2">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="label_RestrictedCashAndCashEquivalentsNoncurrent_2" xlink:title="label: RestrictedCashAndCashEquivalentsNoncurrent to label_RestrictedCashAndCashEquivalentsNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueRecognitionAbstract" xml:lang="en-US" id="label_RevenueRecognitionAbstract">Revenue recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionAbstract" xlink:to="label_RevenueRecognitionAbstract" xlink:title="label: RevenueRecognitionAbstract to label_RevenueRecognitionAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueRecognitionAbstract" xml:lang="en-US" id="label_RevenueRecognitionAbstract_2">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionAbstract" xlink:to="label_RevenueRecognitionAbstract_2" xlink:title="label: RevenueRecognitionAbstract to label_RevenueRecognitionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants_2">Revenue from Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants_2" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="label_RevenueRecognitionPolicyTextBlock" xlink:title="label: RevenueRecognitionPolicyTextBlock to label_RevenueRecognitionPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_RevenueRecognitionPolicyTextBlock_2">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="label_RevenueRecognitionPolicyTextBlock_2" xlink:title="label: RevenueRecognitionPolicyTextBlock to label_RevenueRecognitionPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="RevenueRecognitionMilestoneMethodFactors" xlink:title="RevenueRecognitionMilestoneMethodFactors" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionMilestoneMethodFactors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueRecognitionMilestoneMethodFactors" xml:lang="en-US" id="label_RevenueRecognitionMilestoneMethodFactors">Revenue Recognition, Milestone Method, Factors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionMilestoneMethodFactors" xlink:to="label_RevenueRecognitionMilestoneMethodFactors" xlink:title="label: RevenueRecognitionMilestoneMethodFactors to label_RevenueRecognitionMilestoneMethodFactors" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRecognitionMilestoneMethodFactors_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueRecognitionMilestoneMethodFactors" xml:lang="en-US" id="label_RevenueRecognitionMilestoneMethodFactors_2">Four criteria needed for Company to recognize revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionMilestoneMethodFactors" xlink:to="label_RevenueRecognitionMilestoneMethodFactors_2" xlink:title="label: RevenueRecognitionMilestoneMethodFactors to label_RevenueRecognitionMilestoneMethodFactors" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract">Revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract_2">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract_2" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StraightLineRent" xlink:label="StraightLineRent" xlink:title="StraightLineRent" />
    <link:label xlink:type="resource" xlink:label="label_StraightLineRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StraightLineRent" xml:lang="en-US" id="label_StraightLineRent">Straight Line Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StraightLineRent" xlink:to="label_StraightLineRent" xlink:title="label: StraightLineRent to label_StraightLineRent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StraightLineRent_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_StraightLineRent" xml:lang="en-US" id="label_StraightLineRent_2">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StraightLineRent" xlink:to="label_StraightLineRent_2" xlink:title="label: StraightLineRent to label_StraightLineRent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_SalesRevenueNet" xml:lang="en-US" id="label_SalesRevenueNet">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="label_SalesRevenueNet" xlink:title="label: SalesRevenueNet to label_SalesRevenueNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesRevenueNet" xml:lang="en-US" id="label_SalesRevenueNet_2">Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNet" xlink:to="label_SalesRevenueNet_2" xlink:title="label: SalesRevenueNet to label_SalesRevenueNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to label_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="ScheduleOfStockOptionsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US" id="label_ScheduleOfStockOptionsRollForwardTableTextBlock">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="label_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="label: ScheduleOfStockOptionsRollForwardTableTextBlock to label_ScheduleOfStockOptionsRollForwardTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockOptionsRollForwardTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfStockOptionsRollForwardTableTextBlock" xml:lang="en-US" id="label_ScheduleOfStockOptionsRollForwardTableTextBlock_2">Summary of stock option activity under the Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="label_ScheduleOfStockOptionsRollForwardTableTextBlock_2" xlink:title="label: ScheduleOfStockOptionsRollForwardTableTextBlock to label_ScheduleOfStockOptionsRollForwardTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Schedule of anti-dilutive securities not included in the calculation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to label_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:label="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:title="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xml:lang="en-US" id="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock">Schedule of assumptions used to determine fair value of preferred stock warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:to="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:title="label: ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock to label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xml:lang="en-US" id="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_2">Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:to="label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_2" xlink:title="label: ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock to label_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US" id="label_ScheduleOfBusinessAcquisitionsByAcquisitionTable">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="label_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTable to label_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US" id="label_ScheduleOfDebtInstrumentsTextBlock">Schedule of long-term debt and unamortized discount balances (excluding convertible debt)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="label_ScheduleOfDebtInstrumentsTextBlock" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to label_ScheduleOfDebtInstrumentsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDebtInstrumentsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US" id="label_ScheduleOfDebtInstrumentsTextBlock_2">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="label_ScheduleOfDebtInstrumentsTextBlock_2" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to label_ScheduleOfDebtInstrumentsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of allocation of stock-based compensation for all options and restricted stock awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="ScheduleOfSubsequentEventsTextBlock" xlink:title="ScheduleOfSubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfSubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfSubsequentEventsTextBlock" xml:lang="en-US" id="label_ScheduleOfSubsequentEventsTextBlock">Schedule of estimated net proceeds from the IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSubsequentEventsTextBlock" xlink:to="label_ScheduleOfSubsequentEventsTextBlock" xlink:title="label: ScheduleOfSubsequentEventsTextBlock to label_ScheduleOfSubsequentEventsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfSubsequentEventsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfSubsequentEventsTextBlock" xml:lang="en-US" id="label_ScheduleOfSubsequentEventsTextBlock_2">Schedule of Subsequent Events [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSubsequentEventsTextBlock" xlink:to="label_ScheduleOfSubsequentEventsTextBlock_2" xlink:title="label: ScheduleOfSubsequentEventsTextBlock to label_ScheduleOfSubsequentEventsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted-Average Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">Canceled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">Additional shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation_2">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_2" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Expected dividend yield (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2">Canceled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2">Risk-free interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Weighted-average assumptions to determine fair value of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Balance at the end of the period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to label_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_2">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_2" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to label_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Balance at the beginning of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2">Balance at the end of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2">Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to label_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">Condensed Consolidated Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to label_StatementOfCashFlowsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">Condensed Consolidated Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to label_StatementOfFinancialPositionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="StockCompensationPlanMember" xlink:title="StockCompensationPlanMember" />
    <link:label xlink:type="resource" xlink:label="label_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockCompensationPlanMember" xml:lang="en-US" id="label_StockCompensationPlanMember">Common stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockCompensationPlanMember" xlink:to="label_StockCompensationPlanMember" xlink:title="label: StockCompensationPlanMember to label_StockCompensationPlanMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockCompensationPlanMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockCompensationPlanMember" xml:lang="en-US" id="label_StockCompensationPlanMember_2">Stock Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockCompensationPlanMember" xlink:to="label_StockCompensationPlanMember_2" xlink:title="label: StockCompensationPlanMember to label_StockCompensationPlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="StockIssuedDuringPeriodSharesIssuedForCash" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForCash">Shares sold in initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForCash" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForCash to label_StockIssuedDuringPeriodSharesIssuedForCash" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForCash_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForCash_2">Development Stage Entities, Stock Issued, Shares, Issued for Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForCash" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForCash_2" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForCash to label_StockIssuedDuringPeriodSharesIssuedForCash" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' deficit:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract_2">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_2" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Total stockholders' deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_2">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_3">Total stockholders' (deficit) equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_3" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="StockholdersEquityPolicyTextBlock" xlink:title="StockholdersEquityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityPolicyTextBlock" xml:lang="en-US" id="label_StockholdersEquityPolicyTextBlock">Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="label_StockholdersEquityPolicyTextBlock" xlink:title="label: StockholdersEquityPolicyTextBlock to label_StockholdersEquityPolicyTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityPolicyTextBlock" xml:lang="en-US" id="label_StockholdersEquityPolicyTextBlock_2">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="label_StockholdersEquityPolicyTextBlock_2" xlink:title="label: StockholdersEquityPolicyTextBlock to label_StockholdersEquityPolicyTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to label_StockholdersEquityNoteAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract_2">Stockholders' Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract_2" xlink:title="label: StockholdersEquityNoteAbstract to label_StockholdersEquityNoteAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to label_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteStockSplitConversionRatio1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="label_StockholdersEquityNoteStockSplitConversionRatio1_2">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="label_StockholdersEquityNoteStockSplitConversionRatio1_2" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to label_StockholdersEquityNoteStockSplitConversionRatio1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock_2">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_2" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to label_SubsequentEventsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTable" xml:lang="en-US" id="label_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="label_SubsequentEventTable" xlink:title="label: SubsequentEventTable to label_SubsequentEventTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems">Subsequent events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to label_SubsequentEventLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems_2">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems_2" xlink:title="label: SubsequentEventLineItems to label_SubsequentEventLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember">Subsequent event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember" xlink:title="label: SubsequentEventMember to label_SubsequentEventMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember_2">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember_2" xlink:title="label: SubsequentEventMember to label_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeDomain" xml:lang="en-US" id="label_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to label_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeAxis" xml:lang="en-US" id="label_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="label_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to label_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding">Convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding" xlink:title="label: TemporaryEquitySharesOutstanding to label_TemporaryEquitySharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesOutstanding" xml:lang="en-US" id="label_TemporaryEquitySharesOutstanding_2">Temporary Equity, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesOutstanding" xlink:to="label_TemporaryEquitySharesOutstanding_2" xlink:title="label: TemporaryEquitySharesOutstanding to label_TemporaryEquitySharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare">Convertible preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare" xlink:title="label: TemporaryEquityParOrStatedValuePerShare to label_TemporaryEquityParOrStatedValuePerShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US" id="label_TemporaryEquityParOrStatedValuePerShare_2">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityParOrStatedValuePerShare" xlink:to="label_TemporaryEquityParOrStatedValuePerShare_2" xlink:title="label: TemporaryEquityParOrStatedValuePerShare to label_TemporaryEquityParOrStatedValuePerShare" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent">Convertible preferred stock, $0.001 par value; authorized shares - 68,360,186 at September 30, 2013 and 62,200,000 at December 31, 2012; issued and outstanding shares - 44,967,690 at September 30, 2013 and December 31, 2012; liquidation preference of $58,518 at September 30, 2013 and December 31, 2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to label_TemporaryEquityCarryingAmountAttributableToParent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_2">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_2" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to label_TemporaryEquityCarryingAmountAttributableToParent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityCarryingAmountAttributableToParent_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US" id="label_TemporaryEquityCarryingAmountAttributableToParent_3">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityCarryingAmountAttributableToParent" xlink:to="label_TemporaryEquityCarryingAmountAttributableToParent_3" xlink:title="label: TemporaryEquityCarryingAmountAttributableToParent to label_TemporaryEquityCarryingAmountAttributableToParent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized">Convertible preferred, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized" xlink:title="label: TemporaryEquitySharesAuthorized to label_TemporaryEquitySharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesAuthorized" xml:lang="en-US" id="label_TemporaryEquitySharesAuthorized_2">Temporary Equity, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesAuthorized" xlink:to="label_TemporaryEquitySharesAuthorized_2" xlink:title="label: TemporaryEquitySharesAuthorized to label_TemporaryEquitySharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquitySharesIssued" xml:lang="en-US" id="label_TemporaryEquitySharesIssued">Convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued" xlink:title="label: TemporaryEquitySharesIssued to label_TemporaryEquitySharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquitySharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquitySharesIssued" xml:lang="en-US" id="label_TemporaryEquitySharesIssued_2">Temporary Equity, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquitySharesIssued" xlink:to="label_TemporaryEquitySharesIssued_2" xlink:title="label: TemporaryEquitySharesIssued to label_TemporaryEquitySharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TemporaryEquityLiquidationPreference" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreference">Convertible preferred stock, aggregate liquidation preference (in dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="label_TemporaryEquityLiquidationPreference" xlink:title="label: TemporaryEquityLiquidationPreference to label_TemporaryEquityLiquidationPreference" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_TemporaryEquityLiquidationPreference_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TemporaryEquityLiquidationPreference" xml:lang="en-US" id="label_TemporaryEquityLiquidationPreference_2">Temporary Equity, Liquidation Preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TemporaryEquityLiquidationPreference" xlink:to="label_TemporaryEquityLiquidationPreference_2" xlink:title="label: TemporaryEquityLiquidationPreference to label_TemporaryEquityLiquidationPreference" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates" xlink:title="label: UseOfEstimates to label_UseOfEstimates" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates_2">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates_2" xlink:title="label: UseOfEstimates to label_UseOfEstimates" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="label_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingAxis" xml:lang="en-US" id="label_VestingAxis">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="label_VestingAxis" xlink:title="label: VestingAxis to label_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingDomain" xml:lang="en-US" id="label_VestingDomain">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="label_VestingDomain" xlink:title="label: VestingDomain to label_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrants for convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="label: WarrantMember to label_WarrantMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember_2">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_2" xlink:title="label: WarrantMember to label_WarrantMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember_3">Warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_3" xlink:title="label: WarrantMember to label_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding">Preferred stock warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding" xlink:title="label: WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding_2">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding_2" xlink:title="label: WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="WriteOffOfDeferredDebtIssuanceCost" xlink:title="WriteOffOfDeferredDebtIssuanceCost" />
    <link:label xlink:type="resource" xlink:label="label_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US" id="label_WriteOffOfDeferredDebtIssuanceCost">Write off of Deferred Debt Issuance Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfDeferredDebtIssuanceCost" xlink:to="label_WriteOffOfDeferredDebtIssuanceCost" xlink:title="label: WriteOffOfDeferredDebtIssuanceCost to label_WriteOffOfDeferredDebtIssuanceCost" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WriteOffOfDeferredDebtIssuanceCost_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US" id="label_WriteOffOfDeferredDebtIssuanceCost_2">Unamortized debt discount written-off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteOffOfDeferredDebtIssuanceCost" xlink:to="label_WriteOffOfDeferredDebtIssuanceCost_2" xlink:title="label: WriteOffOfDeferredDebtIssuanceCost to label_WriteOffOfDeferredDebtIssuanceCost" use="optional" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>fate-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0189 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureStockholdersDeficitDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEventsDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEventsTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureStockholdersDeficitTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurementsDetails2" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurementsTables" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsInc" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/StatementOfIncome" xlink:type="simple" xlink:href="fate-20130930.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureFairValueMeasurements" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/CashFlows" xlink:type="simple" xlink:href="fate-20130930.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingencies" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureLongTermDebtCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/BalanceSheet" xlink:type="simple" xlink:href="fate-20130930.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="fate-20130930.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficit" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureStockholdersDeficit" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="fate-20130930.xsd#DisclosureSubsequentEvents" />
  <link:roleRef roleURI="http://www.fatetherapeutics.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="fate-20130930.xsd#DocumentandEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EquityIncentivePlan2007Member" xlink:label="EquityIncentivePlan2007Member" xlink:title="EquityIncentivePlan2007Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2007Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2007Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_StockOptionAndIncentivePlan2013Member" xlink:label="StockOptionAndIncentivePlan2013Member" xlink:title="StockOptionAndIncentivePlan2013Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="StockOptionAndIncentivePlan2013Member" xlink:title="presentation: PlanNameDomain to StockOptionAndIncentivePlan2013Member" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EmployeeStockMember" xlink:title="presentation: PlanNameDomain to EmployeeStockMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="presentation: AwardDateAxis to AwardDateDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="EmployeeAndNonEmployeeStockOptionMember" xlink:title="EmployeeAndNonEmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateDomain" xlink:to="EmployeeAndNonEmployeeStockOptionMember" xlink:title="presentation: AwardDateDomain to EmployeeAndNonEmployeeStockOptionMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: EmployeeAndNonEmployeeStockOptionMember to EmployeeStockOptionMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NonEmployeeStockOptionMember" xlink:label="NonEmployeeStockOptionMember" xlink:title="NonEmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeAndNonEmployeeStockOptionMember" xlink:to="NonEmployeeStockOptionMember" xlink:title="presentation: EmployeeAndNonEmployeeStockOptionMember to NonEmployeeStockOptionMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="presentation: VestingAxis to VestingDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="VestingBasedOnPerformanceMember" xlink:title="VestingBasedOnPerformanceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="VestingBasedOnPerformanceMember" xlink:title="presentation: VestingDomain to VestingBasedOnPerformanceMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:label="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" xlink:title="presentation: VestingDomain to VestingBasedOnPerformanceBasedMilestonesAndMarketConditionsMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: SubsequentEventTable to DebtInstrumentAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:label="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="presentation: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn8August2016Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="StockIssuedDuringPeriodSharesIssuedForCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForCash" xlink:title="presentation: SubsequentEventLineItems to StockIssuedDuringPeriodSharesIssuedForCash" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="EquityIssuancePerShareAmount" xlink:title="EquityIssuancePerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="EquityIssuancePerShareAmount" xlink:title="presentation: SubsequentEventLineItems to EquityIssuancePerShareAmount" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceInitialPublicOffering" xlink:title="presentation: SubsequentEventLineItems to ProceedsFromIssuanceInitialPublicOffering" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_UnderwritingDiscountsAndCommissions" xlink:label="UnderwritingDiscountsAndCommissions" xlink:title="UnderwritingDiscountsAndCommissions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="UnderwritingDiscountsAndCommissions" xlink:title="presentation: SubsequentEventLineItems to UnderwritingDiscountsAndCommissions" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoninterestExpense" xlink:label="OtherNoninterestExpense" xlink:title="OtherNoninterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="OtherNoninterestExpense" xlink:title="presentation: SubsequentEventLineItems to OtherNoninterestExpense" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: SubsequentEventLineItems to PaymentsOfStockIssuanceCosts" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:label="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="ProceedsReceivableFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsReceivableFromIssuanceInitialPublicOffering" xlink:title="presentation: SubsequentEventLineItems to ProceedsReceivableFromIssuanceInitialPublicOffering" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="RepaymentsOfConvertibleDebt" xlink:title="RepaymentsOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="RepaymentsOfConvertibleDebt" xlink:title="presentation: SubsequentEventLineItems to RepaymentsOfConvertibleDebt" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:label="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" xlink:title="presentation: SubsequentEventLineItems to EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="presentation: SubsequentEventLineItems to ConvertiblePreferredStockSharesIssuedUponConversion" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="presentation: SubsequentEventLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: SubsequentEventLineItems to DebtConversionConvertedInstrumentSharesIssued1" use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="WriteOffOfDeferredDebtIssuanceCost" xlink:title="WriteOffOfDeferredDebtIssuanceCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="WriteOffOfDeferredDebtIssuanceCost" xlink:title="presentation: SubsequentEventLineItems to WriteOffOfDeferredDebtIssuanceCost" use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="presentation: SubsequentEventLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableSharesRedeemedDuringPeriodShares" xlink:label="ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="ExchangeableSharesRedeemedDuringPeriodShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ExchangeableSharesRedeemedDuringPeriodShares" xlink:title="presentation: SubsequentEventLineItems to ExchangeableSharesRedeemedDuringPeriodShares" use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" xlink:title="presentation: SubsequentEventLineItems to ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted" use="optional" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:title="presentation: SubsequentEventLineItems to ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" use="optional" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: SubsequentEventLineItems to CommonStockSharesAuthorized" use="optional" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: SubsequentEventLineItems to PreferredStockSharesAuthorized" use="optional" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ActualAndProformaBalanceSheetDataAbstract" xlink:label="ActualAndProformaBalanceSheetDataAbstract" xlink:title="ActualAndProformaBalanceSheetDataAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ActualAndProformaBalanceSheetDataAbstract" xlink:title="presentation: SubsequentEventLineItems to ActualAndProformaBalanceSheetDataAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to OtherAssetsNoncurrent" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to ConvertibleNotesPayableCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to WarrantsAndRightsOutstanding" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityNoncurrent" xlink:label="ExchangeableShareLiabilityNoncurrent" xlink:title="ExchangeableShareLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="ExchangeableShareLiabilityNoncurrent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to ExchangeableShareLiabilityNoncurrent" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ActualAndProformaBalanceSheetDataAbstract" xlink:label="ActualAndProformaBalanceSheetDataAbstract" xlink:title="ActualAndProformaBalanceSheetDataAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ActualAndProformaBalanceSheetDataAbstract" xlink:title="presentation: SubsequentEventLineItems to ActualAndProformaBalanceSheetDataAbstract" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="CommonStockValue" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to CommonStockValue" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to AdditionalPaidInCapital" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ActualAndProformaBalanceSheetDataAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: ActualAndProformaBalanceSheetDataAbstract to StockholdersEquity" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:label="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" xlink:title="presentation: SubsequentEventLineItems to NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: SubsequentEventTable to StatementScenarioAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProFormaMember" xlink:label="ProFormaMember" xlink:title="ProFormaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ProFormaMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ProFormaMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn8August2016Member" xlink:label="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="ConvertiblePromissoryNotesDueOn8August2016Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn8August2016Member" xlink:title="presentation: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn8August2016Member" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ConvertiblePromissoryNotesDueOn24June2014Member" xlink:label="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="ConvertiblePromissoryNotesDueOn24June2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertiblePromissoryNotesDueOn24June2014Member" xlink:title="presentation: DebtInstrumentNameDomain to ConvertiblePromissoryNotesDueOn24June2014Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LongTermDebtAbstract to DebtInstrumentTable" use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="DebtInstrumentDiscountNonCurrent" xlink:title="DebtInstrumentDiscountNonCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentDiscountNonCurrent" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentDiscountNonCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebt" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LongTermDebtGrossCurrent" xlink:label="LongTermDebtGrossCurrent" xlink:title="LongTermDebtGrossCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtGrossCurrent" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtGrossCurrent" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtNoncurrent" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="DebtInstrumentDiscountCurrent" xlink:title="DebtInstrumentDiscountCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentDiscountCurrent" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentDiscountCurrent" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtCurrent" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtCurrent" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentFaceAmount" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentTerm" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: DebtInstrumentLineItems to AmortizationOfDebtDiscountPremium" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="ConvertibleNotesPayable" xlink:title="ConvertibleNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleNotesPayable" xlink:title="presentation: DebtInstrumentLineItems to ConvertibleNotesPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="presentation: DebtInstrumentLineItems to ConvertibleLongTermNotesPayable" use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrent" xlink:title="presentation: DebtInstrumentLineItems to InterestPayableCurrent" use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="presentation: DebtInstrumentLineItems to InterestPayableCurrentAndNoncurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:title="OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_LeaseTermExtended" xlink:label="LeaseTermExtended" xlink:title="LeaseTermExtended" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="LeaseTermExtended" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to LeaseTermExtended" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="presentation: OperatingLeasesFutureMinimumPaymentsDueAbstract to OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="presentation: LongTermDebtAbstract to ScheduleOfDebtInstrumentsTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:label="ScheduleOfSubsequentEventsTextBlock" xlink:title="ScheduleOfSubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="ScheduleOfSubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to ScheduleOfSubsequentEventsTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ScheduleOfActualAndProformaBalanceSheetDetail" xlink:label="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:title="ScheduleOfActualAndProformaBalanceSheetDetail" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="ScheduleOfActualAndProformaBalanceSheetDetail" xlink:title="presentation: SubsequentEventsAbstract to ScheduleOfActualAndProformaBalanceSheetDetail" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:label="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:title="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="StockholdersEquityNoteAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to StockholdersEquityNoteAbstract" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteStockSplitConversionRatio1" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="RevenueRecognitionAbstract" xlink:title="RevenueRecognitionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueRecognitionAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueRecognitionAbstract" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="RevenueRecognitionMilestoneMethodFactors" xlink:title="RevenueRecognitionMilestoneMethodFactors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRecognitionAbstract" xlink:to="RevenueRecognitionMilestoneMethodFactors" xlink:title="presentation: RevenueRecognitionAbstract to RevenueRecognitionMilestoneMethodFactors" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConsolidationPolicyTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="StockholdersEquityPolicyTextBlock" xlink:title="StockholdersEquityPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="StockholdersEquityPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to StockholdersEquityPolicyTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to UseOfEstimates" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_OtherAssetsPolicy" xlink:label="OtherAssetsPolicy" xlink:title="OtherAssetsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OtherAssetsPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OtherAssetsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueOfFinancialInstrumentsPolicy" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueRecognitionPolicyTextBlock" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to EarningsPerSharePolicyTextBlock" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardDateAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardDateAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateAxis" xlink:to="AwardDateDomain" xlink:title="presentation: AwardDateAxis to AwardDateDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AwardDateDomain to EmployeeStockOptionMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_NonEmployeeStockOptionMember" xlink:label="NonEmployeeStockOptionMember" xlink:title="NonEmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardDateDomain" xlink:to="NonEmployeeStockOptionMember" xlink:title="presentation: AwardDateDomain to NonEmployeeStockOptionMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="ScheduleOfStockOptionsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfStockOptionsRollForwardTableTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:label="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:title="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityUnitPurchaseAgreementsMember" xlink:label="EquityUnitPurchaseAgreementsMember" xlink:title="EquityUnitPurchaseAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EquityUnitPurchaseAgreementsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EquityUnitPurchaseAgreementsMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="StockCompensationPlanMember" xlink:title="StockCompensationPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockCompensationPlanMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockCompensationPlanMember" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="ConvertibleNotesPayable" xlink:title="ConvertibleNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConvertibleNotesPayable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConvertibleNotesPayable" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementBasisAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementBasisAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="FairValueDisclosureItemAmountsDomain" xlink:title="FairValueDisclosureItemAmountsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="FairValueDisclosureItemAmountsDomain" xlink:title="presentation: FairValueByMeasurementBasisAxis to FairValueDisclosureItemAmountsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="CarryingReportedAmountFairValueDisclosureMember" xlink:title="CarryingReportedAmountFairValueDisclosureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosureItemAmountsDomain" xlink:to="CarryingReportedAmountFairValueDisclosureMember" xlink:title="presentation: FairValueDisclosureItemAmountsDomain to CarryingReportedAmountFairValueDisclosureMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="EstimateOfFairValueFairValueDisclosureMember" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="presentation: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PreferredStockWarrantLiabilityMember" xlink:label="PreferredStockWarrantLiabilityMember" xlink:title="PreferredStockWarrantLiabilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PreferredStockWarrantLiabilityMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PreferredStockWarrantLiabilityMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityMember" xlink:label="ExchangeableShareLiabilityMember" xlink:title="ExchangeableShareLiabilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ExchangeableShareLiabilityMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ExchangeableShareLiabilityMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="AssetsFairValueDisclosureNonrecurring" xlink:title="AssetsFairValueDisclosureNonrecurring" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureNonrecurring" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureNonrecurring" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="NonfinancialLiabilitiesFairValueDisclosure" xlink:title="NonfinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="NonfinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to NonfinancialLiabilitiesFairValueDisclosure" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsLevel1ToLevel2TransfersAmount" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsLevel2ToLevel1TransfersAmount" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesLevel1ToLevel2TransfersAmount" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueLiabilitiesLevel2ToLevel1TransfersAmount" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialLiabilitiesFairValueDisclosure" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedVolatilityRate" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="FairValueAssumptionsExpectedTerm" xlink:title="FairValueAssumptionsExpectedTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedTerm" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedTerm" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="FairValueAssumptionsExpectedDividendRate" xlink:title="FairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedDividendRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedDividendRate" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="presentation: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PreferredStockWarrantLiabilityMember" xlink:label="PreferredStockWarrantLiabilityMember" xlink:title="PreferredStockWarrantLiabilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PreferredStockWarrantLiabilityMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PreferredStockWarrantLiabilityMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityMember" xlink:label="ExchangeableShareLiabilityMember" xlink:title="ExchangeableShareLiabilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ExchangeableShareLiabilityMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ExchangeableShareLiabilityMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByLiabilityClassAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables">
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:label="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:title="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" xlink:title="presentation: AssetAcquisitionAbstract to ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: AssetAcquisitionAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_VerioTherapeuticsIncMember" xlink:label="VerioTherapeuticsIncMember" xlink:title="VerioTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="VerioTherapeuticsIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to VerioTherapeuticsIncMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessCombinationSeparatelyRecognizedTransactionsAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsAxis to BusinessCombinationSeparatelyRecognizedTransactionsDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2010Member" xlink:label="PeriodOfApril2010Member" xlink:title="PeriodOfApril2010Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfApril2010Member" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfApril2010Member" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMarch2011Member" xlink:label="PeriodOfMarch2011Member" xlink:title="PeriodOfMarch2011Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfMarch2011Member" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfMarch2011Member" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfMay2011Member" xlink:label="PeriodOfMay2011Member" xlink:title="PeriodOfMay2011Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfMay2011Member" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfMay2011Member" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfApril2012Member" xlink:label="PeriodOfApril2012Member" xlink:title="PeriodOfApril2012Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfApril2012Member" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfApril2012Member" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_PeriodOfJuly2013Member" xlink:label="PeriodOfJuly2013Member" xlink:title="PeriodOfJuly2013Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="PeriodOfJuly2013Member" xlink:title="presentation: BusinessCombinationSeparatelyRecognizedTransactionsDomain to PeriodOfJuly2013Member" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: BusinessAcquisitionLineItems to ExchangeableStockIssuedDuringPeriodSharesAcquisitions" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:label="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:label="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="BusinessAcquisitionFairValueOfUnderlyingCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionFairValueOfUnderlyingCommonStock" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionFairValueOfUnderlyingCommonStock" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:label="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="BusinessAcquisitionInitialFairValueOfExchangeableShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionInitialFairValueOfExchangeableShares" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessAcquisitionInitialFairValueOfExchangeableShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:label="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:title="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc">
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionAbstract" xlink:label="AssetAcquisitionAbstract" xlink:title="AssetAcquisitionAbstract" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_AssetAcquisitionTextBlock" xlink:label="AssetAcquisitionTextBlock" xlink:title="AssetAcquisitionTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAbstract" xlink:to="AssetAcquisitionTextBlock" xlink:title="presentation: AssetAcquisitionAbstract to AssetAcquisitionTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenuesAbstract" xlink:title="presentation: IncomeStatementAbstract to RevenuesAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="ContractsRevenue" xlink:title="ContractsRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="ContractsRevenue" xlink:title="presentation: RevenuesAbstract to ContractsRevenue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromGrants" xlink:title="presentation: RevenuesAbstract to RevenueFromGrants" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="SalesRevenueNet" xlink:title="SalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="SalesRevenueNet" xlink:title="presentation: RevenuesAbstract to SalesRevenueNet" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: IncomeStatementAbstract to OtherNonoperatingIncomeExpense" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasicAndDiluted" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLoss" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StraightLineRent" xlink:label="StraightLineRent" xlink:title="StraightLineRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="StraightLineRent" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to StraightLineRent" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="RecognitionOfDeferredRevenue" xlink:title="RecognitionOfDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RecognitionOfDeferredRevenue" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to RecognitionOfDeferredRevenue" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_FairValueAdjustmentOfExchangeableShares" xlink:label="FairValueAdjustmentOfExchangeableShares" xlink:title="FairValueAdjustmentOfExchangeableShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfExchangeableShares" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfExchangeableShares" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueAdjustmentOfWarrants" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets1" use="optional" order="100.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainsLossesOnExtinguishmentOfDebt" use="optional" order="110.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="120.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="IncreaseDecreaseInRestrictedCash" xlink:title="IncreaseDecreaseInRestrictedCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="IncreaseDecreaseInRestrictedCash" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to IncreaseDecreaseInRestrictedCash" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="ProceedsFromRepurchaseOfEquity" xlink:title="ProceedsFromRepurchaseOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromRepurchaseOfEquity" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromRepurchaseOfEquity" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsOfStockIssuanceCosts" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromConvertibleDebt" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="ProceedsFromIssuanceOfLongTermDebt" xlink:title="ProceedsFromIssuanceOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfLongTermDebt" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="RepaymentsOfLongTermDebt" xlink:title="RepaymentsOfLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfLongTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfLongTermDebt" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="LongTermDebtAbstract" xlink:title="LongTermDebtAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: LongTermDebtAbstract to LongTermDebtTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsCurrentAbstract to PropertyPlantAndEquipmentNet" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsNoncurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="RestrictedCashAndCashEquivalentsNoncurrent" xlink:title="presentation: AssetsCurrentAbstract to RestrictedCashAndCashEquivalentsNoncurrent" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Assets" xlink:title="presentation: AssetsCurrentAbstract to Assets" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="DeferredRevenueCurrent" xlink:title="DeferredRevenueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRevenueCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRevenueCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="DeferredRentCreditCurrent" xlink:title="DeferredRentCreditCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DeferredRentCreditCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DeferredRentCreditCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ConvertibleNotesPayableCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to RepurchaseLiabilityForUnvestedEquityAwardsCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: LiabilitiesCurrentAbstract to WarrantsAndRightsOutstanding" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtCurrent" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="DeferredRentCreditNoncurrent" xlink:title="DeferredRentCreditNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRentCreditNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRentCreditNoncurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to AccountsPayableAndAccruedLiabilitiesNoncurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_ExchangeableShareLiabilityNoncurrent" xlink:label="ExchangeableShareLiabilityNoncurrent" xlink:title="ExchangeableShareLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ExchangeableShareLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ExchangeableShareLiabilityNoncurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="LongTermDebtNoncurrent" xlink:title="LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermDebtNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermDebtNoncurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleLongTermNotesPayable" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="TemporaryEquityCarryingAmountAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="TemporaryEquityCarryingAmountAttributableToParent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:title="presentation: StockholdersEquityAbstract to DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="TemporaryEquityParOrStatedValuePerShare" xlink:title="TemporaryEquityParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="TemporaryEquityParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to TemporaryEquityParOrStatedValuePerShare" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="TemporaryEquitySharesAuthorized" xlink:title="TemporaryEquitySharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="TemporaryEquitySharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to TemporaryEquitySharesAuthorized" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="TemporaryEquitySharesIssued" xlink:title="TemporaryEquitySharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="TemporaryEquitySharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to TemporaryEquitySharesIssued" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="TemporaryEquitySharesOutstanding" xlink:title="TemporaryEquitySharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="TemporaryEquitySharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to TemporaryEquitySharesOutstanding" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="TemporaryEquityLiquidationPreference" xlink:title="TemporaryEquityLiquidationPreference" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="TemporaryEquityLiquidationPreference" xlink:title="presentation: StatementOfFinancialPositionAbstract to TemporaryEquityLiquidationPreference" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockParOrStatedValuePerShare" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesAuthorized" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesIssued" use="optional" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesOutstanding" use="optional" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fatetherapeutics.com/role/DocumentandEntityInformation">
    <link:loc xlink:type="locator" xlink:href="fate-20130930.xsd#fate_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentDescription" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentDescription" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" use="optional" order="150.0" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of stock option activity under the Plan</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 750px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="750">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of<br />
Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-<br />
Average&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,432,369</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.43</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">331,860</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.60</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Canceled</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(17,860</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.56</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercised</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(35,852</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.65</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,710,517</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.26</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="374"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="10"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocation of stock-based compensation for all options and restricted stock awards</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt;" size="2">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 777px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="777">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.6%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">581</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">32</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">686</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">82</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">401</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">483</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">24</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">982</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">42</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,169</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">106</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee stock option</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 734px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="734">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">90.3</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Remaining contractual term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.27</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.23</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non-employee stock option</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 730px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="730">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.6</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">90.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.07</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.06</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the change in stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0"M[M-FQ@$``/L2```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6
MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?>O%D>WN#15U%
M<["NU"HC+$E)!"K7LE23C'R,7N(NB9P72HI**\C($AP9]"\O>J.E`1>%W<IE
MI/#>/%#J\@)JX1)M0(4[8VUKX<-7.Z%&Y%,Q`<K3M$-SK3PH'_MF!NGWGF`L
M9I6/GA?AYQ6)A<J1Z'&UL,G*B#"F*G/A`RF=*[F3$J\3DK"S7>.*TKBK@$'H
MWH3FSN\!ZWUOX6AL*2$:"NM?11TPZ**B7]I./[6>)H>'[*'4XW&9@]3YK`XG
MD#AC04A7`/BZ2MIK4HM2;;@/Y+>+'6TO[,P@S?]K!Y_(P9%P7"/AN$'"<8N$
MHX.$XPX)1Q<)QST2#I9B`<%B5(9%J0R+4QD6J3(L5F58M,JP>)5A$2O#8E:.
MQ:P<BUDY%K-R+&;E6,S*L9B58S$KQV)6_E]F]:%:`-I^_MT@[9@C[[;.+RMP
M9WX>70T]EEP("_+=VU#"G!W@Y^Q#'*&B&%IM7"AK+)Q^"ILVIMD=FS`(K"]A
MV\?LZS6VB:'H.3UPIUB!IDJ2(/=DT[:ZZG\#``#__P,`4$L#!!0`!@`(````
M(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`
M]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4
MQQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9
MJ&7<E.4]AK\>4"T\U<%J"`=[!ZH^^CSYLK<T36]X+^9]8I=.C$">$SO+=N5#
M9@NIS]NHFD++28,5\YS3$<G[(F,#GB;:7$_T_[8X<2)+B=!(X/,\WXIS0.OK
M@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`&+@
M!5.R`0``PA$``!H`"`%X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<R"B!`$H
MH``!````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````+Q8RVK#,!"\%_H/
M1O=&WLVC28F32RGDVJ8?(&S%-K$E(ZF/_'U%FCH-I-N+V8M!$EX-L[NS8R_7
MGVV3O&OG:VLR`:-4)-KDMJA-F8G7[=/=7"0^*%.HQAJ=B8/V8KVZO5D^ZT:%
M^)*OZLXG,8KQF:A"Z!ZD]'FE6^5'MM,FGNRL:U6(2U?*3N5[56J):3J3[G<,
ML;J(F6R*3+A-$>_?'KIX\_^Q[6Y7Y_K1YF^M-N'*%?+#NKVOM`XQJ'*E#IGH
MM[P\GLQ'$;&0U\'`F!D-C$DXW.0`R0[.F-G!&<4.=Z[(5"%P<P,4-_?,:.XI
M,(#,:`!).-SD`,D.3IG9P2G%#G>NZ%1Q*PZ0BH-Q>K(.*TS)5"V&A!/B3-<Q
MX&EN'I?R^"25AEOW2##<Y4)6"[!30W*#DR&KI;=5YXKIMTY."R=4\7*K'BEZ
MP(T&2#C(;6V0]C;<-A1)&PK<*@RD"L.@*MPWT=]]!0NJK\:#JHZOE-/%2W#Q
M>]&?(5UL4VBX-8>4'.Y$D7D";FJ`Y`;9?1]I_)#;HR/IT<>#2HX/AR;^9NFM
MUO?ZIXWDQ9^7U1<```#__P,`4$L#!!0`!@`(````(0#\>YIQ]0(``)()```/
M````>&PO=V]R:V)O;VLN>&ULE%9=;YLP%'V?M/^`>%\!AWZJ2=6NK59I7U*R
M]M%RP`E6C9W:IFGVZW=Q&G(#*<J>P)A[./><8YO+J[=2!J_<6*'5,$R.XC#@
M*M.Y4/-A^&=R_^4L#*QC*F=2*SX,5]R&5Z//GRZ7VCQ/M7X.`$#985@XM[B(
M(IL5O&3V2"^X@IF9-B5S,#3SR"X,9[DM.'>EC$@<GT0E$RI<(UR80S#T;"8R
M?JNSJN3*K4$,E\P!?5N(A0U'ES,A^>.ZHX`M%C]9";S?9!A(9MU=+AS/A^$Q
M#/62[SPPU>*F$A)FSP?Q((Q&39._39#S&:NDFT![&W30BZ2$G-1OUE(\"KZT
MVZ)Z&+P]"97K9?TJ2+MJ1@,@L/133R)W!<S'<=P\^\;%O'";AP`?(7RO('S'
M7P/EV]LH0L$I>J><<"OZH-;J"PT6UJH_0&=)&)@+`3?F(4]JXACEJU8Y5Y;G
M%.ZLEB)G(!:]89*IC",4<HY@R/_!`(.&S0`T:>AXQ0^@,W;`JL1T4H22'LCF
M'06S`?D;,L=MF%]FSI3XZY/F51Y79<G,BNH9'0O<$Y;89P/W=&TM=_0Z>ZF$
M%75JZWI(J]`4HH5A"&)SVF9SSX2ACTQ6G/[@S%8&!%'.XOH!JC]KUW_7:C[A
MIJ2W?.K`[;(4SB/XUC`,UO:\#3-V.GLNM,QAN0$4K$WA<#%6-(D[U=74\I<*
MB-.[US;]$T0_Z22UWPULZN`4`W6RV@\$'FRS"CMA$X^D$]9^8W<8X<63=/+Z
M@;5TPJ82-M\MH10OGJ03V'Z+,:$4)S;I1':?R7O8X+PFG<".VU[O0<")33J1
M[7<*:ANG4IS9I!/:?B"H;8#J+;NQ'`:M[;+?<IP=@A6&00OH(\MON6,"#JXM
M(2PRZ82Y'P=;3K#6,&@1ZL\.[BS%2YQTPMP/A$TC.T"=-.\-X5H?BP1*\;:Q
M/IF]>._'9#>%>R#PAD$."/([!-V1!6\6Q&<Y\D3@W,Z8S."'HK[4)[*/5;3Y
MG1K]`P``__\#`%!+`P04``8`"````"$`89_]]@@%``"=$@``&````'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)1878^B2!1]WV3_`^%=H/C&J)-18'>2V62S
MV8]G&DLE+90!NNWY]WN+`N%>9M3I!UNYIT[5.??6%ZM/'^59>^=U4XAJK3/#
MTC5>Y6)?5,>U_L_?Z2+4M:;-JGUV%A5?Z]]XHW_:_/K+ZBKJU^;$>:L!0]6L
M]5/;7I:FV>0G7F:-(2Z\@LA!U&76PL_Z:#:7FF?[KE%Y-FW+\LTR*RI=,2SK
M9SC$X5#D/!;Y6\FK5I'4_)RU,/[F5%R:@:W,GZ$KL_KU[;+(17D!BI?B7+3?
M.E)=*_/EEV,EZNSE#+H_F)OE`W?W8T9?%GDM&G%H#:`SU4#GFB,S,H%IL]H7
MH$#:KM7\L-8_LV7*/-W<K#J#_BWXM9E\UYJ3N/Y6%_NO1<7!;<B3S,"+$*\2
M^F4O'T%C<]8Z[3+P9ZWM^2%[.[=_B>OOO#B>6DBW!XJDL.7^6\R;'!P%&L/N
MAI&+,PP`/K6RD*4!CF0?W?]KL6]/:]WQ#2^P'`9P[84W;5I(2EW+WYI6E/\I
M$).#NI'8/0FTZ$F8;=BAQSS_)UC\G@7^#RR^X=I>$#XQ%E/IZFR*LS;;K&IQ
MU:#V8.3-)9.5S);`//BCU-P<^Y%A(%*2?)8L'1=XT4"6WS<!6YGOD)B\AVP5
M)-"U$6)CR&Z`2.\D;3P\&-L0UF1`#$U2]0`^QVZ<6S<FB+XIAZQ0Y0[4U_<K
M8Q`J&V&AOG6C[P:]G4.HSCDB<#%)/(<0DF2.H"3I'#*2("L<;,5]"R08IL'4
M80^/?JL@[@1"].T>(N*'B.0A(KV'0`;`4*>U<-\`"5[K8.Y88CXQ0$'";B;8
M5H2C.QP-<32>1GV;,"?3*+,"XGPZ#=N1'=RXD5Q8B)Z7*\%$[DBK2EY!H.^;
M(S3?`T(N#8Y-IDR,HB[1E$RCD3>6<-=WJJ)^;W4X=HP4P]+VO&())HI)DK8*
MXOX@P=.H9Y.V\30:T74R4=%!SR2#2NXT[%EL7`^17%AFGY<KP61"DXK=*LB]
M!#]$Q`\1R4-$>@^!#)#GM\FV=G]"2S#.=T@J=*L@*BN.$Y"4[G"8D0J.I^$P
M"NB<1F$O(N%T&O:<R!O9D>3H9R1+,)$\EI*:U`JB)+,H("6Q4V$U`T)_W&.[
MQO&TL1OXQ*]D&K8C=YRTJLA1.`R=L6^DF,%V_7R6.S313!:3;8]1HCW'(PO=
M#L5=1NL@1G'F!%19@@',<TFAI0@0VD$T>H.URX/.TQ7.U+%HNF>%)&7;'J.T
M+SSFDJ3M,,#Q/3+V&`.8'02DCP0C(H\10(H!01!,AHGUR\/-\_K540CI'XU5
M]<X41E7T(K+':=;%=SCNSDJ^C_?^V4Y(BBO!!!Y=^5-"$(5C]6'I\ECSO'1U
M"$+2B;0M4QAU7EGX%LW;#@-<1O,68P"#JPWI(R$(RYILU6K68T1H!<%88-@`
M><J9&"`O+8^/[DR=C9`19*G=]IBHV]<7KA%:T?2/P'<8[A@>64-C#)"W/E)U
M"49$QNQ\TP.^O_=B6^11B-CBPK/[FY^\#=.M8"R\?FI,#UG,AENK.[,"05C`
M+$;J/^Y[ZG<4F"">3SI*,,3RHEFER;<%<KSW_%!O`]0UM^3UD>_X^=QHN7B3
M-WT;DGM[JMY";-D2+I]PAR3/8[:$&R8\-V\!>#EPR8[\CZP^%E6CG?D!*"TC
M@%'5ZO6"^M&*2W=/?!$MO!;HOI[@-1"':ZUE`/@@1#O\D!W<7BQM_@<``/__
M`P!02P,$%``&``@````A`+SNX->O`@``PP<``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C4N>&ULG)5;;]L@&(;O)^T_(.[K8YR3XE1-JFZ5-FF:=K@F&,>H
MQEA`FO;?[\/D8)(NRWH3&^?]7C^\'^#9[8NHT3-3FLLFQW$08<0:*@O>K'/\
M\\?#S1@C;4A3D%HV+,>O3./;^<</LZU43[IBS"!P:'2.*V/::1AJ6C%!="!;
MUL`_I52"&!BJ=:A;Q4C1%8DZ3*)H&`K"&^P<INH:#UF6G+)[23>"-<:9*%83
M`_RZXJW>NPEZC9T@ZFG3WE`I6K!8\9J;U\X4(T&GC^M&*K*J8=XO\8#0O7<W
M.+,7G"JI96D"L`L=Z/F<)^$D!*?YK.`P`QL[4JS,\5T\78YP.)]U^?SB;*M[
M]TA7<OM)\>(+;QB$#6VR#5A)^62ECX5]!,7A6?5#UX!O"A6L))O:?)?;SXRO
M*P/=SF!"=E[3XO6>:0J!@DV09-:)RAH`X!<);E<&!$)>NNN6%Z;*<3H,LE&4
MQB!'*Z;-`[>6&-&--E+\=J)X9^5,DIT)7'<F<18,DFPT_A^7=.<"U[U+$B3C
M+,Z&_V8)W;RZF.Z)(?.9DEL$2P_(=4OL0HZGX&SS22'EM_.!8&S-G2WJ2D&M
MH:?/\T$TF87/T`BZTRS.-6F:^9KE7F,["#P'*`BJ#W49QHI/8.+(?]'B+4WL
M:Y;GFN2@\.@@IC[==9'9(H@6HV-D\=&_BW7A-(.^YD#0*9:7%!XCF/09+R=H
MQ3F&^??84O_-"Z?QV.*!KUF^H3DH/#K8.GVZZQ*T1:>4)PMJX30>Y8'`)>@4
MDV[11L&QWN,;OH?/%IWR#?VW+YSF$M]>83=5%!PWE<<W>@^?+3KE&YWP.<TE
M/J?X6W[N''8'3$O6["M1:]YH5+,2UE84C"!^Y4YA-S"R[?;N2AHX/;O;"CZ6
M#$X9Z`Y&I91F/["GQ.'S._\#``#__P,`4$L#!!0`!@`(````(0`(NOZN7P8`
M`*0C```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)R:76^C.!2&[U?:
M_X"XGQ`@"25J.AJ^0;O2:K4?UY0X"9H0(J#3F7^_Q]BDL6%\PO8B;=R']YCS
MVM@'>/[\O3IKWTC3EO5EIYN+I:Z12U'OR\MQI__]5_3I2=?:+K_L\W-](3O]
M!VGUSR^__O+\7C=?VQ,AG08*EW:GG[KNNC6,MCB1*F\7]95<X#^'NJGR#KXV
M1Z.]-B3?]P=59\-:+C=&E9<7G2ELFT<TZL.A+$A0%V\5N71,I"'GO(/^MZ?R
MV@YJ5?&(7)4W7]^NGXJZNH+$:WDNNQ^]J*Y5Q38]7NHF?SW#>7\W5WDQ:/=?
M1O)5631U6Q^Z!<@9K*/C<W8-UP"EE^=]"6=`TZXUY+#3OYC;S%KJQLMSGZ!_
M2O+>WOVMM:?Z/6[*_6_EA4"VP2?JP&M=?Z5HNJ=-<+`Q.CKJ'?BCT?;DD+^=
MNS_K]X24QU,'=J_AC.B);?<_`M(6D%&065AKJE349^@`?&I528<&9"3_WO]^
M+_?=::?;F\7:6=HFX-HK:;NHI)*Z5KRU75W]RR"32S$1BXO8T'O^?VMA/:W-
M]6:&RHJKP.]!9;-866OG:4Y?H-?]"<'O0>5_]&4SI(4:,C<O!LMQ;UF0=_G+
M<U._:S`/((OM-:>SRMR:H#R8Q5)[L^]G[H%M5.4+E=GICJZ!,2T,N6\OMFL]
M&]]@F!2<\<:,*1+^0-`Q064#U@"?-UG'%H\)!V0X)AH:/HZQ7>F@>,PX4F^3
M,2+U-AT3MKL2>Y<-#)TOD/%;VF%X"FF?GAM#=BE-LSN<HS<T?)RCU'U_3#A2
MWX(Q(HF$$X0CGF#$$#C-FT.VNQ:9>,Q(@1*42,>$[4I]R<;,1QPA^W!1$+)/
M![T-@U_M`CU*<$%N\.6&0&X(Y8:(-8CYVTCY>X!)'F#2*>9)C)6I&2&+<%$4
MLJC.'J4ARW<#Q;(E`SW&P.=M,$ECUD>)`"5"E(A0(D:)!"52E,A4A&`%K"PS
MK*#T3H?9<DOSV`K&//67<LM:+^%''"D^(Z"+-Q7)K`#5".\)VYF($J%18I1(
M4")%B4Q%"%;`,BU8\=BUA1XE6R)-38\QBH3[*!&@1,B(36_\)_-IY'N$2L0H
MD:!$BA*9BA`<@5V)X(CZ.D5IR8F5-/0]QK`<34\.1BB\"E"-\)ZP'1NJ&*D?
M$1HE1HD$)5*4R%2$8`4M\>YWFVHK*"U;(6W"/,;PX4I3-,J2SQ"5%[A(B",1
M&B=&B00E4I3(5(3@ACO+#4K+;DC[:H\Q?&),7,Y]!JB\P"3">\"<G!9HD!@E
M$I1(42)3$8(1M/":,2]Z7+9"VG1['!IFACN>%YQ0F8&*A"*Q'H>)\#`QCB0X
MDN)(ID1$2VCE]OBERF2%GK"G6LD+.(>8):;KF!.>,!VE)PQ1J(12H-4X4,01
M1:`81Q(<27$D4R*B*[3$F^$*JPCO7;%=5]S'>B:#%)GP<23`D1!'(HXP;VV'
M+F;2FA_C*@F.I$(@OFQ*D3*EC&@+K1IGV,**S'M;5O)Y>B:#E+:@2("KA#@2
M<<1Q^UWQ<K'\N*_0WZ>*<8T$1U(L3*;4$!V!O,UQA.+BBK):RELMDT%*1U`D
MP%5"'(FFD+$K:&^2*1WQ^I!.(4MIXY--03<=T1E:2<Z8*ZSP%.>*5&A[].XZ
MV,>7!&N\"/L"L;%'EY5``*R)I2GDA,+^"$=B(0Y=E^2)GZ!$BH?)E(CH!ZTC
M9_C!RD[1C]'>BT',#[BW,G&:OJFJ7_G=;UPFQ&4B'(DYHEAW$AQ)\4"9$A%]
MH47E#%]8#8KXPB#N2^^*//Q\4U7,<E]PF1"7B7`DQI$$1U(<R3CRD\R(QM#Z
M\MZ8Q^YPF:PL%0V2[G1['%)<8WP<"7`DQ)&((WQ.3$SA&"42E$CQCF1*1+2&
M5ISWUJCOKYBL0!4MD>_)<TAIB:K0Y5,&14(\4(0C,4>8:]/K"^O*SXD4#Y,I
M$<$3>-(^QY,>EW=B<B')(94G.!+@2(@C$8[$.)+@2(HC]*T&N@]B3RTD\YDI
M[*4%]@2\(LV1^.1\;K6B?J,O)-`Q<6N]O2SQQ:8/7J5VS]S"X^J)=FOK3?&^
MM87'@V,^L+;PE'#<'EI;>%@([<8M,+PC<<V/Y/>\.9:75CN3`W1YN7!@\]>P
MMRS8EZZ^]L_U7^L.WH[H_SS!VS`$'J@O%P`?ZKH;OM``M_=K7OX#``#__P,`
M4$L#!!0`!@`(````(0"(C>'E3@,``%4+```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;)2676_:,!2&[R?M/T2Y;SX)!`14)56W2ILT3?NX-HE#K"9Q
M9)O2_OL=VP'B0+-P0PA^_?+XG.-C+^_?JM)ZQ8P36J]LW_%L"]<IS4B]6]F_
M?SW=Q;;%!:HS5-(:K^QWS.W[]>=/RP-E+[S`6%C@4/.570C1+%R7IP6N$'=H
M@VL8R2FKD(!7MG-YPS#*U*2J=`//F[H5(K6M'19LC`?-<Y+B1YKN*UP+;<)P
MB03P\X(T_.A6I6/L*L1>]LU=2JL&++:D).)=F=I6E2Z>=S5E:%O"NM_\"4J/
MWNKEPKXB*:.<YL(!.U>#7JYY[LY=<%HO,P(KD&&W&,Y7]H._2/S0=M=+%:`_
M!!]XY[O%"WKXPDCVC=08H@UYDAG84OHBI<^9_`DFNQ>SGU0&?C`KPSG:E^(G
M/7S%9%<(2'<$*Y(+6V3OCYBG$%&P<8)(.J6T!`#XM"HB2P,B@M[4\T`R4:SL
M<.I$,R_T06YM,1=/1%K:5KKG@E9_M<AOK;1)T)K`LS7Q(V<21+/X%I>P=8'G
MT64ZVL75ZU)A>D0"K9>,'BRH/2#G#9*5["_`6<8GA"A?CP\$1LYYD)/45%!S
M2.KK.HSCI?L*B4A;S>92XYN*Y%(11F>-"X`G2HC<[91RDDD93$V$S16)J4BN
M*&8GB<$(T>LR#D=0BE<VF)\B&'B3DZ^*\D9K)AU-3Y$,*0PV,.FRC<NRG`35
MT/G_,)[W&+5FB'%(83#"?NHR#L=/BLWXA7.OQZ8UL:I//^['KCL:!!_4W?06
M)BDVF8(@ZC%IS40QW77^564\,4;##^IL=@N3%)M,X?R\5EUG6J.9_&EH$B?&
M:">*1N[D<=GI(L.YDV*3:7)>JD;2DJ&R&E(8:',3;5SIRTG_*WVM&6(<4AB,
M/G3<\?%3:C.`E\7?BG16HTY?U95F#G>2;G+U3H?AO/JZH1M-+>AMNTTKTESA
MI->0$V-X=CY33"S9E$>7FZ];N(G5WY>M:*J;Q;Q_FB7M>+MQ.ZW&!),->3R8
M;M]=L,O-"9<C68JZBP5QW`.7EZ?S>#?/&DQ?C/2)WZ`=_H[8CM3<*G$.)X_G
MS*`-,GTMTB^"-NK,W%(!UQGUM8#K*X9CWW-`G%,JCB_RXG6Z$*__`0``__\#
M`%!+`P04``8`"````"$`7-(+C*D%``!/&P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6R<F5USJD@0AN^W:O\#Q7U$0`4M]50TF]U3=;9J:VL_K@F.
M2D48"TA,_OUVTR/0(QEA<Y%$>:9]IWNF7W"6WS[2D_4N\B*1V<IV1V/;$EDL
M=TEV6-E___7\$-I644;9+CK)3*SL3U'8W]8__[2\R/RU.`I16A`A*U;VL2S/
M"\<IXJ-(HV(DSR*#*WN9IU$)+_.#4YQS$>VJ0>G)\<;CF9-&2693A$7>)X;<
M[Y-8/,GX+15924%R<8I*T%\<DW-QC9;&?<*E4?[Z=GZ(97J&$"_)*2D_JZ"V
ME<:+[X=,YM'+">;]X4ZB^!J[>G$3/DWB7!9R7XX@G$-";^<\=^8.1%HO=PG,
M`--NY6*_LA_=Q=8/;6>]K!+T3R(N1>M_JSC*RZ]YLON19`*R#77""KQ(^8KH
M]QV^!8.=F]'/507^R*V=V$=OI_)/>?E-)(=C">6>PHQP8HO=YY,H8L@HA!EY
M4XP4RQ,(@-]6FN#2@(Q$']7?2[(KCRO;GXVFP=AW`;=>1%$^)QC2MN*WHI3I
MOP2Y*A0%\500']33=<\?3;QI$/:(XI"B:H)/41FME[F\6+!JX#.+<X1KT%U`
MY.O,2$<]UZ^F"G/$((\8964'M@6S**`^[VM_YB^==\AIK)@-,?"[9EQ.;&\)
M?]HP#BBN94,RVK*["W%5AS"JP\*@W`V]T9;B:5(ZB*!&F!)(6G\E"$/Q6SGP
M9Y,Z+HDC9M)B-&)K(I@V"-+6AL7U8?&;LX6#5C8DH*Z3/YMJ&HF95)4>\VO;
MZ[5F?*.?J8.E/UP=#M+5S;B"#3'=ZJ[7[JJ;_1]U.$A7UZP;JB\QW>JNU^ZJ
M@ZTV/'<X2%<7:KDCIEO=]=I==>A[K:9B7F\(<U7>N%DQE#-B8&75:U(CMB:"
MK;HYU]9O3^`@?=_.M<P18])H(IA&%S9I_P16-,^@'VB[<J.@8%[M66_DCMF/
M^\N#W@+Y"'?DM1$N%QMW[WJ[U.99@PF:-D\%5Y"2.QZ%TW#.?GCRMSH_]Z=L
M?DT#X\JQS_=73J[`E6MIV[@$M=>!'VA>N.V$FB7--6*[[Z^1S(%K;&:OLDO0
M-;MZ+K^XRE5AF^^O"FE]B>IMVR6HG;DF)97PK1'A^C1W,?<@O)F[V>#:AV\4
M9-37VUY<S5_NZ.LPED`WEBKDRI[1_==X$L(.T$M+<0@)JCU2$SQ]FL'<D=?A
M+('N+*[)/E1Y30C7-\AB7'('6->U?]S>=RG(6-[>+N-J-G,G?^0,?-/>E)<@
MJIT[\SNJRXAPTB98]CS-7_J98#5*W\2Z"RK(E$4CPG4.,A:/C,5<9049]5&<
M;H3KPU[?NPEZY`SF*BN(JNR%(=I8O45IES!D.D4GKPDN#QMY2U[/,E/[9S+#
MYA/(03R"NG.D9)H0KA/"M'6:-XN'M'XSIO=J!1GU49QNA.L;Y"7X2'_C=?IF
M5I"I5S/$U*L]S4IZEKG#4D+]-JP*O;*[<Z3*3'&Z$9[&09[BD1?`(C+T;`5U
M?[C2U]M3O$&>4M%Z-[PI,QF&H6>K,(HP]6S-4;#*$UAJ=S9+A[.$^BVK1Y`Q
MBR:$51F_8.B_F2OZWF96D$F?$>'Z!GF*3U[`FN'-C9>"3#V;(::>[:-)M'JV
MN;P5K2W"4'O8V"C(F#[\U*_V.4\?=O7^^L@#S)O8)\BHSX1P?1!F@#ZD]?SI
M7N(3U/V=2'VQ:5/->*YLD(OX'2X2ZL]Q"OI"&47H3BM7UF$@]UN+WV4@^C.=
M@KI%4(,V(ESG(`/Q^QB(@HSZ>AL('$$,67OD#:RUA+J!5"&;9SJXU=/NQ/#<
M`Y>P,A!\*F@AE#XZUZ"O_5.1'\16G$Z%%<LW/+-PX7FQ?K<^3WGTJA.1^@(<
M9YRC@_@]R@])5E@GL8>AXU$`BRRG`Q%Z4<IS=:CP(DLXR*C^/<+!E8"OW<<C
M@/=2EM<7>.12'X6M_P,``/__`P!02P,$%``&``@````A`!-,\R`.!@``LB``
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULG)I;CZI(%(7?)YG_0'@_
M<BG!2]23@Y6>.<F<9#*9RS.-J*1%#-"W?S^[V*6R"\\&[8?NMOU8[E55FU5`
M+[Y^Y`?K+2VKK#@N;6_DVE9Z3(I-=MPM[7_^?OHRM:VJCH^;^%`<TZ7]F5;V
MU]6OORS>B_*EVJ=I;8'"L5K:^[H^S1VG2O9I'E>CXI0>X9UM4>9Q#2_+G5.=
MRC3>-`?E!\=WW=#)X^QHH\*\'*)1;+=9DLHB><W38XTB97J(:ZB_VF>GZJR6
M)T/D\KA\>3U]28K\!!+/V2&K/QM1V\J3^??=L2CCYP/X_O#&<7+6;EYTY/,L
M*8NJV-8CD'.PT*[GF3-S0&FUV&3@0`V[5:;;I?W-FTLQM9W5HAF@?[/TO6K]
M;E7[XOVW,MO\D1U3&&V8)S4#ST7QHM#O&_4G.-CI'/W4S,"?I;5)M_'KH?ZK
M>/\]S7;[&J8[`$?*V'SS*=,J@1$%F9$?**6D.$`!\-W*,[4T8$3BC^;G>[:I
M]TM;A*-@X@H/<.LYK>JG3$G:5O):U47^'T*>ED(17XL(J%Z_'XS&?C"9WJ,R
MUBKP\ZP2#E9QT%<S3#*NX]6B+-XM6'M0>76*U4KVYJ"LQD?`*-\>'Q@8=<PW
M=5!S*-`53.K;2@3NPGF#B4@T$]U@1$"9=9?Q*"&[A`BNC`,F+DY@E.]WH@ZB
M3D+32!<1@4_+7'<9@Y`WB,E%A/B`5=+VP<^$@F'&;*LU$^*BV\Q6A`Q,[H49
M4V+=2TB.(-7#QPRO7L%+&X;F4ID(C-HB9,)FE<U<]644CP!\OX@8$I(C2/'0
MTNWBAS6#.L@T82ST"!DTX8GI.#26Q[H-C*?N)#0F41+`!8F?=$'8M1#V]K,Z
MR+00TF&.D&&&>8T$FIR$,]_P*#D%,@V31SRH@TP/UP[#3D"&\X`$>O`]+Q`S
M.@R2DR`FU`[".+'V3X0ZR#0QI15$R'`FD-"K#3Q,KVNE&0?)21`3LZZ)_G10
M!YDFC&&,D.%,(#%M^MYS74-`<@+$@@>KOST1_/FTH8WB.XF@(:[Z?D2R"+6@
M4K"UEGHL8&;RF>`AQ%KH122K0BVH_&M9&'9J]3`U:4"8YU8-L590!SMB"J=?
MUQ"1K`AUHJ+P?B<8H,1):+1EY'$IVW3N6B/H9!QTXU"R(M0)#%G;2<^R4O32
MGF!'CET_-%HR\I!@)Z(7D:P*K5]E8FLF>NK'!.UI"X18"[V(5!<8,%2W5:@%
ME8DM"P/;`I.4+*;`6-&1Q\6M7DR(Z*"XL2V1K`AUHH+Q?B<8I\2)N3>*/"YS
MM1-$9I@6(W-I2E:"^E#9>+\/3%3B(^CT!Q>[VL<94==4OC`WLM[Y[5M[76I#
MY6/+1D]O8)I>>CMTC>UGY'%YJVOO122K0NKW[TKMANZ[#-+0[:Y$"_V(9!%J
MP4CM8;WM8^K2E63VMH98*ZB#O3WSA6ML(R6K08U`,>VU--"(.LK<21F7!)&/
M$&L$D9^V-BM!?3R4W/Z-Y.ZTMH98'^=P5ZWM!<;EE605J`WXE/9T\*WM*[H5
MVV%HG%0B3;"UHPB#2%:%UJ_2<?"I2=UF@_KYV-804]^Z'Y$L0BT\%-O^D-C6
M$&N%Q+:ZOC-NB4A6A#IY*+;](;&M(=9)3VRS$M2'2L;6HAIXCL(\A3/,Y=Z1
MZ/8V%[HZ-\Y(T]LSXW0M_?/;UX^Y-B&U<5=L^S2VX2K96`B1)M@YZ(]M5H74
MKVX.M*>!/S<U=%]O:XBST(](%J$6'HIM,22V-<1::<=V`'?1C&M$R6I0(RHX
M[VX)@7%+6J*S(]<0:P1USK$MC%MQDI6@/AZ*;3$DMC7$^FC']L3<1+$"U`5\
M2'LV>CI#T=?4]L;F?B$22+"E]R*25:'UWY7:8DAJ:XBU@#H,(ED5:N&AU!9#
M4EM#3)UKC>"&_-;M<5:#&GDHM,60T-80:Z0=VN/1V+C,E:P$]:%R\?XS%*8I
M.4-U0AN>*:L&8GT@@O>SQ-C<D+,*:`.?.N/CU%.\2W_$Y2X[5M8AW<)^PAU-
M8/66^,P97]3%J7G8^%S4\*RX^74/_QN0PC-5=P3PMBCJ\POU5/ORWP:K_P$`
M`/__`P!02P,$%``&``@````A``VJ0H4N#0```6\``!D```!X;"]W;W)K<VAE
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MOWU9?6RK;&^/;=*]+39__?SX\KA^^Q`IOJ]>5[M_]TDO+]X>[]T?[^O-XONK
M6.]_M/[BL<J]_Z&6_FWUN%EOU\^[CDAW52QH?9WOKNZN1*9O7Y]68@WRS7ZQ
M63X_7/ZIW6<]_?+JV]?]!DI7RU_;3]]?;%_6O^S-ZLE?O2_%UA;[*=\#W]?K
MOW+J/N4A,?%5;6IKOP>FFXNGY?/BY^MNMO[E+%<_7G9B=P_$&N4K=O_TK['<
M/HHM*M)T]$&>Z7']*A9`_'_QMLJ;AM@BBW_V7W^MGG8O#Y>]Z\[@IMO3!+_X
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MUW">UZ@"Q[R:/(E9B6H2JP@4Q9OGL"MQS*'.UZE(E<2M`L=IE/F.*U%-XE6!
MXR3J;/R*5-,$5>`XC3*;226J24(U,%4#D1J8J8&Y&HC50*(&TB)PW*I9%3@N
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M*@+'$^-(#1AJP%0#EAJPJ\#QE'>KG&<<)BZ3,1/O!%$N4GPF`9,)D[!.^KJR
M,-,6)FIA9G73TX]-:-_,YBU,?,HHA]^DA4DK4UT799\"4H,6=W-2@\XOZ7OB
M=J;YLBN?2FK81>!3PU8#AAHPU8"E!FPUX*@!5PV,U8"G!GPU$*B!B1H(U<"T
M"APKKJ\K9_[HE.D=#BK[%C&K3+67YFH@5@.)&DC50/8I(.UI<;\M[>GF/9QK
MT1(^74?WU*N286%$RSI<:RO7+2,4!@H3A87"1N&@<%&,47@H?!0!B@F*$,44
M181BAF*.(D:1H$A19$U"*B+QT.*,(LKUPZ6X>#\6B*X^Z"A,4Q&A,%"8**Q"
M7.\?Q^A]O==5'TC8F,-!X:(8H_!0^"@"%!,4(8HIB@C%#,4<18PB09&BR)J$
M5$1Y5\OGQXC-9Z)<RV>BOJY<$@T+TU1$*`P4)@H+A8W"0>&B&*/P4/@H`A03
M%"&**8H(Q0S%'$6,(D&1HLB:A%1$HL-"*J)V%^[Y5,H9J:?<+`X+TU1,*`P4
M)@H+A8W"0>&B&*/P4/@H`A03%&$ABG.XUN_IO6OE0#G%'!&*&8HYBAA%@B)%
MD34)J9@T<<<K55/S*6G/U3)2'BT,2]141TP,)B83BXG-Q&'B,ADS\9CX3`(F
M$R9A28JBZO6TVVOE>#GE)!&3&9,YDYA)PB1EDC42N;;RSK_VEWM:T5<HW33U
ME(<KPQ(UUE:1IX$8G,5D8C&QF3A,7"9C)AX3GTG`9,(D+$E16U^TFQ.UA7LQ
MXOG,F,R9Q$P2)BF3K)'(M95W#)Y16T4_HEQ;RD/)H5:@AL(9,3&8F$PL)C83
MAXG+9,S$8^(S"9A,F(0E*6NK-[@=*`?1*2>)F,R8S)G$3!(F*9.LD<BUE7<+
M?JZM=G=86M&;*->8\EQ\6*+&&BOR-!"#LYA,+"8V$X>)RV3,Q&/B,PF83)B$
M)2EON,20RH&F=/I-)=+K=S6U"S*2A*YW^W?'D1U%-Q$OR9Q)S"1ADC+)&HE<
M8J)U2R4&MUTY5QX%?AI&MM]80ZU`#74S8F(P,9E83&PF#A.7R9B)Q\1G$C"9
M,`F93)E$3&9,YDQB)@F3E$G62.3BRCN"?^/\5?0?R^<OY8@TS$>#BTIL+#(D
M!F<QF5A,;"8.$Y?)F(G'Q&<2,)DP"4MRM^_TTSI]Y59@RBDB)C,F<R8QDX1)
MRB1K)'*%Y=W&GRL,3E]%+[-<6<KUPC#_LPBJ+"0&9S&96$QL)@X3E\F8B<?$
M9Q(PF3`)2U)4UJ"C'#^GG"%B,F,R9Q(S29BD3+)&(A=6WI5\1F$5/<]R8:GC
M++2F[NG]I>.(B<'$9&(QL9DX3%PF8R8>$Y])P&3")"Q)=<H:U"H+=W/$<YDQ
MF3.)F21,4B99(Y$K*^]?/J.RBNYHN;*4/L5A_D=T=,I"8G`6DXG%Q&;B,'&9
MC)EX3'PF`9,)D[`D165U.]?**/DIIXB8S)C,F<1,$B8IDZR1R)65=S9_KJR6
MCPN+/FJIPOI*#^-0:^K(+L]=2`S.8C*QF-A,'"8NDS$3CXG/)&`R81*6I*@P
M\??@@[O/_Y0+EBDGC)C,F,R9Q$P2)BF3K)%(]::K0S;:U=M^,F7H1E\=NE&B
MV_U]\=VM^`0'I2)'DA!_UZD"0P*:=GU7(Z9,NM<U896BX3&++249W&JU)(XD
M>O5%=25P+?I@U9492^+$YO`D(!YRUU+XDLA_KVS10`+]VUY-3"2A]VL@+$'#
MYIHRB9C,F,R9Q$P2)BF3K)'(177>6(W\XP[$E9]\\E*Z&8<E:M@K(R8&$Y.)
MQ<1FXC!QF8R9>$Q\)@&3"9.0R;0D97?8;5[D2I5'$LF/1:J8\7SF3&(F"9.4
M2=9(Y-H29?(;%XAZ/IE:8\J#VF&)&FNLR--`#,YB,K&8V$P<)BZ3,1./B<\D
M8#)A$I:DN.[(S\-J=4PY2<1DQF3.)&:2,$F99(U$KK'?&[.1?Y9-K<;4,1LE
M:BB@$1.#B<G$8F(S<9BX3,9,/"8^DX#)A$EXBO359QVGD/RWNQ&3&9,YDYA)
MPB1EDC42N<Q$$?S.J2R?3!F_T5<>X`[U`C66&1*#LYA,+"8V$X>)RV3,Q&/B
M,PF83)B$3*9,(B8S)G,F,9.$2<HD:R1RD:GC-YI[E_//%53.8;T;Y?)[6*+&
MXN)Q&YS%9&(QL9DX3%PF8R8>$Y])P&3")&0R91(QF97DININNS:_*+?W<YET
M.UWE85HL`[VS?_BSO[;=_Z?54B;R%%I'KY&T)`T-.6LD<J6=-XY#KX_CZ-TH
M:STL4<,"CI@83$PF%A.;B</$93)FXC'QF01,)DQ")E,F$9-92<I*ZW;NNL73
MD:I0:F57-,*C[PTJNO^J7-'&]?SY$];C/R5_4O/-^5->Q:R1R`5YWO@/_<3X
MC[XZL*I$C06)8P<,SF(RL9C83!PF+I,Q$X^)SR1@,F$2,IDRB9C,3I&^TD<W
M/XF4\1'Q*23?3"9,4B99(Y$+[+QA('I]&$A/_7B888D:"XR'@7`6DXG%Q&;B
M,'&9C)EX3'PF`9,)DY#)E$G$9,9DSB0^10;*;4]R$BE7;.DI))=IUDCD`E-'
M@\#-6WT4B/AP=GGN0QV'>(R8&$Q,)A83FXG#Q&4R9N(Q\9D$3"9,0B93)A&3
M64FJ2T2Y-<T;?QLW_C9I_&U:_K;A1)`U$JF0\L^BE!XU-A?2GBN]9>H?O@Y+
MU+"`(R8&$Y.)Q<1FXC!QF8R9>$Q\)@&3"9.0R91)Q&3&9,XD9I(P24M2]K$7
M-XER96<2N=&ED4=R;:FC/=H-H>J=&/4Q4'ND2]188T6>!F)P%I.)Q<1FXC!Q
MF8R9>$Q\)@&3"9.0R91)Q&3&9,XD9I(P24M2G3@[7:4K.*N!X],3N<#4(1]P
M\CHQU&.@S'LHWIV4/^=OJ)H1$X.)R<1B8C-QF+A,QDP\)CZ3@,F$2<ADRB1B
M,F,R9Q(S29BD3/)7@^7-NSB_]??/-`^GMZ*VBC=_%>\E>EMN?BQ'R]?7[<7C
M^F?^5J\;,6;W$"W>.!9H]^(5->(SMI6X>!/9G_LW@"GQH78_.N4-[5Z\0*B>
MQ];NQ3N!ZG%7NQ<O_JG'/>U>O-Q'Q*\.,Q8O(/M8_%@&B\V/U?OVXG7Y+%:E
MV\G?S[4I7F%6_+!;?^S?PO1]O1.O'MM_^R)>-;<4;R[J=@1^7J]WU0_Y#/)7
MI^U?X_3M?P```/__`P!02P,$%``&``@````A`'5W/7O*!@``9",``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&ULG)K;CJ,X$(;O5]IW0-Q/`H1#$G5Z
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M/G0+D%MB1\=CWBPW2U!Z?MJ7,`)AN]44AYW]R=VF*\=>/C_U!OU;%F_MW=]6
M>ZK??FG*_>_EI0"W89[$#+S4]6>!_K8737#P<G1TVL_`GXVU+P[9Z[G[JW[[
MM2B/IPZF.X`1B8%M]]]8T>;@*,@LO$`HY?49.@"_K:H4H0&.9%_[S[=RWYUV
M]BI<!)&S<@&W7HJV2TLA:5OY:]O5U7\(N5(*13PI`I]2Q`T6OA=$ZT=45E(%
M/@>5\'$57ZK`YZ#B+;QUX`;A`R."L?>VP.>@$CW>EU"JP.>[RDQSESA1_;RS
MK,N>GYKZS8+%!%/17C.Q--TM"`\3CM-S"X'O10!,O1#Y)%1V=F1;,+DMA.V7
M9S\(GI9?(-1RR<3(P.\;XU(B&1/1BB)L0$3HB3-S;+@_\VJEG#D=&!'Y,.S;
MV"'`[L<^'>3#$`4LACB<.1X:WL?CT<XF1H)-$!$5X8C`$&ZV^4%(F53/D#'#
M<I@_9@&3,:L-B=K`U`:.#;3_RAA3/4/Z#PMQ?O\%3/JO-B1J`U,;.#9@AA(1
MEPX-]Q.RODT(Z2RL]_F=%3#D2S+1FYMN'^TQ,M"#]V"@1&(DF)'@1B+5$<0!
M2"GS'1#PSH9@?A]=Z-#QQ<CH'#`2S$AP),(^DT6A^%%#5J=!'(#4=.^`2+"P
M@W]G1QV2C3A(=4+)EC$R.B>,!#,2'(EU[X2:=G1'$P]$>:AL,F8/Q$'4`V^M
M]"!&1N>!D6!&@B.!'OBAT__0L$QU(L2*S8]8(0Y2K5`",D9&9X618$:"(X$+
MXX,7;@(P0[%")T*L<&$9/!X6_5'4##]4=MY80CHWS`@S(UPB@R&;J=C0RE!'
M1*5RMU#T%8F+=0W-ETK!%$L(.^BNUNYHPA(SPB2B\9.;D52+4"-$13/?"*Q_
MJ!$^#<O814@SA,2,,#/")8*.^VZT%AF#=B;5RE`G1&TTWPFLI*@32CD<NPAI
MG3`BS*S"S4@J$;E^W,@G\4F=@`[?.S%O)W7%431=>)N1(PAI'3$B3)Y*H\(E
M(F/#<?R)_*F5H8Z(,NPN-F8Z@L4;C1%U8Q47_6";9BR)&6%FA$L$'8D\F)O-
M:+'H^D(-$579XX9@+4<-4;=75U?P]<5Y8D:8&>$204,\3ZR'<?K0=88Z(FJT
MQQW!RHXZ\GZ-@]<BKJ[\DXX8$696X1)!1U9AM/$=I19.M2K4$%&IW1EBV&*Q
MKJ-&J!=EKJ[XDT88$696X1*11DP&ANX\U`=1IMWY,#-W8'%W[\=J?*-'5P%*
M/XP(<XT(EPCZX:^=*%2JGU0K0OSPE&)4'Q<]37<5/U+R5BPA70XU(\R,<(F@
M#Y,EJ%:$^J"4H"(N?$C`!C\F2M%(6:2QAY#6#R/"S"I<(NB'MYI(H%H1Z@?$
M^N/KQ!-'J?&A7J1(2.L'ZF@09E;A$I%Y(W0BI39.M1K4CH?*46]<CH;J-B(9
M[)R+VYVZX25S($:A/CV.MDY.(5%^B1^E/)?0M.W4#V!^(#S$46IX*+DK]A":
M[@2F43/"S`B7",Z`=$0U1-<7:H@HUA[>5\2S%#`$PN7]UI\:I;&$M(;H2L7>
M,V96X68DU2+4$*4F-232<2VZ&@4&,C*]1;Y(<'2^$L^(,(EHW.1F)-4BU`>E
M$C7X,%&!*H.,/61D6O.G;FV8$281K0_&,C;5JE`?1(EVMT`,/F!!=U]P^:-]
M!!F90<.I<#`1S"/$VA^%%)>$QJ=4BU`31'$WWP0L!8D)ZO69AXQ<%.OU^,(Z
M,2.,($%`;D;TZ8-+0FN#KG(E-HB;X/-MZ&FZ:ZP<]5:&A/!F=1`&WOCN4S*#
M83,8+AF=%UH$O<"7$?"A=%4TQR(ISN?6RNM7\:)!`$\>;JVWER`^^>(YK-+.
MX>6(_CF=TAY[VWB*3[PM//\;ZS!O"X\!Q</BFQ"\XW#-CL4?67,L+ZUU+@[0
M-6<1P7;3X%L2^*6KK_TC]9>Z@[<;^C]/\#9+`<\-G07`A[KNAB_B!+?W8Y[_
M!P``__\#`%!+`P04``8`"````"$`B7$('5`$``"_$```&0```'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6R4F%N/HDH0Q]\W.=^!\#Y"<Y>HFU&$L\ENLCDY
MEV?$5LD`;6@<9[[]5M.H=..AV1>0YM=%U;^J;RZ^?I2%]HYKFI-JJ:.9J6NX
MRL@^KXY+_9^_XY=`UVB35ONT(!5>ZI^8ZE]7?WQ97$G]1D\8-QI8J.A2/S7-
M.30,FIUPF=(9.>,*WAQ(7:8-/-9'@YYKG.[;3F5A6*;I&66:5SJW$-93;)##
M(<]P1+)+B:N&&ZEQD3;@/SWE9WJS5F93S)5I_78YOV2D/(.)75[DS6=K5-?*
M+/QVK$B=[@J(^P,Y:7:SW3X,S)=Y5A-*#LT,S!G<T6',<V-N@*758I]#!$QV
MK<:'I?Z*P@0AW5@M6H'^S?&5]GYK]$2N29WOO^<5!K4A3RP#.T+>&/IMSYJ@
MLS'H';<9^%EK>WQ(+T7S%[G^B?/CJ8%TNQ`1"RS<?T:89J`HF)E9+K.4D0(<
M@*M6YJPT0)'TH[U?\WUS6NJV-W-]TT:`:SM,FSAG)G4MN]"&E/]QJ(WH;L3J
MC$"/S@BR9E;@(M?[#2M>9P7N-RO^S+%</_@=7_S."MQO5J;[8G!U6K&CM$E7
MBYI<-:A@B)^>4S8>4`B6GZL+LC+VE<%+'3`0CD))O*\<WUT8[Y#&K&/60\82
MB<T3PA>1:(CXCHALAXCC>R(3<P:N#W]=B4F&S,-?`T2Z*P6U,%TI!C.E6%TR
MZ=9RPT9NB.2&K=P0\P8Q'$FYY`GC/Q@A(%L,B`TP&X;I>`FP3L#U)953L^:,
MTV?$Q&R41*0DMDHB5A+)&"%H!<%,3SZ#ESIDXEYVUEP48,V1H!U#:&X&L+B8
M(K+I(T#X`R+J$Z[C.0-BVR<\^XF-F!-PO?LJ#;2D;\.=(TMP1!`)9LF^2-,*
MBG42Q;(?]<K'#D>\5BS;M]Q!G)L^85E>,"`B3HS$N542L9)(!#]L1\B((!4L
M!7VIQL<<@R6)3"E+:\YPC9`MY*@5<2,`"`22ZBWBP)A"2B)6$DG?#7_>]T+0
M!]:8Z?HP6-9'FN;7G.GTZ7^6JS/^.N*OQ[11$K&22/I.L`GAD2%!&[;#G;QD
M,UC4QI57;(YTTCBV]Z1X!,3R`R%QK8(11\8D4A*QDD@$1VS/G@M#79!I+LHT
M;39BG22YY$KB")?K)3!])M<C4[R<!,9S/32<LR+.C`FF)&(ED0B>!,BT_G].
M0K#X3R^LEA:E<OQ`7,/6'=2)Y<$2]62A$R'7"I[,\%$'C<FE1F(UD@C>N*X]
M'Q&,[1U[(Y&5F*?<0<&A2:XQQY?W!QTT$NY&C41J9*M&X@[AFQ56R'*YLW,@
M"^FYMWQ0\G,>/WJ4N#[B#2X*JF7DPLYP+JSM]];[^?+58OMGJ7V-0MA,#]LW
M*(0]];`]0B%LK8?M6Q3"#AO:C?L'X/AX3H_X1UH?\XIJ!3Z`:^;,AU6]Y@=0
M_M"0<WMPVI$&#H[MSQ/\48!AGV_.`#X0TMP>V`?N?SVL?@$``/__`P!02P,$
M%``&``@````A`$-@TSN+!0``S!8``!@```!X;"]W;W)K<VAE971S+W-H965T
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M.UOD`7>]]5(EZ-]*O';&_TZW;UY_:ZO-']510+:A3K("CTWS)*$_-O(1+/9&
MJQ]4!?YLG8W8%L^'_J_F]7=1[?8]E#N"B&1@B\W[O>A*R"BXF?%(>BJ;`Q"`
MWTY=R=:`C!1OZN]KM>GW*S>(9U'B!PS@SJ/H^H=*NG2=\KGKF_H_!#'M"IUP
M[20`]MK.9SR-6!1_[<5#1BK`^Z(OULNV>76@:V#/[E3('F0+\"PC"R`_'T<&
M(<DUW^4BM130'93C9<VCI?<"&2PU)$-(XCH#Q$;D'R"2"\0#>A>.$/ETCG(1
MX1A?W*LP,H0D*LLRKMQX8!&`Q)@$KB='@B&)9N0IV1@AH0$);41^#6%1`R>W
M4Y/@E0M1#D69VQMG"$E54=G<3[EMSTT[F#^I&'2UR>JVKI*+;':!;^^>(214
M[`*?)LVT)OY0;2MAL4WM>BTEF%!BA!)"8IVP(!VV54V6F_9Y,@\NRRU6<%#,
MA%UG)<&$%2E3AA!,5)*2(N=HU9Q9/(1D<9+3RY"&ZYPDF'`:0L7CAA#<E2<A
M,>=HAOZZ-.=07XO7?`HO"2:\!K?("R&8*\9))O//K!8E!I)Y>ZX4FI`:Z:?T
MN')UMJ#7R5'(M9-S$?UD:#R;&E'XZV5DJ,JF>@6#8\R7QGQ<*6SZJQ";GM1<
MH\MNDPJ&2FTJ63!(D::)&$Q0D-`)E6L?.L,\'D3:)BBEV"#X1?Y0N"UB@V--
M[)JXZ_R=(7*VQL-)L9E)+;Z=&2JWQ8SH0L80@T<A)"V96U8>?:(:\KUH`JNQ
MZ--.SY3'\U$(PG386"?KK/M?*@<CXG]CLXVG0$@X9,KSRM4B8LP>31%=:+,A
M?79!)TT!-AX#(1&O3&/TOD8C:5KFF&#I((PVK4F#@(TG@1&OVC?3&*U=\X1D
M,R=V(]LVL4F3@(U'03A$K(DA!HG-P_F(F&D/TV@098L8GS0.%-H>!_3L91JC
M"QD-BH"%M,W!T`8VK4FC@.,H,`4CI*-`8S0M*L&Y;6:?94L*]<TZQB6:9(M*
MO\9H:4]3JF3:CK2CSY2,3U)^A2:\J/)K#.[+C>[15435U\<B^;2,DW2?CW4_
MI+JO,3I?/OQ<WE(UL_-@^%)BY5?1"<4<RS_-2J8\2FD=]C8JIOF-1X"!L0_!
M!S.`!;#^^F#GXR$0#<=,L<@T!M,8Q1$GQR6_`K`Y3AH$'%4<FN?RYDP%(M,8
M,XE$^_*K$)L>&0ARC#+_ZQ2.)T-$2&0<,5I0:!=^;+2Y39H)?#P3(B(6F<;H
M4QD&,5&;W`9P\^N614W>JYA'X[:W#[7*UI6(]%6F,4CQ+O63A!Y@&Q%',1O"
MM$E.FA'!>$9$)#V9QFAR<1SZY-SD-B+BJ?&N;I,CD^+&#(XG1D25&6X/Y53!
M>P_^P=<M"\#8^.L67A[BW5HMVIW(Q>'0.67S+"\&.=P/7)[BI67&%IFZLR3/
M<[C,5,^]BP'N$D_%3OPLVEUU[)R#V()+?Y;`D6OQ-A(_],U)77D]-CW<(JI_
M]W!K+.!NRY\!>-LT_?F#O.^\W$.O_P<``/__`P!02P,$%``&``@````A`']-
MSK]@`P``[0H``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R<EEUOVC`4
MAN\G[3]$N6\2!T@`$:HF7;=*FS1-^[@VB0&K21S9IK3_?L<V#=@46MH+2I+W
MO#SGV#D^L^NGIO8>"1>4M9F/@LCW2%NRBK:KS/_S^^YJ['M"XK;"-6M)YC\3
MX5_//W^:;1E_$&M"I`<.K<C\M93=-`Q%N28-%@'K2`M/EHPW6,(E7X6BXP17
M.JBIPSB*DK#!M/6-PY2_QX,ME[0DMZS<-*25QH23&DO@%VO:B1>WIGR/78/Y
MPZ:[*EG3@<6"UE0^:U/?:\KI_:IE'"]JR/L)#7'YXJTOCNP;6G(FV%(&8!<:
MT..<)^$D!*?YK**0@2J[Q\DR\V_0M$"Q'\YGND!_*=F*@^^>6+/M5TZK[[0E
M4&U8)[4""\8>E/2^4K<@.#R*OM,K\)-[%5GB32U_L>TW0E=K"<L]@HQ48M/J
M^9:($BH*-D$\4DXEJP$`/KV&JJT!%<%/^O^65G*=^8,D&*71`('<6Q`A[ZBR
M]+UR(R1K_AD1VED9DWAG,@#ZW?,XB,<C-$K>=@D-D4[P%DL\GW&V]6#7P&^*
M#JL]B*;@K#(;0'U>SPQ24C$W*DB'@EK`<CS.1Y-9^`@5+'>2W$A2W^LEL:TH
M7E&DO20$O)X1,K^<4079C$G4V^LT<B-)=9557L7!#0L`"G,Y@`J"8AY4($$.
M@)$,#R1#6U&<4UB(8'(YH@K*?,BZ7Z3$6:7<2"9ZD=&7JX'#=_*Q!0>;_'(X
M%>3`.;^>&TFBX9+Q((G0.'$`+4D,?1/^>HD%F7P$4@4YD,X2YD9B((?#29(F
MDSV!WHC%68D%"2_4Y95400[DJ*^!>16,Y"SD68D%J8Z]BWN*"G(@G;7,C61L
M&@XTOK&=1''ZN84W^0B>"G+P]MW*U-!(3KXJ)Q];<`B:[V'QWFC$2NU@.57)
MM6/FF[5%2+\!!^^`V8&V:*?9;U,;T3DSWD`T?=YJ,D>'A='L$`=IFKCG28%L
MR6"(T'X/VWBJBQ]LOS?P3,\_Q$OW>9N%A=%"5?DLGBUY#<],%^;P;0A?D8+4
MM?!*ME&30PR[NK]KIIH<3>&(@FG"N5_`M*/OA_T#&#8ZO"(_,%_15G@U68)E
M%*30_;@95\R%9)T^$Q=,PIBAOZYAK"1P^$4!B)>,R9<+-1#U@^K\/P```/__
M`P!02P,$%``&``@````A`.C`[12E.0``!=```!0```!X;"]S:&%R9613=')I
M;F=S+GAM;.R=V6X<V9GG[P>8=P@(98@"4A0W45*Y2@V:DMSJKI)HD;+1E\',
M()FN9":=BR06^L(/,3<#S`!ZB[GGH_A)YO?_SA(G3D1FDE)Y@6&T[18S3ISE
M.]^^Q7?_]NER5'RHIK/A9/S]O>W-K7M%->Y/!L/Q^??WWI^\>OCT7C&;E^-!
M.9J,J^_O75>S>__V_'_^C^]FLWG!N^/9]_<NYO.K;Q\]FO4OJLMRMCFYJL8\
M.9M,+\LY?T[/'\VNIE4YF%U4U?QR]&AG:VO_T64Y'-\K^I/%>/[]O9V=QWOW
MBL5X^*=%=>A^VGNZ=>_Y=[/A\^_FSU],^HO+:CPOV$?Q<CP?SJ^+UV.W`/O^
M[M'\^7>/--0-?U;\.!G/+V8,'52#_.EQ=;59[&[UBIVM[=W\X9O)A\UB>[O[
MX?U\M-_*N^I\.)M/2S;XIKRL\E'W7QV<O"Q._OWENX.CE^]/7A\>%Z_?'.:C
M_%R'''-:CCC>H/I4_&=UG8^[O[6UM;VWN[>[O9\_BF`ZN;YJ[V)[Z^'OEKYQ
M5$V'$\%V4+PHYZV7#X#^P&[@U:@\SV>Y?U:.9JUW#A?3*8<I7@UG?0[T7U4Y
M73K__8</MW<>[F[G,P>@^*G>55>3Z1S4+([GY7PQRX???S/)?_(SO!J.JFEQ
MR-'.)],V3-],Q@_+?K]B$$,&[)E_+9GJ<')Y.1FS@TG_IUYQ?%%.JUGQ=C$W
M*F%O^6OQ5E)`O`*CV]OOPLC\=7]3W1/\KH70AQ,0:3SC3/QK-AD-!W;`WY2C
M<MROV#XD.2LVWA^_*+YYD&_]];@XN9@L9I#=K`=YCJK9K)C,+ZKIQ^&L*F97
M57]X-FR3V(NJ#XDY*MK))PUX4<YF+/UMZW$YNS`Z[^L?U9\6PP_E"#QJ0>MH
M6EV5PT%1?8+?S+@#,0?;7-'W^.*6R%<XF<S!Q]5CCJ9PL2EL1I-J$U?"_EXQ
MKN;Y=&\%CZ)[J7<5?&'8%TKI./FK;B?=KP8PC8;EZ7`TG`^K-JP.^L8_9\55
M>5V>CBK;+7@\7;!@@$N^:)C82`E$GIP5@^JL@E@'Q;3Z4(T72TFY^Y5Q"R2@
M&B)E/M26QI-Y!?(`.%L)9B#^GF\*REY,^Q<E6!4.?%W`X$&Z#\!0Q^$2=!\?
MR^F@"Q?\"68BRX)!QH[C7/EZ/TS&YP_GU?22LY]RKP$;_`GSX4V4";-R)?G`
M%S4DVX?DNE;>S,M/0&!\7ME5SL18:F#D"^4',-)<<XKZG7Y^0?GT8G+#N7#>
MT14OB.^B&G0<^O[-YYO/[1EJ'$#ZI]?3*[[9VD2*@;;3`NI>5+\NRL7\8C(=
M_LQ-V\EGQ<-B_VEO=W^KM_UTORCG!7)[7EV>0FM!>!NZ[^_TT"=Z2$4-@O/X
M,9[[_+H8SF8B!^,.-9>N5]G;ZSW;?]+;?V83+%FE8]X1RHJX*0I(X0X(="HA
M^3>/G_8>;S]=L>G6=#GT3+I<3$8#-+/[HL]A?SAO\THGB@SG;PO4[6T#5@#8
MDO-N.Y"&4:W]K@?K=F_W"5!]_&P%&!BSN]?;WG[<>74Y3`X&`]C@9`SS%N-_
M.!S#5*^&,/-\)%0H>!6PPL7E8F02;["82G&`60/.#]5H8AQ=NNUYB]\Y<C>P
MYG>0+^6&)AP!7I(05X;YAH6WFA<6>ANY?0230-6MYD-TK`>WD^/5ISZDA.@7
M@P&!R[N(]EOM*P<2+T5YD$&D5S.!8H,;'4Q&HW**1(/.C1&TE)+.R7J!GFL^
M<J=->)[C>,67O#FI6<N=7B_/SZ?5.1@*J^_D)PE0.D!AJJBG_\A-;PW(].T:
M<!Z4[6.DPSU7=7!;/30!S=*I.Y%=2G[E9!!<]2TH8=S6220D%*AT@>HW_%`5
M/TS03)=HL;LKS<$G3U8^AC]&:[&ERKYSZE);,3L4%I].W'Z+)5K5;TU%6?+0
M\94E#STH8&=!R6N)!C1/#*Z^4Z43AI=?U6^K,6`=.<UQ<#D<FR4[!Z;Y2+<C
MJ<7<0K)T/LZNXFPZN2S\6.R.?(S3F8<X&BZK8L,?XD&G>OT&Q7&DVY4`9WQR
MZ?HYGSD.%P-AN$PU0])><5K.AGV;9C`<+:13)K2U@N'\H1J>7S#\80D30UH$
M5K.0536?V*:8KF-^*;VV]\C-;$E'-!W4?`LJ.)15]&HT^;@4W6OD*/O<HUD.
M.93@H;4M&':9#SH8_'$Q\SH@QYQ6_0GJGU3Z<"Q^U;_-4C-HP,!K!*F7;V'G
MBXIK[`^=\J2++2]EV/]L/^3[>(T")V,5T_,L7JFI^3(0YE7_8CP93<ZO\_>.
M->8AM\XU"7%@%9WS'R1KIS9*&[<XO\`_'&,Y8)4$ZLL73HR`3G/J]9A+@>;.
MRJ'7?QURF_+/[.D#CHR\SLR"ULX.E[P*E%/%.]A%K?>-9J&4P7!V-9FQ-9;M
M-DO#R.J3F,!B.+LPMQ#C94CED'#[FNE,"5Z8X6]'3O2F%HZ\N0UFY0N^-G-1
M[*G&OGS,4;`TV?15IYW?>F,ZZ5?58%886P,^IN;?[MW6,8:WV.*KX1B,7WV,
M0!8Y541;&_^(/VGKO@\G,PP[<Y]P-=#UN()7@``?AW/AM\//J\7I"(XY.0.'
MV,MJJ#!)HN--+E$0\+0Y\W_UFSB6$UN\-;:\]BK`&%ZZ:F03(.EN&D00X1/.
MQ?F!1KYNO#>N^<-P``\YQ2-QBWNQ%R,]&L,PT27.L<*=98R]:Z!LHU,\S..Q
M\`&<E0F#0,%?F^]YY1QX<%>__79Z7HX]#S;J/%Y<7I;<(6L>#\_'N/KZ\G%[
MKY-V<X1#L>T1F,IGO[WI=L<?^L\1_W/Z"`_]S[+XO[^W>X\_^O!M.#AA`R(+
MV_IE^@I'@QMQ,KR$Y;^I/A;O)I?E6$_/RLOAZ-H]MN&/;-[Y<SD@;OM_K6V%
M+6UO_9)[4G#DV]E5V>=HL.%9-?U0W7M>M%8_38#RR^[@^5=?*'>6A%72Z7+,
M>R4+Y@1':'E5+3!&9[V;SZ_'>($WA*U_^?/_.40`E^/KO_SY_SY`"DDB]"=3
MO&UFF\.#-`Q;G%G`MA?52'X^_CTN#JZFP]'-YYTGBLEL/7&2$N-XT8>##<7%
MX$W]X96$EM--T6TD<([+<?%BB+^_A]]_-$17&`_+36T25[AM!M=041;]$?P.
MZ_FAN0**T^'D"LOXDHO309A6N@-;)RYVCO8WT-S:+;*R/X'E.1]QHF+K!'X*
MZ25PT,O)0%Z("78MSTK^F'/8ZK(@XC":;=Y\_HTI*9Q6$T=0_>\9[D]Y@!1_
M\\3_4W6M+=J\[.T2[0>BG5W.>!5&@40>5#;+F8=EOEHO7:/`XUJ<+H;L9_YQ
M4ERQ2475_&23J_GP$I><O>'EJ?>(CUD59Y>VRW_#K1=7.'MQ%'H%(COGMW9=
MBA'.)U>3H7P6-11Z!9S@WX\/>P%8YE;S^[%+UUU?+F9]A"]Z'(`;@BP1BO;^
M\9+W/2NJ(X1'#F=PFNI":FV817/,/N&(R+9:7?8R@#,:OCKA!`J.%A[R>)WD
MXK:ID_N,AY@M3F?#P;"<XDKM%2W**38.RW$Y*!\0`Q0!03PVQOTJ`NIZZ8?Y
M8+/7257OD>9@[7^"0(/)9<^V\0+M%33F;.'J9K9:>P:WZF9Q,I&KJ'+84SLM
M$I(#D)Q68:'D?"`8UOEX(A%688DE8L34_M&(/:--!QI3%'4F5!,1:\2I"U3-
MW$0V234"*\=LQDBQOAO>:5VT+/0I>S);H#B^`FGR"WX+JPBNY9O/VSLN]MLD
MDS/,'KF0L5-"(!3;1QAI/]@S14\,([`V%/R0M'3LK.9U;+%75.A3G%`Z*@RN
M>@C%/=S??,SK;J_FSB&XQEZ%G0D*_>7/L`04JQ7^;%X`EF;UROS9+`X$XNY7
MTH$&[-I,Q1XS%`:Z\W(X=J#.=U*#GN>=9&&W;Y<VK>;3B?&0"@E>FFG)6V97
MGHV`!^>$'7?!0%9>R2F<SB.&#Y:!-(/6;;\?EPM\Q,S[6D@UO"20:XHTQ+HB
M7P`RD*O8L7G=BZ$D;W-`[X1=?U2)JT58'WHQ4H@_Q"G7@(FSX<9SX-:6I@/C
MLZ:6>T(^EI2<%<1B(-Z1@$G@FM`(^.D8CT[@A:(8G!C(;P\.CDSTBJ3.<$Y-
M/FJ4+G0JG71:N]GT6W.EXXJXDKD1#$E"E$IR2EH^.&UK'+\\M"5T70&`G,8%
M[,%#\^D25-).3:RQ_`32G"[8)5YS:`9,8W>3.?Q"G'GJP[DUS(9UT@=O(^\$
M];$2300(?Q33U'5B'!-C^$YRC9K2;0&A"TH4*);(=/%PHZW)%;J`:%10^/++
M\X)\!G,PKQ!L0B(5+//H69\HD2&ZFR!'A.^.2$R^](J/%T.<>>'Q9,QQW;DY
MM<)^QDYJAXV,'#PF,ZGONA`M;NX&$$S$XSPO'=REWAF.`"Z=H]B^8'6\B>)B
M8BUA^WHJTJE]L>;Q"B^9_7-F_BKMHTW#GE(2.`SP*B$PPED%"NE:3+M@"VS#
M$+:^92TU(TUAQ$_"YS+(A3\NQHE5*Q"`LE>FA<)'ZY,F:VNN!BMPJ!A!Z')9
MKI7+@B``DT-D[.9SR'>P`-!RIJEEX673B;(GR&$QL3I(15`,;SJI@]F9;-U9
MZ/H!>I-^_+8_GQ`417(YP55@],M?!D.=%.^@K9O/>SM[&Z</;CX'JN/=FJ0/
M8+W@P?:SW5UT@UJ@!<6].=2I'Y`I#+'A,TBVZ*14MP_!.,7KH[>:QYADQ*H`
MXOG%M'*)#-B[%=J@97(Y8"=R.@+)<8!YQ'<9B$/4982O`@,>Q0/NRM5LZ1AA
MN;,%Z'667"M(*F7?)9($/N;05AQ)S\X6<S"Q,"R(.-T61O`V5G^)IH7&VTX5
M.,GP\78B!CI;*B#$\QQ0W:BE1+Y^*4]DLK"$1Y?E3U4AG=%.8AP!]^#B$@-!
MBIJQXB&D96)<-"BV+XGDU0C@X-R)O9C18,JOCV\X52_$,FQZX5--]0(DFY;2
M!//R<]FXQ(/(M:>48FBX_J3=%._`>(ECJ*&SUB#XHK6FV+6HA`!4QU/F0[RB
M1GJ+G2S8I0491'`,N-)T09Z=-#H$Y^+\0I.`8_6>1`K.W>T%4,KN?AI//J+$
M$KX0+'V"E.)74F*-Z[F[Y,(ORVLGH>>Z=G]2A_2P")@6VPD$96-'#C&@/.&'
MMLL_!T/Y#9W+M+53+5@C4(MV7'SHP!S%+7V=R4*^E9!B1L0JD'EZ8)(F7%(3
M[(9QN/CL4H&8_2$DY1!"IQ$!V)%.9G:;25+VYSC``-T(K`ZOZ/Y,:]4%IJNA
MU(/RD`*!DE+)<3XU@4N:VF65,&9SIP;WL:R'?D-5?^7XBEOKXQ#&A#R+QUB`
M_B-#'-ZZ&F$^<\O<I7;"$=G_W&L)W(:9Y=<("S<)9Q@!;TO6TQ;+I:D4)@*`
MC?PKS04DL\P+WKJMHQAE<&;6'WSVU0\^=:T5F3FI@6<>"&^?G,'YD<7.U^%3
MN`RBP8\=(F^<VD%OJ9/7T6\28'&`XE[BO%@;"5`D^2)9!*8B26+P;:@$#9[B
M[5-V9HF4,[06YQ8Q83NZ%C;Q`I:=2X<#YSQ:.C//'#`RC9M[P3D$"Y7VYAG#
M73<R'.,:01,2J+"[90OZ5!;X8D@HTB,=+;4R?!Z`-$3$I_Q)9H$$>1FV*?'J
M=</+JI1F)D55RT4?$#P`/*KP]R@/<!95CLWB_16O!H7?!;>T%>"$D3@J/%>*
M"KX2".36<G?8(#O_BODM<,`(VDD>!5DA%JM!_Y5?0>R(.<(RS>EZA8=/6&;5
MK<FPZ)<+T$EXJ%,Z4>C0+J*8&#*D!WPE"^=I7&\!IC@#[#>CDC#E<9_E9?28
M2)7]9N$?/(?5R.E\TCP<K,R]F>#V::6YM!!.>F70.62&2^!><)<2U!E81Q)P
M7X_>B6H,N-:J_8WS1U'O^9#@/B2[5`P(QB:,,<1I@<88W6R!O6.<S-M.#:B.
M)Q8,TH76B3?2S\0-$]*KL<Z;BN&U!#,#>NG5;MQH<3RYE722=P[F(H5<3*4\
M+EZ-<W#PY@Q6#='+MCF;+`PMM7QMFO>QN"5);=N7U?Q;,@=0X5%$4>XMY:52
M5,IQ&QG"3$8FD:/"ZA,R<?9K7M$[8!"D#"OQ"`\?=]YS..TC0*;0Q%#A=?&B
M"2ES2@6VE_6VMC63MQ44$U:"\K*=/H%FO#NHV*6\<9`X29R(S8WA!]XBLB.G
MSM!2EV&C.G@Y(W?O%*X@R<\22Z%JXL-9Y<!)$4F2^.9#9%Y!AKX9Q`86;/?1
MM?`=A`H;@<&3#2<-01N/P[TG8$`^A&@1O7["J="DI8]1=P(5`YU$`^!LG1/A
M@9X+>_U0YA)G-((31;-%S=:<S%&%UQ;0B[0'YP^(^UN_(=/1KG`*^E=+_;MO
MK-5KT8$#&&..^,-!JQ)2\I<?5H1C.M7!8P<'"8^<J]7R<@59P9%BA3F<`SP%
MS>3W'I,-0S36NS?B9,G-`6-SB4NN>E]5,54BC7:"-W`Q'?/_1D[,^&7:>T&K
M`:>:6P61S9$`X''?@)#^:")[P_3T+)+RTA$'%1@G%>;40*99Y:?F)`I7@)3"
M,R]D_4T%`T(RJ86KK]A#PUD-H[4E["8A%#V?J,8(NSQ<D`)?+#:18]BPUF[&
MP[U6W9U,\:!)^+RQC,GI'T58R&:=`0BB9(DP`C<`&,DKQ@E8RY`49A/O6)*?
M_RA-WE':9O$:`AB'$1:D(^@!E2^Y<N%%LE(3O^QUC7`L`[DU5>A,VTCH<K/X
M@[B@?@G4(1#A>-.1A+E<$$HSD?-D)4W2<=/\:@!*1K*G3J2X0#&2B\D\TW&-
M:M"\J4SS%J^.X/O(72>;8&VGGB>+8TPXCU2\,1E%GE^&*T&F=^VPA6Z_B0D`
M7%P3J<#PY3B%9!!TI94ZQ<)?4W+Q1:V*1'IL,GS$SP7%8<[*)UX8@I4E/R%R
M'E*;,BTN^!\E'%X[;K=ZJNA>L#D-([QS`;)L"!M==I-*$AL7(3P@>.+KD/I%
MA'1-#O)^__[X[4MS33=H(_A4HQWH6'(;81O+&XK!X(&Z44<0(MSM9-IS=%83
MD9#LFCPFIZ%E+S@OLULO04+EF=1N:4\B.H+X7()?[$#3EQ_*(;FF(PO-#:>#
MAP@UZF0B/Q``3HXZSJ\C(,7`"_<V@"[9*.*-_YJC1PLV;X-74'J-(8\K&";W
M;CO#%5VPB$T9]H.C8MUTM=?6>#06"]JJ"7RA1'V;[",03M":'=AJDS=E(49X
M@3D'X1&XK%&NW01YUT3EI[JY3A9G#-9O$<<+DM"Y0^!+7OIS3].?E*9&G,A\
MY4`4IHR2?86V7N/E&4X3@O]-/4#:EBZP(3B`8^)"0?MW)KMT_UP'2IDWR(@P
MPU04`)W8V6KQD*"T)K2_5+V26R<XX%$S5&!7G&&=BT-V)Q:33>82M8C@$RU%
M7T`[J']S!@B`"CZ\^I')L<EUB8J';J.[X+1>234##A\YJO`'\4RE%??1+6-R
M=0;41-,>3\;8VG!7$R;I(1R*I5J,4W:XD""I/=_TGA3_5Y!1NKD9BLM,M8\A
M-`FC\MH(`HN$?DP"H.5DM#?,9EA$-2AM%]@>#76JM1$SBR]/%>^6O6W$(?BD
M4@.CH&OU)KHED"G77J(4V@`*Y;B8$)&F'W2MQATDE@?OZ8ZG(+Q`X]V_LH,)
MF1!&MC2-:36\/"5*81?CO%T:`;Z9Z:%R%"[<UHPVC;BU9.Z2V?DYZ'B@_VE8
MCCDYA]>D0*DK12,!(V/$85+`Q;!2LGBM8L=]K`!J"^V#A(%K)HB_N-(&6!VM
M?(@=&?PF94(W;%M*(-2,^W%^#1[5]\$SOW=5;/.7"PWJMWH'QMMM>BEPL#BO
M0M<C+LU?):4F-16`7`+*J"%_J.S<,($X.'`'K1O-5F^EZK<PC<-;)P`=#B3!
M.C@EQ\<:E!EFN.VEBF;PY&9J>'I3QG_M;`:(^D@P3[U7N>2D`%?]Y,@*,:(_
M,*Q5]AE,!4!K!*&D+$9@WKBR9M2)Q9P-RE.AP*<DC_&?+]E;L,7U[GK(&,IB
M=N,1XNHX[U6)6$Y@T+#.U\_'K4;S6__T!"%`<O\>%*)&)[\\:R:U7JE@'M\2
MJ9$:^CI0?0.90(>*I2PTD=F)R'+L%'"2V<[(4C:#R!G!P2KS%@YL/$%#@.>]
M6C#^`_A@8#&PM\I$1!K^#"PLV?M2B8="(?S!+6"<W1RW^4V'^3PO;1K:36>?
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M33A4'N*;BXZ8,>JH=A7-*>[D#*:ZX&";Q2LNJ&N?NC@G1L)*7`ID)U>#\9]:
MP_`%-9'F47*T0X]@#31,CJQN+SI`=N3R#-RR]TD(E>X?W`&9;-0*<46M$1TY
MHED>)KQ1_-5IX^;0-!O?3S?X<@B<@HGI*BTP&+JV[`&R_5Q[BF[`P""-:7T%
M6)*3YWOZ*D"=`%7/JB(V.;)(;%`PK0N=:H_"^N`&2I(\O`Z'$B]%DY#6(>@7
M7X_#>O%NTQ%(3;/`3%D@(TE0#LX&B\.T&$\*(V\2XAO/:,S)5,@O=`)Q$/-D
MCL!!PCT,7$3V=3!Q$SCC[%7VY,6F3V1UP+GCS#IDDZ;A)>1@(Y_J3`2O[*LP
MS?,<X_Y?3C@K\/.OPSJ2!5>R@ER*J&['JMN.8$G'*H[/1R!A`)<XK*6XL9`+
M2(O.*!3HXTV0/,-_8S[^<(_Q!1X(S3_F]:3CA;6U$#%I60M%()]B$F\CQB7T
MTBRLSO4YZI$5V=0"-:HQA<+(7+-DVV9!"J>RU;T]?<L])7$VPR2W54<_=9ZO
M#^5'(P>5'QE6?2+%6UD1&<-P&)PAID^O"O@G-2!V@6F1T5S-?`3I[:V=WK-G
M3P,(]=;V_GYOY_%.^"E`SF68K4\L8P8\K>2#LZBRQN#4(YEBFAFO_O[V7IC9
M?GJZ1]./)^&GL-@MD]@ZU]JD?L45*D<4^BO@W#(T68%UZ+;B"I877O.KN6R,
MQ12_EVE"SFOLSP#LEN(CCBQ[B`8NWR(H`B[#ASH3)D!XT^91T0*(8W;(NC<[
M"FF=,=*@-9_3IJAPR$6I70)>(II-VI!\E,Z,'9.42>6(,TE5-R5)JK=\?CXU
MRH*WWKIJL0!SLR(<(E^Q1.*^[3>4KP=ND>QTX,+K(NETJS7^^*3>EB@["I4[
M4*O-KQM+HN>RUKS);Q:=5@A[DT<%V(=MU8M%!GE:N6P)#C3`PIH4'T-P1/&W
MAW%!80+VN/,GD+H.=):@IZ>S!ZVRX1.%)&X^0Y(WG]^`H3>??\0A=3&[^?Q2
M";LY3S^N2S](*<V?'BY'Q)0\\M?^D*+H"F3.WPNI]69,N=O-AW"KB5QPN)J/
M>8T9YQ.\HJ=K_?5">GA5/_@2'X\]ID*7S!?;E'#1IHU\LA`!V/+-SN[F$VGG
M(X\'*>5`T[XXCVOEU2:XQ5]WO17:!%.S?ICXLJM@`1_^8Z$[U8L]_CVZ=O\V
MNCA8G"]F\_`PI@^E,YN+(?T!@\^;Z9Z<,[D9!9E/C/#QY@]4;]$8+Z0"ASQ*
MG#1*D9">C,]8V#R&;@*WM&M=@/`NC:\YHRN&\++/S6=%$\J#<296>B6P,B?!
MH4-YY1(\944V@`_'F>3RF(M8+<KC;EBU#P?D:3E?*+=BQ-R:PB(EWA87(:J`
M69).HX.OPK_LUO2[`)$\F!-4-4INIXPKJU_2V\_CCVCL56F;O!7SVPU7-F98
MVF\X8;'_H,7#+%^4\F14'5^ZP+2_EY[4KG3[KN%#H-!U_GS'3ZARY7^0BF6W
MRV1#_[2URG>_.Z"2%B>/0Z6P%0K3Y,SP--!,*:20,W().EA=@CUS%0XE1)LU
M"9,DNE+HY8*\RC\MB+(&[^;;^1QKKE>\I:Y&R(:4.U<IDZ*K-*[A3W/FBV25
MN07/]'$@(Q3"W2B7RJE6@`*UY[J%V*\M-[)5;V'N,%9IX[L[O'&T)*O1G=WY
MZP#%,]\V3_;GAXGYEX)&<>;*4EWQ9ZSA;HBG8]/_+:QNS,ZXA>\<81I_WWH@
M&!,R=K"]^[2WMQ^U<4A3B6\`M99G<!=2-FNWDS@-1DOHLL<K?5\E-J/K`(R4
M&DOK8!;Y4N8W"L/A\B&=GO(<7_"M0AW"#Q@FP%Z,K:X(BKXF3%2%0D_EX$H.
M)-5S<:6;?8K:O[_U.*C]':=JW>8)I^H`)7X0-$=6(@.7A@<X'\S]!](JJ\^Y
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MXX@:;HF+6`ID#96?'L;H".[X8=NE?[!46Q2A=A7=+=NI\:6PU9H;T5Z\]V1_
M-^Q;L^YM[?:>[FW[GW*SWU_6,BHS78TQ'0JN8\8M"V_-A&(N,(/4GQ).$1"G
MZV*:?GM":\(166XRSE/CRG.`)_N]9SN1*0>3>CD;?1BX9^V/AT<ZMK&#5^3Q
M[K,`TS63=4QD5,)<0LOM[<>]W:?A-J*QOV1G-2</#6QJ%MYBP`?$-`*'XQ9`
MY0@?I+8>W?FR=$U.O5=T7UK";2XKL=:S<Z7)`%A.Y`L3>#^5%*A-M,0_['!)
M]UL7]M04*>"P*V?@R%>)Z%8V)AB&:PNI0'JP""!5>7S8`K1VP*IXSBJ6"X=-
M(-L!M3TX(75@QW=CO+BYNRY49>TTK+[R?5V*>6%"14URHB8A&3M4W,T57>!A
M-,5M325$&T>6,2!'S=EFOQ)?=+K;X(LN26.]FI5%(O5DYKRR$@F49Q*."O4@
MJ4M%Y8,SYH)P614'B'O-<*!V,/K8;=O#DMYETXR:/S^V]?-?7]'H[N;S[]7I
M^>;S4;NSOKUU\WEREK_X7HE`=N7Y$_@P.'WS^5B^QOSA:U=\?/-9"^</_3;:
MBX5.0UO;6_D[W^0__"BB,4]#ZYL%/Y;.)]%Z4,_?:B1:.S+RA72"PK9<_&CN
M55?_T!R&*31_ONMQ.+$6T]Y2N[]D<ZOGMVVVI7%NK\FV_FF-V)67U;173R#6
M/FY"RS,):1(21JX(M7;@B.;YT1K'A[I$Y4F*Q%%PFUEO,8$!\P$=U'%&$*B.
M8"0\@TQN[Y;U')3LG>G<=<4GW9",`3>!FG2HG'"ZD,H^VRQ<I@4211R'+K=3
MUTU$25P(%Y>K@<$0,Y,E:#34ZTXFRT<3"O*<XC^CG0]:OTLS:>;,A=.5Q0\R
MQXL=-G)%L*LA$D]IYOVQ:>[SDU+KO!].:Y_5O38Y;;.18.K01'X16H@W@_6Y
MJ%K"09?G+TI2,!9)HM3B<<8K&!>#PX82!MV9NS&7YWPVI3W(Q\GT)X.'JX73
M;/7+QI`1Q&+5>-=#"PP;;X+8#!2`05:,C0WX@3#F+O2E$QJ$==;8<7D^TTZF
MF>[,O'!3!:/KOYUNCB\@]BE%>W"'!"DYCXP`DN'-Z2F%^4KZ!'8YQQ#0'5[S
M3XRJZ/%G>I>I!58HNURSN"-@1ECBC]`EU&L2B`]5Q-R]QDJP*Z88$KSE=3ZM
MYA]51.OS+ZYPSE`_>:7$J,2)FD"6<\B^4_9VR)JHN:O;<)W+%ORWJ$Q`A/]E
M17:\:+0_Z%C:GYE0CK8N(`DPZ7'CV6R7I-_+&++[#:2M-ZP4,EG0X7H7`C:1
M+:G.2(X>"S4"J9EA3_KZST8OVBLD%A+]@:D!1OM()N'RO4;1"L`X2MW^MGA+
M1OKT@S>Y;$I_D.)/"SRXJL8R7[FNU:*K_D)FOVY*M_ES3_S?TK%'\Y!$#'8I
M#`XLA6=KYA.\P$!QS$F])X__KL`??`+[U#<$])R/KBW%L7L;N]_2'RF9QX.+
M4SA?@K8&$)7L/9]3QL2\A/P\>F!HXRAT`WW&L9V@5JE%/K@<H`&OCAM#FGQL
MH%R+([V*?:Z,E.B4MY3N4X)W^&:X9FXAVXMGT\Z1E'4M76'F@MC++?/(4#U+
M@`=;/"%)2["2,3X,LAMC29KPF^W-W9O//KJ4V^0.CDDX*F6]MA^5D[7(UQP_
M'DT]MF_2(Y+P1KH=L)-+4SL9#Q\1_ID:TM""T5^GR@L<A^%)A^F_$B9!'`[(
M=1P3)I+;A1>NHZP#<]PN=Q/7I+_?B-'@:U=]N5A4PMD=)\\1NL::P(A<=:DG
MEKO@D(\-&P(A!<XJ^YZ0,SE]Q#[AY+K98/`8@_!V2QW>V:$]T!N5D`!8D7B*
ME')8U[Y:#Q"`E1Y"Q+X*-)J#YU[P.?"P8!0\4HZ<3!E)\_#]!T-U=#%8F,#4
MSIP-G,3Z6\3Y@Y=@`NY=8*HSU(S6HN'1=&N;99+2T<CZL99F1+[+5M/#=\&$
MO_G\`E7AYO-[A>%R_+"6__F/OS/FC1UGW#M_.L0F.S!NGC_YT:0MN\$OE#][
M326[.;SS!P>=+6`VC"SP$;5ZZ"=]BO.IWHHQMWZ,\B!_XD1-_FM8>:>U<BH3
MEKVUVWKK8)F;H256?4Y!1/)64Y6__/E_Y>NZ3S8D9)$/<,NWW:FMU4^$Z&O)
M6MQV"='5:4+K4T*-:XJTVBRB/KZ)BR6+0<Y.2],DB=;B><D21U*+;G7H6-K2
MT/C,J8Q>%U-A;G$HD^@^;<I86GMC:R'<NI<H<_*;)9G%)4+D#\)EY[_3OLY>
M:/DFW@UG/SU4:QY$I4*>*`JR]/+W?Y7_\#*T6OLP4;T)VE`+9=_1&\;EA2-B
MK6A,85#!R)B=&JS-6B03Y[4DRPI)<CVL1JW$GN;EN>P'`JRN]X*)1ON:A?\&
M!9BAO*V$5)9Q:H?(02ZG#6T7'5JA,IA6\&Q/U#GH@L!H`<P<9?GHW_AO.2*U
MP^7&;H0M)]1K.:I]$DN;O%I=\`\MB,O-)V24K[^Q^R3_J75I&\]:/K55VVXA
MX<9.ZR3)^Y$*./>2#[L*'=:2URT9C_1[[P@/[9",$T#AB?\]^T:9`HNP(RSI
MA.Z!*YC?"NRGRHZ%6I,TF#W?YK%6E3HR87[0AQ).1$<O[/.&3-CXG-\AY(:\
M)P,1G:1Y>>9+W/.\,'':_;U]B6Z7R8;^:;V(7W!Y3=]B<X+F]6),-SZB82A/
MPPWW#1S06'XF]7X.*5YD8<(G?&\MD/5#2,P=@%D/S*B^O8[:7+NU,P6Q-6W<
M1/Q6A_<JAJ2U_,V-[:?Y3\VEXD2-Z5OO:`/94C)`1@V0Y6]M[.@SB?FO2];/
M9L_?.G3>TW#.]8MWO+#RB!L[S_(U-QZW?NJ8M0D#@V<^D4O-E&U7QS,PW&J4
M>:/$/6]TMJV-UR&YLSE#T[/KX^$I(B+5&U^;D;22DRVFK&+)AR14*T@75+])
MDU9AW"%3R!KFF---@26?">$*'<>66.E\\;4N!%O?^96,0-</5GN7W:;0+C:X
MSU9U3)O_I0R;:50,CX-:?GES>&*[^@,YC5)-:>G'TRT<+-2<M#U*06%;;`*L
M5I&;I&5`2+TMKNC8HL+J`S*V;VBBCKGYK<WW6>7"`LZAVU#VY4]U`5U-C*`K
MSFEQW/#'^-^]J<]?QZ1F5AB$A^'T]L'@7$I;\EATK;E#N-XZ_N1L5A=&]S/4
MTL0K"%ZXKS:AV=4ME[0UHY`ZI.&NMT$V\M_5/)&31MW7!\8+/@XR&OZLA35C
MG8X4!_JN.;$(4LX,:QEL^JT'AA:E1*+V)KCB%&'1K2I'EMQU\RS^("CA8"0+
MXV3;#DXV<H$/EMF@JG5)R$AOIE3#WY&R[.NSM>>.1PV9DO)TDSCI%K2E$.&*
MT#,+*\U7,J/-8)W3>TJ=*1F)JAN9#]WTE"M;<(^[Y!PG.>=WXW5YMGKT<86<
MGY2P\S/?CL?M\)GE<-'R*`<F-^:C2NXS9+$KS9<PMW""IZ:2[M^-N]T%ZQKG
M2-'NKX!+K<1X!QG#1\^NP9"_2C+\UV'BJY*/,RIT\`.^OY9Y_K;QE9,=+LN5
M4(AY^75QM[@J/;P:Q']\`2YHP[?^9&9;/A=?"3*SW"A1B9(FYFS\&=FX."P9
MZ=OS*/YH7\`2MA[#2UJ?8X)+J!HBUG3L^SA84Y*X96P7$D--GH?%A=`4HZI3
MG^`NCP/>&V=Z%OX*"),\9JVDN@_LDFN8_,8^;3+4ALXW/871NWV(IX1/HX<4
M-P<2@"1YT#+"G?1_;&L#]?V6H\F26+RN<9_W`63^G1HSRQ[_RRS[^WU-+;TD
M8F/-:VH:8/:ALI>DY4.-KT$DD)QLC"-*!+]KE)W,GT.6@8MV?GG(@G"GDW)J
ML2<7G=1GQ'R6L2'^;9(7A;0(?Q>/23[U+`2."F4M8E-.M/PPL3!`)W.5`'2\
M[.WM[/:VGNS<?'::7C>V!_9BD5_!J5Y<LTG_ZDQ@:WE`WUCQ=%?RV-ONZKCX
M.=_\+@XP;?D8C(]LY$]_JS8K[?K!0V,4[=\WR*9_NM^R"E\&%IM/O['[N/?T
M<<OO=0)[]NJK5][L"GW.`K=:-S'15<J'>9O>`-)N8P1_76#)5U3^B,]H:1GE
M+2HM5PA\":%4UPM'\$'%0;&[M]7;WMF6F<4QK<^:!T$8JM/71D*63:OYVZ^&
M`G-TJP\4C)%+93&%)%P\QE1#_IW*=>@:QSI=LS8ME[:%84E$8ZQ;#]O$6NQP
M5KK0]_;FTR"F6C3S-<#;V=GJ[3W;CXAAU19?V#`#L<\13!E:"2>GT\?^9G]-
ML&UM[GPIV!;*=0I-TQO$9*U_$HNX"SL3OY@KWC3`MO$,C4AMMGW*`%J][Q7I
M/H2)KK(?]F\:`K0I&]-:(SGD2S8)U08#U`S+)/>!1(5=U!Y315KX(S[2ZCM!
MY#SF,/WRP:S0TJ2S0XQA4,V"6EP]!GG6!(/^#N>2>OA59[-"5M,FBK>N*:]T
MYEOK"3O.W-IMJ,%+]01F-HD1:GH2Q0'E80!?0GL6?[S-KJ+`M\%!ZCOBCC_!
M+OOZ\%GB$NFJ(M.:J9I!G(,/0\3&CW&ZQC$AHFL</4CB!E:1$>8UFRN\1^&[
M\M9MG$<*69*KH(/:J/8O\&E9,+H&EUE6-^=12A@Q0^*22(<+`CSX]M@ZB8^^
M[Q<+\"%I+)\I_ZH5-`@>2E>!@Y(0Q0Z3`UNN&;^JL5WX$BB6#[*&9B8:N]W;
M@FGC50X)_?P&?ZI5.*.?NMJ2(^K[PLY&Z]#G(C3-JQ@L)0?:KMH%#\T/OK6P
MF7ZKIEU2NQ@T4Y)]D,C%?Y3C!9\T(6^C!Y+$+UKC)4T>L%7L):K^]GX5H)8R
MWZ[=)I!U26LII-!Z];Q9R4@*:LM4TZ58@J)JZ?`C^I5@4HFD\]6(F:R003@G
M0-Z\Y24TV>+-+T,'N6/KFW)$.T0ZS"ZU%Q+]P==M[C9H9,FRJ<G00?FK-A')
M_N7QD7U&TE&\_OH:8D_P_<G.LU\0V[6Q7Q;1[:C=];E?B../#<>%F1[=P!W[
MP@?!!(]&?QNT#\5[H6[4&6TP->I#727>WX4HCNM^UB_M(V5-@\G<(<&1PA_Z
MSS_")^;=+I,-_=-&J9=<$$=/NC+X0JSBR'WZ[*V^""<7F23M.[6A162=*-5?
M;@#$9?.2S3T2??'.B];D=1**5WP*C6DDP)4K86VB8=.4)=!:=5`\Z>W3!FQ_
M/W;FRD4I]DS\-AN2W&V0P`:^3(9^L[^)%%9XSPB#WFDSUQR?``U5%]B%+L84
M.P/;'I0ADDB-6M%=9VO_UH)F<5;2AT+H7>H^WUP93>:JPFDEV)CF]%&?Z06\
M(8;O5!HI#@CO+O@2NMY_]CB'>GW$H)!XJ+A>W<FFW`^N6^NR*%)KJRQ*ZXE\
MT8@;MYDS?[G><>-2HOGD"DZD;I'A#?ADU2=R=%G2T)'J2-#(Y/>WYO;"B."O
M,YWJC<6$[SSQQG;OR5XKHZEY"@LQ^(]JLJSP2F03C=(59$/DN-;Q3/5B`LF:
M.ILQ9C(KF-&1@N0)RSN=U*E#&T"9RNDQ,]V@__GSF__G+JB##^[^C<L0EVYD
M>^N7W$GQZ7+TK<4ZOK^'"6+:^+WG!G,7QK/X.;=@'KJDA803M\(K-ZZSZ9VB
MSQ,XV0YJTN-GJ5&P2O7U930I1_[7[:R^G6]V=NK0N"XEU<%BL-OHL!6QAC;2
M*QP;9["+V^WM/WG6V]N*S0SLMFMKSJGO8M[50R20B9TT,X/AJZ/IPH+`%XQM
M-!@6)32WZ<\&;[G=F<2%VB,3G$;<L>4._OHOC/SND:FI\R7\(NM*`A17$7@P
MOLPR5Z@R;;GC<"+VGV&J/)DC]'_J2`/6_;U".Z,J:EP.^`@A5^XF]!X-T"VD
MOE)JZJ6$1K0GBTG55M06Y!)2-4N0_1=RK$$.@;<I3'QAE;48BUU0=]!F<L]1
MG8*'<$*94XLEY^,Q!M4YS^X^4;R]Q`&E]0]=#[2VF^7V&.(7NS5:"/FB%(^V
MQ;\D62K)1-J8!0.N51<ACZ?95G@EK4F:2!F2QIJ83*_XKK!1K*IU7/^M5*W#
MP))F2^[7@J@&_4-D4&R[IE(MO*IEF*W[6`.R08KKJDK"]I-AGW>%I1K*_/D)
M:%;KJ:YP(X:"2<_U'>"P&%4L$AI1VO>7ZUYP6%!R6EZJI)IP,K9<,@!="BI0
MUSUC:CX$K>J\($09D6.[U%_)="#L6O`LE7+K;+RCZ83.)-J<0^O9\/EW^F^:
MFAWDJP_VM`SCPR2K-@-J/BDD&_W&^;,-=<%ZTK+%-I[*`;V7CW;E9,8W?#@!
M/E!LJ"$`^2H/_*>J\[<V,+_WMEJ1;6P4F%FK]"%I"!HL^A0[.YT`BH^Y;C^U
MW0-JU%%:E]%#?2^.53H?>04KY@`I/<GY_44@C0\D9PBAJE.^V%OW0R@'?US,
MS"+7I,*9E0(P<,GLRHC_ZD.<=)X+O0[D8240N&H]BQ/Z+K#1^Y!V><TOXNWT
MO.3[T([XM9-CZQ!D[>V2NDD:J%H!@.C^B(_3J$2DV`C_:EGS7S7KB3*LVB5>
M?`R;#]`K]TI:2]H@^I?J2)W#QNI,;]DZMMA8MNT:GB`:Y36Q&=::J,5]V%I"
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MX@=EKHBQ2`]NH=`[NEI,"3([;)M=D3F>S](Q1)7?PTG7P#'U3F*HYVJ]-QGG
M0UY9K^<IFYT.2R(G-,9UR0K>H)1#WK_^LR8BY+=HY;#?)T"J4`P5S.JC77_C
MV#5#0?FC!LCU%;8RKIG[ZB)\R+[U&/OX@IZ#1=\E?"@S2]Y:ZT2D#[L&Q[C_
MQ*+I=*V/()\-/[%_7@V"27I,_5E$I+DU]1Z>NHQ\5+7X_47ZHB'@,,!S$/T2
MB%7L/"@VWA^_*+YIZ6GHVS^Z;S3,8MM'4QS,:-(W5ZV'L.G!'_6I'O\9S/9&
MO;J!HIM\1"BP/;J^619M2)\00_/JR9PLG-.%TU"Y;OM9':^`9/@8<`Z3-X38
MFM]:RD<<+%,/57GO5FZ!XFWBJZR=NC)48QV>KT3+"@LUYT!?'^YH2W`W#3(P
M@F+C]U#$I%=T7]KVSDK&0$?)S6++-[QO0:;N"Y\_ZM(>Y41<>M?1PX@M%@P<
MJ:+AWTD/GWRM^&$9>1]<$^)X,[6BF\W;M<'8U"-+[@T.@2OXA^_LKGQ*A!@5
M=RV^]S?;SC_47C`N7)_[8/XM!U`(V3>5DHZ+-C?',FKXL>3[,(N68/*L(XVJ
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M:.L6Z7IM%>VF6>G.;SW)74]WEXGO`@'9;D@J=VTY>/0P[VRW>DR`-`Z8?.!A
ML[TP`$@!Y]JX%4>Q!^>!=6TK?)LV2_F-;=D*TVYP`[J^1^V^:WGWQ'POZQCJ
M"L6536=NFN3,2YQ.^?))KR`9W$GRL7/:PD/XF.::MRH$$OQ:$W2/OZ-K9YTL
M6:W[;:_4#&G`L5G0TLMB.?FY5&YK;B*UZ7")_VD\X0U1CN5=.DA_6CZSRXVZ
MZY0OU!Z@6_]\G;8<6\,,S:G&!:GY07[D^]O&AUL_[SKVG/]N.PI9=*$1A+D)
M\Y&I+=&U<'.F))RPLL-&O@HN>6L`3K36.K#QZ2+7*&;]0&(?2\9^&;JNH-2&
MB7D'>U+NC5"1GA_H+:0&X(E%6%D[MNNKA;4F_Q$W-QIF<>0R\V8TT>#3A:]P
M=A*A^2\:K,#)&(@_,9_2)O(DC(:IVO:VX7-_IQLSQ*%=<?CMJL-5SI!OX`OF
M:.5H?L$<^_D^CAO>6E]V7FRLXTNJ^\FG,JZPS$5EZ_CRP_S%H[RB<^V`Q+@S
M)M:JJ\MGL+V%JJG\H65Q=IW(.=UVNSFHZ@'RF;QM$\+F;92JO7*N[*LEL&\G
MI<SN<L90RV[Q1<JKAH2"Y55C8I7RJD'9;EO2<=6[L0;;UUP[-22':+;"$JEM
MZW@[=(5)EX)F_>@&E-8/;P)L_?CL9-VP6S_-06QL9&[<KM"'3R#(07L0FV-U
M5C#GP]]_3:%L/EDT=5"#@[\XL&.SW/WO/^,8)"Q:5[@K,SR?[+Z7X$6PQ/(!
M$=6"8Q)[.UJB#2/TK`[KLPV#:*B9SB>-1T`<MYP<]_>]S;?SN-LFC,^7V(S!
MN(PVXY/N><(XZI^];;G;.=!SILXBP?QD!W47%<=C8AX0M[':X%[U:KY,JWID
MO=@A\1QGIT\`63&?8@<M-$D5TS?*S%TW07N`\V);30D.S!!DOW*5+:%P))_6
M%[Z$QVJ812[2[9Q0=4SM]F48+8G045:1[[%>9T7Q1/Y29VE$EP+LD<^I]RH@
MP)I3Z,GGC+J_.K/>\R5359N69@OR9:#3=(*QY5S[7]H"^`Y;L9GR#;Q/VV0V
M6IHI=QL]4MG;^4MMWX""0>Z;GOE8[WYIYG-Z,LR.BK<;_V&=Q^D_A4#=T=+C
MKYV]SA/SUECSNO+=OE^1V5>G#\(VW`GRU_$W?&$"7S[3<F:RPEBA2U.T8UN^
M4E+TBLX,O78*W/VU"7"UK,46PWBH\]`2<]#R`/Y6V64U`!_-9O/G_U\`````
M__\#`%!+`P04``8`"````"$`TJW"UY\,```D=@``#0```'AL+W-T>6QE<RYX
M;6SL7?MOV\@1_KU`_P>":8L>4$<ORI)\E@^18K8!4O=P<=$"O:*@)<KFA0^5
MHA+[BO[OG5F^9L774EQIC;8G7"Q1VMEOOGGL[))+7G_W[+G:%SO<.8$_UP=O
M^[IF^ZM@[?B/<_W/]^;%5-=VD>6O+3?P[;G^8N_T[VY^^8OK7?3BVI^>;#O2
M0(2_F^M/4;2]ZO5VJR?;LW9O@ZWMPS>;(/2L"#Z&C[W=-K2M]0X;>6YOV.]?
M]CS+\?58PI6W$A'B6>'G_?9B%7A;*W(>'->)7I@L7?-65Q\>_2"T'ER`^CPP
MK%4JFWTHB/><51CL@DWT%L3U@LW&6=E%E+/>K`>2;J[]O6=ZT4Y;!7L_FNO#
M[)`6?_-A/=<O=2U6>1FL`<1O_KD/HF]_%?]Y\[LW;_K_^.;;O_U@K__^XV^+
MW_WXC=Y+NR$RP0;U,M_V:\7"U['D7J+!S?4F\(DB!M"$;%U]]H.OOHG?@3.`
M>OBSF^O=S]H7RX4C`X2W"MP@U"*P,NC'COB69\>_6%JN\Q`Z^+.-Y3GN2WQX
MB`>88R2_\QPP$Q[LQ3V<MY\'1)/J-$48G$XC/$)U\D`E"P_6ZV3]5*(3U]>X
MN:\N_'%],2WJ]9+65]$O"AQVZ2NS%>DG?'R8ZZ8).630[R.MU&`GZFRV[$-_
M9^OL<GPVS4;FR)Q(U8SSQ:+=L,.1*9/*A@[-=Y/W9Z-3?F=5VB5I^%P1@`$G
MET4'0K<FOB<FOL[A)V<>T$YC,2:52_HL]/+<>.]X]DZ[L[]J/P2>Y2.Q=%!C
MO^;&9,[Q3BN^.&)U!5_F6.5V[L1+L820!5PF)<RL.["WX[I9#3LRL,J#(S?7
M4$Y'=NB;\$%+WM^_;*'&\Z'R1T?IQ;]K^/5C:+T,AJS2$6NP"UQGC2@>EZRR
M3$;VY>6MN;QE_1)DHB@JA)KF<G("H;>+V5(^TN5L)EOHT(279*'OQOB2+-2$
M_Y;2.$UBWI`%,I.G10[.!/MO)[/9;#JXG$ZG,V,T,`Q&\D/BT8Z_MI]MG!Q*
MHZF(8`P(9J/I['((0/K&E'5U5@0C`#`9CZ?CP6QHP/\L"9X>@6Q.Q[IJJQ($
MBJQ*$"BR*IN,]"1D_B128%U&<:P2!(JL2A`HLNI$<@:>*+<J0:#(J@2!(JNR
M^E=BK,)ZI^)8)0@4694@4&15:<5GDH%GRJU*$"BR*D%P;JNFTZKE[:W)%E2*
ME5EU?<QF<C!W?`C"-9PL2L^`#"YAWA8?N[EV[4T$L\30>7S"OU&PA7\?@BB"
M4RLWUVO'>@Q\RX6WO;1%^K>F)9Q\@O-,<SUZ<E:?H3-N;2/&&W=QJAZR3&1@
MA6],C/[$&`\OXTF4I*X]>^WLO:)V6=^EO@(T(K?-BA,._:R3Q!WR];4>6B$Q
MGV`+9FIF:<$&X!.I2PBVD*%COM8LJB-I(:8C:2"H(VDAJB.$3EEPI4RN@SV<
M]SPTL&E.^_UX64^TGWJ!!'B)QY2#(&V*?#8V*6&TL4U;72&_%&)C,<07JUA+
M-&UH4=2SH4&)E@TM1'7D_2:U+B<\6T[`]%R"Y(!O[N?'P8".XH8IGH,DF*^9
M2,WR!XK(Z450A69>5<$!8[0;GU.-&^@D&A_=18-?D"Y24`TMZOPU*4V@TEG9
MKOL):X^_;K)R!U;U;JZ?-^3*#+A<!B]=P`L_\"TLG2=OX](F_@"J5S4:5C;2
MK.W6?;G;>P]V:+)K:%@7["@NT>>?%JPFRS^_<YU'W[/9NJ0>B_D^#")[%;%K
M?-@YG"H\HPH\@T20")XN_<.%**4D`D_"?'3I']:]2OL'7I3V#\XEW+],?\"K
MF1*G!A-0IZ[#(Q,!K&ZD",`(*A#@U5<)!^">*A#`K#%%``Z:(P`X-5[1)0X&
M))N!#^1=0O^GZA)R3*HEU^4)M:Q*O]!_C98FEWX[T4SR+3AZ3C-\J`'0J<NJ
M%*LJQ1"S0Z3E%,"'&@I,&'7E#'F#JIROC!"2=`%#S@BD@3I&Y'DER;G09PZ@
MGI&%Q#J$.`6F(M40`(X2",00`T7C[X!B4#0"4V]0-`13"-P8?,:8H);@1DA%
M&`"/DJC(ZX0!-V*<D08"056&)-XP5)4B*095.3(WQ5!5BB005&5(:@E5*9)B
M4)4CB2E4I4@"`1A1DB&I)52E2(I!58[,33%2E2()!%49DEAB=.(4V:/+IO$B
M*ED_G?:/6C_5GC>-"ZEP)CI;/3@T==H\GCW%,T>P!9M+D:DT[G>STK53[2D(
MG9]ADHG[WE:PF&J'.NZ3C)P5/?(UM+;W]C-,1>-3;,^;ZK5>@)6N;]0CK,24
M]P^KWKK6IG/I_'3`TIV(1LW9I+YQ83YSK+)Y=:.'-(+`Q1W5&)#K!(-T%Y`4
M(ABYJFF"05(Y!FHJQ).L.<-AKH;HG,WP7#:?/#0\[XCK:6R[2:\NB>&,2RJR
MQB@BM,`5Y?]%G9>%3RLV8"R7:HJ3`<(EO#JW720KAXTIMS-"V0Y$`=7$57-Q
M(-VU*3)V+0H?\G!.6CC.1X>3VCI;FFP9NI4E8^)J"HHL/[7C\12X&P.4#/HT
M5S9@X<^KI^R9,"QB99D4KNV9[6CX$PT]'2Q=P6X]4!%R*VON8^)(!&4Q)XK`
M/"I3'N$%-!TUN&YG)VV?-ROXY8'"S4H.!AT1@OGTI8+N>E_FV:[TVL8T!;VD
M!2^UM93.:<BD4^=6@/Y?V.!J0QO*T)Q"\P4I'M.]MYHAH+$R@<5$,5T%8X6Z
M:TTN4C`WDH=,-F=M?).605+RB]+.J4V.26Y5L5.L!X0'GV/YX,=+`":AKG]-
M6*BICJB!I/OM,7C$2IV"[5Y9J5.A!9<-CJO7A(/D&/(Q5M/%TZIUKR)L?M@1
M!M@8.4(D0NG$1[&()PAC[$CB22O-(R*\$L\`N.9I/-*H'0E[%2FH(@I.,7I(
MI(N'5QQ=>8.JF?:=U+SBJVKM*EN>V,+(4\=KY>2#VOU4N+G!I@%V"Z`T;;=8
MIZPT/5[G^:I33U,HG6LPH0R>QR<EF)H'VE0[')F5*,[&V32I:P[`-3CBD>!H
MJ!\S9`.JTMG_28;L8R9XYRTJCD&(`WK98E$QLH5CN8W+48)XEVO(RKS'">5H
M40^KJ*UY>$5^1(IK'K4PHUWC!%:_4R,?:`&7A]8-,&KPTFS.C=1%TOD*XUR$
M4H`\H?*]MOTJI)C_%C+ZZ_5?2C?O#RJG9A4T\P`+_B#"L@HWYF`74/-A)I1M
M:_PVOIU?X<JB"D(;`DR$4#Z-"<&7.U@4_+0]ZG,Y!1V1.:<8-(P5Z@$66.;=
M]BB`Q]14N/<D'6]Y"F$G1-UP^[^.L"(#<!P6<I-(*$D->4"P:5H)+J#D75$(
M3TT&C6^R6,B@;'_FB2^?;7NV%FNVE"Y\6S;9*+!5;M-*ULIF'&SW`>PW('=O
MX>_=DNU.T/".^/`$G_ZOM0OMW0HC/KM<9("[5?:."[>@Q&T'N'-DM=_!G=86
M\<'D6O\Z65FA-03WIK(@G[:5E66X(>XF(KA@YMY65I;.1Z`MD04WMFDM*\MK
M(]SKE>,RX'KNMKB@29PC1SSW8T'NC3([LEV1.2Y46007E97;$9@C.J+*;67E
M=@3#45F@<EM9N1T!(9%E0"=M9>5V!"M06>!N;65E=C3`<$366)#[RU([\KZ*
M6YA$<%%9N1UY7QT)^BJ5E=N1]U54N2VNW(X@E?!EP!=M9>5VY/.$(9@GJ(ZY
M'7GNQX+<'V94WN.'@AX?2\EM!^\(1SA'$.$HEI);C??RD:"7QU)R>_'^;0CZ
M=RPEMQ3((QH9\(6X1IF-1CR[AB"["VN=9EW>87"<$8$!SWI;[5UX!E^`3_!C
M6_1P09LHA$6QD*0G>_596\(=US)!?#S@,"HBZ/9YZUJ^%07ABX;;\C)QO-''
M@N)^'P091[R$(7P4`?0'>-XA/$I1`UYBAG@?QBU9;<1DL<#3@S5@&S'0.D;#
M^Q^NN;01`ZUC,7Q2Q?I)1,P'?[O/+,3G4ARZ141\=/S/]IKW')[A(8`4D71G
M[Z/0ROR/#ZFA(#%W>)^^3`:?(N)')Z4W%4SJSSNX+5]*(FY9)+&#-;0(\#_M
M(T(CMB)"<&(O(N3>B>#.L6D0<R(0EI"(`+;*9B(.,HJ@C+]8H8_1PH7N@8]6
M:)1O/(;J?_V<W[.1\1[A$T'9W1RS^0`0M;8WUMZ-[K,OYWK^_H_LGLS@3,FO
MOG>^!!$3,=?S]Q_Q9M<0Q7":#=+-QQW<0!G^:OO0F>O_NEU,9N]OS>'%M+^8
M7A@C>WPQ&R_>7XR-Y>+]>W/6'_:7_P;*\/&I5_#\S0Z/)V6/486MQP/C:N?"
M0TS#1-D$_*?\V%PG'V+X[`ZW`!NV!*5*]';9XUUO_@,``/__`P!02P,$%``&
M``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/
M;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z
M89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#
MB*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;
M*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68E
MPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(
M6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!
M*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU
M4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&
M9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)
MC]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-
M5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^
M]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E
M\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X
M#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6
MQ!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/
M^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,
M2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z
M%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ
M@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*
MNE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"
MOZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!
MO<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&
M2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!
MM]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8
MD;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;
M<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'
M*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-
M,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4M
MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q
M2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6
M'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#
MI#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;
M>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-
M9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4R
MX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(
M.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNU
ML&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8
M/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`<@BN7)0#``!)#```&```
M`'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;)276V^;,!2`WR?M/R"_+V!R:Z.0
MJE!UF[1)TZ[/#CB)5<#,=IKVW^\8$\"F6>E+$N#CG,_''..L;YZ*W'ND0C)>
M1@A/`N31,N49*_<1^O7S_L,5\J0B949R7M((/5.);C;OWZU/7#S(`Z7*@PBE
MC-!!J6KE^S(]T(+(":]H"5=V7!1$P:'8^[(2E&3U347NAT&P\`O"2F0BK,28
M&'RW8RF]X^FQH*4R003-B0)_>6"5/$<KTC'A"B(>CM6'E!<5A-BRG*GG.BCR
MBG3U>5]R0;8YC/L)STAZCET?#,(7+!5<\IV:0#C?B`['?.U?^Q!IL\X8C$"7
MW1-T%Z%;O$KP#/F;=5V@WXR>9.^W)P_\]%&P[`LK*50;YDF1[0^:TU31#&8.
M>7I&MIP_Z%L_PZD`DL@:T$GDWW.:VU!G\=LT_=_GE/?UM'T37D9WY)BK[_ST
MB;+]04&F.91!5V.5/=]1F<(T0*Y).-=14YY#"/CT"J:?)R@C>3)V+%.'"$T7
MD_DRF&+`O2V5ZI[ID,A+CU+QXH^!<!/*!`F;(/!],M?#Z>B;@:P-X+NY&8=C
M#7PSFKI0=T21S5KPDP>/*?C*BNB''J\@\,O5@#)H]E;#$5K"?$5(PI0\;H*U
M_PA%3QLB-@1\M@2VB>1,Z'D#AU8$2C)>1,-:1$^3-HO-B7[>T,D[)*8M88E`
M%<:+:!B>A-YXW8H88M8C9FW>VCWY'V&909#Q9AJ.$(RZG8FYG3<V1-]L81/)
MD.C<+3/H@/%F&K;-EG;>V!!]LRN;2(;$!;/%6\PT;)M=VWEC0_3-L#/AR1"Y
MH`9]-+YH&K;5L--9L4'F=5_.\'SF5#4QU_ON%\3T>W+TFJ!A1\QIO=@@_<2X
MZSW3`T/D@MOU6]PT[+AU8<W"81#+S>F39(AT0:PNP/`F&U^XFG;LG`:,&\;2
M<Z?U!>:2GUY[1T\L-BMU?P7!3AO&#6/Y.2V3O,!<\M-K=,]/OZ*G4--77DIF
M9>][ADY/QM@P?<_.P3R!#;*HVR<,IO,EGG?#M>=9K]@]SU?\S/IN^;FMBX?O
M@-#IHN0%IAN#[0?C?(.?INWG,'3:,X;=G&;Z]0N[Y$T!ATR'&#^S43/[CX**
M/4UHGDLOY4>]\<)0^O9LNY-LMGCM!=B3561/OQ*Q9Z7T<KJ#6X/)$MX(PNSJ
MS('B5;V[V7(%N['ZYP&V[!1V"\$$X!WGZGR@]R+MGX#-/P```/__`P!02P,$
M%``&``@````A`(6^'-6R!```:A0``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C`N>&ULG)A=CZ,V%(;O*_4_(.XW8#Y#E&2U8*9=J96JJA_7A#@)&L`1,).9
M?]]C3!C;R=J9WLP$\OC%K\^Q.3GKKV]-;;V2KJ]HN['1PK4MTI9T7[7'C?WW
M7T]?EK;5#T6[+VK:DHW]3GK[Z_;GG]87VCWW)T(&"Q3:?F.?AN&\<IR^/)&F
MZ!?T3%KXYD"[IAC@LCLZ_;DCQ7X<U-2.Y[J1TQ15:W.%5?>(!CT<JI)@6KXT
MI!VX2$?J8H#Y]Z?JW%_5FO(1N:;HGE_.7TK:G$%B5]75\#Z*VE93KKX?6]H5
MNQI\OZ&@**_:X\6-?%.5'>WI85B`G,,G>NLY<1('E+;K?04.V+);'3EL[&]H
ME:/$=K;K<8'^J<BE%SY;_8E>?NFJ_6]52V"U(4XL`CM*GQGZ?<]NP6#G9O33
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ME`V"+!2"@5"B..5,(#"*C<Q(8".1ZPC))TQ$C6CPPSUXC2@;M+%A,>>D\X-(
M\<F9:$Q;Y'I)LI2!3`(BV&U*L+`$(!0A9:%R"5@&(8KG1T@>P8_H49^M#)9C
MZ`<?NN,&2CD#CY_]*U/+C`0V$KF.D/Q%G_''8#5V2FA2SO#8)4$8)>JQDXE$
M['FQOU0TL$C<U<A%0M60_,'I)L:/G:;F'&6#5)_J7N1,,N:HYR^4,&?\:TV8
ML5X@UPE(#EE)H[POS.<J&R0[1*$[[P">J9S16,B,!#82N8Z0?":R3_U.9+!I
M)W)&Y\](8".1ZPC)'X*7H1A(O<&1EB/H!\H^2B>(;T;8)DF8*$'.)"1RHS#Q
ME?,(2\A=E5Q"5!79)2L//IVNB!<5XEL#A4KAD4Z0+J!F!)N17(O(;EG1(+@U
MQ)27&/#^G=\-M^\/Q"&M2R."S2JY%I%=LHKA<9>\OH`Y"BYO,I=#/'/]R!5*
MK?%PRI`!P"8@UP"R.UCJ3[ACM+POD5J=I(A#VA@:$6Q6R;6([))5#(_'D-<7
M$`,AALHK,&6_QV`IM"Z-"#:KY%I$=LGJAL==\BK#D*EB*1(LW3CRY?=HAB3"
M]9>!<G)AF;BCD<N$K"$[9'7#XPYYE2$Z1*$R_Q3I2I%I-QH1;%;)M8CLDE4-
MC[OD-88A6W6%R.32B&!D1'(M(KMDM</C+GFE(<;R3D7`H>FG58Q<\8?/Y%)$
M8@_R02E],31VV,;6B+#>SP>BB'"/O+7#.Q\-Z8XD(W7=6R5]86T;#^KJ^2YO
M*:5H!>T(Z"HH]S%K-8W-HOD+Z/2<BR/YO>B.5=M;-3F`I+N(X;3I>*^(7PST
M/#87=G2`'L_X\00]/0*-#G<!\('2X7K!VAESEW#['P```/__`P!02P,$%``&
M``@````A`%_#5YK]"0``V"H``!D```!X;"]W;W)K<VAE971S+W-H965T,3@N
M>&ULK%K;;N,X$GU?8/_!\/O$NON")(-8=V`66"QF9YX=1TF,MJW`<CK=?[^'
M(BFR6$KB8/NEU3FL.F1=6"S1NO[]QV$_^=Z<NEU[O)GZ5]YTTARW[</N^'0S
M_>^?Q6^+Z:0[;XX/FWU[;&ZF/YMN^OOM/_]Q_=:>OG7/37.>@.'8W4R?S^>7
MU6S6;9^;PZ:[:E^:(T8>V]-A<\:?IZ=9]W)J-@^]TF$_"SPOF1TVN^-4,JQ.
MEW"TCX^[;9.UV]=#<SQ+DE.SWYRQ_NYY]])IML/V$KK#YO3M]>6W;7MX`<7]
M;K\[_^Q)IY/#=E4_'=O3YGX/NW_XT6:KN?L_&/UAMSVU7?MXO@+=3"Z4V[R<
M+6=@NKU^V,$"X?;)J7F\F=[YJSH,I[/;Z]Y!?^V:M\[Z_Z1[;M_*T^[AC]VQ
M@;<1)Q&!^[;])D3K!P%!><:TBSX"_SY-'IK'S>O^_)_VK6IV3\]GA#N&1<*P
MU<//K.FV\"AHKH)8,&W;/1:`?R>'G4@->&3SXV8:8.+=P_GY9AHF5_'<"WV(
M3^Z;[ESL!.5TLGWMSNWA;RGD*RI)$BH2/!5)$%[YD9<(C@_T(J6'I]*+S-P?
MZ(&U7S2>2L^/KJ(@GB_Z57^@F2A-/)5F>+6(XRA9S#]>ZEPIXOFEI6*?]4O%
M\XM+72I-/"]:ZDQ&MD^4;'/>W%Z?VK<)=A]BU[ULQ%[V5R#3&2*]-.3,>RF#
M7!$D=X+E9@KSD0T=\OS[;1AZU[/OR,VMDEES&9]*I%I")**@S5P@=X'"!4H7
MJ%R@MH`9G#!X`DG^"SPA6(0GM`UK#1C7!([96D*K9"Z0NT#A`J4+5"Y06P`Q
M&]OR%Y@M6%`=K`0(%HZ=:R6#*C9D2>2X8A`9?,&0G"$%0TJ&5`RI;81X!`7G
M%WA$L,`CR+;!VC!T,GZMA#YRR2`RN(0A.4,*AI0,J1A2VPAQ"<J?[9+Q\T,7
M`R'<6ZY7O%8('I8OG/1(!R&MEC$D9TC!D)(A%4-J&R&&HO1?;J@0IH8J1)ZE
MHH2E#,D8DC.D8$C)D(HAM8T0JU"8+[=*"%.K)!+#:4/X@D7B;%TIY"^'RI<I
M(AQN@YH_=Z*>2Z'`ZP^-*/$\Y]@H;%YBE&A2K9/KXYP4PM0HB<0HB\/J@L7<
M,4H*^8$Q2B(15F6I+:A:/@CI5"X4D5T-@L#,1@S#,6P;)H[D(!$-VCM]F]YW
M0H_:*!$G<$NZV%0*V8&32(0U&QN73ESR06BP42(A47O/1A\ECQDIG/J\VWY;
MMY@7KAH):8@\42V'8*#F]J0W4QK3I5-S4R5E!U5!R:+/0C]<.#JY$1BL)30D
M?K[H,*S,O#B`O:)CDN""263O+9U-E"I%.X8*FOMR8_ES=\/F1L+8)&>3/-0F
MT3ZX-GTM7K(!P8&HIULC!+UQ9`\N0R<_E12)EU1,<%Y9&>HT$[E2A)2>L=!<
ML-,HOINCHD/X_VQ6/89MLX2<@,:NS5**!%0IHL@/2^?EU)=222+#[GF10UTH
MB;$8B^/?L=>/K\2[3[\M_VQ?WMN6*$[#OE1-A.WB,'2"NO:'5L-8X\0O-3(Z
M?AF'<@X5'"HY5'&H)A#-?SC!]4T07P']ZIN2('+VN(+P&"(;>FR/#U+&&PS*
MQ=N]H#<=2,&ADD,5AVH"46^(3L/*E)%";6>$ZDOL76"W*GT]3WT&91S*.51P
MJ.10Q:&:0-0^T71<;I^0=D(JH2`92D_J*\B\&F8:(B>F[QZT1DH'OM"0X2HU
M9'.%GK/M*B.EN6H-]5S4"^#Z@A>$M.,%"1$O*,BL//,5A,>0_H'/3N!!2J^\
MT(J&J]00Y7(\6ADIS55K:,0+HJVQ<D'>D)BJ>%FSHGHC>PM(B#A'0<:@#&5:
M>#7I[_GZC9)SJ%!08!1+#4'_?:]61LIXPEX$R0<TZ<03'^_Z7IKF@X*P[_1L
MJ8:L#EM!D9'*.51PQ9)+51RJB2*U3W0_5J0_L4_V2G8_$TC(.=N=HUT)P?/:
M"9F"2.?,CW8EA?6+^S5_Z;D7+`6G+B^BKBAUO/2MEJA/NII04Z^)7NQRK\G.
MC7A-0J1K=_N%-)!"=A.HH+EL=8)YY!2[W`AH3Q><IE00?:/SG*ZI,E*:JR9<
MU"6B";O<);)E(RY1O1[I",S;HCPP`RE$$DE"<YDBX3QPS,B5#@2T&06G*8V4
MR+0@C)S.K#("FJ8F--0;3EOYR;8:VD=-O0XD1!/$<]:4*BF2(5(1H>UW3.AX
M,%<J&-=S%9RE-%*"9>Z\/E=F6)/4A(3Z0K1GEV>&:N:L4T/<`N`\("4F<LZW
M5`F1S)!Z*C,04O:*JY1(:D@EBZ=44O1N@.\6J0@IXQ.;B_KD2\TDSDNWS5`0
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MI7.I7!D13503(NH0IY>]^`X2Z>%6$P61+(G=)%%"=I(HB)2!T&/^D1-:9:#0
M:\!>,.\N;DM:CM,SKS'Z^C-ZZL@OM;<A;V\51#(K])PN(E52)+4D%RD8(;L=
M4(I6P2@T%RS_R'V27M>U.%PZ'56E>*RZ5FOJ_G6-^DFTGA?7(GSTPK),M;/F
M33!54L0I3"KG4@6'2@Y5'!(?XXAUR1FE??+C&OG-Q*$Y/35IL]]WDVW[*CZ<
MB<7]^@#+KWK6\0H_,&*3NGBRPD]T'+_SH]4=9N8CN"9=B4O)L1%,@@NZL1%,
M(U^QG?FST%_E2'ZN@[VTJD9'LC"`3A\3AZW$B$@1SH:OFN[&\#6^=AJ;?1VL
M\'4"YUF'^#IJ!+^#NW"+/:(`;XTY*PL6*W%*<PV<RJMJ=`1'''3ZEW37<(R(
MTXFS9:$'9_7O5JX.1D0!']$)8LPS%DCTVIAG;"0+$NB,I1*Z4>B,C:"W@T[_
MIN.N#2/5Z$@6(/AXS>6KQELS=,9&LB"$SEAT\%H)G;&1+(B@,Q8YO'Q!9VP$
M=Z`K<>\ULC:,B(O.L1%$&S=]8R.(Z2@;[D>1M6/S9`&BC=N8$3:,B*LG/I(A
M$<?FSY!LHW/XF`._-(XP^=C,^`EO;`11DQ7,B?0:MJQ';<'M]"H='<$E-=C&
MO(F+6XR,6N/#',DV&Y:`[PI?-D_-OS:GI]VQF^R;1Y1/K[]'/<DO$^4?9_4K
MTWU[QA>%_0].S_B"M,''%)[XO>6Q;<_Z#Q@_&[Y)O?T?````__\#`%!+`P04
M``8`"````"$`Y$J1(E$)``"A*P``&````'AL+W=O<FMS:&5E=',O<VAE970Y
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M*GU>C!8C6+J[V>[@`85]<"J?;H?WP;*()L/1W4T;H#]WY7OM_']0OU3OV6FW
M_75W+!%MY(DR\%A57TBTV!*"\DAHIVT&?C\-MN73^FW?_+=ZS\O=\TN#=$_A
M$3FVW'Z/RWJ#B,+,53@E2YMJCPG@W\%A1Z6!B*R_W0Y#7'BW;5YNA]'L:CH?
M1P'$!X]EW:0[,CD<;-[JICK\I80";4H9B;01_/88.:,XT8KXU8K75\%D/*-K
MGU'#:#MI_&JU,+"3/J,XTXKXU8JSJWDP7D3S\Q><:SW\?F:>6&3M//'[N7DN
MM")^+YGG2"6UK9%XW:SO;D[5^P`+#VFK7]>TC(,E;)GB4!'JRN5'U8(R(2/W
M9.5V"-]1"#5*_.M=&$4WHZ\HRXV6>9`R`9=8&0FJ03(;^R#Q0>J#S`>Y#PH'
MC!"$+A*H[_]#),@*1<+X\&"`$QK/;2-A5&(?)#Y(?9#Y(/=!X0#F-E:D[W:$
M/:9_=S#Y)B7L`V?SK65@JRN*B>=Y)]*Y+D@B2"I()D@N2.$2%@#L+'X`:'O\
MY`H@*X@(BJOS5BX!+70N))U(%Q)!$D%203)!<D$*E["0P'TW).=K@81;S\V,
M'S1!Q3FQ\'/?"1FU6)!$D%203)!<D,(ES%'L\I<[2L+<44VB;K6O!(D%201)
M!<D$R04I7,*\PCY\N5<DS+W2!-7AI&_J+=U.J$N?((D@J2"9(+D@A4N8H]2B
M.C>O\W5*PMQ135330S><E2"Q((D@J2"9(+D@A4N85[@-7^X5"7.O-$'-.^F;
M>>GKA+KT"9((D@J2"9(+4KB$.1I@([S<TU::NVJ0DT&)8HD2B5*),HERB0J&
MN'_4:EQ<GX%J3'`+,3EYT"B<=6AED.TP8H-04#;CP9AG/+%2QGQJD+65&<1M
MA=Q6;J6,K<*@UA:/`G4>3A14BWE%_73SLMM\>:@P:_C>LWHCM)*ZP53M"PN.
M0BPX&EF'XD`C%*$3'*_S3*R4<2@UR-K*#.*VO#XWMU+&5F%03W"H+7&"TQ,$
M/.ET4=!-C%LB"@5NB6@4=E43!PI-K%0B4:H19FMFGDFI7**"*?+D4X]QN7^Z
M(W']4VC*M[,Y+\A5H*2"13?S6*/(K>1@[E5RHJ7"L7IH":?>LDFEY>PBRSFW
MC,='SW+!+/.@4;_B!(U63(B;X">6"UGP]DJ%:+>R"R&Z]@.II6P)Q-0,P]8,
M(;:*8Z\?2*R4J9U4(U9.?;:B!9]$+FT5QA;KKT-;!CQ^U!DY\?M@4>D^RBTZ
MA7C13;P$KK#F*#"LZ!2:!S\HIT3K0,"&29C)K!0]2D?SR"O;W`H8,P6;#0\'
M]4]../[9!JR;,#OQAT`A7E$3;VM=&2FWHI0BKZB)YV.B%2%E?$R-K1]507NO
MR*RB4["^^=Q*&?/%1^9Y5*E_^]=1)2/>.E7(JSWO)K,*E!2K/:V(<NK6:<^&
MIZ7FJD+]72F5AC.-IF<-YUIJ-FL-!Z)F"V:9AY(ZQ#.A_*-Z_5&'X-X<=9_I
M5JA"6!HFQRM$K%VT;CDJ-+<HT5(.2J5B)J5RB0JFR/S&78?Y?7Z?:J5YK6CD
MU8K_I*VE,`\3A=C80C&<J14MA9_VC=YX[.V`J;2<760Y_\ARP2SSH%&;?*98
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MGWT_CL=TL>-J!&-VQ_4;DI51=,/1*9H*2*14*E$F42Y1P1`/A]=)?U#ALF6F
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MN5R5^WT]V%1O].729((GU`ZKSZH>H@C?5;5'LV)D8KZX\D?"^9)NCZAK,7*-
MD>O>D05&VF=K7R<:XSKMQUEBA+[Y:E]4B)$0(^V;"'\$E^F]2H"KX!U<WYP1
M`;3K?2.(`+K:OI$I1MK`^]</9QAI&Q=O!!^PW??.&$[V^@@7>^4I83USNI\L
M[U$2/9.%%[T</O2Z``_Z''A`UGN3CISWI3P.YDMZ/2EGA'>/2WJS*$?B8`&=
MO@3B-1)T^D;P:F%)+PZDM0PC],PO1W`0AZCWA1>'0)A!7X!QRH,9](W@Y3]T
M^F*9881>U,L9Q,$,.GUQQGMMZ/2-X*1S^=`[:QQX+E>](SCWQ'7Z8H!#/XST
MQ0!'GDLZV9.SQLDGYM9G#<=^&&EU1EWEXP/)U_5S^=OZ]+P[UH-]^81M:-P>
M:I[4)Y;JCT:_NGRL&GP:V;[%?,&GL"4^-AA?8=]]JJK&_(%)C;J/:^_^!@``
M__\#`%!+`P04``8`"````"$`!)%CD5P4``#$;0``&````'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;*R=6U,C.;+'WT_$^0X$[PMV^0(XFMYHZG[?V-AS]ID&
M=^,8P`1V3\]\^TV5E"6E_FJ#V7D93_^4F:7ZZU)*U85/?__CZ?'D]_7K;K-]
MOCZ=GDU.3];/=]O[S?/WZ]/_^U?VM\O3D]W^]OG^]G'[O+X^_7.]._W[Y__]
MGT\_MZ^_[1[6Z_T)17C>79\^[/<OJ_/SW=W#^NEV=[9]63]3R;?MZ]/MGO[Y
M^OU\]_*ZOKT?G)X>SZ/)9'G^=+MY/M415J_OB;']]FUSMTZV=S^>UL]['>1U
M_7B[I_KO'C8O.X[V=/>><$^WK[_]>/G;W?;IA4)\W3QN]G\.04]/GNY6Y??G
M[>OMUT<Z[S^F\]L[CCW\`\(_;>Y>M[OMM_T9A3O7%<5SOCJ_.J=(GS_=;^@,
ME.PGK^MOUZ=?IJM^>7EZ_OG3(-#_;]8_=\[_G^P>MC_SU\U]LWE>D]K43JH%
MOFZWORG3\EXA<CX'[VQH@7^\GMROO]W^>-S_<_NS6&^^/^RIN1=T1NK$5O=_
M)NO='2E*8<ZBA8ITMWVD"M!_3YXVJFN0(K=_#+\_-_?[A^O3:'XVG4^69'WR
M=;W;9QL5\?3D[L=NOWWZM[:9FD@Z1F1BT*^),5N>+2XFLZD*<L!Q9ASIEQTG
MX\$/^,V-'_URI:_.+J:3J]G%X0-2Z7"V]&L<I\N#-:32P8%^^4@79Y>+Q7QY
M^<:A+HPG_1K/R[-YM+BX?$L4&IG#(>GW?76\,@[T:QP6[Q%Q2GU--[WJ=+I=
M#XLQ'3L+_8_QN'K?24VYCZC_,:ZS=[7UE#N)^I_W59.[Q]3VCS>:68T8K87M
M&0>K=ZZ'T3`JD]O][>=/K]N?)S35D3*[EULU<4Y7*BJ/1]V;QQ'ZJP%*(U-%
M^:+"7)]2WZ'!MZ-9Y??/TXN+3^>_TTQP9VQN`C;2(F8+->Q5V,0'J0\R'^0^
M*'Q0^J#R0>V#Q@>M#SH?]`XX)ZU'P:D__16"JS!*<);JAH%M@<A3ERW8)?%!
MZH/,![D/"A^4/JA\4/N@\4'K@\X'O0.$NC3F_@IU59CK4_KO@>YL;&@R&HWF
MGN*CR2@YD!1(!B0'4@`I@51`:B`-D!9(!Z1WB9"?)K"_0GX5AN2G(31*B].)
M,3JD_V@RZ@\D!9(!R8$40$H@%9`:2`.D!=(!Z5TB]*<)7.@?7E7QI*VL!YE9
MGAM#:'0YPE]ZO7HT8K<$2`HD`Y(#*8"40"H@-9`&2`ND`]*[1*A*JXPC5%76
M4E5#9N-D'0-)@*1`,B`YD`)(":0"4@-I@+1`.B"]2X2$M#(0$JIE1K0X(\F/
M7&BH0%)=0RB4TV>OO#X[&HU]%D@*)`.2`RF`E$`J(#60!D@+I`/2NT0(KO)E
M=UUW>"90UE)50W0*IM9B,9`$2`HD`Y(#*8"40"H@-9`&2`ND`]*[1$A(^8F0
M4/79V:5*2X_MM"J2E-<0T6DO)UZG'8W&3@LD!9(!R8$40$H@%9`:2`.D!=(!
MZ5TB%%<IGI#\<*\=S*6NC)Q^BRA!E"+*$.6("D0EH@I1C:A!U"+J$/4"24E5
M'O+^B4"ES%Y7-6A)K68GV,NIUU>MU=A9$:6(,D0YH@)1B:A"5"-J$+6(.D2]
M0%)EE8\<H;).7VB!RV+=J'T&$IY49A0C2A"EB#)$.:("48FH0E0C:A"UB#I$
MO4!24I5D'"&IR4E<237R.JZ?%:MM&BE\@BA%E"'*$16(2D05HAI1@ZA%U"'J
M!9(JJU3B")5-YN&JK)'HN(`2M;4E54X198AR1`6B$E&%J$;4(&H1=8AZ@:2D
M=%$_1E)E[EW$-/(Z[LR?<4<KGC$2M8'GJPPH0ZL<48&H1%0AJA$UB%I$':)>
M(*FR2C6.Z+@F,W$[KD:BXP)*U$:L+RF@#*UR1`6B$E&%J$;4(&H1=8AZ@:2D
M*IEP)?UPDC8U:8FK]IBIN*L(?\.,'>WR+4&4(LH0Y8@*1"6B"E&-J$'4(NH0
M]0+)!E"IB-L`;RQ_3>;BJNPF,\,6>CP%E"!*$66(<D0%HA)1A:A&U"!J$76(
M>H&DI"K7.$)2DYJXDH[9BMMQ%_YD/%K9R1A0.@64(<H1%8A*1!6B&E&#J$74
M(>H%$BI'Q^5M@[F\Y#&R`S]&E"!*$66(<D0%HA)1A:A&U"!J$76(>H&DI,?E
M;1'F;8QH`>#D;4NOXUJKL>,B2A%EB')$!:(2486H1M0@:A%UB'J!I,K'Y6T1
MYFV,W(YKK"Q*T"I%E"'*$16(2D05HAI1@ZA%U"'J!9*2'I>W19BW&10M;2K,
MR-[O3!"EB#)$.2.Z+CKCPKM975@K'A<EH@I1C:A!U"+J$/6,AM.6*JM\RKVN
MZ?OV9^HAC_W#YNZWFRV='$T*@27$C.[/Z[OVD<[*W'T(@X3XVBIRQ0>4LJ.U
MRA#EC.A"Z(COW6$JK)45WQS1[H]4:%4C:A"UB#I$/:.`^"JG<L4/B$R[Q*/*
M.@43*FLD5#;(ZI>HG6;*/2+94[U;&ZFU8K$R1C96;M!"Q+KR=IP+:\6Q2D:N
M\+I>7BSORE*SX_`PV=#?&D8V5LM(ULN+U5DKKE=OD.Z5<FRH_.R(YM'IG&@>
MC43S&&0E3:C8-`]7*D64,;*..2-YSMZ.:F&M.'S)R,:J&,E8WFQ66RN.U3"R
ML5I&;JQHXM6KLU8<JV<TQ))MX>>4;PP53!RI@0>5W:N!0;;J"5O9SI8BRAA9
MQYR1>\[3*V^3L+!6?,XE(QNK8B1C>9-;;:TX5L/(QFH9R5C>V.^L%<?J&0VQ
M9%M0K&/&A3+W5ND:47/SX6(U.:DYRE8]8>2VA;&R*&,KZY@S(F-[<;CR]KT*
M:\65*!G96!4C&<O3K[96'*MA9&.UC-Q8T<3K(YVUXE@]HR&6;`N5"1XQ1YG$
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M\V4<Q0;.&1T,7-C`]O#1Q)MW2HYEPU>,#H:OWQ6^X5@V?,OH8/C.AA\>2?=E
MZ3G*$%BVN,HWW0OTQZX3.FNEX<OM>3/3:.%6?.ZMUV-C1#NN[)<8M(R&%HXN
M+[TV2*T!^V08)C=H[EY'H#T+:\6Q2HQ56:L#?:.V5ARKP5BM0;\\O<X:<)A>
MA)&MIS+4_[[U=)XK6L^DOC2-CJ,QFGCI:CS35F(8:S2GF6%T#`QC8S4?&GDV
MF7O)0X:1<X,.1RZ,U<(]/K1[B>&K=X6OWQ6^P?#MN\)W;/4K77H1678%E:4?
MZ@K_VK[\:J>,]AAX$V>FDWW1%TS^/Q\':6RLQ+C55DO[]&]JK!R4H6..5@6B
M$ATKM*H1->C8HE6'J!>.4NKCDOT9)OL&J0W[<91$$Y@=M:,87AK-[9Y[:F(Y
M*#/(<<S1JD!4HF.%5C6B!AU;M.H0]<)1JDP+-=&A#V^IS)2YEZIH)"Y!@;6(
MMA)]V<2BG[%Y`I.8L;K2:Y%+;Y&3F1HY@7.NY,'`!5L=O':5&+YBQX/A:[8Z
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M=2^=C8?CT`Z2LU=K$&4%*H.(SJ"AS+%D8%AB&RN3,)Y!;WTCBFA(E>,=H<9@
M+AO2(+DW,_6W/HV5D^<E!M'26*EQN3CS+D<I^XA=GZDOAPQS-3OS#/*WPD@]
M_.7XX8ZM]DJ\CFV0O&\V]?>JV,KI'1Q+M^O%V<+3,$6?3/I<GLV\+I4+'WFF
MQZV&%[@:-LAK>7\U;*Q$R^M8IN7]:9H=WFCV0S'RMV)()8Y;L:J]<K_-#;)7
M^9BM+$H0I8@R1#FB`E&)J$)4(VH0M8@Z1+U`4M+C5JP+7+$RDI<V;XJ(K=6X
M8D64(LH0Y8@*1"6B"E&-J$'4(NH0]0))E=7B\OU78;4GY'=<@VPOC=G*H@11
MBBA#E",J$)6(*D0UH@91BZA#U`LD)3UNQ;K`%:M![LJ-D5V?)(S$I3Z"J=`L
M=>UC6AD[VE@Y(S?6U+^G75@K'BHEHR&6E,%?U[YQ&<0%[,*L5FW&'C.R54\8
MN56/(N\BEEHKKGK&R,;*&<E8WNJHL%8<JV04D(%BB0'VH>6]>B#:'W<:B4YB
MD#VCQ#@Z#V2EB#*#G+P@9T0K0;M"]64MK)65PJV$[!%J57G$7&,6H<X3#@N-
MW!4_([N63PRBE(LKE2+*T#%'JP)1*1S%"9+*QYS@8"Y7P@:IR<51W4NJ8F/E
MY@4<B\0?'7'KG:U,]N`W9X:!<W8Y&+A@*QUXX<\<I0@L-3MNM4R/A/D#P2#U
MH9+QU*/(SZ78RNDG!JD4U3KZ#R"EUHI[4X:Q<FNE,I$+;P5;V&(.4HH@4A)_
M6?VA*8.>=P&E-%K*WN4E.[%Q%+W+K)3E9.`G%\:14E0^R8PKX?:>*/(RF=PZ
M.@T1@89C)3A\^59X*>MQ:W1ZA@+TTTAE!K;#1/Z"TCBZV8I!2WUO9^K?MTYM
M.9]:AE%R:Q6\>UC8<HY2BBA2C>.6UW1#%M30R.M-,.ZTE>A-&JG]%2LCCKO1
MBL\F,Y5P8N4&42RER6SN]<G"EG.44D21FJBEK'N!^MC`,PMBY[JE-*++MS=%
MP<`S5NX4I9&JLI5JYJ_Q3'BRXI/,^(@B`\:!9\)K]:97ES#F1@..7')DW!9;
M^@O?C\F'Z^$A\/6IO"KZ^Q2QL7)Z1\*.%'*4+W!5U$>D-9SJ0[#LS3!P_J[`
MA;&B'Q48'ZPL1639%?W5LZ_E^^[ITHP#P]8@FYS%;&51@BA%E"'*$16(2D05
MHAI1@ZA%U"'J!9)2TSPD1OWA1(4^80^2&D2#9>QFT<Q+&V)V=%4>'7EXI6B5
M(<H1%8A*1!6B&E&#J$74(5+?]Q_$&<Y1JZR_UZ^_#/ZT?OV^CM>/C[N3N^T/
M]2W^*:WE/W\:N?Y+`3>+^4KM69`H4+*@DB&Z7[*\H#\O,&0^4'+)?WC`+YG3
MGR2@F_V!X\PC*AFF./"94<GPR"644*WIWF`H&M6:;G$%2A84C?;``B53.A_Z
MH$NHA,Z']H9#)5=4,BR__+I%DY7Z)$3`)R(-:/\U5$(:T-OX@9(I^=`GZT(E
MY*-7/GX-IG2F]+6PD`_I1O?=0B6D&]U@"I4LJ61(\/SCJ`X2\B"'H#W)'%29
M1`YJ3!('%9Z2PG2!Q[HFR_DJU==FKZZT>EFI%4K(9T$^H?/(EPOR"970W]?X
M$FXMJEC@&#>J>4.<&BK43E_FJR\TOK&R-ZK?!WBRG-))A`Y-Z1*=1*@D64;D
M$ZH690GD$RI)EC/R"569ELSD$RQ9+%=J/PO/AC:!J"34)6A/A$I""M`VV*H,
MEM!FQ$KM/H2.<T710B4W\^7JAK)2](FI)`Z6T)WI51HLH5O/*W4;%J/=4*UO
M@K6.J20.EM"N(YU/2#?:B*.2T'%H$XI*0KK15N1*;3YAW9(91:,GE;&$GJM>
MJ0>IL80>G%ZI)Z6QA)Z,7JE'H;&$'CBEXX1:@1XBI>.$2NB14#I.J(0>\*3C
MA$KH)1LZ3FB4T'LS=)Q0";T%0\<)E=`[+72<4$DRH_:AY^CQ3.FI?SI.J(0>
MZZ?CA$KHN7TZ3JB$/I)`LT1PNIO1J-?WNOWICDK42X]8-WK)D6H0*J&W&*D&
MH1)Z29".$YH/Z"U`.DZHA%[SH^.$2N@]/CI.J(0^+;%2;ZQBK>D+$ROU_8A0
M">FF=V8]#>CM>RH)]41Z%YQ*0F.!WDRFDE"OHM=FJ=:ANM%;O:1!J(0^N[%2
MK^YBK2LJ4=_6")50#PF>#WV9@$I"YT/OR5-)Z'SHK6TJ"9T/O3],[1.J&WVP
MAJY6H1Y_0[6^"?K$5!('2^C[)]1W0L>A#YRLU$O2J`%]YV2EOF(2*J&1%52'
MO@%!)2%UZ(L$5!)2A]Z/IY*0.C>DP4U0@YA*XF`)?<QHI3Z@@[6F#QBMU'=T
ML(2^8T3]+7C5C&C>T3[G8\>FOZ'U<OM]W=Z^?M\\[TX>U]]H73\9OA?TJO\*
ME_['WKP-]76[IS^?-;P8]4!_+6U-7X"?J,_U?]MN]_P/JM3Y^/?7/O]'````
M`/__`P!02P,$%``&``@````A`'8\R2YC"0``4RP``!@```!X;"]W;W)K<VAE
M971S+W-H965T-RYX;6RLFMMNX\@1AN\#Y!T$W:\D'G2$[84EGID`0;!)KF6)
MMH211$&DQS-OGVIV-_OPTUISDIOA^.NJ(OMGL;K8XL/O/\ZGP??B5AW+R^/0
M&4V&@^*R*_?'R]OC\%]_1+\MAH.JWE[VVU-Y*1Z'/XMJ^/O37__R\%'>OE6'
MHJ@'%.%2/0X/=7U=C<?5[E"<M]6HO!87&GDM;^=M37_>WL;5]59L]XW3^31V
M)Y/9^+P]7H8\PNKVE1CEZ^MQ5P3E[OU<7&H>Y%:<MC5=?W4X7BL9[;S[2KCS
M]O;M_?K;KCQ?*<3+\72L?S9!AX/S;I6^7<K;]N5$\_[A^-N=C-W\`>'/Q]VM
MK,K7>D3AQOQ"<<[+\7),D9X>]D>:`9-]<"M>'X?/SBKW)L/QTT,CT+^/Q4>E
M_7]0'<J/^';<_^UX*4AMND_L#KR4Y3=FFNX9(N<Q>$?-'?C';;`O7K?OI_J?
MY4=2'-\.-=WN*<V(36RU_QD4U8X4I3`C=\HB[<H370#].S@?66J0(ML?S?'C
MN*\/CT-O-IK.)YY#YH.7HJJC(PLY'.S>J[H\_X<;.2(4#^**('240=R1XT]F
M+,8=/T_XT5'XN;.1[T[GB^;L=SQ]X4G'7F>DZVFF2\>>9YP)3SH*S^E7IC@7
M;G04;HX[FCN3I3>_KPT]H,V5TK'GE2Z%)QW[7*E#N<=3@26AN,VD[YV[X+39
M0__YVE6.>?XUZ1QLZ^W3PZW\&%"-H`C5=<LJCK-B<64B\].WJ?U99E-*LRC/
M+,SCD-2FI*WH<?S^Y$RG#^/O]`CMA,VZP\:TV$@+]KRPL($-0AM$-HAMD-@@
MM4%F@UP#8]*I%8L>M/^'6"P,$TM.<RV!4L^UE)$6TB6P06B#R`:Q#1(;I#;(
M;)!KP%"&2@DH0_7WDWHHLX9Y4>6[FS7"AF*UJ>5;XK0FK3I`0B`1D!A(`B0%
MD@')=6*H1(\UJ,16C9X/&PM#LE&6MI+@TR:,[NG6FK2Z`0F!1$!B(`F0%$@&
M)->)H1M)9.C6O<K*K&+6C3QR6FM!*'DUP696%K5&TBT`$@*)@,1`$B`ID`Q(
MKA-##5H*>ZC!K$TU!/':^K,!$@`)@41`8B`)D!1(!B37B3%U6F!Z3)U9FU,7
MA*35$F%N)4)KU"8"D!!(!"0&D@!)@61`<IT8:K"7"7WMOO]8,&M3#4%X?\K6
MVPV0`$@()`(2`TF`I$`R(+E.C*E3DV5,G;4M[G1$-[9G+66!3%4$,7-D8>5(
M:]3F")`02`0D!I(`28%D0'*=&$*Q]M)0ZGZ2-.:F'A)I:8(H0!0BBA#%B!)$
M*:(,46X@4P;6TNG/"DL8;\%>SOIF#.N2K921R,R9I94SRJI-&D0AH@A1C"A!
ME"+*$.4&,E5C[9ZNVI\D#^\.J3&1$UP[`NG)`RA`JQ!1A"A&E"!*$66(<@.9
M,K"&3I?A?T@>T1OJ$@ED),]L8B=/:R6U#1Q`(:((48PH090BRA#E!C)58^V<
MKMJ?)(_H_G1E!-*3!U#@``H118AB1`FB%%&&*#>0*0/=5T.&7UZJV)N"77@$
M,G/'L7.GM5*Y`RB4X97:$:(848(H190AR@UDBL8ZP!ZY(QI&/7<$4K/9.(`"
M1"&B"%&,*$&4(LH0Y08R96"M7P\91*>HR]`VCUK'.[-W%YS62B4(H!"M(D0Q
MH@11BBA#E!O(5(9UACV4$8VDKHS>6S:[31L'4(`H1!0ABA$EB%)$&:+<0*8,
MK._K(8-H$W49.')G[9J]<012&U2!0*S*J1>GF6?6F1`=(XE(6<W1VAF,E97,
MOT0B=1&I1&8LJ\O*E)6,E4O4Q#+T<_MUQXVYV1T+I.LGD;KT0"!+/VL?*T3'
M2")SSM;61:RLY)P3B=1%I!(9L>96HY$I*QDKEZA#/[NMOK_&N]@Z"V3HQZU<
M=>F!L/+;)`VEGS**)#+F-[/>[F-E)>>72*1BI1*9L:R$SY25C)5+U*&5W4RS
M1L"9CM@/$O7AN/NV+AGHW#/U:$N=;[2[V&,+9$C(K0P)A:.:9"@=%8HDHA*@
M/:_6VV^LK.2\$XE4K%0B,Y:5])FRDK%RB3HT9"WOU^N=*SIDK=X)1&NN/-U&
M(K=%@41J-J%$RBH2R%>Q8D0).J9HE2'*#4>S;+&6MX<,HD/69>"(K2SJ/L_M
MQM$55DM-&8ZH)#0_\G@+W^XF0O2*!/+,TUEM2"RMECSV:&;5]@0CI]+G;N1,
M6O'(KF<E86X$-J5FC7(/J45?K4O-$2L,FM16*=FPC0AJ[NDE5.9E(!`]#4SJ
MI>M-K.<P1*=(('_^B8:Q,I`G2C!,JJSX;WG6BI.I<1DE-Z*8&O;KYJF0V>\Y
M`EGI:MW%C;32TY7'DNGJ3+V%M>"%Z!4)Y"\^%9&')0,Y_03#I%:8I=7V9&I<
M1LF-**:(K"'OD8BB?]<3D2,K$:V+VM":`8DH''DB3N>SI54H0G2*!&H3T8.%
MF$<E`SG[!,.D9IBY]01D:E@&R8T@IH14)`P)?VT%9E&L)I`C*SVM9V;C"BL]
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MW`?Z>+>@W]PG[$?KU[*LY1]T4>/V<^"G_P(``/__`P!02P,$%``&``@````A
M`#$@,/2]#```^D0``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6RLG-]O
MX[@1Q]\+]'\P_'ZQ]=.QD>2PD4CV@!8HBFO[['64Q%C;"FSO9N^_[U`B10Z_
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MH>CS<K:<44\/=T];\D`/^^38/-]//R4KM4BFLX>[;H#^LVW>3][_3TZO[;LZ
M;I_^OCTT--H4)QV!SVW[18O^]J01*<]`6W81^.=Q\M0\K[_NSO]JW__6;%]>
MSQ3N@CS2CJV>_JB;TX9&E+JY20O=TZ;=D0'TW\E^JZ<&C<CZ>_?[OGTZO]Y/
ML_*F6,RSA,0GGYO366YUE]/)YNOIW.[_VPMU'@V=I*83^HUT<D$Q,XKT:Q23
MQ<4KY4:!?JU"[LR]<"5RIO.3?JWBY2N51H%^K<)U5Z)NNRO1KU6,7FG61Z(+
M;+T^KQ_NCNW[A%8+C?7I;:W77K(B31O1WKDAQC\*,<56=_))]W(_)7V*WHGF
MY;>')%G>S;[17-H8F<>(#)>HK(2>.+K;.@0B!#($R@,S<G'PDV;+G^"G[D7[
M:2U\M,`YG@9.60FK4H=`A$"&0'F`.44S.70JHT4=7XXV5EJ)%M[%6!D9ZFL(
M:![X-8@,C@$10"00Y1/F'*VZT#F]UXR<F;H7\I:FQ>`)3DTC=,G=061P%X@`
M(H$HGS!WR37?W<LQU,*=5]::1T-HIC@_TWD0LT'(JM5`!!`)1/F$.4'[U_5.
M:&'NA"'9L+XJ(#40`40"43YA%M.>=;W%6IA;;`A%U1OV)!CV06@8=B`"B`2B
M?,*<T/65MXE?GCM:F#MA2)^Q]<9;`:F!""`2B/()LWC)+=9II\QN%C2Q1JYO
MW1'WQA#JR@M)N"L/0D-(@`@@$HCR"7,PH<WD^IATTMP-B[RH(*H1"402D6*(
M6ZY3Z-6S*>D3+FVP=B0?+>*+(@L6A9.RBC4B@4@B4@QQ9W3JO-Z9/M$R9PSR
MPP"H3@`)1!*18HA;KA.C9[E>(MFMKJO'+I'$I%@_1`;Q11*F>*OH?*\1"402
MD6*(.ZI3HN?HY=TK,0G4=\8@9V9EI1RJ$0E$$I%BB%M.PS?"<BT=K'&#^$HI
MPI4R2+F5`DCHVDAWGP\+42)2#'%G=(J\/@PFH?IA,,B->94`JA$)1!*18HA;
MKO.B9_G_L5),AO6],HA&UTLG91BB0<J%")#0MYLZ1&Z$)"+%$'=4IU//T9^L
M%)-\?6?\?-S=8E4)H!J10"01*8:XY3I/7F^YR:J^Y0;QE;((PS!(N3``$@D@
MB4@QQ)Q)1Z7V3IHO>XO</*@0U8@$(HE(,<0M#U)[=[>?=X<U8Y-*BGG?(KY4
M;H,8.:DA1H@$(HE(,<0]U0GYZ@F7FO3M33B+_!A!DJ]12B"2B!1#W/(@[U]>
MY"GF=HOX4@E.8RHGY<)@^G(91*"41*08XL[HU'Q]&+1TL%0,\L,`J$X!"402
MD6*(6Z[3J6>Y7BH+.JP<77WI@BUTRB#Z<3DE"V_6K:)SO48D$$E$BB'NYZBT
MGV+:MZ@<ZHX*48U(()*(%$/<<IU-O0C]9*&8W.LO<8-H\GAA"&_>TT'*+11`
M`J4D(L40=V94:D\QM5OD9DN%J$8D$$E$BB%NN<ZF7A@^7GVE)B_[(3*(KY3P
M9MXJ.M]K1`*11*088H[JDU7?T<OSK9/F>YE%SLP*48U(()*(%$/<\B#M_\1R
MS.SZ^+2_M_!72GA'[Z2&E8)(()*(%$/<F5&9/</,;I$?!LSL*"40242*(6YY
MD-F[ZBO)/W+JE6':MX@OE?"6WDFY&)F^W'@(E)*(%$/<4YV/O3WA)Q/.9&]O
MW=-=;'"G5"&J$0E$$I%BB%NN4_/UEFOI8)$;Q)-*>$M/MX!F0;DP`!(H)1$I
MAK@SHW)[AKG=(C<U*D0U(H%((E(,<<MUAO7"H)=*6GR@^LI,JO;GED$TWE[:
M#^_HK:)SO48D$$E$BB'NYZBTGV':M\B962&J$0E$$I%BB%L>2?L?.\'/,.U;
MQ$,4WNT[*;>(AGK!(H%2$I%BB#F:CTK[G33?$2SR0H2H1B00242*(6YYD/;U
M(BJ(C7S"DF,]8!&/3WBG[Z1L,&I$`I%$I!CB7HZJ!W*L!RSRXX/U`$H)1!*1
M8HA;'JL'YG3IL0'"8B`?<KJ_QX5G`$[*!6A0M$B@E$2D&.)NCBH&<BP&+/(#
M!/5!C5("D42D&.*6ZY0<9*%D<?N!-)3KGH)MP2"VAO+P$,`J.M]K1`*11*08
MXHZ.*A1R+!0L\@X!$-6(!"*)2#'$+?^S"H4<"P6+>(3"\P$G95=,C4@@DH@4
M0]S/485"CH6"16XB58AJ1`*11*08XI8'A<+E>X$<BP&+6$6=AV<`3LJ%P?3E
MG6>BE$2D&&+.%*.*@4Z:KWJ+O#`@JA$)1!*18HA;'BD&D@\D&UU`!#N917R=
MA*<#3FH($"*!2")2#'$W1U4#!58#%OD!PFH`I00BB4@QQ"V/5`/:SY'%0('%
M@$4\/N')@)-R\<%B`*4D(L40]W)4,5!@,6"1'Q\L!E!*()*(%$/<<AH^OQBX
MO(\56CI8^@;Q?2P\&;"*;M.J$0E$$I%BB#LS*N$7F/`M\L-@I!RJ44H@DH@4
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M8`J+W'!(BYR4LJB3XI;K'.^=&$2F'#V*'^:<J0B\P^FR1_I-*C>;BO!4P$HM
M!_]J@^C='_WUS2)-E\4R4!.H)KE:.2^+9194AHJI<7='E1$EEA$&Z?=X/'?#
M6VPCQ6+7]T6OT6AWLW*^"*P6J"3MU7ZHI)@2=S6H.WX262PMRAX%D0T6166E
M_,CVBB:R^>U\4<+R,WT[+6DZLEKS[#8/AE6Q:W%G@]+C8SLJ5B1ECX)P!]Y4
M1HJ%VRCJ_9J^+5LD\R()<KY`-6FOUZLMTJ3(@HU9,2T^")$J9OR6BQ5,V2-Z
M]<AM3CVB5PXMJJU4OWTN\Z)<YC#%04UR-=H&%MEMD&^5D>FOQEQ>!`5-&/??
MV[<?95)O6^MZX86.1=Z&C*A&)!!)1(HA[E%0Z&B//O:8BKZK#>_H+&*U:!%$
MJ7)20W`1"402D?ZXMS.B*QA[1_N/=?MO.O?-\:6IFMWN--FT7_6'N!3KA[L!
M]U\)/Q:W*UV]DSG0LJ26;A:&+>5\I>O)B,Z"6B@`L9;A<^2PMR*EZW3I$UHR
M:NE*`FC)J:5;--!24$LW)-!24DLWZ:!E02U=3@];<M*A`^>(/SGIT!%MK(5&
ME(Y`8RTTHG2>&&DI:-SHO"[60N-&1S^1EIQTZ(%?K(5TZ"%9K(7&FAY"Q5IH
MK.FY3:R%QIJ>B\1::*SI04*D)2,=>K$BUD(Z])9"K(7&FMX"B+706--S\U@+
MC34]EXZUT%C3@]Q(2THZ]`I;K(5TZ)VO2$M&8TWO5,5::*SI!:58"XTUO0`4
M:Z&QIA=F(BTIZ5`=$VLA'7JW-M9"8]TGD'#VIC36M!?'=&BL^WL9T*&Q[F]I
MPI:$=/HJ&EI(A[Y4B%PGH;&F*B?60F/=9YVPMY3&FDJ5B$Y*8TWU0J0E(1WZ
MBBW60CKT25BLA<:ZKRM""Q(::_I&*:9#8TW?`,5::*SI@YI(BUX^,4X*47D:
MYN@JH$&.CC$-<72$:8"C<[E,5H]T<XF6TEW[JHJVT,W[2M^'HP[=\E)+K#>Z
M22='8BWTERD^Q?BC#E7D&H]Z4<2X7D81_BE??:+D2,;.ALC27YYX6[\T_U@?
M7[:'TV37/%-"G'?G`L?^;U?T_SB;JN9S>Z:_.=$5.*_T-T8:^A!VKI_U/K?M
MV?Y#7V#XJR4/_P,``/__`P!02P,$%``&``@````A`.RR;[SN!@``A1X``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<6=N.HT80?8^4?T"\VZ;!8+#&
MLUIH;1(ID:(HEV<&XS%:VUC`[.S^?:JI!KH*&]OS,C.>.EV<NG2=-OWTZ?OQ
M8'W+J[HH3QM;S!W;RD]9N2U.KQO[G[^_S$+;JIOTM$T/Y2G?V#_RVO[T_/-/
M3^]E];7>YWEC@8=3O;'W37->+Q9UML^/:3TOS_D)++NR.J8-?*Q>%_6YRM-M
MN^AX6+B.$RR.:7&RT<.ZNL='N=L562[+[.V8GQIT4N6'M`'^];XXUYVW8W:/
MNV-:?7T[S[+R>`87+\6A:'ZT3FWKF*U_>SV55?IR@+B_BV6:=;[;#R/WQR*K
MRKK<-7-PMT"BXYBC1;0`3\]/VP(B4&FWJGRWL3^+M?0">_'\U";HWR)_KXV_
MK7I?OO]2%=O?BU,.V88ZJ0J\E.57!?UMJ_X%BQ>CU5_:"OQ96=M\E[X=FK_*
M]U_SXG7?0+E]B$@%MM[^D'F=04;!S=SUE:>L/``!^&D="]4:D)'T>_O[O=@V
M^XWM!7-_Y7@"X-9+7C=?"N72MK*WNBF/_R%(:%?HQ-5./&"O[>[<#7WA!P]X
M66HO\+OS$LR7KK\*[^"RP+C:-,FT29^?JO+=@MX#YO4Y59TLUN"YRP]&TV?L
M6L(@4\K)9^6E]06YJ*'*WY[#\&GQ#0J3:4B,D)5M]1!!$4F'4%507N78Z\KK
MURP@@#X*R#"/PH->N5SECK1:1$F[0>^^91!?@%!$,D:LEA0BQQ"W1Y`HH#_,
M**;9*S!THY'/,.K=(GN$0%7[E#-JR4V$G$(0\O"8^\DK\,:&Q/3,(H>11TC8
M-M-,P%[Q*2"A`,<)67"2`$)GM1H>09C#1C:9JRUPNWG4(IK^B/5SC!!@T0?)
M&"8W$7(*08((:!#3O:/`+/U#2V+O(&39IG^Y9-:$6+TAK[AOT1JT:UUO-;0E
M80RCX/&TJT6,^3`2D#E"D+E@QJ0S7JV)[!!JB/FKON<(=74Z,(;F=+(5F%%F
M?1`C!!,F1#`DK(TH0;..R&$S2I+%D3?,74(Y>H2R`C/*;/?%"-&<7,[8M`:L
M!M(TNJMAUQ"^`L;W_3ENT8PQRU.L,5UCL!HDQ!P-A<>6UM:N1/[@G+)6DG5W
M9P@4.',,+GF>-099ST3([`FS&^77Q/$9.NKH2G<(I5'W\T9%,WGSA,6MQXVM
M>?,>2*;-LC=?VJ<TXTJ@#.;W36^!LD8B&%*#<T1CNC'FC1JFDT8U*6:"C4A)
MEX=&X2A_I5*/\T=M(_S9'HP%8G0%W&&?X5"A9H_UE:3F8`B>LE?Z9+"?GH3J
MX,WFBG"8>,0:I!N6%27IK9<:0W=\IYFJ+L((C#)7(G4_<Y0T,]_"81F-1:>*
M5[DE/41Q\UP^&:G9&UJ*4E<295"_L^51V*!I^^.(<(8GZ)[OU&\`#977?7,3
M(L44A(:BQ.OQ4%#RS&KP,T@L3-&<10%KLX3:78>%*;4==_],!,&UB:_4[/$(
M4`-)!$QR8H$8+3F>/XK`U-&9QT>L).N]0`Q;B93`?4AH6S056N&P-HXUJ,N=
MLXK8=$DH(@I#%IRD@"#RO6&W4?H/*:Z+:D@W`2M]K$%3!_?;$#D)H2%`&Y@M
M-#U$787F%6#YC35(S_Z(19A0\U(PN]1V74#/%]>2KR3PX>9W43C-YA?\5!MK
M$$8P[#V<0;WQZIB2/41-6M>YUOQ,?6^D?JRZ_%00NYWJ7J66W(;('J+/%L.<
MIIWSD/RJ=TVCSN%31X-TY_"W.`DU7^@<?$;7.?!ZZO(W*/<A^6W1]-NV,$J*
MVJ5!D]OVID++22\T^4KE'F]^U$;:_/SHYG8"VC8O&Z\)M3I#AML\2&H.AP)3
M]A]27G>LO$*PV1UK4#?^O7"8'GK[=MI\=8_("1\TC`_)KSN67V',.-U/IO["
M:PQO-(4Z`9X(P_3AN:[A@X2AWC>9O30]AUHTDP#^_2/6H*GM<!LB-01K&2R-
MTSKE_Y`*>ZC"9`_P-S6Q!G5=Y!N/QB[2@(D`)?6Q%,89BM)7FOKP5O;4*EX&
M)J6Q!DVP3#0$(XW@J-F/3-S0Q.Z'P7(`T"@^I,;>!346;*;$&H0404U7@Y[J
M8J`7'8-GO-71,1"[ZQCO*6@,D*@/5$*MXI48LM12B#T$:8K1Z$RJ[=V9:?3E
MC*P7D1->$66/B?)]7\_:53R$87;K$$QU!0;,GF@G&&+@<;O4]LO-2.O`]/G.
M(%!?Z<9FK1+#=9\J%K[9IWG4O60"_*7Q[D'WDFFG#C`&O`W$:ZYC7KWF27XX
MU%96OJF;/@'OI?O_XBUD+-9)>V6WZ`UP"7A.7_,_TNJU.-76(=_!4F>^@@I4
M>(V('YKRW-XAO90-7/^U?^[ANC>'^RMG#N!=63;=!W51V5\@/_\/``#__P,`
M4$L#!!0`!@`(````(0"HGZOC^P(``!4)```9````>&PO=V]R:W-H965T<R]S
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MWIS])B97^T]:IE]E)2!L*!,68*/4$Z)?4FR"SOY%[\>F`-\U247&=X7]H?:?
MA=SF%JH]A@'AN.;IZX,P"00*,MYHC$J)*L``7$DI<69`(/REN>]E:O.8LHDW
MG@8L!)QLA+&/$B4I27;&JO*/@\*#E!,9'43@?A`)QUXT&D]OWZ/"#BIP?[<5
MWPVK2>F!6[Y<:+4G,//`N*DYSN-P#L)OQP)Y('N/<$RGE,"(#93R><E8M/"?
M(?_DP*P<`]<S9MQEUI=,V!(^&&O=06#7NT,8W6$1T>[JV'!N9=)^J&'6CCFW
M.VJ)CA4(YWHK"'>L]!O6KN'\NXQ-W_YRU/TRSF`&ZV"X5-@)N+,RA.&LU7?Y
M.`:N;:EZQ5P/$9UT8"U<GP[",87DV^\R=MOSYI@A;T<"I^$_:C9YCRN$NXDQ
MUD_,,4.NAHA.8K"*KD\,X5YB4=!+S#%1LRP#+QSW:WE\?TK]1'2<X<EW]9:`
M<"^UZ+28W3QSS%!J0T3'VZSK#=?"[+]K`3OUTSO-&.?1,4,>+PD6L;8&SJ4[
MAMP&6PJ]%6M1%(8D:H='S`AJT[:VI]\]PQVKU[X:S5=-N]^^@%.IYEOQC>NM
MK`PI1`:2@3>%=:#=N>8>K*J;;7VC+)Q'S<\<_GX(V!$##^!,*7M\P).S_4.S
M_`L``/__`P!02P,$%``&``@````A`%]04'O-$0``)&$``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3`N>&ULK)U;<QNYCL??MVJ_@\OO1U;K9EF5Y%3<]_O6
MUMESGA5;B55C6RY)F<Q\^P6;1)/@OR-+J<Q#;/\(0$T09`-4-^?#/_]Z>;[Z
M<[,_;'>O'Z^#T?CZ:O/ZL'O<OG[[>/U__TK^L;R^.AS7KX_KY]WKYN/UWYO#
M]3\__?=_??BQV_]Q>-ILCE=DX?7P\?KI>'Q;W=P<'IXV+^O#:/>V>:66K[O]
MR_I(?^Z_W1S>]IOU8Z?T\GPS&8\7-R_K[>NUMK#:GV-C]_7K]F$3[1Z^OVQ>
MC]K(?O.\/M+U'YZV;P>V]O)PCKF7]?Z/[V__>-B]O)&)+]OG[?'OSNCUU<O#
M*O_VNMNOOSQ3O_\*9NL'MMW]`>9?M@_[W6'W]3@B<S?Z0K'/=S=W-V3ITX?'
M+?5`N?UJO_GZ\?ISL&H7M]<WGSYT#OKW=O/CX/Q^=7C:_4CWV\=J^[HA;],X
MJ1'XLMO]H43S1X5(^0:TDVX$_F=_];CYNO[^?/S?W8]LL_WV=*3AGE./5,=6
MCW]'F\,#>93,C"9S9>EA]TP70/]>O6Q5:)!'UG]U/W]L'X]/]-O=:'X[G@8D
M?O5E<S@F6V7R^NKA^^&X>_F/$3*FM)&),4(_C9'IPAHYH3@UBO33*$[N1LOY
M?+98WM+'G]"<&4WZR9K+\S3);M=C^FDT@V`T6<Z#^4)U^<1G+HSFK=6<C8+9
M^#T]FFO=)])/\XG+L[QS9_3H)_?Q3.\$%$=Z6%5`Z2&CJS_1MZ`/!/J%_3(?
MW0;CN^D[0Q'P\*M?+KU0CH#`AL`[%\HC']BA/W<`U<30;K&#_T[`W>CYTDV_
M:'U<?_JPW_VXHC6-W'1X6ZL5,E@INSSQM(_[J?BSF4A34%GYK,Q\O*:(HDEV
MH.7CST^3^?S#S9\TY1^,S#W*!%(B9`DUOY79R`>Q#Q(?I#[(?)#[H/!!Z8/*
M![4/&A^T#K@A7_<.I^#Z'0Y79I3#V57W#)P1\+S+$JP2^2#V0>*#U`>9#W(?
M%#XH?5#YH/9!XX/6`<*[-/U^AW>5F8_7].^)<#8RM#+U0C//X[U([W(@,9`$
M2`HD`Y(#*8"40"H@-9`&2.L2X7Y:RWZ'^Y49<C]-H=ZUN)P8H5/^[T5Z_P.)
M@21`4B`9D!Q(`:0$4@&I@31`6I<(_],"+OP_G#[QHJVD.S>S>^X-H=GE.'[A
M174OQ&H1D!A(`B0%D@')@11`2B`5D!I(`Z1UB?`JW<DO\*J2EEXU9-HOUB&0
M"$@,)`&2`LF`Y$`*("60"D@-I`'2ND2XD#*#"URHI*4+#:'`=P+SU@O,7J@/
M3"`QD`1("B0#D@,I@)1`*B`UD`9(ZQ+A557]NLG;Z>FNI*57#=$%E4JX0B`1
MD!A(`B0%D@')@11`2B`5D!I(`Z1UB7`A%247N%!)2Q<:0FN'$YA++S![H3XP
M@<1`$B`ID`Q(#J0`4@*I@-1`&B"M2X175>%V@5L[<>E71DYL(HH0Q8@21"FB
M#%&.J$!4(JH0U8@:1*U`TJ6JH#A_LJM"V`M51C)6[[Q8M5)]L"**$26(4D09
MHAQ1@:A$5"&J$36(6H&DEU5A<8&7=1U"F2H[ZU[M'BC'NX$+*$*I&%&"*$64
M(<H1%8A*1!6B&E&#J!5(NE15"Q>XU!07KDLUFBQZ+X=JGX6\/+$%<&20VD^Q
M2_%B+,,[1L6$$=TC',6)5$RM%`]UQJB["-EGE:&[?=;;*B.U!75\VC[\<;^C
MCZ(I.G#'GM+VB=E4,7F^ZPJ-A"L,<EVAD=K/<7KD[;;$RE/2APDC6M@=Q:GO
M"J-XUX]'QHH#KJ"+$*X8Z#)M6/9]5N+>K4"CP!U^@R;]%42JLZ086#?$C*Q4
M8M#,VDH194)1#JS*<-V!?:<W)B%V1U"C0$3;!%9A(V5='%'_N^$:=]MKP6PZ
MF2X\M=C(!%8M,6CJ?EYP"]%M+O1.&Q_-O#'/A&7I$I6>7N`2D\VZ+M%H(NK]
MA;^90B/;#;`=S<B@R:2[ZNDT6.)\!ZW$:,UN.ZWYR*MO4]MN9[IK1?9>9987
M]%Z)>^&MD0R(A;=Y&JIF%=YV9".#IG*R>KV)68KT[92>>*538J1F2S/^<\],
M:@6L4]Q+DDY1B:'KE%];_DQZZ4:*1EZD>)T)R4D0*1K-:>6R7EAX>7K,BB(0
MT5?:EHF?\<@?J]28(0'K*_>2A*\F?JK\2[[JK,BX,FA.ZZ+M\M2["81&RHTK
M@[I%^<]/`7UW,@\\%\>HEAAD0FA"W]/=N?]YODZM>.\D850Z266SIP+J7[NW
MG]U/G9N+BAMO]AE$Z0M?1H@H0A0C2A"EB#*!9"\O2SYIV8/>0*89LI3-1R-$
M,:($48HH0Y0C*A"5B"I$-:(&42N0=.EER><$DT]&8AKY-][02G$818AB1`FB
M%%&&*$=4("H158AJ1`VB5B#I9940NM/S=%8TT?FC6S4QLE$:(HH0Q8@21"FB
M#%&.J$!4(JH0U8@:1*U`TJ4JG;W`I3K[%2[5R"T5:"E4*X9;-3$2Z<&M7S59
M*0[O!%&**$.4,[)WQX*1O`CO5E5:*;Z("E&-J$'4,L)ZA?PE'?]K]V.33SNY
M2V>8G&]+CY"1=47$B/*%_JX=S/P\WTJQ*Q)$*:(,4<[(7D3!Z.1%E%:*+Z)"
M5"-J$+6,!L9#I=[N1/BU\=`)O)@?;D[?%=PA38PN<;3?U$0&4>'>/=0P#KS"
M*+8"[(6$D363,NK->`589@783&X0[3(P*JS4\-645H!U*D;63,WH9U?36`$V
MTQJDKT8N5:H.<$?HG=5?EPUB*#2B&I,_+IP89/.RR""G=H\1):B8HE2&*$?%
M`J5*1!4JUBC5(&J%HG2I*A<N<*FN+H1+-1+9_]);UL.)%A+)OS%%[K?KC[]=
M$!M%*CU5',Z7WE*=H.&454X:SEA*&YYZLR1'NP5KG+1;LI2VNUAZY6V%AFM6
M.6FX82EM>.E=<"OLBB&>_I:ZK[,BZSZ#YE0*]"/H#U!HA)RR)S)H,>O&=#;V
MQC2V[3Q)$[226BD5&8$7<9EM9B,Y&BFLE#(R6WIK;FG;V4J%5FHKU2V6WGY2
M8YO92"N,R-%ZKP`]:T.7)JA?L1E$B2!?16B0.RL-FE-6T8\I;.+%+*4WMN[\
M8$S0<,HJ)PUG+*4-S[P@S]%NP1HG[99&:K'0NTZ!7U95:+D^RW+#4OJ*@[$W
MWUMA6(ZT7X3[^<9Y6PU3+,X9.7<Y1!&B&%&"*$64(<H1%8A*1!6B&E&#J!5(
MNOJRXGR*Q3DCJFOZ>3'Q[U:AE>(Y%B&*$26(4D09HAQ1@:A$5"&J$36(6H&D
MER\KSJ=8G#-RBG-$$:(848(H190ARA$5B$I$%:(:48.H%4BZ5-71YZ=G]%TP
M+/L&R<#U[G,A*UK'1XAB1`FB%%&&*$=4("H158AJ1`VB5B#I955#7^!E)>ZE
M0@99_X530!&B&%&"*$64(<H1%8A*1!6B&E&#J!5(NM0OID^7:E.LFAG)P/5R
MJ]!*V177V+)C$:-4@BA%E"'*$16(2D05HAI1@Z@52'J92H9+`E>)>X%KD'56
MJ+[`55(618AB1`FB%%&&*$=4("H158AJ1`VB5B#I4E667K`6F"K6V7Y37Y-J
M_[FI@O\UJY6R@=LK,HI1*D&4(LH0Y8@*1"6B"E&-J$'4"B2\//-KTM/+0R<N
M`Y>1C=(0480H1I0@2A%EB')$!:(2486H1M0@:@62+O4+QW=<BA7B3"/:(>7X
M"QG9+=N($:T23B;LU_!6BFTEB%)&N!D[>Z\X.JL,[JQX<:/+)=%)@]Q.&D0S
MLN\D;HX;\[3U8CO9*S)*66J@DWY9XE>`YW42JY691LZF2\C(;LY&C/K-62\K
MC%G`ZB2,>AVO1$]9H-.1`7I9>3##\L`@=_>6D;-[R\@.9\S(2B6,K%3*J).2
MEZZ2Z/-O"C.3<SLW!8/4PRU]0$T"/YMA*1M0$=O2VWZ!_PQ1S.W2L'>W25C*
M6/$>L^/6G]F0OK@L6:9-=#_G,$@]GN#XPMLX"8V4$\.10;0&JGVV.WI#6W8D
M9AUI&9RA+XG-3$>>0/J>&>F/RS)=>E8'_*&1C(U;\(>1<F/#V#)[S:.Q__",
M^3!G@R_AS^]UO,])A8[L*<7');-`B7N+KT;>R'L/[(3T8(]2%".OD1DR;Z\W
M9H5WAOV4C?0]&](3*E.[8#TPB9V['D"N%\X`18AB1`FB%%&&*$=4("H158AJ
M1`VB5B#ATOEE&6$G+H.+D2P8O2D16BF^04>(8D0)HA11ABA'5"`J$56(:D0-
MHE8@Z665XIT?N',E[GG9("?O9BF+(D0QH@11BBA#E",J$)6(*D0UH@91*Y!T
MJ<KX+G"I3A#I:P&.OWOU!1IYV4U)&=GL)&)$JYB]:][Z>;>58O,)HI01IJ3S
MWY*2=E:\N-$IJ>BD06XG#:*EL.\DYMW&O)MW(TH9#732ST1_*>]6C_CZDT,C
MY\X5&BGGV8J(49]#^WFW$;AU\FY&^CO3R3CP4I^4C6+>K;Z9OR1`,7GM+-`-
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M(RH0E8@J1#6B!E$KD'2IRNC.#ZZ%$O=<:A#=_?J[]N36#RY6M`^@1(AB1`FB
M%%&&*$=4("H158AJ1`VB5B#IY<O2Q`6FB8S<P#52%D4H%2-*$*6(,D0YH@)1
MB:A"5"-J$+4"29<.Y:K3I3JWSYS<=O:I8@N==[I9.2-93GK/1X=6BO/M"%&,
M*$&4(LH0Y8@*1"6B"E&-J$'4"B1'P$^D3W_G0$_\P=)AD)-:LI1%$:(848(H
M190ARA$5B$I$%:(:48.H%4BZ]+)L?8'9.B.Q&L,3N5;*!JZQ91?H&*421"FB
M#%&.J$!4(JH0U8@:1*U`TLN7%1;TW"`$KD%VZ0U9RJ((48PH090BRA#EB`I$
M):(*48VH0=0*)%VJ*@`WC5!%]2^NQKJ8$*NQ06(UAH>-Z>#8;IS<$0`4HU2"
M*$64(<H1%8A*1!6B&E&#2!V.:_NH1T`?=JM/VWS9[+]MPLWS\^'J8?=='61[
MJUZU[K$^9?=^L:!C=KL5%EIN^0!>:!E32W>Z+K2H0WN[:@-:)M32%?;0,J66
M;K<"6F;4TBU"T#*GEFYP_9;I<J4>ZJ"U#%KNJ*4KW?R6&?6':I(!G1GIT%;U
M0,N<=&A[=:B%?$"[A`,M4_(!/9LZU$(^H.<IAUK(!_18X%`+^4`_F^/W9TIC
M2D]D#>G0F-)31`,MU-'!?@;43SHB:$`CH'[2L39#+=1/73KZ5S:A%GIU=D!G
M0AZ@USVQA<Z!_CRHH3Y^0/Y>?<005RX>X)]GJ\\TE?"#[\GS@XXGOP^&GII)
M0W;(YX/V*5('`W46K.[I60&\(GH*8Q4.MM##&"OU7`7J1+,)M0Q9HX<N5NJ9
M!-2AC>C5/>V:8DM(+>%@"VU+K]0.,^I$\RFU#%FC[>>5VIT=T)DL5^I5*VRA
M5ZM6ZETJ;*%WIU;J92ELH9>C5NIM*&RA5U!6ZC43;*'72E;JW1%LH7=%5NI]
M$&RA]S]6ZB4/;*%74%?JM4=LH3=1Z=J&XHG>B:26(1UZEY1B?*B%7AXDOPU%
M&[T/2'X;:J%7_,AO0RWTUAY=P5`+G6JS4L?88'_HK!-J&=994LO0*"3!';4,
M+3]TQ,-*G=N`GW-//K@?]$%(+>H]5]2)J$6]'SS4LJ"6(9W["2T#^ET9?S$+
MIJM[.H4(K=%94:MPL(4.@UJI4Y!0A\Z$(A\,S04Z(HE:AG3H.*A5IEMN^HNC
M,^K?UM\V]7K_;?MZN'K>?*5;_[@[!VJO3[G7?QS-^15?=D<ZG;X[RN*)_F\$
M&SJ3<3RB[.KK;G?D/^AR;_K_O\&G_Q<```#__P,`4$L#!!0`!@`(````(0!2
MT4V0_PL``'D^```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*R;76_C
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MBIH7D\6$6GJX>]R2`GW;1X?FZ7Z\2I9JEHPG#W?=#?K/MGD_>O\?'5_:=W78
M/OY]NV_H;E.<=`2^M.U7;?K;HT94>0*U91>!?QY&C\W3^MOKZ5_M^]^:[?/+
MB<)=D"(M;/GX1]T<-W1'J9F;M-`M;=I7<H#^'>VVNFO0'5G_Z'[?MX^GE_MQ
M-KLIYM,L(?/1E^9XDEO=Y'BT^78\M;O_]D:=HJ&1U#1"OY%&SE3,3$7Z-163
M^=DKY:8"_=H*N7/WS)5(3*>3?FW%\U>:F0KT:RM\[DK4;'<E^K45HU>:])'H
M`ENO3^N'NT/[/J+10O?Z^+;68R]94DT;T5[<$..?A9ABJQM9Z5;NQU2?HG>D
M?OG]@4)Z-_E.?6EC;$JT2;A%92UTQ]'-UB$0(9`A4!Z8D,1!)_66/T&G;D7K
MM!Z6%CCA@>S*6M@J=0A$"&0(E`>8*.K)H:B,!G5\.-I8Z4HT\+Q8)<F"1Z(T
M-M36$-"<FU2#R2`,B``B@2B?,'$TZD)Q>JZYL&?J5D@M=8M!29)F7$MIC,[)
M'4P&N4`$$`E$^83))6F^W/,QU,:=*NM-:0@U_W.=U6!DJ]5`!!`)1/F$B:#Y
MZ_,BM#$784B_=.@9H`)2`Q%`)!#E$^8QS5F^QWK^RV[UZG5I1],-<36&4%->
M2,)A-!@-(0$B@$@@RB=,H,Z]_O\)7K?2J?.U%,$P,D;GAM%@,L@%(H!((,HG
M3.Z"RST_C+0QCYDA?!@%.JO!:!`!1`"10)1/F(B$;J$?M/,J.FLNPR)O)"&J
M$0E$$I%BB'NNU]^@NUTWGI)^):>9V][ETB(^HF:\%U;.RE:L$0E$$I%BB`O5
M:W(@](KE*>F7]F!]"I=C:W5N9#D;)]LTWB7U748ET$HB4@QQV7JY]F1_T#/-
MXN['T"`^P@+!53)8.3&`!%I)1(HA+D8OQI\7HZV#86:0/\P`U0D@@4@B4@QQ
MS_4*['FNEZTY;:4N7K5TEPU%&40_;MW*IN$H&ZQ<A``)V[R[01*18HCKU.MV
MH%-;7Y@$)F;Y9UE@%FP_2FMU=I29EMR0JETU>R<$(HE(,<1EZ]7<D_W!*#-K
MOS_*#**>Y\4P$%SI[:\.?CY,L34B@4@B4@QQ,7JM_KP8L[+[8@QRG:A*`-6(
M!"*)2#'$/=<+M.?Y]<EA8I9Z7Y5!?)B%NT=;T6FO$0E$$I%BB`E-@WSCRE.`
MKIENAO1[7;C9LE;GAIFSL6.J1B00242*(2X[2%;.#[,4$Q*+^#`+!%?.RHDQ
M;;F1)]!*(E(,<3%!0O*!F"'OL#Z5J4&NJU6(:D0"D42D&.*>ZY4]&&9)DM_,
M+Y_H4Y,D>./,(C[.PFV8L[+WHT8D$$E$BB&N5&<"H=(K5)J$@B]GP2ZE3(W5
MV7$VV#C9@(1KR5I)1(HA+ILD^K(_Z)K:FN=9>CO>+U3^Q!((KIR5=;-&)!!)
M1(HA+B9(23X0,V0>UJ<R-<@?9X!JM!*()"+%$/<\R"KT+)\65R2-*28<%E&@
MO(0CW)HY*WLW:D0"D42D&.(Z+THX4DPX+/(CA`D'6@E$$I%BB'L>23AFV543
M(28<:33AF`=YO;-R(1HJ6B302B)2##&A^I3Z\S-"9\UG!(N\$"&J$0E$$I%B
MB'L>Y`QZ$!7$+MR1Z`U_,,E9Q(?0;1`?9V6#42,2B"0BQ1!7>5$RD6$R89$?
M'\@O:K02B"0BQ1#W/)9,3.G2EP8(,XG,(!Z@\.C"6;D`#14M$F@E$2F&N$R]
M2GN9Q/E5B'9XT-L,\@,$J+85G95`)!$IAKCG>BWW/._V&O/;*Y:A3+<43`L&
ML1#EX=F%K>A4U8@$(HE(,<2%7I0H9)@H6#0;MN<5HAJ10"01*8:XYW]6HI!A
MHF`1CU!X,N&L[(BI$0E$$I%BB.L,$H4KM[W9D$%XN4\>[.1+:W4N'7<V3K9I
MW!TX";22B!1#7':097PP=V`FD1E$\X5+]D+!E;-R8H:*%@FTDH@40TQ,?E$F
MT5GS*<,B-QE4B&I$`I%$I!CBGD<RB>2*E2K'5,(B/LC"<PEG9:-1(Q*()"+%
M$)=Y42J18RIAD1\@3"702B"2B!1#W/-(*G%%JI=C)F$1CT]X)N&L7'PPDT`K
MB4@QQ%7J53]<C\FQ"_.EW"0/U!F].2'8HI?6ZMPDZ&R<;-.X-PFBE42D&.*R
M2:(O^_PDF&OK8-XPB$^"@>#*5G0'?34B@4@B4@QQ,1>E&CFF&A;Y8\Q8.52C
ME4`D$2F&N.>15./*L[\<DPV+*%1>IPQ/)9R5ZW"F+2=>H)5$I!CB2H-DXX,.
M-^04UJ<R-\CY5"&J$0E$$I%BB'L>Y`M7GQOEF$I8Q",4'DHX*WLW:D0"D42D
M&&(ZBXM2B<Z:3PD6>1%"5",2B"0BQ1#W/$@ESO<MO88%DYE!='9H;W!ED7O9
ML;:(.J(WG((3"N&L;%L2D;*H:YZ+"1*&/BOO#L%.+]O-U[*EBY.$B,B,7CWM
M7T@M,(\PB&GLK>@HT;I:6ROJJI[&8),OG)6M*!$IBR(:(ZE%4ERJ$1.+HD?T
M_H;UJ[(H&U!M4=&]J9M.DR`S%-;`U9$6#76"_8VR!ET='M`@PX@$CH[;A\@-
MB8254!8]HN?E%E46.:&U12Z8PB)G)2UR5LJBSHI[KM=X+S?ZP'.3$7@/GXH>
MZ4?,KC<5X7F$M5H,^FJ#Z-FE?IEZGJ:+8A%4$UA-\FJSZ:Q89$%:J5@U+O>B
M-*+`-,(@_9#2DQMN[HV5UTEK6S'MY&:SZ3SP6F`E^6$EQ2IQJ4'>\4%D,;4H
M>A1$-A@4E;7R(]M7-)'-;Z?S&0P_T[:K)4U#MM8TN\V#VZK8M;A8G3EXW?BZ
M&=6D'W[O[E$0[D!-5?16+-RFHIZOOS\D\V1:),&:+[":-(B>K_:#(BFR8&)6
MK!:_"9$LYO(I%S.8HD?T]---3CVB]RTLJJU5/WTN\F*VR*&+0S7)J]$T,,]N
M@_56&9O^:DSR+$AHPKC_WK[];"7U)N2N%9[H6.1-R(AJ1`*11*08XHJ"1$<K
MNNX!&7TF%29!%K%<M`BB5#FK(;B(!"*)2'^KU3G1)8R]T/[;J_X3G5US>&ZJ
MYO7U.-JTW_1W5;,9=?T!]Q]]E;/AJZ^P),^6>N=/C@8EJSQ?KNCJ6$);=*K3
M=>:@3ID75-*Y"B4S*NDZ`Y3,J:1;:Z'DEDINHQXLJ*0;.V&=8KK467#$ZQF5
M4+>)E&2DAYY&Q$I(#QW?QTI(#QV/QTI(#QTH8\DJNUVNHO>:3GZI3E1I1DKI
M:!-;*W/20T>'L1**-IVVQ4I2*NF2F/"^I>0!/76.U$G)`WI,&RG)R`-Z#!HK
M(0_HT6&LA#R@1W.Q$NJ)]#0+2U;I=+FB&1U+2BK1+V_%2L@#6G5B)>0!O6D4
M*R$/HM=9I306HC&E5VBH3K3OI-1W:(Z,78?Z3K_'@"A0W^FW&D')*DF7*WJM
M-=(:E>BWL6,EI(=>;8Z5D-?TZG"LA+R.7F>5S,B#:#^@$OVF:JPUTD.O?<9*
MJ+]19A0KH?X6OXZ>=F(UR.7HG2&WHEZ14S&?5C0\Z6W^B$OD:]15\C1^0ZA;
MT@<0D982ZI;Q:Q3)LJ3=(-:A;?:RBI;0;GNI-\Y8A_:H5!)KC7;5=+=B)?1E
M\"K&2^URY!JE'D<QKL=QA*]H#'6W?3+T;?KP]VW]W/QC?7C>[H^CU^:)%K!I
MM\<]])\.]W^<3!;RI3W1)[]=0O)"GW@W]/G75#\5?FK;D_V#;L9D^&C\X7\`
M``#__P,`4$L#!!0`!@`(````(0"D785QR@X``(U*```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$W+GAM;*R<VW+;.!*&[[=JW\'E^Y%$4B>S8D]9/.J\M36[
M>ZW(<JR*;;DD)9EY^VT0:`*-GY$L3W(1VQ\:3:`;AVX0TJ??_WQYOOJ^V1^V
MN]?;ZZ#5N;[:O*YW#]O7+[?7__DC_VUX?74XKEX?5L^[U\WM]5^;P_7O=__\
MQZ<?N_W7P]-F<[PB#:^'V^NGX_$M;K</ZZ?-R^K0VKUM7JGD<;=_61WIS_V7
M]N%MOUD]5)5>GMMAI]-OOZRVK]=:0[Q_CX[=X^-VO4EWZV\OF]>C5K+?/*^.
MU/[#T_;MP-I>UN]1][+:?_WV]MMZ]_)&*CYOG[?'ORJEUU<OZWC\Y76W7WU^
MIG[_&717:]9=_0'J7[;K_>ZP>SRV2%U;-Q3[?-.^:9.FNT\/6^J!,OO5?O-X
M>WT?Q,M><-V^^U09Z+_;S8^#\_O5X6GWH]AO'V;;UPU9F_RD//!YM_NJ1,</
M"E'E-M3.*P_\:W_UL'E<?7L^_GOWH]QLOSP=R=T]ZI'J6/SP5[HYK,FBI*85
M]I2F]>Z9&D#_7[ULU=`@BZS^K'[^V#X<GVZOHWZK-^A$`8E??=X<COE6J;R^
M6G\[''<O_]-"58]J):%10C]92=`*A[V@U[]`2]=HH9]&R[`U[/6Z_>'@_4TA
MR:H_]).;<G%W^D;'H-;1LSI.F('F5/5L^FF>';8&0><FNJ#]`8T`[1`U%(RQ
M+S=#4/N5?C%JNA]0$W%KZ)>_T1IV;6!]&UF3GAYE;3UBJPF0KHZKNT_[W8\K
M6E6H9X>WE5JC@E@->1[ZVD/U9/C97*!)H+3<*S6WU^1K&N8'FL#?[Z(P^M3^
M3I-N;61&*!-(B80EU`Q3:E,?9#[(?5#XH/3!V`<3'TQ],//!W`<+'RP=T"9;
MUP:GZ?TK#*[4*(.SJ48,K`="S[HLP552'V0^R'U0^*#TP=@'$Q],?3#SP=P'
M"Q\L'2"L2S/L5UA7J:%%7`SGKC3GR,C0"E./>4\DJ45JDP/)@.1`"B`ED#&0
M"9`ID!F0.9`%D*5+A/EI9?H5YE=JR/PTA6K31F'/L[\1.F7_6J2V/Y`,2`ZD
M`%("&0.9`)D"F0&9`UD`6;I$V)\6<&'_Y@"&%VTE79F9S3,R1,<X:@5.@*1`
M,B`YD`)("60,9`)D"F0&9`YD`63I$F%"BELN,*&2EB8TQ#$AD!1(!B0'4@`I
M@8R!3(!,@<R`S($L@"Q=(DQ(8<`%)E32TH2:A/UZ<TL,L=M=JHD*A>HE(NQW
MY!*10;7<$`HNG6K>1EG40CPO2E>1Z*K*`#%\:JE8]?BT77\=[>@YM(XU3,2(
MPB0=/"DET@*:N!8PQ+&`)BIF<[KB15095,L-N1'5O%"MJ(5J"[B*A`5(D;!`
M0T\I?>&N*FG954T"Q]F&A+7[4T-LYS.0R37I6CT%D-*M)3JA$H8+>E&)RVX8
M%)"=K#O"&SD@$Y:ZL7TS*.Q447/0I;BY[U7+L%IN4.0^+QCX(YFE;K3R5M=S
M="DT2Y.H`-8=VJ<=JW(ES[,&A>XV'O;]&,E(!8Z[N6)8M3J*@B',;*R5&]0=
M5+5ZK;ZT?6'+ZT$MM,C>JP#S@M[K>)0B%M8]H@XI@\@!T?>"F(2EW`%A=-%@
MM2.I[_4F,Q6%_\-P(/N<&ZGNT/B_YZDIK``WO!1-DD91<9]K%)TL7KC:!29Z
M=&VED3=2O,XDIB*UC]N:&M23V\!06B'CBF(@HJUT(\SXZ;1\7Q5&#0GP\TO6
M7#5)VDK%:'_?5B;2<VVE44^L^Y&W[B=J8U2CSQU7&E6+\?>[@,Y4>H%GX@RK
MY0:9(132`=B-^\^S=6'%K9'<MD@CJ2CLE)'^V+W];/MT-A6U!_IKCT;.6$F,
ME(-21!FB'%&!J!1(]E(%2MA+/@Q\_QF+";C<81R%WHP>T4Y:&>-47F1EV$DI
MH@Q1CJA`5"(:(YH@FB*:(9HC6B!:"B3]H:(YUQ]G=C8=_(FUW2`Q!_U=.PEJ
M*6ME0!E*Y8@*1"6B,:()HBFB&:(YH@6BI4#2RBIBO,#*.L`45C;(2:74;JIF
MND4IH@Q1CJA`5"(:(YH@FB*:(9HC6B!:"B1-JN+7"TRJPUUA4HW<Q(*V"&72
MT.YJ*2,RMHU`!GYR9:5X>.>("D0EHC$CVX@)(]D(;Y^;6BENQ`S1'-$"T9)1
MU0AA>`K.I>$_%/A46F368)#K#T;6%"DC\E3MCZ#K)PE6BDV1(RH0E8C&C&PC
M)HQ.-F)JI;@1,T1S1`M$2T8-_E#)ACL1/N8/I<7SAT9.C)"HH)2D*-+C'J4&
M49*O7G2$G<#+JC(KP'5R1E9-P:A6XV5OI15@-6.#G-9,K%1S:Z96@-7,&-G6
MS!G]K#4+*\!JE@;IUL@9<UG^%&+^9!!MX_RXA)&3`!CDI/T9HAPK%BA5(AIC
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MB$I$8T031%-$,T1S1`M$2X&D-U02C=ZX^#R%4IYJY@EW>"O"B(5.NL,HJBZ9
MZ8LKMAI[*$.4(RH0E8C&B":(IHAFB.:(%HB6`DEWT&;X2]RA]%3AN%W/HM`[
M7QR%1NJD/VH9-GYJJS'*$.6("D0EHC&B":(IHAFB.:(%HJ5`TA\JH7>GQYDX
M4>?_(EHPR)ZR)"&@%%&&*$=4("H1C1%-$$T1S1#-$2T0+042)E6+\04FK<1E
M8LG(,2FB%%&&*$=4("H1C1%-$$T1S1#-$2T0+062)O53^-.CE(:G'R491/L$
M3^F$D3VV2!G1DE!'2>'`CV.M%.O*$16,\$`B\M/=#QU(5%J\<:,38]%)@]Q.
M&D23M.XD'A`9]33,;2?KBHP*EFKHI)^`?JR3F)=&&CF)1\+('E"DC.H#"B\#
MR(S`P-;)&>G\A4YJO#"U8*55'3E`_5SLS`#%I"O2R#W!8.2<8#"R[LP86:F<
MD94J&.&[1SH>OVBYTBD"C6X>!*-*@__R.O!BHX2E[(!*#8ITZANV8**99XGI
M&'AOQ7.IA6[!RQ>Z!9?_3(MTI!^\GW&D#M*%-4S<3FM0/;W"P$L?DDA+.:,X
M-:BK[W;<=%HP9$T=J1G,H:58#5WZ]NUQ1HVTAQ\^G[&'"6[=T:&1>E'AV,-[
MEYQ$1LH='4:7'AV#EI_\9%@G-\B,**KCV;`0=61/J8&7;-M*W%M^-5+GG$Y/
MO9@T49<PU!&QG:^I0<9EWHE'QA6D6L^K^4D=Q3D=TA(J?'-C0KUT7YPRD1=4
M3VG7J,T1^9><1D9([?VU%"P=)IYT4B9;C9>A#%&.J$!4(AHCFB":(IHAFB-:
M(%H*)-Q!P^*7N*/20R/6,704>J8>L=`I=U@9MGV**$.4(RH0E8C&B":(IHAF
MB.:(%HB6`DEWT#S\%;.CJ_14"X@=^)C!LM1)?QA-SO2PU=A%&:(<48&H1#1&
M-$$T131#-$>T0+042/I#1:7N:G5ZA^KJ(-;=L1DYZ1:B%%&&*$=4("H1C1%-
M$$T1S1#-$2T0+062)O5C]S,FQ2"]:Y!K4D`I2F6(<D0%HA+1&-$$T131#-$<
MT0+14B!ITLL2A"XF"`:YR1TC&^>GC"C(J+=3S&"M%"\/.:*"$29W73]G^%!R
M5VF1(91!HI,Z":`C16YKRE*G,U@KQ15S1`6CADZJ.-E=6#[621UMB_7&!.`V
M`DSHE705%-IL-&7TTPR6!6R=G%%=Q\^%6``S6+JH*GM[9LZ;X-P)]"L-%-@Z
M1RR,;$]31M:=&2,KE3.R4@6C2DK.+151NXXZTW0=@`N/F)A<S!K(8.E6:^4D
M)T<QB(*WZF6E?XT\XW*IV(_=6<IH\?(U+OV9#FD+-W8G'YTQA0FL72]JY"4Q
M?OK:U5)N$F,0!4[*%)2^>F,OXSJG\QA/#::OY]0(<_3<V/FL.2IIN2`9)+/7
M@6\.EG)&!NO2/NVW.E[&FV&='.IXSRE$'=E1-RH]W]$Z]N2E<43?F%`E:]([
M?O)JI%R_&V3\[B>O7$&J]2?`21W%.1W:$/K[&O3'U5\V^R^;9//\?+A:[[ZI
M[V+HJR6QQN:+(KI!?$_*R09>R8A*5,C95!)22;4&09V(2JJ%U2NY#X?Q/67@
M#=JH1+V<:2JYH9)J/'G:1E$G5D?E#74BJD-+44-)E^J0A[#D/NC']_0N&TOH
M;GBL[D4WE0RHI%J:_;8%U!^:*PUU0M*FMW6_3DC:].[NE=`7>=PW6IJ<T^@;
M<DVC/#FFT2_=^)XNXC<TMDO6:N(]^F:1)DY]:S14%,0C.B+')]#+ASAI+*%W
M$+%ZG8!UTBBDDB9M]*XA5D?Q6&?4[<8C"G&P)*&2I+&$8LA8A8-8AP(O*FG2
M1K%BK$*IACIA&*M;=EA"M^IB=8T.2^C:7*SNR6$)W8N+U44X+*';1_2<IE;3
MC2)Z3E,)71.BYS25T-4?>DY3"=T^CM6-5VP!74*.U4WAAI*P0]J:ZM`U8AJS
M325T;Y3ZTS0.Z"HH]:>IA&YW4G^:2NC")K6@J22_B>FSC]AF^H1<K#X%UU02
M4DF3#_(@HI*FJ48?#**2)GN.R`*C1@LD5)(TEM"=\UA=#,>VT>UGLDV3/4>#
M>-2T,"6#.&GBV2"FS\/B$_)!3!_Y;>##F#X(B[P<Q&7%V_7J1E\&]+;ZLIFO
M]E^VKX>KY\TC;5"=ZH-Q>_UU0OJ/H_D\T^?=D;X&B")K^L(5^MJG#7W2OM.B
MK.AQMSOR'_3@=OU%4G?_!P``__\#`%!+`P04``8`"````"$`H@??V,$&```+
M&P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RL65UOHT84?:_4_X!X
M7\.`;6(49Q6;3ZF5JFK;/A.,;11C+"#)[K_O'>9[ACA.MR_+YG#OF;EG[MRY
M@^^_?F].UFO5]75[7MMHYMI6=2[;77T^K.V_OB5?[FRK'XKSKCBUYVIM_ZAZ
M^^O#K[_<O[7=<W^LJL$"AG._MH_#<`D=IR^/55/TL_92G>'-ONV:8H`_NX/3
M7[JJV(U.S<GQ7'?I-$5]M@E#V-W"T>[W=5E%;?G25.>!D'35J1A@_OVQOO2,
MK2EOH6N*[OGE\J5LFPM0/-6G>O@QDMI64X;YX=QVQ=,)XOZ.YD7)N,<_#/JF
M+KNV;_?##.@<,E$SYI6S<H#IX7Y70P18=JNK]FO[$84YNK.=A_M1H+_KZJV7
M_F_UQ_8M[>K=;_6Y`K5AG?`*/+7M,S;-=Q@"9\?P3L85^*.S=M6^>#D-?[9O
M654?C@,L]P(BPH&%NQ]1U9>@*-#,O`5F*ML33`#^M9H:IP8H4GQ?VQX,7.^&
MX]KVE[-%X/H(S*VGJA^2&E/:5OG2#VWS#S%"E(J0^)0$GI0$>;,`N2L_`)(K
MCG/J"$_JZ(G!K_@!ZSAK>%*_Y4WC+:D?//EX:.XN<:Q7A@NH&SRY&]?HBA]L
MLG&:\/S4-%?4#YY\O/>GZ9`E'3,D*H;BX;YKWRS8=K!H_:7`FQB%0,52@TR8
M)\M[N0))@DD>,<O:AM`A#7I(\-<'WT/WSBLD94EM-J:-9K%E%C@#,6VD`[$.
M)#J0ZD"F`[D$."`"5P*R^W]0`K-@)5@,&P8(:3Q5F"VS8"Z1#L0ZD.A`J@.9
M#N02H(0-^U$/VX<*,UT;V'IC)Z@"TGI[OJ^&M:$VP,638JZ:;+D)#]U`8@-)
M#"0UD,Q`<AE1!("ZH@N`B^,G=P!F`44@N7BTOJ>M](8:79.$FW!)#"0VD,1`
M4@/)#"27$442"%^7Q%O,/B\*YAE%8<%L*`(/+I/G+[6TX$;,+3*0V$`2`TD-
M)#.07$84#:#\RQI<WP_86`V4(N0XQ<5L:R"1@<0&DAA(:B"9@>0RHD0%)?KV
MJ+"Q&A5!O"4O;UN*B((7403.,['$R%67..9&;(D3@RCE-C*1MJ4R;L2(<IE(
MB1VWL\91-\/=QW"LR^=-"_.%_3NQTCX<:>2@PQRJ)`21):&()`E%X'R5)-%.
MOY@;L4@2@RCE-C*15G@S;L2(<IE(D01F)$LR$3IT/2QV;*S&3A`DI0-%/)X@
M$4'FPB8VD,3P2@V;S$!RV4N)"D&!O3VLT5J-BT(+G!JLH?'\0,WA+;5"*Q$L
MXP+!N2,*M)R-J97GCIV2YRVTW9&8S.E-S)G*#)VUQIPKS*IHN"_2MH<'>^GV
MO8%(9P5G($N\#87PJ%P/S[_3A22.2,H:ZKB$(THXN@O5,196;,2$C2BX4F$E
M<?DKE2L35HPK9UPP/3$)3Z2!JA]NL"3]KN\EB%7?3!12DVZN+>"66BE)1UL[
M]$XZQ=0G$`N3F#2IL!K[]\#7TC83!D(A,C29C2H'[K<D.<C%XI/5%M&F34Q\
M0R$UH^9:+=TR*Y$%$874C)IK,<;"BL68,*[WLF`\&%+A*.6*3I\)*T:??T2O
MJHI;MI]6E?9]LJH$TG)/.UBVB%@IN4<=H>'@6V2BX%&K@&2H7I42DSBET.(J
M<4:MELN1&!DYFRO,JI2X\[LBY;?V\EX[()V)^*:@'8H4DD]%!LGI2!P#`<74
M2H(2TS$UK3(3RA5'-6[<&TIQ?U"G:"<IYPJ!M%S1KW80/A9&R17*]<'A2*S8
MX>BZ6@5,3.:40OY5YHQ:O<N<*\RJ:+BIE$3[;]6,=*;*^4B@!911OGV\N7;,
M;1&Q@OK+JD9$(:V::1>I6%@QQX1Q?5#-R(@:O3CYQIJ7F?3Y1_2JJK@O_6E5
M,8G6OA%(RU"CZR!62H921TA!OAP3U8Q8L:*S"K33)X%ON5KNIQ3ZJ)QIS/JY
MAK\2"V:B)?GJ2[[I-55WJ+;5Z=1;9?N"O^AZ=U`9.<P_-S^.J:3A&_P9&J>8
MCGLA?#V:P/T0OJJ8^.,\?"2?LW6B>0C?'$R'S2*$>_@$O@SA)FOB<):'^*0V
MW\`Q'.)#UGP3H07X3(T"%15\IM[`+@.?\1ZG19+"&YS^YCAY$,)UR\2C50@7
M'Q-/5R%<;4P\0@C&GEH.Z&=A[*DW$?+`9VJIH+D#GZDWFR#<3,UW&X3;*3P"
M2:;BCNY"N,&:<21!"/=8$T]!P"F>]"Z$"RS8.UQR^"GB4ARJWXON4)][ZU3M
M(;'=L97LR(\9Y(^!GMA/[0`_0HR']Q%^=*K@XXN+/U[MVW9@?^`!^,]8#_\"
M``#__P,`4$L#!!0`!@`(````(0"Q.CR?H`P``)8]```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;*R;6V_;.A+'WQ?8[V#X_<36Q5<T/6AT!W:!Q>+L
M[K/K*(G1.`YL]W*^_?XIDA*'?S:U>_I2-S_.C#074B-*>O?[M_WSZ$M[/.T.
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M`_\ZCN[;A\WGY_._#U_K=O?X=$:Z9_!(.;:^_S-O3UM$%&9NXIFRM#T\XP3P
M[VB_4Z6!B&R^=;]?=_?G)_QO>1.ETSFD1Q_;T[G<*8OCT?;SZ7S8_\_(&$O:
M1FQLX-?82.8WL\4TB:XPDA@C^`T8>>/HJ5'$KU$<''A##>YUCN/7J,6SFW@Y
MBV:=ZV]HSHTF?HWF_&8135?)`K;>T%L8/?Q><Z*8J=V)XO?*$UT93?Q><J(3
M71I=I>6;\^;]N^/AZPC3%]D_O6[48A"M8<N6F':U+[KOU1R*31GYH*S<CN$\
MZNF$B?+E?;R,WTV^H+BW1N:.92(ID5D)5<G*;.Z#P@>E#RH?U#YH'#!!$/I(
MH,)_0224%14)Z\.=!4YH/+>MA%7)?5#XH/1!Y8/:!XT#A-N8D[_`;67E=HQ_
MWR@`(X-EL!=*O5#T(GTLB!1$2B(5D9I(XQ(1$2PVOR`BR@HB@FKKO>4Y883>
M"DDOTH>$2$&D)%(1J8DT+A$AP>+GAB1\`;*+@1+N/+=G?&<(2M")1>+EOA>R
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ME:9+85KZIGJ/RWW3G8KP3:.9O(`LY`EDD9;"CPU*;E"*!:/W+5XNI6(Q2%G%
MTMH2E^]X.*+T3[42CG_=!)VK>[+OW*K9*V5D>A`WC1IY:5S),\Z,HDBC5DS=
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M-0))_U1?<W%*8R7M^:?1`M.IGVWQ:KAN=]>@S"A"RJXP.:."4<FH8E0S:@22
M+JNNY7*7=8_C-D>Q1HXS&:.<4<&H9%0QJADU`DG_5'OA^/?3=R^QZ5.<"6R0
MEVVOO<L&J2';VI83LX*E2D85HYI1(Y",ANH^G&B\O6;%NE<1V=;(.?/,2#DH
M9U0P*AE5C&I&C4#2/]6)./[]?+9U2R-<U\C+MM\:JZX;BX*(!J&"I4I&%:.:
M42.0C(9J6YQH_"#;NLD1+FOD.)/%A')&!:.24<6H9M0()/U378OCW\]G6[<_
MPG6-1+83_Z8SBWNI86X3*EBJ9%0QJADU`LEHJ$;(B<8/LFW:)G<YTTADFU`>
M$RH8E8PJ1C6C1B#IWU7]5LS]ED%>2KU[MFR0&E*J;3F!*5BJ9%0QJADU`@F7
MDZOZK4Y:]B,6S?M.(V.4,RH8E8PJ1C6C1B#IG]=O_?0$QLSU6S&+L/CVK5@R
M]6^!!ZD^VXP*1B6CBE'-J!%(1N.J5BSA5LPBI[MFE#,J&)6,*D8UHT8@Z9_7
MBKV]0"7<;QF$"X)-5F:1TTI;A'6J3WP<^3M1@Y2U55HTV*HL<FTE4V^KH1ZD
MK*W&HLZ6C,)5+5C"+9A!(@I:"M<&>P*YE7+//(Z\Q:X8I*QB:=%@J[)(VO(B
M6@]2UE9C42`*JB=R+E9JYKN;!A?MY26ZL<*,LD>\,T@$1TN)X&@T[]Y_Z>[)
M"J/HH-+:<B-A;.&"X-26%]7:*@Z[W(U%@4A<U:0EW*09A&TK&X7,(F<KVJ!T
MD"H8E:Q8L53-J!&*LMY5/^1D^@>S7G=/(J4:>5M?WHYTHH6P=6&#D!N4N%7+
M.U]&"GL"ZK61:#7U7QPIV71UD>E:FIZM(F?'L"NZ1IB64<-97Q$U)>U=^342
MFZ2)MW!E*C;0<_=(#5KHG<!XD7HZQ2!@(UVRF<H@^>1CZFTJUH.4M=4(6S(D
M5_5_"?=_!HE"2OR]&2,D"LFT?[I$DD7LN5$8G<6PG)1LIAJDNA>4DM3;>*X'
M@2$:^M#Z;$0TTJM:PTY:%HA!LD"FWCEE1LJM$(.0VF[&^!$LAG'K1LE6JD%*
M65EXM]'U,&R--,*(C(771KZ]Q*3<*QHD*B/UKF^9$7(KPR`DWJ24G@`-$M:/
MDNU4!LF'9S1;!BEKJQ&V9$RN:B93;B8-$O61^NVS$1+EH4W9\IC[ZX=1P;CU
MHF0KU2#E7&@Y(OVQK*U&V)(1N:K]3+G]-$A6B;]^&"%1)=J4K9+ETE\_C(Z[
M?K"9RJ`?%8D^F/.$M1&V9$BNZD53[D4-$D62^&G*C)2H$FW+7&9F\UGL/?<H
MC!(D;&Y+ME,9](/KS"!E;37"E@R*ZO$N;EA2W1&Z#8M!HDZ2J>=?9J1$H6A;
MR%VWLLH6IS`*3F9+ME$-4MV2Y"UB]3`\1$(?-72-N:HU16OI-R$&B?*8>=6?
M&2%1'=J4J8XH3>;>-"N,DJ@.K>38J0:I+J#)/%EYN_/U(#($Q#4D2\/K9;O]
MBDL>T:OZ]!HT@T25S*A(N*TU>F(92*84'ZTHBL6<`WJ^X=[%;TFKL'F*&IEO
MK(O?,R\#J1K/R^>8;E/%'--(5%8R];J(3`7)ZV\-4F?;1R&AW8%!RE9%:6VA
M>^@58PZ?/J)=UV:)_WI!;>PXE=M8T]WMFHS353UORCVO0<ZDR!CEC`I&):.*
M4<VH$4CX-[NJB^VD91=KD;/EQ2AG5#`J&56,:D:-0-(_KS/]Z0U.?.?C+R`6
M8?GN"S+Q=WBR0<I6<LZH8%0RJAC5C-0G2=VI=BG1T="?&.D//_;M\;'-VN?G
MTVA[^*P^'^K>G^JQ_K;I+IFNU<8Q3II&\-F37@IH),9(-XG\D1FL(4L!:[/^
M(RI?)T[7ZDEC0">>8:1SCW3F&.DZ%AI98*3K>6EDB9'NA3@:66&DV]'P1R+H
MX,V4P+E%T-&7<E\G1@RPS1'0B1$#O"$0&D%$\6P]-))@I'O1W#\.@A.,#4(3
MC`P"$XP+7`QZ"`?#,8%_>,&5SS5/%^L""SZ/X&JWKH,C>;J$3NCX%4;4(L[6
M\#W>AV"L$-YP=!'"@)T[A#84V0_I^@,F%Q_X#I4:*M0\3>%$:`1],YP(C>3I
M##JA!**UA$YH)$_GT`DE%QT8=$(C>1I!)^0-[H:A$QK)TQ@ZH9#A?A$ZH9$\
M3:`3"B=NJ*`3&LD3)!\;41QI[&NMU:X5C^3)"CJAPL3&#W1"(WDZQ;F%2A;;
M(SBWT`B>4JS5SC2?`1Y6X#@A?["!CY%0MJL$.0U:PQ,,5&'H.'F";&._-W0&
MR'9P!&]"K]5[SJR31\@/7@L.C:!Z\09M:`0UBO=00R,X-[T3[B]+\$<]'6`=
M/$-:9\&1'"-%,*)XO(*1X+DAHNIA`HXSZ4\!7\6^;A[;?VZ.C[N7T^BY?<!E
M;]J](GG4W]7J/\[F5<F/AS,^B.W>FGS"]\\M/@69J@\N'@Z'L_U#':#_HOK]
M_P$``/__`P!02P,$%``&``@````A`+"@'*I;!P``P1T``!D```!X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULK%G;;N,V$'TOT'\P]+Z6=;%E"W&*V-:]!8IB
MVSXKLAP+L2U#4C:[?]^A>!')48RX[4L4'\X<DH?#X5!Z^.7[^33Y5C9M55_6
MAC6=&9/R4M3[ZO*R-O[\&GY9&I.VRR_[_%1?RK7QHVR-7QY__NGAO6Y>VV-9
M=A-@N+1KX]AU5]\TV^)8GO-V6E_+"[0<ZN:<=_"S>3';:U/F^][I?#+MV6QA
MGO/J8E`&O_D,1WTX5$6YJXNW<WGI*$E3GO(.QM\>JVO+V<[%9^C.>?/Z=OU2
MU.<K4#Q7IZK[T9,:DW/A)R^7NLF?3S#O[Y:;%YR[_X'HSU71U&U]Z*9`9]*!
MXCFOS)4)3(\/^PIF0&2?-.5A;3Q9?F8M#?/QH1?HKZI\;Z7_)^VQ?H^::O]K
M=2E!;5@GL@+/=?U*3),]@<#91-YAOP*_-Y-]><C?3MT?]7M<5B_'#I9[#C,B
M$_/W/W9E6X"B0#.UYX2IJ$\P`/@[.5<D-$"1_'O_?*_VW7%M.(OIW)LY%IA/
MGLNV"RM":4R*M[:KSW]3(XM141*;D<"3D]C3Y7SN+I8>L-SP=)@G/)FG[=UT
M<)D#/._L"@;2SQ2>G^MJP1S@R1SF4]>>>\M>FAN3@AGT/<&3.5HPOQL.L!E[
M!WA^;F@KY@#/^X9F08#1]2:1QM;2G=K+N35?D!6_,4I+Q`K\<W.<)@VR/F9W
M>9<_/C3U^P02`3BVUYRD%<LG=#Q:::\B?C\*7XA;PO)$:-8&R`N1V<*>^_;H
M6/,'\QOLDX+9;+"-I5ILN079%(1VIP.!#H0Z$.E`K`.)#J0ZD$F`"3H)L6`W
M_1]B$1HB%I_FA@.#>K:F#+?@+CL="'0@U(%(!V(=2'0@U8%,`A1E8#<A91P(
MZ/&DQZ.&>$%ZDZ+&FNM1PVR`2X26JXDC3(0Z"`D0$B(D0DB,D`0A*4(R&5%4
M@A2)5")'PYV;C="`;!"E0A+'6JBB;)C1+=V$B=`-(0%"0H1$"(D1DB`D14@F
M(XIN()&BV^VH(M:]/'Q:&X;`0PAF+?0M)HRXVPXA`4)"A$0(B1&2("1%2"8C
MBAIP^MVA!K%6U6`(K3U(FMTB9(>0`"$A0B*$Q`A)$)(B)),19>IPP-PQ=6*M
M3ITB]D*DWBU#AF2\HX@%P2@%BZ/NK@"YA0R!@D%RTY)9)(QXC,6(*!$V,M%*
M[3\51IPHDXD4S<B]0C[A;V\>8JUJ1A%9,X9(FE%$TTQ+TP%R"QD"#TDS+9%%
MPHA/-49$B;"1B+R9IIDPXD293*1H!E7<'9H1:U4SBLB:,432C"*N",4`F80,
M@6%*^GCJM")AQ*<5(Z)$V,A$6DRGPH@393*1H@\I6A6!:-DX)7>+[E@5KYL:
M1@P'U$BP.5`>LJ*1L*C"]<1K0U:.0Y)T#'(&*,!6(8=@%I)\2TV^P8I/.^;0
M0)]P2.72(CP=K#A7QJ&>2]605)F?WYBD.-?%HI`EI3-F9=DBK'8<&F83<&BP
M"AGD#EP1AF+LF&"K%$.9XJC*0$K*.V2@%2@4/USB#4R6*`-W>FF=/72W8%8K
MX;ACCO:LO[!8SM+5BX*`<P]>(8,<M3NMFHBXU8IR3Q=:!H\Q<\)];C*GW(HR
MVXX6A)E"K$I-"M,[I&9UK"PUA6P(O&%+>5HBV9*[-5F0(;QV#++M7HZ5[<RT
M?1A@IY!!KO>!AM%@P(,AQC3)8$7NI7"K5C-`.K1SEDQA434D1>H=&K*:5M:0
M0EJX:JNX)6<IT7`(O!V#>+A:<V>I'7$!]@H9Y"X_%)'V!`9\^C&F232:E5;9
MI$,[9\D4%E5$4MO>(2(KA641*:0%HC:H+;E;Z8'('&D@SKW%2DL4`78*&20"
MT='/X,&`SS[&-,E@10+1TW9`.C1SDDPA424D-;(LX;\[@5FE+2M+(2T\M3VS
MA3,'A2>%7*L/-!#6UG)B@)U"!K'H=*>NEB:CP8"+$F.:A%O1G.BXVG#3H9VS
M9`J+*BTII?^[M+0@5PXJ"D'/?!1;BT%RJJ202R/47<Z\A99@`^P5,L@=;G41
MAF+LF'`KR-E22M>6+N56+LTBLYFV3IG"K,H)Q]E-.;_6UX]J17C_*8I%0J,5
MBQ22SIDM"5M]QR,HP%8AAB(,Q1A*,)1BB'QP&,9%Y:$?$.C+V'/9O)3;\G1J
M)T7]1CX..&3Y!4R_7&Q<']Z10.SH^-R'MP4C^,*'JS3&(9_Y$:06W`(IRB=Y
M"+?`3@6?,3;8?.`SU@)!"3Y]W:F-&+[!//4AK^$;\FUFI/>-[<.K1SRJC>/#
MVS:,/[G^$TB.&Z#.A2&-=0&%+$QCK`7J$/`9ZP9*"_`9:X%C%WS&%@M.4O`9
M:XD]GUP]\*`3SX<+_PB^]-.Q228K'RYS(_;6#+H>ZR'S0/>QAHWG;T8;MIZ_
M'6T(/)]<QG#O(03#V"S"I0]W_!'[E0]WVQ$<9A'1'DP1/O`![9J_E+_ES4MU
M:2>G\@![:-;?1QOZ"8[^Z%BN>:X[^'36IYTC?"HMX2W8;`JEP:&N._X#NC;%
MQ]?'?P```/__`P!02P,$%``&``@````A`,`LEQG\!```^Q$``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULK%C;CJ,X$'U?:?\!\3X!<PD)2C)JKCO2
MK+1:[>69$"=!#3@"NM/]]UO&AOB2G4EKYJ433E<=ZE25RW8VG]^:VGC%75^1
M=FNBA6T:N"W)H6I/6_/OO[)/*]/HAZ(]%#5I\=9\Q[WY>??K+YLKZ9[[,\:#
M`0QMOS7/PW`)+:LOS[@I^@6YX!;^<R1=4PSPV)VL_M+AXC`Z-;7EV/;2:HJJ
M-1E#V#W"08['JL0)*5\:W`Z,I,-U,4#\_;FZ]!-;4SY"UQ3=\\OE4TF:"U#L
MJ[H:WD=2TVC*\,NI)5VQKT'W&_**<N(>'S3ZIBH[TI/CL``ZBP6J:UY;:PN8
M=IM#!0IHVHT.'[?F$PISY)O6;C,FZ)\*7WOAN]&?R37OJL/7JL60;:@3K<">
MD&=J^N5`(7"V-.]LK,`?G7'`Q^*E'OXDU]]P=3H/4&X?%%%AX>$]P7T)&06:
MA3.&49(:`H"_1E/1UH",%&_CY[4Z#.>MZ2X7?F"[",R-/>Z'K**4IE&^]`-I
M_F5&B`8UDSB<!#XG$O?#)!XG@4].$BQ6ON\M5\'CD2PY"7Q^F,1BJ1DSG11#
ML=MTY&I`^X+X_E+0Q8#"P#2F%+.$S$G_OYQ#GBC)$V79FN`/Z>RA45YW+G(W
MUBL4M^0VD6Z#9(MXLJ#II[2)"J0JD*E`+@`62)QU0OE^@D[*0G5.$483<!/N
M**(FB\DE48%4!3(5R`5`$N7JHEQ89??7QU0KZ@0K0:@50FLYZ(C;`-=<4$\V
MB6>369B&I!J2:4@N(I(X6"L_H6*4!=1"6\Q*7*1HB;C1M^3.)K-<#4DU)-.0
M7$0DN3`'1+G?KB$U'E5-T40<86.0+IY80Q(-234DTY!<1*2(80X]'C$UEB/F
MB!"QAB0:DFI(IB&YB$@1PX!Z/&)J+$?,$&<Y+_^8([>!D'`$CB!SOR%O):^=
M=#::RI=I2"Y22R+HZ4:;V`NZCPSGJGR."+P8VOU.`[DPF=F\IARR-H:(VC@B
M:./(6M*FC(YT-IJU:4@N4DO:@/J'M5$.61M#D'.K&T?<&4DXXH^;EV.KNU>J
M>62JAS+X<]%#$HE@SH@J[U0*SB=3J49K60^'D-"($W33F$S0K8#I!-VLL@FZ
M6>43-%K)D=/=5>B][T3.]F*8O5,K1(A!"!K@MCQ\6UX>\62UGAT3#CGV6)_`
M<=;^6G%+=;=,=EO:2W_M*L,_E]QDN73??5PNVZ4EN0QR0+4@5SOV,"NA/Q/X
M3IO8<4:Y[M(.E*A3;B$X9=]URB4G62K=AA^7RC=ML;(,4BJKK(D8<2NQL@SB
ME?56=K!43HZI[I5Q:/*RW96GI#67O&2Q=!,6Q+)#[P='*.([N9@#!BGE5M3$
MW%&H7,(AAP[HUQT*D.VC0%X4J>Z6R6Z!@WQ7F<:YY"4G@>[K/YP$?C@0D\`@
MQYL7;TSO;-#-2*PZMV+S=NWYR[6GM;CFEG&F<3R^[F`,!.Y*V5SIC?3V-B:9
MW3#9O:?!W0G'N*Y[HR0O]/8(C;+;S#"[VD9>"$<UF%LJ[H=P(+J#+T,X=MS!
M@S!:W<'C((SOX4D0PEE`YTE687;//@]"V$UU>[B:/XWS6XV?7MGOV$=."+<,
MG2=R0SBAZ_B3%SY!HN$?UOP&N'I?BA/^O>A.5=L;-3Y"<NUQ677L\LX>!G(9
M3RA[,L"E>_QZAA]9,!Q:[044[TC(,#W0%\P_V^S^`P``__\#`%!+`P04``8`
M"````"$`RRFJU700``">4```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
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MLCE\_?;VV_W^Y8TD/N^>=Z>_6M'KJY?[J/CRNC]L/C]3O?\,QIM[UF[_`/F7
MW?UA?]P_G@8D=R-O%.L\OYG?D-+'#P\[JH$(^]5A^WAW_2F(FO'M]<W'#VV`
M_K/;?C\:_[\Z/NV_9X?=0[5[W5*TJ9U$"WS>[[\*T^)!('*^`>^T;8%_'JX>
MMH^;;\^G?^V_Y]O=EZ<3-?>$:B0J%CW\%6^/]Q11DAF$$Z%TOW^F&Z!_KUYV
MHFM01#9_MI_?=P^GI[OKT70PF0U'`9E??=X>3^E.2%Y?W7\[GO8O_Y5&@9*2
M(J$2H4\6(><>AY%RH$_E$`P'P7@X%1?M\1LK/_KL_'H=2*ZM'GTJA\E@'$YF
MMVWU>JXT58[TJ1SGYSG.E"-]*L?1X'8R&4]O9_UUHQ'9WBI]*L?9>5><*T?Z
M5([!8!8,YZ-W+AA09Y-M+WJ=:OSS+AETW8;^HUPGYUV4^TJ@.\MY;1]PIQ'_
M4=<,SPMMP/U&_$>YSLYTY1XD!I5R[;W?&SG`VO$:;TZ;CQ\.^^]7-`E2I(YO
M&S&E!I$0XY$J.V$W=G\T=&G,"I5/0N;NFGH7C<HCS3=_?!P%LP\W?]`<<:]L
M%F@3V!9+MA`3@I"-79"X('5!YH+<!84+2A>L7%"YH';!V@6-`6XHUEW`J8/]
MBH`+&1%P#M6"@6Z!T(DN6[!+[(+$!:D+,A?D+BA<4+I@Y8+*!;4+UBYH#&!%
MEP;AKXBND*$UQ^C.P<SMSLJ&9JFNSX^=B'<F7<B!)$!2(!F0'$@!I`2R`E(!
MJ8&L@30FL<)/$]FO"+^0H?#3$.I".PIN[>`NE%%?_#N3+OY`$B`ID`Q(#J0`
M4@)9`:F`U$#60!J36/&G"=R*OS_?XDE;6+=AYO`L%*&/+O#![=0._+(S8K<8
M2`(D!9(!R8$40$H@*R`5D!K(&DAC$BNJE&U=$%5A;4=5$9GHBG5M"20&D@!)
M@61`<B`%D!+("D@%I`:R!M*8Q`HA9087A%!8VR&4))QVZ]U2$;T"QD`2("F0
M3!'*;XTN[\SU>6?$7;X`4@)9`:F`U$#60!I%VJI:417;94S>!B+#/CWM[K\N
M]E0GFD4]T\"(DC29N@D1.]B2F,%6Q`@VD`1("B13A/8$1K"=B3WOC+I@`RF!
MK(!40&H@:R"-(AALNFDKV)Z@TCZ1HRJL[:A*8D95$2.JBM`]&/&9V_-OTAEQ
M?%(0RB296$+SH2V4=T8L5"@R[X99V=D8=S1W5H159\1"%0C5G4V/T+HS8J%&
MDA";0^P3+VB/UMQN$(7,%F%D-`FC]K2D'3$)HI21=LP8V6W@;'ER;<55+AAI
MK9*1K>7,4BMMQ5H5(ZU5,S*UPJ%S7VMMQ5H-HU;+FH?$QON2MI![(\KO6'O1
M*MQ=6VTAK633J^V@0F9;`$I92]<Y8V36.9@[&Z1<6_%]%8RT5LG(UG(FL96V
M8JV*D=:J&=E:SH!?:RO6:AAYVD)LC<Q%H7^>$@<>SD2ED-46TLIJ"X7,M@"4
MLI:N<\;(KO/(F9NT%=>Y8*2U2D:VEA._E;9BK8J1UJH9F5KAT.DC:VW%6@TC
M3UN(C=(%;:'V5>:XD,AJ"X7TK<?B[(D:,33;`E#*5MHQ8V36.9@[V]A<6W&=
M"T9:JV1D:M&QN]VN*VW%6A4CK54K-&I/F=NQOT;46([VA"1V2&;@Y;'6A9F1
M.)=SQX9$5GLHI&\_5HZA7D<31"DC[9@QHE5/)P#SB1W#7%MQ#`M&6JM4:*IC
MN$)4H6.-5FM$C>5H!U]LI,S@OS,#J7V7V>LE"HQT7YQ-4EO06.,ZQPJ-M56"
M*$7'#*UR1`4ZEFBU0E2A8XU6:T2-Y6B'5&RL+@BIVH>9(94HL$>G,^LN*>)M
ME'7'C16::JT$48J.&5KEB`IT+-%JA:A"QQJMUH@:R]&.LMAH71!EN2^STAB)
M)N:A5#ATYM-E(*VLOJP093-ZX,^<Q2=1CN-A>\(>3)WF2U$X8]0KG&MA??EP
MZ,P[!6OI,5@RZI5?G25?L9:6KQGURJ^UO/CB`<+2L$HK;+<X#0>KQ7]NG1`J
MSMY"HHEYXV,G7U^*P2CF-'.T230-VQ8.;V^=-DB4#QGP/)BB3*;0V%Q'H#US
M;<5:!6J5VJJG;ZRT%6M5J%4K],/JK;4!RS26C-UZ8G-HCM>?:SVYQ;2&L403
MRF>[T1@.G5WODMH-EB2)QI1\=8X!#F-E-6X;>30<.YN'%)4SA?J5<V4U,:\/
M[5Z@?'F6_.HL^0KEZ[/DUVSUH[@TEK+5%4+W-,#M"K_OWWYT%&:<VK0R]DA6
M*!QW`VZI$-T-=])8H>FH0PFB%!TSM,H1%>A8HM4*486.-5JM$366HQUJFM.L
M4=>?WH7"W`FI1**D&R7AT)T=E:.Y2BHTUB?I":(4'3.TRA$5Z%BBU0I1A8XU
M6JT1-9:C'66QES;GMG>B++?>YB062F0M09B+*"NK+RLM6HJZYL%)3#F.YC(7
MN762G!2%,W;I%<[9BB;)[O(XAZ%\R8Z]\BNVZI6O4+YFQU[Y-5O]("R-)6RW
MN-BQFRWN3F%GG>:'<M]O=02)K*04<A'E9XTVZ3>5T_%DXAP1)LJ%RGD:3%$E
MTU8]S9EK*]8J4*O45CU:*VW%6A5JU=I*)(U0N[4N9Y7&4K';[I><-]`:`U.E
M1!/:_1J#P<U$E*,UB)4C;>@Z1\\@5E:S=A#/1DZVF:)PIM"D5SAG*]K6=)?W
M#&)Y>>.^2W;LE5^Q5:]\I:P,^9H=>^77;/6#L#26L-T1Q#%%WR`^,P^1IQTT
MBG7X1H%SKKD0CR6*I=7<;3K3\%+;<#>.$26(4D09HAQ1@:A$M$)4(:H1K1$U
M%K*;@]K9:HYW5E%A[N0J"NF48TF'?ZV51C&B!%&**$.4(RH0E8A6B"I$-:(U
MHL9"=DC%2879P]\)J3S8L-8CA73\EO3%`H044()6*:(,48ZH0%0B6B&J$-6(
MUH@:"]DAI93BDI`*<Z>72D2MQJ-\25\&""NZ*J-8(7%RJR?EP#FA3]`Q]3LZ
MIU.9Y6A74&QXS3[S<ZF-W#9;74DBJ]X*F?662!RO&O6&=`8<4SK`%S%T')U3
MMTQ9R4A;]18SLU7O_K'2FML-JQ"=67(K+AGI$Z"8D:YSPDA;I8RT5<8(3\;$
MTG/)K<LMG=DVK0(%C_JA$75W?6(K8R^MD-I9A`.WH;C<%G93%[92B?C`[:U<
M_B,5NR$OVXV-<#>FD-CP&=%P$SEE96;A"JDSW]O)P,D"$O:QE2$<\I:4S'PT
M<`RR]V3L>+A[E7<Z-FY*1A(YO<,]`V`KLW<H+=FNL\'$B6&"/JE"JD?=#D9.
ME\HL'[NF(D4UIZYW:BHS6NI</%X7(XF<EG>._);*RFIYZ:B:S)VFV>&=9N_3
MR-[3L"/A3VWY19>S7Q48^7+;T*G>@JWZ<EMMP\&.$26(4D09HAQ1@:A$M$)4
M(:H1K1$U%K+;X[+<=H2Y+2-[773FEZ6VTE&&##A!JQ11ABA'5"`J$:T058AJ
M1&M$C87L*(LT](+QK[)6<_Q#(KL<`8H1)8A21!FB'%&!J$2T0E0AJA&M$346
MLD,J,M,+0BK,G:Q((C/M&RFDDYN8$97H)=>=:!)MQ=T[9:2U,D:F%GS1F&LK
MUBH8M5IV&$1R>4$89"YJK2PJ8S630X7TK<>TZK4;`?/6P]!9`1-MQ;>>,M):
M&2-;RTFM<FW%6@4C#`,M;W88?FIOT*K8G40ALY,PTC6*%3*>DDD0I>B8,:+H
M&KW+"6NNK;I0,/*$0B31Y_>(L3!WZBR1N5U05F9BH9#YX`RB%!TSM,H1%9:C
MU>7'EZ71K;E309G&VN>AH;,C6RI'X^`O9BVSY^)Y*%O)Y!)&28K"&;OT"N=L
M)84G[I,;A25LQ^RR5%M\0>QV"I5JFZE4&+H;,>5H]1/I.*;52G=Q]ZF01#F2
M%7?Q%+4R;26.VV=.^IOK8A8I+!$[)"*I-<?)STT9,C4V)]2Q1%,K(0J=G=)2
M65F]2Z79]F3@[DR4(SV5P95,%1*KA`YQZ&R#,NUH6D$,NYM@^>(]>3NL;H+?
MO]6A;V&AITED/S<1N@FE<K1ZFG2<R@/WP/TR,5$N5,Y52U$ETU;>KW1R7<XJ
MA:5B1^.R])HF4XB&1$YO@G$GK:S>)!']0(/1W#CN.BNN3:INPM#*%"(M$9/1
MV.F3N2YGE<)2L6,B\M;_?^"I[-?(D<44(P[:["D*!IZRTF=:L7*D[R"-4(V<
MS62BK;B2*5_1VC[CP)-7G,KH!?-;&'.=`2L7K(QG:J)!?T'XA(JS*DIDKXKN
M(<>RO3P%64\_L4+]7^8E;*5&I[MXI2B<L0OUT6Y>@^4V5U;3:=LY\6FWPE*6
M75'^YHC\#8.7[>'+=KE]?CY>W>^_B=\3F8N6ZK#ZL9/1)/I$2M1"3@F=,D1B
MA^TKF5))FUB#SXQ*VHG(+2$QKQ9)^90^A71?=`3CN3J5B&^U?"4D)E-:]^HA
MW9<\@W9*XO$T2FA0HQK-#I&8`;"$!A;Y^&J944GN+:$?E?G4=GKG^@OZL9EV
MK+L\I!OV7'LQH@![^*<QZ7O#-:9?L_$XQ.,15<(G1>D(5<)7$H_'Y.-3HU68
M?'PE\7A"/K[FHB6)?+PEH]M([!<Q]+3)HI)VD#H!HST'J;7/\SLEM,V,"F])
M/`[HWGSAIVR>U'PEB_`V6LB7%YSKT+=*T=);0E\;18FWA+X7BL1W)%C3!=WU
MPGO72RI9>DMH5Q^)/3NJT4:72GS7H4T>Q<`7-]KJ1V)SYU$+*6YT9HLE]#!9
M))X>PQ)Z6BP2CX=A"3T.%HGGO[`D#JF/TH,E6$)/SM!U?"7T'`Q=QU="3[70
M=7PE<4!QH]-VSW6H1#P*C"7TZ&\D'NS%$GJ0-Q+/ZF()/0E)]?%%E!YUI/KX
M2NA91JJ/KX0>5J3Z^$J:.4TJWL$8T&"D;^SPUNB]#ZJHKX1>[*"*^DKHS0VJ
MJ*^$7HR@Z_CF3GKS@:[C*Z%7&^@ZOA)Z=X&NXRNIYI%X20>K4\\C>E_6PP.*
M&652OA+JA?3FH*\DI!+?9$RO8E&)KT?1>T)4XKLS>HV)`N`K*>:1>%4);Z"<
M1_06L8=39<1[K;X2&FS>RM!;@53BJPR]HT8EOLK0VU)4XKNSAI957T=?S*.%
MUV$YCY;>@ICF)V]!.H_$RV!8QXQ6`E]4Z-UB"K`O*O2F*Y7XFIC>NZ027U3H
M+4`J\45E,8L6OKHO9]'2QV-*&GP\G47T8P">^LTB^KD##Z?9I;6_Z=8?^G6X
MM\V7;;TY?-F]'J^>MX^4[0W;%_H.\O?EY!\G]9SWY_V)?A>.LEWZ22OZ'<`M
M_>K&<$"[S,?]_L1_T(5ONE\6_/@_`0```/__`P!02P,$%``&``@````A`"D=
M)&,Q`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````)R104O#,!B&[X+_H>3>IFE!);09
MJ.SD0'"B[!:3;UNP24,2;?OOS;JN3O3D,;QOGCS?EVK1ZR;Y!.=5:VI$LAPE
M8$0KE=G5Z'F]3&]0X@,WDC>M@1H-X-&"75Y4PE+1.GATK047%/@DDHRGPM9H
M'X*E&'NQ!\U]%ALFAMO6:1[BT>VPY>*=[P`7>7Z%-00N>>#X`$SM3$034HH9
M:3]<,P*DP-"`!A,\)AG!W]T`3OL_+XS)65.K,-@XTZ1[SI;B&,[MWJNYV'5=
MUI6C1O0G^'7U\#2.FBISV)4`Q`[[:;@/J[C*K0)Y.[#^S36)]_L*_\XJ*48[
M*ASP`#*)[]&CW2EY*>_NUTO$BIR4*2$I*=<%H:2DQ?6FPJ?6=)_-0#T)_)MX
M`K#1^^>?LR\```#__P,`4$L#!!0`!@`(````(0``T@"ZC0(``%0(```0``@!
M9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)Q634_C,!"]K[3_(<H=4@I:(>0&L13$2B"0$MBCY3J3QB*Q
M@SVI*+]^)\GV"]Q(]&9[WLP\OYF,PR[?JS)8@'7*Z$EX<CP*`]#29$K/)^%S
M>GMT'@8.A<Y$:31,PB6X\#+^^8,]65.#104NH!#:3<("L;Z((B<+J(0[)K,F
M2VYL)9"V=AZ9/%<2ID8V%6B,QJ/1KPC>$70&V5&]#ACV$2\6>&C0S,B6GWM)
MES41CME579=*"J1;Q@]*6N-,CL'-NX221=M&1NP2D(U5N(Q'+-K>LD2*$JXI
M<)R+T@&+-@?L#D0KVI-0UL5L@1<+D&ALX-0'R38.@YEPT-*9A`MAE=!(M%I8
MO^G69>W0QG^-?74%`#H6$:`_[);;V.VU.HO'YQV"5KO(-D+/A`R['%.%);C'
M_$E8]%&FRF\X=RQZQCVA514Y]0:_T4AZ\3^ZK[8RV\S7=[@V5&CM(..T<J94
MF4#:_!:ET)+47`-;7?HLPRXGW_%)D+)5WTKSW\6?YM'.A58?74]U(B1-50F[
MY";GB?(RNW(.D%_)MT8YU?9BBWT!JPQ/"S^S6^HG_B+*!O@#"-=8NH+>[8RU
M6/=&SU.P%9_"#$GCJE+8H3MZ7D8)&OE:F#*C"4!N]'DJ]`.;F8.WAG+SF\5>
M!L.:'*+CV,MF6$A_GCU*\E3,Z#/PIAD6U)_&I^A0CN2SL$/@87U/O9<8]CGS
M^@SKZZ_)/GVG@$+1E%VWZ>;K'G;QZSM<$S^U81^_;-XZ]G?Q-\O70AZ$YCM7
MV!G?GP;VO=*O[KE.S90&V^I%VCUD22$L9#2K5_;-`;NCQ\B6;9#K0N@Y9"O,
M5T/[?M*<:G\2XI.SX]'IB)[&K3,6;7X'XG\```#__P,`4$L!`BT`%``&``@`
M```A`*WNTV;&`0``^Q(``!,``````````````````````%M#;VYT96YT7U1Y
M<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@``"P``````````
M``````#_`P``7W)E;',O+G)E;'-02P$"+0`4``8`"````"$`8N`%4[(!``#"
M$0``&@`````````````````E!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"+0`4``8`"````"$`_'N:<?4"``"2"0``#P`````````````````7
M"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`&&?_?8(!0``G1(`
M`!@`````````````````.0T``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+
M`0(M`!0`!@`(````(0"\[N#7KP(``,,'```9`````````````````'<2``!X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A``BZ_JY?
M!@``I",``!D`````````````````714``'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"+0`4``8`"````"$`B(WAY4X#``!5"P``&0``````````````
M``#S&P``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````
M(0!<T@N,J04``$\;```9`````````````````'@?``!X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`!-,\R`.!@``LB```!D`````
M````````````6"4``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4
M``8`"````"$`#:I"A2X-```!;P``&0````````````````"=*P``>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0!U=SU[R@8``&0C
M```9``````````````````(Y``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L!`BT`%``&``@````A`(EQ"!U0!```OQ```!D``````````````````T``
M`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4``8`"````"$`0V#3
M.XL%``#,%@``&`````````````````"*1```>&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L!`BT`%``&``@````A`']-SK]@`P``[0H``!@`````````````
M````2TH``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````
M(0#HP.T4I3D```70```4`````````````````.%-``!X;"]S:&%R9613=')I
M;F=S+GAM;%!+`0(M`!0`!@`(````(0#2K<+7GPP``"1V```-````````````
M`````+B'``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``
MIQL``!,`````````````````@I0``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M+0`4``8`"````"$`<@BN7)0#``!)#```&`````````````````!'FP``>&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`(6^'-6R!```
M:A0``!D`````````````````$9\``'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"+0`4``8`"````"$`7\-7FOT)``#8*@``&0````````````````#Z
MHP``>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0#D
M2I$B40D``*$K```8`````````````````"ZN``!X;"]W;W)K<VAE971S+W-H
M965T.2YX;6Q02P$"+0`4``8`"````"$`!)%CD5P4``#$;0``&```````````
M``````"UMP``>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@`
M```A`'8\R2YC"0``4RP``!@`````````````````1\P``'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0`Q(##TO0P``/I$```8````
M`````````````.#5``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4
M``8`"````"$`[+)OO.X&``"%'@``&`````````````````#3X@``>&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`*B?J^/[`@``%0D`
M`!D`````````````````]^D``'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"+0`4``8`"````"$`7U!0>\T1```D80``&0`````````````````I[0``
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0!2T4V0
M_PL``'D^```9`````````````````"W_``!X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L!`BT`%``&``@````A`*1=A7'*#@``C4H``!D`````````````
M````8PL!`'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"```
M`"$`H@??V,$&```+&P``&0````````````````!D&@$`>&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0"Q.CR?H`P``)8]```9````
M`````````````%PA`0!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`
M%``&``@````A`+"@'*I;!P``P1T``!D`````````````````,RX!`'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`P"R7&?P$``#[
M$0``&0````````````````#%-0$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+`0(M`!0`!@`(````(0#+*:K5=!```)Y0```9`````````````````/@Z
M`0!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`BT`%``&``@````A`"D=
M)&,Q`0``0`(``!$`````````````````HTL!`&1O8U!R;W!S+V-O<F4N>&UL
M4$L!`BT`%``&``@````A``#2`+J-`@``5`@``!``````````````````"TX!
G`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"4`)0#U"0``SE$!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERBAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">77 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenue</a></td>
        <td class="nump">$ 209<span></span></td>
        <td class="nump">$ 208<span></span></td>
        <td class="nump">$ 626<span></span></td>
        <td class="nump">$ 1,075<span></span></td>
        <td class="nump">$ 2,927<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">320<span></span></td>
        <td class="nump">345<span></span></td>
        <td class="nump">952<span></span></td>
        <td class="nump">2,084<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
        <td class="nump">209<span></span></td>
        <td class="nump">528<span></span></td>
        <td class="nump">971<span></span></td>
        <td class="nump">2,027<span></span></td>
        <td class="nump">5,011<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">3,378<span></span></td>
        <td class="nump">3,315<span></span></td>
        <td class="nump">8,976<span></span></td>
        <td class="nump">8,596<span></span></td>
        <td class="nump">53,955<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,979<span></span></td>
        <td class="nump">863<span></span></td>
        <td class="nump">4,768<span></span></td>
        <td class="nump">2,944<span></span></td>
        <td class="nump">28,839<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">5,357<span></span></td>
        <td class="nump">4,178<span></span></td>
        <td class="nump">13,744<span></span></td>
        <td class="nump">11,540<span></span></td>
        <td class="nump">82,794<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(5,148)<span></span></td>
        <td class="num">(3,650)<span></span></td>
        <td class="num">(12,773)<span></span></td>
        <td class="num">(9,513)<span></span></td>
        <td class="num">(77,783)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
        <td class="num">(925)<span></span></td>
        <td class="num">(463)<span></span></td>
        <td class="num">(2,382)<span></span></td>
        <td class="num">(571)<span></span></td>
        <td class="num">(2,987)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
        <td class="num">$ (6,073)<span></span></td>
        <td class="num">$ (4,113)<span></span></td>
        <td class="num">$ (15,155)<span></span></td>
        <td class="num">$ (10,084)<span></span></td>
        <td class="num">$ (80,770)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted (in dollars per share)</a></td>
        <td class="num">$ (4.81)<span></span></td>
        <td class="num">$ (3.51)<span></span></td>
        <td class="num">$ (12.24)<span></span></td>
        <td class="num">$ (9.52)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</a></td>
        <td class="nump">1,262,546<span></span></td>
        <td class="nump">1,171,012<span></span></td>
        <td class="nump">1,238,567<span></span></td>
        <td class="nump">1,059,113<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Deficit</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">5.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stockholders&#8217; Deficit</font></b></p>
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2007 Equity Incentive Plan</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On August&#160;12, 2013, the Company&#8217;s board of directors approved an increase in the number of shares of common stock authorized for issuance under the Company&#8217;s 2007 Equity Incentive Plan (the &#8220;Plan&#8221;) to 2,423,072&#160;shares.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock option activity under the Plan is summarized as follows:</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Number&#160;of<br />
Options</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-<br />
Average&#160;Price</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,432,369</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.43</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Granted</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">331,860</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5.60</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Canceled</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(17,860</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.56</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exercised</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(35,852</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.65</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,710,517</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.26</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="374"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="10"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="80"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt;" size="2">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30.6%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%" colspan="5">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Research and development</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">581</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">32</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">686</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">82</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">General and administrative</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">401</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">483</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">24</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 31.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="31%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">982</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">42</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,169</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">106</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013, the outstanding options included 340,121 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at September&#160;30, 2013 was $1.8 million.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013, the outstanding options included 220,496 options with both performance-based milestones and market conditions that were determined not to be probable of achievement. The aggregate grant date fair value of these unvested options at September&#160;30, 2013 was $0.2 million.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013, the unrecognized compensation cost related to outstanding options (excluding those with performance-based and/or market conditions) was $0.6 million and is expected to be recognized as expense over approximately 3.5 years.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.14%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.6</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">90.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.07</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6.06</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="33%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">90.3</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Remaining contractual term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.27</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.23</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 62.52%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="62%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2013 Stock Option and Incentive Plan</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On August&#160;28, 2013, the Company&#8217;s board of directors and stockholders approved and adopted the 2013 Stock Option and Incentive Plan (the &#8220;2013 Plan&#8221;). The 2013 Plan became effective immediately prior to the Company&#8217;s IPO. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, directors or consultants of the Company or its subsidiaries. A total of 1,020,000 shares of common stock were initially reserved for issuance under the 2013 Plan. In addition, the number of shares of stock available for issuance under the 2013 Plan will be automatically increased each January&#160;1, beginning on January&#160;1, 2014, by 4% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December&#160;31 or such lesser number as determined by the compensation committee of the Company&#8217;s board of directors.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Employee Stock Purchase Plan</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On September&#160;13, 2013, the Company&#8217;s board of directors approved and adopted the 2013 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP became effective immediately prior to the Company&#8217;s IPO. A total of 729,000 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of stock available for issuance under the ESPP will be automatically increased each January&#160;1, beginning on January&#160;1, 2015, by the lesser of (i)&#160;2% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December&#160;31, (ii)&#160;450,000 shares, or (iii)&#160;such lesser number as determined by the compensation committee of the Company&#8217;s board of directors.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUZBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-Term Debt, Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">77 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013

</div>
          <div>June and July 2013 Convertible Note Financing</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>June and July 2013 Convertible Note Financing</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>June and July 2013 Convertible Note Financing</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2013

</div>
          <div>August 2013 Convertible Note Financing</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>August 2013 Convertible Note Financing</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
        <td class="nump">$ 2,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,250,000<span></span></td>
        <td class="nump">$ 3,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentDiscountNonCurrent', window );">Less debt discount, net of current portion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(18,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of debt discount</a></td>
        <td class="nump">2,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,250,000<span></span></td>
        <td class="nump">3,732,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_LongTermDebtGrossCurrent', window );">Less current portion of long-term debt</a></td>
        <td class="num">(2,000,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,000,000)<span></span></td>
        <td class="num">(2,000,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">1,732,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentDiscountCurrent', window );">Current portion of debt discount</a></td>
        <td class="num">(29,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(29,000)<span></span></td>
        <td class="num">(59,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
        <td class="nump">1,971,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,971,000<span></span></td>
        <td class="nump">1,941,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
        <td class="nump">129,000<span></span></td>
        <td class="nump">63,000<span></span></td>
        <td class="nump">271,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding debt</a></td>
        <td class="nump">23,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,700,000<span></span></td>
        <td class="nump">3,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Outstanding debt</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount related to beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest, current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest, noncurrent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentDiscountCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the current portion of discount recognized at the issuance of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_DebtInstrumentDiscountCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentDiscountNonCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the non-current portion of discount recognized at the issuance of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_DebtInstrumentDiscountNonCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_LongTermDebtGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_LongTermDebtGrossCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest payable on debt, including, but not limited to, trade payables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">Schedule of estimated net proceeds from the IPO</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated net proceeds from the IPO were determined as follows (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 820px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.4in;" border="0" cellspacing="0" cellpadding="0" width="820">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Gross proceeds (including over-allotment)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">46,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Underwriting discounts and commissions</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,695</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated total offering costs (including costs paid as of September&#160;30, 2013)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,900</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Offering costs paid as of September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,381</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated net proceeds to be received subsequent to September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">41,786</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Partial repayment of August&#160;2013 Notes subsequent to September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(1,741</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated net cash impact of IPO and related transactions</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">40,045</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ScheduleOfActualAndProformaBalanceSheetDetail', window );">Summary of actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company's IPO</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company&#8217;s IPO noted above, as of September&#160;30, 2013 (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 797px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="797">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Pro&#160;Forma<br />
September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19,082</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">59,127</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other assets</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,743</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts payable and accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,725</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,344</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">137</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">79</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible notes, net of discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,481</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Preferred stock warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,526</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Additional paid-in capital</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,367</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">136,398</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deficit accumulated during the development stage</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(80,770</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(81,024</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stockholders&#8217; (deficit) equity</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(66,402</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">55,394</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="424"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ScheduleOfActualAndProformaBalanceSheetDetail">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure summary of the actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company's IPO.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ScheduleOfActualAndProformaBalanceSheetDetail</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 855<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfSubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHQBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">77 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2013

</div>
          <div>Subsequent event</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2013

</div>
          <div>Subsequent event

</div>
          <div>August 2013 Notes</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash', window );">Shares sold in initial public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,666,667<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Public offering price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds (including over-allotment)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 46,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,695,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoninterestExpense', window );">Estimated total offering costs (including costs paid)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,900,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs paid</a></td>
        <td class="nump">1,381,000<span></span></td>
        <td class="nump">1,381,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ProceedsReceivableFromIssuanceInitialPublicOffering', window );">Estimated net proceeds to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,786,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Partial repayment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,741,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions', window );">Estimated net cash impact of IPO and related transactions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,045,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued on conversion of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,229,590<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Outstanding amount of convertible notes converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued on conversion of convertible notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,679,401<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt discount written-off</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">480,763<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableSharesRedeemedDuringPeriodShares', window );">Exchangeable shares redeemed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted', window );">Warrants to purchase shares of convertible preferred stock which are converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">230,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion', window );">Warrants to purchase shares of common stock issued on conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,074<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump">110,000,000<span></span></td>
        <td class="nump">110,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, authorized shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ActualAndProformaBalanceSheetDataAbstract', window );"><strong>Actual balance sheet data and pro forma balance sheet data</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">2,743,000<span></span></td>
        <td class="nump">2,743,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes, net of discount</a></td>
        <td class="nump">3,481,000<span></span></td>
        <td class="nump">3,481,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Preferred stock warrant liability</a></td>
        <td class="nump">163,000<span></span></td>
        <td class="nump">163,000<span></span></td>
        <td class="nump">184,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableShareLiabilityNoncurrent', window );">Exchangeable share liability</a></td>
        <td class="nump">2,885,000<span></span></td>
        <td class="nump">2,885,000<span></span></td>
        <td class="nump">551,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
        <td class="nump">$ 56,526,000<span></span></td>
        <td class="nump">$ 56,526,000<span></span></td>
        <td class="nump">$ 56,526,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ActualAndProformaBalanceSheetDataAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ActualAndProformaBalanceSheetDataAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the warrant issued to purchase shares of common stock converted from old warrants to purchase convertible preferred shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the warrant issued to purchase shares of convertible preferred stock, converted into new warrants to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the estimated, net cash impact of initial public offering (IPO) and related transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_EstimatedNetCashImpactOfInitialPublicOfferingAndRelatedTransactions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ExchangeableShareLiabilityNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value as of the balance sheet date of exchangeable share liability, which is expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ExchangeableShareLiabilityNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ExchangeableSharesRedeemedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of exchangeable shares redeemed during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ExchangeableSharesRedeemedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ProceedsReceivableFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the estimated net proceeds to be received from the entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ProceedsReceivableFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_UnderwritingDiscountsAndCommissions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of underwriting discounts and commissions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_UnderwritingDiscountsAndCommissions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for each share of convertible preferred stock that is converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionOriginalDebtAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoninterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other noninterest expenses that are not separately presented in any other noninterest expense category.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoninterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued as consideration for cash for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityCarryingAmountAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WriteOffOfDeferredDebtIssuanceCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELTEK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Deficit (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="9">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Aug. 12, 2013

</div>
          <div>Plan</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Research and development</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>Research and development</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Research and development</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>Research and development</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>General and administrative</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>General and administrative</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>General and administrative</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>General and administrative</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Stock option</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Stock option

</div>
          <div>Performance-based</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Stock option

</div>
          <div>Performance-based milestones and market conditions</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Employee stock option</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>Employee stock option</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Plan

</div>
          <div>Non-employee stock option</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Plan

</div>
          <div>Non-employee stock option</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2013

</div>
          <div>2013 Plan</div>
        </th>
        <th class="th">
          <div>Sep. 13, 2013

</div>
          <div>ESPP</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' deficit</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,423,072<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,432,369<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">331,860<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(17,860)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(35,852)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,710,517<span></span></td>
        <td class="nump">340,121<span></span></td>
        <td class="nump">220,496<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.43<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.56<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
        <td class="nump">$ 982,000<span></span></td>
        <td class="nump">$ 42,000<span></span></td>
        <td class="nump">$ 1,169,000<span></span></td>
        <td class="nump">$ 106,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 581,000<span></span></td>
        <td class="nump">$ 32,000<span></span></td>
        <td class="nump">$ 686,000<span></span></td>
        <td class="nump">$ 82,000<span></span></td>
        <td class="nump">$ 401,000<span></span></td>
        <td class="nump">$ 10,000<span></span></td>
        <td class="nump">$ 483,000<span></span></td>
        <td class="nump">$ 24,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue', window );">Aggregate grant date fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,800,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of unrecognized compensation cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.60%<span></span></td>
        <td class="nump">1.00%<span></span></td>
        <td class="nump">2.10%<span></span></td>
        <td class="nump">1.20%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90.20%<span></span></td>
        <td class="nump">93.50%<span></span></td>
        <td class="nump">90.30%<span></span></td>
        <td class="nump">93.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years 25 days<span></span></td>
        <td class="text">6 years 22 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years 3 months 7 days<span></span></td>
        <td class="text">7 years 2 months 23 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,020,000<span></span></td>
        <td class="nump">729,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized', window );">Additional shares authorized (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="nump">2.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">450,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the aggregate grant-date fair value of share-based compensation plan awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-Term Debt, Commitments and Contingencies (Details 2) (USD $)<br>In Millions, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 26, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_LeaseTermExtended', window );">Lease period extended</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Non-cancellable operating lease commitments for 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.5<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Non-cancellable operating lease commitments for 2015</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.9<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Non-cancellable operating lease commitments for 2016</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.5<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_LeaseTermExtended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the extended lease period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_LeaseTermExtended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Organization and Summary of Significant Accounting Policies</font></b></p>
<p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Organization</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Fate Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware on April&#160;27, 2007 and conducts its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells.&#160;Based on the Company&#8217;s understanding of key biological mechanisms that guide the fate of adult stem cells, the Company has built two platforms that optimize the activity and enhance the therapeutic potential of adult stem cells: its hematopoietic stem cell, or HSC, modulation platform and its muscle satellite stem cell, or SSC, modulation platform.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Principles of Consolidation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics (Canada) Inc. (&#8220;Fate Canada&#8221;), Fate Therapeutics Ltd., incorporated in the United Kingdom, and Destin Therapeutics Inc., incorporated in Canada. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Reverse Stock Split</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On September&#160;12, 2013, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a one-for-6.5 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company&#8217;s consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Unaudited Interim Financial Information</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&#160; In management&#8217;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&#8217;s financial statements and accompanying notes for the fiscal year ended December&#160;31, 2012, contained in the Company&#8217;s final prospectus dated September&#160;30, 2013 filed by the Company with the SEC on October&#160;1, 2013 pursuant to Rule&#160;424(b)&#160;under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). The results for the three and nine months ended September&#160;30, 2013 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</font></p>
<p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Other Assets</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other assets consist of the Company&#8217;s deferred IPO costs. These costs represent legal, accounting and other direct costs related to the Company&#8217;s efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Preferred Stock Warrant Liability</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. The fair value of these warrants is classified as a current liability in the accompanying consolidated balance sheets since the underlying convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets instead of in stockholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock can cause its redemption. The warrants are recorded at fair value using the Black-Scholes option pricing model with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The warrant liability will continue to be remeasured at fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company.</font></p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Revenue Recognition</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company recognizes revenues when all four of the following criteria are met: (i)&#160;persuasive evidence that an agreement exists; (ii)&#160;delivery of the products and/or services has occurred; (iii)&#160;the selling price is fixed or determinable; and (iv)&#160;collectibility is reasonably assured.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#8217;s control.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Beginning in 2011, revenue is allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#8220;VSOE&#8221;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#8220;TPE&#8221;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&#160;the consideration being earned should be commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&#8217;s performance to achieve the milestone; (ii)&#160;the consideration being earned should relate solely to past performance; (iii)&#160;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&#160;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#8217;s revenue recognition criteria are recorded as deferred revenue on the Company&#8217;s consolidated balance sheets.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award. The receivable for reimbursable amounts that have not been collected is reflected in prepaid and other current assets.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock-Based Compensation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice based model.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition has been achieved.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Share</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 102,998 shares and 166,252 shares for the three months ended September&#160;30, 2013 and 2012, respectively, and 111,614 shares and 184,517 shares for the nine months ended September&#160;30, 2013 and 2012, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, warrants for the purchase of convertible preferred stock, exchangeable shares and common stock options outstanding under the Company&#8217;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 66.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="66%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;and&#160;Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock outstanding</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,229,590</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,065,934</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants for convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">480,763</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">403,841</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,710,517</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">721,539</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,456,944</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,227,388</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In addition to the potentially dilutive securities noted above, the Company has an aggregate of approximately $23.7 million of outstanding principal as of September&#160;30, 2013 under convertible promissory notes, issued in June&#160;2013, July&#160;2013 and August&#160;2013, that are convertible into convertible preferred stock or common stock upon the occurrence of various future events at prices that are not determinable until the occurrence of those future events. As such, the Company has excluded these convertible notes payable from the table above.&#160; A portion of the convertible notes were repaid in cash and the balance of the notes converted into common stock in connection with the closing of the Company&#8217;s IPO in October&#160;2013 (see Note 6).</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">3.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Fair Value Measurements</font></b></p>
<p style="TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.5pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Level 1: Observable inputs such as quoted prices in active markets;</font></p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></p>
<p style="MARGIN: 0in 0in 0pt 46.05pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Financial assets measured at fair value on a recurring basis consist of the Company&#8217;s cash equivalents. As of September&#160;30, 2013 and December&#160;31, 2012, the carrying amount of cash equivalents was $0.3 million and $1.3&#160;million, respectively, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of September&#160;30, 2013 and December&#160;31, 2012, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Financial liabilities that are measured at fair value on a recurring basis include the preferred stock warrant liability and exchangeable shares (see Note 2). None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities measured at fair value on a recurring basis are as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 93.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.25in;" border="0" cellspacing="0" cellpadding="0" width="93%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="8">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Measurements&#160;at<br />
Reporting&#160;Date&#160;Using</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Total</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices<br />
in&#160;Active<br />
Markets&#160;for<br />
Identical<br />
Assets<br />
(Level&#160;1)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant<br />
Other<br />
Observable<br />
Inputs<br />
(Level&#160;2)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant<br />
Unobservable<br />
Inputs<br />
(Level&#160;3)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,048</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,048</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December&#160;31, 2012:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">735</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">735</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preferred stock warrant liability was recorded at fair value using the Black-Scholes option pricing model and the exchangeable share liability was recorded at fair value based on the fair value of the underlying common stock.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following assumptions were used in the Black-Scholes option pricing model to determine the fair value of the preferred stock warrant liability:</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 73.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="73%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December<br />
31,&#160;2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">85.9</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Remaining contractual term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.56</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.31</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 73.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="73%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Warrant<br />
Liability</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exchangeable<br />
Share<br />
Liability</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">221</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">563</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance of exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(37</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(90</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance of exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">346</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(21</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,988</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt;" size="2">The preferred stock warrant liability and the exchangeable share liability were each reclassified into additional paid-in capital at their fair value in connection with the Company&#8217;s IPO on October&#160;4, 2013 (see Note 6).</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">6.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Subsequent Events</font></b></p>
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Initial Public Offering and Related Transactions</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On October&#160;4, 2013, the Company completed its IPO whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Estimated net proceeds from the IPO were determined as follows (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 89.34%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.4in;" border="0" cellspacing="0" cellpadding="0" width="89%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Gross proceeds (including over-allotment)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">46,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Underwriting discounts and commissions</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,695</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated total offering costs (including costs paid as of September&#160;30, 2013)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,900</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Offering costs paid as of September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,381</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated net proceeds to be received subsequent to September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">41,786</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Partial repayment of August&#160;2013 Notes subsequent to September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.42%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(1,741</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 82.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="82%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Estimated net cash impact of IPO and related transactions</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">40,045</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In addition, each of the following occurred in connection with the completion of our IPO on October&#160;4, 2013:</font></p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">the conversion of all outstanding shares of convertible preferred stock into 7,229,590 shares of the Company&#8217;s common stock;</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">the conversion of $22.1 million of outstanding principal and accrued interest on convertible notes into 3,679,401 shares of common stock, the write-off of $0.3 million of unamortized debt discount and the related cash repayment of $1.7 million of outstanding principal and accrued interest on convertible notes and accrued interest outstanding as of September&#160;30, 2013;</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">480,763 shares of the Company&#8217;s common stock became issuable pursuant to the redemption of an aggregate of 900,000 exchangeable shares of Fate Canada and the resultant reclassification of the exchangeable share liability to additional paid-in capital;</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">the conversion of warrants to purchase 230,000 shares of convertible preferred stock into warrants to purchase 36,074 shares of the Company&#8217;s common stock and the resultant reclassification of the warrant liability to additional paid-in capital; and</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;">&#160;</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 58.3pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">&#183;</font><font style="FONT-SIZE: 3pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font> <font style="FONT-SIZE: 10pt;" size="2">an amended and restated certificate of incorporation was filed on October&#160;3, 2013, authorizing 150,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company&#8217;s IPO noted above, as of September&#160;30, 2013 (in thousands):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Pro&#160;Forma<br />
September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19,082</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">59,127</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other assets</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,743</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts payable and accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,725</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,344</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term accrued expenses</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">137</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">79</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible notes, net of discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,481</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Preferred stock warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,526</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Additional paid-in capital</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,367</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">136,398</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deficit accumulated during the development stage</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(80,770</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(81,024</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stockholders&#8217; (deficit) equity</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(66,402</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">55,394</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="424"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt;" size="2">In connection with the closing of its IPO on October&#160;4, 2013, the Company recorded an additional aggregate non-cash charge of $0.5 million in other income (expense) related to the final fair value adjustment of the exchangeable share liability and the preferred stock warrant liability. This final fair value adjustment</font> <font style="FONT-SIZE: 10pt;" size="2">is excluded from the table above.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-Term Debt, Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Long-Term Debt, Commitments and Contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt, Commitments and Contingencies</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">4.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Long-Term Debt, Commitments and Contingencies</font></b></p>
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Long-Term Debt</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt and unamortized discount balances (excluding convertible debt) are as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December<br />
31,&#160;2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,750</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Less debt discount, net of current portion</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(18</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt, net of debt discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Less current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,000</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,000</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt, net of current portion</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of debt discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(29</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(59</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt, net</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,971</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,941</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">June&#160;and July&#160;2013 Convertible Note Financing</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In June&#160;and July&#160;2013, the Company issued convertible promissory notes in an aggregate principal amount of $3.7 million to certain existing stockholders. The notes accrue interest at 2% per year and are due on June&#160;24, 2014, if not earlier repaid or converted in full. In connection with the issuance of the convertible notes, the Company recorded a debt discount of $0.3 million related to a beneficial conversion feature that was recorded as a result of the gross fair value of the shares of Series&#160;C convertible preferred stock into which the debt could convert being greater than the proceeds allocated to the debt instrument. The debt discount is amortized as interest expense utilizing the effective interest method over the one year term of the debt. During the three and nine months ended September&#160;30, 2013, the Company recorded debt discount amortization of $0.1 million.&#160;As of September&#160;30, 2013, an aggregate of $3.7 million of principal, $0.3 million of unamortized debt discount and $0.1 million of accrued interest were outstanding under the promissory notes. The notes converted into common stock in connection with the Company&#8217;s IPO in October&#160;2013 (see Note 6).</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">August&#160;2013 Convertible Note Financing</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In August&#160;2013, the Company issued convertible promissory notes in an aggregate principal amount of $20.0 million to certain new investors. The notes accrue interest at 2% per year and are due on August&#160;8, 2016, if not earlier repaid or converted in full. As of September&#160;30, 2013, an aggregate of $20.0 million of principal and $0.1 million of accrued interest were outstanding under the promissory notes. A portion of the notes were repaid in cash and the balance of the notes converted into common stock in connection with the Company&#8217;s IPO in October&#160;2013 (see Note 6).</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Facility Lease</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On September&#160;26, 2013, the Company exercised its option to extend for two years the lease on its office and laboratory space in San Diego, California until June&#160;2016. As a result of the lease extension, the Company added an additional $0.5 million, $0.9 million and $0.5 million, respectively, of non-cancelable operating lease commitments for the years ending December&#160;31, 2014, 2015 and 2016.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2013

</div>
          <div>Subsequent event</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Pro Forma</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ActualAndProformaBalanceSheetDataAbstract', window );"><strong>Actual balance sheet data and pro forma balance sheet data</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 19,082,000<span></span></td>
        <td class="nump">$ 9,087,000<span></span></td>
        <td class="nump">$ 5,464,000<span></span></td>
        <td class="nump">$ 6,387,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 59,127,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">3,725,000<span></span></td>
        <td class="nump">2,268,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,344,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Long-term accrued expenses</a></td>
        <td class="nump">137,000<span></span></td>
        <td class="nump">110,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
        <td class="nump">1,000<span></span></td>
        <td class="nump">1,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">14,367,000<span></span></td>
        <td class="nump">12,789,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">136,398,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(80,770,000)<span></span></td>
        <td class="num">(65,615,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(81,024,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
        <td class="num">(66,402,000)<span></span></td>
        <td class="num">(52,825,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">55,394,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability', window );">Aggregate non-cash charge related to the final fair value adjustment of the exchangeable share liability and the preferred stock warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ActualAndProformaBalanceSheetDataAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ActualAndProformaBalanceSheetDataAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of non-cash charge related to the fair value adjustment of the exchangeable shares and the preferred stock warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_NoncashChargeRelatedToFairValueAdjustmentOfExchangeableSharesAndPreferredStockWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 210<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A
M;FEZ871I;VY?86YD7U-U;6UA<GE?;V9?4VD\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y!<W-E=%]!8W%U:7-I=&EO;E]O9E]697)I
M;U]4:&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&
M86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DQO;F=497)M7T1E8G1?0V]M;6ET;65N='-?86YD
M7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M:&]L9&5R<U]$969I8VET/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ871I;VY?86YD7U-U;6UA<GE?
M;V9?4VDQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3W)G86YI>F%T:6]N7V%N9%]3=6UM87)Y7V]F7U-I,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%S<V5T7T%C<75I<VET:6]N7V]F
M7U9E<FEO7U1H93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<U]486)L97,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,;VYG5&5R;5]$96)T7T-O
M;6UI=&UE;G1S7V%N9%\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VMH;VQD97)S7T1E9FEC:71?5&%B;&5S/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N
M='-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^3W)G86YI>F%T:6]N7V%N9%]3=6UM87)Y7V]F7U-I,SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?
M4W5M;6%R>5]O9E]3:30\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!<W-E=%]!8W%U:7-I=&EO;E]O9E]697)I;U]4:&4R/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-
M96%S=7)E;65N='-?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N='-?1&5T86EL,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQO;F=497)M
M7T1E8G1?0V]M;6ET;65N='-?86YD7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y,;VYG5&5R;5]$96)T7T-O;6UI=&UE;G1S7V%N
M9%\S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O
M8VMH;VQD97)S7T1E9FEC:71?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S97%U
M96YT7T5V96YT<U]$971A:6QS7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S
M/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N
M8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@
M(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R
M93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O
M=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-
M"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E
M(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!#
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET
M>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DYO=BX@,3$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO
M;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=&051%(%1(15)!4$555$E#4R!)3D,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<P,#`Q-#,T,S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D)
M,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG+2TQ,BTS,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B=.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TYO;BUA8V-E;&5R871E
M9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#,U-RPQ
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I
M;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=1,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S=D8C!E
M93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8PT*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\W9&(P964W-5]C-#0W7S0P-F1?.3<P95\V8C)E
M9CAE-&$T-F,O5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44E!
M1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A
M=&5D($)A;&%N8V4@4VAE971S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S
M<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$Y+#`X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PP.#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,S@V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PW.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PQ-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW-#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A
M<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$L,#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPW,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!P;W)T:6]N
M(&]F(&1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0W5R<F5N="!P;W)T:6]N(&]F(&1E9F5R<F5D(')E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T
M:6)L92!N;W1E<RP@;F5T(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#0X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<'5R8VAA<V4@;&EA8FEL:71Y(&9O
M<B!U;G9E<W1E9"!E<75I='D@87=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,;VYG+71E<FT@9&5B="P@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DW,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.30Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N
M="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PT.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA;F=E86)L92!S
M:&%R92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L.#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B="P@;&5S<R!C=7)R96YT('!O<G1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S,R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M;VYG+71E<FT@8V]N=F5R=&EB;&4@;F]T97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG
M96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K+"`D,"XP,#$@<&%R('9A;'5E.R!A=71H;W)I>F5D('-H87)E<R`M(#8X
M+#,V,"PQ.#8@870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`V,BPR,#`L,#`P
M(&%T($1E8V5M8F5R(#,Q+"`R,#$R.R!I<W-U960@86YD(&]U='-T86YD:6YG
M('-H87)E<R`M(#0T+#DV-RPV.3`@870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N
M9"!$96-E;6)E<B`S,2P@,C`Q,CL@;&EQ=6ED871I;VX@<')E9F5R96YC92!O
M9B`D-3@L-3$X(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@1&5C96UB97(@
M,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#4R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4V+#4R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&1E9FEC:70Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E.R!A=71H;W)I>F5D('-H87)E<R`M
M(#$Q,"PP,#`L,#`P(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@,3`P+#`P
M,"PP,#`@870@1&5C96UB97(@,S$L(#(P,3([(&ES<W5E9"!A;F0@;W5T<W1A
M;F1I;F<@<VAA<F5S("T@,2PS-S<L-C4Y(&%T(%-E<'1E;6)E<B`S,"P@,C`Q
M,R!A;F0@,2PS,S0L,3$U(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#,V
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#<X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E=F5L
M;W!M96YT('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M,"PW-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C4L-C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<R<@9&5F:6-I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C8L-#`R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4R+#@R-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!L:6%B:6QI=&EE<RP@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T
M;V-K(&%N9"!S=&]C:VAO;&1E<G,G(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C,L,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PP-S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S=D8C!E93<U7V,T-#=?-#`V
M9%\Y-S!E7S9B,F5F.&4T830V8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\W9&(P964W-5]C-#0W7S0P-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R
M:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%54%!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@0F%L86YC92!3
M:&5E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU92`H
M:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D
M+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C@L,S8P+#$X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8R+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#0L.38W+#8Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#DV-RPV.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PY-C<L-CDP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L.38W+#8Y,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!A9V=R96=A=&4@;&EQ=6ED
M871I;VX@<')E9F5R96YC92`H:6X@9&]L;&%R<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-3@L-3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U."PU,3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VLL(&%U=&AO<FEZ960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL(&ES<W5E9"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,S<W+#8U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,S,T+#$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!O=71S=&%N
M9&EN9R!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S<W+#8U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S,T+#$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R968X931A
M-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E93<U7V,T
M-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H965T,#0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$520D%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS
M(&%N9"!#;VUP<F5H96YS:79E($QO<W,@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XW-R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E=F5N=65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;&QA8F]R871I;VX@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`R,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPY,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT
M(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#`X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#(W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E
M<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS-S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3<V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M."PU.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,RPY-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DW.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S8X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M."PX,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!O<&5R871I;F<@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PQ-S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPW-#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PU-#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,BPW
M.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-2PQ-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,RPV-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L-S<S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL-3$S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<W+#<X,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]T:&5R(&EN8V]M92`H97AP96YS92DL(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.3(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#,X,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-S$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY.#<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W,@86YD(&-O;7!R96AE;G-I=F4@;&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@V+#`W,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L,3$S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,34L,34U*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`L
M,#@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H.#`L-S<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R(&-O;6UO;B!S:&%R92P@8F%S
M:6,@86YD(&1I;'5T960@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T+C@Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RXU,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R+C(T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H.2XU,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E('-H87)E<R!U<V5D('1O(&-O
M;7!U=&4@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(V
M,BPU-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$W,2PP,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#(S."PU-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U.2PQ,3,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-#0D<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE
M;G1S(&]F($-A<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XW-R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T
M:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N<V]L:61A=&5D(&YE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$U+#$U-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P+#`X-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#@P
M+#<W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L
M;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V5S(&]F(&-O
M;6UO;B!S=&]C:R!F;W(@=&5C:&YO;&]G>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DS.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO<G1I>F%T:6]N(&]F(&1I<V-O=6YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;F-A<V@@:6YT97)E<W0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$U-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$S."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@9F%I<B!V86QU92!A
M;F0@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@97AC:&%N9V5A8FQE('-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPS,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@<')E9F5R<F5D('-T;V-K('=A
M<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,@;VX@9&ES<&]S86P@;V8@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@97AT:6YG=6ES:&UE
M;G0@;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R
M96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.38P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#8V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L-C$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L-SDU*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL.#@P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8Y+#4S,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^26YV97-T:6YG(&%C=&EV:71I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA
M<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-3$Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S
M86QE(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S
M960@:6X@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S+#0R-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6YG
M(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@
M<F5P=7)C:&%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T<R!P86ED(&EN(&-O;FYE8W1I;VX@=VET:"!I;FET:6%L
M('!U8FQI8R!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PS.#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,S@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VYV97)T:6)L92!P
M<F]M:7-S;W)Y(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,RPW,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S(L,C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&QO;F<M=&5R;2!D96)T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM
M96YT<R!O;B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PU,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L,34P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K+"!N970@;V8@;V9F97)I;F<@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$V-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#8T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PX-S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#,W,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR+#`S.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C:&%N9V4@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PY.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y,C,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,#@R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T(&)E9VEN;FEN9R!O9B!T:&4@
M<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#`X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L
M,S@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!E;F0@;V8@=&AE
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PP
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4L-#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q.2PP.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T
M830V8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W9&(P964W-5]C
M-#0W7S0P-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R:W-H965T<R]3:&5E=#`V
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G
M86YI>F%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG
M;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T:6]N(&%N9"!3
M=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O
M;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3(T+C5P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`R-"XU<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
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M;VQI8VEE<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TR-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C0N-7!T.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,CY/<F=A;FEZ871I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D9A=&4@5&AE<F%P975T:6-S+"8C,38P
M.TEN8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3LI('=A<R!I;F-O<G!O
M<F%T960@:6X@=&AE('-T871E(&]F($1E;&%W87)E(&]N($%P<FEL)B,Q-C`[
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M;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY0<FEN8VEP;&5S(&]F($-O;G-O;&ED
M871I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C(N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^5&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A
M=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT<R!O9B!T:&4@0V]M<&%N>2!A
M;F0@:71S('-U8G-I9&EA<FEE<RP@1F%T92!4:&5R87!E=71I8W,@*$-A;F%D
M82D@26YC+B`H)B,X,C(P.T9A=&4@0V%N861A)B,X,C(Q.RDL($9A=&4@5&AE
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M;VXN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,BXU
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/E)E=F5R<V4@4W1O8VL@
M4W!L:70\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/D]N(%-E<'1E;6)E<B8C,38P.S$R+"`R,#$S+"!T:&4@
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M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY5
M;F%U9&ET960@26YT97)I;2!&:6YA;F-I86P@26YF;W)M871I;VX\+V9O;G0^
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
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M;6%T:6]N('1H870@87)E(&YO<FUA;&QY(')E<75I<F5D(&)Y($=!05`@8V%N
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M;F]T(&EN8VQU9&4@86QL(&1I<V-L;W-U<F5S(')E<75I<F5D(&)Y($=!05`@
M86YD('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE($-O
M;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@86-C;VUP
M86YY:6YG(&YO=&5S(&9O<B!T:&4@9FES8V%L('EE87(@96YD960@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,BP@8V]N=&%I;F5D(&EN('1H92!#;VUP86YY)B,X
M,C$W.W,@9FEN86P@<')O<W!E8W1U<R!D871E9"!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,R!F:6QE9"!B>2!T:&4@0V]M<&%N>2!W:71H('1H92!314,@;VX@
M3V-T;V)E<B8C,38P.S$L(#(P,3,@<'5R<W5A;G0@=&\@4G5L928C,38P.S0R
M-"AB*28C,38P.W5N9&5R('1H92!396-U<FET:65S($%C="!O9B`Q.3,S+"!A
M<R!A;65N9&5D("AT:&4@)B,X,C(P.U-E8W5R:71I97,@06-T)B,X,C(Q.RDL
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS(&EN:71I
M86P@<'5B;&EC(&]F9F5R:6YG("@F(S@R,C`[25!/)B,X,C(Q.RDN(%1H92!R
M97-U;'1S(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E
M<'1E;6)E<B8C,38P.S,P+"`R,#$S(&%R92!N;W0@;F5C97-S87)I;'D@:6YD
M:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@
M9FES8V%L('EE87(@;W(@86YY(&]T:&5R(&EN=&5R:6T@<&5R:6]D(&]R(&%N
M>2!F=71U<F4@>65A<B!O<B!P97)I;V0N/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R-"XU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0R/E5S92!O9B!%<W1I;6%T97,\+V9O;G0^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A;GDF
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M:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,CY/=&AE<B!!<W-E=',\+V9O;G0^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P
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M961U8W1I;VX@;V8@=&AE($E03R!P<F]C965D<RX\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0R/E!R969E<G)E9"!3=&]C:R!787)R86YT($QI86)I;&ET>3PO
M9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,BXU
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
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M:&5R(&EN8V]M92`H97AP96YS92D@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS
M;VQI9&%T960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&%N9"!C;VUP<F5H
M96YS:79E(&QO<W,N(%1H92!W87)R86YT(&QI86)I;&ET>2!W:6QL(&-O;G1I
M;G5E('1O(&)E(')E;65A<W5R960@870@9F%I<B!V86QU92!U;G1I;"!S=6-H
M('1I;64@87,@=&AE('=A<G)A;G1S(&%R92!N;R!L;VYG97(@;W5T<W1A;F1I
M;F<@;W(@=&AE('5N9&5R;'EI;F<@<V5C=7)I=&EE<R!A<F4@;F\@;&]N9V5R
M(')E9&5E;6%B;&4@;W5T<VED92!T:&4@8V]N=')O;"!O9B!T:&4@0V]M<&%N
M>2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(R+C5P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^4F5V96YU92!296-O9VYI
M=&EO;CPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E<R!W
M:&5N(&%L;"!F;W5R(&]F('1H92!F;VQL;W=I;F<@8W)I=&5R:6$@87)E(&UE
M=#H@*&DI)B,Q-C`[<&5R<W5A<VEV92!E=FED96YC92!T:&%T(&%N(&%G<F5E
M;65N="!E>&ES=',[("AI:2DF(S$V,#MD96QI=F5R>2!O9B!T:&4@<')O9'5C
M=',@86YD+V]R('-E<G9I8V5S(&AA<R!O8V-U<G)E9#L@*&EI:2DF(S$V,#MT
M:&4@<V5L;&EN9R!P<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4[(&%N
M9"`H:78I)B,Q-C`[8V]L;&5C=&EB:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U
M<F5D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5V96YU92!A<G)A;F=E;65N
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M/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY&;W(@=')A;G-A8W1I;VYS(&5N=&5R960@:6YT;R!P<FEO<B!T;R`R,#$Q
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M/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY"96=I;FYI;F<@:6X@,C`Q,2P@<F5V96YU92!I<R!A;&QO8V%T960@=&\@
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M,C`[5%!%)B,X,C(Q.RD@;V8@9F%I<B!V86QU92!I<R!A8V-E<'1A8FQE+"!O
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M<75E;G0@=&\@,C`Q,"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5V96YU
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M-C`[=&AE(&-O;G-I9&5R871I;VX@8F5I;F<@96%R;F5D('-H;W5L9"!B92!C
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M92!T:&4@;6EL97-T;VYE.R`H:6DI)B,Q-C`[=&AE(&-O;G-I9&5R871I;VX@
M8F5I;F<@96%R;F5D('-H;W5L9"!R96QA=&4@<V]L96QY('1O('!A<W0@<&5R
M9F]R;6%N8V4[("AI:6DI)B,Q-C`[=&AE(&-O;G-I9&5R871I;VX@8F5I;F<@
M96%R;F5D('-H;W5L9"!B92!R96%S;VYA8FQE(')E;&%T:79E('1O(&%L;"!D
M96QI=F5R86)L97,@86YD('!A>6UE;G0@=&5R;7,@:6X@=&AE(&%R<F%N9V5M
M96YT.R!A;F0@*&EV*28C,38P.W1H92!M:6QE<W1O;F4@<VAO=6QD(&)E(&-O
M;G-I9&5R960@:6X@:71S(&5N=&ER971Y(&%N9"!C86YN;W0@8F4@8FEF=7)C
M871E9"!I;G1O('-U8G-T86YT:79E(&%N9"!N;VYS=6)S=&%N=&EV92!C;VUP
M;VYE;G1S+B!!;GD@86UO=6YT<R!R96-E:79E9"!P=7)S=6%N="!T;R!R979E
M;G5E(&%R<F%N9V5M96YT<R!W:71H(&UU;'1I<&QE(&5L96UE;G1S('!R:6]R
M('1O('-A=&ES9GEI;F<@=&AE($-O;7!A;GDF(S@R,3<[<R!R979E;G5E(')E
M8V]G;FET:6]N(&-R:71E<FEA(&%R92!R96-O<F1E9"!A<R!D969E<G)E9"!R
M979E;G5E(&]N('1H92!#;VUP86YY)B,X,C$W.W,@8V]N<V]L:61A=&5D(&)A
M;&%N8V4@<VAE971S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
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M=',N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY3=&]C:RU"87-E9"!#;VUP
M96YS871I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
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M;F<@82!L871T:6-E(&)A<V5D(&UO9&5L+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^3F5T($QO<W,@4&5R(%-H87)E/"]F
M;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
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M;V-K('1O=&%L:6YG(#$P,BPY.3@@<VAA<F5S(&%N9"`Q-C8L,C4R('-H87)E
M<R!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,R!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY+"!A;F0@,3$Q+#8Q-"!S
M:&%R97,@86YD(#$X-"PU,3<@<VAA<F5S(&9O<B!T:&4@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@86YD(#(P,3(L(')E<W!E
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M0V]M<&%N>28C.#(Q-SMS(&YE="!L;W-S('!O<VET:6]N+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^4&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R!N
M;W0@:6YC;'5D960@:6X@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T
M(&QO<W,@<&5R('-H87)E(&)E8V%U<V4@=&\@9&\@<V\@=V]U;&0@8F4@86YT
M:2UD:6QU=&EV92!A<F4@87,@9F]L;&]W<R`H:6X@8V]M;6]N('-T;V-K(&5Q
M=6EV86QE;G0@<VAA<F5S*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U=)1%1(.B`V
M-BXV."4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494
M.B`Q+C(U:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0V-B4^#0H-"CQT<B!S='EL93TS1'!A9&1I;F<Z
M,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,SDN-S@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,SDE(&-O;'-P86X],T0S/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5&AR964F(S$V,#MA;F0F(S$V
M,#M.:6YE)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\8G(@+SX-"E-E<'1E;6)E
M<B8C,38P.S,P+#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U-24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3XR,#$R/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4U)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-34E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@;W5T<W1A;F1I;F<\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXW+#(R.2PU.3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q."XP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+#`V
M-2PY,S0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4U)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-34E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY7
M87)R86YT<R!F;W(@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,S8L,#<T/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3@N,#0E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,S8L,#<T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^17AC:&%N9V5A8FQE('-H87)E<SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C0X,"PW-C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT,#,L.#0Q/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V]M;6]N('-T;V-K(&]P=&EO
M;G,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,2PW,3`L-3$W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@N,#0E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<R,2PU,SD\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#4U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-34E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^.2PT-38L.30T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X+C`T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXW+#(R-RPS.#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C,N,#5P=#L@34%21TE..B`P:6X@
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M8VEP86P@87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@=6YD97(@8V]N
M=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<RP@:7-S=65D(&EN($IU;F4F(S$V
M,#LR,#$S+"!*=6QY)B,Q-C`[,C`Q,R!A;F0@075G=7-T)B,Q-C`[,C`Q,RP@
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M,C$W.W,@25!/(&EN($]C=&]B97(F(S$V,#LR,#$S("AS964@3F]T92`V*2X\
M+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%S
M<V5T($%C<75I<VET:6]N(&]F(%9E<FEO(%1H97)A<&5U=&EC<R!);F,N/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M07-S970@06-Q=6ES:71I;VX@;V8@5F5R:6\@5&AE<F%P975T:6-S($EN8RX\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S
M<V5T($%C<75I<VET:6]N(&]F(%9E<FEO(%1H97)A<&5U=&EC<R!);F,N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F
M;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TR,BXU<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,C(N-7!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M/B`\8CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#(^07-S970@06-Q=6ES:71I;VX@;V8@5F5R
M:6\@5&AE<F%P975T:6-S($EN8RX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,C(N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#(R+C5P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^3VX@07!R:6PF(S$V,#LW+"`R,#$P+"!T:&4@0V]M<&%N
M>2!A8W%U:7)E9"!697)I;R!4:&5R87!E=71I8W,@26YC+B`H)B,X,C(P.U9E
M<FEO)B,X,C(Q.RDL(&$@9&5V96QO<&UE;G0@<W1A9V4@8V]M<&%N>2!H96%D
M<75A<G1E<F5D(&EN($]T=&%W82P@3VYT87)I;R!T;R!G86EN(&%C8V5S<R!T
M;R!I=',@97AC;'5S:79E;'D@;&EC96YS960@:6YT96QL96-T=6%L('!R;W!E
M<G1Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^26X@8V]N;F5C=&EO;B!W:71H
M('1H92!A<W-E="!A8W%U:7-I=&EO;B!O9B!697)I;RP@=&AE('-T;V-K:&]L
M9&5R<R!O9B!697)I;R!R96-E:79E9"`Y,#`L,#`P(&YO;BUV;W1I;F<@<VAA
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M:6QE<W1O;F5S+"!M87D@8F4@97AC:&%N9V5A8FQE(&9O<B!U<"!T;R`X.#0L
M-C`U('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R
M,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^5&AE($5X8VAA;F=E86)L92!3:&%R97,@=VEL;"!B92!A=71O
M;6%T:6-A;&QY(')E9&5E;65D(&%N9"!E>&-H86YG960@9F]R('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!U<&]N('1H92!E
M87)L:65S="!O9CH@*&DI)B,Q-C`[07!R:6PF(S$V,#LQ,RP@,C`Q-RP@*&EI
M*28C,38P.W1H92!D871E(&EM;65D:6%T96QY('!R:6]R('1O(&%N($E03R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T
M;R!A(')E9VES=')A=&EO;B!S=&%T96UE;G0@9FEL960@=VET:"!A;F0@9&5C
M;&%R960@969F96-T:79E(&)Y('1H92!314,L("AI:6DI)B,Q-C`[=&AE(&5F
M9F5C=&EV92!D871E(&]F(&-E<G1A:6X@8VAA;F=E(&]F(&-O;G1R;VP@979E
M;G1S+"`H:78I)B,Q-C`[=&AE(&1A=&4@=7!O;B!W:&EC:"!H;VQD97)S(&]F
M(&%T(&QE87-T(&$@;6%J;W)I='D@;V8@=&AE('1H96X@;W5T<W1A;F1I;F<@
M17AC:&%N9V5A8FQE(%-H87)E<R!A<'!R;W9E('1H92!R961E;7!T:6]N(&%N
M9"!E>&-H86YG92!O9B!A;&P@;V8@=&AE(&]U='-T86YD:6YG($5X8VAA;F=E
M86)L92!3:&%R97,L("AV*28C,38P.W1H92!D871E('5P;VX@=VAI8V@@=&AE
M<F4@87)E(&QE<W,@=&AA;B`T-3`L,#`P($5X8VAA;F=E86)L92!3:&%R97,@
M;W5T<W1A;F1I;F<@;W(@*'9I*28C,38P.W1H92!D871E('1H870@=&AE(&AO
M;&1E<G,@;V8@=&AE($5X8VAA;F=E86)L92!3:&%R97,@8V%N(&5X8VAA;F=E
M(&9O<B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VL@;VX@82!T87@M9&5F97)R960@8F%S:7,N/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY!<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,R!A;F0@1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,BP@=&AE($5X8VAA;F=E86)L92!3:&%R97,@=V5R
M92!E>&-H86YG96%B;&4@:6YT;R`T.#`L-S8S('-H87)E<R!A;F0@-#`S+#@T
M,2!S:&%R97,L(')E<W!E8W1I=F5L>2P@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VLN($%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S
M+"!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&-O;6UO;B!S=&]C:R!T;R!B92!I<W-U960@=7!O;B!E>&-H86YG92!O9B!T
M:&4@17AC:&%N9V5A8FQE(%-H87)E<R!I<R!S=6)J96-T('1O(&9U<G1H97(@
M:6YC<F5A<V4@87,@9F]L;&]W<SH@*&DI)B,Q-C`[-S8L.3(R('-H87)E<R!F
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M;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^070@=&AE(&1A=&4@;V8@86X@:6YC<F5A
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M:6YC;VUE("AE>'!E;G-E*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(R+C5P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07,@
M;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,L('1H92!C:&%N9V5S(&EN('1H
M92!N=6UB97(@;V8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M
M;6]N('-T;V-K(&ES<W5A8FQE('5P;VX@=&AE(&5X8VAA;F=E(&]F('1H92!%
M>&-H86YG96%B;&4@4VAA<F5S(&%N9"!T:&4@:6YI=&EA;"!F86ER('9A;'5E
M(&]F('1H92!S:&%R97,@87)E('-U;6UA<FEZ960@87,@9F]L;&]W<R`H:6X@
M=&AO=7-A;F1S+"!E>&-E<'0@<VAA<F4@86YD('!E<B!S:&%R92!A;6]U;G1S
M*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE
M9G0[5TE$5$@Z(#@V+C8X)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M34%21TE.+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#8E/@T*#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#@N-C8E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+CDE.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^17AC:&%N9V5A8FQE/&)R("\^
M#0I3:&%R97,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$
M,3Y&86ER)B,Q-C`[5F%L=64F(S$V,#M097(\8G(@+SX-"E-H87)E)B,Q-C`[
M;V8\8G(@+SX-"E5N9&5R;'EI;F<\8G(@+SX-"D-O;6UO;B8C,38P.U-T;V-K
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^26YI=&EA
M;"8C,38P.T9A:7(\8G(@+SX-"E9A;'5E)B,Q-C`[;V8\8G(@+SX-"D5X8VAA
M;F=E86)L93QB<B`O/@T*4VAA<F5S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#@N-C8E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T."XV-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#0X)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07!R:6PF(S$V,#LR,#$P/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXQ,S@L-#8R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$N-CD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-30E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C,T/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-#@N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1T;W`@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DUA<F-H)B,Q-C`[,C`Q,3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^.3(L,S`X/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2XV.3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$U-CPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#0X+C8V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#@E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY-87DF(S$V,#LR,#$Q/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXQ,34L,S@P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,2XV.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$Y-3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#0X+C8V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#@E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<')I
M;"8C,38P.S(P,3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+CDE.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4W+#8Y
M,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$N
M,S<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW
M.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D
M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0X+C8V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#@E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY*
M=6QY)B,Q-C`[,C`Q,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C<V+#DR,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C0N-#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,S0V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#@N-C8E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C0X,"PW-C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PP,#D\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
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M5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0Q.3X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0Y,#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0Q.3X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N
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M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T
M-U\T,#9D7SDW,&5?-F(R968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V
M8R]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A
M:7(@5F%L=64@365A<W5R96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,C0N-7!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#(T+C5P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXS+CPO9F]N=#X\+V(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`S<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[/"]F;VYT/CPO8CX@/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/D9A:7(@
M5F%L=64@365A<W5R96UE;G1S/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3(T+C5P=#L@34%21TE..B`P:6X@,&EN(#!P="`R
M-"XU<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
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M979E;"`R(&EN<'5T(&%S(&1E<V-R:6)E9"!B96QO=RP@=&AE($-O;7!A;GD@
M8F5L:65V97,@=&AA="!T:&4@9F%I<B!V86QU92!O9B!L;VYG+71E<FT@9&5B
M="!A<'!R;WAI;6%T97,@:71S(&-A<G)Y:6YG('9A;'5E+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
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M=7)I;F<@9F%I<B!V86QU92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0@-#8N,#5P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DQE=F5L
M(#$Z($]B<V5R=F%B;&4@:6YP=71S('-U8V@@87,@<75O=&5D('!R:6-E<R!I
M;B!A8W1I=F4@;6%R:V5T<SL\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="`T-BXP-7!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`T-BXP-7!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^3&5V96P@,CH@26YP=71S+"!O=&AE<B!T:&%N
M('1H92!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S+"!T:&%T(&%R
M92!O8G-E<G9A8FQE(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I<F5C=&QY.R!A
M;F0\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="`T-BXP-7!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="`T-BXP-7!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^3&5V96P@,SH@56YO8G-E<G9A8FQE(&EN<'5T<R!I;B!W:&EC:"!T:&5R
M92!I<R!L:71T;&4@;W(@;F\@;6%R:V5T(&1A=&$L('=H:6-H(')E<75I<F4@
M=&AE(')E<&]R=&EN9R!E;G1I='D@=&\@9&5V96QO<"!I=',@;W=N(&%S<W5M
M<'1I;VYS+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T(#0V+C`U<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D9I;F%N8VEA;"!A<W-E=',@;65A<W5R960@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!C;VYS:7-T(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@8V%S:"!E<75I=F%L96YT<RX@07,@;V8@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@86YD($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3(L('1H92!C87)R>6EN9R!A;6]U;G0@;V8@8V%S:"!E<75I=F%L96YT
M<R!W87,@)#`N,R!M:6QL:6]N(&%N9"`D,2XS)B,Q-C`[;6EL;&EO;BP@<F5S
M<&5C=&EV96QY+"!W:&EC:"!A<'!R;WAI;6%T97,@9F%I<B!V86QU92!A;F0@
M=V%S(&1E=&5R;6EN960@8F%S960@=7!O;B!,979E;"`Q(&EN<'5T<RX@0V%S
M:"!E<75I=F%L96YT<R!P<FEM87)I;'D@8V]N<VES=&5D(&]F(&UO;F5Y(&UA
M<FME="!F=6YD<RX@07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@86YD
M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(L('1H92!#;VUP86YY(&1I9"!N;W0@
M:&]L9"!A;GD@3&5V96P@,B!O<B!,979E;"`S(&9I;F%N8VEA;"!A<W-E=',@
M=&AA="!A<F4@<F5C;W)D960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN
M9R!B87-I<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D9I;F%N8VEA;"!L:6%B
M:6QI=&EE<R!T:&%T(&%R92!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@
M<F5C=7)R:6YG(&)A<VES(&EN8VQU9&4@=&AE('!R969E<G)E9"!S=&]C:R!W
M87)R86YT(&QI86)I;&ET>2!A;F0@97AC:&%N9V5A8FQE('-H87)E<R`H<V5E
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M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,:6%B
M:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG
M(&)A<VES(&%R92!A<R!F;VQL;W=S("AI;B!T:&]U<V%N9',I.CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT
M+6%L:6=N.FQE9G0[5TE$5$@Z(#DS+C,T)3L@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N,C5I;CLG(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DS)3X-"@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S<E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T,RXY,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T,R4@8V]L<W!A;CTS1#@^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3Y&86ER)B,Q-C`[5F%L=64F(S$V,#M-96%S=7)E;65N=',F
M(S$V,#MA=#QB<B`O/@T*4F5P;W)T:6YG)B,Q-C`[1&%T928C,38P.U5S:6YG
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,S<N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S-R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/E1O=&%L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^475O=&5D)B,Q-C`[4')I8V5S/&)R("\^#0II;B8C
M,38P.T%C=&EV93QB<B`O/@T*36%R:V5T<R8C,38P.V9O<CQB<B`O/@T*261E
M;G1I8V%L/&)R("\^#0I!<W-E=',\8G(@+SX-"BA,979E;"8C,38P.S$I/"]F
M;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^4VEG;FEF:6-A
M;G0\8G(@+SX-"D]T:&5R/&)R("\^#0I/8G-E<G9A8FQE/&)R("\^#0I);G!U
M=',\8G(@+SX-"BA,979E;"8C,38P.S(I/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#$^4VEG;FEF:6-A;G0\8G(@+SX-"E5N;V)S97)V
M86)L93QB<B`O/@T*26YP=71S/&)R("\^#0HH3&5V96PF(S$V,#LS*3PO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S<E/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W
M+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,S<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY!<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,SH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,S<E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY787)R
M86YT(&QI86)I;&ET>3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XU
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ-C,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C$V,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#`N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,S<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY%>&-H86YG96%B;&4@<VAA<F4@;&EA8FEL:71Y/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(L
M.#@U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXR+#@X-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S<E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A
M;"!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,RPP-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C,L,#0X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S<N,#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N
M.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XX
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,S<N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0S-R4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S(&]F
M($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S-RXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#,W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^5V%R<F%N="!L:6%B:6QI='D\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3@T/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C
M.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XU-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXQ.#0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S-RXP-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#,W)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^17AC:&%N9V5A8FQE('-H87)E(&QI86)I;&ET>3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXU-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C4U,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S<E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4;W1A;"!L
M:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XU-B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-S,U/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
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M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
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M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF
M(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
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M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW,S4\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`P+C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,C=P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
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M<FQY:6YG(&-O;6UO;B!S=&]C:RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS('=E<F4@
M=7-E9"!I;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E
M;"!T;R!D971E<FUI;F4@=&AE(&9A:7(@=F%L=64@;V8@=&AE('!R969E<G)E
M9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>3H\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#<S+C,T)3L@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#%I;CLG(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#<S)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#4Y+C$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS
M1#$^4V5P=&5M8F5R/&)R("\^#0HS,"PF(S$V,#LR,#$S/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3Y$96-E;6)E<CQB<B`O/@T*,S$L)B,Q-C`[,C`Q,CPO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#4Y+C$E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Y+C$E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0U
M.24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+C$\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2XR/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`U.2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E8W1E9"!V;VQA=&EL
M:71Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS
M-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX-2XY/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/CDS+C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)3PO
M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#4Y+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0U.24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E)E;6%I;FEN9R!C
M;VYT<F%C='5A;"!T97)M("AI;B!Y96%R<RD\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<N
M-38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,38E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C@N,S$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C`N
M,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXE/"]F;VYT/CPO
M<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&4@<')O=FED97,@82!R
M96-O;F-I;&EA=&EO;B!O9B!A;&P@;&EA8FEL:71I97,@;65A<W5R960@870@
M9F%I<B!V86QU92!U<VEN9R!,979E;"`S('-I9VYI9FEC86YT('5N;V)S97)V
M86)L92!I;G!U=',@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F
M=#M724142#H@-S,N,S0E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-
M05)'24XM3$5&5#H@,6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S,E/@T*#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3DN,30E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U.24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V%R<F%N=#QB
M<B`O/@T*3&EA8FEL:71Y/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3Y%>&-H86YG96%B;&4\8G(@+SX-"E-H87)E/&)R("\^#0I,:6%B
M:6QI='D\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4Y)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-3DN,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D)A;&%N8V4@
M870@1&5C96UB97(F(S$V,#LS,2P@,C`Q,3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(R,3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4V,SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#4Y+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY)<W-U86YC92!O9B!E
M>&-H86YG96%B;&4@<VAA<F5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXW.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Y
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY#:&%N9V4@:6X@9F%I<B!V86QU93PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B@S-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B@Y,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N
M=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#4Y+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY"86QA
M;F-E(&%T($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ.#0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$V+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXU-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4Y)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^27-S=6%N8V4@;V8@97AC:&%N9V5A8FQE('-H87)E
M<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,S0V/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3DN
M,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-H86YG92!I;B!F86ER('9A;'5E
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^*#(Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C,W-7!T.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PY.#@\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`U.2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Y)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0F%L86YC
M92!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q,SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
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M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXQ-C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-2XP-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPX.#4\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P
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M>28C.#(Q-SMS($E03R!O;B!/8W1O8F5R)B,Q-C`[-"P@,C`Q,R`H<V5E($YO
M=&4@-BDN/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?
M-F(R968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D
M8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S
M+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY,;VYG+51E<FT@1&5B="P@0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY,;VYG+51E<FT@1&5B="P@0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQO;F<M5&5R;2!$96)T+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,C(N-7!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(R+C5P=#LG/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CXT+CPO9F]N=#X\
M+V(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`S<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO8CX@/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/DQO;F<M5&5R;2!$96)T
M+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO9F]N=#X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TR,BXU<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,C(N-7!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY,;VYG+51E<FT@1&5B=#PO9F]N
M=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^3&]N9RUT97)M(&1E8G0@86YD('5N86UO<G1I>F5D(&1I<V-O=6YT(&)A
M;&%N8V5S("AE>&-L=61I;F<@8V]N=F5R=&EB;&4@9&5B="D@87)E(&%S(&9O
M;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M72414
M2#H@.#8N-C@E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM
M3$5&5#H@,"XU:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0X-B4^#0H-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C4E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y397!T96UB97(\8G(@
M+SX-"C,P+"8C,38P.S(P,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,3Y$96-E;6)E<CQB<B`O/@T*,S$L)B,Q-C`[,C`Q,CPO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3&]N9RUT97)M(&1E8G0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPR
M-3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,RPW-3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY,97-S(&1E8G0@9&ES8V]U;G0L(&YE="!O9B!C=7)R96YT('!O
M<G1I;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXH,3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#`N,S<U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY,;VYG+71E<FT@9&5B="P@;F5T(&]F(&1E8G0@9&ES8V]U;G0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M
M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPR-3`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,RPW,S(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY,97-S(&-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXH,BPP,#`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N,S<U<'0[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#(L,#`P/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M+C,W-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3&]N9RUT97)M(&1E8G0L
M(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C(U,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PW,S(\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8U
M+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E
M<FT@9&5B=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXR+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXR+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8U+C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D-U<G)E;G0@<&]R=&EO;B!O9B!D96)T(&1I
M<V-O=6YT/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@R.3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH-3D\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#`N,S<U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#=7)R96YT('!O<G1I
M;VX@;V8@;&]N9RUT97)M(&1E8G0L(&YE=#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,2PY-S$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$L.30Q/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/DIU;F4F(S$V,#MA;F0@
M2G5L>28C,38P.S(P,3,@0V]N=F5R=&EB;&4@3F]T92!&:6YA;F-I;F<\+V9O
M;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/DEN($IU;F4F(S$V,#MA;F0@2G5L>28C,38P.S(P,3,L('1H92!#;VUP
M86YY(&ES<W5E9"!C;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&5S(&EN(&%N
M(&%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT(&]F("0S+C<@;6EL;&EO;B!T
M;R!C97)T86EN(&5X:7-T:6YG('-T;V-K:&]L9&5R<RX@5&AE(&YO=&5S(&%C
M8W)U92!I;G1E<F5S="!A="`R)2!P97(@>65A<B!A;F0@87)E(&1U92!O;B!*
M=6YE)B,Q-C`[,C0L(#(P,30L(&EF(&YO="!E87)L:65R(')E<&%I9"!O<B!C
M;VYV97)T960@:6X@9G5L;"X@26X@8V]N;F5C=&EO;B!W:71H('1H92!I<W-U
M86YC92!O9B!T:&4@8V]N=F5R=&EB;&4@;F]T97,L('1H92!#;VUP86YY(')E
M8V]R9&5D(&$@9&5B="!D:7-C;W5N="!O9B`D,"XS(&UI;&QI;VX@<F5L871E
M9"!T;R!A(&)E;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E('1H870@=V%S
M(')E8V]R9&5D(&%S(&$@<F5S=6QT(&]F('1H92!G<F]S<R!F86ER('9A;'5E
M(&]F('1H92!S:&%R97,@;V8@4V5R:65S)B,Q-C`[0R!C;VYV97)T:6)L92!P
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M;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,RP@=&AE($-O;7!A
M;GD@<F5C;W)D960@9&5B="!D:7-C;W5N="!A;6]R=&EZ871I;VX@;V8@)#`N
M,2!M:6QL:6]N+B8C,38P.T%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S
M+"!A;B!A9V=R96=A=&4@;V8@)#,N-R!M:6QL:6]N(&]F('!R:6YC:7!A;"P@
M)#`N,R!M:6QL:6]N(&]F('5N86UO<G1I>F5D(&1E8G0@9&ES8V]U;G0@86YD
M("0P+C$@;6EL;&EO;B!O9B!A8V-R=65D(&EN=&5R97-T('=E<F4@;W5T<W1A
M;F1I;F<@=6YD97(@=&AE('!R;VUI<W-O<GD@;F]T97,N(%1H92!N;W1E<R!C
M;VYV97)T960@:6YT;R!C;VUM;VX@<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H
M('1H92!#;VUP86YY)B,X,C$W.W,@25!/(&EN($]C=&]B97(F(S$V,#LR,#$S
M("AS964@3F]T92`V*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M)R!S:7IE/3-$,CY!=6=U<W0F(S$V,#LR,#$S($-O;G9E<G1I8FQE($YO=&4@
M1FEN86YC:6YG/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY);B!!=6=U<W0F(S$V,#LR,#$S+"!T:&4@0V]M
M<&%N>2!I<W-U960@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<R!I;B!A
M;B!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D,C`N,"!M:6QL:6]N
M('1O(&-E<G1A:6X@;F5W(&EN=F5S=&]R<RX@5&AE(&YO=&5S(&%C8W)U92!I
M;G1E<F5S="!A="`R)2!P97(@>65A<B!A;F0@87)E(&1U92!O;B!!=6=U<W0F
M(S$V,#LX+"`R,#$V+"!I9B!N;W0@96%R;&EE<B!R97!A:60@;W(@8V]N=F5R
M=&5D(&EN(&9U;&PN($%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S+"!A
M;B!A9V=R96=A=&4@;V8@)#(P+C`@;6EL;&EO;B!O9B!P<FEN8VEP86P@86YD
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M3V-T;V)E<B8C,38P.S(P,3,@*'-E92!.;W1E(#8I+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#(^1F%C:6QI='D@3&5A<V4\+V9O;G0^/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D]N(%-E<'1E;6)E
M<B8C,38P.S(V+"`R,#$S+"!T:&4@0V]M<&%N>2!E>&5R8VES960@:71S(&]P
M=&EO;B!T;R!E>'1E;F0@9F]R('1W;R!Y96%R<R!T:&4@;&5A<V4@;VX@:71S
M(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C92!I;B!386X@1&EE9V\L($-A
M;&EF;W)N:6$@=6YT:6P@2G5N928C,38P.S(P,38N($%S(&$@<F5S=6QT(&]F
M('1H92!L96%S92!E>'1E;G-I;VXL('1H92!#;VUP86YY(&%D9&5D(&%N(&%D
M9&ET:6]N86P@)#`N-2!M:6QL:6]N+"`D,"XY(&UI;&QI;VX@86YD("0P+C4@
M;6EL;&EO;BP@<F5S<&5C=&EV96QY+"!O9B!N;VXM8V%N8V5L86)L92!O<&5R
M871I;F<@;&5A<V4@8V]M;6ET;65N=',@9F]R('1H92!Y96%R<R!E;F1I;F<@
M1&5C96UB97(F(S$V,#LS,2P@,C`Q-"P@,C`Q-2!A;F0@,C`Q-BX\+V9O;G0^
M/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L
M9&5R<R<@1&5F:6-I=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@1&5F:6-I=#PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VMH;VQD
M97)S)R!$969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TR
M,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C(N-7!T.R<^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/C4N/"]F
M;VYT/CPO8CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#L@1D].
M5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#L\+V9O;G0^/"]B/B`\8CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^4W1O8VMH;VQD
M97)S)B,X,C$W.R!$969I8VET/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3(R+C5P=#L@34%21TE..B`P:6X@,&EN(#!P="`R
M,BXU<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0R/C(P,#<@17%U:71Y($EN8V5N=&EV92!0;&%N/"]F;VYT
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY/;B!!=6=U<W0F(S$V,#LQ,BP@,C`Q,RP@=&AE($-O;7!A;GDF(S@R,3<[
M<R!B;V%R9"!O9B!D:7)E8W1O<G,@87!P<F]V960@86X@:6YC<F5A<V4@:6X@
M=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%U=&AO<FEZ
M960@9F]R(&ES<W5A;F-E('5N9&5R('1H92!#;VUP86YY)B,X,C$W.W,@,C`P
M-R!%<75I='D@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[4&QA;B8C.#(R
M,3LI('1O(#(L-#(S+#`W,B8C,38P.W-H87)E<RX\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/E-T;V-K(&]P=&EO;B!A8W1I=FET>2!U;F1E<B!T:&4@4&QA;B!I
M<R!S=6UM87)I>F5D(&%S(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M7
M24142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM
M3$5&5#H@,"XW-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E/@T*#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#LG('-I>F4],T0Q/DYU;6)E<B8C,38P.V]F/&)R("\^#0I/<'1I
M;VYS/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V5I9VAT
M960M/&)R("\^#0I!=F5R86=E)B,Q-C`[4')I8V4\+V9O;G0^/"]B/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0F%L
M86YC92!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$R/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2PT,S(L,S8Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XV
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C,X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$N-#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^1W)A;G1E9#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C,S,2PX-C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXU+C8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@]
M,T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/D-A;F-E;&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#$W+#@V,#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2XU-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN
M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY%>&5R8VES960\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^*#,U+#@U,CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/C`N-C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^0F%L86YC92!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,2PW,3`L-3$W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BXR-CPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT
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M15A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^5&AE(&%L;&]C871I;VX@;V8@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&9O<B!A;&P@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C
M:R!A=V%R9',@:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X
M="UA;&EG;CIL969T.U=)1%1(.B`X-BXV."4[($)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($U!4D=)3BU,1494.B`P+C5I;CLG(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@V)3X-"@T*
M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+CDT
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S,"XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S,"4@8V]L<W!A;CTS1#4^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3Y4:')E928C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I397!T
M96UB97(F(S$V,#LS,"P\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S,"XV)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,P)2!C;VQS<&%N/3-$-3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0Q/DYI;F4F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#QB<B`O/@T*4V5P
M=&5M8F5R)B,Q-C`[,S`L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S$N.30E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P
M,3,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
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M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+CDT)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@V
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,Q+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE
M;G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-3@Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/C,R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C8X-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXX,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+CDT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXT,#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#@S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C(T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S$N.30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
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M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXY.#(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0R/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
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M.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ+#$V.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,3`V/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,L('1H92!O=71S
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M(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S('=A<R`D,2XX(&UI;&QI;VXN
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY!<R!O9B!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,RP@=&AE(&]U='-T86YD:6YG(&]P=&EO;G,@:6YC;'5D960@,C(P
M+#0Y-B!O<'1I;VYS('=I=&@@8F]T:"!P97)F;W)M86YC92UB87-E9"!M:6QE
M<W1O;F5S(&%N9"!M87)K970@8V]N9&ET:6]N<R!T:&%T('=E<F4@9&5T97)M
M:6YE9"!N;W0@=&\@8F4@<')O8F%B;&4@;V8@86-H:65V96UE;G0N(%1H92!A
M9V=R96=A=&4@9W)A;G0@9&%T92!F86ER('9A;'5E(&]F('1H97-E('5N=F5S
M=&5D(&]P=&EO;G,@870@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3,@=V%S("0P
M+C(@;6EL;&EO;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%S(&]F(%-E<'1E
M;6)E<B8C,38P.S,P+"`R,#$S+"!T:&4@=6YR96-O9VYI>F5D(&-O;7!E;G-A
M=&EO;B!C;W-T(')E;&%T960@=&\@;W5T<W1A;F1I;F<@;W!T:6]N<R`H97AC
M;'5D:6YG('1H;W-E('=I=&@@<&5R9F]R;6%N8V4M8F%S960@86YD+V]R(&UA
M<FME="!C;VYD:71I;VYS*2!W87,@)#`N-B!M:6QL:6]N(&%N9"!I<R!E>'!E
M8W1E9"!T;R!B92!R96-O9VYI>F5D(&%S(&5X<&5N<V4@;W9E<B!A<'!R;WAI
M;6%T96QY(#,N-2!Y96%R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P
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M;G1S('=E<F4@87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL
M93TS1"=T97AT+6%L:6=N.FQE9G0[5TE$5$@Z(#@P)3L@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@P
M)3X-"@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,S+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,S)2!C;VQS<&%N/3-$,SX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG
M('-I>F4],T0Q/DYI;F4F(S$V,#M-;VYT:',F(S$V,#M%;F1E9#QB<B`O/@T*
M4V5P=&5M8F5R)B,Q-C`[,S`L/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,SPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#LG('-I>F4],T0Q/C(P,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R
M+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,2XV/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXQ+C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)3PO
M9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X<&5C
M=&5D('9O;&%T:6QI='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY,"XR
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXY,RXU/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>'!E
M8W1E9"!T97)M("AI;B!Y96%R<RD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+C`W/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^-BXP-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@
M=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+C`\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4
M:&4@=V5I9VAT960M879E<F%G92!A<W-U;7!T:6]N<R!U<V5D(&EN('1H92!"
M;&%C:RU38VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L('1O(&1E=&5R;6EN
M92!T:&4@9F%I<B!V86QU92!O9B!T:&4@;F]N+65M<&QO>65E('-T;V-K(&]P
M=&EO;B!G<F%N=',@=V5R92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE
M9G0[5TE$5$@Z(#@P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%2
M1TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@P)3X-"@T*/'1R('-T>6QE/3-$
M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4R)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,R4@8V]L
M<W!A;CTS1#,^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y.:6YE)B,Q
M-C`[36]N=&AS)B,Q-C`[16YD960\8G(@+SX-"E-E<'1E;6)E<B8C,38P.S,P
M+#PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-C(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O
M;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3(\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4FES:RUF<F5E
M(&EN=&5R97-T(')A=&4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+C$\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$N,CPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXY,"XS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY,RXU/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V
M,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^4F5M86EN:6YG(&-O;G1R86-T=6%L('1E<FT@
M*&EN('EE87)S*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<N,C<\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW
M+C(S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG
M.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0V
M,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/D5X<&5C=&5D(&1I=FED96YD('EI96QD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,"XP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXP+C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R<@<VEZ93TS1#(^,C`Q,R!3=&]C:R!/<'1I;VX@86YD($EN8V5N=&EV92!0
M;&%N/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY/;B!!=6=U<W0F(S$V,#LR."P@,C`Q,RP@=&AE($-O;7!A
M;GDF(S@R,3<[<R!B;V%R9"!O9B!D:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R
M<R!A<'!R;W9E9"!A;F0@861O<'1E9"!T:&4@,C`Q,R!3=&]C:R!/<'1I;VX@
M86YD($EN8V5N=&EV92!0;&%N("AT:&4@)B,X,C(P.S(P,3,@4&QA;B8C.#(R
M,3LI+B!4:&4@,C`Q,R!0;&%N(&)E8V%M92!E9F9E8W1I=F4@:6UM961I871E
M;'D@<')I;W(@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!)4$\N(%5N9&5R('1H
M92`R,#$S(%!L86XL('1H92!#;VUP86YY(&UA>2!G<F%N="!S=&]C:R!O<'1I
M;VYS+"!S=&]C:R!A<'!R96-I871I;VX@<FEG:'1S+"!R97-T<FEC=&5D('-T
M;V-K+"!R97-T<FEC=&5D('-T;V-K('5N:71S(&%N9"!O=&AE<B!A=V%R9',@
M=&\@:6YD:79I9'5A;',@=VAO(&%R92!T:&5N(&5M<&QO>65E<RP@;V9F:6-E
M<G,L(&1I<F5C=&]R<R!O<B!C;VYS=6QT86YT<R!O9B!T:&4@0V]M<&%N>2!O
M<B!I=',@<W5B<VED:6%R:65S+B!!('1O=&%L(&]F(#$L,#(P+#`P,"!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K('=E<F4@:6YI=&EA;&QY(')E<V5R=F5D(&9O
M<B!I<W-U86YC92!U;F1E<B!T:&4@,C`Q,R!0;&%N+B!);B!A9&1I=&EO;BP@
M=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@<W1O8VL@879A:6QA8FQE(&9O<B!I
M<W-U86YC92!U;F1E<B!T:&4@,C`Q,R!0;&%N('=I;&P@8F4@875T;VUA=&EC
M86QL>2!I;F-R96%S960@96%C:"!*86YU87)Y)B,Q-C`[,2P@8F5G:6YN:6YG
M(&]N($IA;G5A<GDF(S$V,#LQ+"`R,#$T+"!B>2`T)2!O9B!T:&4@;W5T<W1A
M;F1I;F<@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&-O;6UO;B!S=&]C:R!O;B!T:&4@:6UM961I871E;'D@<')E8V5D:6YG($1E
M8V5M8F5R)B,Q-C`[,S$@;W(@<W5C:"!L97-S97(@;G5M8F5R(&%S(&1E=&5R
M;6EN960@8GD@=&AE(&-O;7!E;G-A=&EO;B!C;VUM:71T964@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!B;V%R9"!O9B!D:7)E8W1O<G,N/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#(^16UP;&]Y964@4W1O8VL@
M4'5R8VAA<V4@4&QA;CPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^3VX@4V5P=&5M8F5R)B,Q-C`[,3,L(#(P
M,3,L('1H92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S(&%P
M<')O=F5D(&%N9"!A9&]P=&5D('1H92`R,#$S($5M<&QO>65E(%-T;V-K(%!U
M<F-H87-E(%!L86X@*'1H92`F(S@R,C`[15-04"8C.#(R,3LI+B!4:&4@15-0
M4"!B96-A;64@969F96-T:79E(&EM;65D:6%T96QY('!R:6]R('1O('1H92!#
M;VUP86YY)B,X,C$W.W,@25!/+B!!('1O=&%L(&]F(#<R.2PP,#`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!W97)E(&EN:71I86QL>2!R97-E<G9E9"!F;W(@
M:7-S=6%N8V4@=6YD97(@=&AE($534%`N($EN(&%D9&ET:6]N+"!T:&4@;G5M
M8F5R(&]F('-H87)E<R!O9B!S=&]C:R!A=F%I;&%B;&4@9F]R(&ES<W5A;F-E
M('5N9&5R('1H92!%4U!0('=I;&P@8F4@875T;VUA=&EC86QL>2!I;F-R96%S
M960@96%C:"!*86YU87)Y)B,Q-C`[,2P@8F5G:6YN:6YG(&]N($IA;G5A<GDF
M(S$V,#LQ+"`R,#$U+"!B>2!T:&4@;&5S<V5R(&]F("AI*28C,38P.S(E(&]F
M('1H92!O=71S=&%N9&EN9R!N=6UB97(@;V8@<VAA<F5S(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!I;6UE9&EA=&5L>2!P
M<F5C961I;F<@1&5C96UB97(F(S$V,#LS,2P@*&EI*28C,38P.S0U,"PP,#`@
M<VAA<F5S+"!O<B`H:6EI*28C,38P.W-U8V@@;&5S<V5R(&YU;6)E<B!A<R!D
M971E<FUI;F5D(&)Y('1H92!C;VUP96YS871I;VX@8V]M;6ET=&5E(&]F('1H
M92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S+CPO9F]N=#X\
M+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W9&(P964W-5]C-#0W7S0P
M-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N
M="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3(R+C5P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`R,BXU<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4
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M=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TR,BXU<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,C(N-7!T.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,CY);FET:6%L(%!U
M8FQI8R!/9F9E<FEN9R!A;F0@4F5L871E9"!4<F%N<V%C=&EO;G,\+V9O;G0^
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^3VX@3V-T;V)E<B8C,38P.S0L(#(P,3,L('1H92!#;VUP86YY(&-O;7!L
M971E9"!I=',@25!/('=H97)E8GD@:70@<V]L9"`W+#8V-BPV-C<@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!A="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC92!O
M9B`D-BXP,"!P97(@<VAA<F4N($5S=&EM871E9"!N970@<')O8V5E9',@9G)O
M;2!T:&4@25!/('=E<F4@9&5T97)M:6YE9"!A<R!F;VQL;W=S("AI;B!T:&]U
M<V%N9',I.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI
M9VXZ;&5F=#M724142#H@.#DN,S0E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!-05)'24XM3$5&5#H@,"XT:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X.24^#0H-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X,BXW)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.#(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY'<F]S<R!P<F]C965D<R`H:6YC;'5D:6YG(&]V97(M86QL
M;W1M96YT*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/C0V+#`P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.#(N-R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^56YD97)W<FET:6YG(&1I<V-O=6YT<R!A;F0@8V]M;6ES
M<VEO;G,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B@R+#8Y-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O
M;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`X,BXW)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#(E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%<W1I;6%T960@
M=&]T86P@;V9F97)I;F<@8V]S=',@*&EN8VQU9&EN9R!C;W-T<R!P86ED(&%S
M(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S*3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^*#(L.3`P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M*3PO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP
M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@R+C<E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X
M,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/D]F9F5R:6YG(&-O<W1S('!A:60@87,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L
M(#(P,3,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$S+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#,X,3PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17-T:6UA=&5D(&YE="!P
M<F]C965D<R!T;R!B92!R96-E:79E9"!S=6)S97%U96YT('1O(%-E<'1E;6)E
M<B8C,38P.S,P+"`R,#$S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,RXT,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^-#$L-S@V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`X,BXW)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.#(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CY087)T:6%L(')E<&%Y;65N="!O9B!!=6=U
M<W0F(S$V,#LR,#$S($YO=&5S('-U8G-E<75E;G0@=&\@4V5P=&5M8F5R)B,Q
M-C`[,S`L(#(P,3,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C0R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH,2PW-#$\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N,S<U
M<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#@R+C<E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0X,B4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D5S=&EM871E9"!N970@8V%S:"!I
M;7!A8W0@;V8@25!/(&%N9"!R96QA=&5D('1R86YS86-T:6]N<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
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M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
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M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXT,"PP-#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(R+C5P=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DEN
M(&%D9&ET:6]N+"!E86-H(&]F('1H92!F;VQL;W=I;F<@;V-C=7)R960@:6X@
M8V]N;F5C=&EO;B!W:71H('1H92!C;VUP;&5T:6]N(&]F(&]U<B!)4$\@;VX@
M3V-T;V)E<B8C,38P.S0L(#(P,3,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@
M34%21TE..B`P:6X@,&EN(#!P="`U."XS<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`S<'0[)R!S:7IE/3-$,3XF(S$V,#LF(S$V
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M:SL\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,&EN(#!I;B`P<'0@-3@N,W!T.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@-3@N,W!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<@<VEZ93TS1#(^)B,Q.#,[/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,W!T.R<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/B`\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CYT:&4@
M8V]N=F5R<VEO;B!O9B`D,C(N,2!M:6QL:6]N(&]F(&]U='-T86YD:6YG('!R
M:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!O;B!C;VYV97)T:6)L92!N
M;W1E<R!I;G1O(#,L-C<Y+#0P,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!T
M:&4@=W)I=&4M;V9F(&]F("0P+C,@;6EL;&EO;B!O9B!U;F%M;W)T:7IE9"!D
M96)T(&1I<V-O=6YT(&%N9"!T:&4@<F5L871E9"!C87-H(')E<&%Y;65N="!O
M9B`D,2XW(&UI;&QI;VX@;V8@;W5T<W1A;F1I;F<@<')I;F-I<&%L(&%N9"!A
M8V-R=65D(&EN=&5R97-T(&]N(&-O;G9E<G1I8FQE(&YO=&5S(&%N9"!A8V-R
M=65D(&EN=&5R97-T(&]U='-T86YD:6YG(&%S(&]F(%-E<'1E;6)E<B8C,38P
M.S,P+"`R,#$S.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3`N,C5I;CL@34%21TE..B`P:6X@,&EN(#!P="`U."XS<'0[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%2
M1TE..B`P:6X@,&EN(#!P="`U."XS<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`S<'0[)R!S:7IE/3-$,3XF(S$V,#LF(S$V,#LF
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M96UP=&EO;B!O9B!A;B!A9V=R96=A=&4@;V8@.3`P+#`P,"!E>&-H86YG96%B
M;&4@<VAA<F5S(&]F($9A=&4@0V%N861A(&%N9"!T:&4@<F5S=6QT86YT(')E
M8VQA<W-I9FEC871I;VX@;V8@=&AE(&5X8VAA;F=E86)L92!S:&%R92!L:6%B
M:6QI='D@=&\@861D:71I;VYA;"!P86ED+6EN(&-A<&ET86P[/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#4X+C-P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T(#4X
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M,T0G1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^=&AE(&-O;G9E<G-I;VX@
M;V8@=V%R<F%N=',@=&\@<'5R8VAA<V4@,C,P+#`P,"!S:&%R97,@;V8@8V]N
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M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!I;B`P:6X@,'!T(#4X+C-P=#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#4X+C-P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG('-I>F4],T0R/B8C,3@S.SPO9F]N=#X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#-P=#LG('-I>F4],T0Q/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.SPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^86X@86UE;F1E9"!A;F0@<F5S=&%T960@8V5R=&EF:6-A=&4@
M;V8@:6YC;W)P;W)A=&EO;B!W87,@9FEL960@;VX@3V-T;V)E<B8C,38P.S,L
M(#(P,3,L(&%U=&AO<FEZ:6YG(#$U,"PP,#`L,#`P('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@86YD(#4L,#`P+#`P,"!S:&%R97,@;V8@=6YD97-I9VYA=&5D
M('!R969E<G)E9"!S=&]C:RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1C96YT97(^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(R+C5P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
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M;W9E+"!A<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,R`H:6X@=&AO=7-A
M;F1S*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N
M.FQE9G0[5TE$5$@Z(#@V+C8X)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@34%21TE.+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#8E/@T*#0H\='(@<W1Y
M;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^4V5P
M=&5M8F5R/&)R("\^#0HS,"PF(S$V,#LR,#$S/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^4')O)B,Q-C`[1F]R;6$\8G(@+SX-"E-E
M<'1E;6)E<CQB<B`O/@T*,S`L)B,Q-C`[,C`Q,SPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ.2PP
M.#(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-3DL,3(W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P
M861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^3W1H97(@87-S971S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,BPW-#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C,L-S(U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N
M.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPS-#0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY,
M;VYG+71E<FT@86-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C$S-SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C<Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V]N=F5R=&EB;&4@;F]T97,L(&YE
M="!O9B!D:7-C;W5N=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(S
M+#0X,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY0<F5F
M97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ-C,\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17AC:&%N9V5A8FQE
M('-H87)E(&QI86)I;&ET>3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C(L.#@U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C4V+#4R-CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#;VUM;VX@<W1O8VL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$T+#,V
M-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$S
M-BPS.3@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY$969I8VET(&%C8W5M=6QA=&5D(&1U<FEN9R!T:&4@9&5V96QO<&UE
M;G0@<W1A9V4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH.#`L-S<P
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXH.#$L,#(T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I
M;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY4;W1A;"!S=&]C:VAO;&1E<G,F(S@R,3<[("AD969I8VET*2!E<75I
M='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH
M-C8L-#`R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU-2PS.30\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[)R!W:61T:#TS1#0R-#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0Q
M.3X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE
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M/3-$)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^26X@8V]N;F5C=&EO;B!W:71H('1H92!C
M;&]S:6YG(&]F(&ET<R!)4$\@;VX@3V-T;V)E<B8C,38P.S0L(#(P,3,L('1H
M92!#;VUP86YY(')E8V]R9&5D(&%N(&%D9&ET:6]N86P@86=G<F5G871E(&YO
M;BUC87-H(&-H87)G92!O9B`D,"XU(&UI;&QI;VX@:6X@;W1H97(@:6YC;VUE
M("AE>'!E;G-E*2!R96QA=&5D('1O('1H92!F:6YA;"!F86ER('9A;'5E(&%D
M:G5S=&UE;G0@;V8@=&AE(&5X8VAA;F=E86)L92!S:&%R92!L:6%B:6QI='D@
M86YD('1H92!P<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='DN(%1H
M:7,@9FEN86P@9F%I<B!V86QU92!A9&IU<W1M96YT/"]F;VYT/B`\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CYI<R!E>&-L=61E
M9"!F<F]M('1H92!T86)L92!A8F]V92X\+V9O;G0^/"]P/@T*/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15='04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC
M:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE
M/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R
M/E!R:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO9F]N=#X\+V(^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,BXU<'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE(&%C
M8V]U;G1S(&]F('1H92!#;VUP86YY(&%N9"!I=',@<W5B<VED:6%R:65S+"!&
M871E(%1H97)A<&5U=&EC<R`H0V%N861A*2!);F,N("@F(S@R,C`[1F%T92!#
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2979E<G-E(%-T;V-K(%-P;&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0[)R!S:7IE/3-$,CY2979E<G-E(%-T;V-K(%-P;&ET/"]F;VYT
M/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY/;B!397!T96UB97(F(S$V,#LQ,BP@,C`Q,RP@=&AE($-O;7!A;GD@9FEL
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M<V5N=&5D+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$
M)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/E5S
M92!O9B!%<W1I;6%T97,\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,C0N-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE($-O;7!A;GDF(S@R,3<[<R!C
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!!<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE
M/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R
M/D]T:&5R($%S<V5T<SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^3W1H97(@87-S971S(&-O;G-I<W0@;V8@
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M('!R;V-E961S+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C
M:R!787)R86YT($QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R<@<VEZ93TS1#(^4')E9F5R<F5D(%-T;V-K(%=A<G)A;G0@3&EA
M8FEL:71Y/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#(R+C5P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
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M92!#;VUP86YY+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N
M:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.R<^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0R/E)E=F5N=64@4F5C;V=N:71I;VX\+V9O;G0^/"]B/CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!#;VUP86YY(')E
M8V]G;FEZ97,@<F5V96YU97,@=VAE;B!A;&P@9F]U<B!O9B!T:&4@9F]L;&]W
M:6YG(&-R:71E<FEA(&%R92!M970Z("AI*28C,38P.W!E<G-U87-I=F4@979I
M9&5N8V4@=&AA="!A;B!A9W)E96UE;G0@97AI<W1S.R`H:6DI)B,Q-C`[9&5L
M:79E<GD@;V8@=&AE('!R;V1U8W1S(&%N9"]O<B!S97)V:6-E<R!H87,@;V-C
M=7)R960[("AI:6DI)B,Q-C`[=&AE('-E;&QI;F<@<')I8V4@:7,@9FEX960@
M;W(@9&5T97)M:6YA8FQE.R!A;F0@*&EV*28C,38P.V-O;&QE8W1I8FEL:71Y
M(&ES(')E87-O;F%B;'D@87-S=7)E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^1F]R('1R86YS86-T:6]N<R!E;G1E<F5D
M(&EN=&\@<')I;W(@=&\@,C`Q,2P@<F5V96YU92!W87,@86QL;V-A=&5D('1O
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^0F5G:6YN:6YG(&EN(#(P,3$L(')E=F5N
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M;V)J96-T:79E(&5V:61E;F-E("@F(S@R,C`[5E-/128C.#(R,3LI(&]F(&9A
M:7(@=F%L=64L('=H:6-H(')E<')E<V5N=',@=&AE('!R:6-E(&-H87)G960@
M9F]R(&5A8V@@96QE;65N="!W:&5N(&ET(&ES('-O;&0@<V5P87)A=&5L>2!O
M<BP@9F]R(&%N(&5L96UE;G0@;F]T('EE="!B96EN9R!S;VQD('-E<&%R871E
M;'DL('1H92!P<FEC92!E<W1A8FQI<VAE9"!B>2!M86YA9V5M96YT+B!7:&5N
M(%933T4@;V8@9F%I<B!V86QU92!I<R!N;W0@879A:6QA8FQE+"!T:&ER9"UP
M87)T>2!E=FED96YC92`H)B,X,C(P.U10128C.#(R,3LI(&]F(&9A:7(@=F%L
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M(&%R<F%N9V5M96YT<R!S=6)S97%U96YT('1O(#(P,3`N/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(R+C5P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
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M('-O;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E.R`H:6EI*28C,38P.W1H92!C
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M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY2979E;G5E(&9R;VT@9V]V97)N
M;65N="!G<F%N=',@:7,@<F5C;W)D960@=VAE;B!R96EM8G5R<V%B;&4@97AP
M96YS97,@87)E(&EN8W5R<F5D('5N9&5R('1H92!G<F%N="!I;B!A8V-O<F1A
M;F-E('=I=&@@=&AE('1E<FUS(&]F('1H92!G<F%N="!A=V%R9"X@5&AE(')E
M8V5I=F%B;&4@9F]R(')E:6UB=7)S86)L92!A;6]U;G1S('1H870@:&%V92!N
M;W0@8F5E;B!C;VQL96-T960@:7,@<F5F;&5C=&5D(&EN('!R97!A:60@86YD
M(&]T:&5R(&-U<G)E;G0@87-S971S+CPO9F]N=#X\+W`^#0H\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[)SX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#(^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N
M/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
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M=&EC92!B87-E9"!M;V1E;"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P
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M/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@3&]S<R!097(@4VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R<^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0R/DYE="!,;W-S(%!E<B!3:&%R
M93PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R
M,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
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M9"!S=&]C:R!T;W1A;&EN9R`Q,#(L.3DX('-H87)E<R!A;F0@,38V+#(U,B!S
M:&%R97,@9F]R('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q
M-C`[,S`L(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2P@86YD(#$Q,2PV
M,30@<VAA<F5S(&%N9"`Q.#0L-3$W('-H87)E<R!F;W(@=&AE(&YI;F4@;6]N
M=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S(&%N9"`R,#$R+"!R
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M/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
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M)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M72414
M2#H@-C8N-C@E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!-05)'24XM
M3$5&5#H@,2XR-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$-C8E/@T*#0H\='(@<W1Y;&4],T1P861D
M:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0U-24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Y
M+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Y)2!C;VQS<&%N/3-$
M,SX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E1H<F5E)B,Q-C`[86YD
M)B,Q-C`[3FEN928C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I397!T
M96UB97(F(S$V,#LS,"P\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4U)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-34E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@N,#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3@N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1'!A9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K(&]U='-T86YD
M:6YG/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^-RPR,CDL-3DP/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3@N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M-BPP-C4L.3,T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A
M9&1I;F<Z,#L^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^5V%R<F%N=',@9F]R(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,V+#`W-#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X+C`T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C,V+#`W-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1T;W`@=VED=&@],T0U-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D5X8VAA;F=E86)L92!S:&%R97,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXT.#`L-S8S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3@N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#`S+#@T,3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T1P861D:6YG.C`[/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@-34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1T;W`@=VED=&@],T0U-24^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!O
M<'1I;VYS/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C$L-S$P+#4Q-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X+C`T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW,C$L-3,Y/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1'!A9&1I;F<Z,#L^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/CDL-#4V+#DT-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^-RPR,C<L,S@X/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S+C`U<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY);B!A
M9&1I=&EO;B!T;R!T:&4@<&]T96YT:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE
M<R!N;W1E9"!A8F]V92P@=&AE($-O;7!A;GD@:&%S(&%N(&%G9W)E9V%T92!O
M9B!A<'!R;WAI;6%T96QY("0R,RXW(&UI;&QI;VX@;V8@;W5T<W1A;F1I;F<@
M<')I;F-I<&%L(&%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S('5N9&5R
M(&-O;G9E<G1I8FQE('!R;VUI<W-O<GD@;F]T97,L(&ES<W5E9"!I;B!*=6YE
M)B,Q-C`[,C`Q,RP@2G5L>28C,38P.S(P,3,@86YD($%U9W5S="8C,38P.S(P
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M>28C.#(Q-SMS($E03R!I;B!/8W1O8F5R)B,Q-C`[,C`Q,R`H<V5E($YO=&4@
M-BDN/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R
M968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E
M93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H
M965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!A;G1I+61I;'5T:79E('-E8W5R:71I97,@;F]T(&EN8VQU9&5D
M(&EN('1H92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E<B!S
M:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y
M;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,
M24=..B!L969T.R!724142#H@-C0V<'@[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($U!4D=)3BU,1494.B`Q+C(U:6X[)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V-#8^#0H-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U-24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,Y+C<X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Y)2!C;VQS<&%N
M/3-$,SX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E1H<F5E)B,Q-C`[
M86YD)B,Q-C`[3FEN928C,38P.TUO;G1H<R8C,38P.T5N9&5D/&)R("\^#0I3
M97!T96UB97(F(S$V,#LS,"P\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4U)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^,C`Q,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X+C`T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q
M/C(P,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XU
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I
M;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@
M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4U)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C4E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`U-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^0V]N=F5R=&EB;&4@<')E9F5R<F5D
M('-T;V-K(&]U='-T86YD:6YG/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-RPR,CDL-3DP/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@N,#0E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q."4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^-BPP-C4L.3,T/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.
M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@=VED
M=&@],T0U-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/E=A<G)A;G1S(&9O<B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O
M8VL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXS-BPP-S0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXS-BPP-S0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#4U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^17AC:&%N9V5A8FQE('-H87)E<SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0X
M,"PW-C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q."XP-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT,#,L.#0Q/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T
M;W`@=VED=&@],T0U-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/D-O;6UO;B!S=&]C:R!O<'1I;VYS/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$L-S$P
M+#4Q-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-S0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$X+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXW,C$L-3,Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-34E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0U-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXW-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O
M=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$X)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY+#0U-BPY-#0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S+C<T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3@N
M,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3@E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<L,C(W+#,X.#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-24[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S=D8C!E93<U7V,T-#=?-#`V
M9%\Y-S!E7S9B,F5F.&4T830V8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\W9&(P964W-5]C-#0W7S0P-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^07-S970@06-Q=6ES:71I;VX@;V8@5F5R:6\@5&AE<F%P
M975T:6-S($EN8RX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E="!!8W%U:7-I=&EO;B!O9B!6
M97)I;R!4:&5R87!E=71I8W,@26YC+CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!C:&%N9V5S(&EN('1H
M92!N=6UB97(@;V8@<VAA<F5S(&]F('1H92!#;VUP86YY)W,@8V]M;6]N('-T
M;V-K(&ES<W5A8FQE('5P;VX@=&AE(&5X8VAA;F=E(&]F('1H92!%>&-H86YG
M96%B;&4@4VAA<F5S(&%N9"!T:&4@:6YI=&EA;"!F86ER('9A;'5E(&]F('1H
M92!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CY!<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,RP@=&AE(&-H86YG
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M(&%M;W5N=',I.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)W1E>'0M
M86QI9VXZ;&5F=#M415A4+4%,24=..B!L969T.R!724142#H@.#`Y<'@[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!4D=)3BU,1494.B`P+C5I;CLG
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#@P.3X-"@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T
M."XV-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0X)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y%>&-H
M86YG96%B;&4\8G(@+SX-"E-H87)E<SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/D9A:7(F(S$V,#M686QU928C,38P.U!E<CQB<B`O
M/@T*4VAA<F4F(S$V,#MO9CQB<B`O/@T*56YD97)L>6EN9SQB<B`O/@T*0V]M
M;6]N)B,Q-C`[4W1O8VL\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S
M:7IE/3-$,3Y);FET:6%L)B,Q-C`[1F%I<CQB<B`O/@T*5F%L=64F(S$V,#MO
M9CQB<B`O/@T*17AC:&%N9V5A8FQE/&)R("\^#0I3:&%R97,\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#@N
M-C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-#@N
M-C8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1T;W`@=VED=&@],T0T."4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/D%P<FEL)B,Q-C`[,C`Q,#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,3,X+#0V,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N
M,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXQ+C8Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C(S-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`T."XV-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#0X)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^36%R8V@F(S$V,#LR,#$Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXY)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXY,BPS,#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXQ+C8Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,34V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)
M3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0
M.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0X+C8V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I9'1H/3-$-#@E
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY-
M87DF(S$V,#LR,#$Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXY)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,34L,S@P/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,2XV.3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/C$Y-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`T."XV-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#0X
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M07!R:6PF(S$V,#LR,#$R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXY)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU
M-RPV.3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXQ+C,W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-#@N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0T."4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DIU;'DF(S$V
M,#LR,#$S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXY)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^-S8L.3(R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N
M.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-"XT.3PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXS-#8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-#@N-C8E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M."4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXY)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0X,"PW-C,\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N
M,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,2PP,#D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,
M1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P
M>#LG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU
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M9'1H/3-$.3`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
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M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R<@=VED=&@],T0X,3X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R<@=VED=&@],T0Q.3X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R<@=VED=&@],T0X/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[)R!W:61T:#TS1#@Q/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[)R!W:61T:#TS1#<^/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9A:7(@5F%L=64@365A
M<W5R96UE;G1S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@
M;VX@82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY,:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER
M('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES(&%R92!A<R!F;VQL;W=S("AI
M;B!T:&]U<V%N9',I.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#@U-G!X.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!-05)'24XM3$5&5#H@,"XR-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#4V/@T*#0H\='(@<W1Y
M;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P
M<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,S<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`T,RXY,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,R4@8V]L
M<W!A;CTS1#@^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y&86ER)B,Q
M-C`[5F%L=64F(S$V,#M-96%S=7)E;65N=',F(S$V,#MA=#QB<B`O/@T*4F5P
M;W)T:6YG)B,Q-C`[1&%T928C,38P.U5S:6YG/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P
M<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,S<E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y4;W1A;#PO9F]N=#X\
M+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E%U;W1E9"8C,38P.U!R
M:6-E<SQB<B`O/@T*:6XF(S$V,#M!8W1I=F4\8G(@+SX-"DUA<FME=',F(S$V
M,#MF;W(\8G(@+SX-"DED96YT:6-A;#QB<B`O/@T*07-S971S/&)R("\^#0HH
M3&5V96PF(S$V,#LQ*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I
M>F4],T0Q/E-I9VYI9FEC86YT/&)R("\^#0I/=&AE<CQB<B`O/@T*3V)S97)V
M86)L93QB<B`O/@T*26YP=71S/&)R("\^#0HH3&5V96PF(S$V,#LR*3PO9F]N
M=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E-I9VYI9FEC86YT
M/&)R("\^#0I5;F]B<V5R=F%B;&4\8G(@+SX-"DEN<'5T<SQB<B`O/@T**$QE
M=F5L)B,Q-C`[,RD\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[
M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)
M3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,S<N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE
M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XX)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-
M.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[
M(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,S<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY!<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,SH\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M-RXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#,W)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5V%R<F%N="!L:6%B:6QI='D\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,38S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ
M-C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$
M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M
M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,S<N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1T;W`@=VED=&@],T0S-R4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D5X8VAA;F=E86)L92!S:&%R92!L:6%B
M:6QI='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,BPX.#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C(L.#@U/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[
M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,S<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY4;W1A;"!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,RPP-#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C,L,#0X/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,"XX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M
M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,W+C`T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,S<E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'
M+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(
M5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M-RXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#,W)3X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^07,@;V8@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,CH\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$R+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#`N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`S-RXP-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#,W)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5V%R<F%N
M="!L:6%B:6QI='D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,3@T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,2XU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ.#0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.
M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S<N,#0E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1T;W`@
M=VED=&@],T0S-R4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/D5X8VAA;F=E86)L92!S:&%R92!L:6%B:6QI='D\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^-34Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N.#8E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3(E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q
M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXX-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R
M+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!C;VQS<&%N/3-$
M,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXU-3$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P
M+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,S<N,#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S-R4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1O=&%L(&QI86)I
M;&ET:65S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
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M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
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M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW,S4\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B8C.#(Q
M,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3$N-38E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C<S-3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#`N."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/CPO=&%B;&4^
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y38VAE9'5L92!O9B!A<W-U;7!T:6]N<R!U<V5D('1O(&1E=&5R
M;6EN92!F86ER('9A;'5E(&]F('!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@
M<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`V.#)P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.+4Q%
M1E0Z(#%I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#8X,CX-"@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`U.2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4]
M,T0Q/E-E<'1E;6)E<CQB<B`O/@T*,S`L)B,Q-C`[,C`Q,SPO9F]N=#X\+V(^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R<@<VEZ93TS1#$^1&5C96UB97(\8G(@+SX-"C,Q+"8C,38P.S(P,3(\
M+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^
M)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[
M4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)
M3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@-3DN,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Y)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$V+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#4Y+C$E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1T;W`@=VED=&@],T0U.24^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E)I<VLM9G)E92!I;G1E<F5S="!R
M871E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+C$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXE/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2XR/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-3DN,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#4Y)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17AP
M96-T960@=F]L871I;&ET>3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M.#4N.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$V)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXY,RXU/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-3DN,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#4Y)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5M86EN:6YG
M(&-O;G1R86-T=6%L('1E<FT@*&EN('EE87)S*3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M-RXU-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^."XS,3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V
M+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C`N,#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S8E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(')E8V]N8VEL:6%T:6]N
M(&]F(&%L;"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E('5S
M:6YG($QE=F5L(#,@<VEG;FEF:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C-P=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E1H92!F
M;VQL;W=I;F<@=&%B;&4@<')O=FED97,@82!R96-O;F-I;&EA=&EO;B!O9B!A
M;&P@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!U<VEN9R!,
M979E;"`S('-I9VYI9FEC86YT('5N;V)S97)V86)L92!I;G!U=',@*&EN('1H
M;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`R,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A
M8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,24=..B!L969T
M.R!724142#H@-S$U<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($U!
M4D=)3BU,1494.B`Q:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W,34^#0H-"CQT<B!S='EL93TS1"=P
M861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P
M<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-3DN,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^5V%R<F%N=#QB<B`O/@T*3&EA8FEL
M:71Y/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT
M97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y%>&-H
M86YG96%B;&4\8G(@+SX-"E-H87)E/&)R("\^#0I,:6%B:6QI='D\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[
M/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.
M1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'
M2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M-3DN,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U.24^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N
M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4Y)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^0F%L86YC92!A="!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,34N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C(Q/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34N,#8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-38S/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!
M1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'
M+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#4Y+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY)<W-U86YC92!O9B!E
M>&-H86YG96%B;&4@<VAA<F5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q-BXS-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXW.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`U.2XQ-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4Y)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^0VAA;F=E(&EN(&9A:7(@=F%L=64\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH,S<\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N
M,S<U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$V+C,V)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH.3`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#`N
M,S<U<'0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-3DN,30E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U.24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/D)A;&%N8V4@870@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$X-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C4U,3PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,S0E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`U.2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4Y)3X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`R,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^27-S=6%N8V4@;V8@97AC:&%N
M9V5A8FQE('-H87)E<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#,N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,S0V/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4Y
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#:&%N9V4@:6X@9F%I<B!V86QU
M93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,38E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/B@R,3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`S+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,38N,S8E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$L.3@X/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#4Y+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3DE/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY"86QA;F-E(&%T(%-E<'1E
M;6)E<B8C,38P.S,P+"`R,#$S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,RXT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U
M<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34N,#8E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/
M4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$V,SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
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M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`V)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+#@X-3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,S0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO;F<M
M5&5R;2!$96)T+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DQO;F<M5&5R;2!$96)T+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@;&]N9RUT97)M(&1E8G0@86YD('5N86UO<G1I
M>F5D(&1I<V-O=6YT(&)A;&%N8V5S("AE>&-L=61I;F<@8V]N=F5R=&EB;&4@
M9&5B="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV('-T
M>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CY,;VYG+71E<FT@9&5B="!A;F0@=6YA;6]R=&EZ960@9&ES8V]U;G0@8F%L
M86YC97,@*&5X8VQU9&EN9R!C;VYV97)T:6)L92!D96)T*2!A<F4@87,@9F]L
M;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`W.39P>#L@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-SDV/@T*#0H\
M='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M
M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/E-E<'1E;6)E
M<CQB<B`O/@T*,S`L)B,Q-C`[,C`Q,SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#LG('-I>F4],T0Q/D1E8V5M8F5R/&)R("\^#0HS,2PF(S$V,#LR,#$R
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE
M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P
M<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!
M1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8U+C0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/DQO;F<M=&5R;2!D96)T/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(L,C4P/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L
M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,L-S4P/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8U
M+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DQE<W,@9&5B="!D:7-C;W5N="P@
M;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF
M(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@Q.#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY,;VYG+71E<FT@9&5B="P@;F5T(&]F(&1E8G0@9&ES8V]U;G0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M,BPR-3`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#
M145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^,RPW,S(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U
M)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P
M:6X@,&EN(#!P="`R,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M3&5S<R!C=7)R96YT('!O<G1I;VX@;V8@;&]N9RUT97)M(&1E8G0\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L
M<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^*#(L,#`P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C,W-7!T.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@R+#`P,#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS-S5P
M=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY,;VYG+71E<FT@9&5B="P@;F5T(&]F(&-U<G)E;G0@
M<&]R=&EO;CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/4#H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,C4P/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
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M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXQ+#<S,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#=7)R96YT('!O<G1I;VX@;V8@
M;&]N9RUT97)M(&1E8G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXD/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,BPP,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3(N-30E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPP,#`\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^0W5R<F5N="!P;W)T:6]N(&]F(&1E8G0@9&ES8V]U
M;G0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#(Y/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P+C,W-7!T.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B@U.3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,"XS
M-S5P=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*3PO9F]N=#X\+W`^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/
M5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@
M,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CY#=7)R96YT('!O<G1I;VX@;V8@;&]N9RUT97)M
M(&1E8G0L(&YE=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52+51/
M4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,2PY-S$\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C$L.30Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^/"]T
M86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W9&(P964W-5]C-#0W7S0P
M-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%4DI!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO
M;&1E<G,G($1E9FEC:70@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&1E9FEC
M:70\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71Y('5N9&5R('1H92!0
M;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL
M93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CM&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`W-3!P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<U,#X-"@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C
M,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^3G5M8F5R)B,Q-C`[;V8\8G(@+SX-"D]P
M=&EO;G,\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y796EG
M:'1E9"T\8G(@+SX-"D%V97)A9V4F(S$V,#M0<FEC93PO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$
M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M
M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@-C(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/D)A;&%N8V4@870@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N
M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C$L-#,R+#,V.3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q,RXS."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+C0S/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)
M3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))
M1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#8R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY'<F%N=&5D/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^,S,Q+#@V,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C4N-C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED
M=&@],T0V,B4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/D-A;F-E;&5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#$W+#@V,#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,2XU-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A
M9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17AE<F-I
M<V5D/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B@S-2PX-3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#`N,S<U<'0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXP
M+C8U/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@
M,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#8R+C4R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY"86QA;F-E
M(&%T(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T
M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#<Q,"PU,3<\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXR+C(V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M
M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y38VAE9'5L92!O9B!A;&QO8V%T:6]N(&]F('-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!F;W(@86QL(&]P=&EO;G,@86YD(')E<W1R:6-T960@
M<W1O8VL@87=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CM&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)SX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R
M,W!T.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&AE(&%L;&]C871I;VX@;V8@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&9O<B!A;&P@;W!T:6]N<R!A;F0@<F5S
M=')I8W1E9"!S=&]C:R!A=V%R9',@:7,@87,@9F]L;&]W<R`H:6X@=&AO=7-A
M;F1S*3H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(S
M<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`W-S=P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%21TE.
M+4Q%1E0Z(#`N-6EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$-S<W/@T*#0H\='(@<W1Y;&4],T0G<&%D
M9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X
M.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,Q+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S,"XU-B4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0S,"4@8V]L<W!A;CTS1#4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U7
M14E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y4:')E928C,38P.TUO;G1H<R8C,38P
M.T5N9&5D/&)R("\^#0I397!T96UB97(F(S$V,#LS,"P\+V9O;G0^/"]B/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S,"XV)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P)2!C;VQS<&%N/3-$-3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/DYI;F4F(S$V,#M-;VYT:',F(S$V
M,#M%;F1E9#QB<B`O/@T*4V5P=&5M8F5R)B,Q-C`[,S`L/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]4
M5$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P
M<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+CDT
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E
M<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE
M/3-$,3XR,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^
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M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS
M<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3(\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR,#$S/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@V)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3(\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I
M;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S$N.30E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0S,24^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I
M9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#8E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)
M3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,Q+CDT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,S$E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-3@Q/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C,R/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$R+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#
M0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C8X-CPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q,BXU-B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX
M,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z
M,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$
M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S,2XY-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,Q)3X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#`Q/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C0X
M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$S+C@V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S,2XY-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XS
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B0\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/CDX,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0D]21$52
M+51/4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#(\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,3(N-30E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/C$L,38Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
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M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ
M,#8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y
M964@<W1O8VL@;W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@9&5F:6-I=#PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@
M=V5I9VAT960M879E<F%G92!A<W-U;7!T:6]N<R!U<V5D('1O(&1E=&5R;6EN
M92!T:&4@9F%I<B!V86QU92!O9B!S=&]C:R!O<'1I;VX@9W)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT
M+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)SX-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`R,W!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#(S<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`W,S1P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@34%2
M1TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<S-#X-"@T*/'1R('-T>6QE/3-$
M)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z
M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,S,N,3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S,E(&-O;'-P86X],T0S/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^3FEN928C,38P.TUO;G1H<R8C
M,38P.T5N9&5D/&)R("\^#0I397!T96UB97(F(S$V,#LS,"P\+V9O;G0^/"]B
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N
M-3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0V,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+5=%24=(5#H@8F]L9#LG('-I>F4],T0Q/C(P,3,\+V9O
M;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@
M<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X
M.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/
M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@;65D
M:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494
M.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@-C(N-3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1T;W`@=VED=&@],T0V,B4^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/E)I<VLM9G)E
M92!I;G1E<F5S="!R871E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BXQ/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+C(\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2
M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^17AP96-T960@=F]L871I;&ET>3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E
M/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN
M(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/CDP+C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S
M+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/CDS+C4\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@
M,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU,B4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG
M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4F5M
M86EN:6YG(&-O;G1R86-T=6%L('1E<FT@*&EN('EE87)S*3PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/C<N,C<\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW+C(S/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P
M<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!
M1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8R+C4R)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C`N,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]N+65M<&QO>65E('-T;V-K(&]P=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C
M:VAO;&1E<G,G(&1E9FEC:70\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('=E:6=H=&5D+6%V97)A9V4@
M87-S=6UP=&EO;G,@=7-E9"!T;R!D971E<FUI;F4@=&AE(&9A:7(@=F%L=64@
M;V8@<W1O8VL@;W!T:6]N(&=R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N="US:7IE.C$P+C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,C-P=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`W,S!P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<S,#X-"@T*/'1R
M('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/
M4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ,B4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`S,RXQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S,R4@8V]L<W!A
M;CTS1#,^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3Y.:6YE)B,Q-C`[
M36]N=&AS)B,Q-C`[16YD960\8G(@+SX-"E-E<'1E;6)E<B8C,38P.S,P+#PO
M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF
M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0
M041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.
M1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`V,BXU)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,RXQ,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1C96YT97(^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#AP=#L@1D].5"U714E'2%0Z(&)O;&0[)R!S:7IE/3-$,3XR
M,#$S/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^,C`Q,CPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX]
M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY2:7-K+69R964@:6YT97)E<W0@<F%T93PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P
M<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R
M/C$N-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0
M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,34E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,2XP/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P
M/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"
M3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z
M(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C(N
M-24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#8R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^17AP96-T960@=F]L871I;&ET>3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/CDP+C(\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/CDS+C4\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C(T)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/
M33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X
M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T
M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CY%>'!E8W1E9"!T97)M("AI;B!Y96%R<RD\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`S+C$R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q-24[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXV+C`W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,RXQ
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,34E
M.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-BXP-CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V,BXU)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$-C(E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[)R!S:7IE/3-$,CY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF
M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,34E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C`N,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,34E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,"XP/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-"4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R968X931A
M-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E93<U7V,T
M-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H965T,3@N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S
M97%U96YT($5V96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!E<W1I;6%T960@;F5T('!R;V-E961S(&9R;VT@=&AE($E03SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G
M9F]N="US:7IE.C$P+C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,C(N-7!T.R!-05)'24XZ
M(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17-T
M:6UA=&5D(&YE="!P<F]C965D<R!F<F]M('1H92!)4$\@=V5R92!D971E<FUI
M;F5D(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\
M=&%B;&4@<W1Y;&4],T0G=&5X="UA;&EG;CIL969T.U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`X,C!P>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M34%21TE.+4Q%1E0Z(#`N-&EN.R<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#(P/@T*#0H\='(@<W1Y;&4]
M,T0G<&%D9&EN9SHP.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[
M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#@R+C<E.R!0041$24Y'+5))1TA4.B`P:6X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O
M;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X,B4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D=R;W-S
M('!R;V-E961S("AI;F-L=61I;F<@;W9E<BUA;&QO=&UE;G0I/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q+C,E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3(N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-#8L,#`P/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ)3L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@
M,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$
M1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M
M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^56YD97)W<FET:6YG(&1I
M<V-O=6YT<R!A;F0@8V]M;6ES<VEO;G,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`R+C@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$S+C0R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@R+#8Y-3PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,
M1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P
M>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17-T
M:6UA=&5D('1O=&%L(&]F9F5R:6YG(&-O<W1S("AI;F-L=61I;F<@8V]S=',@
M<&%I9"!A<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,RD\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B
M9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C0R)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@
M8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/B@R+#DP,#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P
M861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P
M<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^3V9F
M97)I;F<@8V]S=',@<&%I9"!A<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N."4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N-#(E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C$L,S@Q/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,2XQ)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P
M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@.#(N-R4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R<@<VEZ93TS1#(^17-T:6UA=&5D(&YE="!P<F]C965D<R!T;R!B92!R
M96-E:79E9"!S=6)S97%U96YT('1O(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M;65D:75M(&YO;F4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[($)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P
M=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M-#$L-S@V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-"CQP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN
M(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^4&%R=&EA
M;"!R97!A>6UE;G0@;V8@075G=7-T)B,Q-C`[,C`Q,R!.;W1E<R!S=6)S97%U
M96YT('1O(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$S/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,BXX)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXT
M,B4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[($)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@
M,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ
M93TS1#(^*#$L-S0Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P+C,W-7!T.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4]
M,T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D
M:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[
M(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@.#(N-R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)3X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^17-T:6UA=&5D(&YE
M="!C87-H(&EM<&%C="!O9B!)4$\@86YD(')E;&%T960@=')A;G-A8W1I;VYS
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^
M)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3(N,3(E.R!0041$24Y'+5))1TA4.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[($)/4D1%4BU43U`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C0P+#`T-3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,24[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(]
M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/CPO
M='(^/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@86-T=6%L(&)A;&%N8V4@
M<VAE970@9&%T82!A;F0@<')O(&9O<FUA(&)A;&%N8V4@<VAE970@9&%T82!T
M;R!R969L96-T('1H92!A8W1I=FET:65S(')E;&%T960@=&\@=&AE($-O;7!A
M;GDG<R!)4$\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M('-T>6QE/3-$)V9O;G0M<VEZ93HQ,"XP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#(R+C5P
M=#L@34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
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M<R!O9B!397!T96UB97(F(S$V,#LS,"P@,C`Q,R`H:6X@=&AO=7-A;F1S*3H\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=T97AT+6%L:6=N.FQE9G0[
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#<Y-W!X.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XU:6X[)R!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W.3<^
M#0H-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$
M1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E
M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N
M=&5R/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1C96YT97(^/&(^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`X<'0[($9/3E0M5T5)1TA4.B!B;VQD.R<@<VEZ93TS1#$^4V5P
M=&5M8F5R/&)R("\^#0HS,"PF(S$V,#LR,#$S/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$8V5N=&5R/B8C,38P.SPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!"3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!I;B`P:6X@,'!T
M.R<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R<@<VEZ93TS1#$^4')O)B,Q-C`[1F]R;6$\8G(@+SX-"E-E
M<'1E;6)E<CQB<B`O/@T*,S`L)B,Q-C`[,C`Q,SPO9F]N=#X\+V(^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,&EN(#!I;B`P<'0[)R!A;&EG;CTS1&-E;G1E<CXF(S$V,#L\+W`^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@
M,'!X.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0
M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SXF(S$V,#L\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V
M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I
M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@
M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z
M(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@
M,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY#87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,2XS)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$R+C4T)3L@4$%$
M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#LG('-I>F4],T0R/C$Y+#`X,CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,BXU
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU.2PQ,C<\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C
M;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U14
M3TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P
M>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R<@<VEZ93TS1#(^3W1H97(@87-S971S/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P
M.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,BPW-#,\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q
M-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%C8V]U;G1S('!A>6%B;&4@
M86YD(&%C8W)U960@97AP96YS97,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`R+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%
M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P
M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE
M/3-$,CXS+#<R-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(L,S0T
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/DQO;F<M=&5R;2!A
M8V-R=65D(&5X<&5N<V5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,3,W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^-SD\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(
M.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I
M;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^0V]N=F5R=&EB;&4@;F]T97,L(&YE="!O9B!D:7-C;W5N=#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[
M)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN
M.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#LG('-I>F4],T0R/C(S+#0X,3PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R
M/3-$(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO
M<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%
M1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$
M1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU4
M3U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@
M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^4')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA8FEL:71Y/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^,38S/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,30E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A
M9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS
M1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C4E/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-05)'24XZ(#!I;B`P:6X@,'!T
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY%>&-H86YG96%B
M;&4@<VAA<F4@;&EA8FEL:71Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&
M1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN
M(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS
M1#(^,BPX.#4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R+C@X
M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX
M-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU4
M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP
M.U!!1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$
M24Y'+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P
M86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#LG('-I>F4],T0R/C4V+#4R-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#(N.#@E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#$S+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O
M;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#LG('-I>F4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%=)1%1(.B`Q+C$T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=P861D:6YG.C`[4$%$1$E.1RU"3U143TTZ
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@
M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@-C4N-"4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8U)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P
M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^0V]M;6]N('-T;V-K/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$
M(T-#145&1B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N
M.#@E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M5$]0.B`P:6X[)R!B9V-O;&]R/3-$(T-#145&1B!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$S
M+C@T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/C(P/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z
M(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C
M,38P.SPO<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!
M1$1)3D<M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'
M+5))1TA4.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#8U+C0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-24^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3$P<'0[($U!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/D%D9&ET:6]N86P@<&%I
M9"UI;B!C87!I=&%L/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!7
M24142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE..B`P
M:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@
M<VEZ93TS1#(^,30L,S8W/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,BXX."4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A
M;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@34%21TE.
M.B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R<@<VEZ93TS1#(^,3,V+#,Y.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#$N,30E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W!A9&1I;F<Z,#M0041$24Y'+4)/5%1/33H@,'!X
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$
M24Y'+51/4#H@,'!X.R<^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`V-2XT)3L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/
M4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-C4E/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ,'!T.R!-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S
M:7IE/3-$,CY$969I8VET(&%C8W5M=6QA=&5D(&1U<FEN9R!T:&4@9&5V96QO
M<&UE;G0@<W1A9V4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`R
M+C@X)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO<CTS1"-#0T5%1D8@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q
M,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXH.#`L
M-S<P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#LG('-I>F4],T0R/BD\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q,RXX-"4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G
M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C
M;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[)R!S:7IE/3-$,CXH.#$L,#(T/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C
M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#LG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#LG('-I
M>F4],T0R/BD\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=P
M861D:6YG.C`[4$%$1$E.1RU"3U143TTZ(#!P>#L@4$%$1$E.1RU,1494.B`P
M<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@-C4N-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8U)3X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^5&]T
M86P@<W1O8VMH;VQD97)S)B,X,C$W.R`H9&5F:6-I="D@97%U:71Y/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,BXX."4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG
M/B8C,38P.SPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^*#8V+#0P,CPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N.#@E.R!0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXI/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,3,N.#0E.R!0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M5$]0.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@34%21TE..B`P:6X@,&EN(#!P=#LG(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R<@<VEZ93TS1#(^-34L,SDT/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,2XQ-"4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#LG/B8C,38P.SPO
M<#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G<&%D9&EN9SHP.U!!1$1)3D<M
M0D]45$]-.B`P<'@[(%!!1$1)3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4
M.B`P<'@[(%!!1$1)3D<M5$]0.B`P<'@[)SX-"CQT9"!S='EL93TS1"="3U)$
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M15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0X,3X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R<@=VED=&@],T0W/CPO
M=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R
M968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E
M93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H
M965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5(2$%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!
M8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,3(L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CYI=&5M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('!L871F;W)M<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V97)S
M92!S=&]C:R!S<&QI=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E=F5R<V4@<W1O8VL@<W!L:70@<F%T:6\\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,34T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2979E
M;G5E(')E8V]G;FET:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F]U<B!C<FET97)I82!N965D960@9F]R($-O;7!A
M;GD@=&\@<F5C;V=N:7IE(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG*&DI('!E<G-U87-I=F4@979I9&5N8V4@=&AA="!A;B!A
M9W)E96UE;G0@97AI<W1S.R`H:6DI(&1E;&EV97)Y(&]F('1H92!P<F]D=6-T
M<R!A;F0O;W(@<V5R=FEC97,@:&%S(&]C8W5R<F5D.R`H:6EI*2!T:&4@<V5L
M;&EN9R!P<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4[(&%N9"`H:78I
M(&-O;&QE8W1I8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T
M-U\T,#9D7SDW,&5?-F(R968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V
M8R]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$504D%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O
M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS(#(I
M("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A
M;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&5X8VQU9&5D(&9R;VT@=V5I9VAT960@879E
M<F%G92!N=6UB97(@;V8@<VAA<F5S(&%T=')I8G5T86)L92!T;R!S:&%R92!B
M87-E9"!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`R+#DY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V-BPR-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3$L-C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T+#4Q-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@;&]S
M<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT-38L.30T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPR,C<L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.2PT-38L.30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-RPR,C<L,S@X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!P<FEN
M8VEP86P@=6YD97(@8V]N=F5R=&EB;&4@<')O;6ES<V]R>2!N;W1E<R`H:6X@
M9&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,N
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(S+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3F5T(&QO<W,@<&5R('-H87)E/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-E8W5R
M:71I97,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,C(Y+#4Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L,#8U+#DS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,C(Y+#4Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#8U+#DS-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@9F]R(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@;&]S
M<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,#<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L
M,#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S8L,#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8L,#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&-H86YG96%B;&4@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S
M('!E<B!S:&%R93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06YT:2UD:6QU=&EV92!S96-U<FET:65S("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.#`L-S8S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`S
M+#@T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0X,"PW-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,#,L.#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@
M;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,3`L
M-3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S(Q+#4S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-S$P+#4Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<R,2PU,SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E
M7S9B,F5F.&4T830V8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W
M9&(P964W-5]C-#0W7S0P-F1?.3<P95\V8C)E9CAE-&$T-F,O5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$A!23X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY!<W-E="!!8W%U:7-I=&EO;B!O9B!697)I;R!4:&5R87!E=71I
M8W,@26YC+B`H1&5T86EL<RD@*%9E<FEO+"!54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,#<L(#(P,3`\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C<75I<VET:6]N/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M8VAA;F=E86)L92!3:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U86)L92!O;B!E>&-H
M86YG92!O9B!E>&-H86YG96%B;&4@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,S@L-#8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#@P+#<V,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,RPX-#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA
M;"!I;F-R96%S92!I;B!S:&%R97,@:7-S=6%B;&4@;VX@97AC:&%N9V4@;V8@
M17AC:&%N9V5A8FQE(%-H87)E<R!B87-E9"!O;B!A8VAI979E;65N="!O9B!C
M97)T86EN('!R96-L:6YI8V%L(&UI;&5S=&]N97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW-BPY,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W1E;G1I86P@:6YC<F5A<V4@
M:6X@<VAA<F5S(&ES<W5A8FQE(&]N(&5X8VAA;F=E(&]F($5X8VAA;F=E86)L
M92!3:&%R97,@8F%S960@;VX@86-H:65V96UE;G0@;V8@8V5R=&%I;B!C;&EN
M:6-A;"!M:6QE<W1O;F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$Q+#4S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!I;F-R96%S92!I;B!S:&%R97,@:7-S
M=6%B;&4@;VX@97AC:&%N9V4@;V8@17AC:&%N9V5A8FQE(%-H87)E<R!B87-E
M9"!O;B!A8VAI979E;65N="!O9B!C97)T86EN(&-O;6UE<F-I86QI>F%T:6]N
M(&UI;&5S=&]N97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,34L,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YI=&EA;"!F86ER('9A;'5E(&]F(&5X8VAA;F=E86)L92!S
M:&%R97,@*&EN(&1O;&QA<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#`P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8W%U:7-I=&EO;CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S
M=6%B;&4@;VX@97AC:&%N9V4@;V8@97AC:&%N9V5A8FQE('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X-"PV,#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M;W5T<W1A;F1I;F<@9F]R(&%U=&]M871I8R!R961E;7!T:6]N(&%N9"!E>&-H
M86YG92!O9B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^07!R:6P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C<75I<VET:6]N/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U
M86)L92!O;B!E>&-H86YG92!O9B!E>&-H86YG96%B;&4@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X+#0V,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=64@<&5R('-H87)E(&]F('5N9&5R;'EI;F<@8V]M;6]N('-T;V-K("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$N-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);FET:6%L(&9A:7(@=F%L=64@;V8@97AC:&%N9V5A
M8FQE('-H87)E<R`H:6X@9&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-87)C:"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-Q=6ES:71I;VX\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&ES<W5A8FQE(&]N(&5X8VAA;F=E(&]F(&5X8VAA;F=E86)L92!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,BPS,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E('!E<B!S:&%R92!O9B!U;F1E<FQY:6YG(&-O;6UO;B!S=&]C:R`H
M:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YI=&EA;"!F86ER('9A;'5E(&]F(&5X8VAA
M;F=E86)L92!S:&%R97,@*&EN(&1O;&QA<G,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36%Y(#(P,3$\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8W%U:7-I=&EO;CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M97,@:7-S=6%B;&4@;VX@97AC:&%N9V4@;V8@97AC:&%N9V5A8FQE('-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-2PS.#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E('!E<B!S:&%R92!O9B!U;F1E<FQY:6YG(&-O;6UO;B!S=&]C
M:R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA;"!F86ER('9A;'5E(&]F(&5X
M8VAA;F=E86)L92!S:&%R97,@*&EN(&1O;&QA<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07!R:6P@,C`Q,CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C<75I<VET:6]N
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!I<W-U86)L92!O;B!E>&-H86YG92!O9B!E>&-H86YG96%B;&4@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L-CDQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!P97(@<VAA<F4@;V8@=6YD97)L>6EN9R!C;VUM;VX@
M<W1O8VL@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@9F%I<B!V86QU92!O
M9B!E>&-H86YG96%B;&4@<VAA<F5S("AI;B!D;VQL87)S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2G5L>2`R,#$S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-Q=6ES:71I
M;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F5S(&ES<W5A8FQE(&]N(&5X8VAA;F=E(&]F(&5X8VAA;F=E86)L
M92!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BPY
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER('9A;'5E('!E<B!S:&%R92!O9B!U;F1E<FQY:6YG(&-O;6UO
M;B!S=&]C:R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA;"!F86ER('9A;'5E
M(&]F(&5X8VAA;F=E86)L92!S:&%R97,@*&EN(&1O;&QA<G,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E20D<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;65A<W5R96UE
M;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')A;G-F97(@;V8@87-S971S(&9R;VT@;&5V96P@,2!T;R!L979E;"`R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R
M(&]F(&%S<V5T<R!F<F]M(&QE=F5L(#(@=&\@;&5V96P@,3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&]F(&QI86)I;&ET
M:65S(&9R;VT@;&5V96P@,2!T;R!L979E;"`R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A;G-F97(@;V8@;&EA8FEL:71I97,@9G)O
M;2!L979E;"`R('1O(&QE=F5L(#$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S=6UP=&EO;G,@=7-E9"!T
M;R!D971E<FUI;F4@=&AE(&9A:7(@=F%L=64\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@
M<F%T92`H87,@82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BXQ,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+C(P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>2`H87,@82!P
M97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4N.3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3,N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296UA:6YI;F<@8V]N=')A8W1U86P@=&5R;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,@-B!M;VYT:',@,C(@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<X('EE87)S(#,@;6]N=&AS(#(R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&1I=FED96YD
M('EI96QD("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296-U<G)I;F<@?"!4;W1A;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU
M92!M96%S=7)E;65N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPP-#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S,U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C=7)R:6YG('P@5&]T
M86P@?"!787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!M96%S=7)E;65N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38S
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E8W5R<FEN9R!\(%1O=&%L('P@17AC:&%N9V5A8FQE
M('-H87)E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!M96%S=7)E;65N=',\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX.#4L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-34Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5C=7)R:6YG('P@4VEG;FEF:6-A;G0@56YO8G-E<G9A8FQE
M($EN<'5T<R`H3&5V96P@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;65A<W5R96UE;G1S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#0X+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<S-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E8W5R<FEN9R!\(%-I9VYI9FEC86YT(%5N;V)S97)V86)L
M92!);G!U=',@*$QE=F5L(#,I('P@5V%R<F%N="!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L
M=64@;65A<W5R96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-U<G)I;F<@?"!3:6=N
M:69I8V%N="!5;F]B<V5R=F%B;&4@26YP=71S("A,979E;"`S*2!\($5X8VAA
M;F=E86)L92!S:&%R92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;65A<W5R96UE;G1S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.#@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4U,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO;BUR96-U<G)I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;65A<W5R
M96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N+69I;F%N8VEA;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.;VXM9FEN86YC:6%L(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%R<GEI;F<@86UO
M=6YT('P@4F5C=7)R:6YG('P@475O=&5D(%!R:6-E<R!I;B!!8W1I=F4@36%R
M:V5T<R!F;W(@261E;G1I8V%L($%S<V5T<R`H3&5V96P@,2D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@
M;65A<W5R96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,2PS,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P131(044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1F%I<B!686QU92!-96%S=7)E;65N=',@*$1E=&%I
M;',@,BD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5C;VYC:6QI871I
M;VX@;V8@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU93PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N
M8V4@870@=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I
M<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E(&%T('1H92!E;F0@;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-H86YG96%B;&4@<VAA
M<F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY296-O;F-I;&EA=&EO;B!O9B!L:6%B:6QI=&EE<R!M96%S
M=7)E9"!A="!F86ER('9A;'5E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!T:&4@8F5G:6YN:6YG(&]F
M('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27-S=6%N8V4@;V8@97AC:&%N9V5A8FQE('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DX.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DP
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92!A="!T:&4@96YD(&]F('1H92!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPX.#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T
M,#9D7SDW,&5?-F(R968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7
M;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$556D)'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DQO;F<M5&5R;2!$96)T+"!#;VUM:71M96YT<R!A
M;F0@0V]N=&EN9V5N8VEE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C<W($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@
M,C`Q,SQB<CY*=6YE(&%N9"!*=6QY(#(P,3,@0V]N=F5R=&EB;&4@3F]T92!&
M:6YA;F-I;F<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CY*=6YE(&%N9"!*=6QY(#(P,3,@0V]N=F5R=&EB;&4@
M3F]T92!&:6YA;F-I;F<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CY*=6YE(&%N9"!*=6QY(#(P,3,@0V]N=F5R
M=&EB;&4@3F]T92!&:6YA;F-I;F<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^075G+B`S,2P@,C`Q,SQB<CY!=6=U<W0@,C`Q,R!#;VYV97)T
M:6)L92!.;W1E($9I;F%N8VEN9SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D%U9W5S="`R,#$S($-O;G9E<G1I
M8FQE($YO=&4@1FEN86YC:6YG/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M
M=&5R;2!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L
M,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPW-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@9&5B
M="!D:7-C;W5N="P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT
M97)M(&1E8G0L(&YE="!O9B!D96)T(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-3`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPW,S(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQE<W,@8W5R<F5N="!P;W)T:6]N(&]F(&QO;F<M=&5R;2!D96)T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`P,"PP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M,#`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#`P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B="P@;F5T
M(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,S(L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@
M<&]R=&EO;B!O9B!D96)T(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(Y+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U.2PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R
M96YT('!O<G1I;VX@;V8@;&]N9RUT97)M(&1E8G0L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY-S$L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3<Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.30Q
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$96)T(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M(')A=&4@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M(&]F(&1E8G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E8G0@9&ES8V]U;G0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,CDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<Q+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@9&5B=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPW,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@9&5B=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$96)T(&1I<V-O=6YT(')E;&%T960@=&\@8F5N969I8VEA
M;"!C;VYV97)S:6]N(&9E871U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!I
M;G1E<F5S="P@8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T+"!N
M;VYC=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R968X931A-#9C
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E93<U7V,T-#=?
M-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H965T,C4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5:14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO;F<M
M5&5R;2!$96)T+"!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H1&5T
M86EL<R`R*2`H55-$("0I/&)R/DEN($UI;&QI;VYS+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,C8L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/<&5R871I;F<@3&5A<V5S+"!&=71U<F4@36EN:6UU;2!0
M87EM96YT<R!$=64L($9I<V-A;"!996%R($UA='5R:71Y/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V4@<&5R:6]D
M(&5X=&5N9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,B!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUC86YC96QL86)L92!O<&5R871I;F<@;&5A<V4@8V]M;6ET
M;65N=',@9F]R(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N+6-A;F-E;&QA8FQE(&]P97)A=&EN9R!L96%S92!C;VUM
M:71M96YT<R!F;W(@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N+6-A;F-E;&QA8FQE(&]P97)A=&EN9R!L96%S92!C;VUM
M:71M96YT<R!F;W(@,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Q414L^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD
M97)S)R!$969I8VET("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M.3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^4&QA;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/E!L86X\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY0;&%N/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^4&QA;CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#$R+"`R,#$S/&)R
M/E!L86X\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CY0;&%N/&)R/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/E!L86X\8G(^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4&QA
M;CQB<CY297-E87)C:"!A;F0@9&5V96QO<&UE;G0\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY0;&%N/&)R/E)E
M<V5A<F-H(&%N9"!D979E;&]P;65N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E!L86X\8G(^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY0;&%N/&)R/D=E;F5R86P@86YD(&%D
M;6EN:7-T<F%T:79E/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^4&QA;CQB<CY'96YE<F%L(&%N9"!A9&UI;FES
M=')A=&EV93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/E!L86X\8G(^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CY0;&%N/&)R/E-T;V-K(&]P=&EO;CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E!L86X\8G(^4W1O
M8VL@;W!T:6]N/&)R/E!E<F9O<FUA;F-E+6)A<V5D/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4&QA;CQB<CY3
M=&]C:R!O<'1I;VX\8G(^4&5R9F]R;6%N8V4M8F%S960@;6EL97-T;VYE<R!A
M;F0@;6%R:V5T(&-O;F1I=&EO;G,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY0;&%N/&)R/D5M<&QO>65E('-T
M;V-K(&]P=&EO;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/E!L86X\8G(^16UP;&]Y964@<W1O8VL@;W!T:6]N
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^4&QA;CQB<CY.;VXM96UP;&]Y964@<W1O8VL@;W!T:6]N/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M4&QA;CQB<CY.;VXM96UP;&]Y964@<W1O8VL@;W!T:6]N/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,C@L(#(P,3,\8G(^,C`Q,R!0
M;&%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,3,L
M(#(P,3,\8G(^15-04#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&1E9FEC:70\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPT,C,L,#<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3G5M8F5R(&]F($]P=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PT,S(L,S8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,S$L.#8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&5D("AI;B!S:&%R97,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.#8P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-2PX-3(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW,3`L-3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S0P+#$R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R,"PT.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT
M960M079E<F%G92!0<FEC93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A
M="!T:&4@8F5G:6YN:6YG(&]F('1H92!P97)I;V0@*&EN(&1O;&QA<G,@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XT,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D("AI;B!D;VQL87)S('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC96QE9"`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9"`H:6X@9&]L;&%R
M<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@=&AE(&5N
M9"!O9B!T:&4@<&5R:6]D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06QL;V-A=&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DX,BPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PQ-CDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#8L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3@Q+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V.#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`X,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0P,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#@S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@9W)A;G0@9&%T92!F86ER
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C
M;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O(&]U='-T86YD:6YG(&]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@<F5C;V=N:71I;VX@<&5R
M:6]D(&]F('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S
M(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960M879E<F%G92!A
M<W-U;7!T:6]N<R!T;R!D971E<FUI;F4@9F%I<B!V86QU92!O9B!S=&]C:R!O
M<'1I;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@
M<F%T92`H87,@82!P97)C96YT*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-C`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C$P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,C`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D('9O;&%T:6QI='D@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,"XR,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M,RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,"XS,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S
M(#(U(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-B!Y96%R<R`R,B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5M86EN:6YG(&-O;G1R
M86-T=6%L('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#,@;6]N=&AS(#<@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE
M87)S(#(@;6]N=&AS(#(S(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV:61E;F0@>6EE
M;&0@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R97,@<F5S97)V960@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%D9&ET:6]N86P@<VAA<F5S(&%U=&AO<FEZ960@*&%S(&$@<&5R
M8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!S:&%R97,@875T
M:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R
M968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E
M93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+U-H
M965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5(44)'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U8G-E<75E;G0@179E;G1S("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-S<@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`P-"P@,C`Q,SQB<CY3=6)S97%U96YT(&5V96YT/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,#0L(#(P,3,\
M8G(^4W5B<V5Q=65N="!E=F5N=#QB<CY!=6=U<W0@,C`Q,R!.;W1E<SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S
M97%U96YT(&5V96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!S;VQD(&EN(&EN:71I86P@<'5B;&EC
M(&]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#8V-BPV-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=6)L:6,@;V9F97)I;F<@<')I8V4@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1W)O<W,@<')O8V5E9',@*&EN8VQU9&EN9R!O=F5R+6%L;&]T;65N
M="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#8L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5N9&5R=W)I=&EN9R!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#8Y-2PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17-T:6UA=&5D('1O=&%L(&]F9F5R:6YG(&-O<W1S("AI;F-L=61I;F<@
M8V]S=',@<&%I9"D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L.3`P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!C;W-T<R!P86ED/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X,2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S
M=&EM871E9"!N970@<')O8V5E9',@=&\@8F4@<F5C96EV960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q+#<X-BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087)T:6%L
M(')E<&%Y;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PW-#$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D(&YE="!C87-H(&EM<&%C
M="!O9B!)4$\@86YD(')E;&%T960@=')A;G-A8W1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP-#4L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES
M<W5E9"!O;B!C;VYV97)S:6]N(&]F(&-O;G9E<G1I8FQE('!R969E<G)E9"!S
M=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR,CDL
M-3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@86UO=6YT(&]F(&-O;G9E<G1I8FQE(&YO=&5S
M(&-O;G9E<G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(L,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@;VX@8V]N=F5R<VEO;B!O9B!C
M;VYV97)T:6)L92!N;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPV-SDL-#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^56YA;6]R=&EZ960@9&5B="!D:7-C;W5N="!W
M<FET=&5N+6]F9CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U86)L92!O;B!E>&-H86YG92!O9B!E>&-H
M86YG96%B;&4@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT.#`L-S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC:&%N9V5A8FQE('-H87)E<R!R961E96UE9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!C;VYV97)T:6)L92!P<F5F
M97)R960@<W1O8VL@=VAI8V@@87)E(&-O;G9E<G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('1O('!U
M<F-H87-E('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D(&]N(&-O;G9E
M<G-I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#`W
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@875T:&]R:7IE9"!S:&%R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YD97-I9VYA=&5D('!R969E<G)E
M9"!S=&]C:RP@875T:&]R:7IE9"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-T=6%L(&)A
M;&%N8V4@<VAE970@9&%T82!A;F0@<')O(&9O<FUA(&)A;&%N8V4@<VAE970@
M9&%T83PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPW-#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPW-#,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E
M<RP@;F5T(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#0X,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#0X,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!W
M87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA;F=E86)L92!S:&%R
M92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M.#@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L.#@U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4U,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4V
M+#4R-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4V+#4R-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4V+#4R-BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-V1B,&5E-S5?8S0T-U\T
M,#9D7SDW,&5?-F(R968X931A-#9C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S=D8C!E93<U7V,T-#=?-#`V9%\Y-S!E7S9B,F5F.&4T830V8R]7
M;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$545T%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S("A$971A:6QS(#(I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y/8W0N(#`T+"`R,#$S/&)R/E-U8G-E<75E;G0@979E
M;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CY0<F\@1F]R;6$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06-T=6%L(&)A;&%N8V4@<VAE970@9&%T82!A
M;F0@<')O(&9O<FUA(&)A;&%N8V4@<VAE970@9&%T83PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C
M87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$Y+#`X,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#DL,#@W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PT-C0L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#,X-RPP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U.2PQ,C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<R
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#(V."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#,T-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!A8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S<L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30L,S8W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R+#<X.2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S8L,SDX+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@=&AE(&1E=F5L;W!M96YT('-T
M86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,"PW-S`L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8U+#8Q-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#$L,#(T+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R
M<R<@*&1E9FEC:70I(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C8L-#`R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U,BPX,C4L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U+#,Y-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G
M9W)E9V%T92!N;VXM8V%S:"!C:&%R9V4@<F5L871E9"!T;R!T:&4@9FEN86P@
M9F%I<B!V86QU92!A9&IU<W1M96YT(&]F('1H92!E>&-H86YG96%B;&4@<VAA
M<F4@;&EA8FEL:71Y(&%N9"!T:&4@<')E9F5R<F5D('-T;V-K('=A<G)A;G0@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R968X931A-#9C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S=D8C!E93<U7V,T-#=?-#`V
M9%\Y-S!E7S9B,F5F.&4T830V8R]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO
M9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB
M;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R."YH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?
H-V1B,&5E-S5?8S0T-U\T,#9D7SDW,&5?-F(R968X931A-#9C+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>191</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/BalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/StatementOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/CashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc</Role>
      <ShortName>Asset Acquisition of Verio Therapeutics Inc.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Long-Term Debt, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingencies</Role>
      <ShortName>Long-Term Debt, Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2010 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>3010 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>3020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncTables</Role>
      <ShortName>Asset Acquisition of Verio Therapeutics Inc. (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>3030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>3040 - Disclosure - Long-Term Debt, Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesTables</Role>
      <ShortName>Long-Term Debt, Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>3050 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>3060 - Disclosure - Subsequent Events (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsTables</Role>
      <ShortName>Subsequent Events (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>4010 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>4011 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>4020 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails</Role>
      <ShortName>Asset Acquisition of Verio Therapeutics Inc. (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>4030 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>4031 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>4040 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails</Role>
      <ShortName>Long-Term Debt, Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>4041 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureLongTermDebtCommitmentsAndContingenciesDetails2</Role>
      <ShortName>Long-Term Debt, Commitments and Contingencies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>4050 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>4060 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>4061 - Disclosure - Subsequent Events (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails2</Role>
      <ShortName>Subsequent Events (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_AmortizationOfDebtDiscountPremium had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ConvertibleLongTermNotesPayable had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '4030 - Disclosure - Fair Value Measurements (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4040 - Disclosure - Long-Term Debt, Commitments and Contingencies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4050 - Disclosure - Stockholders' Deficit (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4060 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '4061 - Disclosure - Subsequent Events (Details 2)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 0010 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 0030 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>fate-20130930.xml</File>
    <File>fate-20130930.xsd</File>
    <File>fate-20130930_cal.xml</File>
    <File>fate-20130930_def.xml</File>
    <File>fate-20130930_lab.xml</File>
    <File>fate-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred, shares authorized</a></td>
        <td class="nump">68,360,186<span></span></td>
        <td class="nump">62,200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">44,967,690<span></span></td>
        <td class="nump">44,967,690<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">44,967,690<span></span></td>
        <td class="nump">44,967,690<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, aggregate liquidation preference (in dollars)</a></td>
        <td class="nump">$ 58,518<span></span></td>
        <td class="nump">$ 58,518<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump">110,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
        <td class="nump">1,377,659<span></span></td>
        <td class="nump">1,334,115<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="nump">1,377,659<span></span></td>
        <td class="nump">1,334,115<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityLiquidationPreference</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.27(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.27(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.27(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Acquisition of Verio Therapeutics Inc. (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition of Verio Therapeutics Inc.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock', window );">Summary of changes in the number of shares of the Company's common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013, the changes in the number of shares of the Company&#8217;s common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares are summarized as follows (in thousands, except share and per share amounts):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 809px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="809">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exchangeable<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Per<br />
Share&#160;of<br />
Underlying<br />
Common&#160;Stock</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Initial&#160;Fair<br />
Value&#160;of<br />
Exchangeable<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;2010</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">138,462</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">234</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">March&#160;2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">92,308</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">May&#160;2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">115,380</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">195</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">57,691</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.37</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">July&#160;2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">76,922</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">346</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">480,763</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,009</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="316"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AssetAcquisitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_AssetAcquisitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of changes in the number of shares of the entity's common stock issuable upon the exchange of the exchangeable shares and the initial fair value of the shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ScheduleOfChangesInSharesIssuedUponExchangeOfExchangeableSharesAndInitialFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESCBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">77 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
        <td class="num">$ (15,155)<span></span></td>
        <td class="num">$ (10,084)<span></span></td>
        <td class="num">$ (80,770)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">442<span></span></td>
        <td class="nump">430<span></span></td>
        <td class="nump">2,379<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuances of common stock for technology</a></td>
        <td class="nump">13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">1,169<span></span></td>
        <td class="nump">106<span></span></td>
        <td class="nump">1,938<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discounts</a></td>
        <td class="nump">129<span></span></td>
        <td class="nump">63<span></span></td>
        <td class="nump">271<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
        <td class="nump">134<span></span></td>
        <td class="nump">97<span></span></td>
        <td class="nump">1,156<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Deferred rent</a></td>
        <td class="num">(185)<span></span></td>
        <td class="num">(138)<span></span></td>
        <td class="nump">198<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(63)<span></span></td>
        <td class="num">(63)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_FairValueAdjustmentOfExchangeableShares', window );">Initial fair value and change in fair value of exchangeable shares</a></td>
        <td class="nump">2,334<span></span></td>
        <td class="num">(12)<span></span></td>
        <td class="nump">2,885<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrants</a></td>
        <td class="num">(21)<span></span></td>
        <td class="num">(35)<span></span></td>
        <td class="num">(64)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
        <td class="nump">18<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">135<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">323<span></span></td>
        <td class="nump">332<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(960)<span></span></td>
        <td class="num">(204)<span></span></td>
        <td class="num">(1,666)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">1,350<span></span></td>
        <td class="num">(363)<span></span></td>
        <td class="nump">3,618<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(10,795)<span></span></td>
        <td class="num">(9,880)<span></span></td>
        <td class="num">(69,531)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(94)<span></span></td>
        <td class="num">(414)<span></span></td>
        <td class="num">(3,511)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="nump">6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(122)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num">(88)<span></span></td>
        <td class="num">(414)<span></span></td>
        <td class="num">(3,425)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfEquity', window );">Issuance of common stock, net of repurchases</a></td>
        <td class="nump">23<span></span></td>
        <td class="nump">205<span></span></td>
        <td class="nump">287<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs paid in connection with initial public offering</a></td>
        <td class="num">(1,381)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,381)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible promissory notes</a></td>
        <td class="nump">23,736<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,236<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
        <td class="num">(1,500)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,150)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Issuance of convertible preferred stock, net of offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,166<span></span></td>
        <td class="nump">58,646<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">20,878<span></span></td>
        <td class="nump">9,371<span></span></td>
        <td class="nump">92,038<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
        <td class="nump">9,995<span></span></td>
        <td class="num">(923)<span></span></td>
        <td class="nump">19,082<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of the period</a></td>
        <td class="nump">9,087<span></span></td>
        <td class="nump">6,387<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the period</a></td>
        <td class="nump">$ 19,082<span></span></td>
        <td class="nump">$ 5,464<span></span></td>
        <td class="nump">$ 19,082<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_FairValueAdjustmentOfExchangeableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the initial fair value and change in fair value amounts of exchangeable shares during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_FairValueAdjustmentOfExchangeableShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow resulting from the entity's share transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepurchaseOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecognitionOfDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StraightLineRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 19,082<span></span></td>
        <td class="nump">$ 9,087<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">304<span></span></td>
        <td class="nump">706<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">19,386<span></span></td>
        <td class="nump">9,793<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">789<span></span></td>
        <td class="nump">1,161<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">2,743<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
        <td class="nump">122<span></span></td>
        <td class="nump">122<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">23,040<span></span></td>
        <td class="nump">11,076<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">3,725<span></span></td>
        <td class="nump">2,268<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">63<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
        <td class="nump">45<span></span></td>
        <td class="nump">251<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes, net of discount</a></td>
        <td class="nump">3,481<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent', window );">Repurchase liability for unvested equity awards</a></td>
        <td class="nump">106<span></span></td>
        <td class="nump">143<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Preferred stock warrant liability</a></td>
        <td class="nump">163<span></span></td>
        <td class="nump">184<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
        <td class="nump">1,971<span></span></td>
        <td class="nump">1,941<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">9,491<span></span></td>
        <td class="nump">4,850<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump">153<span></span></td>
        <td class="nump">132<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued expenses</a></td>
        <td class="nump">137<span></span></td>
        <td class="nump">110<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableShareLiabilityNoncurrent', window );">Exchangeable share liability</a></td>
        <td class="nump">2,885<span></span></td>
        <td class="nump">551<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current portion</a></td>
        <td class="nump">250<span></span></td>
        <td class="nump">1,732<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Long-term convertible notes</a></td>
        <td class="nump">20,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value; authorized shares - 68,360,186 at September 30, 2013 and 62,200,000 at December 31, 2012; issued and outstanding shares - 44,967,690 at September 30, 2013 and December 31, 2012; liquidation preference of $58,518 at September 30, 2013 and December 31, 2012</a></td>
        <td class="nump">56,526<span></span></td>
        <td class="nump">56,526<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 110,000,000 at September 30, 2013 and 100,000,000 at December 31, 2012; issued and outstanding shares - 1,377,659 at September 30, 2013 and 1,334,115 at December 31, 2012</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">14,367<span></span></td>
        <td class="nump">12,789<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(80,770)<span></span></td>
        <td class="num">(65,615)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
        <td class="num">(66,402)<span></span></td>
        <td class="num">(52,825)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' deficit</a></td>
        <td class="nump">$ 23,040<span></span></td>
        <td class="nump">$ 11,076<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ExchangeableShareLiabilityNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value as of the balance sheet date of exchangeable share liability, which is expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ExchangeableShareLiabilityNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value, as of the balance sheet date, of repurchase liability for unvested equity awards, which is expected to be paid within one year (or the operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TemporaryEquityCarryingAmountAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4HAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of liabilities measured at fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
        <td class="nump">$ 184<span></span></td>
        <td class="nump">$ 221<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value</a></td>
        <td class="num">(21)<span></span></td>
        <td class="num">(37)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
        <td class="nump">163<span></span></td>
        <td class="nump">184<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchangeable share liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Reconciliation of liabilities measured at fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
        <td class="nump">551<span></span></td>
        <td class="nump">563<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of exchangeable shares</a></td>
        <td class="nump">346<span></span></td>
        <td class="nump">78<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Change in fair value</a></td>
        <td class="nump">1,988<span></span></td>
        <td class="num">(90)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
        <td class="nump">$ 2,885<span></span></td>
        <td class="nump">$ 551<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>34
<FILENAME>0001104659-13-084191-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-13-084191-xbrl.zip
M4$L#!!0````(`&&!;4-KJRY@4Z0``'3X"@`1`!P`9F%T92TR,#$S,#DS,"YX
M;6Q55`D``^7J@U+EZH-2=7@+``$$)0X```0Y`0``[%UI<]LXTOZ^5?L?^/JM
MVIJIBFP>.BAG,EN.CXQWXV-LS['OEQ1,0C)V>&@(TK;FU[\-4*1(BK<EFY)1
ME<0.2:`;C:?[:8``^,,_GVU+>L0>):[S:4_9E_<D[!BN29SII[V`]A`U"-G[
MYX]__]L/_]/K2<<>1CXVI?NY=($]CUB6=.QZ,]=#/E0@]7K1@U^P@[WHT;/@
MO\2G@73N^"#)1U,L_?X;<DSILZSHXV6I5*'SF_-;Z=IS?:CWUU!!J;\O[ZO[
MP[#`\[UGD4/VKP2-<"C_E7S:>_#]V>'!P=/3TSZ[LN]ZTP-5EK4#XH!LQ\![
MB^<G("KU.+O@/X`*,QSXQ*#[AFM#4463QYH<E;*(\T>)$';['M%8"-APBM`L
M+C%!])X_O;C!Z^_)2D]3]A+M,)<-2=8_/`AOQH_2=(.?M.A)Y>#WBZ^WQ@.V
M42_;<$+=OJJ,RDP5/A$WPO<*'QX?P-U8GQ7K+#12QN/Q`;\;/6KB3!,I-O:G
M[N,!W$@:!;I:DGY@)0\I;\X-GDB\ID-_/H,.I,2>6:QM_-J#AR>?]EA/]J*>
MVW^FYIYT$%84HL9P`8K/OD3,3WOG[+F?M5!0_`1V?.+/%]?BJ\1DUR<$>Q)7
M)HV?J`7'Y__>^U&&/NAK?4T9_G"0+1R).LB1M9`TPQYQS17YO"?]'T/[C'N:
M'%>^N).N.5%+=&G1]#)KJ-MF"[4'?S1EW;8XV2)D0(L]_P1@O\#&"-PGJF5Y
M+U,(.V:B2!).T9TUF?`_=R=;:46E4U8\WT(K,B#V>^JH(U94M]&=U>;NK&[4
MA%OISFIS=]Z@%<&=OUW(XRWAVFQ<'/>4YG%143?'+M].GXT'Y$PQNK?P[0/R
M\%>"[HD%[;O`]CWVOIW]^@:67AH03VT<IR3Q#1/4>)Y9Q"!^J*9D$G@N'(TM
M1@B'9XAXOR(KP)_G<:..+43IT3.A>S^R7/>PJOD_'.2*6ZIYD*?G3A$HQ*UO
MQZX#@UV?@)6N8:``0UALWOJN\4=HCFU%R!'4:1(+!JV/^!8;@4=\@BE@P@I,
M;)YYKGWLVK/`YZ/TJ\DI\AP8X--K['&L?)[G5Q#B*Q)28;LW05@7F5&`;/=`
MUK'$02!LMQ#6Q?&Z`-GN@:QCV=AOR/.0XPL\5>(I92F1:469E@#05@&H8UF4
M0,_VH*=;&1(CK],_`VC(+P[QKP//>$`4'TT]C%F3J8!4):2JS2=H+J(Y`;4=
MA5JW"%%D5%O'B1T:T&F"$W<T4'4K]]($)^XTU#H4TEB:SV?MF,&AF[C%KRWD
M"(!5`JS$;B*QCQ)[`:Z=`5>W4GF!K!U!5B=S+P&NG0%71[*M\WA%Y$A3TF^>
M79M0ZGKS2]?']"3`5X[:_U?@8"C1WV[,G>![_]RAOA>P*A*+^1JV_[6PD]Y\
M,MK`AHLE#/1J&.A'P32@/A09OD\<K!C@;8"@;VCGC?RS"D#HRZ-OO[+R=XF-
M>>>.L=U=_CF@Q,&4'ADP#J>$<4&BWXO;^R8T(;,='/*P"4V$148;S$&*;?3M
M`CT3.[`%0O(0TD2'&[:B/)W"I&S[SI.66F@4^'MWF%`%'-X6#JVF8U([B%^7
ML*YYO5>3HYE'+,:>`BLOI:Y(!QAMWQ.'#[9O\0RQTR6L^0TVW*E#_L+FG8=@
M*&ZPV\G=5`4=(F);`S!?(,]X@!**`',WP)SI$`'F1F">"RAW"<IS`>07I1BJ
M@'(WH)SID'<.YF@"6+P!V((W`)LX?JI9-/M78#$BT+8;!;L3S-+](6)9G5@F
M7F-UXS76I@[38Q"(3W"YP(@&7KC,\M)U/+90P"/.=+M[/G%`3:*!9Q[^,\".
M,4^_0:AIB]T"@9H/@9MTFY</G3NSP*=?\2.V%J.<;\?(\^;PZ`V>N9Z/S2/;
M#<#(48D30@W+936_=RS=-`-22^7B7W\"`["9E3GOK0+]5OMS0VHE#/$949(]
MEJ`9AM[`!S=TDF=I(!9>*+Q0>.%;IT-9+SRE/K$A?;R:Q(\7FNA;^I"5Q=:\
MS!%XPA<[X(M->G5#>A:>H5@'1._4&?-"J"9\;[M\KZ03A:MUQM4:\5[5L:_"
M[SK@=UWFO*Z<&]PQ)RSC.^%S6^!S'>(ZX6(OYCGA4AUPJ772V(YBNB3J"`AW
M`,(O8(7M0FS-]TUBCFT74=[E\49'!_X;?.WT@E>_8H9MRSRO0Z,.X6AB?NV=
M>%V7^:Z#@_^W=T$QN[;E'M<AGA,.)N;6MM^A.CZW]O:(%C-KW09PMV;6-OL]
M>+8YZ9T,R;=B>-G1_3_A43`"*!T%2G<.B6$TJ`B@=`@H"2I1-IGZB#[O9)]O
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M`IG&W,UG&33DMO:-\,"^7*4UPP/_V-5FTC2!AU?'0RK6I[IVO;$^ZMJFAZ/N
M%A9>[<S8W0%HIP.6=GOU!E!\J9<KB1Q@K:\"?]:VS1KJ!E^";YLM-O22.#%U
ME\J#PY'K=L?SHR?D\7A2DN\GV_G.)^,24+ATG5U'`R?VLG:^<S0L5H^4357&
M$>/(,7<1,>N>NGTI6FN:^PT&)YM>U2)0*%#8A:\`"2`*(&X9CY_4BJ$WF&*V
MFPYL><)VR[DS9HO3YQETQ)9OS7U+V(((UP9(@E"F_U?70,L/:L4?MJ^VO5A?
M4@/#7["#/62!&8],FSB$^AYBCPD4OP:*:UE?X+@:QP*A[P8+JN#E#D>TKO*R
MVAS#ZEMB6/"RX.4=P+%`Z+O!0JW9'D'-@IH[/^U3#6/!SH*==P/*`J3O!@ZJ
M(.ANQ[6N$G2K+=IO"V-!T(*@=P/*`J3O`@YK7;7S[5=,?>),/R.*S2OG&GL3
MU[,15"HPU<'%%$W46/1L0HF*OMZ=)46OY"+\R@6QX+[K8`KU7"#O#^P?NXY)
M6`54.-'[<:*Z:-@=-VN\<D^LU5N_9XAM%VL:"`J0OC>0=B>GKQU)Q<+GS:<9
M8K7SRX.IP.D[Q.D6QE,Q3=(I2'=[A"<HX%5=2TRO".?K[O1*1]US^=T1]XQ9
M;KM=)'Y[>`L>@<`6Z>%DNI$[-['&3@A4AUMQDLKJ27OJH+$WJ,,-D14[(U53
M&A^_M:U>\VH';6TJENKPIR%Z]#6=UAXX)(3.+[<GF?ZWPZ]Q_DBHVU>5T2$\
M$544W4I6SFK*K9E_4($65+YH-'^D5>W7\&1IW3/XM57-YQ"*"VKFZ")POU7%
M8$@@>FZ63/TF>007R?8\*W@)V/:0[Z[D';7[*8F-_!H3XDZP`_[BE`NLZKNL
MQ-5*H[N)=J]:+W+S8T39`C#V@^6-C\@"CZ-'_C'RO#GD4/PC']S`=VBJ[$DF
M-HB-+/IIKZ?M20OLW^!)G#3L24P(O\+1KXQE'=)/H+=&(M-:7GMXAHBY6-`#
MA:_\!^P=48I]>AQX'E00Z:BVT%&3^RD-:XA+ZY>KB=;*6IH^3.E2(A7"+\0C
M?\XR?!^T9-;D:_@N<:Q$OX42(WV<,4>QG+1&"3M!]F^D[3%HH8HZZFLI77(E
MI)6X@>S>(X:/S7RDK6HV;--3:AK5]:7F02?29-3&1B%\5S#S`D?7J]10LTJ`
MEX]>T<O'C14<R<,-^+@B-[?4:*RMT\.5RJB\HH*B#)66'M[<N93*B+RJW[I\
MRS#<`.Y?HSG["!5;(&H87H#-Z$M4!*]T:)NHK8W40;I+ZPM.:WRR^-#E#=PY
MAI_$S^K7)J#WT]H5"LE$C&6BS]/[16.R"K4)ZUI?3P.P7%9:K\7W/]GLS0V9
M/OCT*O#9D-F$J!)KU2JD#]..628HK=)7UYG>8<]F@Z:L?=J$=&4\2MLG1T!&
M@V)$5P;S'`7&_7%&@<;`S8D$E5$[SQ0#K0*\+_'^5275RHB>IZ0V:NS_6;4K
MOIF7HVF;=%S5]3`8U!97C/0<E=IDWSQV%F"]2(UCU[:);^/0.R%ZL/E>[!A@
MUU@7$/1,R:%#K$][/AB_CC+205K.';9GKH>\>3BI'B4O1S;KWB,?6.D^\)GU
M[MQKE+)$FS@]&`[4=);26/Z+"5"MC.<K=*VJ0WW=]/>(G2!+-6IE4%]1;5@4
M/)+U-Z1@M3*BKUIHH+1AX#I,IS;/U16]OWZ>4YNGY,JXOS:6TYHGXGT]&WC6
MP'%:BVQ<4U^5X;06";DBOSZ_:96I^(J>@X6?;83<M,J0OFJW4:9OU\1MVJ"2
MV[*ZK(W9M.91>.V\QDSD.ORM<FK>0FN5;&=&(NFJ,QYGAN^)D76-B'GN'*,9
M\9$5RV^3:RM];9A)'_.E9*-1O&?WUD=3?`J"O)E'*(8`PMZS@$L&=F"!*Y@G
M@0?6S9:(M6Z3E^OR:"1GXM9+%4HWD/?!@VN9V*,A3.))S38Y>F\X[,MI;UR5
M4$@WX(DE^K3*Q%>F[:K$-8)BO\VT2W;F]Y6!V&\>\8>#H9*=W7@U&#8GA-Y`
MU3-S16L#8?/$'6A]-'P)!%-SU_WFQ+"J0.[4=4&T[S=/Q)O$^@Q'`0]=>7PM
MB<D?CMXVQMJD8O_YY5F-*+!\8RGORVSI3T/9+U-X7*FP^HKJAF^TCP+_P?7(
M7]B,7QO)#>T:O1H?ZMI05O1AH9I9B>W44QI9,5:.3W&7I$0ME#NG-$@HIK:T
M6[\_'HZ&XRK50FG-U=):V6O=2N6,I`?]S1JL<%1=6\'!)DU75[VO!'Z8_!B.
M:X\-56%H$L>409MY]X$^4/0R7\@5^0(EF_/&.E1,L$U5:!ZLDTMJR&VOZ/HX
MY"5J%@7G85ON""<\BI*%\MA<1Z]VI!$IM1:MTF%YV)8M%&TT&@[&)1KEQ>25
MAW+"W;":*=JJ5!CKJJQ431&Y_:9I?449;,)&[2BA6J$2"SF^APR?+N;08TU*
M(_])P1A8'F?0G*X\N_:`7[S!ACMU^+@T7LI_@0'UYAD4=;UX0#(<Y2KQGSN0
M_!WY7IK!L"9`E#QB";.E<HPB_`?D2\B1T-3#?-&XA)\)]>E'Z3L"14QLP>/>
M7'(G\"B69IYK!J`O%#$/7$^BV'LD!J;2`Z*2:_#Y/9.7A<*L`,66Q?H/!J2,
MD*@T(<^`+RAJ8ABGLI5\]Q;^R.J#4H_?0P,L"QL^"6<N60D/(^JRQ^82HFQ=
MH)E<*5'/1)DA+H)G%D43*TN&I;-9-;LT4_?*:I+B(^AB-4JGIPK4T+11FJ]+
M1:6UJCA/+%ZK53H+5:"7,AZE[5,A++.^;L96EP)^%G>7Z\9*9Z`*=!EH@_2\
MXTKU!=+#4]F^NG0IOW2VJ4!^;Z#T]7P%EA)R%AA>NHZ;?C#;,Z7S2$7:C#,3
M,^6RTGH!LG.,4CH_5*3&4!ZE7UJFZDZ+/46>`XK1*$'Z#-',8`@G5N`O:6N4
M8@FUAA[++*W7W]<365J%Q,S[2\Q>)V+S"$(FFN++@"W\OYKP@@F"*=(ZQ2AR
ME=8QMZE#==!/C/K;:5&/]4:E0XD$X62G+3/O0VH1WYGGVE_XF]I8?)T(G2->
MRZP(6Q%0BQ]&=0)SCO3LXJ:74X1>)Q3G:**/,]./ZV<)O4YDSE&M/\HLJE@/
M4>AU`G6..I!3]_MK(@N]3GC.T:&GJ*-,;%P38>AU(G6>1JJ6V=SP8M+02Z?Q
MRXPS4`:#-1.'/JPFCA5=$MRAJ/MJ_TW(0Q]5DT=:\R5_:/I@.'H=_M#K!/#S
MU=Y6Q^IH'02BUPGA>?+ES!JB=@PRKA.W<\0/9&7=%#*N$Z?S5-'&@RR9KIM#
MQG6"=EXOZ;JVB='&N$X`S]%'5T?C=9'(N$[(SM&A-QJ-](V0R+A.Y,[32!UG
M]LZ\F$3&=29C\E197=510B)%06U<F12K>?,&^CH"VK@RH.;(YHNT7A[,*F-I
MCNB!JJ\YD$%@;&,"3=ET%%/DRA";HYB>6<*[G@BFR)4A-4>7OC(JF*]H'+X4
MN3*&YBC0TX:9-:MKBEV*7!E.\]3I#W-V9[XD<"ER91#-U4-1UCUGHLA5N>^*
M(HG$5]L?O,VDB2)7);YJP0LO&)0KZNMDO8I<)TKGC4+ET6`=+*'(=6)UWM3%
M(+LSL0U3*.7;1HO%JW(F[5\#793O'RW611^,-SUWHI3O'2VQTS@S6;$FUBC?
M'5J"6V70+XC;S9FC?`MHL1*]\4#92.*KE.\!+=%HD)D)?#E_E&_\+%$%%,D,
M:=?`(>G-G_D<4C9_,MX?J&]#(^E=H_DT4C!_(@_&X"CK99(K;XH<\A=?7P,Q
MG[K68K$-%+@&L1!H^'^O)F?$08Y!D!4?^T5/"#4LE[TI96M:R=0A$V*PC>[A
M+A:0?>VRDXDPO8,6?K9<XX^E'<;%[Y#_8?D?3?(H47]NX4][$WBL1\E?^%"1
M]^69_Y%?F"";6//#.V)#'+G$3]*-:R/GX]X_IO['O_^-53&+*K@[_?VN=WYY
M<GIY=RCUU/[^`"J1+HYNOIQ?'DHR<<*_,U]:W..5L"KNHU^8R*BZLZO+N][9
MT<7YU_\<2EGY$K][>_Y_IX>2PI0-+_QV>O[E)Y!^[UKFQSV)M8;AEE6O[#,!
M!TQ").W@OEJ!4(16+D$)6X+LV<?_58;R+OZ6;SNICO'J]4_21?CR@=O`ME&X
M5"$!>FF)>BF"?4G''LS6!]2T,?(JSJGB=4&>-&)3JQ0K7]WPE$55K<"<2UNT
M-T&ZO6<0(Z4[(%TTPX%/#/IAJ2R0W[[T'5NT$E[3557^>.S:,^3,XRO*Q^^E
M)P3\"TSIL061G$2<<*T+B\`,?B?80D]LU2`@\VCF$6LI1!U]D-CII!RQ$&C#
MU30$_L)S$,=GR)(6V0"$?5;S+7*D$X*G[@?I&%EDX@(IHGW6"&FA'%LD@R3#
M@CS/0%:/\BTF]\2=`>/8R.`-A6J-Q=/8F<(#L=8FL(7+U_@PE<QE)LM:LJC"
MM=PI,23;-=D^$K;D".XA^`_K%&Q+!K8LNK]L)3]WE+7>7VH9F5`9?:3`HFR/
M1;2X"RK[`\^9REP.Z&ICMI>14)N&*Y2F`3$QKVVRL'%6^H>D++X<Z3X@\(3_
MY$HS4)H=B;JHS)WYQ`90\!(PF"*/;*41:SUV'E"X*HK_C5`BS5R?'<S'^F95
M\B'OO@=L@V5F+L&L0'SW`UOJ]-/M\8?(>"Q:1?IPF:RP'0!C`X"@;99%?)PI
M?UM0/H>A7NQL6Q"TKD-/@9$@ZXY4>O1V,4PM)(7U1S'F^T;<;/"T290$AC&(
M9X$L1%F!&:$\W,`<K>.+_"0"(`WN*3$)\H`=/T@K45+Z[A@YR$3?2V&03`1(
M_FQX-QDD\RKYZIO['W(CYR^05,/__@W!P'3M#URM$WZH<;H&)GVUAE`ZA$17
M8N8((P&:3CT\Y<%B&4[#UL-(+ME>"!:/6')<7[K'V`%#+W,'I@>R+!#B8R^*
MGS"4=B@+&ZQ&]L0]LEC46%3$*\$6X8<4A@H:28BV<MI*=&V!V[)I&P]LSU?=
M2K<S"'3O(>6X`@K',Y\?`KM44U%9'J!H:=J:$`L0PY;C@@N;G(1]ESLHO\#O
MF1*,__A>`2`(S^=0#2EQZ1<`LP\2GDS80EK@5P14C'O`&+WA_@"*A_U`>3]0
MU@^9L)"B:A*N"&>"W<2"[/#$3E;0X&NIP^KVI2/F+OE%D@_RFS-V_B_?7H'L
M,#RQH2<BSC(RY&E4'?J6CNAAWW,YQV.V?MC\;T!9*;"JAR=LH3%(X6N,5VT"
M]N+.'YZ!RQ(T/N[&YCNEW5\<%)@\3I^S<$AL*9Y[@"O\R/FWI>#B<=EF*)B1
M*D<GWZ"PL`G+Z=GDG5D#I@SY0615GM+3Q(6XR@J(S]C)CE[H,DPES^0Y[!/Q
M'R)BY7-#5)J&L\+,$0R#Q20S2@P62_2CM"I)\%^.CJY3PQ_FN1/7LMPG5HHY
MJ8?_#(BW4&P12M*2;[$1>'R;-2\>'54B\;,_*#N).R7S]O0X)9*Y8F0-:*WK
M,84AUE#FG#;QF20^I`#1+MC0"RR6Q[#X"-$$BKN^PX[98\FTRQ+[A$W)$KJ+
MW1`>RP;@$C/4HFE`\G.)64*"O`#,GNAF5F6H0F(`!`XA`8I@G,6,DHI>[@S&
M:2P^,RNU[^S%X(H",4`"0MD0D(:)SZ+"?,2Q?&^1%[+8%@9$?N^#]/1`C(?X
MMNM`\T,[@!78S@Y.)<D"#H:LA[(Y%]9!X>B,>%&@#$U:PBQ+#6<N)?$\#J,[
MJ`$&61Q,B?0M'#/;4/\#.[X=;&*QN?"HD('H@S0!7%*NSVK<7GA8PAZFRQ._
MI$G,>/:4KO;^_[?WIKUM(]G"\/<+W/]`Y)D!$D!6<]&:[@[@V$Z_GIO$GCCI
M1G\*2F3)XC1%JKG8\?SZ]YPJKA*U<Y5J<&_'DLA:3IV]SH)3>3,GL`Q$`I>2
M2+_[3V`SC9"3W?8=+YU)AI5P5(U!"NN!%UXH<26N`UP#V+/:A*8P;0)TBIT$
M*"[#PEP>;P$2,/`DSJ-RU!1-YFI*J)D`&-+J2KQ7H%=$R#O==[):3OCV(L#,
M(Z[-?`':3)[HJ;W7DS?)YXB*:9IE7.I,0U'&&NA+)%&&EITUV5>RY@@_)ION
M<$HF9A(A@(*)!;:\`WH4P_TTA[J]OTN/S_TQ$=9&1^?/7$K9^=IP)&#!V_[,
M"P]Q$[`Y!_)C^C*!$DW0H71VAQ>15#0;_8&GB!0?84P`:)Q&&U1DX+@XYXL8
M#2>/Z+=IX`/&QX_S'P]2=+9*X3:H.AZ#\@U8H'.47^>CTQRF;R/";E)#D'=R
M$N%/;14-VZ<,63/Z3I&KS,E?5*+1>7&>"E;(?,$E!Q/L)LS#%'X:*A&H_\QC
MOPAAI5@ZDI74A.DPP\`.PA%I=#^.'R+?*9<5W!`*2Y?YX5CLN=1PQQDU^7*"
M@W7N>'[&<Y&`XJ@Y78IU@Q#`.,83L8+XZ"BOQH..;B,4S:$'6O)='(9@B3QB
M>6@3@EH6/,Y"YTOJF%RFO&SV%?]E.\\@?!XYC,,:=7@L,4Q"7[D/6/#"]4`?
MT2'<.6=M'7PN8+H,9YOL68NO!/@K_H/+AC\-$SF^-'6=^>J*LXBU#X>\_'C[
M&Y`PMBFC[AJ2!@T$#O'75_RAUO!+%L<@\5I&9^'38?L-B1RIR/0V^E",L,2E
M!&H#/._Y7J2+L@_(CKB2*EGTD5B=M%G&O"AL/@/X'?"OZ!56T2LBS;Q9Z10T
M`G@4G1W$Q,G"DFF@ES!R))&*XQ&+>Y#8=M+NG`]<+^!S/IN@6(#>&V\'EVBQ
M^9$M633-UF&KL`\_M"J`?I@G^B4>!/9B`02QD1/;!8EKKTG8J.`"%;9PO:CR
MP?-X5Y:=`'58G5)C+SH\(9<,+[WB,CL;'5=A95LIKOQY/O<AZ9N_T/\X!>T[
M=CX^AT5_$=7`'-'A.9IR8G+,CXORHYX20C8DA*^1=?O$2K+%-PGQN&"!IQ":
MH6PDK"(5X"4221DQGI'"X5T"K(PB;_',Z#J2B34K>F'=.OG%)SH*LFOQH^H]
MD=C>=R'8I0^M7>9FYG.%A?)2+`<9`U8<S%,!":_3XG,3!N]SV6^1S1(M5T_B
M.<(N4/%5='0'R[PR!J5SK!PA>;'-UY6^+>#5R.D3>IBXW>>[CA7I#+&3!WW3
M>*V\60_%5SNAAP"A9"65CSHAXW3YG1`J#:$:B--EA^U((;RB[S>=(CJ9=!)@
MR"%C]0;E^@9'PQCE<!/`1@'.>,I^&C\#+W+.O;>(_M?%@P[3(ZHO^`VR"^<$
M#\P=@UKA`0'Q<)@QG3$UUH3BHRZOL?'?&+EA7XX='DYD6F+XH/0ZU)/?;,>R
ME*JYBZLGL_\463&9PM7O@&FK3+Z$"+0"&B:TO""22J'?+`-5VX'Y`!1NY@(C
MQ-44*7HIOV;FM12&1F@6'GH.;ISUE2">6*I^RSFHCVEY%9.5E]B:SX#SS!<Y
M=0(WPI7$Y:X#QJ&MPE!N3OVWTFLSY4+;O\Q/\NXQ]7Z240XI_).\O4L%H'KT
MO;KP)2(3QJ$>0W[)F/8<+5A0O"5JI5PQ!)3HE_]RM3J"-D6L8EP:3R=^/+S.
MX+T3V2V$`T?'7#24Q3ISUTABCL`!Y@XT#SP,H(@>#=V13%*@*++X:-G!LE%L
M?`U>=MCM"V(6^6)AF>&K[&^=<=Z0H"(:8Y(O)AX8EQ*0`2&F1S."J.=?A*0`
M&XD7PZYAN!`)S2X==@TBST7_!9&8H+@@(`+".YEXL-3)19<-")GP0DYR,6(<
M5^)2,+=L;MPA`8?3K*Z%Q\ADE_H2>FZC[M_1UE!>K>S%#`U7@WT-=#YA(&,7
M',&$M63FNA;BV68?$DJT\R+(#Y'*%_F>F+LFHA]@>?B[@\Y\)78ALK!1@*BC
M1W8[0[_P0!(WF!D9]WC^*;6%"05G\A_*@AG"0!!4@:P4GX<33[W">'Q$B2!.
M4E3%A$&"E%WI=HI?1:O!M8*69JS%Z_BR+VT.95[GX@.9/VB5[F/J?B)\JBO]
M@5O*7"@1#`UE6T+X>-@2P<1+O62F*9,@*^C,V9*]M*9<S)^!&1-'>\5S4"-[
M4DL^C@SXGF'`U")@;OY0:G(]NB.,3PP=BQ$O#H_$?LE=X7G1TGOZ:-HV#Z%8
MHAAS$\$0[LE'`WF1=@NE66UB!<44E=5+YJQ(8'@]X"5$2/C=W86/+<IG\!],
M]'N);ODV#17?2[`Q&;J'SF-CZ05$@2P+2#G#`0"&XU[@!2U:Q2G"CVD]?1WY
M^\/=329B(L,(HJO]V,VXCCHSRV'T9#*X,%8026$+Y4PGQ.#X::2H%^J'QN+2
M"YW4?"F*P_OD)$HBY`>XE24^!BO`X<D3,2UD#CB<Z1H7,#PHB+D`^7J_`1X,
ML5@$#!\-=P(+]Y)K$WQ^18,-\&Q`Y-K49/H/6ZD-+\-D;,AH?5WI<MMP21!!
MZ#YF$(]NI9/3AA<CKA&A,A\@\:RF^2<;-)),D7H0'RBR+78R+GT,+.+B2>;R
M]W2<`[$\4$+X?0JZ:;GF!>?F_D5]%@=C9DUV6$B"MU->?S.KZ:'Q@`>:D9H`
MQ]0=S-PQ0N<5/+^LY6858517@.C"8$G@('(3&&B5_L]][`.\]HK"74!/9GFM
M4\JO.GD^\TH>R(*\A#KG/"JNFOJ.NWY2=Y_)3TQ'<5Z(Q1PDS*WW$IF4S'6&
M8M8%-#?X91M:?F02!K`NX4S*3K8=VZ53D)Q,44AO@F\ZC<Z<WDEL7$=B([R/
M"#^E$=.#V3V.>CSX,U&G@6T]\K6%>TO6M+(*)_`W+X0Y)N<3C!*/(U*6-8(U
MLZ^%#-EZB.D58-8/!P;PE\0MF3J#E+^`A*H^T=/7YFAMPGPV:D\.>KW,^21P
M/78P_,Z(%4_GC;_@F22\)QX9A1-UZ;K14T8*]^OQZ1!\L2`&E&(Q@7B)S`VF
M-.#B(*[4Y(F-&*]C`U!7T#Z.E?/2B!\LG,C?"2K#4^RY3@]@<@4?/=E@Z[UT
MEC`B7#L&YL"GA,&G!O"BX0T>HA<R^>2).7/8(_*F;=U)!I2QB?=$XYO(Z.%T
MWDCL=%KR,86^3#8<QQ0N]\/#24NW.8#!"YCYSG`\%)[K[,GTR3%QP_:ZM,7(
MD.#I6A&<HQ"%V!PQ,8LJH:;P&A&O__FQ)-I5X#//-?\1-Q)=_A^\QF7/VFX0
M"^,M0$BCFH6V)`$U(C5?KJ]MIY.(G6@TXUY@(8\<1/@;%^,1LT#&$$>0I*1+
MGMLN>T)+^HT1ROD,\G.-@=C<&),FYC1P]3!G!KT^"8[R&#H8*/55?/^``2:8
MRA0R#:!<RD1*.NC0W4-"QN8[EP0OD=Z5APD;/4S9ZYF421DSX!U#<[)W<<V(
M.:G;%\H(]!%%F,U0]3&^A8U!S@R8C$A*`KA24BDE%]@@>;>7D92,;^_XDRSX
M*;(*$>W8+--E21BA)M,WLMEFH;,;<=Z+4E(XI;!(.=-(Q7]$U\D\[N1,0QY8
MH,,%3S!&PH'S/)OL=;YW[B/04WN/\'K9P$<-+(NPR$^6?&1TOK"<%QKE/H47
MQ"$YI2Y]8VV1Z5,>RU+FMT%Q*''H@.$1@:\#X+YHRC&QS)(Y'\,GWT1FITO0
M\7UAF8ECT:9LR8G3!*AI"CH#QN-W)72\YJUSROQ_J"U%,YG,,/P/R_!RTA(T
MA%\LJD)G9@3"-`-);7E.N`&^M&4R]<-'%HX9^4QR5,`5'2YVN(>J3%JEB&WJ
M))HC4OD.A\`$>,A&,/"8BV6KOK,9,)'Y=@18-JSI*$"EM?DD?G/5;YT'S'VB
M)SJ)A*`_4K[(BHZ'#XKRC.W("-=.)%#Q?#R2<"!<:A/\(O7<LL?Y[],E\O'B
MC%HX4S\.P`EYF(_I0?9%Q"+3B)%"(K`F,<=TU@VC\`X:&4\PR["`D,`T`5TQ
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M@<DN-[PY#!-Z>$M43CXK9,CN]H!(XK-F]HC.W>@A=N10K)&$`N4M.<&G,,'Y
MO#2P^U3(MA&A9RID-I5Z'><K1P<0:M'&>LJ<4!XBC4%NCN0YX>TGQJ#!I!?Q
MA"PBS@M=V6"7\HN7/!()3_C-VRI/R>=DPH?$NIL7S!_WUJ)3_^<_;J^__G]O
MI<&@.QC]\V?I_=V7ZYLO%U=W'S]>WC\`T-EMS<*CT<P7'V\^P&*4KMHW;3B-
M"2IL+B]HBK7*%@0-E_CS`I-NPL_/IN'/?GTU&/PSK-49+L^-UA8^_%9.%_/T
MC>CG^\OKZ]O/OUV\O_OZ]>X3`\'/4O0E7Q;[*MQ2O__/Y.<O7"/*O/+U[IY_
M\PK5;.:A!"/)=^;Q4F&(O+*B>YT!^\LW"MB0UAWVCMZ2EKNCHEVY&S8=8EBT
MYV?3-IQGQ$I)6?@2<TG':,AA,*>&&<S1FJ')3G>%V;@['*T!6C@)@UEFCO"'
M\-G<Z7<`]/B?6.@6*0)^U`J'^M$&PVB7"K)?4>5*3AB$4O+A,Z@-R:=/3$5*
M/M^@KL16Z4H_\<WG*TY;#9#B*$CI'L\3E*H)B/_IIK8O&*9@F&4Q3*4>;@G3
MMI1#HME7(0L3.'T(3G?E=4`3:+T6K54AF4]>,F<+SW,?<E[9>:7](KLH)62)
M=^4QC5,6PRR3;`L)L6<$ME2(+0T6<$U"F/+$S*'X4K\,>7]Y]7^_?;G[]OGZ
MK?3_=)W2Z307')-'[-+@_OKJ_UU=W=Q\^)``R'<6)<B9`MW$5QLJ8:2<[6N<
MLI7PJ^-/H5*V5I@X*WK;Q3.D`O%PV%'5<:<_E@6FE8=I&T3A62';H",/^IVQ
MUBL=V=9+U>(A?F+"=X/:T7BI^D?Z_G[#?7V=S*XI9D!1\K).S;Q`U-&`.0W+
M9TRGB!CKQ9O`#6$*"E-P"W;=K(:."65<F'VE<K3>2.X,!SFWA`+/A-%7,*K)
M6F?44X3)UUPAVV:3[RHGP%IH\2)&IW[&IW2&BHSY&P(=17A-(S!RJ"J=OC86
MAFPK#=F3"Y]IF06PGH6I7;4/(#6<@)7WKD"JYD&N(,9V&E;'N-/K#SKC7JT>
M78'@15O)`L>7[NZ''6TT$K;U#G*?_XE.UBT'6G[AL*Y<79W46SON,A87BMR>
MHHK%VR;.$^VLE`IE#34>7?H8EOAEA4!^1!T%_P&;&V(]#2NJ")-*'`Z;;?/F
M9O#;IJQUGA:=O<)UL&VVX[[P)I"=J#X`0.Y?03KO"P?HP'?62_8[EMA\&3P&
MGK_\<-P?*3TCJ\BWJ671<F&$N%)!V"4DK$[_1%S3";RH&$'4QM'G58U3S9DP
M-SC=*235:RX[(N_XG1F/=0;'!C^K1T:C$@U^V'XOV1%ON[P@+[R(6U3"@>?G
M,@Q(-_B^E**2HSG]G/A0K-YR6,4-DXZQ/774.30JZ1>^S%\(AX@*(&;@:>;W
M+\;VHZPMQ_H>5M@GS\QISLS0X+5'J?099I<&;S8GI_]DF$_XZ9>?`N_BD9#%
MVSOWD=CF?UFN]E5<KQ`^7-K&?:H'^-WT0]1;]"'N]W0=MTZ%IQ^2SJ67<6>/
M>QA/!QK\"E+WO04P>/>__R-)OT2S?R"F^SO6WTE&2AZ53`,X#7E45,QTAAW!
M#U_H]-=7U[CK?VM_?KU^]0YW!9N*.`MN_`+9Q5M%[B+S8%],"5#PR]ME3K/=
MW-C0NC=JZUM0QLANM66TG..=;%\`GT+;)2DEQ?Q/[Z]\V$F[`&^W\T%\EAA"
M2Y^2SG=[MU,]$`F;6T3B*RL*X;JL#FNZ77-4TBOBV&%_9!?E8+KI<FX5Z;A2
M8KJENNFFZL*D*GQY<:V)D,UZ,^#]%ZQLMDW\L/TS%T38*-$->!\/Z7VZM_'$
M<5W>P,MEI>C"<I[8U"IJ'+!42X2%;ED.L:/"YB;P(N+RHE_9&M31[HCT$8M^
M2RHL9!'XO.RLI[OF!*O74,MYSLI$^`H+;J7:562KXV$[.[Y1@T[\M(;C\9Z9
MT<FP-\ZKO,G7&4TWHHI[6F(73*S8EV[`D72]X+T3XYX/4Y?,Z;/C_L4.F[<L
M9)6`4O7E>.MQ^,=+=QR/&W;,R7^<L!MQIN/XBX35E!]12US3"A%+A_)RW%@8
M&Q$R;/'%2NQ'GUEESJ[T(=,_@V^2%]7&`J1FJ,)U$M**"A9QHN48]IR4HP[+
M-+/^7I;%E&FV!6QBA2H3TD+45I-D>ZC"LZRP"5873=HPP;#^,Q;+"LLD8GL0
M$Y7LK$JXU`<D?#HJ?Y=J.LH6G!2R3A5C2OK$+/>8SYDZW#/KYIG4CDQO-]X;
M6R4)>W"$<9N,LEF)/>Q8F9JP$U;47$7`++*E.MFDMAXWM8GX""M[#1SSOV&5
M3,8_HJ8G]AK,C,OJ5%HR9Y,I+/4&W*0LG-PY8U7>2G<3K'9(N%G$@!0>C?1W
MP,S%T)9!1.6BA&.%EZ-%'+:K1D)&?2O=,G!$/4&`(+CDVP*6E,GI)*`-&1-O
M>LYZ#L&;T2=6@/ZDH:F]E;[9S@JFF:FN$+R^&?`-GY?'M9V(_8`91I*F3ZS]
M15BODQFMV!X`6(;_PAM$LB8A3)H[SQF6MJ,X+P+"M77RBRS3L*KZ!DF9%I&<
M0X=B?&,#:33Z,T4B+[?Z>U"&7X-X7/I9Z82U"_U5C9C5Y%N:BK6Q^X?<U6(?
M%`[\#Z6K)8.&ORS78`R+"J>5O25]A+?(6Q*(S.<3LLD08;O2U?*R@`T`FH)1
M':M!K!CAW+'I2X3`V-VG,%@E#49YXS]LQ,U:[42J,M!.2'32=!D?8M:TIM%V
M'F*<EQJ<D%#:ZHKAM@]!I5O/+#L85[M^<[UXM=9DXM-2WW3A#WMCBW<LP[QR
MZBFE+#(A-YT_CK&B+W].]%<O5DTMQ+.PDVS4/UDRN&*5%/Y,5;(\+USZF`+Z
M/HB34^,1R_=Z:#,UKYSC6.MJO3W*.<J'EW,<Q]>DY<9Z:,,B,E^T89/BEE5>
M=/.X+:EU%W/:]WI3[8X&QT<LJ>GRBFJ[0'`:YUYME&%/ZX[56J(,>UH:U4:%
M0_WHZYF="GJA<RTY8'8-D"K>F;X/2*I]^FQM<?W.+Y%QESQR#:I[\NF;EUM%
M8^D^H3@ZDKN'DU&UM),*C1!B4K#+"H*R-TC9DH.R2Y;,U;#+K]B>HD)6)G!<
MX'C5./YOYC5/COB>N<^S,M^TD]\OF?LN^_LG[F%/'IHZ;O:)6P-=P3JGIN3K
M2^8'R7[WFCG)DK&4-X("!06>,`6FPM*RE'"'MR]+7\57-4OTQ=S@FPE)%80D
M".DL"2E]Q;D_W6A5THVP9JNU9IN6O%<BWVQ7->.V\,(F5386R".01R"/0!Z!
M/`)Y6H0\!>N\C:]8L4FA+;;Z8G%*[Z&&6T[TS=9PNW61-)6PJ\+3J\OE:D7R
MI\(3R]O+D@2""`01""(01""(0)#*M=["H'1JRO$&<Z!`K5<MLU%&DEA0IY+;
M%)M\7];2U2JO<E@@"ORC]"-7E&Z_@+#J[4U4:ZSQ6D$-=4$Y@G).CW+B?#1U
M78:XH"!!08*"!`4)"A(4U%[M35PG-?0ZJ1S#>K695S-L[)9Y^1H4ZMJ(,M2E
M.A8+1'^U,QKU!9X+/#]Q/&^([BVP76"[P':![0+;6Z?#B`O7(B]<2TNO*1"O
M6/Y^NL2:\-K5TG-HK>.OY)#H5CD+:SB7#?[&],ELE*-''E&3G95:1^Z5W^E)
ML`S!,@3+.!&6T1"[33`.P3@:=BZ"<0C&(1B'8!R"<;312!$Q%67VF&Y]:9IV
MWQ/44`K@]*\'!"H*5!2H*%!1H*)`18&*YX:*XJZ]R+OVEI3T6=\AK]:*/DWQ
M:17(GO;P7;27AX@C%4<JCE0<J3C2QBAOPME[@@ETC:I,TS)#M;A+QL(K8[7J
M7K'(2\'"(=GDZS]EU!/D*LA5D&L[R+4A83Z";`79"K(59"O(5I#M"9-M%<JQ
MN.EJZ$W7>54;:HJOM4$I^"UNMU,@PO;[BL!+@9>-P\N&J-0"/P5^"OP4^-DZ
M_*Q"KHN+X%9D_12(58VJF-,R=U>C<E8;$;_<*B];PU);MQU@$?FNI^'E&VJB
M_JW@4H)+"2[59"[5$'M2<"O!K02W$MQ*<"O!K02WJOWX!+=JBP78VC@/_B?&
M*VSS-JK:&F?C^BDW#C?</%R1;LL9E18NG5+7I7C`COZ7]+R<U@+?>))+=<<U
MX"'B2U-BNG@&`94"S[0?)1^&>6\1_:^+!WWF6+`"9^&;C@UCFSH^,'<,:DG$
M-MBC=$,LR*;))L2#[V!8'"3UO3-EWP2V05WK!>?3G?D<GF,;ZJY!\0T4J5/;
MI^X6DN0/'7;"6Q"FX!.>.I;E/"-<B.<%<W8TGO1,73P_@*AI[WJ"OB,9%'8]
M-VVZYA2VHM.ZG/9C*#CD41RA^/O(WR_84;VUZ-3_.61'0ZVKX55%R.ZO[CY^
MO+Q_`-@!C['(PJ/1N82L3.$L"-$1.)#\"G##PDLN!$K\.;Q-89]#OC_4(KY?
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M8E++.$G#0UBDQ^&*W)5/$B^$07I^>'9>]BC_<TV*0''Y`'5%B_-XZH7KH`CS
M),+B\FW=M$S"8L.=*2!LINJ)-*?$"]PU:0(?Z1.U)`UF?+3-J:EC6'A@.Q./
MND]L*M->!+['[$U_Y@0>L0WOS8[QXL5D9)QK"/GQTD'$D*]AYB*2=A>IN4?M
ML(9&U8;M@-AL<5#MQ_4U;D44N<#]4\']='7G+`$\8'I?_32A<)%=AEYZ*@'F
MI:D`(L)<1`P?P_.:%#TL<$?@3@-E4"O<_)5=N37R1N`]L8BM4W2,K.WW?M91
MPJ)'TM$X5D&/I'Y7KNY*L]]@;[JJ"FH5U"JHM1W4VA_DU'&H3K^K'6U;H`96
MYF<HI\'9K><%3,%SICD%KLKO!]!\R[2V&_E6]"6ILG*HP)5VX\IP5*<P$\Z*
M!CDKRA%F5TQ\86'`)(A#6#LMO+ML1#'CMK#5U]JP`"3O:L,^4FLK$;U`:!Z0
M+"0(IZ6$,RXBLG0[X339PJZ6<AJA"]41&5#QC4SY%3":;XN)&^5F<%EEU!/8
M*+"Q(=A811]=X80X9R=$<SWJM9MIIY4DW@I^UPS_O,"\\\,\K5=^08PF6]8M
M$,@MO[MNF+N_H::&R$&JFQ.^+B3F[A@'?7FH*3SO`M73SI[.>"1N^86!79$#
M/&F&E7C`9>8!+S]N\F2L'='&N#EW:.UH8[QO?'9];8R;'-RM5!#<+9B48%*"
M20DF=7B^6&<TJJ0>>/O]>/S/.CJO'U!I[<C>ZKOU1,=6W93H,ZS`9A'/,Z<F
MZ]OM.Q+:1%B-C5C2@IC&!2Q8)PO3A\^@U\/0IINNQ(8_.[9-=5;![=GT9VSZ
M*V<.%O%+?,DQ_-F3;N_OL-GZG>X[&<.@Q^T"Z;5'J?39\:DT>+.YR?I/AOF$
MGW[Y*?`N'@E9O/T`*_H=%W1M>KKE8,TX[RMPB?<6@.G=__Z/)/T2/?K1L1^_
M4G=^32=^_(AD&G!VY%%1E5>L8#G\\(5.?WUUC4O[M_;GU^M7[W!JF#DZ+ES=
M!9[06T7NXGFQ+Z9D;EHO;Y>I>;NUIJK=_EHW+?\MQIK)\=QD0PT>CF^]G#.8
M;%\`GT+;I<I/BIS:^%<^=*1=P+/;"2"F7B"J2HBK'22JN>G/J>U[C,ZO8'`3
M:-S6S;SKZTD>Z1R+?-LYX$9V5P7B9L&V+US:6&:3[9BU5C!@QPPW`IO,'=>'
MA[!FM*<[`4PUX0X:3WH-XL$*C+`[PQ.%!U%.X-MO))05Q`OK=C:^>N9HT!V,
M]JB>*7?[YF'U,T=Q,=YR'8F#?@'7!8-\W;6FBWBU.QH=O27US&H(:MW16MV[
MW$L-[11J""8N:"O3EE[.MJ7/<?4L"0A!!H(,VDL&<2I"E@J4+!7DY"641@5*
M$7$OIUL[LTSQW[32F24RQ';E![2%R36I_J%`'H$\311"C8]4V2!A"G?J%R>(
M2O.7E'Z)LH%1%0[O<OE9N3>UYW/KNB\<U6Z_NFNX[09FG;>>:K_\KE."8`7!
M"H(M)MFH,ZR`8#=H<[4C;O.5OLK<"N5D&WVDGL<OOJ*+KHYD4Q_3?/7`=2G,
MLL"K,,>N4W`TU"05WMNZ.625B<`"/P5^[ITDIQ21-[1+,:X:/#(%PJE)5;:$
MAR?CX8GU@8R6(,S(%OFQ&Q'9WQ:6+;PD`KU/&+VUSE`KOY"B\"F<NT]AR7N`
M"H35F)LC8:\)>VU-49..+%=3/[D6]*S69!/H+M!=>"B$AZ(J#T6#;BS:;<2)
M0@3MNF&OX?CVO:2OKQ!!DV_XA:M)<"G!I027:C:74H3/4/@,<S1ZD:%2]]5'
MB]T8`GD$\C03>41ZTQF[EJZ:?&_5,GNM7&/K?`RGLJV>DS5<BKK>$`0K"%80
M[,D0K/`TM,W34*Z"UYC(YH;:IB)0HVZ^^%H=%X"7(BA)X'H+<+U?#:Z+B"3A
M-JK.;<2"E(0I*N[ZS\,"%G?]+;7`E<YX6$1C3\&G!)\2?$KPJ1+Y5*]\/G42
MGD+^YYH63L>T[#BP6\D^_4C^%=@T60DVY_A78+UDB]!C+Y>X#0?K@?3!M(F-
M+2E6$622194"H5%7`Y-;6]H%2IUT;RG)]+R`&ID&)@O7F</7COL"O,.'%<""
M"?S?XZ-+'XF/#Y@`U`4VLYJSEBA@Y/Q#ZPZEN6E9:/3XCJ3#:`1>I#],#_OK
M2*S7U@P.EKI>5\(^7'QPHNLN:X$%%A+U?.R/I?Y36E!7>J'$96U8L)>*`<\X
MRQM4>=<K^*\YQ>$D>,,RX5678MLMR7&CC;'&7-(TL*RN=)O?;0LAP3KOPF[P
M<QHD;*E9P+E4Q^8GL+JLVY@!0^YJ,3!<:A&<']N"21-JTZFIFP`[/KZ'CTPI
M\0/8I#^#W3\3+S4X``@^>8'E1^MZ=!W/2W</"[]G_<D\_/1`7>QE%(/I:NEX
ML^W/6,.RYYFI<S"PS<!.K!@I8-%X@'#ZL`\7%VFS)P%/@-L9L$++<O1HC_$8
MINWY;H"-EOAQ9Z%D>E+26X=XR?G3'PMJ>U0*?-,R_XL3LTYLTRF>UU,*4>;4
MGSEPQD]L38@=E*,,,[5#H."D7>DZ<*.!_)E+*<,JVX07YD![,T^B-@)[0[_E
M-6>?W5.X(1(9_H`&2H0&W63,R_"0-DR6(;=EZH+/,05VLK@&/V5Z%F67!YM.
M+PF?YM1G)%!E7>V<P/=\>!R!%@!HW.B\,WPA3<5I,D/J=^8`V1C!]NIN9^9T
MM]NSM5UIK0R*D7O%=>FZ#!X#SQ=2,"L%\Z!2DM13Y:Z<)_9L6*X)@P,%'"/N
MEG<R8@QBL)^\.X3?9/:59C@E<)'+M+/4CR'%Q@@WABR$>+.X,6?8@RW[0I-Y
M4'&]46OG.1^(SAN@?J3$H^?`4N[L/.I1!WFJ`?U!7=WT$`E]H+N%'S(&L-1!
MR9"F0*+^L\.(W6,O6@A%I'7V_!240ZZ>6&3BN,1'.L&V>JQ)[`/0Z;5)'YV.
M=`4""P:S30*T!:K2LF8,7()1_K+VR*=CJT'5,[MX8C"=TT[WKP5:[T>TSK2-
M<4SY(2M(_0QS+;B>9KUT<$K;L2]T)%6+=2%T@-$19@[P=>BI9IP,-#,:@H9R
MOA$W7DJ8EA+I_/#?/EL#V^Q&8ESM=9O;P#;;XS;I@GLW10@!Q)AJ]X4K]%>.
MYWL/J'2_AZT8]^2%[2.G&ZXJNN%R0NJ+;K@U=\-]2%GA*:D'=(96Z=Y]7D^W
M_ZTJRT/IYN\`!=VMC68!&I_WH':<B<1;5CT5-4?<912GB4-<@X71F6`@H^(K
MD06H>T]<IH`"Z3*F;W+W@1T@8\?G$\]%1F<C`1CX+C-D43;$_IE$E\Q;Q?J#
MDU[C.]'#JOPS.\WHH_+S&Y33:J>G:AUYJ"8[Y\NK1]NK"P$8GXC4%X(2'>&9
M0)[!T_0D+YC/B1LY<<)NQ\UK;RS_<Y_>QL.#FQO+%34W!F:J'A^5VZ@<`JVK
M'+\E[<S:NO;KB2#<$'C5[#ZNGX.L,>%,V<1Q1]<[QO"\K2)>H/V9HGW[6QG_
M0?$:GAH76<R_?`++_#'E0;AW37V[=Z?(&W95-#2N2>0WK>1'B4RQ754;&BO?
MFU2F06!+[=C2V@(?I<F<YB=V;A`HQX>T^<ZB!*%3H(/C?7B#2/SU=PSEESK;
MP+H*#RLLE\,5QJL*CZ8L7)@5B(5*IZ>I'6U01**;P+0U/'[0U,#=`A&I@MH4
M6E>K+%5#V>[1J)%HNSVM?'"O5TUJQ]L6:#`;U+?&JR:_N<3VJ5&G2&B*W524
M5E&G[5L@9FB@F(X&Y=?%$9A1N9U;();TNQ6@B#"=S]9TOF+Q?/4*J!.W681U
MC&.]5H9UB[O:\:Q`<!Y0$ZG1>-L*8:QT^P-A+#9;9K?96+R)\@V$47!&82B-
M97>OM7YGU"_BXF1[W;9:$/(TY/$)6KUR=]`75F]KK=[2`I4*1+'4G?&&;-JS
M-E<:7S-K+PNE\I)931;M2F>HR)V^,A0(?AI^GU:(=6`$PGXN0_H?%I)X`$=,
M2&W8>[6?0*A@4<JX>6L:R\U;4Q/AI#003J,&KFFXO*04U^!_KJD)V+1DUK52
M`NOKA%7(PCHR+(7X8H*5&3"K."[>P%*)X=$PM]5C!22P9HUKZGY<$XT\$]?P
M6)&R.*M5>LT2EYW`@U>\-\U+<AUT!Z.]\EP/3G,=5)/FJBG=\?'FME:LQ#UR
M3R4VUCC9?#\-4'5M$&>IOE9-3JO)_9:F_'W%FH?)"7]B-0^3SS=8_)`M)<X&
MS'=OK'*\TK(!!9D<1":"2H[(#3?MEA%)B8UK3B%E5J@/@B^VJM560QEC_J7&
M[ERMDN3738U$"NZ;(*AJ'ZHJ$>(G0UXY\1)"LVXAK@L)(B2(D"#[4-4N!JN0
M(,V2(,+LK,_L;%JEIO;U,"^I]DY;-(0FE=\1R".01R"/0!Z!/'4B3SUW1BU&
MGA+UW\8G`6Q2;HN/S2U,!S[4_,H)-?I"/4I<G?>B,N@3M9P%-GY9-<!$J^RB
MZ&VO/M=5!N<6B%<55/#:M^'T49!L<L_H_DATMA?D*LBU)>2JE5^(55"KH%9!
MK87`>C`J/V%+D*L@UZ/)M;JZP$TFUU'YPG6#PZ1VK&V!7Z6.2\,"$>PW:E,W
M;!Q.C+EIFYZ/38"?<KH+G;V;5P0RU<T/>W*MO@&!EP(O\\MOE%\'4Z"E0,N]
MV>6H_()'`B_/Y-JV0+Q4>W6:->(>N)GWP'4%E;3,*55#7;;]_%J5%V9KE2^L
MAN/;U_M=='S_:?CBQA4XXP27$EQ*<"G!I8XP^023$DQ*,"G!I)K,I)2.4D%7
M7<&G!)\Z8SZU5P2%X%/YUSI5E+<^@?@+_N>F0K4%YHUO\C0>4KCV0.2X]+"4
M[89>$QW)GU')"7S/)S:Z=^.RMJ:M6X%!#4GKR1U%5:0%=:>..\<&%F%9W.A1
MK(C[/#/U&1N,Z#.3/E%,:<')\:O55Y^HY^-L"]=Y,CTVRC/Q)(,"4.>F#4_8
MCB_YCC2A^,P$CZTKL2J]CX\N?20^E1ZQS;%DX)]38KJ(4`$-I_2H%-@X26J9
MF[MNL/G_H71'TMRT+'BANX:LCCG:T\84594[O?$@_N'9]&<2D/<L!P$`R'`Z
MP)IY`>4Y<?^BOJ0[,#1_V9_!>3U3EVY&"EQU"N.JP!&YJPH<V8`C@>U2W7FT
MX<VETMFZX_F22RV"((=SS,.FU_0'HA-^Y<\<.".&1:L(!*_]!'QG!7'>1(<T
MB`Z)(9CI2?3'@NKAS(!!J442_J,-LSE/U)7(`M#KASF'=5HODM;M2R^4N-YY
MG382TC-%G84:%P3`0AZ!LCPOF(<G%>`QF#8[\_<6T?^Z>-!G#I!U>)9`HR96
M`I?FCD$MA'I,R>R=%8*4Z'QA.2\4"Y5C$?5P&$;#'N<%237U'<NGEU4K7?[G
M/H72AP=72I>KJ92.O;F.OHI>TW.KIDCW$KO[G6Q%+4W;H.F76P(Z$Q>B%0YU
M2Y2`7F/:E=:0\!1J<0F^*/ABHSOU-I01'ENP4^"TP.D&XG2U53*%9*Y),C<M
M,+261N5-K#;66);5I/)B`EL$MC1"S#0^"6&###G^7M-W%LWN1O_%]/ZZF+J4
M2B9*=XJ^>>*7GU0MNG.7?XG>Z#[PW?(C%IJ,8P6"\I^E`U+@;(BSY6=/-[F)
M?+4XVP0%8(/RTWC)?A/==#\Y%O%-R_1?ZN2X3;$ZBF)]==H"!6+)6.Z6GXA1
M"UJ<AH0]%333NOTZ96=Y5NSY"<4SL(ICV8FA2M)KF(O%?KTY:Y-%F,45E#WM
MRD.!9`+)RD:R*M)%FFO(-M_S?!*&IV$^F0:U#>G%I)9QFE:&,#Z/P!2Y`H>:
ML#T%EM7JMCU!TY/_N2:+4J2Y[)3F8COV10FI+L7D'9UK]LOQDD*$>;<])%;;
M9!Z+]!>1_G*.0;:",0K&V-Q0RH9RPF/S7RH)D-U1VA51:T>0T<YD5"*X6TU/
M(O?F/-0"D7PCTBG:FTXAL$5@2R/D3"NN0,N+16C\5:G(OJG8[A<1(%R3[I;?
MGK#).%;MS9G`V6*R;ZKH,=S<H*5J<;81&L!)1$&)]!L1F[(I_:;\SI<B!.KL
MT4RDWYR.5#P'NYC.B6EC/)4.([I$]P-BB62<VJ7N>5D<PZXJDG$$DI6.9.5K
M@$VV:UO@B3X).U1DXP@CH?8\"6&*"BP3V3@59N,4W(=FX_:/"P'C@G%]#)@:
MQU1*#RQ=YHZGRV!CGUL;`Z3,)RK=6\1>A=Y2C-@)9"S=V=)E\!AX?K)&=91N
MP'3ES!?$?N$_CU1E^+,'\"2N@0E(ANF"4N"XO.\6RSZ:`:PI?H%MCYYX;R6)
M&,Z"E<&``7>!O/0:GXSF5&5^7.Q,HN^4G]_P_ESQ3]*$ZF1.)=`\85$XE#G'
MR`_>>&GAFHZ+"57K-G5[?]>5OMFP^&29.&P&#-*<O(1]P-*Y5EXG_(B[IKK)
M.U0QQ@<_X7V\:S+EB3VU^HT4V*;/@>C`;*Y$G@'"'B[7M)G"%1#+DYYGCD1<
ME@EFQ_V-8`)G.C5U`'HG=2"P61T6%E@^RP(+L\6B;<"O.*$73#P3(.2:U.M*
MES"?3RQ\5NG(JMR195GR9C`C>U]WYG/8%5\PRRHS8=4FL0"Z\`AU\;2Q?9_I
M>0$VUX)=K4"S"R<MH<*-$.*@M0-,VL`9DKE":#X1TV(I9-N&!69K6=B(BP3`
M>P'\.EN6:>LN91V^*-%GTK^('1#W)4%UI0/O/)HV<Q'!WO(>@#EZ\-B+U/MG
M!,5TJ[&\U:]#L0P$'9X%F,51JE,VZC7\L93*HN"A>0%LPZ(>0#N:.=OI$-:)
MHRYU2IO/3=^G=-/:5FEZGPYEY76[K%U2W$3)E9QGW0>N/@.4.B<)D9-9A>)A
M?R&Q429L`O2*0+AYN+]?E07X;1%B(,4)A^JX0#Z("RR6!;(ME\K]^IV(JX2,
M!Q;WVGR34AAJ9HP=6$YZ/;U^6G1UD&_"`^DGFL-&?P+ICI]^^2GP+AX)6;R]
M-CW=<KS`I7?3J]3\7WBKRRO'\[T'W-E[/-I[\H*M2KVO](?_W@+PO?O?_Y&D
M7Z+!'D#`T[\#>.+F*?.89!K`4LBCHFJOV.4(_/"%3G]]=8VT^&_MSZ_7K][A
M`F%]$1?!/5P@:WBK@/6UX"SF8DKFIO7R=IFK;/=@J6JWO\Z'%?Y6*:,?Y)S4
M9/L"^!3:+HDG*2[?QK_RH2/M`I[=3B#!5HFCZ[[R]4`$:X$6<LM%#$C%B67J
MTAT(-Q?Y(4K2D#-(7\$N\8C.#)+Z-)/U0"]%-[D#)IN1![T<Q80Q<HLBD-#L
M`1D/MA1(;F#S)LN*,Z1A9S`8P/\/UTEZXDM$6G#P.Q'XL5P'DP?_&'1!XBQ`
MD+#7N]*-Y[.>OX9D4Q\[3.N4@D4W=9TY6QE;PU)'ZJ1*![N>]F=.X,$!>V]J
M[D\[[FJ]O8IT],P#:W2,JZG1,5*[PZKNL49-O,WYS74\+\'*U[SM.M,#GZ@+
M.&`Y/NH5Y0='J-U152?1J,H!2E=KZDUJ@7CVC_)]]&J%@0_*!EJN_4:D-T"K
MIX)+$:6IB-N0$(`-TF7W:Z-&B@WF'G]V014%26&`H>H$=NBW9M:QY^7KGI7)
MC-WAVRQAH'5[Q]]G*YFZ3VIS.=5KM3,85Q%(O(Y3M>+V=@?=JPDL[3P4YL2<
MBSS#H06HHS\NK4#S+Q;$9/8<F(;Y=<F8D2K4ZSHX:O%Z2HL8[_B\5<3SX\\M
M5SGOLHQV-[XJ--"JBY%M8K?E%FEI"^]5.MJH_&H)=>B\S3>[STU'S5PY^`Z&
M!N`-NHF1"5YRR0:_-).)MDPWK:8(UKX:;4%\]_2TX)[2&8ZJZ%S46"VX^1R[
MY5KK/7'9=;U+%SQ`!Q76E4!KC'K[[/C4:P53%IJMT&SSO0K`3WM%J+9=;<AB
M1YJEWIZ?R^`<U66=>#/)G"^(SG@UAN?@M98;QE;Y&V.KA&*\+ZM6NRJ0NF0X
MP<0J5$O>+ZRB<AVY5:$8-1S?OM$<11>[/Y%0$+DC]^J\8&V/A</_++T'7951
ML9GT$I;Z$28L\.!2%N6GZX'K\EYTNF/;E$DV`+8_BQ,?+,J^@W>=P&4"T5D?
M;GM06[FM0-D3RA<RL"5$OSPEHC_J:CM!^^%E/G&L;4`.US;25N/B-Z0(M#8?
M(+U':<,F<R#%\<E^HJX7XA.QK$RJ4#KB&I_S30Q*7KAT2AF2\@!LTP;3>-A1
MU7&G/Y;WS"K*R5XH$)T$GC;EKT+Q]!_`H11I;EI6S`@3I%VXIJV;"V+Q;$9=
M=P/&3\/ZZRQA+$%FF[EY&`IKG<%PW.G)RII,`YZY@%%V],*93ME"P#1.KR.P
MR=R!D?^+]7CHQ(]C\=A:\/7(;F%F3<8+]0^E.RQR3_E/I@;=>ELK:%/0YA;:
M[(WDSG"@[9M*&J8"L[19)E("%Q-H_2@!&(0+Y:UYF5@"O>GQT:6/0#GX>2SS
M/%+Z0Y\1^Y'R5)EX!1_PL2MB$X.DR"ZLN(#W;1;Q/'-JZB2:`)]8'4RR3#)A
MA9UQ69'F!C2(L0X7J*"1A>D32Y")().]1=@S<7D;:$"M1911KVJKM3VVZ%VY
MXVB#CCSL[4N4N]-*..G.!()#"R(11+(94LCF01DRPCH4J*]P50D)@*$@X_Z@
M"3GNPG$Y1CYC;J9IP6-Y1G!<#(,$_LQQS?^BWJ/P,@2;JD?@_/V<A["\@V<^
MVFQ=2_38C+(L]7DWOF8<&6'^:C"?$P`[C(.G2&#NL-;SA%BL8(8WHQ349.)S
M6;UP'2RH,2=Y#P"3`9!;5/<9%T*O_Q.P'!@\O@W86#^$*<:`7!/GB7:VJ[_-
MRO4==`>CO7)]^^:!N;Z#:G)]!_WN\47\!OFE$&L*;E>[H[(NZ4^W7:[6':VM
M7=RD>_R&-LU-&!C.YTH_\6T`$\L&M*QRKTF6CPDR$&307C*X=YWD?#^@!I&E
MAP:2B=)51/_I>O2#IK6?+I%CMBV6NAU<L$G]A07R".1IHA!J?)C[!@E3>)Q,
M<8*H0)?-%5Y"LB(A^`?].S!A]?GU_:KC62T+I2PW#O)\8AKW#TCL5]?RJ,DQ
MA<JX(X_*;YTL*%90K*#80F#='W>4"CH/;E#M:L?<YFN`=?@8"L2Q.]ZNQ/-H
MO=I<4RS0`FW)IMB%!6*+VAGV*DEA%6C29C2)+]35=3%OPC$A'!,%(-JE'E8P
M79`7%AR1#F:F/[#W!A5.BEK8VOD6Z=,Z0[7\W#V!=`+I,IJ9UNL)4['1,KGE
MIN)'QWZ\P%XGC9*PPB)H`WM2M/+]6`))6HXDP[&P%H6U6.(U]G+N:X=5#F+-
M'GGZK=#:A=9>J=:N=7H5%!466">PKGGN66$QGKK%>+^4B;R2#RQL`F$3;#$<
M!^*^42!).P2:L"!/W8*\V5#\16CQ0HNOU';LC$;BFE$@W3E*6F$ZGKKI>+6^
MH)6P!X0]L"5P?M#IJ^4W"!)XTG(\:8@T$W;CJ=N-5ZFB<4)E%RI[I1Y4@7`"
MX2IU3%32H%R8AN=J&EZN+2`L-'ZA\6\1AKV.-A"AJ`)/ML8K#SK:>"2L0F$5
MEB?(KNG4U$T?TRF"><`K4QN!R\IBSZADT"=J.0O6]\7SR2,5BKQ0Y*MD@J^Q
M:<NP?&V^R6A7(#AW:!XLT+@4-%8ZLGK>R9'5HG$35(B6&[E?';!GN<-XYE@&
M=;U4EPKIM<%5AS>L&*.(HQ4&S58F.!AT>G*MY?_*0Y23$=(GB'C]/AC2M0K?
M]AG2AY7!/J!V=;SSGMI[M>5`JE^4,F[>FD8-7)+2O#6)HVOMT0V7EY3B8_Q/
MC'[?IC`7WAO^L!YU:\72+6N%;%.==P<T_1GSN>F6XZ'_#?L'^KP97%Z_P%[4
M+S#510Z[8&(3-8/UH4WNJ)*6M`#G"U9!79\1]Y&&C:'[<3-GV(W#RG%BZ\(Y
ME5Z']57>+/>MFYHX\)28+DJR@,)T_PD\/^H0O;5-;=3!<[E3Z$I^7E?Z.C.]
M3?-E!/N>C1QA9%BF%2#,IJXS9VOB3>Y8[[W-G1)_,LPG_/3+3X%W\4C(XNU#
M,/'`'H)5W3QA=?JO](?_WH*-O?O?_Y&D7Z+'KBGL6S=97TCXVZ+XQZ5M7/*6
MW+Q?I&D`_I%'!>2B9,#3<V)YO[ZZT%#ILK&[TQ<Z_?75-6"!^F_MSZ_7KZ3`
M-OF7WQZN7[WK:3+\+UG;+I-FE_F`A_:>>-1`!`,\6%I8_["%*?(@L[#\:;)+
M22_R;GI-)_YU6##AWJ5S9"'QJ@:'K6J@91:U=<+L^NZ):=S:_V?:\-^P@7F\
MH.%A"QH/,PM:G6'IL'R7H/K\T;3I%R3#>/[1@<>DC;+'M#1!=OHOP'H>;3,"
M%R?J+Q2H`(@U7LJXD+/9-!=?U11XU=L/P"U^1V9Q&?.*NVDZ?^J!=TN-5J?)
MAZWN0E'9\O:9-`N\W)?^B/HEQ^M3#ER?UL^`;^-LV87]1DS;^^AX'O7N[)L?
M/@BFP/1F_!4DBF1QZJ&+4[.'NW7*[`IO;=VEP#NN*?_WU@;ZQ*",""]NN`0#
M1L<*35^R.M/)LK7#EJW*O<RJ#UO&MJU$Q47O>6U19-:\[MG'4#R::?0]4$Y<
M:$OD==@ZLGOY3'ULV7+O.D\F"-?W+]^`O=_:=PN*W9#MQ\NX(^X5+-*T`_@N
M_-&Q4WLZ4,1<C$>CK/0[;D'+S/YESJ2[<ZG_'9@NA5'A4?_EW@(2`NC<P+?\
MUC3>R(%2J:?TEJ3`KE/O=!ZW]A,(DCW.XT!9=K&\C^/6LW0<KJ-3:G@?0('[
M0J/6\L!UF6,Z6?N!<E"5L^QS\W3KEW;K>0'VB;Z;IC*+XOH4#TS]C==ZH*`<
M*X/!VL7NL("=D.8#Z.*VOCO2]`Z4JV-MJ.R"-#NN)[LW'`C(!?^Y2;I)W5/7
M=(QE!ICLY%`)/%X2<OO,?H3IT-LJE+5\KM-3CS0=$EQC>`7/1@K&!\=]H.Z3
MJ8-\=Z\L8LY3F+)5&N>O5UD28/M,OI?)T]LJ8]<L4!F,2[1Y>EO%Y)IEJ>.2
MC)[>5GFW[B27Y=V!5D]OJZ1:LX!1OVBKI[=5\.0OI1JKI[=5U.2O3M7"HRK;
M[.EO%1_Y"[Q0E6/,'C1![FS`_X7CA4#G2KN2K&RK.%BS,F6T8O*LGZY0>Z=_
MH$08#^2FV3O]@X5%?]M>:K-W^@?*EPM%'H[[33)X^@>*I'$Q]DY:[WT`[>IN
MNL.2#Y19ZS7N+3.78J+U#Q1\%Z-1W19:_T!!N:1<[V6@A?@5JHJ1YGCE>&FF
M>:"(!)-3R<7FO-G60RQEK65<;H,#!:.J#;7U.+LTV[*^LXBW@,7XOU)WGEW3
M@2)183PYH^WDSU2*A3HX4"JJ\FBX$]549Z(.#I2*X_&2_*C(1!WL(O%N<Y%X
M7(N-.MA%L.4LN#^LR$8=["+&<A:HC)<O?`JU40>[R*6\@UYR`A5GHPYV$3=Y
M@`)-H1@C=;"+8,E9P84RWN5N[B![<+B+5,D[IU%H.9=M#PYW$3%Y0!OT2K8'
MA[N(D=SC7+JAV\<@W/V*;KB+:,A;GJ:I*\NK[HIN>*"$`$8X:)K-.CQ0>&B#
M)9=!@VS6X8'RYF(P[FL[.?BKLEF'!XHHK:_DZ_E56*W#`Z48Z*[%V*VKJ/@%
M)*!KZCYEVF.RT@.EG:*J6W`_.V$I9O7H0+%XH?74G1PS91K6HP-%ICH:EFM9
MCPZ4F"5;UJ,#):6FJH=:UOD7M;DV]NA`@<CTG^V7P^NM[:W6_^A`\=93^H=8
M_X?>KH\.E%C]T:#7O.OUT8%2:ZS*6L.<%Z-#+;*Q/%(+\E[`UCS',@VVJ7OX
M2W^)HWB3A8[7^E7>862P83Y%`<@8/'R!,<=O%;F+$<CLBRF9F];+V^5,IKV3
MSB;')TOQ+_ZXX0'Y$\<R5GJHF'#\"PN&<:92!CZKX=&3O$#IPQ*9BH_%/S03
M%L/RXVUCJ#BG")8>"U\P1H4A\QA(SD+(2=05/(R%CP+T,>P=H_J]8.*9ADE<
M$UO`?<#0?)C$)0L:^*;N2:^OB$T,\D8"7.U*KZ/$6U7^F3W+?XV_57Y^DS?(
M1]_H=E@DO[MP7+9P@!`NYQM0#WSZ/Z!?PYEWV+*NF?:1'0%G7QV!S]Z5OCH2
M@H.G("0Y!D["HOCN@<#3^Y5FY(EUOY,FE-H`Z$?;G)HZ1OVSWNF6!9/XU-5#
MF/E@D'M$YR/B$Q-B(9\-!V*#4,N<PYF$"]33*+IO"/\F^L]RBF],]0&HS6'B
MA!^/Y3/B#0`#/.48"O4QA%[%#"$DZ51.O+<#D\`LF`5Z'5R.JL@H7`/1F6<`
M_79Y>8\I+]%3W+6;Y2)[3NE29H("@OJ8O3,G?U&)QEC+2`XTE_F"$Y@_(Z#/
MP3RZS^:$53@NCDWF,4<CS#'2B9-T&!-S>20*'S%JRQSG^6![2\OQ`I>AB\[4
MAT<T8_E8[#DK[3"QC]@QVY,>\@_,I6*M-CE8YV`19'A.`HJCYN3Y45%Z%.8H
MQ4?'"R1(Y)FX!E^<;IDVS&X!;\-A6#-K4'FZTJ7ESYS@<1:RS=0Q`>`FZ(K'
M9+!UJ_S+=IXM:O"\+CT`M1/W]Y2"2:@Y^H`%+Z!#&:"E(CJ$.Y\&/AQ0!Y^#
MY<"6O,""5]FS%E^)]2+A/[AL^-,PIZ#=QIE3W@;$VI<-9YGK&C_QW?1#=!:W
MMN>[`3L+SK03?JR<$3].^MUQDR?T9TL?U_<(.E6-+=*Y9@0P'A"1I?A10%#`
M3&0*S]'%`M!LY,K@>8I>E'RIKV\!P;E)*B$QUG7B<4T8P`(2`$Z#_!-((B;*
M)!$R)+T,N\IPFU#;@9519)2>B1_P%4:^5O3"NG6R[3,=*;L6X%NHTKDO$7O:
M=R$F$!PE!@.5O;9,3%@E)D_4D0!XG6L""S5!C7L,3/[;U''#/%B^7)WS460G
M<[#6@$%%2:8+X.H@1Q@G@OU2.N>IIA2@S*1(5_JV@%=UY'*H%K++IU!!]%W'
MBG@CDWG(89W`!S65;I&W^&HG5/<12I;Y=Q#JBQW)`TM3PBV@UHK,,11W.%UV
MV(X4PBOZ?M,I@JB"_P_05F;"QJ"<KW(TC%$.-Y$D`?MI_`R\J*K?>XOH?UT\
MZ#`]HCH;!R8TT<0'^6A0*SP@(!X.,R8;4V--*#[J\H#4_\;(#?MR[/!PUJ01
M;\6RE$C%41);@LE->,FE,Q@*40;T"2^S_Q19/9M@1G`U(V!2>8*`"1%H!33P
M&`CS0`>Y"WR&D<<R5&T'Y@-0N`Q)(AX2XFJ*%!/L6WHMA:$1FH6'GH,;^TK+
MG23BLC./Z6NIJ.)USHZQ>D8"-`K>3L&E/I&IU2(P8[KV$J7^&8B.F>93)W`C
M9)TZEN4\,Q(&E$>ED.'\G/IOI=?FFV2[0,5>0!C14G0M<A&&3!<&?02AS%@Z
M_6%ZOO<SO)I^%]@1O`=R*IQTX3I&H'.-]B>@/R^,E6&"SM&9A#78(.E1\$V/
M6A8N%ED=E5A1@1^H4+L@I6#UZ$``ZOR9<9K7YE/J;1TVBG4:(IF-@"&>@\^_
M,"47IMQ,LH<=<'/Q)2(3QB(?0X;-I,8<384%<#EJI6Q>8A/KY;^\?D0$;8I8
MQ<0$*Q<1/8ZB;H(6(W-"HR_(@:-CMC!E?E]N@W(/6\B$<P>:!Q[ZF*)'4?^#
M1YFH0EEH\=&R@W%Y$E$"7X.7'7;[@ICILUA89O@J^UMGK#\DJ(C&F.B-B0?&
MI02$4%1`(YP1=(UI6(Z7D0)L)%X,<X%Q*1::GCKL&F2NBX8BD9BDNB`@@YC]
M:":#I4XN<ETB9,`H!Y%K\7)=N!*7@E%H<_L6"3B<9G4MW(V87>H+'@Y0/P!^
MSK2[<&LH,%?V8G([&R".7P.=3W@A#A@5_8>PDU#90SS;;*RC2#TO@OP0Z9R1
MD4]9*%I(/\#R\'<':\8HL:\&-!P/F;JC1Z5=&/J%!Y+X&\S(OX'GG]*;F%!P
M)O]!UOC$#PH>,]FIQ7P>3CSU"N/Q$26".$E1%1,&"5)VI=LI?A6M!M<*:J*Q
M%J_]/'LL\SH7'\C\>?D;(S8VPJ>ZTA^XI;3''M\+F&!@\/&P.(SIS=(S39D$
M64%GSI;LI37E8OX,[*C8(1[/08WL21F12<#UU0SXGF'`U")@;OY0:G)@3P`]
MX(?QB:$')^+%X9'8+[DK/"]:>D\?3=M&3@XS9"G&W$0PA+M,T4)?I/VV:5:;
MF&$Q167U$M">9HX1^F&]A`A!/,Q`4[H`T\*59O`?XNJS%RZO-@\5.X#9F`S=
M0[^:L?0"HD"6!:2\C@``PW$OO`75T2Q/$7Y,Z^F+JM\?[F[2-U191M`!VC!A
M(A>CMKW0"L^CSLQR&#V9#"Z,%412V$(YTPDQ.'X:*>J%^J&UNO1")S5?BN*D
M"3HX;?*8Y@>XE24^!BO`X<D3,2UD#CB<Z1H7,#PHB+D`^7J_`1X,L73$&SX:
M[@06[B7^:7Q^18,-\&Q`Y-K49/H/6ZD-+\-D;,AH?5WI<MMPWBQB$$P*>SZ#
M>%26+#EM>#'B&A$J\P&('QYJAG^R02/)%*D'\8$BVV(GX]+'P"(NGF0N?^=J
M`%\BL3Q00KCC&F@PU+S@W-R_X+AA];SR6>(S@(4D>#N%=3BNE]7TT'C``\U(
M38!CRMD]=XS0>P;/+VNY6478B\N`A3)7;@(#K=(!NX]]@/<+T>4YZ,GH*)*F
ME-\I>139'#O(=#.**#JH@Y7K`*4139+ON.\I=<F4_,1T%.>%6,Q#P_R*+Y%)
MR7QW*&9=0/.P'AQ:?F3BA$ZH+,ZD[&3;L5TZ!<G)%(7T)OBFT^@<UJ^+C>M(
M;##74\RBTXB)B1<>1SV0^1EU&MC6(U];N+=D32NK<`)_\T*89W0^P8OTN"3A
MLD:P9O:UD"%;#S&]`N<I-.*0OR1^T=09I/P%)%3UB9Z^GT1K$^:S47MRT.UF
MSB>!Z[&#T5GP(3X!^,8<!1WNNPM#&,*143@A8UHS>LI(X8Y%/AV"+Q;$@%)X
M;XH+#@VF-.!"B6RD)T]LQ'@=&X"Z@O:10.5&5(3XP<*)'*Z@,CS%KO/T`"97
M\-&5#K8>",8L1H1K-QVVP83!IP;PHN%13P!.&3+YY(DYNS%`Y$W;NI,,*&,3
M[XFR?0/FQ@^G0VMBI].2CRETIK+A.*9PN1\>3EJZS0$,7L#,=X;CH?!<9T^F
M3XZ)&[;7I2U&AH0]P^?2=3`SY@AL:)[2TTE((,`3^;$DVE7@,]<Y_Q$W$M>G
M/'2-RYZUW2`67FR#D$8U"VU)`FI$:KY<7]M.)Q$[T6C&O8!X$H((?^-B/&(6
MR!CBJ_J4=,ESVV5/:$F_,4(YGT%^KC$0FQMCTL2<!JX>AA6AUR?!4?8DL/WT
M5_$%"-[D8[17R#2`<BD3*8L`_:!<*W#WD)"Q^<XEP4ND=^5APD8/4_9^*&52
MQ@QXQQB([&7@/MI-6`Y>9YK6EGKP_*&FFXN1KL,(]!%%F,U0]3&^!HY!S@R8
MC$A*(F524BDE%]@@>=>GD92,KP_YDRS*)+(*$>W8+--E21BA)M,WL@%YH;,;
M<1Y7/HT^V#PDR308ZH<Z5GB?S:-X]KVUVGH%M4O>Z]TB3/2]M1%=@,XP7V4E
M"&1](O3IW6&QT(\+!BDI#:ISN,CB>^=."SV='AT2VK+'`57"+`4A@UMRVM'Y
MPG)>*`TOX\,K\Y"^4]?@L?K*%#S/1+G)KZ<B%2KR"/%8L-<!B`.T+9F>P--_
MPB??1'8P3^R]L,S$TVE3MN3$BP/D/04E)G`QY@$]P7GKG#*')*IOT4PFLU31
MKF=R/1'I(?QBV1EZ5R,0ICE::LMSPCT"2ULF4S]\9.&8D1,G1R==42KC&X!0
MMTKK.+&1G\2W1#KHX1"8`%/;"`8>A;+L9NAL!DQD3QX!E@UK.@I0:?,BB=Q;
M=:3G`7.?>)).(K+HCY1SM*+CX8.B@&4[,L*U$PET3A^/)!P(E]H$1TT]U_YQ
MSL)TB7R\T+,0Y5B&/X8\#`X&NPI$+#*-&.ER_0M`4D"\;AB7>-#(>()9A@6$
M!+82**])O&U(=CASB$5,2VH17]R5?/?M3;"_^I35OV[`?H-]8!85&VMMO%#O
MC'2MS\!KL!2"!%"1&%C.0<L"-`*Z0ST$@_`08\,.'^A^(I8>MA*>A"$4$4.(
M7YAPE>>9HFY#C0N"MOXC/!#,)SQF,@G$17^-8T>DFPJ^FR;B#NBI$_LXL[X'
M?"HS!$WR`;O2S4KWCQW6E%H#8TG\:\Y#DIRD,.8X=L%1=KM!?U!7-[T5L1H&
MS&<Y'`_(C_D2/A&P-'&:PS5][->(CRFRVAF/1]&Z\"UE,.BH?37Z*H(<NU$$
MN6?[,_2!(!P>0#K3>:;5C";S7C-L)*QQS!SSB^@.F3N>%47I#)1>9M)1K]-7
MALN3VJC)'CEG5[HVK0#W7B8.KD.;#5B8OE!/!*'OLL#3EPL^%+^7#?<0.H[R
M)^+NYCDH4^P2=KHI1KB3!*S&:XK"VK>]N=JK)[X\2]%>B*CIW2>.BCR744;<
M+D"N<"D<WF(`N%!W9<88>N)]YG1G-ZMA9@F[0PU]?2MDR.X^@4CBLV;FD<ZO
M&4+LR*%8(PF5REMR@D]AV9WS4@CO4S'U1H2>J9AF]!*%WO@XFS0Z@%"I-]93
MYH3R&'8,`G0DSPEOAS%&#R:]B"=D$8->Z.H',YE?3.612'C";]Y6>4J\050X
M)*HY%\Q?^=:B4__GJ"_PH#O`-J1AN[.KNX\?+^\?`.CL-FOAT6CFL'F:TE7[
MO`$SZH_NKZ\PBY1:V%T3[:CX<]BWD7V.N@</HJ:1Y;8Z[O>/;F_9SV]T7%,#
M7JT[/+YCI[:^=7.!KNX-FU[JS_=LVH;SC%@I*0M?8B[[38WZ]H79N#M<UU[W
M@)Y_^P!ZG.XWJQ4.]:,-AM%F>T$)+6Y0N9(3!J&4?/@,:D/RZ1-3D9+/-Z@K
ML56ZTD]\\_F*TU8#I#@*4KK'\X3\EK<E$A#_LX+>\()A"H8)5E`MW!*F;2F'
M1+.O0A8F</H0G.[*ZX`FT'HM6JM",I^\9,Y8F!?<AYP#G=#V;K7(+DH).:S!
M^,F(899IMX6$V#,"6RK$E@8+N"8A3'EBYE!\J5^&O+^\^K_?OMQ]^WS]5OI_
MND[I=)H+CLFC[EB.^^NK_W=U=7/SX4,"(-]9E"!G"G037VTH59)RMJ]QRE;"
MKXX_A4K96F'BK.AM%\^0"L3#84=5QYW^6!:85AZF;1"%9X5L@XX\Z'?&6J]T
M9%LO58N'^(D)WPUJ1^.EZA_I^_L-]_5U,KNFF`%%R<LZ-?,"44<#YC0LGS&=
M(F*L%V\"-X0I*$S!+=AULQHZ)I1Q8?:5RM%Z([DS'.3<$@H\$T9?P:@F:YU1
M3Q$F7W.%;)M-OJN<`&NAQ8L8G?H9G](9*C+F;PAT%.$UC<#(H:IT^MI8&+*M
M-&1/+GRF91;`>A:F=M4^@-1P`E;^O`*IF@>Y@AC;:5@=XTZO/^B,>[5Z=`6"
M%VTE"QQ?NKL?=K312-C6.\A]_B<Z6;<<:/F%U;IR=75D;VT)%9Q,(<WM*:I8
MW&[B/(6M2=.E5%G#D;A3Z937)?D1M;;[!VQNB.4]K*A`32IQ>,';X&*_/E:7
M8%/6.D^+SE[A.G/3\QSWA7<C[$3U`0!R_PK2>5\X0`>^LUZRW['$YLO@,?#\
MY8?C!E;I&5G%PDT]I98+(\25"L(N*F'U_B?BFD[@1<4(HGZ"/J_ZG.J>A;G!
MZ4XJ80GZU1']F>/1['A=Z=)C'9A6CXQ&)1I\7A0TM2,&22P-R8O<124<>'XN
MPX!N`BKI4HI*LN8TW.)#L7K4894[3#HFWBQN81F5/`Q?YB^$0T0%(C/P9%G+
MMDWUI)HNF]5R6&&`#4W&;N_O\.T[W7<R^,70X+5'J?099I<&;_:M`;.EA,M2
MO3U]1HW`HG?32SC(B-0>8DJ+:F?PWO;S1>#SBC+3Y5ER2L3TRRD1LR>KV<[K
M*LWC/RSA/,W\V1>1V!OT!HL?U62@]P8A+->;IRLR&]>V)+/37T5B.OT=E\CP
M3;-S0$1V9FLRV40ZNTAGK\+S5W?2G."^@OLVC_LV]]ZMH>Q6Y,:W`*<;?'G7
M7+06N?%"S)_J36%#HQA$HOW&JPZ!+2+1OCD(T]*@E/8(I#-(U1!9^[6'U8N8
M^D>1M2\2."I$-I&U?VZ2?(-"U'@1+4H`B!(`S4[S/D7$$"4`A)':"M%V!D:J
MJ"?0!)EX7C:"J"<@S-&J4$W4$S@KB=UF8U04)VA&0,F)W(\5B)FB.(&(;VH6
M1HKB!"<BL$6E@[;;)J+208OXIJATT`X$%Y4.1*6#.BH=L$\K><S%IR;SU.<I
M\>G;SZS3^-WTWB+^U''GWE?GQIYA[O?7&77)@L)D>MPH&Y8`*_$??#J_PFS9
M),=Y\$HRJ&[.B>7]^NKV\X>U*<]28)O\RUL8Y=4[]9>?"EC(4C(W&O$SQS*H
MZ]W\'9C^"Z:0LV\?%I;I\]@P#X#T!4&E)-L8IK>AY6[B^R=YK*BI?=P'+GWU
M3NXJ_5[JT/9<0G8#'XCI_DZL@'ZBQ(/AY[#K/TQ_]LUV)AYUGQ!A;FTX:>\+
MA27JIF6R,_^"2.'"F;\GGNE]-,D$?O%?;K'Z0NJP1NE=7N1O$\[J>_IZ@F%0
M/.(GEKKX_</O*3A\>[A^]4[K#6193N!0RDY2^,N6Y5WZOFM.`D9(7QWV';Q'
MC7OR@A->8IS!(YL[0RU_4&2!U+B$HR"/-$)!/N9=JAQ&#+GQ5C17_ZVE8,*'
M>O5.&0S4?H3JE:RY+ABILKP+C+*L(`;3J-=7AN<!)F47CID'(UD=CT?G`2-U
M?ZD2@TE1!DJO>C!%C.](67TY=P)0R&)(:+L0U?=4T/-]%$/%9`[GUSE@&LB#
M_EA+":Y"UETJ*'H[\I?S@$9_%Q(Y`!1#51WWQW*;0+&K#GH>T!CNQ#'"&,RU
M&]<&\K!5]##:E3N<W,ZWZZ;:"1ZXLI.Z^9W;8-]@MV"N@57CT<M'EW)AOQ86
M/5D;]90V`6.[4AEB_YG`8U<%\O3(8KO"J!U,%B-Y.-#:!(SM*J-V#%FT#A[;
ME4;DF4PEPG&I[;&![RUB;U"1E+XV;A,4MNN+(;,\=4!L5Q6UO=%!&2HR\^6T
M!PP[J8[YQL%0&XW:M-6=_)CYCI7V[5;=KB+FN]K&O?Y@W&N3V%=W\BKF'VP+
M=[NS>M<\WG5-)_ZM[?EN@,K%!Z*O;"ZCP5TL%1&^C2^CAIJ2=6A$M;?QPLF[
M#NB=K?:PZC:\T5O9,K^T&<IRYM9FW>(V;>$6BSM1S_]"\)X+_F/`]K'D$WFD
MR:8V:V+)KD;;=S7B]<'AE<'*MJ([.5E=MZE-RTT[O./+URMV%>;=VAQ+V$V4
M\6WAV-$M&9S[\GV9=VD;M[`FDUCQ1=A7YGY>KA*MJJ=1);K`2(++;97G>?ET
M#G(/:XBS4N7,/8]O\GRJ3:7'LQ7,X4!Y)?>H-#P-CS,:(I.MQ<\W+IAN\E.6
MIG#,&$40Q&^%R\"B\5XPGQ,7MFA@6?VI8UG.LR>]9BMW`@_&\CHX*\505GR-
M#;^`[82?&!%Z;]ZNB:TX)C[AF.+;(WF\3_%MN7MH[6V8J'VUMWNC[F!P=!QK
M+S_HIZ8<)[4[/GI'ZIG5RM2ZHYIBR4NH2FI54BLSS7'9E$GY[#7)LJ75T52[
MH^-K*@B4KQ#EDX+S:DO1'W7&Y("9]IA\!'4UAR22WYUI]N=OV*;'>@EKGB7?
M\\2WY+V'_)(K@K`$89T,884V67+&C-(R9+%$;<O4U"#)I'25`BJZB!+/M>OR
M3<N2*D_);U?9WB8K[DTJVUNB)!<(4X9T%L@CD.<DD*=$%>B\,L4WZ3?%UF,K
M3@<J\LIAX9HIJT"5E?++-J_7L@I/8RR7/1;)Z`I/X"Q<DRH0ZQ1MU.D-<IH"
M52=B3QS5NEI3,X4+1*-_E(Y`BMKM5T>RVWUZ-9)L=U!^^1M!KX)>!;T6`FNU
MDI8(:XV0VM'VW&R5#59?XXV03\359QDCI/P*JLUW]19H7=3I@"T03\9J1Y/+
M+[/3`L=<;;A1GKOLA'15@26MP)+^H$X-2;AIA9MV#PWII3'ZT8E;XL))&_%'
MI=_11E5<!YRKTZ=J5&N'6!:.1H%S5>/<N"^<96>D,;;96;9Z8U_%/:IPEK5-
M?>L/.X-Q%7:"<(.T6_9UM?+[[`@L:3F6#*NH;B]\9<)7=CRJ_BNPLLZR\CM_
MGHRSK$%)?8WH.])D!6\XZ(Q5$4,I7"658EVOVQ/N.<%03QW-M5ZME\/"(]@<
MCZ!(9:Z:-9;6Y^Z$\IJ+%.DCN3,<5&$E"2?0B:6AMN!(:V`SZY,YRF4RK<KL
MJ.%<-B6'I$YFHY)^Y!$U.65$Z<AR%2W.A9LW7YT]K-K"`3PE:62L#%[M1Z85
M+$H9-V]-8[EY:VHBG$8-7)+2O#6)HVOMT0V7EY02'OS/_-[6E=163Y5QS[R-
M!2[Y%-<!MAB^IZ[I&.&@^M^!Z9E8Q]]+:K-O[Q0C_UO]_DGNR</OO^-HJ9[5
ML"M];:>!<5AX__!%9DOROP\\TZ9>^@G>TB@J=Q_"]LZ]#<N=9]N9\E^3C6_O
M#'/@QA5MU!NDBO,7L_#4B><,N-*Q]8/C7@:@2!%8[1=JT/D"'P.\2M`N+/,>
M`V1[CYBPX\1Z:'S_1'Z8\V"^OI]4/X44A>ZC7&39J0'A9MCLT%VK2$PI"1+:
M#CT)]P3"4N>]*LAE:<![QZ<V<EM8ITN)1V_M[)B7^LRD3ZQ7&G!TZOK$M.]=
MJENF;>K$^F1:,`Q(CX2:M%V[U>P'K.%@K*KKR:>T?96+4SOWNCF"\XR`*<O]
M=M':3HT.M\"%"]>[*8LF1J%6B]PJ"T([=S_<`4*L.`&FW*U7:8#]C=H%H)UZ
M:.\,H)>-X%&4OC:2VP6?G1MK[T%BZEH(]8%_ER3JHC&C5^_)"[YP%;@N3;7>
MTH:[M-XZLNF6LM1S*W]-FT5T;/C<39/R_KR@_X.?[BZE9?16M1P>"=N*.I[!
M]KJ#\7H9O&WA16U[7-BVUS.^YFV[)Q>X[7QVUL!-*X6C^"J/6MJV-JQ_VVIA
MV\9087QA\ZXQY.W874<\+\5"/SKVXU?JSAD##7E@LLF=>B$>T2^0<615EI=X
M\I;U93<3;_VC22:FQ5I$?@*#(G!!.-E?L&TD.G+>$\_T5OO_]7JB_U_V`BX%
M1FD>PE$B?J;%GBT1R8T@*TT0M*S3WKKV>KNVSMMKST5WT^L/]NNFIQ[<3J\_
M"`^\17%KVK`K'W]EJ@V;%#FC=@<GT`-I_P"$T?$!B!A#4&9#(G'N#8OJ[FG=
ML5I+1%$O$YDV*ASJ5OU-Y4)]!7V=7O(M\=G:XA977^C"`:W(?DP>N09],/GT
MS0O;S%74`DON'DY&U=).0X)KA,P5O/>PF,&U(KOD:,Z2Q7PUO/>KXQ.K0KXH
M<%S@>-4X_N_`\:F1ZE/KFCKOAYDH$&:JW^RE[IM/2STT/Q'W+YK60*;.4GO.
M6P,O;75.3<G7EYZ'[V6^>_V1/M%4C2#EC:!`08$G3($/,*\Y!>*PE_3V.W^V
MW#3Z;N)1]VFUB^VMO0BV$9(J"$D0TED2TC?;.8)NM"KI1IC&+3:-FY=&71H3
M;E>3UK8PUF9EQPKD$<@CD$<@CT`>@3RM09Z"%>B69V47J!T76WRS.`WZ4),R
MKSJY)SE3Z8$N?!9PEC(!Y8Z$`5[KPI$JX7TM*QY7)+,KH_EI2_F;0!"!(`)!
M!(((!!$(4KD*71B4A*9]F!^Z0!5:+46%_H.X+H&AK#`;X*5.C;DIWH)]^=3:
M$GQ[6/"M*J>W+X"4;K^`4/1\&#6DG%TE)4T%Y0C*.37*X1@V4A7U9T%!@H($
M!0D*$A0D*.CDM#=QT74.%UWE6.GITI62AX4BFF&PM\S_V*#PX$;T1RK5Y5D@
M^JN=T:C\GND"SP6>"T5>8+O`=H'M`ML%MK=1AQ%7P8V]"BXM):E`)&4%%&+3
MTN1YY>?N3Q0]W9KIQJSA7#9X0JOJZ=9D-ZK6D7LCP3($RQ`L0[",5AF!@G$(
MQM&P<Q&,0S`.P3@$XQ",HXU&BHCV:&RTQ\G5!FKW#48-M1A._^)"H*)`18&*
M`A4%*@I4%*AX;J@HH@`:&P70DII*UU1?+JFDL))*:JTEE9KB;2N0U^WA56DO
M0Q)'*HY4'*DX4G&DC=$$A1NZ9C=TXY,.&U4:J&4F='%WJ877.6O5]6F1=Y^%
M0[+)MYS*J"?(59"K(-=VD&M#HID$V0JR%60KR%:0K2#;$R;;*I1C<0=W#G=P
MYU7NJ2E>X`;50&AQ6Z<"$;;?5P1>"KQL'%XV1#\7^"GP4^"GP,_6X6<5<EU<
M43?VBEJ4+#IM1URCDH8;$?/=*O]?PW*+MQU@$0G'I^%_'&JBFK'@4H)+"2[5
M9"[5$.-4<"O!K02W$MQ*<"O!K02WJOWX!+=JBP78V@@4_B<&/\2?#/,)__[E
MI\"[>"1D\?8#,=W?B170CXGG[Q,E7N!2X\[^0O7`=4W[\3WQ3.\K(-Q[R]'_
M>O>__R-)OT1#/.@S:@06O9M>>EXP7_BF8WL?'#<>^M*[F[XG%K%U^C"CU+\F
M/CQ\:_O4I9[O7<'9F79`C:_.>_K_4<MX__+5);8WI:[C/E#WR=1A!3`V];V[
MY(O4@N.%2:8!F$D>U5X?+P9L))$O=/KKJVM55K1_:W]^O7[U#@$!<(@`C:AS
M@3CU5I&["&7VQ93,3>OE[3(Z[HFKV[R\JK;&R;O^J(]!DY`0>#@,?Q\A=,&0
M\:U%I_[/:;)F7T14,!BIZ'T/F<S5W<>/E_</L%'`;(LL/!IM(R0@A2.^XQH4
M\%Z&TZ`6WM/@R<6?PPL!]CGD-C!-"+46W1[TQUWEZ"O!_KA)P:):MX#6#%L%
MATZ1"6R1'/RA%MR##KI:3?>@@^(A#0--CI+6(V1M[/,?-WQW$\<R8OFML&D>
MZ,+G!3)P/E?ZB6]#DSO)42/K7A7RD[+$O<!\@?D58'Y<&2:+^$H6\=4*$5]9
M?XA['$C5F-_.>(,R-8:F55PMCZ&VJU!;DYEDDVIM"'P1^-(0N75>07`;A%*Q
M95J*$UP%NA*_F-Y?%U.74LD,/5.22WQ:NGMQ/;LK/O"P21Z&C?RM\#3*PEE:
M@9BG=LN/#FXPEA4(R7^6#D>!M7'R;S?'.*U.M)]2SOH.:'MR&L4&U:SQJL+-
MCP75?6I(3XY%_&K2B9MO%17(2>NT50K$DU&_.SY)Q#@9D7TBB#;6NN7'0=1B
M9PLI*^SV+78[G1/3AJ-A`1\NT?V`6!)8\'/I-4S\0HGKO3EG^TI8\=6$HG7[
M`X%F`LW*UBF[6OG>HB;;W6?F>3\).]DPGTR#VH;T8E++.$F32-C*Q^&*W)5/
M$B^$J7Q^>'9>EC+_<W.:08-R!++)"_OD/WRSG8D'0^-6;^U%X,//CJW#6P3W
MDY.%,#B)+(0",>OKC$I3Q[*<9S38>2;"PG50._`D(KD9@&(#/6)EBM)(\_!L
M).)+4S@[I)Z`2H&'XWVD3]22-)CQT3:GIHY=5X+4H4DFGIK'_`+^S`D\8AO>
MFW6=^$I)W#@L^6*H]*M(OH!IVIE\<;Q8%]D7:Z2PB$'?1=W9HPI=0^/1PRY5
M;+8X'/WC^FK)(O]"X/ZIX'ZZ3GB6`!ZP:'C]-`$&Q?%$(5(SZM<G1&Z&B+4_
MAH$V*>Y>X([`G08*M/.[.:KL2KB1ETRAUQ`=0G%.;7S2FM*15%DYZ_AZT53L
M:!RKH*E8ORM7=^7>;_`%C:H*:A74*JBU'=3:'^349JE.6:P=;<]-IZS,`U).
M1\!;SPN8MNA,);K2';#\GA?-MYEKBQAI12.?*JOC"EQI-ZX,1W5*1N%&.54W
M2CF2\8K)0@GF2,)JA!W6POO>1E3_;@N/?JT-"T#RKC;L([6V$M$+A.8!:7:"
M<%I*..,BPJBW$TZ3;?]J*>?T%*LZHBDJOG@JOT1.\ZU$<0O?#):MC'H"&P4V
M-@0;JVB)+=PCPCUR\A<'M1N0IU7XH17,LQG7$`+SS@_SM%[Y16Z:;/.?FW1O
M^7U_PVXU&FH$B?2TNMGJZT*"'H^YAR@/-<4%@T#UM!NJ,QZ)R(B34`Z:9OJ7
M[N=/VA4FCGZ9.?K+CX(]&3M,]$IOSKUC.WJE[QMM7U^O]":'ZBL5A.H+)B68
ME&!2@DD=GOW7&8TJ:670?@\C_W-SW<4RRAMF"RCRFHOQ/->FIUL.CO_9L=UH
M_*0BXO"59%#=G!/+^_75A9:MCWC+ZR-^CT<+ESJGMN^EQ_O$E/!74F";_,UO
M#]>OWLG)OG=:578C\,O4M$'3-XF5@E;.&,EN1M7L9O>EK2ENR<'!RB,J7QWV
MKQK5S_0NYTX`Q!MO:KS#IC8L=I])MR]7#=]4UBVW+Q>_W'63;B\=NAN(^TI!
M:]YUYAT7OAW8:DD+WPWBUW3BW]J>[P9(0]]L,G=<'X2'@0207:B666@_GS(_
MR4--^7[EV$\4Q@&V=^\Z<]/S'/?EL^-3[SJ@=[;:^U=@4WBCET^GFHS_2_:X
M=9'9/5T1;W9I&_C/S=^!"4($V<,FKM/O;=N;FL]SOF093O(0X_8A!H6_71'7
M?8%'O]`%+)\:_#AREI4/%&49*CMO\VCH]'<Y^;KA4Q!X/NPIL/J#@P76,G!N
M/!^&P2+-\>-K=__]WJ5`TZ!S//B@0(2E)N-">FM0:*!E0+3C7H\$T.'ZR2[8
MH[4.'H=K.$<A3+HB(ZO!N`4X*E@--4!G%U7I>&QI!S`&NRABQ:/**F?MC6K8
M_"X:W=&8T)"];E4"=]0_RA<AH][AX#&H^?;&]F'P*XI]Y:Q;VZ`__H^^)(!8
MVGJZO#_,J_2TGJ8,?OEI[4A'GD.OH',H7%(=`_:#H=&O`ROW9<W]OE(#:+9J
M?04@2CL@L56]*P%)EG<^U.J0SEL5N>-QH)R-IOPS4>.8+Z;WUP>7TJ@]S!<X
MB62G&:5L+8O>E[/=P\J`K7=E5<EW'FU:W)%;&LI;MJ0>O!M%+6,W4>.WW^/^
MZ-G]**4>T:@_WKRI_.4=ORVUK&,::_UR=W0=-NC+[D<KEY+D-6[838L[=DN]
MTBBIW-U\Q7[&\2[ZQYW%N_OAGX-/JGJ]VXIQ[D-7FM,!:T<0O[L?_:D5LLB4
M./O#]&<K]UQ>]J++RUZ+Q>MB8R4[VZI**`<ISZJJY*-2D;NH%%`[:!Z%6!FM
M!]1.WJ1"7(=M!]5HJZ])V=\@.3D@;?5)J<=;;:T'TBXWF@5X8)L+IS4S8,(S
M]1(X:9O@='T0,@U'A<!HXP8.[_;)4\=N[6^V2XF%%[B_$=/^Z'@IH&STP!VD
M3C+`7&C#?,@<M>QR0;'1_7:XL<#AL4XG:C`\-OK<#J.7B['<.C!LU))3:+$-
M%M\__+ZBU8Q':QA(@?!(&A=GXSJ2?L+)7D>BVV\VF/.C8S]>^&@/&@`\B=@&
M'&$<#R,94=3.A&?8>-)K^D.W`DR%0DA&43GL[3<2((5$O+!]<!N;^(X'^S3Q
ME;M]\\`VON-!B`4MRC,;]`M(31WDAS;75$%"[8Y&1V])/;-6IEIWM#8TN]P$
M6NT46IDF&8I6NFFI)G>28\]/5YQD&:<@`T$&[26#N"!GE@J4+!7D5.<LC0J4
M(FJLB!:^M>L23>O@6R)W;5?)S;9PS":U817((Y"GB1+MO$JL;!!7A6>C%B?5
M2O,3E9[]NX'K%0[O<IECN24&SJ=<P+YP5+O]ZO+'MYN^=:;KJ_TB&H$(@A4$
M*PBVBOJ]G6$%!+M!-:P=<<],@ZS,X5%.`=^/U//X[6%T6]B1;.IC&7Z\SJ4P
M"R9@FXY=IQ1JJ+$LG-1UL]LJ"_4+_!3XN7?=::6(4KR[M/&KP5=4()Q.MC^?
M\#UE?$^Q<I%1.82!VR)W?2.*9;:%_PO_C4#O$T9OK3/4RF_!*KP=C=%93L';
ML>370&W$:LP%F;`DA26YIH-11Y:KZ0E?"WI6:TP*=!?H+GPG[=5#SMIWTJ"+
MF7:;EZ+K2+NB$FHXOGT#&^KK.M+DJ`CA!!-<2G`IP:6:S:44X<T4WDR1K';J
M-SPM=K`(Y!'(TTSD$<EJPNE5C!9VU>3KN999DN6:@>=CTI5MCYVL2574+8X@
M6$&P@F!/AF"%#Z0Q2F4=/I!RM<7&A)8WU&H6P2UU,]G7ZK@`O!2!7`+76X#K
M_6IP741QM4_W$`ZM)+!+&,DB/N(\;',1']%2WX#2&0\5P:<$GQ)\2O"I9O.I
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MOI^N+2I0KW,N*YWA:'#.^OF9L?^6Z]/WQ/5-8@$+7Y`7O,E$5?HR>`P\/SE)
MY-C29\>'@=O`X87.+73N-=V/.L-"(K%V2O\0;O!V<?)S5.1UXLTD<[X@.F/\
M&,J%]XHNM;BGW"6V![_5?,'8;I5=Q%FW*["FECCK_6)S1)QUKNTE=^1>G3?<
M[;&]^)^[QEFOC9O.!EIGP[&OB.N^@!9P.<=XE3C">BR_D@RJ@PRRO%]?76C9
M>.M;'F_]2@ILDW_S[>'ZU3M5[<OPOV1MFZ;*+@IKUG^E[AS?2!:A%+&(]-!\
MTBE(S<S7+'XT2KB,9U</F5V6^>P;YT@M(PNBZS!N:&4MVB%K&2<KV3C-(?C1
MV[8@=7DYH(SOBQT;EO[9L5>`U-][3<IH&XB2>79!V,$!4-'48M!UN/?<92'K
M:.^5](M`U5N8Q*6>_P5&>?!1,[ZGK@X_D$>:+&Z<7MSMYP^YI/3]DSS4E.]7
MCOU$7=\$!GSO.AC#Y[@OS,-R'=`[6^W]*[`IO-'[Q-PKJ5W=!RY]]4[NRNHZ
M?-^TVDV[Q".*=J/)<FXBS'?UT]YK?W>O_+ENK3AG=DU`I3#V?PG:'#S#)SJH
M>Y?.48N)EYAEXOW\!1\.:4['<I:U;%W>P;M1=]C-GU^O:]Y0]OB^V82_3HWH
MK61#VJ8-W19S/)J\B?/G+&_3;CX0G6:ED2;W=MG$)WFTG:9'W*L*KPSR]Q(R
MS;6[29:WE-\V(RY]3SQJ7#GS!06#'<_RT@7;_9'BB^]?DD?NN9?W\IFXQN<`
MEP'J'?[J70;^S'$15LGN^SNRM)&B?K_Y.S#]EUL;.8WY1.\M8L..ABM[Y;/!
M=GNJ)@]37*SP?63!!(/.'?O!![7UBBQ,GUC\^2_4H^X3-3XX[H?`!^YZZWD!
M@6TD8!CL"@9U])U-<+=@2[>-)7`HVEIP*+*:/?R]UYL2IP>#,I$4=]-+PS#Q
MM6CB/`09E@B96-+U0OE=\JX*0Y?1CD`9*]KWF_G"<EXH91.M18YAJ'&W"C=V
MU8>V@R&M\U2/"4?SI1V`I<@;@75]`,[TEHRB$K>Q!"]<%B(>2-T`8_4`Z*9C
M\)?X]X"?5\SS'&U?V6'[O>^?0'GI?5_R1JPGF@'^;YB"P,X+RVXHE&PA*<%+
M[(TE34')Z&_J,1L`;2":Y-6[03=]B)N6DEWT?1BB\P%4D>CY6YC!)-9],+%,
M/8ZDC'>PT16P]Q8``P?+"LW.BTKQJW3Z4Z3%>2!`KI+<IV0+&YT'!VQ!'8S[
MB0&YPU*RAW#GSZ@+AKX9FF0W/Y#P$E&A;'0L'++>\1+$UZP@!=_H3+ZP("YT
M">Z!,EO=$ONBC#(<#1*`'["V92F>TLDI/.%2@[&!--%_6S@V?Q"/,-G<+LK-
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MQE4MM?&2=G`\C&)C[2Y/SJB]4KB9/.P=!Y?<5:\UDM>:-NHN3J1]MZ?T5YQE
M&]:RK!FOBMF\=>_B]=EWW?U5C7C38M8J,XSU@Y'&:A[%*Q[NX*Q<D>':<`60
MN=,L:;8+ZA+4@S]20!J/>QL^F;8Y#^:A\8BB:>D&1U,WJB!KEMA?UFGWFON@
M==_:7Y^=/REQ4XQ[?,#25]3Q?:<_=/4SE]+L^C6Y.M"G%\!W8%#S[;6C\TN?
MET6"M)JRON*:(E_\^Y>?EE]='9!+M!O;N`9VEXR<:X3SD?'/"WE\H<G9\3,C
M)1-=PF\&\\%;)+%^M%R5C4\P!2A3/G;FY63,$#T_@!U)+(34ROI[ZX>_N%#4
M"TWA$ZP;*9GKQO9!SPF?`R4/+T7L1[P<#%((LO;.Z=6[SPZ?:M-`R]-],"WJ
M7L$Z'D%73689;)K%OB"Z3BU$,F#%;(3TQ)DA5_$@@<`'^":UL^%F3,CBP-(H
MZZ;AJ+(TT6C]1/_.G28URC+\OM!'T\,(3/\SF:?08D.)P@^77V^DK__?S9?+
M^YMO7V^O'J3;SU=I`&;'7$&091%Z%_B>3VPC;?/W-KLJ0T;R<)>GK<E:?ZCT
M1QE<VC!GJ39';Q>;@]VX_HYG]'4&2+F@@6_JWJVMAV86/[Z[Z;\"ZV7C]<YP
M,%;5<FR1C'MSYE@&:&I\L'O',O67E2J76F\#9\18L$.K7.X=Y3DY/@20?_''
M#0_#F\#VEZ("OU!47:G$P",]+"PSI[;])!LL>'PURC5U.[7*JG;>V7G9.8K*
MLW,ZK'(G7@00^T6:`ELU)&)+)!)5F-QC8I$I_(+]AD'A'HLFD734#J>FCL+*
MF4JFK3LN2`)VG]"1Z'1*=5:KBDB.32^FCGLQZ/;A=7X.'CL'#\\!WTZM@R]S
MI"K#GX&E<FK%B9T4%_*X-0TOZHQQ\.&ZTJ5EK7LE_2#[$708/@YLC]?20F(@
MK'`I*U::OR)XB`77,AA,39O8.F9.,:`PQ4>:D2<J32BU8;.^ZV#@_!.U7B1B
M_"?P>.49^&5J`7Q@%M/+A0G`2R*PFP5C+5A\DGHP.C6Z:R);.<+EQ&]NXP=+
MU@7Q9NC+AG_PZ2=BX9XNX_"YWXD5)%*HMS5N4,W1)GN#7M;4V&7.HY:Y-9I0
M65[D0!L-#UTD,[=!+0IMZ8\FF9@6ZBV.^PV,*L0!?A+L8FTYTD[K'1!GV-,2
M!\C>,Q>SZATN`59009$'1Z\[QV"-0@US[>/>UD#&]7&W^?9QWG1KBT\GX0_>
M%\>R8(>XI:_X3HZ(WJ!)'B.BBRY$O46@%2P?"R[^/.SO6?QYV#^P^C/,U+[J
MSP.UVS^^0.*@457%M/69-KMO2=N:!(-!)M3=D@7#'VI!9G&_GK3B#<VS#@7S
MT3;':+/)H;!IN*V6G*DS91.[TD]\/Z$4V&J&"+0_4[3?(YN^H23P!\5+)FI<
M9#'_$C0G\DB3<[]W39U62`A*5RVK+6.)A-#.7/M2]8<#LNC;JEBTJY148Y6%
M/1.3!;:<-K:45[&FY'XHI0FP\ZKIM4DZ'9_([SN+$B18@?<#[XG%LE:(+UU3
M?;F(E\*N"=32:RELX(.%%U,HEUT6QO@*KR%1N&0L$`N53D]3.]J@B)[L`M/6
M"(Q!4\N5U%OG9__Z>EIE!:J4[;Z6&HFVVRN_O.,&/:=VO#TW=6B#8MEX/><W
M#':B1IWRI2D675$J2IU6>8&8H8&6.QJ4WTM%8$;E%GB!6-+O5H`BPJ@71GT1
MR'J%)KU5K[0[<6M*V.TXUFME6+?LK!W/"@1G^5T$J\7;5DAVI=NOHE&',&.;
MH@"TV8R]^4%=W?2$(7M6<4"-Y9VOM7YGU"_B?FA[*XU:$/(TA/L)VN-R=U!%
MB7=AC[?`'B\M4JQ`?$W=L]?9+:O)AE3CNZOL93M5WERER7J"TADJ<J>O#`6"
MGX9'JA4Z`C`"8=DW7I4X+,#T`/::T.VP]VH_Z5+!HI1Q\]8TEINWIB;"26D@
MG$8-7--P>4DI%L3_W+D5U2Y9U.M2L./"V=1],G6ZIB*V!4.$[3"^4-UYM+$2
M&R_T<N5XJ>Y72;+VAI(\N*&6)&OG2>"U,O;KC&*9BA!46)"#%;&XF"`\L>9&
M#-"XHH7#CRTN)N*:.A;%"`MSL/Q^R82?/7@#1G[VI->L'(<3>/"*]^;M&IG>
MI(SRX7"_C/*#$\J'P_"\6^0-T)3N^'B_BE:L-G1\U]*R^E"?;&:M!GB_-BBY
M5*>Z)J=-F'Y+DVM9<<7DA#_!1#,O^7R#)9O84N*\VWS7TRH_+2WO5I#)060B
MJ.2(*@RFW3(B4;J*2$X7NHA@LE7>[FO=T5H_7KD7_-HI%/K(O[W:G456DF:^
M@3"*;J4NJ&H?JBH1XB=#7CE1-D)-;R&N"PDB)(B0(/M0U2[6KY`@S9(@PH8]
M$1NV:0762E1-VE4RJRWJ1I.J9@GD$<@CD$<@CT">.I&GGMNL%B-/B<ITRX-'
M"]24BP\/+TRA/M0PS(G7^D(]2EQ]QJ*O#/I$+6>!78M63</J&&#AD&]4JPFE
MJS4U/KQ`O*J@\)[:[5<7:;_=S59C+:*1(LA5D*L@UW:0JU9^_61!K8):!;46
M`NO!J/R<04&N@ER/)M?JRGDWF5Q'Y0O7#=Z7VK'VW)PT=5QG%HBMOU&;NL1B
MSA=BS$W;]'QLF/V4T_OL[!W0(EZK;N;:DVMU-`B\%'B97TZF_(JS`BT%6N[-
M+D?E%_`2>'DF%\H%XJ7:J]-&$C?49W!#75?L3,O<9344+=S/XU9YU<)6>>EJ
M.+Y]_?)%YT2<AI=P7(&;4'`IP:4$EQ)<Z@C[43`IP:0$DQ),JLE,2NDH%;3I
M%GQ*\*DSYE-[Q78(/I5_1U1%[?<3B`SA?^Y:>+G@VLGK2C0GX]Z3%\Q/N<2Z
MP.FJS[\3*^"3>5XPY]]ERS_'=9G[\KJZS-_C[20C?V*U_UI5L7EM]>)F%$/6
M>OL50QX>7`U9ZX6P;)''_\!6A;LU/:HISK/$7FTG6^E&V]2ZIMPZKYF+3*UP
MJ%NBSNL:]:&T]G*B1H[@LH++MJJ+:T/9:BO*\NTH.DLL$B?(J%)PMYJ>JJW#
M)W2,D]`QFA:4U;[^\"45-&JL0M&D"D8"6P2V-$)HG5<T<;E]UWUGT>RFZU],
M[Z^+J4NI9*+F03U?<HE??JZE:$)=_G58D]N=J]WR\R:;C&,%@O*?Y5_B"IQE
M]^7=*BHI-+=7>K4X>WKJQ`;%K/%ZPLV/!64]B)\<B_BF9?HO=?+OIEA$13'2
M.NV4`K%D+'?+S^^M!2U.0UZ?"IIIW7Z=DK@\"UN(6&&Q;RU//2>F#6?#`O9<
MHOL!L22PW>?2:YCXA1+7>W/6MI6PW\MGP<.N.A1()I"L;"0K7YULLL5];@[W
MD["0#?/)-*AM2"\FM8S3-(>$E7P$ILC=\HNS"2-98%GY6'9>-C+_<]<TL"+R
MLZK)_5+6YGY]=NQS2?^J,-=+KBS72VYGKI=(0CC[Z&E,]:JGEJI(]1*I7N<0
MABV8[-DSV>:&VC:4JQZ;Z25P6N!T`W%:9%L),2^2K43ZS/FDSPAL$=C2")EU
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M4S`L>I^5@5';"D;MWUIY@!PJ<E\9M@:0O\&#OG=K\XYRO[F.YR6@[&T$9;KW
M6TG0U#1E-)"+`V;.;HL%YP?'G5+3#V#UT2P)./MU@U,9%@K-G,TN01/7=`N,
ME1K7@0L8S!_BRTESX9L?U-5-F"4!UJ!N8&G]45]-`6OOO93&\?Z@J*Q0X_*)
MNN211A/>NZ9.$P`.TP!4JQ`FWQZN`2AL%X!KW9Y6"A?<M/L]0>[MQ2YV`_MH
M`]A+Q-H,[/O=O<B\.#`4#/\<!K/;(8P;<`A*MS\H\!#VA$7!)Q&-O=\Y#.0&
MG(/<'?0+/(>](%&O"!@H6T1`&8IP!O9J5]V'!LH0`F$#96KDSXX>0]M+P2QC
MA5UHN3B[!6A?J$>)J\\`:-?TB5K.`G<2SI0',.#8(T664SQ[MU4?MU/M^)W^
M1FV`OP4;O33FIFUZODOPL8U[[<G5[[5W]%Z7=S$>J97OHK]M%VH9N*E5O]'!
M\1L]"#41,2O>ZO#HK:[05_7G-=J!O+8+^@-P<P`&;=6;'1>RV<-8YTBK>KM#
MN8CMKA":,AA7OA-E!U(K!4NK%Q7#K6K,3GL]"$G57N6[W:K*[++;56%P/&\I
MS\\]W.R<+52]__X[]7Q8`EOE'=H]4\>=$QATO?<,M#Q5:8T;?`.<-WMM*X(S
M^^:3:<'OCDT]&.<3<?^B_I4#:V8[6'L2JBKWQN58886>Q`=BNG@;1U,W<9@)
M^<&E]#;,@_P"Y)><3$9+/%0.[V+3W@?<D2`K1<!QUXW6!M?A%KCN)#KV@VL1
MMQ*-A^NH"'S=T0T3@[80)MQXT(Z+0-E]0:NHIP':*&KN]SB/+`/<D5PUGQW+
M94$V?ZLUPE:IFM>.M7V\X:V&K5H#OQW+1=QZM@*\6@T\MP'8.]D^X62?";]2
M=ZXD4.T5SE_?W0_^5/O72W`K91O5@ZM?.,MDX%+K`E?1Z'P=!L)G2;=ZRTDN
M2\//VVAM<*W><JH;KH?0Q=;KW+AUW572N0X)1DT@/2I#G+^['_ZI?1H60?N'
M[[%!0!Z7(=01R.HG56L<E"MA$>-"C*E]+=6ZN40UH"W$EFH!:*?PU^%S?75\
M8K&0OFL8)YXY`6/VZBA'P2HR:FN/JP5^*3.2^1U]*4"H!+Y:,^![P)4"O]XK
M_P`B>HIW1=TG4Z?YD\'NGV`/P/)Q7(\-G/[]RO'\SX[_)X4]Z,ZC;?Z79C*`
MDH/I;3J8$N/E7KT;R-G`DTHV7A&L>93D!\<-O\+G$@-N7#+^@[JA_3GX5`%H
M<_>98B@W0(=SO#[^##1&O-GM?`'ZR-WT%A\EUGTPL4S];CJEF%P`N_I"+7SZ
M*]"(!P]F475K@)3V[][W3XHL][X_!!./_AU@C,(3_&==3)[<ZR=D7<!:L]CU
MAVOZ%%ZXFUY3>,L%L48G/J93("M"<"9[&V[GCWOM35LBKNUKR:X=`0![Q'\0
M)9^(!5-YEP`8UWV!_2^Q]XVQ4!$7N7>=#\B'UT2#CA5UF%GS3FM8BJ'0=2>`
MAX#K8CXCQG#HNAM0XZ-))NC@,JEW%<#V[13L-\8V[;9X5>LM!8#LOI#]=P"4
MJF<W`9,?OXGA>.\M)"M90A]G/G=LQI@RF-*3-\8C[0CL+&HOS[4$3X,+=B!@
M8AJW]A59F,#8D@5M#!K:;4&*-@`2R`(O?]KLVE*A5`\^1G3CU=?"-3T*1&KJ
MI@\`#^8!8S,\_VKYC60;&Z.!=MO&2)&7PIB.7V!.;MS,L0SJ>ES2)1O8&*V\
M(POI@SZ3-4Y6)DP)I_>!9X(2Z%WJ\(O'CBL2O_P*TKMW?)3#Q`*![%(0F+<V
M#_\(LZSAU9D).\;MWDVOJ.N#X7UE@?&M$RM1,Y--[IP-^3L*UJ\SL.<7-/!-
MW8,5K(]V4138>2C&*MM5!9`$RL8<!V*9_V4J2!Y(=\Z9W`ND"-&14C)(UV\O
M!=N/.!RZ;VY^P!Q&DB[:DX?Y(?V?Y+$Z`!U0_3-<_\H0J>&1@X.`O8)5HN>(
MJS1.8IL;_PD\GR_[YH<^0Q,'I4&X*]NX=T-]@I':'P2M(#^2$"GR'A6LX/33
M%EFYFTA!Z]+SJ)]"@Y6&L3TYQW_($?"XGK#;ZPZI:K>_KO)0^%M!K9-XA:/U
MO9-XC0NUNUKD8K)]`7P*;9?N3*EJ0&W\*Q\ZTB[@V>T$&+9**725G*G$V*"4
MYH,2,*U-9Y7;$OA`W-O>:WBOUL4%EF2YLZ5+4&VL9(G#C@3$*W<D?T8EM(2)
M_2(1A"9PBG5PE%[S`4:J*O_,GHD_*S^_Z4@$V&"L(L&Z48G3P[%GE!A_!\1%
MH0)LWI;N?)\\DXYT9_L$9_,=Z1$$!RQ"!W&$'TW?D^@/W0()!:.^2&"B8D"V
MP;IH6!9ESG]IX3H+D#DO.:=\]!$T]T1O;>3$-F6VN?1L^C-VDH11!<FA"G[2
M7DIG3`C&I3H%$!L2&$D=D#S8UN?BR4$WH^0Q.8+/?D#?_!6QB4&DUSA8"AG2
MDD?BHB>-&C`W\:5G.'HX.^9Q@..DZ7?@2!U)T4:=WD!-S>D$+F(0V$!\Z1*Q
MC8[D!9/_P,X11W`=6`+)(-%N=:Z`2)YNHMH"JKP$/Q)\DX,HT5;2CR\`"*$:
MV)%2?\5Z#!M@:MK$9I_FL3[3D>;D19K0[(:FCBL%"USB:-3K#.3^AEV=%^H"
M6Y%R\`60V+(0C"3P81@?X0]8`MR"PF$9#/P1A`T&W@2@*286H9TR_-G+HDZP
M@#_Q24I<R\0F/,[TK?3:?)/`:HE)*AKCDL`K7YOIQW`0@]U4S;$/%OP%"X57
M84UPWL26;N_O=E[6(G#14<6PF<!V'\.D'/8`#,T0=0K89G`R1SB`MFD1Y*-T
M.D46\$2ER0N;[N'FBJUV>;G)@VSA*<3G$&7?X)6J8TD4-5,/AWG*VS2#X_/,
MU&=2BI,`?5N@B@/S`7+XC^.B@AR"`/X?*#.YTLT]?;(`1O[$'F9GSB_-,J?.
MI@$<"8?=,B*L?]ORX3O@2/`P+!U%#@PA]?J<!>:M,3TCG/7KIURD8+P./Z6@
MXZ_!>1UFC+=W`$XCA"2?_+@P0B5?FA#/],Z+H5PR>.7W,4?ZU1@678.06_I9
M83^KG;7'PR36JISJC>3.<*!%AX6C]V2M,^HIX5<=0&%OP0G.>NGL>IQ=:>M6
M^%IMGM($C^Z)+[!XX+`FJWK$*2%-7.O`8'IID3L-7"0<``5W!X#2`:AK6<ZS
MM\1.AX/.6(W%.:+W9@%\$<G=C'3-\EY543I];;SCH#D#LN-:XI"*TN]H(V77
M09=]&ZG1FT!YZ^V5$FB/L[I(J``[B]'"M(_#5<12AH4,3]&&V`57C8!&>N'2
M\9'DF!!E#>KIKCE!S6("@H<3UI28+NJ3030'HG?L[D[M8&FE*$5=U$M\U*9Y
M/G$HJ1.#B/*$4J!R#C0L9PQ#45@GO+1P7*9P+]BU8X=MF&_/BT"975W>[N'_
M`XL-,W6=^>;W\9O`!@EEX873DES)G!$3D:`?.RZZZ`!VA)EU`$@.62?B!\Z<
M2J_#;;XYB!2VXFZ+Q1!'L:4S*8@\&#[M0!Z1%12:83DH$0DU.'(OF,_!-O\O
M/_20Q[-^&/[,"3P8"]@SS$JQG3N^QH8'!(X^S=DEVYNWNV'"`8?."L=&[Z-?
M\H*5PWUKT:G_<UA/=S3H#D;_C!O87MU]_'AY_P!GJ,.&R,*C$7Y$M7B[?5Y_
M'M'=_?65_`HXOV5Y"Z(#G<2?PV+P['-8='<TB*KNKJ\<7T2Q]]ZH.Q@<72*X
M-VI2?7*U.SYZ1QLJV)?3'7Y+Z^9GTS:<9T1+24$2<2S3*+*'L]8=K6VR4&X;
MY_PBYD=!^FC/_6@7MWJ:)[(I7>DGOI/0:[7-55PDQH]&`N7;A/(H,4`,V)'$
M;Q_ZX[5A<L#L`C'Y>`]*RRI))+\[T^S/WV+E,?L]#UI)WF,7CX*P!&&=,&&%
M@93)&3-*RY#%$K4M4U.#))/25<KJ0%$B`:6:2K18_3Z@WU)+]?*B#(TE1IG'
MH=K.'[<0TI[]<$K&E]*$KT"8,@2J0!Z!/">!/"5J+:7VDBQ;)2FV87-Q:DN1
MKO=LW`9&MJUQ.5>A&!7>X+1<CE8D;RJ\M6OARD^!6!>&JU6`:6NEXHFC6E=K
M:@_A`M'H'Z4CD*)V^]61[';/68TDVQV,!;T*>A7TV@YZ5;5>^=!>;S?4CK8M
M,"\VV%:-MQL^89Q6QFY0:K0;FN+B*-`@J-/-62">C-6.)H_J5!S.'C?*<TJ=
MD'HIL*056-(?U*G4"&?H:3M#/Y&7QJ@T)V[O"E=HQ-)8`DT53O=S=:U4C6KM
MD*3"G2=PKFJ<&_>%2ZK92EZ;75*K5]E57#`*EU3;-*[^L#,85Z':"V=#N\55
M5QL*+!%8LAE+AN4[MX5'ZFP]4O\*K*Q+2A,NJ1:F@>4!KJ!HY-/P@O%Z-\(A
M(1P256)=K]L33C#!4$\=S;5>K;>FPN\FDE\;:-:NYV9J5^T#J`PGF%BGDYO6
M6/84UH04KI:3=+6(K-?*V<SZ7()RF4RK$@MJ.)=-N0FID]FH5Q]Y1$W.6%`Z
MLER^.792SM3#4NH/8`/QSC5E\&H_RJI@4<JX>6L:R\U;4Q/A-&K@DI3FK4D<
M76N/;KB\I!2_YW^RPF7Q6G\RS"?\%'8Q6]M<+-6`[`[+2+,'O7M0%_2DPYHB
M5]=X;*.J-SE>7=C:V8J!0>)P6%4DXA4454*Y]KK9?+^L<Q&6N+8]D[5F65L%
M.VYU@5U6=,?SO2ZVJO(H_X"EU+$$NXT-21ZQAP_AS5ZQR#G6I^;5R@W3Q7X&
MT2NLK5Y4.#YO5CJ=.J[/^E*YQ,3)PF:K_LQU@L>91*0%ZZ(L><1BQ;1-?[F[
MPX?`#]QHF5&[FW@[N$2+EPB'^2T:-33";V"K'6RQ$O8M`0#CUR_Q(-B\""!H
M3DV^BU3-^@4QC0LXNVB]K'P[S!?H2Q-@)RV=4F-+#X,EPEXAVA1!/^@SF,>B
M=]-+UJN+=2-T6+_Z]\3"YLP/,TK]:^H3,^E:JRCE$/N>.+J50JILLX`]DWC]
M=<3BL.IY5)W=BSM3$-X2;<*!*WD(W:3[%9ROQ("?]P!K7#"U6(\/UCO!-Y]8
M&^1=B`.QQW;\I)<"V=J2)5-%OJX*\6F3D7T1V5?#\7#QHXJ2\3!1B&GKC:85
MVQ"7MF0;IK^*K,'T=]P:A&^*N`,8]+O'6Y^#?I.<D*)F<-MN`MI?,SAACU:Z
MW"^PR&W!4DM*H"`#00;M)0-0"5-ELU$_R=)#`\GDA`MDGY6RT;QX@[;=!(KZ
MM^(:62!/^Y&GK1>*;1)7A8<0%B?5"G1571&/M[[4\0_Z=V#"ZK&A=.F7XJ<3
MHUQ<K$S=4:L%(I:HNUEED8../!*9+()B!<6VA&+[XXZBEI_I?>(9$FU2)^OP
M?I1T[5^GH&F*;7R"4?,%8HO:&?9$<H5`DRUH$D<EJ#_7*0J%RT2X3/:I^<4#
MU#QI05Y8N`JZ3XBNNP$U)/IC06TOK_^K,,9$68$2\ZT[0[7\2H<"Z0329=0\
MK2<ZOIR1@&^Y$?O1L1\O?.K.&R6NA:W2!EZGB,*,`DFVEA03N<2G(.;.PXZ]
M<NPGZOHFFK"8#N)U))NR7"[#])B)*^P)84]4:D]HG=ZHUBK9`NO.#^L:XH46
MMJRP9??`VGLWRD1FZ<K2,W%=@EG4)IF8ENF_"&M%6"M;3%I1`$\@24NDH[!M
MA6V[!];>_-!GQ'ZDO)S`C+BT&8)1V!?G9U^HG=%(7,T*I#M'L2V,6F'4'NB2
M7F0-7&&I"$ME2T[%H--7R^\Z(?"DY7C2$-$H+%IAT>XE&I/:E,*8$,9$I8YB
M@7`"X2IUF<C":#T?`=YRH_5R;?5F88L(6V2+9.UUM($(+!9XLC7Z?-#1QJ+M
M^RF(N_.P5Z_IU-1-'S-M@GG`:](;@<L*XL^PC\(3M9S%G++9R",5)H8P,:KD
MJ*^Q`^BP?#NCR6A7(#C?E"^:!!KGHK'2D=7S3L*M%HU/3A]IN?G]U<$^2<PO
M/G,L@[I>JMF-]-K@>L@;5MM41$4+4VLK1QT,.CVYUFJ:Y2'*R4C\$T2\?A],
M_%HE^9F;^-6WZ>RIO5=;3E>T?15M7\71G?[1[=ZQEWW*MO7<JW5GJN7G^\`S
M;>IYJ5:_MS;\0ZP/Q'1_)U8`0Z9S*1XPE<)+FG^JKR2#ZN:<6-ZOKRZT=:U`
MO_].7=/Y.J,N6=#`-W7OUM8_L391W^_Q)P-6OG!-"]Z0^?>OI`!6PL;Y]G#]
MZIVJ]619#O=[X+J+W+E6W,X_$5>?P1M*_LZ5_J!1.^\5N?.7#?L>]QNU[W[Q
MN*[F[WPX:M3&!T=O?.5H97G<J"T.BSO;?P46(K66OW.M5Q0Q!][%(R&+M]=T
MXM_:GN\&>)GR%:N;Q=L:Y6[D^R=YI"G?4\'V("SFIN<Y[LMG+`1S#?/:H\O@
M,?!\>&40;N7=O?;G+S^MGS>[KM3P;-#[L%IJO+AQ!N;][%)OPZ5N6:3:^U=@
M4WBVMP;<0UEF\-ZRJNS2;[%''_7\\,>KP'5ABR!4/SNVSC_$VU#E`K:Q"NM5
M@LEL8X<5PI9^^>G'Q+7,M_A?^/C_`U!+`P04````"`!A@6U#WC]>$0X,```=
MH```%0`<`&9A=&4M,C`Q,S`Y,S!?8V%L+GAM;%54"0`#Y>J#4N7J@U)U>`L`
M`00E#@``!#D!``#M75ESXS82?M^J_0^*\BS+QQ[QU'A3&MF>4JTS=LDSFWE+
MT20D(2$!+0#ZV%\?@"(E'C@IVH)9^S*'V-WH;GQL-(`&^/'GYR0>/`)"(487
MPY.CX^$`H!!'$"TOABD=!32$</CSO_[ZEX\_C$:#*0$!`]'@X67P"R`$QO%@
MBLD:DX!Q`8/1J"#\#!`@!>EU^CMD-!W,$.,ML6`)!M]_#5`T^'1\\M/YCJO"
M-)O/[@??/\UO"EFB@2NTA`AL&&*(_O@@_G@(*!@\4_B!ABN0!#<XS(@OABO&
MUA_&XZ>GIZ/G!Q(?8;(<GQX?GXVW7$H*\;]10382/XU.3D=G)T?/-!H.N-,0
MS=JV:*0@YQI6J)_."MJ3\?=?;NXSY4<0<0>A<,?%94)-*PWZAE9Y.R?GY^?C
M[.F0>V\PV/B/X!C,P6(@_OXVGU48%[PKV(J[?@U2!D-Z%.)D+`C'GX)8M'F_
M`H#QAC-)[&4-+H84)NL8%+^M"%A<#(4<[L*3L^/SLV/AP!^K_..]]9D&='4=
MXR?:1ID2\_Z:W#/^*`&(W2YF_#U*0!N-)$+VU^P2TC#&-"7@!J/E5T"22_#`
MICA)(!-MT0F*IA@Q_N;S"``!O00L@'$KE[9OZW!V3H,X/'U+8_,&RQ:'_*<T
MSJ+7#?]_11GPS`"*0%2H(XQM\[IFS14-QCBL-!*+V(E)U>2\C2SN+`+ZD(43
M/C8L@V`]%JX8@YC1XI?,.:/CDSQ8_IC__-L-#!Y@#!EW`'?(/</A'RL<1WQ`
MN/IO"ME+T68</(#X8FA+SB`3?C"3CSTP?)H2PA&A-K5&T#1N2U`UIP2<":E:
M%I"P$,?_V4!-=33)*<8T39),V@CR2%3P+PA.''H&6YA64OS#P"1YP/!`)C&E
M7!)>"R%!/!Q@PEGR9.8)P.6*\?\<$`"3,,0ICP-WP4OP$`-N&O^%I"`R(J,%
M9^Y7)TXOL%2W`^]CO@I6.;4`DI-PSQ%V"18\&P?1'#P"E`(YF/1$N>-41+Y"
MQ,HH"S2HY,@[_M2_CD>,S\TBR$Q]KZ!K='^#SG\$Z$US`D%#E!P'9[[@@.>7
M?!+/(`]D7S`#15"3@\&..'>;B=A76#@9:8$-DSPY0/ZV/T":$P[QRV]SL$Y)
MN`HH*/1]N<;D&U>2,A!M\J7)4T`B16K1FC]W60M^7Z&RKRLLT-.B"3F@_NY+
MQ/DU("383&[G0AMZFS*Q$B56#FM0LR'-7:DG]15`#@9:8$4O30Z+?_@"B\H2
MB'RVJZ8HIKLR"E_[WFR.19=+A<A[^I^^]'0S6?J"46B9?39)E0EHF=0+$!@7
M/1S,=5[^T,OV?+9B,^56@J@=L\-RR/L#VEXN<8:>:VNO-F529,17SSS!0DL@
ME+M?!627:BDQY<*2N\V.Y7W@IX7YSJBQ:^/59D_=9S5*,.F))+G-^P.,E8GN
M2_H*J9[/@$HK`H4%Y94!]:*+CKJYZB*G?A]X<3/:&3A&\9Y/EKZ"1)3.D)>-
M25,^\7OAD[Q)(L;9"6,$/J1,6/(5WP62B-.:/W=X"_[W@;M]'>.,Q!8->CZ]
M,V[0&[?DS9OPOL+':)HS/F02Y0#XR1<`B`(6C#+%_Q/$:7,\DS_>#F#UQX?K
M>M,8I36DTM6J8:@NP?/MXDD4P8UN=P&,9F@:K"$3BE8GW'JJ8F:MHO*UO^W,
MLNAVI2#/5V$NP2.(\5J4IMV+6MPK496[)I""2["`(61\6I\FPG@07::$#V-U
MCL;R7E<"MXN`^POT%7Z=.\L"J5VT:;&:,SIH3*,4,%H/894?BXB5_WA@5145
M7[)G%<4]V!&IN17KU:X`=$.8A<\JB^=#IB@2%W6\_"_Q7CT&<5;9RXI,7YHB
MN?`4>9,=SZ'[7E9PT<):"33*)1=V$CU'SAT!:YX?7#VO`:)BU?Q6%&GK8H`#
M1^Y'*PX/,>-NJ1XQ5O(\3\_N"%X#PE[NX@`Q;H*`?C80?P%-H)A)MPC1D1X:
M&E5,6!NE&%GT$CSO_A)BE3L-6IK<-PH:GWK:Q@Q%%RM8/:_2G`/*"`QYEBT?
MVI0=[LZXK=*S9_0)&JT-5N#%19[+7N3'<=U9-_S_KW^B:W=FT:^$^`X0B*,9
M"@D(Q.QR\[=57JQGU:;'*M:#O>A\H!$J\H'H$?(._O3RC0*NW^TZ.\>,EI.0
MP<=-$5AV,##EO^4/,:I/8KL1ECMP7V&'"Q*M4(,[=E\EO+AH)(+0OIIX/M'A
MYFU.*]]@*L%P\]D.DN5GAT-81TC!>G,K$-JOR1Q4Y:8\Q\@E6!,0PDQ]_N\8
M9!V+HDF""8/_RWYOK"[;LVS7CVU8^@"T%L[I&']V&G@^Z9I1FHH3\K>+;`&=
MJU\4X5]C<@_((PP!O273.(!)/;2UXLW[PI&W#XC=QUT=0]=1%<\GEUEQY2>>
M:D13G(CU+UDPU1,5A1L*HC[`S\H!'>-,U:;G1:_E"'Z[$,69XJ834=!T1T`"
MTZ2&+6OZ8CO+3-\'Q+FZI6/P633O>9WMIKKBWQ!%V?UA@#:6P94$Q>*WA*`/
MT#(:WC&69.UY7F)[ST@@M+B!",R;"ZNJQ]L2QOKC/L#&8'37HU^C-8O*UX.6
MDLQ!B)<(%A&S<C%(8V'>3+I=BM>1]@%7#L[H&&/ZEBT*;5OB37$2[3J`)"M.
MF$2_IY1M;O)K'(2J3R0=N7)/6G/U`6'M7-0QV*R5D./NW)>A46I',0.VP6:=
M5H?('6UO<:APQUN@;]>T8OWWV!?0?0X@$BO5MXA/0]:8YC%[LU-[4D.='7'N
M9Q-Q'W#GY)".@6=J6X&\$V_2.F$`%18`;L/5L[`ZA72U>8/$Q%B"/BOZ$@`-
M]'W!H(M;7@&&AN852#SU!HGUS>$9R@L7B]156L!8WW?82TBQ`=%22!^`W(D#
MN]Z2:*F3`O+^',]H&F9SG8@1\BY"E)"W$])/R+=PX*M#WDXG!>2]V3Y1>&:6
MW?G740V8HS!]#9BUL-[4@+5SWVO4@%EKXGDA!7]ELT\>?,63D+N#`&4M?F,/
MQY5QN[=CS^A="'<%(-[#439AVU*?S5Z0O1X616D'34ZXZB$`$;WF?77/W^#;
MA35LW3EW!W+L.7L!W-:NZAJY+HIX'F^;R5/UI(,Q@9:3*U/E.GD?@.GHE([1
M:&[=]Y/W"A]<0Q2@L*-$UU&8/M&U%M:;1+>=^UXCT;76Q/-JR_(@LKO<_78A
MO2K+CEB2&,B(O0NYKN#"C@ZQ";B6.M2'?UG;GI^@*/+NO&BYJ&&>8MI8(;8A
MK<VBY*2]@)R],[H&G+9EBP33F[E1Z;Y-R7Z9!:4DQ#4H>P$V:U>\8G!K-/R.
MAM3=T8SRY<`:P.D9)+A3,?0-?E:.>444JMKW_/`#SPRV85L#01/9[F-)"K(^
MP,W2"1V#3-VJQ7D&;X;4W>M1"M=W)-_MS1(&JZAGY-:&0`UW'P"ZG\O>)#AJ
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M4RP*2Z,$(DB9L/`1R+%A25V<`C%1>XH/-RO-"#'*\WV`$!/=+QCA:CR40\2.
MN'PSKX;8QXF:BWV&.9M!E`LL#K7:(6Y0B3%-":A\N!DG"<P.9(KO0&V6?Y8`
MA1#02\`"&!_NLM8W^BKW/F?FR^(_$PX6LYXR,HFR5;(#?H%,XV)L;5GUTV--
MD?4/:E9%O=K`K.A5H<$,\=B?BO>BN'E(WK56M-L;'K6TWG:RBXTV/6V0YWN*
MKME9TVPDZ7;0WO0NT[+OJY]\U$);3BI%=IW4#V"K$:TU30GH)I+K<OR(6SQM
M<0E=37)M]"J3^][/1A,=^EHFRREPO;<T<,K5.?4B%WS#F/O_M*_V0NV;[QTH
MT>L>A,JOGEA];5Y%Y'>'VWV_1-?=YB^6.,Z9\P?BCX>``O[+GU!+`P04````
M"`!A@6U#XM>`ISX@``!(*`(`%0`<`&9A=&4M,C`Q,S`Y,S!?9&5F+GAM;%54
M"0`#Y>J#4N7J@U)U>`L``00E#@``!#D!``#M75ESW#B2?M^(_0]:S;,L69ZC
MW='>B;*.'DW8+H5DNV>?)B@2)6',(M0`*;OZUR_`H\0#-T$2+-5+'RH@D<>7
MR<25^.7O/];QP1/`!*+DW>'K5R>'!R`)4023^W>'&3D*2`CAX=__][__ZY?_
M.3HZ.,,@2$%T<+<Y^`@PAG%\<(;P(\)!2@D<'!U5#7\%"<!5T\OL/S`EV<%5
MDM*1TN`>'/SKMR")#MZ?O/[I[7.O1J>KFZO;@W^]O_E0T6(#7"3W,`%%AQ@F
MWWYF_[@+"#CX0>#/)'P`Z^`#"O/&[PX?TO3QY^/C[]^_O_IQA^-7"-\?GYZ<
MO#G>]A*V8/]W5#4[8G\Z>GUZ].;UJQ\D.CR@2DM(/K;&(%5SRF&C]?<W5=O7
MQ__Z^.$V9_X()E1!2?C<B]*,TFW'^A!_.2Y^K#>%$H8ZI#L"E"R]?OOV[7'^
MZR%5],%!H6J,8G`#5@?LWU]NKAH=5]1JZ0.UTB/(4AB25R%:'[.&Q^>0A#$B
M&0:W*0J_/:`XHA@X!RL8PO1S<!<#0OG)!T@WC^#=(8'KQQA4?WO`8/7ND)&G
M1GC]YN3MFQ-F@C]ID3T>EOMSD`8P=L_^EJY+_C^@Y/XSP.MS<)>>H?4:IFN0
MI&211&<H2:F[4[>'@#B1R70LIW;*[@CX/:/C73RQ0=T8241T!,Y/!V']U"WO
M2WP?)/"//.Y2,]]FZW6`-\O5+;Q/(`5UD*2+,$19;OUK%,.:_7L*V'-HEUI8
M$`+H8+]GD$#&SG+U%6"(/M>Z726A$T0:#N52RLL`XJ]!G(&/(&#_OW;F9G+*
M8\G0$X\*TG4I`AQ6@I3_69=E^_&&27H<P?5QV>8XB&,UBX(LH,H96$KSEYSS
MG)H#KNA_@X2ED4<16@<P<<ABE[0+?G-21VNPO@/8);--N@XX?:!,X3"[`T=;
M13CDETO=+1[`*LCB=!A`5+3K'-,_PB0/BQ_H_S:&!3]2D$0@J@9FK#K,9',F
M*C9B%#;&CMG$!&&NS+F\JX#<Y4+3B==]$#P>LQ!S#.*45'_)@\[1R>MR)O*G
M\L__OGT(,'A/)QLTPUH_4MT4GT.,`YILL0CT?O/<Y#K8L#\MO@<XH@H"5RE8
M;R-W'-R!^-VA.X(I3)F*71`\GDR]=&X693&@685*#"*2(T=(6\NNZ5;*=D>W
MJ?-GSUK@IO:IVU=,E!'`Z$.VPFCM%'5H..T^*^'G@_X<'Z3HP"&G&:$<HD?6
M*Z#:19@&J7)AIXBB/[,@!J)WARG.P/,?Z<2,QL:+.!^$AF=PS_YC0I_+A3JG
MT7CQ`[:C$_>WTCJMWX;$K^3#7.+9.0*17/@&-%T-SA#:&E2"LND!<][(/]N0
M:?[:!LUY(\$<!C:B3+G`#-^\2"5!W?(-$@WK55UG;[]_GWIBP69N:V;"CA`N
MC'@ZJ1$O:%:/-J!(D9<Y;Q\;,ZS2G,IVI48D[08U,&]RV#)NRPV1OE!<,Q?D
MF*$E9-SZ;7<9@_WEWY]0HFM&G::ET/*F_AG30#2%/>64?/3B6NKPS#"Y07%\
MB?`V+_A,$\;WE(MOXEF-2>_NW$6O]T30&6RN8J&S06<D>OSX#>.M_P'\!$,@
MT%$<EUO'R]4-"-%]`O^@*F+KZK0=28D:\`.-TW$-Y^/LF!,-:X<AW<TYYWS'
M?..)8_)U4X\Y;"^E$)J0;%W\3??SXY"X9&6M#_$=\[L!-#[.:EL?=OD>]N=G
M#_OEF+,M,>U^1;6KNM^PV&]8[#<L]AL6^PV+_8;%R]NPF'9ZNM^PF&K#0K#P
M6<V]%DEDL`9JV*NUL*WLY=_*J)W`FHO>2J(^;EWM_JZ'J<TM=T,TA]GODOAN
M?,O`8&#_^>VJ7,=!\BE8\_)#WD^E>IH_[5YV*!%]L.2P.::/7Y2*0VYJR/^Q
MA9?I$T.N99&"_;K-ZP3J9O/Y%(N!X3K'/R8R'>\(BY[MI`=8[*QG&Z)%*?WO
M&4PW5TE(8P!\`HR'TY.3O_&S,YVV588F;SO1AUK@6<A,-IX1:XFZG-(HN5?M
M@T\SA18OK]]PK6O4IUJ6U.OCG;5M9)5;79.BCVE7(TM43\O4$S)OS:Z60^':
MO/X^[A]3_*$U99/&`I;<53?^.8FU1LM2-=*6NY=VZRMFL"Q<RL*,8,=-];3:
MRJ$W?0:O`Q(QEI3YO82\!!\^9__.$-+)K/W`"&^JX`(DTHG$$#"9-B6Y`010
M[3[05.H</($8/3+.+WZP.`JX*8I!CU*#6CTF2F'T`@:R$5L#.,\)CQ9Y'^-,
M41(IIGPOHC65EZ2L0-(3D$'(J$^I3<T^OL/(1G0C(&D.X&,L^@H(JXS"R9TY
MOY2Z:?RR>[FQ6/#!<N'&D,H#A=/!A)O)<']K0F7Z7)9G5"3GO6[M6O>:O7S.
M1;4MUDF^IK$9+[?4,9HT=[0QF^,EZ'+,W/>7R37`*X37K`X?]RNMV;II*7'K
MB;[,?*]"IN)Q+/G\S562&F4I6LA%_I>/,*:_HP2PXG<?`_P-I&<HB7*1B)G]
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M%A<_``XAZ2[=6!.HGYHU)+"[_M-7FR.YAP6;/FY3.M30;P#>/Z0@6CP!'-R#
M2O!K#$/`M+<:>@G&D`'WTT-M!N;FO4,OW=A9SNME'6V17G!4F"843./_\W/Z
M_FXZ7I`8)P?0E'_$2#+3A2GA^2[N_-YE"'$_LFX8<3GR/I2,:ML9A!.7LL]R
M(4VE`,YZQ)AQQ7)X5\'%>/A]A!G?RCL09HP5X.6*8%\M5#).$FFL!G<59PP'
MWT>9L2V\`S'&4'P?UU?*>O0@XBNCO`75B@QFG:JZEYJ=YN:)W!5)*PVY7T74
M98./S+\X+OUB*])GE`9Q/FU@A2>WKS2[6K-3D.^[."<DOQ-`'UCK'BVL"QGF
M.\]?_:B<(WN+Y!-*G@!AGRLF'\D%K/_.WB/YA-+_`^GS2R7U#<66`XXZ9KNZ
MS[!C[H2K3F$?]_X[DA1\I_[;;CIUD;S2&7/Y)];N]5C>+1U\:#<7#+[W][X6
MFY'C"\3A1X"?_%X/$FERFZ[4'D-B]QY!^H`B%*/[S>*.5;X(4U=9M?F(?1-M
MDQ%WPL''MXU'Z;B)#'Q7?KL[KGP#R;=+#,!5D@),X]\-G:$,Z<BR\89P8_YX
M<W-B"[=S[>4:AG/BX_JB.@\"?!%G>3C%1&RVEA?2Q.<KBBF9&*:;H8.`?,0A
MPH!HQ'T@&,9X<P\%(B&]/59RIQ;\SD3PSP"OVQ/YX0>JN_Y``[T@CQ_#5%,Y
M^D"R>7N4PT9>Y1;W#6!XI7\_0TFNWBR(F2).73E^?P[Z1H0^'.Q#Q3C&G5,,
MZ2.TCZ<X!LF:SN$3C$`2C36/X(TWY"RB.=X+"A,C&FY79A!-$=T>EW$3`JBP
M:Y3DFYAGP2-,@SB7DK!"Z?@)L/V-RXP=AV57A5D5Q)9+6_<O+6W1?VXNQUV$
M[ZLW]TOJ%AP)5L=./#D`=@TP>[6*?I>7JT54U.BLI')?Q])LM+Y?*-W1=L)9
MQK6)1[M5NOP+''&FZ]15G<_A?59_)%=5:/>^ZLP6'OFI#N\"'ZTM'_]RW#(\
M9>Y;\0OGAP8DP(^4IIG/*FJ`XOOW[Z_8ES1]H)/41Y"E,"2O0K0^SI%Q#DD8
M(T(_[!]0<L]FJ^?@+F79`$R9@"QG9M-9.JL%20@!.0=I`&-R.%5<8>Q=)31S
MSQA['1"6,4'1JL20L-5D4;/)4>.E$JYDS;=,>%*5+8:,+D$<-V.*2OM(1XRZ
M@PL(,J_E$I)LW#(IHO1G!GH0O3ND_<#S'RG0J2]=Q+F[OSLDX)[]AS=XX#S:
M(V[`18,'3_C(+-\!AN)-'@ZM+B;\??6]R:?P&7%5,ZZE_7@37F+-CJVUWHCO
M$NP:W/<WXWN:O?,`SN2&YSWE8V=YZ>,^;FSO^+F?,W9X&*>0AIYK*C@D!.'-
M)Y323"D#R^3TS__,$D"[_9G[_(ME[^WRF6'OB>882C]'?34AADGSR6OC449Y
M5$C!U4^+[#XC*>WW5QL0";OKH8C3?;XP4NG"$8XXP_AX?*@IX5F`\88]GK9&
M6=(^TJ_3E/LY:C?U`CL:4Q*IB%9SDS;%43Y/31;8;)\-_@DE9QG&0&%F<7.N
MJ7G-YV)NI:A6)N=1]?&<47WMIX4(WD^E2IH_^6MIB0B:5FU2<'N80^"X]2'S
M%P+X#JMJQC%5L]D\S"81S<*$36H^;LS7N:7!(U3:OMN(8_EZHWG872B6A=7K
MM-R67S#Z]II\>$V^NC/P:!,A>WUO%;X][8W\QD:+TK'5\7P&AE<+9.'/"B-/
M>^FZ*<-E$`*-:56W&=?CZ\W\M;FF:%9^7J?FXSW=)K?U2X6W*:NL]7RR0XH'
MG8Y<A,@[S@4S!N);H4A.W_'QMD'VAVDDE&\/UQKP=X?S!G,!!$<<NUWBG(Z7
MQZ9H5,,I_",_>K)<,;:KG.8:@S7,VO;6;E\55%2W]Q<-IL)J@D.#K/KXSB2G
MM[>+T/G2\W6PX1P84;3J;@(T6_F+!CW!-#$@)%:9>MH%NAI[50JL9W)9ZZ[I
M^:UG`0$-0<VAP"<J"`;3WN9J"O0E"8J@QFZA%+%,FBA(VG/S!FY[?W%B*JQ5
M5L$E*\#*M*N+5>);(IJ_""%O5"I*U,A?*&B)I6E_$2V!T:>M[LIG=I%$PO5E
M@QY2.+1ZS`T;,H%[`:5%N(+)W_PY$WZ;W1'P>T;9NWBB__#L\/<PQV'G<Q!0
M*MK^_.<`YS_WY[?VY[<\.DC<"L^=;UIU04[1K+K=)FSFBX"\^S"R)GS!IK@1
MHS0!TI*D<>E-0#*_RL8EM3.W8MKBT?$XN8"BE0`<VU:37I*18H&#%;YL$KAL
M[\H(*<T@X#%FN1F3LIW8^-/G3"K;\LVOS)P$9`48\/G^3&\4=&Z93(\#WA6:
M/D"07J1Q"86)"V`VV>6FU](V?`!,G"BKW;MK>F4Z+"3*,;MQTNO9Y]'H$JGH
MRZA_BW1B'V!%>UA9'A"=9Q@F]\7;%$4-@N+OEPB?!>2A[1C&'2MO,>CHAPOQ
M$VY;^;73<(,!?$36Q>\93#=5Q2?*?,XY]R";3M/J71YI4X_Q8B"C+D+D)'V\
M*G*-40A`1"ZIVBJ^KYBH07R=W<4P7*Y6@&&]!1#C?J4F#?IY#!U;Z75Q9$!_
ME-LK7Q)*]3N&K&Y,M1E:E))9L\4VV'T(T*!'J1NM'AYCPEQB731H4?;QVLN2
M;4A]0@DL]\OX+PDK6I7*$K;R&!)ZDNG"0$C-Q\='RX):9+G:9DTLB+&WU]JA
M0J=I]?60-O48"08R:G\CI"3=WI01?!:JS]0-"`%\8A,MVS3"@D(KH3"BX#-2
M>FO$-,DP&LG'RSDWX''K"[6=0,[M9XV6I1*E+3V&C[Z$NC"14G1[6T<09BY(
M"M?L/L<GD++9]=7Z,0C3Y8H+49H7W8"8M?Z,@X30AISLU"'%:A;L@J+'N'*O
M,>TYM8N1O;S]TSBU`*@`N'R!NKZB].61O5C+&M;737E'3<PH\$Z;Z%+P&*?]
M-:*+2ZN1O+RDE-^^W3*YQ/`>4N[87XN5J_;K8=KM:R?9%.T]1I2IM+KXT:#K
MY36E)M^E%X#H>6NECG\Y='0[<W&D[CP;4!GJP0YAZD$$<)MV@?HW#%-`/^_L
M)E\19/.-O-ILMP4Q_0ZE.G4Z>`PE8WEUX:-#V,N[4^\S0N4@9!'^GD&22UIN
MS)0K9R7DES@7AMT1+$N^UQVB!2NW1$M3N"+J,3P'T9LNA%T-[OC:EVB>^R-\
M8(\3,#ZJYWHB`-:\[>;VA-:B:S5S->KJ,=)ZZ$![+FHTA.-[8Z+;"G%`R'+U
M6\!>MDB7^(8]8EC^7PG@S^@ZPY1S4C+=6,AI3EZV64)[ICGL*-5L=*A1/(;M
M.)K5GM4.Q8W`&1SO2%BROWTL;2E9:QF`=#_8"TCO'M9U=#@PP`4L"%`][7Y(
MC5O%6UL:+;M/._KSUI76>J"NA/KK?A**`CQ,6[Z,MSPIA(1>X^WFJ[RQQ\`P
MDE-_2U5.5'`JU/$;FXO\J>I%$EUCM$)X';P/8C9EOWT`(#T/TJ#]*G!5?,JT
M7U6$2K^?QX"PE5X7&P;T!3"9=I<@/WZT(`2D1%AB0MJF?I"KVV8B9)A;'>F)
M68>%]B#;8UY=XC[>W!)4V>(7H-%K+*]?-G5!&BNT&`EN#1O5*#Y>2*C2;K9K
MS])PLLQ2D@9)U#THIM.T6L^7-IT3<@R$ML:-?`RW5Q9TUST_P.`.QC#="#\T
M)EU$ZYS<+G."AX42K&&B-Y;;RPAN@LQGL'Y$.,";8N6_^6S/(DTQO,M2)A:=
M]@<<J%GW+U5NT7].(.RK'FM$6@RLO"/A:8&NT\DJ=.U+TNQ+TG!GL_N2-/N2
M-'*XV):D\:H"Q;XDS;XDS;X.R61U2$8MNT'SL_Q09`B2`$/$B_>R-MMB&MPV
M?L=Z#;FT(CV?CI?F+CG\DI!'$,(5!!$_SJO:5687MYLPSDOMBO2E:QB?1S2W
MOIC83B*@6W9L<@QPRXY9@T!>=,P9#*9-^*XQNF1+#=QO//_'YYO'C1^G^JHK
M?1@I!&F8542MO#'<H#)*->;];O9N[F9/NW,9D`=6087^BRT?/@4Q6VY;;!]U
M_QK$6><9'I,^U3ZF7I\Y+?C:J,%^5U-O,!_SBT58%.HI-V*I%/0O.`-1M7,"
M@>`1<(N>V]AET'-.H+-7B37TC(;T,<;I""#<8+7K;`##N6ZZ]E+,H&!4;\1.
M_>C=]N`L]_,J^+E[`'F.'TVY<#U._;3I^K@%OX@B6#!T'<#H*CD+'F$:Q.V0
M(V]5Q191JSG!04]4^V@A(N]CD<!S\`1B])@O);"GFB_8U<Q'#`DXI_*',*61
M+EMG>5&7XI9=NT<+1^X(;NL.]"<X)W0Z5Z`UD%UPXF-UQ#Q@/Z"8LD**XRN=
MG091@WK-[E:#.6%,*:`U9GB41ZF&R/(O.D\]>PCP/:BJ4*'+`.+\T[R(_I.1
ME`%SN>K>(\Z%JU\>*<]E;H_9M0`RSF"E+88>S.-UM%'UK+OX-C13RMG#U.?D
MEO@^2,HGWJD\M]EZ'>#-<G4+[Q-(/PQ4G'+&Q"[EHYA^*L#TA^D6E)T(QE2J
M)W`+Z%PMG[91"\4950@KODG3^<<L+5^NOPAP0MDG51GY#CZKO-DQV2K1=D9V
MPBV^!Q!E,5BN>@K#/18X"/'M5J);XJ,>170.2#2PMANYAB/FBZU0MTSOS/'*
MGNIXO^$3X!S9&6$D-_%2/M*TQX>&\3TTIG6:>]PNY<D77(:4P\O-+2Z_PB>O
M=9M+7<F/)[#'@*S0,[3>U!Z00S'6AWNDVTO`=HY&>0-9WA$P3S`K/4_F*6HG
M/J8B*JRE?GA>W%I5^7OB\VS:D4]6[5MYSDTUBK3"M\_GV,O5'"Y`N+\U;\W/
MR/@R:4Q-W:+E8RPHUK*_4*FJZF2+>PSR*1WA6EN_0^,E1WF'&>#"6&Y3L.@,
MX.,!C+(DXYH]&Y9_1J_C(.'?;5*WK.]#B5K.`"SZDIJB1$K9RU,:_3(P[CNR
M3FFZ66B9^&7:(19'A]#R4&NBCGA5?J&GWJ+**WC5ZHXO5U]9<>C/M6Y725CN
M24VV)<4ID"[:9M)I*BYK[]=V$(=!0F>0S_\GW_`QZ][9TM'M/NJFC99Y46\M
MU,.*;,CF]HGN4#NS0<(1F+.YH6@E]D:O-A4,<<1_4T)[R5]O-,'C$?XNR/.8
M9?])YR7<!4[M]A(0M=I/MR:OPH,`,C)Y%7&J6E;4(/LBT-)9VO4'+[P%<1>`
MD:YF#P$9V^4GP7%%7CK*70Q0-RP5(&LXT6Q+W^V1@:`J2S=&8#:74?8Y/M"I
MV!U,\JG8+7@,,,5-O+D!(;I/6$'S^ANKDO3$DDHKDAA3F7UZTT]OKM(?8RY\
M7#RW$$;Z(;2F8P]J?](L6US:05L[/3-DRQ+C<TCK)D.Y,`WT%^>R]'`*H&NE
ME3Y`W7$Z6CR=MUPM'C&,Z<\G_((\\E9591Y1JXFS4/NHAW1%[XF66JT?T7"C
M%/VI1O](M?M`?WXM18.@50L-G5:[@`:YZ,[1T!ENU-CP,=AH8('3IH.$S>[A
M0"SV`"C8J#'@^)&(=CPZU?H^G&I]'TYW"0ERT0?[/IP.<[1!@89_9C&#XALI
M&/B-6EAH-]H%*$@%=XZ$]F@^%INX87=A.4M5G;^72JK]?;;+22+9^BX0U>CZ
M>-HM9X\;%SB_U,T]2@20+K1T+89D7-<-N>VZM9#/Z\Q:-NK,B*>P$F^90&4F
MZ53>U%#3KI]^#'[`=;;FFHK[6REQZ[>)/JH\UT%RQCNF*EHQ8[6ZC3(?;I1Q
M8`=+BY>JBYHWQ0>XK.Y0"]LM._6BP7M$39^&/[M_'WAGFEQHQN1@D^5X/@8&
MCJC%\?@K5JH)D.I-]25F_V8"?\J8H9:K0L+B5_5Q@QY$Q2<2K(AZCN5!=&<"
M;E<,C+*JP&&VX*+V"N8EPHLLI99)87@#(K#.>5HD4>7&%>=J%/>G+09S']KS
MP[0S3?:$=A\^1EDI4;OC-4I!DL(@ODI"#`("KI*F1R["!PB>0%%0Z@S@E-KS
M&H.0#@[#(/X(8TH&)3H.,/C0VL'>Y=#S<Y^Q[.#VP^&23;>K4^,ZW]E$GB<>
M=UBWXXW[,GU.:0$/'(['H]LBK"-[&UJO`0YIK[+BX.ANIV9@8/^3,?!"'5';
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M1[L&1M34+R<7+^_>@$>$4Q`5+'/DX9>HM>N]?4W9L/=$,VJCB(3Z:H4+/<G(
MQ;O*AB-Z'=P:?G:)\V>3PHUVXL;M(4W>6CU>2@(G4]3(25R+%1\C)6_)9\NV
M_-.K[M&&IZR';UD<'T;(1G[U9[<Q6`-/LD&\#G<N\23.Y#Q`E'XBUP=2%KF<
M2U#Y%Z3(-C!S<SB3+A)0=;M,G:UI1!T!HA3B<P$E'DT$J.XH<PE3I/YYUP>5
MN)<,5[Q>,X:64@FNT,4;R.N0]7ZS_<]_0(!9:8+-!_;^LSSSU^C43?ZEG78Z
M_]=7UQA3`"DW/EY#Y;I:5PKM_$W95Q8:Q7V]F"/H0$T4)C75(LCM)",+XZ5X
MQ-E\EH?`H=:,8GHD*N860T!1=Z(Q!A@G?LN(I'`=I&"YVO*MNX)LT[6ZO&K4
MU:.441W<4"_%J#)(X?CY95:C<;T.C5?)8Y:2W-GX1:8T6K:#'J_EW*"E+W8O
M)$F'\3&,\1CFER+2:"D!SM1%B9P"1UV-R`EP%&6(/)D4U!CF%S33:"D!SM2%
MS9P"1UW0S`EP%(7,?CHY.?$#.^\WU91Z<Q8'1'%03=RVN]C!:[O3:QQ*Y8RQ
MM,%CPL=W`K<LR\7.Y?R2H#L"\!,3-_<Q5DPN"6FO_!Y26VCY['/H\=J.,-QX
M7JRV2$"/QM>Z8"[<9;+A-<,QY_5$95<\3[Q6-'O?4ZPO3>Q\NDM1GKF?Z[K2
MC5?=RS?`M_SP:\H:=*DJS&IUF3I#'SS,(ROE<7$Y%*]Y-5LM'L<O^E<\I"N#
MIFYS7BD_;O.7`$E#I8T.1S5_/BZ,G07D@4Y[V+]8_8*G(&[,Q)^7A3O'PPW[
M;0^&:_>;&M2NKR#:JFS0*X8&3/D(WT(-'';K4K>@:]2G>LE>K\^N0=9&58/"
M59,A'U>2*8=4,4'"BKO4M*`.M>8=2TN8=-PUY%HK;5#XFG#E]8)BH9!BW^\S
M*E;C\S<G:$9.BBM*HA4*@Z[\8@:*KKN&Y!Z*&[,X@8(O'Y\8X4EP6DKPVAS-
MJJX2-(N[O@0T:RIN=#2+^7);)'&X)6>K`&W:7[(@_%)#M:4*QT&X/G-N"PX.
M#'/3R&W:7P7S%QC#+54X#<Q-H[EMW4-',+>:*AKVJB#]4B>)=NH:%K[]IH=O
M_8C-5!M9\9P"4\E'D#Z@",7H?L/>7.!H:G%'4AR$LBR[%SU.ZFU);^=<P+&*
M1TO2+9D5;`=Z<E"P)M<-)-\N,0!5/>F;()45C]3I)O$"?C</P-X/DP*`:RA)
MA&,K?D38Y?/A]7FF&O<7/QY!F(+H*XJ#--_HU,2HO*,$I:*.NXI3+46-@E01
M)S[N"<KX_PSPV@"A]>8:N"R:[SH:.4H9%8/%^#YN\<FX/H=/,`))9!@C>=TT
MD-CLMNN(E"AI5&0V^5!NX/E<Z?YT^E+W4]Z:V1\5WU_2V%_2\/:2QOZ4N!='
M<O>GQ/>GQ#V#Y/Z4N.<Y2F<5VGU:TEWH=IZ)?/#I3:+^XDB?)G),WKTQ)GVH
M:`BXNLT7M9\M<BB*XZQRE$>,IJJ4X-K"+@HF..+)NFZ")[L=_=5P%L1A%N?_
M>8/B^!+A[P&.A@NU\O'<QU[1>///-8<.RUJ6FEF<%LGD=4Y;6_W\#:8/'1%)
M4T9RTSJ@4,:TG);(L8<80U*TT\$8\W=@A8,):H*Z-L]`'LP73E1TU(%07G^G
M#4452'I%2-9Y:7K0,7JZL&*,O0N[,<]L7%@AE-=?80U]GN4K9U?)EP2#((9_
M@.A7BL$/B/192U(3M4B:941?E%>Z-,!T;MA3"N51%=%!@/+O[!]W`0'T+_\/
M4$L#!!0````(`&&!;4/WQTI5<'\``,KU!P`5`!P`9F%T92TR,#$S,#DS,%]L
M86(N>&UL550)``/EZH-2Y>J#4G5X"P`!!"4.```$.0$``.V];7/<.)(N^OU&
MW/^`V^=$;'=$:=HOO;/3L[MU0I;M.3KKMG1M=<]N.&YL4$64Q&D644.R9&M^
M_07`-Y`$0(!,D*B2/LRT7$QD@L233R;>_^U_?=O%Z`&G6422?__NY1]>?(=P
MLB%AE-S]^W>'["S(-E'TW?]:_]__U[_]/V=GZ"+%08Y#=/N(?L%I&L4QNB#I
MGJ1!3A6@L[-*\"\XP6DE^O[PMRC/#N@RR:FE/+C#Z#__&B0A>O/BY9]^;DJU
M"EU^NOR,_O/-IP^5+F;@77(7);@H$$?)[W]F_W<;9!A]RZ(_9YM[O`L^D`T7
M_O?O[O-\_^<??_SZ]>L?OMVF\1](>O?CJQ<O7O]8EU)*L'^=56)G[*>SEZ_.
M7K_\P[<L_`[1CY9DW+:!D4J<UK`E_?5U)?ORQ__\Y<-G7OFS**$?*-DTI:C.
M2&.E)]^K56GGY<\___PC?_H=_7H(%=\O)3'^A+>(_??73Y=*0S__R"1^3/`=
M:Y\/P2V.J46N(G_<XW__+HMV^QA7O]VG>"O7%:=I2Q7[MC^S;_ORC^S;_H^V
MA1^%JL;LIP_TKY9=_"W'28C#RC+3K?E<W'3S$6K=9-/2&C,,D;3].EM:,5K=
MEZ]?_/SZ!:\L^^6_WV5YM&-U_HCSBR"[O]SM@TU^M;U,HCP*XNO#;1QMKK9;
MG%*G.D_"3SAFTC=ID&14D"(UJ^SP5_SW[P`UYE'.O@>(QA_;GXS5M?714IR1
M0[K!G;?A_X'\2D9-W$)H\1$@*[*+Z>LQCL3)V:^?OT-1"*E_72M!5`MB:E"A
M!Y$M*C6A0A6J="'&J*4V)*K[MQ^;YN@WX7G:AGZ0;JKO1O\<^-:EQ(\;0BEH
MGY^U/OLV)3M8,!,':!+!\6<$H!CE!`'6<FFO^^]7-G['`CS^<,S.1]]7<+^$
MNM^&N5_4N-_U%7>UM'2U_-G5C"'T[&P#7^JUC;.%9'/8X23GZ>[1^MOK[]:?
M\)Y^6?HFM#WO,<*5UI7,_Z(R_.V+\$>J\/<]=<P?E)[YAV?7U`/NR%QS0L+^
M^3Y(\1O:,PLOR&Z/J0UFXCREYNXP\Z<WCXW(=?#(?CK_&J3A#<F#^"]4+']+
M];P/HO2W(#YTR<"5^K*!X-5/(CU7;PO#?PYJIR9#<&-=7@SN[E+>/49W3/@L
M9']NJ3AZ8/*,'#-FX(P-.X1H(]0"[6FE4<"L+4V%SOR#N,9DFR*AK31\>>(N
M;M>C4/?DC]JY63>#%T"\!!*U(D$M&PH5Y4K5B.M&7#GBVA%3CYA^Q`T\._E8
M5#Z[.<P'M>K+#`P<'+>OTR[.>3MVHT[L?O;6L>`Z&6^=T*,YW^2'(*8]I^N4
M;$FZ"]X$,9L4^GR/,;,:G-]FM#.\R3N.;UVN_-@6Y291DG7]IB44-N;4[&&N
M95V(\C&+2AB5THB+LZ`>H"]5B?]O69JPAPL9W9)MMS8NWOBK=Q@%'4B?&:HL
M6RW!>EOB,^/X#!D^&7[W*4$%@/L"IX]:5?(X*VZGS&%_V]RS.!;<QIA'L0]1
M<!O%4?[XD7[80YK28-:=I+8H4LU"&Q69-@9O4:N)\\AFEC1CYR8*UJ)4V1&L
MY1`51*7DPL/;-F`@8QJK,SQM4%(8?_8#=[`SJ7/`C\^%B@#DPXLHKB1/%73*
M"<NCA!WTG.(LR.O/"FZ"-'UD$WW%8'>0L?%N]J"7</"1<*S![0I]O8\V]RC*
MJ-@>;_AD(4&W&.V#*$3!ECH?(@E&CSA(T?<DY782%HUC1/9\-2*MR.9Q$^,5
MBK8H)M12^L/2DXSN'$(U3>C>(29D-75?^SS\VR'+&:ROMKU*=%??698J/XAQ
MJ4G^;EFW:1F.N3&UKYOJ6#<#UZ@197[<3X`67F5CBP\RLO':GF98N'$VKP`)
MFOK,B$N6`%7++86)5M;A+411E'1F8/MQY\3QJDJ6CARQP%G3G*#MYTZ1!8:#
M'3FP<G(LH_#`5ULQK301BDBX<-+C'-Z*U&<V>$](@#X>=K<XO=I>QT'.QI*R
M&_(NN6?)\LT]36+W^)!'FVN2TZI0=%QMS\-#G'_.\>X"QW$W+X)15G[$J<HF
M40#,FTQ+KB;704T3$U6OB_+,_VL-#,6E#B0H0;46)LWU(*8(<4W+\@(07`DL
M:-H<,DUG0RU'[$V@F:&W3L7RR,:M]I6.9P^1`>'91[J?!C@7]==-^IEKTO<:
M^GN0([+/HUWT#URLC-WDT0.;$6%9+2X#%7N0"\%J+P:K@`>KC`6K#3.]<!;K
MF2\J<EY/?7'J7H#L/,_3Z/:0LRS\AO27\32+?#*:L,>'$(?O:;/]%4=W]SD.
MSQ]HI>]P]5:%SJM#SG9FLYWTL@T"<]D4=PVXMSE]`>)<WP5@Z?$,51U8H^B\
M!NNR$RO:86XL79$L&$.5-<3H#57V4&D0-;E0:4`PZL%2R-F<DRR"?<F22=>F
M.^LHGYDHN0/M^3P10JIW3;")6Y%AOE8,$Y0,T^2-Y;AET*&P8DJXV"FU+VJW
M<'_LE*E'N[OBF7SF)Q_@+N53X9]^!S63T1%[4%'2F9*2B`!1`WI"@9AA10DS
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MVEYPF]EE4F0>ESQ)_I7FR%5U9&MRSI.P7`58+^*YX?D/_I:_H?7XO3O"/Y.Y
M:G#?N;EI'=J9OL;$(7WWM=1T7ET;7U<66+^OM,'6_96#:9="7[%2KUA\S7N!
MU9I88=7V%VX1,9.(VUPXKYO-!\G<..]T`AU;%?I_3YMF8,?K3YEM^"C]8;<+
MTD=&(IN&;MHK.JIAL&(;%SM6(T@>_REC!Y?M*!$5PU-L&(LS2S.0)1`4^[>*
MI!0+G\M2A?%GCG+E),\LM0Q+00_LGS11T2X>_>40!RD*HVP3DXR-=YMS%EN@
ME(^@+%F7T92REAYH/SW.4@VOGRYG3>A*_\8V_0C+]&A=-]+A]&'!\G/K!"=Q
M[7`-IG49M?K5K*8IMN;/Q"T6M&^6;#P9*C=H46+^[=O.II9OW&0!H(`F_>!X
M88DV?WH*N%"ECKXB`SC1@@>'Z?BUG',63C.`,*4([<"8,@FGY<?@'R+#FS_<
MD8<?0QS]R"(L^X.'VK,7+\M+QOX'_>F_SRED0@:;MSC;I-%>!$\)4YU(=5JC
M5&3:H7<:JQ//8)1KUIQA)RNPKG]%PL\+GT.G:REB\F4[9\M))(5CY$P:?4(:
M>$T?XC3%X6?6Y?DK7YJ4Z]=7V!0I7]6LR"0HV]0*(`<P-*?&NY&"=?F[+W/A
M5DU/QC1-VS=,2C:^X@G*['+-X8QB%JBQ%-0HR^`'1E0*RX&2KUV4^C%;[@ZM
MJASW./%JE0&K0_X\.*79<"V'N""J2-*W)6D.\:?(AV?`G_,<^7T<='=:2I]U
ML^+B&4PZ+-H!RH-+E08),)<4,E_V;T]2WM;W[^>ZDN;I)KE,1)+=2AMO0EK[
MYI!%"<ZR\\W?#U$6L3CVCOZ5/_*[JW&69_6V9-H=3'&0X<NDO9CY?',?X0=<
MG.]S4<3`"[+;L77W01S]@P?'7Z*8*B-)[_3!Y2I0?O@E*C#)^9;[8M,\?)%Z
MJVED@>JL*YM(,(H*JZ@V*QPR5!EFTW*]+<2"=;[(J;"/>A5`30V69<<%79TL
M[SQMGI^_'DTP>6:\P0J#3H,\>>)C?>:&U"*!U,JE`/4"`LI6XM(!V4JG8HL@
M%0S:_+<I^6_3X[_=,_\MR'^J(8!G!O2;`8&G^YY)L+^5NAC\XV=]U>Q8;D$6
M2=)R`6EQL+^X&UJ[@#3KT&IQO)@UM2X\A/E$N54QO/7$N=7#\1!J.=H$\>S#
M($J[CD<_)':]#(#*[^/G6(>LNO,'N7XMYAG9*.V>_("&VFF=QYHAOG`<8'KF
MW<>5HV6JHQBC\)2PYAV1J'CKU`<B?.*MN8<=GIG+HFV.9&S!5_(Z@9&$/B6>
MZ`""5YPX\W"!EYPX90TPO__I:GN^3Z.8/GXA7_:KEZI6^JJDIBUCT]N>N&Y-
MJ5RS5$U19ET\X-?HL$>(/?-E.=I``Q+#K]U9<B87%E:9S8D(T,X#(#!88MX`
MXKAQH%S\ZA<2@),Q2##T$YV]C#:^WM.0X<.^=?J\VE>/E[XG<#)Z54MGH=`+
M$(A_H=_AGCY^J0W$"JE.(.Y)@3B;PC9,(.XK'W:Q;ADA$/-'S*->>A:(50W8
M@["^I3L`[@CW`3P+(IP$8@!@L$#<`.*X<3`4B#U!@J-`#`$&72`6:.,Y$+M`
M[T`@GHQ>D$#\:!"&)3*](/SHP,TD=J$"\*.U8SVJ@N^CGZ%7UF@2R*K;M@?7
M1SU8'2/`4<"=!(0BV#YZ%6KMVWTXS"[<\LX"[+3&UP?7Q^?0Z@:M@V%U`EH!
M!YE?&0TRO]*&U9X4Z$#2*_O0:C^,],K"O;IE#`:17CT[F,D@4A=FRD$D.1X5
M0TBOAH:0G.+6+B$PGQZ9@%B^/$4&4K^2P[&H,!T87Q@75NF"Y13)%'"\%J9(
M7ATY$@P'F4<C`>HV+4;UQ>&D;P]IE-P5]JN)Z'H.N[NL>Y(.V;U;YCK@+K:Q
MK;>#NVXLJF!X`8ZQQO5'23K0#NEU'H!#%')M8IJQ/Z0T0TCX!8.!H-FG*W*L
MH2F_-V<DPDNG'Z5*<;^.SWX"E7!XXB&]6\F*PX8N6_Y09C/U`O^F^-/U`J/K
MS4[9#R`3+%^<X;7L$LBLC`Y/&.LFUZ<MA778_8*%0>&*U_<D/3_DA)T2N/F$
M0[SCAY.>)V%SQGU1IN-:3G2K]_U-T0V][GSZ>SI;63ZI:E:KQR=84ES:+5S`
MO4)!A@)$Z2(L-NMM28J"2CM*:_5\J$H<TJIVR-`GZ+;:]B<DMOXMY`;P&MUB
M;3"G+#D1U(1VR?5IN#Q4/GVDSL[R;^GVVQ(`XMWFS,EKK>A3V\G%BQ"+LL^>
M;(_!9U^>]!TA^P3'ZM"T#_&Y%[!M`_2S[]IC[@1\U[^S3ZY37&WWF_OX$ZUI
MMR>@*$S[N$%7^Y7\/5M`5>W9=^C**S+?^0+[QOZI'S&@=VC7.VI-Z$0=.YS5
MP/FNVF/G,NB+1IXDH74N/CG&4P?D1.G?>-6),N7,1[(\<^6H1@*ZY.9I<N3K
M>4["$XR?^F%X/O+8O,>H^,QCL*,-]6W>5]M?DQ"G\6.4W%WPW(!/[@X/&IAJ
M4/?]AS5`4[EIG<'YV,"P%:T.ZI-S(RN&>#E&<4U)5!0MEA-YQVW&2--1E"5<
MU3PSI$A+%_Y!WO71EG,CG_6=WC<[//8TQO-N"P/\H0%\JQOT/8WS(8GC(,V:
M`C\\33^PZ#F<FB>X/RIQ=F?H[W?<6OK&$:T]F<<_S#/2>?UC0G[X%M_FETF6
MIQS1;Z-LPP:;/I+DXI"F])>.AYF*EQ]H6'R2IYO69EI.9V!%[;F#A==,`C4B
MJ))9(2J%2K%E'<ZXU8EMR[0=::A4XS4+`\LP<_JY@%:"[ZBKA>K<R2G"6%;T
M@1%XR(`6UNA*<#%J6W[:/4D9]YP:T%0YS?%`#3@U<8NU?M*1D.2L@S$&NPJ'
M*,4;<I=$_\`A"O)BLS:;M*40X6+4X,+9A@-,*O((AYB<D"%\(,G=#4YWS.9?
M4I)E\LQ@2*Q\5;78)"\:LCXM`]!H5_N*LM":/4'L$6_Q%>)/5WZ$^L%F)*:?
MO(UME72#Z9F1`1S"02%2AVP)<<:TS%G.P,.X\=C!H@K/_L$%.`S#XH6=55"O
M$F@C9(5N\9;0COXA"78,1BS2UM&7I&RZ?A<==BN4;>YQ>(CIXV)M0(KW012B
MKU%^'U'H)1@]XB!E18JXGNZ"&)$]3NE;LJ&#QTV,5R@J*H#3/[`YM_@08DIM
MMX><%LA1'.VBG!M8L7_C#.V#1[:^@(J0)!3^2:M.7^R0LM*LVG?!'::*@Z0X
MU*6Y(Y$6V3-C[[X5QM`FV$<Y_3WFTWWD-H[N>#,LO0(!P%D4>0.@LX"/)-@,
M(]B,(;A,OF<8/1B?;!N,&WB12)@U\4#./&*TP#!7G@$_LPP23`82RS4N^FE&
M:[#@=)!D-QS@$99F&068#J9^__\$^_XCH6?5ZY\(O2D',I7+6C94;_2`KRD.
MZ.?Z%^GYB$:RU0%+>MEI!V.8U&/B,3`#)C0G7&A+KNM%:^5SQ`00D_#D'#JS
M1B96;=$YGD)71#B&8BD$0:]L=X2ESMKQ*-FR/AIGW7VQW(R?F44*<$EQM_1I
M68!04Y[[XSO80,_K<80T&N?9+R>$%M7).2[0,B$Z\P4`5]4^U8[!EZ^E4=JJ
M3/GZAF4FN8%5O6"8U]2DVB_,-)CR\,O7Y3EN5\TF<Z\8V0X[9%33MCW.J&CC
M>=X`%>I\E)D@RI*%`>@5^/0C"76)0U6F<+1(A,P@YH(CS2@XW)9/*YQ"39%F
MS`*U*6D'6ROZAFW^9-M)<9+Q<':>IFR#*`NY;QX;D>O@D?UT_C5(PVN<LLH%
M["R-\[`X!"V(RPTQA_R>I&SXIYNPS&.M2G5<6YOF\?-\"PBF<%Y3#<<XMKUN
MGM5W2]1/T??\D+]]H6KAS0-S^0Z9&:`=OG1K5&#:ITP.T.->)\P0DG,;]G5!
M-IL1Z`B$'3I63WWP[1@T'4<XRX/;.,KNJ00O<U8<O[`17@#M6:)>\$]*A$D6
M\4RS:DD$W]:Q=(?RQ/A)V7EX9J@YOC[0.0JGS$S5.8>(*T"B$2180;>/2)0K
M+2%N"EVWR$S(AJHC%&I[S_3B!N!/A%Y,.JDE0#@X,KSYPQUY^#'$T8^LW\K^
MX!W8LQ<OSUZ_Y%U8^M-_ES/E[Z-L$\3_A8/T71*^I5W;#FL-B96MH!:;Q)9#
MUJ>1G$:[FIV4A>I50\4CQ)XA^A"QI\N2P&`C$M,/WG8ZE73C+<:XF#`6P_>$
M?DTCMNJV6@>2G2?,/W<TB8SZ]V-9E"A?V*C$)*A;U&D:ZLT,J1W`I/Q:%*I7
M8A9+E06Y9;W"!@5D1#.U?<6@8.,V7L`->+WF#+ACG<X6\L(6\C:GCCQ5W^L(
ML0>\OG,.\/77>C8G51Z,4+GP4(0S6"IR=N>PM,V=MT%VR[_8(3N["X)]D4#C
M.,^J7[J9=/GS?_,,GR4VY]^B;K8A?59^B<ZS26XEM3,M5^BJ5#M(6W)==))Y
M+OB%_;+P;+F\"8CVR[6QVA)I4*EOORGWL:=D@W&8?<(;'#VP/6#OZ9M<EF.B
ME\7]W=>'VSC:7&VWF%T\U@'%!`W5/>YC-$R[$WE\G:<!?9QAS27*(_2MJT*H
M*848?E%5#I4%45$25447OHUY`M`(0,MW[G"V5R3<[WP,B`<]ILX#X/.;7+,\
MVK'^`S^&95\Y0K7QENE:>B1U*9@KKZT_?:`#=P)\P'J_DX!-H%_$`2Z>T'=B
MI]=OHS1C?8NR:=DY]]5):GRVE=M=N$>QF,\H>AR+^\P"/9*W9!=$2<<G%4^[
MO9+J*4R_I&T+J&=2*S7HFY2RK=Y)\9LO_9-.<_1[*-+VZO91"B%)+T71GE-V
M1XI7(?.Y+'9Q&-[);D/NH&-,T6KOI%51N#O&#6LY<6>EG47#J\2'%$GO#Z_D
M45$`%2567MS3.0H^\NO$[<!7>IN-!L75X?X@%[1/L0B`>2]"<D-/6I9X*F!5
M;O,\*;@"]PR60:SD<,CZ)A:L@3(*"S8N%U52A4MO4YX/W:IMJ?.C>T+2=!$'
M67:U_6O`5@WE5^FGZ.X^+_^57?(KR&[(-?64^R`K*W:UO2#)`T[SB-;UFBK'
M*84#W_=2/NCM&G%LI5KYX\K*M(5#;M]]XKHC9Y73+%MR9'/-%3/&*I6Q\_"X
M\NJ'#!7JF=M5!JK\DETNU=A`M9%R$W!M9N'E4XX=B<R$VL[B+3?&A+5?3XD9
M0!/H$R((EI;71$"AL:\8(*L98",PP+YF@&(P\^M]M+E';!'VYID+8''ZS`8.
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MZCJQ*V%M5$-7EKK6[>F6J@3B11`MPW*&5S\A5HP==_F3)\==C@45F=C2'1JP
M4R)XNL^HADVOEP,W2Y(Y;MFNRO]SB!^+\UI%Q+/"Z'V4!,EF\6TS<T-:F=>>
M)JBA$]`%<?W:\/AL?KU,*PVL^;VX7"XL^+T@]Y]6!<&7J>CMH["]8.F$<6[7
M4*5]2[F&N^3M3^>'NT.6TW)_').]*8N;I6^2XBY)05E;IPF<S.IH,N@K,TKA
M_H2*<LS%_W@<.9P:6J9N/01.,Z_N:3%VZZ71/6<BYQ;D+)5K`'RT.9P#2(_,
MXHX8U/,F<HYQ#9W*E4[RIU5!],>7R[EPD7'9W!&[R$\V+D)5WQ)_F?^G-O-S
MT2>'X)^\0_"4B[!+3CY/PG><D2X;VCN_S?(TV/3NP[8H4EV+;51DVHVT%K6:
MUL,PM*2YE=9$P;J2XB-FA1P2!!>^:]8&`V1,&W7NG34H*5P_.P9N$YR(9@WE
M1-"'*+B-8FKQ/4E_I5Z=Y3@LKMOCV[RSSFV\)8)'ER\_THCRDWQM='UALL0Q
MYM7>:*^M=VMTD*:/+#=\".(#7K$+#LB6/[D-8GXT5':/<8Y"BI45>Y36)E%<
MV>37*AQ*JP@7]YT&W.ZJ7&D?90A_V^--N>+REF:>012BKU%^'R4TX<3HD1UK
M_#U5Q(P3FK4&_$S#S>,FII:C+8I)<H?3'Q9..\?CG4R&8)M7K-4T)..]TT'=
M\;>PNY67E50.\Z'E,%6YZH+@HF1U]O730[EJ!.*D<0YY@^#28'_=`KM)='B"
M(%>,(2P*\@GIXT>2O-OM8_*(L7!7HG0&R$2T_"AZT4DN:E*+:3%GP(+:X[0%
MU_0IJAZW[S+V8Q;&J'F)33.T/417HG&&A9`#.D/B!$`L%:'/SW`%H6(5*-DO
MWR&'0XXJA?`;.\`3$6[@TYY@8%?A"3=:?;W'*;ZE41TE(L18IR_A=>.=OO+,
M2<1.D*-]O.TA/Z2T:Y<=;O^&BR$0%K)8IX\-&Q$JD](R69Y&&U81VI?<%',9
MPG$VY>+F4F4Q,8&"G-8DH[W-:!M1TWNJH.C:AG@;)7PS9W&,_EV*^0LLW*<$
M=`!%>N'``::<[5<:.4]"B_S!LE1UHI]IJ6EG3-G5;>(Y?L;&-.=)&>I8URD'
M\TG?<Q!;B)"1[=<Y(\JLL'`\E$^8A#VA;SYHLH3FLS<YC&OD*4_?.V[L01^W
M-R/\C!*B6YK%\!N&119]SI+\=#'5$8!SN9BK&SFK*<7BU$'Y=9Q:F<Y,>$<&
M9.I;:A=FKKNK>GARNUVBF<TN?O?D[DU]B_7FK74-VYFH;HGV9Z;US3^A6_!;
MP6O\@MNKA)KA$]_T`TB[`X;2Y2L.2D]"L6%=IN%YV(@:V4-EUZ5`>24U3>@%
M&4^2>],&)Y:MTG:"@4*-.RR**-"DW2&P6)(N_'AVR^1."T:JS/Q(@`2<@;O$
M4O_4@RH3OJU8:]\46CA;!8>9(CMU!C,7@9S_\DL4T^<DP>R6S5^"]'><7Y"D
MN+<^LPOUMOJ&D@%S?6Y\TO9]'/NL175&>+6Q]D&O#S;W$7XH>MZTM[OO!ART
MJZWP3O..VV'[($I#OG*%-;Z'V62DRPRQC:E:`SXZ%B>$6J/FN?NQ%$[;.RA^
M_*7M8H4NU"CSO1.QH*M99Y!/T=D@%\KY[G&O)9VFP1CV[%=JS!R17TVYVIL/
MS%UMV1$U[*DTE]8+51=T*X2F7=2JM3PMABIU:RY9E1=9EX.\-(]LCOKQ(W8-
M-!TQ^]"=BTNELL+=I/,A`?;Z:2A`%(<_E4`XYO977O?L$0*@[V4&`T%_Z&DO
MH0D^Z]NY;ZTY?;-UR7+O5%U^']MA3\HIVO("L;J<Y-8VE@6P9U%Q03#:!E%:
M;./B]YJ$4;:)"8U"2U_5/`VUJ@N785`[(=I^P#3$W^!T]^Y;CI.P=TN:\GGY
M(I+GDUQ*:6]:9)6I5;M/7WK-?T+L-U3]N"P@U0U#!K]E&X0]L09_SEL7-%I.
M;&06(XMF+ED1'VU#JZ+DHDT-'!:GMG8_&%;MC6(!!0O'G5&MKX@VDUI_VNZJ
M39#=7]"`?X<_X9C^%MZ0]S30_\;B_'GXMT.6L\:^VO:O'*5]SO:5-.4)T/4N
ML0[ZYC'6[/!R:FSJ;HT9OL3D769NZZC=)^+2]+K4CPH#J+3`7([90-P(:JRP
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MW_(W5,'O`TCOR2F@+LB!8KUG'Q;LHGISM#>E)'#_PIXB_GCAN?WAME0B7-7L
M"HC7XFJ,"QHA<TRE&;L.ZW!Z"(P<UE.\*2=OFXG5`_V3G6S&=OYR8`4"L#9D
MMX\Q2\["0\J/7J^GC%<H2C;Q(2Q6,&]^OTMI?D=_S:,=_6G%L[(4;\A=$OV#
MEN>ZBURMRL>BQ2]>A$"KJG=V#'B%7(P(#=;7QQS71P%)D5"[!-*$Z'[%=NQS
MP]DUB:--=QI&^;Q\.\GS22A7VH/A8IEZ-:S[TNOSS89U@!E=[OE/1;^WO,^B
M./^@),GBJ.%-P&^GSJ*L[OU>4#H.$K;N)JRZNI?75U0JRY>F4G5SD\$6:N.]
M)];@7*(!DBA[ZD%'H"<BB$5O_F-!"`NODQ[3W*I(Z5.#6T5$=<X_M:U?M]L:
ME=_E2_E?;]+]43!0Q#E(&$R(:Y\W]S@\Q/AJ>[[)#T',AXH(7P__ICA*_C,[
M2?XMSH,H[J!J5-GR*UB6G83[4?6<YA&V)M7>8J=I78FS&%H4*&?4BR*H+(-X
M(524HAUJ/L#LC9^-`Q:9U-YM[[12T7BNI65(<K<R#=UU7PCNO(L?W![B(!7[
M]]EAMPO2QRJ-#`HWZ-V,$7#/V*<$%:XA$>`'>VUC?H)7H2EZX#WY[BQ.DZK2
M#'7AW'1.[U$E.:?N/Y!#"4LY#\VZ/C>>,KN7/"$G4:2`/CC)A-3QS2&+$IQE
MPDC,9;&II9Z6E$U&=KQOHI;RBX[6,HDS)M9]6HHYWKB:0,;J7%<%6\.795%Q
M_:=\T>>R5#`5@00(#FUR&*FLH8G1M8&,JB,K`9V?>N0KY>52XEHAV5;`>OF0
M;`G0]U&"0A+3M#=;^F*UI9U'E8`^;?>!3$]]\AV:LE[VG<7`2YZXDR@24%^=
MQ-61RL75K'_%<?P?"?F:?,9!1A(<7K)KTGOW5IC(5K=5Z&6GG<EN4H^)-U,,
MF-"<NJXMN2[O$&;/SWYG`JB20(7(PD>3&S4QL6J)SB'DNB+"T>-ZS4LZRV\D
MIHE(D#Z^CV(:)Z1.HI!I.4=/!L`I%'8AG*&O>L@)NB4J\->_H^*!#Y!7-1@Q
M^KXRB'=$N]#N:5H2TN5]BC0))RE;D/"9=AP.<F3K15L`5XD"X%Q?"PBX*RT,
MH5Y1L`)_=>ME_1P5`CXXP4#;$ILVD+F$O$37,U1ZEW00[J0708[O2-I=YZ21
M:+E#1P+`"Z0V(<#?53R$^;9\!77^*ZI^]@'@\D8B!E]5!N>68!?%'2U+@O?Z
M<!M'F_<Q";I;3)3/6\!M/0>`K<0>!&C;:H<@*TI7@"U^0_Q''^`J:Q@R^"UE
M4!7$ND!M:5@2II_P7<2VI"3YQV#7Q8].I`76K@@`7N56(2#;TSR$VDZ!"KC-
MSXC][@-V%4U%3#ZM#,%MR2Z(NWH63:9I\I(&\642XF__@>79@D*FG3YW92#R
M9KE=D(2YIWHP4^Z4J%/DXG?$'R#ZQ`<\JUJLFQ1K&[:=#;=%>VEP5].BF.:G
M//*-LL5XY=4AS_(@89M_Y``W*-!&N[8`!/0-:@3B!WH[@TZA*UY[2''H)I=:
M5<<$"8)>.(P)`KK>8XZ:MBMIRO7\2FMC&2>K;J1['V6;(/XO'*3OZ2_=`9@!
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M@"T_J[("[K4`W+($$HJLJKG2IP%BY3$B"\/8K]#$#GT;'9WZA2T"E%C8N:?W
M:SI3F&H9GN;R@JKU^='%)0E6K+Q:B34+MVYTV'FV:'ON&-78GC-,.8&M7;!J
MRCTE<$^)6D<.;ZL=!0\XO25>DC/;0?"!)'=G.;O9Z/@Z$(!85IV_Y0669\S#
MPN)FSR"^#J+P,KD(]E$>=(\Z&9"J,BN5U#1/U=N&R)64%C1^IRBS;A[0SGH4
MGD4)VA3/%G:O@28DAM^[XRYR8<$O5-I`R5QN!"PI@<,'3S,:A+!GB"+DXA00
MHDP/'&%D3I*LCA?/RH/(+W.\RV[()\R^9Q3CCSB_3#9DAS^0C/Y^046N4_(0
MA3A\\_AKANE;7>UQRD\`/*\/B%`=!CZ3N9JV79N;Z-SS?(VI'.&\ECJR<6Q\
M+5A858?^(VYDQ?RXMH.H(5180M\S6S^PQ\P<JNRAVT?T/3-)B>\'5%M%C5GT
MI3*\]/G6<SDBF1OL789V:U6D>M?O!YM7N*TMZ(FC)\U`1=Y4VRC.7*HX)Z&<
M$U.M[%?V-R>G0\$PB-0$TQS,].=G6G$%Y*=*+#,FHS%7CD.^HO%-0&O.#A;#
M2<8/@'E7#.9T4TJK0E5B:%AH&L=:U0R")TT-:MC.3,6ZEBONJ#J[99+\FH5*
MM!I[6YB0[-!!QK5=AQJ,R@H.;F@+-/X;V00;9I@+F#R8UM#DHB4T16'T[O2A
MJ8Q;BX!SQABR8]NM_\$K=[5]BV_SMU'&!["O4[R+#KMN^#"5KR+'L/PTQS2M
MST2/-#"C<<;!TFM1A)WCQ(10)86^+^46/K[)O/&)=?MTW&ZHF.!QPQ9`(\&0
M.=BNG%O<<?[O("\L19:>!'2`-27)'S':@.>C'>/M]7=KSFP5R-CYCG61$P2<
M:FYY1L#-F$LD>11&\8'VF/%GO#FDO-_\[AN[+@Z'[^E79JG0(2_?Y5V0)K2'
MG5WCM$B6'N4*SK]%W7U",UBJ\A>7EJ91@_MO,#%G<EI!#0LYM+L6GZ'F(?K"
M'B\]23&#5Y`9X=?A3'<&!;9U^58GPM,?H@3S(5584NZIA6%@0>V2=-M[.XC.
M`5R5G+%I8V3]L9J<V>.T.)KXJ.FRCU<H;E1Y`@P1UMK!6$^H+VC?!ZA68*.R
MQ^1NO&>OR%4J;8CY`1+T\5LI2HUL+WDQ(HR^,*W%&H_CSG!F<%GE$,/1.NW2
M>0D[VNLMV0518I1O],6U>80H[H"M^K5QP4$M*[;<(A16,<:*GR^'OA1B7G*`
MI-D'?%L)%*W'-J6&/%'4[[>'&7/&.;^,!3;M;^N$R?DKG4NF'^WW6C[;K^OC
M+/<H+7`2.:M9)&OR#G8/27$ER=+S6*"0A<HAI)X`DSX4JL%RAZJF'F7[194\
M2?7G\C7`)'^%"I7/CCF,K>-WS1DS#GY[>S=E:/U8Q?SRQVDLTM)L%'5)'L2:
MJ%LIU+AR(;*^89I0P/^UL!NUOR^1?YT.C/DS`8>E+"C'<YU@)&W:-)PFO6\6
M);^,:IBY/;P\5D:UCTTGT_+_G@P`X!1V(7)RA?XA1'9+K*NC?`KV6'I7@K:U
MB-''E6&X(]J%=$\3//5T3,`RT608-#Q5'X+ESP:X"9C0,QLL*N;F/2WA:9D.
ME.*<<9L%FH4]HMX$VR&DFM"6"IDNB<H-0XUHS(:3/*,BTY;5D\_4METHS=*E
M5[JT"C*(@G>RC`Z=;$F67:Y-*WGR`9SJDR$U+26+BHIHZ#`W<I(3F;>I)`<Z
MG@8U2G1&-NG<3%/?6\V6&\<D.Z3X(TE2-B*5]J]_L2K38J;!,@#0-JP7!."'
M30TYPI"&VCV8(.*2J!'E9W+4PCZXCBDHR*@VDSG:0-&N`PY:@N?:`9.P6XCF
MP24C;OKOLVV4!,DF\FHDU`T$]6P_+PCGBPYO#EF4X"R[(+M;VM2L/I_Q/DB#
M',>/[(B%NR3Z!PYOTB#)V#D;))%MX)BHI?S@H[5,<N&)=9\69<8;5_OW6)WK
MJB`22JY04Q8UA9%8VHO=$E,A2(#PT":/D<H:.AE=&]\(YGSS]T.4\>,`-02B
MD.H01$\*A``4MF$<O*]\V(&[91H'%9YXY7RJYNLYE[Z=.\[3$>X[1T^;Q^#_
MH-AN8R*J=@-!%-H7>K4`2&('S%BY1E-P+?SJG3_T&U/G%*JF5WM&74+K'H)>
MR&Z0SA+4")03S+!NCIQ5/_BR20(.2ZH>CGLT+9MNL#]3+-]U8"RO24$Z\N#)
MB+0^\&E)UXQ=@M(N+76J%:JD/-E[8-[XV@1&AQ=-*M,JID]J.A9\<S:+SHG6
M"4?K&3^``.JTH^L_^R""A9/;:YTPD.`5+8R'XY3!!!,:L58W:4#!5]H1&/(=
M_2M_O$QHOP-G>7:990<<7J7LO^S6EH^'W2U.K[;%7?'%T^%$8()2=;8P2BET
M2C'AS=ST_L95R"I#&6-B7?P+1:40X@>[;NZI4<PV7E1_\V?%7B@_J`L(Q;JT
M9[IWJ'.C$;JU"=2HNCKN((^HD\.NM)\.J.J>KU"A#%7:4`D"DJ)*WPH5&IF?
M?GYV36-HG8)SSI>+7`1I^A@E=Y_PGJ0Y#HL-6Y+IWU\P>XT..8PL73:1=>E)
M%#:RKM.8RMZHFI)L=:TKP7)5SB\X8$]W?!U_(;-P1V4L?,C$-FU3A*62A@NL
MK4-&9$OCH&MX%D0UBZA5$79:Z^)[A.?&L"K0^8+B.4-7=G^>A.P_+`0_!#&[
M9.4:IQ$)+Y--2ND.O\7%?WMQR[YH';1LBDYT<?M:3@U75A9U7FVA:,VO86-W
M6O,_A`(K5!1!51GT?55JX3,[1B&(3&G9KKN;:Q!]W<8N;+@RMVP9J_2;.1:!
M-%]]RB[\*D9:^%6[)<3Y'[A1\%1@K(Y;2P-YZ8AUGE<AF`=<HU"E**.-4;TR
M#AQ:42^0G-/,GJT#=S4TP>@8/%6%@P$7U<-'ZYF=HD,NV;/D/JAT3$(-.LX$
MP**#H\R'@KS.](MN_>FBTBYB'!\NK:Y*V?/0]CD/TGQQCF37IBA9DB'T%M]%
M"3L'BHU=Y_<8%;4_8:@J+E8Y%:C^9`_5=TFX/%!_&@`JIK\_%8C^Y`]$E\ZX
M)8-;1EFWIIPV\Y:6<^"VFOHYR\#E-FT=5Z:E<%W/$W`=)`8<=!A-6A>5%!]R
M4ZE%]]%$8M9M4NX,DP/)N70+_.FCUBY1GP>W,X88LMM%Q07OK.8D8?>TXV03
MX>X6*0/)*HSH)*=YZ'`=($*%UHK&$37EUL+#(J$3'R_L908M2RR:H.-'Z@*"
MY^BT@G*\VA`8J\/#AS-W!T`7IP<@)14[AM"\=$N2SSG9_'X=I%?IYYQ=;\ZC
M0W7HM(1V#4L(]#M88K(3&=8)B(Z'K>G]:JC\NA!"&9-:H7V0H@>>";%K%D(2
MQT$J7+6V].RM!23(B#;K.]]`P;83#EJ!YO,!@Y"\[AB'%<]3)'XND$@EV;+:
M0K;,SNM[!DX3AKHH,"<0%XD*TDE4Q>,^WX-,C2JLP3*YP1AI5[C#T?_SQ1]>
MO'C94/6_HN"0WY.4[VLK=H.@,_3RY8O5BQ?\?VS(]#/%<K&"[/6+%6+-P7.I
MER]:4F_QIA1ZR85>_2O?@T+U,F%RR+.<_L%F"!H[J]?_\B^K/_[SSSHKJ]>O
M?UJ]?/G/4AO>.+-JG%:/PKZ3=L=>>^4=Q0'8>=,ID.W3.?]Y5>Z7.+86-R#F
M9=O<:D[R`:>WQ!E;\5E&@:^.KJU5<X)@;;U(>-5L01V0Z@=;P$VB`[9A0Z_Q
M+C)5F4X@+D.C#QLPA]I0!O?A+9(*82GTW6UB5!AQ$.BF`J0?]HJGWL6]41@Q
MB(*@*%F0)\_KA'J(*_N2*KX4)6']H5\'%[S9LF+A&D*Y#G_VNBV>^8>D;=4^
MH@2"RDN:`AI/$;4ZY=3&D#->G0X@%;^B1N0T(&1,M<`@6H1R+X)]E`=Q4==/
M.,/I`P[?D_3](3^DF._'3GHP'EV^3\^FY:$<SJZ^L%1N;-O(/PVU5<>9I*4$
MVI*T.-N$/O7&82UA)'/C44CLN[:9&JG#F];`42PQ,^\@PBR!ZWXT*LM54>F3
MB/>B++I\LK`WB&F+`W_!+L=5,[@^U.>0B*HZ'2U1V(Q14@L7W8ZV&8NT42S8
MZ7CT)S*\<4=U"ZOS1C4>5&FC4$*3-[;T.NU]"):<=3\@@*0>X!&$3@5+QIT0
M<#3-2<-)1N(HY`=27M._-H\W^%O^AIK\O4?#PZ(U#>M$)[K.<"U`:%AK1N<]
MFH+KZS1*-M$^ILD1V:*6[-)>8]"XQ*81NCZC+B'ZC$XO+`.K+<$QL`,,%0PL
M/%^A0@)]*?_+1!&77?J8+#!,J9G8-:IF96)^5RY-WA]P(ED*)'_<,&[G\53W
MD%J#8=:N:JTGM(4I]F/ZB*2\,5%:_+PXSN5-0X8^9P_-+:D6@COE@;FPI1V0
M_\:W=,ESQ6_HTW&VLX:W@%IZ5GYZP&D>L:-!28ZSZ^"1'1/:IRF=5,-6<JFI
M.-;9G@QFA7(MIJ5EUL(#Q)^@\M'B`-<V'C'\TCVPRX1;F)=K`R8YF1'8\R7A
M,,+H3^Q6[HN.0Q"C0Q+BE&TBJQ&TIXT791E)'U'"P21L75A\P\(T1&D(U&-,
M0:]&A$/5ZS:J0GR[]#&D4P&B7*WH!B"+Q-MKJA:G*0[Y:)+\1&LSZ7[\E4M#
MN86N+K"$J[!DY"+2LJT@O:\DBA%T<0#=&__1MKO,CPR`TO<F62&I5\FU.Z)?
MF3'`;HPKD)6=G!IFM4PQNN[+<>?`&#,(ZDY1M@B'?R#)W0U.=V9])YUTG\/E
MTE"^I:L+F&<IC!AYEK2LNH^UHO],-@<*FL7/8#=L<)EC&2"D[U:R0E*WDFMW
M1-XR8Z[Z9=`X8PS.?C^C5=BU>F6\*W9:^#(@[B-"F+->&CC&?.ZUP0!KN!?G
M%%@>].K$C2&_[DE2"&:TOJ8]O6$-0[T_G08WF?IPG5WV$K761R3U&GWBC8;L
MOK2DC!7L(5L*T![/:W4VO7%U:[@-=PB,,3O415`K,N@VZ&HQ2X=570'GG=CY
M?&"@LUOO92EWSQUH8=24?II>8-U57L@/%I^&O"CZ<V:SD1UA_:1D+>QBJJ!3
M$W=S4(TAZTF#JFC+>7GO9H42G+/H%4;9QH,KS<Q:>VA*08X._;Q"669P>J'6
M/<,T5&G+002!!58W+G0&:RX\&ZD!@);EK"8PN.;CZK>THWJ99'EZ8(<S?H@2
M?)GC7?=XV0&I\A,II2:YSH!M`#Y66U#[BZJ,,-*T_!C`4+,1PV_<=@&%<(-]
MI39(1E48@:)20$PP\F2/4/,,?6%/$7^\\,S15(RHB-(52I:BQAO);)!&0DJ)
M-P"S/AJ;D(B_&1P1E<FO/V_N<7B@&0+-.!LF[*`_0U^XN%?(OY&/B@XWL13O
M-^VQ3ZD6GW#>=".OTN@NHA5BOQ;W];Z4H-Y(7O"!`?G)'F%4'Z!48<B6WF7T
MI5N3",4=U-VAQV+]8/G+TH>)F&.!6#=7W[^TQ=K>-F`!.A/1FH/,21R"K\Y3
M&JD5JN3X]U^A<P^N17>!.5T6,Q?JEF+\BXI*F@@ECC+JZ=^TL#06#!<&=$S3
MFH)'"0/#IEX[J,IF#LN#U0\CL:3P:TLL2EU\2(?*WX=MNPLY0[;=Q)\982V-
M3'4AH6?1F:!Z2N`VBV!+P7NI7OO[8(.+\*OMNO?%I/UW40RP$]^W#MF3;VDW
M[<X+A;IC5^PNN@WV)A/4-J*B&Z]L;FE?OI%6=>A%?>[&.!LKH"LO0=%2,W7D
M"0%/@X?9X"8D0)8BRNJ270.RE(M*";,K"N@-\EJ`^T//C*E/=`IZ/"^D:$^%
M<VA;7^H>[1(J%^GJ=<>C;4MN)HR`8-->NEX,P?PE)9D'W388_)@1K`L$+3:/
M1%M2/XTD",AGD;@`Y"228!&<0$OEQO-(3'S-_I\O6O*,*EMMHYHCZK>??(J(
MO:-JAHCK<$>!3+\;XAO1W)+Y\15B#XZQY<T(;6K;+T5>Y]\B_=(@44!*7H4`
M()1%BY!`+O6:`IF+]Y=YL)^]FN9N-9`"QY)&E**8R:E07.CP$\4?@QU^2W9!
MU-VW,R0F1;0H!HCKOG5(=+>TFV)<*-0G;/80?2D>>X5X23,J<*]L<"GZ&VF5
M#XCZ_/2$7Y-@1]*<7;OQMEP?KG4)C;S4-Z3R@$ZBJ0]X(BNW9>H[LM*%$U4+
M\U&*8WZ/,$73+4[P-MI$02S.WVUQP`Z*]\FY=(!0>-DPAJ3N)BFF\CNI!7?)
MM,2<F]P:'('2S%N00V^]V#3B`G)F>;I;T"W%^I<))3Z<Y9\HW117;U]C"O4D
M#^[T*UQ-"DKC@+X@H"^:U!`\,@P8-750K9IU]12E]`GZ/LA0@/;%\X4/$!R!
M$86?6N!+ZJZZ\BJ_U=MT%S5T=MV$CQE@*@TH-7)9B14JRJ"FT%-`KUFXF1N_
M<P:@8@_S)S9.3_\;Y<T!3[V0,RQ:!QF=Z$1G':X%2"#1FM'YI*;@NGJ*EM^6
M:=2<Q.:S=SU(74+T&9U>6)976X+C=0>H*;B[Q`T30(6$/V>QP4%)3<>NP;0$
MY?)3ZN6G+^B%>C3;%@+R$YEE4&KM&#!QCU:1=;6[>\\Z>,5"ZK!A6`^N/1AH
M1HE/:)J[YPNBK,P+VKK<D*EH`YY&)R*D0YW\D2>G(DQ#QC!/0F)CR71TB!X5
M<LI$%)HD%?:=I*!VCM`M-<"6_CB$JDDU&80A87;$=9F#8]KLF'&7@$["C#KU
M](Q#QT/&/..$`\V<?+I/\2;B%W[1OV/,_CA/PO-B2)S_WJ-6\R(URYH4F>@Y
MYK6:ZD)&EG3>9*!@+4JM4"V'@B1$HN32'F8!!C*FL;I>-UQ2=$`3.[`$/FP1
M>!/(#&@L:+Z1XR`,G@`(U>0_-PSG#`D/."9[OE.0C46_8^/4^S3*\%N^M"$_
MWVP.NP-?\O#VD$;)7;=$+V!`*:S#R72%$[T<ZHVTX/^Y8(`$WS%%.@X`J(Z.
M(2:K7Y>2*&A$4<AE47Z/:3>C+H`R'Z:6P!!+X#'3I:*I>D6BFEY'V&@ZM3YP
M_2;/7:P(T8T7%2W;Z&$I9.&"@BI4Z$*]@L_NIX/2,3O@C'E$E&UBDAU2?+6]
M(+L]3C*>Z7PJ5DM>D"S/^%$$;X(,A]?!(WN'K'>)>95$P&BK,HBIVJ;1&LR[
M0/0>)M=$PVD3=:_YL>GW)`[I._Q315\+,Q,0"@DP%#J,-$VI0$=3:P>:#$RK
M#%@FX*_+\!R@5L&&[T4EJ-2"N)KRP)VS6Z8)5:K0%Z8,<6U+[P7QS-64X?](
MG,W#P'\KOLCY;9:GP:8WD0>BS#;L*Y3-PU_:-YF)O%1U`.`NN>JCCO9Z[-DS
MD`F6;>E'JG,$^RCJY@OYO`O2A':+LFN<5F09;<Z3\&T4'^A[=#S34+K\Y(/2
MD_C!L"X`6?^P);6;#Y5=?\0YHD#*V!X'M"&['<T\,B:Y0K=,EL\=A(4T^CY*
M4$CB.$@+>2ZX\*X(4TP0RX9K^^U`H<8Q![5#YM@#QJ!R:(<`9#EP)<*V*A1I
M[@J]J;%7"IX6R%39Z5PP6X[@KTD<;1Y5PT:&T@J"[TF#.I>B+@X(OF_)W+^Z
M93G!?V`$7WN77ZZD:F*E*^DQH7"D3B&U(_6TN^3KCC%7?`V()Q5?%V+H2_E?
M;X8EH-%F2MRN\#8C<>_V,7G$F'?TKGA]?L&[6YQV*7M(KB)KM=PTGQJR/]&7
M-.HU7J0LM:X>%3>]HN(A^E(\7MI;!MN2&'_VCG^HQ`7/4&L$Y6"5&=!U7L"P
MX;1;`8??A(V*SW'\>%$RJD/$+,2BP_PYS)SPG&G/EC;8MT5]39.?KZ\]`K<1
MK(T)4`MDYZ0WANX,`^2XUFZQ6Q$6/8R'%A`PXC0`$"S`8SA]B#:XF=@2!Y\_
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M;N-H@\AVB_DVX7W*Z,K+-;LFK4UL6J7CUIH2@C=J]8+&=HTEL)#L`E3*;>JT
MQXQI?"O*HJKPJED2YL6]U7`X4P80YTB;FZY_3:+\FB+YGL:E\[L48[YS1+YT
MP;A`B[KU!0`<S:1&8#0^8&S([[3%U^^^T0?)'0YN8UPP]]))HGF3$_M&D?F6
MKES7P_0VX!E=9P^6UQVBC'=R"AYG8JB20XV@+\LQG(!/3^USP6]&FL_R:!?D
M^&K[/HC2WX+X@.L_FFV%<L(?4;2B?JNBTWQS1"TAPH&=68W+VBA:\_[APGXY
M!A9D2G-U/-5"@^"S5G9!@X>%9;`PL@0Z>6@IY=E:%B:(N"3Z!0=,CO<J/(DN
MLZ%8&7$6Q_%\4:BNXIM'`0KO4_SW`TXVCY(+L"U*E)_5J,0D3[:HTS3W-3.D
M]EJ3\FO1)^M'7MRM;=/V9$3CM/W0H&#C?D96O/.Z\RP[[(KQXFK]X6\D#O(H
MIGDLN^),Y7S&!;L^:%`0QA6-:PB0\UD9-?#.837-<M&'^H%7MU2.0$K?8VU1
MUG7<P?(2_S6P"9D$FMN%2@%G!RM+_X243Y!?H1K&31%^;^53`*\J_UL6O@M$
MH0]1<,OJ%^&LC)WA5?()LRO>HN2.G6F17?#QS\N$K?8)8C;7^9<@2MB!!JH(
M!:*T&[TF*H5A"I`W@XQZ4RMD0#+33*R+9RA*T)81T0-3Z0G%P."T3S^0^.\2
MTR3=$M*:6%<G\7A2G<!CM>\NUH[Q*R0HJ\9X0L1/,RWU\:.=V-*HVC,;I8AI
M1=\SO;YDL5YZZ6`"<51^NDSW%^?9>1+J7XP*?"1LF;'PGC=L+E;3.P;1*^D\
M3]0+UE<!>3^XCLS4ZICU<Z99$3M!PA@1)<&&%=E1=V)Q](67]67<#0S8TNX2
MI,](^E*3U,N[6A-K[!TAOGFL__S?$4XI-.X?/["%7_J!>(-"_;%X;2&HX7B#
MFH&-R.MM&0W*ZU2T\JOZN6_C\B90D`W-FT.H/SJO*2L=H-?:\M`G*WYYO(B#
M+-.[HEJV[X$R62C'4]<#S-^D)HS<3%)R7?^&^(^^^96F767N-`B#OA?UBTB=
M1Z;9.Y\1TZLZ$$O7,MD4Z7J0M@B,(QG4"G(D3V_.P+=T"M;U#YYXE4F3]YW+
M'"A='].4E+B:UHZ3(2^-1?`!+9=(ZPY&J3I;?BPX<@?'P?&AV0"YV-@.3^Q>
MW1#^WY<W:9!D6\J%TLUG8XK*1V@&BD(.PAC5$GB)@X%9X_$4O:)U]0-;-ACP
M`HAY#8J9.'K%4<K_?.F)$]M@1S4(8H,\^3B'5H-R*&/`KJME#T.672Q\F`W"
MW5A4%%FA#PV`BS]?HKKDRHM=<_-!VF0AQ#*@7K;K4J\>?$MV0908]%P4)30=
MEUX)\%1242?X/+)OR"Z-[)97Y9#BHMA"U,,,4H4$;0*IAX\F>^P4U">//2O>
M^:"PB.I3E/U.*XPOV9W..,L-%\7JBFF6Q,J+@2\PU-7.T7)8A4F[]852)6OV
MZ]F6_HRB\G>4LL5QOB^'U6)$NY[0`%V2$*HKK5])*+?G>AFLS*K+1;#.(*I;
M`,OD64#!J"KAZ?I76+3:K'V=!Z_+KGLMLU-29JMFXQ2VY36K60?*@R^I,ZJO
MHS6J0[;MULKIM;4&,&)A49PPBO&R&<5XY8G?6R-+N[+-!IQ='C!5HU^M-E`#
MUPM(M>9=KA6=$>J:%:"K>HBC'NUXY>UHQXS0MUF_N13XE^A]A7\[9#GK*5YM
M_QJDM+ZY<L&#3K;7SY+*`J6MFGI`9:IR$R;IJ:QD*R.M!5B8JD0\<4AM$TL2
MSV%$]')-21%9@BG5[*87)#$%>C&=(U2Q("#;:\-@M:=<@5.V#Z"XN>[KR<%L
MN%/C#FA^;MO[-2&W&4X?V'+7RV1_X&>5)AM:BI]AVEU-I!_G=FUOQ&:_D?9F
MVZ$TZ7O,MW5I;#5A=C6-LR[&S]O'.MVMEP_Z-3/@W'=&;6V"<%=-S@QJ=MQV
MJ)%OZ!W72[:5W^!T9S`3(A,W.!2D$'=VM()8&\<'@)2FQIVDP`NO/V$&"[9D
MC8(G3X--?@AB1.NT\X1>AMK;Z'0$"4(TH\)B*;-S$`K]<QW>P:S-<63'9'@9
M'<]Q<X)8&W/^!BS:EET6:3O=8%%4LRS2]22#12T=+8N<-MYJHFA@6:2'$PHV
MV-&N(1LYC6"@0;^";.;)`P/++I=%.H>P?EGD44P4.(>TS;+(>4&]]/F@O&ME
M?#9H3UI[+J@@[>!,T%Y=7)P'*AJQ/0NT*=LZ!Y3_[-N>2&T;#YS_J0)%U\?D
MA8;._12T>^=)0JYZGH2_X/R>A"0F=X_O22H[TN#\-N-=3H.^_BA]FL$`2WW@
M?;E1[^-H.,&V+G8=0COM:Z$D`SB_7C/$;$`B2C#*[[%_YZQ-AJFV7SD%^9IN
MIY5:?;_4LH:NATFLJN-R',4COU*/Q/!S@01%_';T0A5_)!ZW]J52YTN@]LCS
M;(9\?/6]XSHG[0,-")<YWJE7\`#J!CPO3="]^)EIO?>$'[B:7"^W!Z@UE@J"
M+!:5[(0-Z?YP'1R:00])4SF+?%!AF@G8P]*$FCL<:YM6-4>#<<?BEO+AO%YJ
M(C\)MG?F83G8P+0CKMZC3,9W[S8<-#Q*_UYV-_9?H_R^MYPC:Z_G^-1YL7)M
M![OR%2LS(!<V-#N^`6R`[Q$'>V]'AV%!U,]N,_ITB^OJHF$V28A]NT'6+?JU
MN]RAG:S+L)"F]#OI`=[$]4%BDZOH\N2Q(W1KS=EFZ"M5CD3MJ%"/VOI7_5/X
M:R.K^A+W9WX`@.SI,X0?:U'?1@]1B)/0\LHZ63&#M:GM8LY6$,IJYWBM:L?D
MN$6%+27-175A^3-ZC'`<>G\ZAQ8C1FL,->@R6&DHEC9;<=BV-]<Z5]'J'.M=
MP2%JM/ZU*N#IX1RP8!VS,-8M7/WO^6>**,IU`?7\C6Q,[/D/V%BD?V#TWB:,
M0Z--1,+/>9#F\/W_H5K"=Q3T%M=O@IAW_X.<K\BXQ7=1PC>1D"W_H?@:GI"9
M$U>8G.;;>-S$)%]K:GJ2/_`F/@P#:*MHEUH4T'Z7A"?OYBQ[Z3@Z2U.>71P8
M=<]./H>3OUYVK,\WWWX]>:POTPWV%7J?V6$Z7$^?'3PX'M'V&@?;\D/'([J^
MT,&VOBZ/1YQV+KZQ-I/C$3V\Y,$:6<-GQ(V\[L%4C<$)<3-?_&!JWOGQB/-`
MW>!XQ*.X#&)&Z%L?C[@`^!<(BV^C;!,3%O@'MV9I1+O!3BH*X^F:6@"YM-R"
M@??*"JJN:?;$`75MVO>U801TG4I20N(_4KW>N8K8?.*R0_.;(-6E=)=!RDK!
M7]&GKINK*R&E%BWOZI/H6-/?SNH?/?$S0Q3H+^0;A(^FQR@I/'`IG\R:\XLB
M^T:=WA7I!H+Z&R-;B],]OC02$*965T?.`-2%@T?]8WUCN/&57(-E=8%$71;>
MD8?JZ<"9-28M75JI2<SFZF>^G<YI!1>]*QNB3>?.*A4#3JVV[)UK7VW?1TF0
M;*(@ODQH]GK@+W!-XFCSJ')IDS)=5]:7@7%ADWI!YH,#]@S\5JMA?5T?$_Z9
M'Q->'H#=S%IXXK-&>.C[J@6,NCZJ*RKQ3;TE)WFASB1X5N@6B)U5@62+:EDD
M"*]0^?V_E/^]P=]R](:2V.^^!!<'0!W,#F>$ZK(C<*RY>6L;#,'U9#5C<((L
M^"!<KQZ0X4%AQVXLKBEY/(-Q_=;5CL:IP*`9CJN+Z,?C!,U.2%YF"IS<86'4
M(7-!!'WQC[`!0#5(T`YAM2@ALWWDQ<S-P&4B!D74]"PI`NU;REJ!.YC,DI6?
M]14H6-NW;K<)!G3^-H0<M=/U2FI]3V+'.Q?4'_M@<A?&8"KEP`3\E3_@B9N#
MMW:T<`B@>K-<Z"-DEY\W]S@\Q+Q_E[:$^,GJ<=Q:E+2KCJ\)<O%NLT/&Y@6*
MA1NO41;=)=$VVK`QBX.X/C/B2_(\H3X7ON3B"B#3-!G0DI.+?EPGY8`U=+G@
MZN@H0K-L2W&:5;G(NK\TN[,RF_8\^#/_^A]'QPTV"\6.FQT62.R*E>0\NKW6
MKYM12W;3+)DD#`^JZP"9]$BM&!"3I-SZLY`OR/9S?%\F%KX<D:!IY;Z3#T*B
MZZG]`A*'DVEU$E7[AL"#(QR4NJ&JD%C5B:EG"U<FXFB0\QTAZ2B[UA=!O#G$
MQ6$_)([?D_1KD(;N^MEZ>_"=;I4]7W)K_??PJSNNK.LLB;?"^OI3KW,^W#'W
MA.B<NY.+W-K(@^'3;+E9)SFWZ@T][9[+J^MA7]U'_G#7BU\AP2+ZPFRBTJ@O
MB=8)\<\,'7WO&>@H$U`^U.5P7D=4[V!.IU#O2RAHO:TWO%_5:I[Q66[,[<CL
MZ?!WVSV<#,5*'-#!("QO,B<#L$7]3Y!Y/PS=O^3`!#P#?X"^C<G!6_O5C?]@
M=PD,I$'/KVAR`7@7G*IR*WA>_:"YUP7T/3SM6W]P=HO3,?NQRZGO#]Y=[71T
MK#!#7]@37EAVTONE\:3W2^-)[Y?.)KU?SC+I_7+D3&55;OW_'@@[5?TZC3:4
M3:($G6_RZ`&C7X+T=W9Q'+O>]C*D24.T">+J-KER)OREAS/AW:;7SF#*<:*9
MOWQI,G_Y<JZ9\)?N9\(GXDL_$_[2XYGP,3BRF0F'1-*RM/S*F)9?&=/R*V>T
M_&H66GXUTFVJ<JVU2%?Y/07*E6H]TBL/6;C;TEKOD<-"XSNO3'SGU5PL_,H]
M"T^$DYZ%7WG,PF-P9,/"D$CR<U`28B\/Q&:=)7;C++W=!GZQO&+#C,'6&-K7
M#]C&FG*`X)9I\\3?1R%P5(\><`_+Q&7H'NQ"672;B4/7&#E:=M2[0*#]`V)(
M:RX/F3'N5D>C"-6O7ZG9)-R-M':EJMAJ6FH:7]C5#2)^&EO4T(*ACK7P?&%?
MML0`&=E`'6\U*RSXIZDUT)AE9A0L2LT'0!Z)ZK.JQ#C4Q"?A")33AJ@RI"P$
MTOG"QE^"*/E`LNPJH;7;DRQB-;K:%F/I+SL^829<?L(AX4E^:5:3:<XX:$/M
M@P-%U^PY^IY)_,"R/4&(]9@*L64]SK"IB5V#M+U+7Z9QJB'=D(2OMV7(\S\7
MT$KP79!CS>6"SA#&R)T]9>`*^7/*\>RHBI-#EHJYY\'6O#R=L8IB6M5WWW+:
M$SE$V3U;,76U?8MONY=[&,L+;#T@/]FOC.HSG;.'S.B=2E^:,W=64#<NR+LM
MQ[R,22[O8V:M3ZP;J.]GVF)M5QNP`,WD6G,.R-PA]$1*QSW(A2<).1VYSP6Z
M&2D>)S@-XO,D/`]W41*Q^W+8<I=WW_8XR;H@-Y2NZ'U(>IJKF=4%8(1FV)+&
MQ0;*KDL!%"0A"EHB"[N685,3R_;H.)6^D.!20]I!65QO#&K@Q2&N&'&+R&H+
MH5+JM!"F).Z9,.8-:4N7'UF5,2-PD"5)5O5R3^8&ZTK,-!PKL:O6EXS!CYD#
M=E><&%J:D?!AUS/-A$"S$.#)4B>7H!P9%YS`<KX8<9ELR`Y_SFG_D?4[%->Q
M#DB5'TPI-<GI!FQ/<S*U<K5;J<JL+T@2LC8.$?TK(W$4LEXYJB4SUAN^VN.T
MN,N>N]L%V>U3?$^+,6]CG<%E/6RHI8EAL[1]2"'<>(U2FZ=^\H%9HG4Z_Q9U
MMR4;2,K]I2T)Z3.R.H#Z3<>`L>^TRJV+AXV_H.HQ^L($%HX])NVJ\@X-".0>
M(A90>DE;J^>>(KW+PDA6[RT@MU<8U<.)QQC<5Z$OJ?,:+^ZJ,&OC(<_1W4ZA
M+3+H/;[=1T&KF>(@PV]Q\=_+Y'RSX3=G7`>/;*4E2RTWF_2`0V$A1]^Q)BAI
M/&Z4DJFN.*'FDWUTG&VM\XY1N:[*H>^KDC\4FTR+PJ@L7739BO+(FU5[$]%'
M8+#0(XD1NEKL,:HND.,/X^I@-R`Q,"[FC8NP<8O:&_:"-P2E-^"BP_VD74$U
MIN&G,RP98\MN>7)W$>RC/(C5`R&6!96Q5%T0F".&:@@=,S7V;$A`J485&^L"
MJ"Q!NXUEF>538%O4:!S?$'%*5U>5U[FWVJ;;^*:RZSBF.88PBUT7]U1+<7((
MJ8%;K('D84S8FOCGIX!>\U`U)WZ7#$G7*=X'4?BVO$R^G$"@D96?:U"L`AT,
M3S9*E*'*3`FPZ]O4'#J$&=JVX0(CE:K05A:N9^,8012G6_BP'G\BZC1D,0*]
M2MHPT:6C$+.ZN`V')G4`7CKJC7.PH%GY0=6WXXY`N".P+;!L]-.';03+.H1Y
M)/7!)9:,L)\PS0*B#<7_19#=#\92N;@R:G;%@;E`7AOH2-BS8N/6G<*JZ-:(
M(2;GF^\JFEWCI5J@*+VQ74KG=UW];H-.VYKS\`*(.!8R!'!M3A!<YF3O"EYS
M$CCMR-.ZE6.,%T7$I^'F(_WBQ3]Z'&Y<HJ9Q@Q(3'<RX3E/)W,20SKN&RZ\K
MH7I"JA1#5`XU@DN[G3D,R(AVZKK>8$'1^PRLP/+[H$'@P37G*"RG@OBL3U2*
MKU!RXN!3,_^\\%N:_XTHWXCEG7B6<U<:X3TR=_'85TS=P\8?AEQ@#M*%VBD`
MA@M&I-V`OJHB^C$CPXXKIV)C1D;,LD-`O]G5]G-.-K]3WOYKD*9!DF?O2?H9
MIP_L</JK]"(.HM[U2:/*5OQI5W::[XRIYT2'LC2I\3,K3>M*G&T4X`7X`&=5
MA-\I4!5"].^BV,*..0I&9%+K=IS81H7@VW:60<.!C6G8;'P99//`4A;@NV`V
M9+<C"<HXQAFL<[RY3TA,[AZ?#IR54<D#0,\7PX0%8O*,7BU0?C:9P"3_5%LT
M<D&2![':!:7*U7XF$5_?,`OUC%?LR[)?34.1X4_;]H&^7`-TF0Y(>N[KA\K4
M)[<]/VFG^=63Y'Q<PZOH#[;I%R$RRKV<@^])'-*`_.[OARA_5-.:5KQ/<@IQ
M*,QK:P-+@"I31BXA+UR28RPZ"87N`T[SB(U/[]-RMKI,/EB"G0EJ_@F%>!MM
M(G]<2H\.F8.9X*GO;-)24M=3Z'?$P5)K#A@9'HP=MN98*YZ<&K@,N-PQO)9,
M6!6;!88%E0DLT&:`X1H`]"FU1FR2&^$DA7YJN_`B:(.VU*0Z^B7Z:GE=XN-F
M";[:CKL<>")<5#FQ-]L_8+!CGBY#HL>?]'F89(V*&:;3\`1L5#M8.AXR.3ZS
M::BZY7DGF&@;N:H-\@PS(ZT3#]B;,Q%W&![<PU>=H/L8/!SA<VSN[@ZA,P8=
MDMS=X'3'3EM6!1B-2!5,I"+3W$YC=:*#R35KG$E68,U^/6,_\R/E5^P@LUV4
M%\><%0>;)6R_'4XVRX]+ZUJ0F'SQCF-()`4GD.KQ$?`:H&L`#@ALR$'%MEHS
M-)<HSAF*0X[B!-='UK/+2?B9!OZ`5P_:8;#*00J<+PB:P7*",8U;7$I0->_R
M]UZ8-Z0R($]NRF5X1G65LE9&PCQ05R%K[4+TP!3ZS7`K7%5\I#%6<ZFJ29-+
MT"ZY$E6AR165@5_Z"P22/LNA+][<Q#L%%"8D"`6+96A1L=I%+2&A1*#U+FJ;
MP'1HM.I!(M]+U*K%+WN2LD;U!^?J!1"##2M!>'\!A$R+*]*#7OTR'0A]NFN&
M^W\)\D/JPS*HD6@P83P_\/#:4<=M+"A>-S.&)1^P3ES<[]L=*3!>SP.,9<*@
M<O.N7D@2#,&VZ.HM`X=$PWV0BB*]P!CC+/,W.NKV/!JUMP3ZLGV-*EVNF''L
MYEFS8#D)(K*0^>[;)CZ$_*A$CX.G/5A,0JAG<'$52Z=AYK5R:/2$J,4DKL*A
M9;[H^DOP+=H==M+[W:3/RM?O/)N$=JD=@,C9U:M&=EMR7?YS6;S*OS[1?K0V
M-ELB#20[)2%YJZ4:*KJ-;$86R\H?/+F1S*9%5=$)HDWG8Q?*>-LH"9)-1$-1
M,^'_/HC2WX+X@-]&V28FV2'MPLF^8/F9;`I.@KI]#0$8S<JHVD\LU*RI[%DM
M[,_^L1$`(>.;KNV#YN4;![6Q"<G(YG:AZ'IVC#*B%Z7%Q4B(R2->`#4EG@)T
M50%D6?#.&'IPSDZDNT[)0Q3B\,WCKQD.+Y/WQ7LD=^>;/'HH5CGSF=$#_:VY
M;U&QO@M6:16R@)1.XPG0-YO((%!UT;`+C(DUU<//(465)G3[B+YGRE"4_(!J
M?:A1N$*-2O&&3U\6D0)CG+A!6(?40'0+A`=45]!(#E(GT!-"CL9168K0^&)0
MEWGV-!.DG(*O+9YXU+>*0"8>(Y7J$P]KI2YH;>2;N2,U^PI9DYJMB75SBY7G
ME#86IT.4-@W_>D*SU#U(:-9UG2%YL*P3V!#!L;@8'UK0I_B-#QY]BN^)EUHF
M'I[[Z;$D'J`)!VBBL2CU^4!X#HD.DMZ.F=.@N<P%@T$QET^9A>5PA'Y)B[=>
M5J41[%(9]O'#SDV>)Y&\0[N0FS1@+B=:/.P;CI^`3G"`3FPL.ESJPT2&PW%1
MR(D++SG+%K!`8Z<N1DRA1DI]FHV8(^PO[V6ML+\7_&Q[8E,1T&[D9NIA+D=:
M//1?)@\X@^KQ6RK3AWYC92ZXR?)-G(1^\SI8DY*IZJ'07^LYTM!O"]@ASAKG
M`'K&,M0YR%C&=9LA]!O698[0O[R727O\4>U9GH?]A5S(,NQ[YD3'$O;M5AB,
M5`J2!KA=83#RS99,"Z;,?-J:`$P3?)_W'(MQ(-H;M3K!4C<4"<ZZ.L&R3G,L
M;?3/48M[.$\KL7#M:6X2C:5\;=;$XS+9D!W^0#+)\$'_69,&B,^F<D7?#DQ7
MHJ57Z[>")(^3,?V+G[)'?]ZG^!XG6?2`^<^+^Z&D58CV8_9\HA%I05LL"1P-
M&M6`2\[&-&_5CRM^0=^SWWY`YWF>1K>'G-WSRS[)=;#\O6HV+:WAOT7;VNY\
MB\$`/JK!V?E0E'Q)'(5!3G/=I'3O(VI=Q5$5$*T[7ZRIY^$_X"##V?M#?DCQ
M+U'"MKE?!X_\8-.W!ZSHS8XL77XPZ]*3?&!D7:?QH;U1M0/9ZA+6K1<E5J@H
M@\I"J"J%:#'Z,,HV08S^"P=I=?;0PI>BC847F=CF;8>V5-*XO+5U[TCAW;<]
MS;&P:C!K4*[KZ'TY&)=6V0<(<#H;!K[:*R5X)2Z?+7R/VG`K]OUIH,&[GM,5
ME_A(7R-D`J0T`Y7X`L.$)<0-4*JGWHSP04!&E1V[!,V"%#I$G4.4">T`@'UZ
MF6X+S%?W`Y,>,7H&<@-P&T):`V7'O.>,[^S:7,YOQ]?>QB0VH<6]ZPQ>)C?4
M*F8=!26MV6NPZQ2V-<S1,935&3*_M+(^N9?8TL=/']L$U#/BF`^V-50<,RUL
MO+6^Y61+4D3Q\T=/G'4$T&R[AQJTVG411476W<1V+9P$"?,*@(>1Y=#?#D4#
M(R4K-E3"%AGQ\GRLQ)>H-;,C#$8^3US!N^@IOV-F7&&[F`ES,\VXFLX7*4UN
MK+!4-28^_G04M*"\\V(2'NVHH'=/AJWM!6(A\#4\BT';*O@5TP0?V55F-U]Q
M_$`E2)+?'T<`!$+ZQ+#G&.L+!#OE2A6-1#=L@:U:T=B$'.<RG/&6R:_YK#!#
M;A5$%M_@H6NHOI<,+621"$K0[FJA@\0`.$>/;_TVV[86NQPG!`;9$`@$WB7Q
MM`?RE4P;`.N4MQ[^JLO/U/?OU'?6H:_&-D37O](V)JW_9T\<U1I>(_KZ<H1:
M]_-+-6-Z^74-EAGN*LW//]CE!.\C![J^DN,:YH(#_O0A+O?0GS$RIG=!$OV#
M9ZS-TDWZC_,DO*8.1ZO._WFU?5]=8O"9_H+Y.ZD6$$'JK"(HC,YI%`/Y7A-)
M!Z@J&B("L;`6U?!%_I\/NUV0/K(;[CY'=TFTC6BLSM'Y9D,.">>P:VIJL_@F
M'%@0$R<8ZA`8A&J!U&!J>A)$U]S10J4%V#:HK4![@[_E;^AK_`[)B1/,0]#G
M*//+,>V$KP71_9F_ZHY(?$QEGBC?3W%0F-`PG2(@HLB(6@`%G%'O#]K_G+GV
M8-W7I\Q7O/,LV.1G,#16.8&)=AF+U9918UJX'J\@/3W3H2^L!HA78>DUWT^.
M]I3]_V?BFS\IS^]Q>IYE.,_ZMXI7F;-.IDIOY3+3"%UG%R)15.C7L*.TQ)K_
MC`+^^\)DHFTJ8O1E.TXI$Q4\1ZX)-*[+3(`%7Q@,\##&45`\6:'FV?$B0DG4
M#C`Q,^71BD4)Y0><Y>5^`1GIJ:5$VI-)34>\VC8`XJ7*!S`O*5-B7GA2[3GQ
M`/2:QB.&7UH"^[YP!_@R;>!TV#=B2(@_%_!(\!T['F(@-L*@A''CNRR/=OQ`
MBKS8D[;=XI0EY!N2T>3]^RC9Q(>P^6$?1.'2:S<F8DA+G@Y0-#^!DO:"$SV/
MZH4[=*H2!G$<?4V@\DJ=H6$74A0M^38J5SB5^SE_6+%C7OSPEH%F[CF-$2PZ
MGB,OTW<@E6X7;"RW!9JEND!4D[>*(O42NE+*$R:&P=80+[M%UWPL?4U#Z&7R
M'U%"_[\()!T`JP7*#R,3F.0L:HO3W$.J5^T2$O$U^^TL2L[8KZCZ>5G8:]J'
M#'_1-KC[<@V@93H@*;*O'_2HT\F-SP_)H\W`#@NNNS'8AV[,.`2H"`X6`W,2
M6;%^ZX:<;_Y^B%)\G3+NS1^O8S;*FH3OZ*_[77_<TKY@37SF!2>ZAFT-IQ*E
MA3V=#QFK6=>;G"C62FE4B:\0+[#B,S9UF:5]SAHT9'QS=CW4M+SHN>8V85G=
MU"[PR,3L&&;QX9I^AWNV=)ULV5587)"C%C\EU*HCRY*XG3\276T_YV3S^V66
M'=@NAPLV9*6(/3K13K21BX(XJ:X6,!%%86'8_Z0%FZC!%BVQYZ@20%S"#V_3
M-F[/OPR@T/$G68F^!\GUNN!ZF25'[`Z*)\;@%_6X,MM]01LWP1N^H.1KE+.\
M/\K9@I+]X3:.-O7P]*G`;(BXCP)HD,=KNX'9Z^_65^V)#8:WDP&1XF!N]R":
M,<+39O\8[/!;L@NBI!O3I0^K*-YY.,T/I)8F1NJN3@W(VZ)K]F_$?D!?BI\6
M7C*G:`BB_WP=U+9D!)QVROJ&S/-O42_7E#SJH+)X!())T0H,(DN-PWCD@B(:
MV0^>8+'U\7M(E#1-!X=,HH_"HIPW&*2Z<)KBD%/XY_N``N;\D-^3-/H'#KNH
M-!*N<#H@/`VY1C6!R"J&#&D@KB^Z_C4)<1;=)7P-Q;X21AF37J&@ED09+[JP
M3Y@U/;%KH([?:,L(GC2@&S1]U=J"F@QVAC(^T%5#ZW,!K4((-5*G!"UEOV@6
M<,U*W*PG4LY1GR>AL$13?FZB18F&PH=+3'4OTSK!D+F!-:VO#99?ET+UR>Q\
M3)GP!1G5LEH?EI7;H(&,:*Z>]PT5;+G@L!5@DA\R",CTKB%8<CX'8;74A6&P
MO9C]PH>5[*Y`J`D"L\)PSG!`WI-T%_R"=[<X[3&_[&%-\NV'$SU)9@F$NCN*
M=2[2$J6^0!#_86FL2QN!Z#]=%[^BC`C5=EE8<A1UP_'@R/8LV*UL4?2E^''I
M`0.KIE63$T3CSDHY&XS#[#W]!I_POIQ.O]JR6=[\L4]!!L(-)6F%I^+9H":3
MT:VWH46[KNBZ>EX<C/I](X+(]@=42"WN#29-3>P:I.<KFC(MW]'J!B9*C2W8
M!9*N\,7O;J^FY<F6'^M(DFI,BMT\2W],ZV*+]V$@D:;AY1FPM@QO7Y#D`:=Y
M=!OCM_BV/V(P*"EA[)XDF%<IZ@#L4'TK9M[4+=>AZDWSF*TWVT591M)'E)#<
M)S=2-;/4A_28D+A/IX#<=WI:79%TQQ!@:@N-I3+I%=`D""`F<1H(,J%@%QA:
MAGRK0'NU%:K;'G_6$+)%:0E)&Y4&\S2+NL+YGIE1,W\TT=7Q4#&-$KVU,QWC
MC^/:`$KJS/:(E+BW@1*YRQM9=Q5*#(P[ZP#,C/-^%T',:SJSV&6/H7TVP-."
MO$E,6Q+T2\>^#R2YN\'I;J#_H2^@C7#M`@Y\7E8C%W&L8\?6I5O%-=&*R9U1
M`MIYEED.0&#`036PT7JD6&[("=LVW`<;T=X,\040?_T>35RC+CQ1U-E%`E>X
M6Y;O+XM=&==\4T:ULMZ`]K7E-.RO*`?NB]KZP<<"E3D[EY1K446&4AH5XNC*
MCPTUUEC1.JP)S#1>*RVN=UZ%1=>Q0VK6>0AQ"%L64/Z2LMO3]A5\A2/(",V-
MSX(X)OR*JH4/OYD#LS:Q9B[4+A-Y/@<QC9"#FZ<EL<>PI"3Z#)8$\V?#.L)%
MH&&#9LX\I*<3A9@XZYM<^WS.Q`CL2#W;#G@2SQY0(/?M0:NN8M*`86=1:28H
M][LZ60GFO8_'3LP$8I,`M02,9PU2\BI^Q)*H-"C:A"&-Z%2?':P%C(OJS&A]
M4EUP?2UU-@_.V31J7&+3"#V/4I9HN9!&+S#U*RT!SL'#8Z@D<C'_:*<?*_3Q
M=,"D(6C'<)J/@C]1$,BV7_=^+S^!\/LD%^CIGX9V49T:VHW4FO_IQ5[K_I<F
MRH_4QF']N`&=4,(KA$DW94B>B"@#V8XAL0&`-(,U^Z)<A38OSIF0?76B^5P2
MS'77Y[=*>8,[O"%W;)"&W7#TMIP/_H0?<'+H0L5$M$*F5G0:5`UJ,1&[>@L:
M,.L*KH6GK$]7/4>EP,)P-VE;8M,&'8?0E!`\1*L7,K?460(^ULP)G%B*62,H
M/2T$J1)*]QB:DW;W]:%8FH4M0V(UW:K$)CJ)WOI4FE5JU_F$HM"Z>>+;TI3!
M1B2F'[SK#W)IT1=4^F"Y5&X%G$<!\<*[Z#5>$J\6E4S'BYI!72%F&>;4[THR
MD)3P)^RN)(,Z@#N'S5X273GJ("E?R)%60HQ9_?*/P4TDYB"0^(AR"XE6JRMN
M=;0-R0%T&+NVX[%?VY"@$&3"LRXP-"?;9IA^T/OS)'Q+<^B8\+%9^75O1K(U
MXVIE)_J,03T`YI^&[.A<1U=R73WFDP9A(["TTY@T+[%JA:[;:(J(CJ/5#$N_
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M(RJ+K:L9[+1YN+1G#38E,?_H7;]1R8M^HM8)2^LJ.W`T#HR6@J8+O(CKB;Y4
M`HOG^A#049.N2_#,3JIL$\I?TB#I72"J?-ZF4/$YA"/T[<$19DOW(/(%Z37_
MKR]+G%3MT@6ULNG:2&[$>@`6-3@@O48],->-;6B1V?C>M^+GXVOP`?(":?(E
M\[]K$D>;QQO\+7\3]P\>-)979H,]>>`8KZB/D]RP;\LFZ'=+RR*_%_YAT-J:
MJ*\'B#+T=XKI,H">!;=99,><NV02%%Z*U'*%"CGTI?PO*X!X">]RS>G@,\\\
MW<%O27+_)8IQEI,$_X+S>Q*^IVDS217IJ7$Q)=6KB@'[H[YVT$ZIM&;CFPHE
M<@>MA5$AO4*EO&_^.0`3C9L:`4SIJ_+2.I=5V7,;..1608^UF!6O+*2\IQ\`
M;=*(UBL*4()QB$.T)2FZ(+M]D/!K$<J1KW]@K[IY#H%K'F;F@N[L02?3CR/W
M'K>#2`8[9MRS!N=IF<V(7]8;%<[^[(4O])NCBWE5@[61G2D'[#*G8[R9HY'=
M<:TKI-J9;T.W%BT]P&(`;3T?*WVF]8GN[O,/44+)M+>`0O6X?/'^XTF@55F;
M!EF)5C5D>\+KZA?$?D*?%I__538)&?J,;;1VI1JT]LM#,E-7._!NN4FMW=E=
M?'Q-K:(FN,:>D9K8U>*W089#EC+C)`OXK%::LN,DV&JU-X^-2+FG\?QKD-+4
M+TI_"^(#/L^RPXZ_2,96MK$5"&Q?W\LNR3DW5-&E0T/3?-+Y%P!(+)U64L,1
M[LRNJW\BM@-W8:YQ[P1D/KAUV,^9/8%'';X3:/AU5D^H+L;)^3G+*GC1,UX6
MB?J18`#=/B)1KC2"N!4VN!FEB!M"@J45JDGDYIE$@('\E&CD"!*[J^*UK@YY
ME@<).[?^KYCEKC@\?\!I<$<36':"&OW]@B2\HWT(8O;RKZ`RONDUF)H*3JG!
M,H%C^C=;,GF<5'L'T69"?=;U(W8G7?7LF'-/`'><'D_`.&%JF!E?$8#X,^4K
M>)'?CG^!Q1/?T^$HH%3YJLJ-A2JL4%4)5-8"-7PHU..8T^@CYT/PQ/M$&7'&
M5#V(<5;.7O5O75`\K5+<[M-IO"ZW990:DCR(-:EA3[.&$CNRZQNFVX_E&ZK6
M(`.?L.-K;2'!#[JE0:-V6SE81!W?M,)<M0>W%MBVK9))@5IW1@;:X"1((_)K
MDNWQ)MI&."S.2>]RT9!<Q4IJN6D('K(_$<D:]1I,*TNMJT<K)#STY`SZX;8D
MQI^]@W^5N.`):HW^^,0]#@_L%B=^@7F9:'PB<?R>I"SUN`EN8ZS:JC*R=.T_
MEJ4G>M6HND[U-5NC.@^TT[6N"K##(XM[[<LRB!5"92GTA9?S9U/"6%"1B2W=
M=6\K):+36UH'37[LC(.NBUX0Z[RO?]CM@O21@3WC8"\^*:*=H>@ARA_1(0G9
ML47WF%\G];0PKDSB/$'Y$@'O/,FC,(H/%![X,]X<TBB/</;N&[O'&(=L)RGK
MI1]RWDF_VKX+4M;!SJYQRCOIPS$1VD`O;,(9`"(=Z#<&927`RID0%YBY5AP/
MJ-:S2BW*:KTH(3DJ[N"FN3=+0BG/;8)X<XB+$4]V[#@K1I\FM+<6\]N[*1]F
MS)@O9`CN,1*^=.25/4*%LB/C7+AW<)-\0-4/;/#FV$F`)S@"#8AZ4:,859J+
M\Q\$W:Q0I1U1]<5`N,>Y_S%1P7!V=0ID<(PY&D.WL_Q,5`Z>FQ7*/>%C\4U]
M8>*R3G.P,#?ED']/AG1;'N&`<"4>!TZU/"`ZH-FB[OY1+*_=F^Z,L]BK9VM!
MBYGJ9CVHZ;`PH/+^J#&(<JCQ-L`W!1MSAJF3T3`=A*GVB+5Z34YK,'N%:LWB
M8G:/4UM0IY"-",([77^X$,"&=#01I.Z.AM0!ZN9JQ/VX/+W;G?U:KF8Z"\KE
M=('@R`?&`!0J(6;+B]G.:3:VM65;6![X%I;NB/^=!\<>'I>W&TP/'+&_+])Q
M;2K[GJ3"CIJK[9N`^M@&?[['.'\;Y%3X,J'(QEF>L=5[47+`X0UY@_\WCL,W
MCS<4S-D6IR3]C-.':$-S2JH;Y]E5\\.'*+B-8IZ/&LQ*^%*S?I=Y^9I!];>7
M?Q,7$R@>O)51=W_Q>K:G;+2QK!W']FEU9$01T2@9\K.;X]+*HR]1;?EOK!MF
M\*9RJC&*I2LH'>!8NE+.9J.6?C$'TUA+O]*Q4'%OXDP@8W:$HK`3/N"W+)?5
M0KQ>B%6L+(;9+<PI$HS0?DC`CM6/F1!UJ*:._Y2A\AW8CJ#+Y('$#\5F(W]'
M)19O*J\9W6"*;^DJ'B6G+]$W>W/(:.:59>>;OQ^BC)_XF;UY%/ZEGS:T*][K
MY9@6!PI^=K6%BD_&5DV"B*&R%L]799!8:,7V>@H_^#;]9HDL"4^.PF:/RLRT
MR/C&U+Y_I/`6W^:729:G!Q:G#<91A@KT'%]=`,C5AVH$.AB@,6;BT\KB+2^.
M27)WQGK*M,-\F_/;%`])L"-I'OV#]I'#*-N0`]O"7<2R#'V/^7QL>2[%`Z:"
M#*FL]`^^>/D@<"1^;0BVGB>KRLE\5VW#3;=,90^^M^0(J]V^Q8<:K:P$$HIX
MG/9#HG$X29X#CTM$CW>[?4P>,2YR8=S,:K0V^L>\+GQYR*?JO/[P&J<1H7*9
M2=!Q9*<7J\#M`'&&H_<'C8SP=30A*6BK[2'LNEP]V5JNS-B(IZJP`14J6L[#
M9CQ>I\V-R,60=L`F^+R9G77E4!+6=.N[/:H%-B=C:/`W<I-H`%<3/C\Y"<;H
M9D.5>E3J;RWH$DVLT'F+7AHSJ+"#N"&/<ZCC)9'AC.WT:&391;:*DY^R\NBG
MWE(8_5@DD%[-TMJ1>L&7W$UZ/_@%M6.K8[?";IP5Y3):U1%XF?8,/-]&2:$P
MKUU+!^%.FD5TH]3KU\^-K+&'7'FXS?#?#[2>[Q[,AF('2_3Y35T"BKF&Z@2[
M_E=CS8ARE.5;9$+[<M$NJ/:0[U.RP3C,BLU.;%'NY?65-RPQB`F9_QL"J>_9
MJH)2GU5;<;1P7640OBOC#(C=[D4CB`I)C_L'L%@T6*P]"QIG/N5?%^14,6[P
MW-1WWW"ZB3)\G=*.!SN]9EN<7M,--8M50#SC?^8*3#\[>Y$O!G7"_]R5'S@\
M>][JK"O!L^J`:R[BP5G6RW@A61[7DG.L9ZU'YQCKF;\!^+G^L]8?]%C_ITQ,
M\Q[J7]6B(#]OKAE^FCRH/='_F0G]2\J5(T_ER_^%;].]3(HQ?-W[VV;C\)9-
MTW!(RVYC'/PWFB/Q!JWUA,`&6(\UEZ51Y_LH02'U]"`53F9<>M7B`JYF'F.<
M^;EI:(&K@$5,@7SK6=-JN(K/ED^?'M^89M#Z.4$AA2Y,LR-G"^.#>?0SH\WK
M(L^<=J0)\GN2;G&4'RCK+I$ECS0/E2I;FU\V>(W\6CXDS?95=QC);"NSOF`[
M?^)3S9_'.B%<R)E&`U!1Q[(6@*''^OV]RJDM:^]-8GW,G`2>8@OVGTZ>?73,
MYRSC/AGN\RCW5KWXQ\/N%J=7V_,PC(JWX'+9^2&_)RE;<@ZU-,3<TM0U(":6
MEIE0-?\&2Z[J,*JE@UE2`[OKYEF1[V8HJ)]Z'@``'&/Z=*2U%TZ==1PV"#"]
M:/)67JRH&*[HXDLG_/5^H,40A2%^REE#)H4M=/Y,)H[0_+3H9.G,SRAI,\JW
MG#"E2XH;P4YJ6O&1!4P=V,;SAIQFCO`)>U4`%#9XT%$<`'',Z+!CYJGX6)H/
MS9>HM6?>_I*2+`/>'*&Q`+3[06IAT27$FG?V8/^"O';NU@'+[+66115=6]_G
M<B;@'&Q=[;`S`2V;E1B"6Q<K?0LO.JSJ"B[>4?7'>:%7Z?>7&'$SSW0P#:>G
M30A'D&)]B!)\F>,=6$;54S@U@1(4+L.WO3=:,CT2*^.`4!OU10_KGL0A?9-_
M0B'>1ILH/U*^ZX-R.KVI@#Z5RVJ]`-0EU-&+U*6NS^*9REQ^!)*'H"],'^(*
MCW7CGU,7!$\H%G%"C]*%H549U9J+158%CS(.M2;8TOBR2^]&?2D?U@/;5MSA
MRCN[JJRK?Y[H8N!QO@>W(&Z*[T,MAK.J`^!2.,MW]VH1L%7=O5D"?*PT!+[\
MM[;^=!;_'A73.5OX>Q)<YU%BK7IMX5Z\^KJ\=]_VF-U:\#9ZB$*<A)^"W#J7
MAK(W=13/W-XR(Q.VWV/),4"+NCH8VC"VOJY^16'Y,WJ,<$P3XR!#`4N)-U2G
M[PDQF`--'^X8Z;-3QT),S0(,E9B_H1?#F:;577RT\S@8`VC.5KA/63#(<MB2
MCBJ;B!E]IA]W:'^Z!'0$&:=Z?QWPXCJ-!:#%=5(+BR[.T;SSLDMSY!5SMS1'
M9@]T88YT8_*1DKJ!PX`MRQGV2J!%.1)#<(MRI&_A16ZHKJ!A-OAS004)OF.W
M7;A;:>L!([#$KW6&"I\J.?;%MDNYL:O5=;XY\A'D6+IT\C<24S5QE#_.-:XG
MM^AR9*]KT;]NNOR;^#JZUZOMS+WUCOUFA.^A?G#ZHWL*-W+;P=;ZKLL.=MNP
MXRYV]RV]R.3,*^SU.)]?W#'76%]C]51'^SR@HUE'_#PFI"/(2*MS%/A3AT=*
MJ?1#'235U[_LZ3&J]_7AT"A)W1P>%M.S5O#\"9T*I<0VW/$M`^XSE5]59@`/
M:NF_@1?)G*IZBZ=N?C@K^'E.I>^?S"%."_B^LP.;//+^(\B<9&GBIRC[_7V*
M\65"8SC.<M<C>3I[+L;QY/;\Z8;KOH='77!%-6?J@$NMN^Q\,X.(6425R5/K
M>VO]T$W/V\#U7?2Z968=];GE;^A%UFA:W1G.2SL9"F*I)OO];,N8(JJ8(F4`
M.]DY!$^(8Y8!.\^IXTA3SO,D_`73M#HD,;E[K*X#=IETZBVZ2#M5%OTA?_TW
M\8W\E;6=B?X5]M?5GJZSH-Q`&#1E&%.$F'ZE'3OZ8LM2S0>>:I(MRMC1-*CP
M[&,]@FN$I[F)#T;N[2(^R`T[BA"JM_0VO917>/%ARN.A%Z<SS"A(0B0815\J
ML\=Z/H_G?#1+QGH$C'0$66NYHO/JD&<Y=9,HN8,\'`C6*M`&%&.KBZY%M_PV
M)A%FSU?JODL<KD\WK[6[->NF=5B_"6*VCAT%E#7N,6*;#&F^ROXLOM1Q'@H$
M['-@B]_'.3O0<GA#XW!+Y(W?UHN<UJ[2B^>UQT<VT"=<"V:/_6B?(^<K5QMX
MGAD+LI%>V^=)G_,@S9\SI>+K=7.E6WP7)0DM]YPQ+<]`KY\9R*=>=_$VYTEX
MF;`9T>@!7U/?R:Y)'&T>C7K01AJTO>$!#0XXVZC.SN9:AJS;<JA>7WFAV9M>
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MS`HJS7@YU`3F1"X(6^VL\)PMV')"W*UW\31Y$^KHQR9$WYB"=<Z:8RFNCGKO
MB!=N/4-?S"/'GC$MRX.<O\?G#4Z"-"+GWZ+>[>PZF2HIDLM,(RR=W8DIB4*U
MAB>D)=;5O]`7]N^E([>VH8C1=^VXETQ4\`ZY)N_`?;6]"++[]S'YFJGVL!J(
M=J$N%85!O*860,"76S#`OZS@^H(D(25'GA4G&8FCD!TCW\`G8V&0E4.\H"=N
MHFOKOK<,(Z/K-)(2$M^1ZO70A=Y'29!LHB"^)EG$H^"@*PT6Z;N4I@B4:PW6
M"LS%=):,7$VM0.5RU93`YWN,<W\<;1@),H<SQ4_?\90EI0ZHL>./(Y+-[V(.
MRA9'_()E"PB&)6NWTTA.]+;!.D!T%[56=`ZF+D?]:K<CB5>[_@T:E%A\^:[3
M*`N(OJ+1"CI(H38$MCP-'C5\N1D'3&M0D`F@+X7(XET#&`PI^^&.430ST5YF
MV0&';P\I[;<7]\/P7G[&'Y9=^VI-=V\28K0"D98M%4QWNE$UAKE3:HSY`3^U
M4[>N__1HQ<1X&)'I#2OQ;BL]':>WK`-X1+&R#QIHEL0U]*;-2K$_=Q\NXB/:
M&.B-EW@2,8O?WY.4#7+81$II09,(V2GHCCRD-83JUI@:'<D7;375I0D9B4/F
MVU%">\%!C/:'VSC:(++=8J;`8V>7H\7,R75(,W'M5GE#E^[8G"W@M>S.$NA<
M`)8%MK?X`<=DSP/5YYR?&I#06D68!JJB+U84696W`JS*?Z,M2?E0]%-`\ZA0
MY1S/,X>F>\IJE''?_?T0Y<HS3`<%Q="C$)SNMMH:0(46E9$!SY076XO/_@F%
M>!MMHOS/'CB7OC6)^7>7N(Y4ON,J"IW@5"^U`TKMD("IA\IJR!3/T7F>I]'M
M(0]N8[XE_YK2"J5V;XXZ!(&4EH^=@6I)OAWDV4%^!?<1*SXE>1#;\*FE6WRW
MOF$6BNF&+HOZAG@3I)OB6X=KUR3ICAPM6]^2#(\1#^:,MR@BK/8A/>#TEMBE
M6;;`>"TGAN]+9O@!82YWE(A0[:L!1<22,:\XLH"='<&/CA@,@0IY943LR0-[
M@Z(^3OH??5LV?M(MO?Z$'U@-RA&`S_O8ORBJ:FV-R^@!HO2?3C&=._4LN.7;
MCCEW`1D47JIPO?+WV!@'Z#./Z.[PMR2[?R0Y-AY%D@DK>;TM#.QRLIHX8?2.
M(1M_:Q6MN9RG0"CSD<NES:MQ)0T<E%XDEM&Y4%NW6_X6;;DC;R`D*7M93,CC
M`:8IX#(G:1?P6IJ>^:\\^;L@"2,16LU/;-G#2R/"'BZNI7!=<0=^.%Q;%WZI
MM6KKJ1IE:L]=B4G^"C4E$2_JHS<;`&O`OXVAJ?5WM98A!M#9=Q]RU-9AMR$O
MB7A^4VD_\V%7E3X]4-N%L25@/6.H.]QF^.\'G.3O'MB6.N7XTI!<%;S4<M-<
M=\@^A(=J;&A<45EJW3Q"Q;.%/6VP#8GQY^YXCDI<<!&U1E"*5YD!ZU#`@H1W
M([HP05_\&>L!P(R2;QVB9CD&58WB#(@I^!-JY&;`.JQ/F'6O585\ITU-[]FL
MC17PE_27E?H\!?\-FUK6`[\E(@=]*0()^)954+!7FHV!7A3H@9QR/GO@%]VW
M&TN%<UF3RC%^4RT]T.GQ%-L?H@1?YGC7.\AF0$R.<4$,$N<]Z_!IL6C"&/1-
M(1'XV#]V[S>?"O6JAI8COY96HE_0YS`AKJTXRH>GH4.6#:,O[#'BS_UBQQ%8
M,4R%`=&R&%_*CY'0R<B9$N;H")U=>(XTV?@O+=%C1Z\`K]S:;]"J<J#W-O/+
M-3DD1.!C(&!P(.=!/\Y\F``)0_8#`<5R?2!J[RW9!5$RT!'JR2EZ0X(<:)>H
M9Q^V7R2J-^\<-:7Z#L`>HB_%8[^\0-*6RLZ2JMD5/:9:7-UM$C1Z[!.R,T#U
M4FI_@#@'5&\;W!>&SP)5E%'Y@0]'@PZTG\X'-,>#RH6U^/?KB-`;O-N3-$@?
MB[G`8C.K<&AO!Y"FXN5G&A:?Y!BFM0'(F@U,J?UEL/"ZF'7-(S;FM*?-B],4
MA\7T]ZH\C@>1IL"ROF0,`F+;4&WO&BK5N-FP?LBT?,@:5(;N%',L;Z]EZG7<
MY3D85Z<+-55B/Q_8%B/WZR"]2OFIG^%O07S`USCEE==S_%`I.=6K2T&ZWE#=
MX(E?8]'8%Y4Z]&%@'Z3H@<GS,]I"$L=!FK&+[HH`L?!Q;;:H43FL(=SD7JLJ
MK'1>M36'`4-EU%'<<`E9>12ATHBDQ7'$(>(%V'%I170Y;9@:AI?9@+I8L+D(
MTO211L/S'3DDN;B?^X84N[GU8<>\O#P`F92'=&KS^L(')2/;QKYNH$T?J/[G
MBS^\>/&RB5?_BH)#?D_2Z!],IL@PS]`?_[1Z_<<7JY=_^B.[OO4S]==B+/7U
MBQ5B$./7T__QU8I^E-6+%R^8T%N\*65><IE7_XJBXDPK)BOTCQHK/_VT^OF/
M_[+ZX\\O-%8D>N.(?HNP."FR>$',3I4G6_0___E/JW]^^2<;=5Y1GH5CJ<C/
MVC?E)#BL1DF')C5P&,&'S3N*Y7-[NCR^5^5047#EY7$=2\#>,/J?-/!A3Q)9
M&O^OM;'N"2)<<7B)3PA?>/3\O$YV3`;/^]*ZL7-1&GX,LU\75R/G+4N6@YA"
M6;EOUB/F3=KIE:,J&UX_B*E$BFX$LRDT,(`I:G<^6-X8<SI6#H,R[4CY^8E"
MS&J8W`'(%N;PXCA?$_YN2^JXNY*$=Z=V'5QQ=FW%TI/*<D9SG$5WWD-7ZC2S
MWHVDF-`Y4'DRM]YY*JW.V;DPY)29IV%)R\B7)P0A*Q8&!-%B[/NA&7:[KD?=
M]#2L+2+G8T412$_2U@J>H57FC-U+KD#/V<'=7<KOME*-E@KSE'[-3NHQH_),
M$Z3)'51:4NFI"CL.>5]JT5$`<`-5>4@01%$C>ZI0-(P6,X!QOOCQ:X:OMN^R
M/-I1'NHNVI4_+#].]^$D?Y);`N#YGF*UFW1$U_3?;+ZJ_F59V"O:@NB_8!O(
M;9D&LMVRD$S9U@W%B:.;E?%<MV']/7[5KM%5_`73[/-QTF^8UBFYD^PBD#PI
M7[7U9!)@)3:F8;6M4`U446Y=_L.+M?^RKTXTGZN-/D&@@5ZKE&>XD^[HDCYK
M8P]DYY;4#@C^#'9HM24;#'JQ#TO>`ET<ZO9;M41Z6/1M7]5?`W;!JGQOM?19
M^;*=9Y/0*+4#D)5U]:HAV99<E__,^"5\&U\GEN7-0[1?M0W5ED@#U4Y)R#RM
MI1HJ31O9SBQ)*W_P9"NT38NJTK"EVQ1V8<G8IGW=-&T<!;=1'"U]"XU5VRJ6
M;T"T[>RA)3M/PD_1W7VNV;!H(MH./`I1""!K:P$7EE1F!B$N+[B^;L<F]-5+
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M-H<`L6^DCG\.EA-\T<`&:&@:M`=ZT8YS_/'IXB38D33GR[-#AKLPRC9L;PWZ
M2LOG5"M%YRG"3QD@Y@"@^$$_T+_HC]5/]/]H(HSI+_\_4$L#!!0````(`&&!
M;4,=!_5E@C8``"[9`P`5`!P`9F%T92TR,#$S,#DS,%]P<F4N>&UL550)``/E
MZH-2Y>J#4G5X"P`!!"4.```$.0$``.U]69?;.)+N^SUG_H-OS;/+6]_N<I_N
MF:/<:G(Z;>EDILO=3W68)"2ABR)47-)6_?H+<)%($"L)DB!2+U[$0"`B\$4`
M"&Q_^^_ON_#5,X@3B**___#NQ[<_O`*1CP(8;?[^0Y:\]A(?PA_^^[_^X__\
M[?^^?OWJ,@9>"H)73X=7GT`<PS!\=8GB/8J]%#-X]?IU1?@SB$!<D=YD_X9I
MDKVZC5)<4^IMP*M_?O6BX-7%VW<_?3R5:A2ZO;]]>/7/B_N[BA>IX#K:P`@4
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M^"%*LA@\I,C_;8O"`&/P"JRA#],KD'HP3.2:$/Y8TG<?WG[\\#:74XVO4?FS
MIP3\GH$HO7[&?R1FA.<Q'4'R]X.(_MZL['<HVCR">'<%GM)+M-O!=$<J6T3!
M)8I2'"9QN(3`3&/HUC6=GCV;3KNR"31]])Y",$Z#5E4-Z7,FU.'Q-"GW,MYX
M$?PC[\&QG1ZRW<Z+#\OU`]Q$$`=7+TH7OH^RW'PK%$)CWM>OYLEM8**!>U4\
MN06JOR>PP:GJ@4<L1MR8SW;R-C33O_2LVJ05;CP8_^*%&?@$//+_G;&AFYCS
M6#KT;"D):Y-:+)($X&;_/8,)),!8KG\!,42/M6*WD6_"P?1J&E]'(_#3K&IP
M/)IH."'C\=MIC`8RH==#BC\16RW7F"/:@2Z",YA,WAM-T`N-X"D#^(@)J2^]
M9'L3HF^=Y*L5GF"N.,HLT81F%UY(DH4/6P#2+D(WRYN59^7%6.TMP!2>0G)1
M+!S%;.!1N?'Q^+"Y`+-9`".R(C\CH/>BX!I#/CW<1FL4[_+0V4E:(;^ZO/L8
M)(20?+G#/S0J`]]3$`4@J*HCLIK,.^=R5)*$R&]4'I)U#!0S4^IY.GWM)4]Y
M3CU+7F\\;_^&F.`-"-.D^B4WRNNW[\J%B_\L?_ZUUD>M<<39@RC)#7`/0I)\
MOT1)FCQLL0N1]8M@Y1V*@/24I+'G']$>DAS]WW\PPPPW$K%M7V9OIC(I6;X)
MLA"+G8MW0<2K*["(8P]'\ES<B\.)IE1A\<V+@WRD25G7.-_2T`;Y-FU>=ZA%
MW+2_%Q_'M/B?+6]JKFR5%&_V>2A_[6]A>'3$=8QVQI"'AK-RW1A_?=5/WE<I
M>F50SBS!\J$]*45Z2!3C^%2N`$_F1"O<@7_V=F#Q'2:4'[`^E49N?IH,C>8Q
MA(1J-[%EK'8"LV:M-B/E"NT\&'&PTOQ(H:7Z.!E>F$V+)-(W&[W.HMYN55&S
M+=<>9I%??KW^/<L'6#Z6"SX#(@.VP%\^@=T3B*F64:(M59703MYN5/L@/>W8
M#5GP)$TIX25H6<QY#>*XW$,A4#77D^S(`8W=%B8PD8]YE_LR\T%I\>X#$QM:
M9:I1C%H9"['215L99A1YLK'S?G3LF.D)KO%\$!U`,<UB!QT^115J6!06@D:N
MB32LL#BP`?%AIH#(AS)7.`HQ1I',;Z7IJ&]NC2-%B@\XD*2J%42>Z>'"'$IR
MOM*0F7PPR6Y?)%.@V?0-)HWF&W=`6<8HW(=]1E$C8A6=FS#**Y:B(K^TU/0M
MR^\.]%3FM'F[CY"RM640.L!`0@%HJM"R"4RZB*''',JP4JRH-22Q$V"<0*41
MG33\T](XU`$ZG8.2!GJZ1*BY3G6*?1''C1+501?&.%>!LC2\D-*M,;"Z408<
M$0N%$$S$;`,=<[2L1"L&WN0C:164\,&D,,H65"``R#`C<#,0N<?J8<-N<;B^
M`L\@1'LB^?5WXB&`V1UJE"AMJ%3"-M"TA^SZBBN!YS1X5ZK`EG&5&?@5YT-#
MK/$BV,$(DN52DO<4`5"K3-D2BF7L!V$7Y35AJ%B%6^.S7T!"MNLQQF.,+Z5=
M&U_<&F_QE1YP?-6HE`VO/TW:698",L=/S&]-H$P^/F*U*A*+WFSN&H-:@XV:
M82SKS%&TC%8@SC<'1CZ[KU"D;K83GWKJEFOW!WH*,EOS%/FES&P9?.AB(__E
M$PSQ=Q0!LCW[DQ?_!M)+%`7Y`8M$#SVZ_&3X4N<W(P1V-%)7C*I7Y];(1=KQ
M\OK=.QB!6SP(I`<\YAA6.ST,,'1K>&7<Q`..RDS(RO:X__?2/.YS1@)0V2K)
M(DNW*(9_G,XH]'5`&?^^_LCG/YU[FO.D/GZI:'G*37O+WLL_^3+;,LR;V%V+
M]:ADF:7DGBYRK]H]"L,;%)./IGQ6J9*^CBNIY*5[KTX;6.7"$L'/`UV.E8K0
M-YP+-_F;]]Z*__P<5\W5S#HSLS4,^;%0'\.^7>EAK'O>DTLE@H?4B].S<VOR
M__7]V;UM<N]6>SCGX!VFRX6#7T?!W-W[9TR8)K<DWX<5^CE&B;&LE;P&0P[.
MK.'LXCU:9"XNSM3D/#BOFPA;>PU@FN$6K>QDV,$%-1AR<&8-9P?OT2)S<7"F
M)OV/YC%O;I_.Q<D>[=LDR4!PE<7DWK-B^I"G#VL;N)/K[R#V8=+.:W=F4#\R
MK,G`9?_K:\_1W*N#H(+]/_/T'G/6_0K@9HM56CR#V-N`RFBK&/J`6'X]=(9:
M4P#S$V1E`>;G_4-GMKNUG>59;V6EW#HN/Y(%IPDDTT2/.8:,_DX^7H@9:P2B
M:($1X]`Y;S^[$#1DCO\<A*8+0N.M%<PG##F]NL#=Y<A,T)H,1.9K5@U%)FL^
MAZ.16W<6`<FD]B]L-41F.D9"><RHU+%Z4Z%)N_IS?)JBG9T(4MHF>&$I))G]
M*NM,$J<Z56XJ2FE6?HY1X[>Q$Q%*TP#]%\YLBD^+,&<.`K89RSLIJ+BB5ZBZ
M$%2QT/S\F+FDU,E&0RP#J0IB"ZYYUZ9W-<8C2KTPGRJ1JSR/3[29RGA*V/=-
M;'+9.^(F`]O=JG55KLAN'=\]WCD)XF=(WIQCF>LSBIY!0CI98IDD-TW].WGP
MYS-*_P72>^"C340.3M9WLE#N.VJ=]"6VP];IB*-/T4)#>/](>K!#PI_/(:%I
MM&+`?H/B\B="]VZLV""L?.@@P:G\'"WZM]FLP@9'(7;\^,M,XT?G-C@.LA9)
MDNV*X$IN+@+I%@4H1)L#Y^7.$6OL.T70J=&1\#!^ZU@UD=#1@AT(?CH'@BBY
MA\EO-S$`MQ'6#<?=>SPK&S(,B.H;(@BPZYM?".C@M*9CA$+3&8H0ZLH:#R%L
M)<^7%7$-1G*G/AZN_8)"S":$Z6'H$"*N<8@@PJOQ'$:&:K[Y!Q*>F@YN0GJ2
MF^Q)QV2/(-[1"8SA*ZH'CH$J>E'Q8HS&FBY,#*2=@QM_NEA*NAGB'I"[FO'O
MERC*&R;S0F+"]Z;"1G\)^L:3/A*<`\U8S3NO"-1';5OV1E@\![J"SS``43#6
M#(A5WY#SGV9]+RK(C-AT[LQ]FDJZM<,#FVF'HGS!^M+;P]0+<_LDY(&U^!F0
MU:B;C&SY)G>2D+<CJ(#0N7R)D@[EY^>PS(6/OI8;8AFC@TQL=_@X^[V&*Q#[
MQ+P;L%PO@N)9E,H<YI\CT*NM;^>H6ILCGC9NJUBUO*BJ`6=EX.U,>[7.]JH>
M>AC>X]5K,O44R=G3#;:&55ZN(CW'PXTL_OWM30LV6+'?BF_,3PU(@>\I'EV?
M3-P"%>G)TRV>V>]!ED(_^=%'NT*6*YCX(4KPB.0A>TK`[QFNY/H9_Y%<@=2#
M8?+#9"&(DH>W.4E"5CD_EVRZ&-L4J?%P%UNYYMM>3,5*DNG"D:PYD))65'3@
M,,U]GLG,QN?/:4EQ?8PG@"54G%8_4MG2\.UGZ)3T$K;[Z9DX'J^9-#OS45\I
M';_I)W_L5]:X[/97>`28PY@#@F$>!QX$!LPW8(4T[.:?_*U6>;NV&U_A+58N
M6T;3V_9BL!G`7(&G]#;"'5V6#U/;/06?H+0HB\`:G-#]@U0;M:Z!Q4:PU<:2
MUOWL[=B=@HR,V=)ULLG:6]">K=;FZM5L\S;+=HO768WR1OPE.:<2IQ#C;X45
MATF"XL-GE(+D*@/+Z*=%MLF2%)?[,S/D=RU^S/[K%K<$$(PF1[VM(8++J<(B
M3Z];D;'.!=?[A*;O7J@`VLH&L8<D[:01<U1R9\-CVGH3$IYFG68D=[+GJ&>[
M74+TND+Q^PV*+[UD2^-(NZ#*.QQ405NPQDZM=K6`$('-_*=&%6X-EJ]_SV!Z
MJ!95L=JYSHL=RB(Z8:A"6AU8%I):C38-+=7Q)6;JUHYV/"SP`0B2&VSR2N-;
M<J38"U?94PC]Y1JKA'V,@I=VN;(5-,I9#;RN^JNC4*,&6[91<^8.7R(LS[<8
MBQYMR$(,\2.R-XOL(L%#4MB^VT6C1&E7I1)6(TI?9W4L*?%V[7FH)5D*_(PB
M6)YM9%]L)Z$J3<VELAI2:KJIPXC+K_]>1[N@4RZ:)\OU<:Q)PB^YC(,.52JD
M5=\G)+4:21I::O1P0J:V7(?$Z=2J[OD>^``^DPERUR%4!P[48$J+@]TXZVT3
M_0&65EUN7;)S#_9''ZSE"DE*D0*K`F79`$)*J\&GKJ,ZR(0\^U_48JK;Y`2Y
MZR2%.\+Y,TA)/N5VM_?\=+EF.@<>3]Z#D%`_QEZ48$+&R-X@QRI[88*CU;@T
M;S.-7(B)NFW9^V_J*$QM4:64/A_`U!.07_;D[C9"2&97HM4P/0ZL!3%5#E:#
MO+]-U$'=J2['MKZ3'NBDWC*&&XCU(K\6B4[Z1@IE^MI:O83>:CSJZJN./@7.
M0V["GAQKI?>!X+1J7?<[,?!4"S-1*"\\(TAJ6J(K/N75<,`ZUQ61KS%,`1[1
M+-=7I>SY#HM:<H("J'J!LBE4"E@-1&V-U<&GPIH#N+E>&W.1)=@"2;+P?\]@
MDA_,*5<@RS1KZ6K+.#<#'K14YWCJCDB!TBS3LAE-,;4:W(-83MT!3%7/<1)K
M'G>Y_NYOR7DUHD%U>#P`8,?:TT'G$#H4K9(%6D6MQFD/*VA,_[4JX6!N_#LO
M>)M80R])ENNO'CDJF2[C>W(94/F_TG$>T2J+L<Y)J6XC:]><+!Y'1O3L?MA:
MJ@S`4+58#?IQ;*N121A*'HXK6;/\U5'QX[4A2T%V;`#6_9R&P]I%3U&QXN#N
MP1&"XQ-S77RKZ2FY/$*!LGU-DDV7-RCE?U5UU,GS"GART#379Q)8B6PNH-2(
MC[L,Q,16PTI+4YV]`V*V''!9<]W5(K_J<A$%JQBM4;SS+KR0)%@>M@"0IPH]
MSC44VN6JEV#5RUD-IZ[ZJR-+HP;.3O2YKDCENPL720+2Y#.*_"PF#<7:K<FC
MJ>_5;--,ABM]S"`U19N@4J[FN).SS=ZMTS*U>59^YG'E'4@>XY*)+#7B]O([
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M:8\NANBS*J%6G5L`7?C%'4#E$@S6'_\29UB%,F\)0<)>)^M0\A@W-4K."[+=
MC=(#N%J5NK6VIJ(Z=X&D6V$-$,]WT:27:0:&LGPAI<.(U));BFL;%9E#`\[G
M]J;/>7;X8O5Z[3B@.1M;@K,$.:>GO%8>#&ZC\CE..N2)J:K8QJ.:%YS4E.T3
MK7@5N/7D[Q5X!B':YR>^R<N0U^0`XCZ&";@":^C#%,?H;)?E][T4I\'H$A0*
MS3$\GN[OSW!>V#9NPAYN8$*6_I?\V75Q9-[5;%&(U4B*I7,Z&<DEJ%\$3Q',
M"Z-2%7M@CL7;V)5\O;MT3H*2C%R]9'NY]>(-J"[(0J>7Y(-_9TE*G&*Y;I^W
MS0U3/VQ0[F<[;C"B`#9.965+#EV9U?G342VMGG0=6BRW,@FX'TKS-W,??!!Y
M,42L#0<BFF/89M+8`N#VTI&"3HKK1FQ.5JXPEQ)^B9(]\.$:XH$)<Z.!C*YJ
M=#[==`TO;%BDKAS5^BRV>?/SV=D(`3S(N"&##.;N`O;'TV7+C8_3M;"T`9%$
M%:II>?S*2Y(;?`9<!K%AC^<=BC:/(-X5=Z#M=C#O*8NG$B+R>@*(?`@F?S1\
MC$<SSZ]$FG/9\RN1YU<B!8!PY)7(\><`W6#X_D__FT4`%_M3%Q3R2JN!L%UZ
MSAB4V,(8!-OUN+4=HS[LX.Q6$Y&4YF:36-*KLPYO""B8??G41S>$;=#JR.6G
M-EC\VKVX[H&-R4)(W\?.&=STWCJ?=FK9E+.5,F1BOIU89.'^SH*]R%I-S5.K
M0WO?R?8ASS7SV%2S><)2B!DV*1,X-*DEZ&&FTS64%,&HD0L7\[1E#,$9Q3:%
MKYYM_(PB]L9,57(F4%CD\P&+5-F.@&'Q[1^$[%JQKH]!!$-.P5#3;J0(E%!&
M19.'N>,P*/5"XV&C+NS/,4HX^[AE9(R&;I+-I=$%RG4"0).?:X_FUC7E[J`6
M$S&08\6.:$W<*.YS5D2-?/=REVV"@P00=A^H,^C0&7',(I[HJ-ESK"&)+//=
M&M=86I.&%7EO-`O@R%7J%$TD(.ER(W:_4#+$E/C&\X'"=+A-QHPW=3*;$:.H
M7,<H4^?7__59>],IU6,Y]SCRY5M7@A6(?6(PQJYTW8),?(D+S@=Q&@;HB$%Q
M#6Z]%4NE.''X%B^!U`C8*R`YP7S0Q%"H(VH*3HX]PHI#<9S"/W);D!?OGH[#
MP%4,=C"CT:),7YWHDM/;C"5==96AI<#8W!.LEIP4Y-R^S-_\P*(2WW]M-YK4
M5%/&$)==CP=0[8-*->M0@XR(N@T=-O5,(*2@:A<HL=F:>_'4$H0UC?$E\HJ`
M#((J#@N'20)ZYJB)26\SSG35[3BF8C*VYN%0,TBK9AO"QQ_$1*61>40V`TE)
M,67T\+A9\^[GD)!91`%W042CA!!,5(GY(4ND<D^84:R-OH@YOZ,GT]TZOMQC
M/8@\=\!+0'*3I5CX3S""NVR'6RP7^BH#G&VL'4M73SOIEC:XK$YJ).US335V
MM7C!^UXM7;2_3^;>71L!R=5L.KEF1?DR1[L"6_9IC>H_[(%*M\)ZWC/]P*8'
M/GL9J#=X=6MW:T>KHO:WT>,W]"_@Q?36Z,[E]?!=+^\PQ+EF&@OE=0%LN4)Z
M;*#C6D$_J+<X:(.]QL%MN/-,-2+@:R(,^-C7C*8K^:F.Z0[*.WFP[L'?@B`+
M0;%R=9I$)X^X92]PQ;]1*JH7.%YL(B]@[2D\;6W5#N6IL'7\=@SZE:F)G=O]
M]\^.D&M97NKITA(M5Q>4L.4:*_9C:=HZ"R^V2MA.+^!M2WZ"D[DZZ2"^:C%/
M+'+QI%&VA2RELC/!F+X=NJ!-J1:3Z0(;NI=EO/&B<E<.5OTAV^V\^(!=#VXB
MN(:^%Z7E1?%X>+E"(;3A*J:ZT'CDFV"Q@DJ#5<UDR_4-C'`30B\\WJ7&Z[&,
M\JSFBV9X&KP5-2,W>2S7J]!+"<231W0=;0G('T\X62&,JQ3+@ET">T;Z@`6Z
M!&%(SZ?-,*MN->W);+I9ME'<(,-FI:;A)F3-[SOM*:,MO?=0%U"3G42\D;$2
M,?=BZB:Q.ZC7,LM`J);)X-;*`5O;_->'?0C38H-<@I6])^9[IX1C>7$ALD7%
M)[S=50F:7!`KVX2^_554+1^OHNK<BKOW`(_F,W`/?(0'JSD2V#%73EBV@(C0
MG5BK;(Z!XJRH?K<6K=J:?H(A2%(4@4]X:H:"&ZPT:JU4Z1;CHI=7;#(L*T"/
M"5`E_9MPY5?%QB"O"L?SRYT2`!,GH<_S_[%SX0O<_`$,,8J>P0/PLSA_'O#Z
MNQ]F&(`WV+<OT6Z?5>I<>W&$X9*L0)R_<2%/G9NNH)T/-5:!.P.!P<T_U$1M
M`+G/8;X=YJN_SX'>\4#?D#EO]0,O9*N0GHX="DC=":,:)ADH((HE<&O6W\YZ
MB`&K3,_-3#D,75WCC)9Y503Q7).O7Q(\>+E.4KC#YJ"G_^R/90O0']W!HE#M
M@8!'UVE+^HFS?KLDP[Q%DH"T&)O1#U%ROU?CE/9W=_`C4WX@"#&J-;GO>(+@
M='RWLJ9[;>\E$WE:9<H&42SC#D*[&&D@U"J*XM;KZNVDKWCHJ$S/3<`[/'34
M-<YHBTF*0T<CA]BGF/^0Q-6%EX"`I+9`E!1VVI?&NXW(M7[P&:Q"+V+'ZAX<
MJCE2%P[N0+^_`8>:1W41S-Q]MC:X!YWB%4=X1>JRU:34[D!<SS`#P5DJQ(#7
MZ=J0M*^G1:[`&OHPG7CEM;:@L*Z'F/+-^TN4I$G>5$\D"%7G-#F9>#/,JMO'
M>C*S8)&5';T7<>Q%F\(Y+@XGFE*%Q3<O#E@/_1GGVSZ\U)?O='<MF4$>&L[*
MU,5-O>2E#E7UE=/&=P!S^:ZP+1CO<C._59?U-K]-^+Z\:1@AL>+47E-3U><7
M_3:KM1HNS#?/.5]IR$S^PCF[?9%,@6;3-Y@TFF^85\P-C?)W^Q`=0#%"*N8W
MS'>EI735R)Y/-WWSMI^(5E6+T]2G-Z`%C&Q9->8=94.1*@A42*MC:$)2&Z&@
MH9P4#6)>;JW`2CLZ7C]WQWEDV!Q#89)-CZ%;`QKC)AYP%&1"5L<\[F3>4W!)
M[E$8WJ#X:#N%6S9T2K<GK6JEIW,<<QA'?:U&N4=OR:B)J)I$MHQ#3#O!L:<%
M\3,DMTPPK1OFLN3)TG*)ZX_\[2:(BEF_W%T&JJ?E6,;K<<X%AVV)89W5N.S.
M]FU,J]9C'=EV49@K2;)=\9MJUV>0N2"=VX>Y<UX[@,T'[E>-"#S@3D@;EM;Z
MW'LTX3L`Y_,PW;)%N4\DBS2-X5.6YE!';3^IS>_J1\B^`KC9IB!8/&-,;4!U
M^4W!<YFE2>I%`88)*R$P5IWUG,'P=;JSSV&*1AIR\\_PJK@Z'^M[E%2X!&^2
MN?&CS1,OQEM\K%FZ,&_AD6;1(OW[:5==^VEV<6`S8"WY#U]3M1H\9$T69.^-
M>A`:LV5XN7T3&N7KY$-J8N.:.UO>S]Z.LXM"D5SH2'7RZ59?1\`LUS6X!J-6
M<X>3D0_VNFPV(K;VQN^J&IKF>1#F-@%%ZO:;RFQJR^#*P!'2U5D%<J=ZJ%>6
MV?S=FDU\]<CT*F7"B_FM-"SU;1;0$>FC#Q2*FUNK`\65!E\BF*ZRV-_BZ?AB
M$X-B$L#>MJ9<H-J_IE!@%JC2UEP?:BI5V'(/@,$K4^J+"^3\%Q-X"I3U:U)X
ME+.`FKJN^A@3\A[PE3)KI@7*(\_6ZIN9*7Q[4<_(?/W.JJUUEDW.>3:W?"9^
MY^J&NYYV6>S(\J=9MVSR-..3%4_+.IT>;M/?%9EV-IHQ:&P^,"2M6Y/!VMR7
MW,N?K+P#8XU(0M7.-C2IW%FU43/$<!<HLBMW?!O,\1J@3\`C_R^>U9WX>:^C
M4"<Y>9M75$CIVZ:8I--?ME5<(8:!>P>])QCF$;1LE6`9W9.H&N.@B0D^HRBN
M_GOA)3!AK3T;YTN;L3_?R6*7$FK0<#9L!C&1-(VKNOI+86.2_JC>Q:$6A'*I
M&2N[BM0T6'G4TT/0&+20KG$X*.PK4`.R/$&L!N+)#\D`MQB<)LPU3ITB_&Z(
M461Z7$H@A#HISX$<NZX&D(1UV(BF2R^.#]@Q[L$>Q61C72XR0Q_V6F2WTM5L
M0;?T]'!3P1#J:Q=IO]NJ.Y\;Z-;IUC26[:4W<?Z@LG]0[J.9)83]-%5B>I`.
MWU>+C#1Z?TT)8^.60M;\]2BVN,N6EZ#!*2HQ/3@5<(2ZJ*_29S>J:P!*5(V-
MW38S(7)T(F9?K5-$`*EVD>DQI0`2#J8D!N"`BE\?#U3M>ASM?>LZUP.Y.B3Y
MI42H9)6:-3"E9C"'3595;BTQUKJ#XS__!X(8-^7V<`>>02@>'RH4:@\1A86F
MQ^9`HT1U4XTS4!3*(U@VF1ZK=1=M:Z$\:I26%855?MGI`:R&-5Y\5;0*=U@I
MJ)L;:/EUVCC&K-X;6JZ/<JOFA;H4K;:(:A6='H5:F$*]3"/O\;D2Y!M*M6IV
M='QZ&^VS-,E=]9UX3,JGI`,FBW)^P%17O"<.A14Y.NZLJ?I!&78?E&'WP2W8
ML14?`'8?Q+";ZT9ZEJKOE6'W7AEV[]V"'5OQ`6#W7@R[G]Z^?3MWY%T<JNG;
MX3+T$LD>"3YM>UK-HIT>?P/-IJ6&&6<2S1)#<#QD>OB)U<[U_!*AIP3$ST3=
MW#?)58"1CTOEQJ25%L^WAZZ/=H/AZIO>E82H1^,;G9L":(O9<)OAQ#.;+>#<
M1=8\"%T>?#W*PQQ-Z!0IC:M69'I0#HXUU,E\'&P.)2W!MYJ4MJ0/.."^_NYO
MR05C1/ORG(@(V*KD50Y+2OXR`*UIM@G`+)?0T81$CP'B'><H[""\#6[GO[/@
M4.RP\X4!##_&_,*,V&Z]`7[I)5NL,/F+7`3Q[(6-1,,I7]_:D:M9[K@75[G<
MK)VGC7/4W6CFG>.N?EQ50RQ;AEN&3H3G!F0H6K<7!7RM,M6);K4R[@&^B[$&
M!KNB2&X-Q[!NZ^K$;\U^\C"O7_#T<IQR0?=PW]EL`X-?1RY'EZH*4Q:+P8^H
M6"9YC+THP1HES#L^NA1E3R<D1=WS@QZF&]@3]"1SZXHJEN[O2]W?Z?N"K*C`
M%_A%7X8O*)IN`E_@2^;6_)>5_>O4.>B6%ZRTO=QNHJ,1Q_(/=?'83O)GUYQ$
MM]?0+2]SDA?9?W0TXE1.HMN3_&6N3M)I@JU9JG*(ESNU[F:PH<'?;U+]TUPA
M7[-C]7`BMM4GD&Y1@$*T.=R@F&5CV?5E??DQIAP=^3GH0(:-/.+DI*.X;*?[
MZ)#3W</DMYL8@-L(BPB2]-Y+11?@J103N!"[F!6>T@_0'.]0,!/?"3I)Q`,^
M6Q*W%N58>E]_WP,_!<$O*,0F)MMF%!$N+BC`.*^@NRA7,M5(..?)XM:JG$CS
M1Q#O-/!=)U=`=4'N/I899AD9P84$[JZET?I>P6<8@"C0C,^L8@HX;A9S'\\"
M,XV,ZZ8D`ZZ/V7XM^/OI[P6?\@S<^=#5^=#5^=#5^=#5^=#5^=#5^=#52P+T
M^="5M?.R%_503'\$"=^+,<S>_%AO=J_'#&/1CH_(&!-&>=@VS_Y@B,M##$G5
M^0X12Z[6[F^&UCJO^2#67DHV'LCN;#HW.Z3'#-<:(SJ:424<'8?UM]&E%_I9
MF/_S'H7A#8J_>7$PG)N+ZS/O\[SZ7`@`;2<U&P24VFJPB'`GV_QI6"M;<@[#
M7;[]%:;;EG&2IG62>VJG5#G6R7GQPL(0=0@N\S90APON+W%/SGWAIAMH,/]G
MJ\>[DMR`6L8"P![$$`4/J1>GYS#0L8Y?WY\#@>6!H-5$KH>"#ML-BE!P'05S
M#00<.]TF20:XV8`AZN@9!B1UG,.`J0::41"0J/5R<P:7^:K6;?0EBH$7PC]`
M\+,'HSN4],G_R9EVF/V+F+XPGS;9!%,Z<4\]!MP):\-.P7Q+Y<+_/8,))+4L
MU[^0(<9CK=AMY.?9U*3#QD'.A@>Z5LZBKXRL?EL9D\S<%HT'?PN"+`3+=0$6
M;)5\A3[)HWOP98^B:O5^N6ZMXY,]J[<1%LX+C[C,;?J(&_$"R_$;I?E8U946
M'+ZZR8*G%$-H=&LWHR%/0!+$AA=LP"SE?,);N3/Z1<0W,Z._$S`OL@1&($EJ
M\B47A]K_6)M5NA9OA2O5XC,)/YVLT26<J%9DXSX$ANR,`P02JM)V7*K)`-,9
M#$A5YR9>=.LC..+6,Q>XD'_&`#!/42C3"R!$T4\&)AD@.)@1J=M$#Z<"'D@H
MQJ.<'&!U^,QMU7+"T@0B0JN:FMV.2$-5>6LWZB#M+N+MUIIX98Y+M'N"46ZC
M!X!;"*,N/)`\Q28BN83\&BG<`Y-X*NBH.G*AHI`VEUEW=/UL9JXCU)9#D`N>
M$YR%'6AG/MTA;4V'VQ68W;"MT5%K"M81Y.,>#<S71)?KQ3Z&(?[\EGT:4$Q5
M'0#D4<T)48RS?$K*]T9,[5@>KT);1@`2+'W"#;/%G]E/H4NH*"RUJ-S`DECY
M`;#4JM"6!54IE@X*2&+0M'!T<!%%?,4'P=!!CJ#QK[E1[-G83Y5+J#@]V_1/
ME`_2LZD\56ZT9Y,\63[^DPL2+/UO%A(7^""$$IN(0A)-Y`:0A*H/@".Z/K=>
M*[@G"Y*,I$?K]]+`M=]GF9C@Z=4_U5#C+.BUIFUH9DQA?*DW]N31H]UD2"1T
MLR6/A8]-I##1F:R1/GG?X2[;,9N)^:W4F?HV;5-1$B*QZ(SF*NA(@U$%;9F;
M#K;N=<<Y=JU"RE_MJI'.,F9K:#_(TFFM,LO'D(T=1N2^I6(;TE5&=E(6`YIR
MXU'-#A36>O%@W6BDSF/R`:H08?0-11UM(UVQ.];<NG%(O4;G(R5Y5C@]5+>6
ME]OMEC'YFYCJ<T9ZC.6ZOAE/'E-[,.5'WTY,K?>$0:RGYQJF1+`\2\E0LY!_
MF:5)ZD4!#@3DZMTLQ5/7%/KW(`#%U;J+*#AM/BW*R'V@/V^^*_3A/4>/,&;+
MWH[11Q++<[#R,+!"*38>],+;R(^!EX#;J!D)%KC9P7-^C&RYO@1QZL%H%0,?
M5PY]+_P$0\P&12KN,WC5RAV-R:KGZ'QCM83I3LNDH)9/5P8RQN5$?LNO=UBG
M9=7[4CU6V@96N"M+2EO6%4;V5;3;@9@\=`C_R-MD=*>5"S"P]XH$>+%NK-PJ
M=OBS2%Q;7FY6=^SC8<3E^DN$I0T/>,9`=,03B;1]%K8'![YKR3G,T3<T[=(;
MW/+Z;'DR61V=](E9UL%:.4)UN/!1JL9ECDCM8)_>:%6KT^03QS8<@6:^!=7Y
M0H?SQ?^#WI3#NP^B%X\.]^#8<'/#$/?TJUW)8/(R_G'N6ICT"H#::WLW**X]
MPK=<7WBA%_DXM@*07N%@M5P?1\*7"(^#HPP$C^@"_`\(@XM#OE,.VP'%#R!^
MACYY;CM_\F]Y^J%F<OGE*=9(UKJXP`+)K'=LJZS5(UQ8I8<MRY'6W5QOHNO5
MK6*`QW5FY-\C6':Z1W9D'O?";I![$7<K*4K,BS12.H[,-OB\RCU'JOJI7V@D
MX.C&368/F&69"\9.A'9@LBE[4?U1'H[72:C*!N9237=\`3P#/,+B)2%XGZN#
M#*W/D_FAK`&05)FF]W'XY<<=6GPX$]RW,QU<DG$W42PI-:5`P?M<VK']>;IS
M$[P61U(MJ/,3%","@S8#QV!0ZG6#3?DS>5VX=9:-][T9'>K?K42"3`\Y%!@<
M.-/-N6+AP0M!!?3/@.XF.%^KY`_]U4H4B'608Z!5GC/]Z8(`E'KAU`A8[O$X
M+<6SP.OO>Q`EW"&#E*ZTJ(#.YD&$JGK*HPD!0\=BR#VV"+G*9!$%5]A/0K0G
MMBC5;O4M"K3'?D9(.QF:Y%!!>HHV,<5E7_1(0K:.C51^!A&V18B5700[&$%B
MAQ0^`S:V%*E+HTNI[<:7GK(:"),R=BQZM8PAZ_=D_9WMR)$II($5!BM71T=%
M3\]XXD=`02.D3C&+L1!7)?U14)V5:Q@AJ<[/*$)-7=F=E!IQA1P)L=4@TE%4
M'4\2KIP3/'/MG/"$DQMXF-]*>U+?;,:)2`UE6%!,.&=#YAI@KKTXPE!/5B#.
M-W62]5J?S`!@F*6M@_J*U-75$S)JF[&CIZHRFJ1L.4<4YAIEO@*XV6+%%L\X
MJ&Z:Q_YK9Z#%L.O'I&RBKDQL!JD1PRACMVMMG',-1B!MPZZ.9;SQHO*T$=;[
M(=OMO/B`#0,W$5Q#W\-F]'V4D9UIFQ4*H0\GW$]>E_8210F6)ZA$7]5LM5S?
MP,B+R$FJ(QJX"5R3/*L!JAF>TPW=^\A?VS*$`27"$6^#S%35FVB]3M5/EQDQ
M"GXT>=-121H3VN73J]&U&C)C;4._PSRM=#ZG-)6RTDW1(EJ!NC;$..UMR@JZ
M=MQOS.;LIJ]?>LGV)D3?IO/JVJ;*HS`<KU8AK;9W"$FG3(D1<58Q>H:XP2X.
M7Q(0W$;'1//"3^%SOM.]/&:"?RL_DC>`V&8QR_24A#/"=+I+:%7`@@:R'G4U
MK4"4,@%H1`3'%M#GGC\VC"RM=+.9NI6ST[/%V"+X=Y:D^;CV,XI\;++\SH)'
M5!T@`@W]'Y&B57GG8$:JKCJ;,GAU#CG7R&TSE+\.KX9C>VBN`!;:+PX*XG^'
MH$P9+'8H3LMT`N7&.D7*YE8K,MV)L;'`CSI9CSJ$-K"PQ(W4A'2L-\SOSHY\
M<A\PN3`*J_O5B_.S`S?5V7:0+./+T(.M9RLZE:V.H.F5?1%>TL>>X[N+IK2.
M=2'50CL(+M&.;.9A=1IBHBIOP2%Z$9!7LM#XV.:)97`GH`T@KO=LR_45>$I)
M(I0L?JQBL(/9CI[+J-)7DQ$Y_8M`N:[=Q@>\@H2.;55<>1";Y1\P"JI[?BBP
M\PFJ=S@9!"\"SE++C(]?ED@&=U7:`-@'K"S9*W4'(W"/C=E:*6%_/JZ.T)]?
M!%0E5IE@9-$2R,#FS(\%3".P\=*2=M+SE?G+NU574BC`OL)!A?1XNE)$^B+`
MK&&M\8$M%L[`=DU3(.=<$G6Z#/!H+(6;IS5+T3LR9*5>!*R[V7!\A"O+R0;[
M3W,=>##UKG(]*OY`TXJ\X$3[<K'/L9<EB#])Q\;YQ[GB_&</1L14RPC/??>H
MNDVQN-?U'05T->+J[+Z$^$5`7<MBXV-=)AYOW6>^XW2B<4)4!ECIZ^_$-!E,
MMH67DQ00`_)*]#742^A?#/!U[#8-]B42<N"OM>YI%_RK!Z"N0/40U-%*E]X>
MIE[(OV-3L^#IVDWE@B_",SI;<H+53@U1.;XRV[7.MNZK&.P]&%33_/(Z@T44
MY/<=%'VFU&MTF'`]2(W)E.=M=1'.](L.MFH=P544A(UV-0$,;(ZQO9,H3X<E
M*^]`YOQD?Y#OQQD6]71GO13Z.DRXT%=C,GOH=["56>BK">#8_I9^NU.-'E<Q
M>DS%J?W+1NTZX&F"7D(Z=OL6QQRWT3-(3)\'Z\A4[&C:3.=Z'JR?]8R<!],6
MP;%>"'>YQ7.9*']D)`;80%CK]+`*R4']*""O.^=7RK8V[^@6/&[J42]H6T_2
M%;"HA[V4>@U-P8H-/>H".3?KP+KZ``0)N<B?W.>^7"OC7K]D!7R=DBXAO[/%
M!H.^CD2.!?SV[.L>FR^&/O9*8E[IS)I-SIU#T^0.`5O3-D.A62Z&@0&^7>&[
MG_&,#NV-#NF=<@^C=AW*>?H*:7#/OL5SY_)N+[-SYXY,Q8ZFS72N<^=^UC,R
M=]86P;'#7?5AY#W89[&_Q=WO<DT&C^E!,&_@$S.F"BQBVWJ)KF!$FG91Z@4T
MA:$G!"PA'#N27DW]RX/%U3GC2Y2T%I552*G$#IO4)<BJVV0PP`I%,#!EM6N\
M7_=/;)IG/%6'3R%@;*%3H&3$V!:E2VA5ML@8T;4E@<-C@M/]#7<HVCR">"<!
MK+@``[>\`H["5\D^8Z"8)XAC)[CQ4.C8SP@@+",[GB_DD3D$5T5;#`52?O4&
MSFK;.R8X^6.M?UE56N5#)*6P*RTMC,&"T@XAO)_EQHW.`JD<>[&GGR6-)NR,
M)NJ<<AVC=AW*D_H*:?#=(!LRXL06BRA?2"/9H&<O)+WK"L00!?3*&^5&78J6
MC:M7U/H<=@]+Z&6J]2IR;/&&K?P"NW,<'["7Y@>-E3#**2,$9ZO,3%$IUMT$
M'%LUF+M':9\C'8L5I\ZB\=?W+QF/+>U'1&27T7&!R.NH.5^TX2&F^OSX$NUV
ML#C@2*R3#VPV()KTR;^Z?)R5=1%)"0\VR611H2X.[^DE(0U#+1N>6A*V!%+3
MJ>G)+([$@SF<W'Q*Z<(+R4S^80M`:L-K2L='[E;E_17R5Y6D1=JO*PF*3'>3
M;7X`E?<$!_-C=4<M]=&&?EC>*$BB%;?;Y;+.;X&E6#JVL:!0[S*+21,(L<*A
M:4"F13/=E0UL)"`U;:B[%!J\3J!H\7`,&^?9:1U+/,08F98RJ^@]^I\M\LJ;
M%9@W*I1&:JT.*9<XK@@IE+`7<_H**R).B;%C1VQ$R!*9=#9H,8`+)03,]@@Z
M]SC99\#8_R,E/:TZ"TCMA8N&BLI11<31L5TXM8A)+M]BAA4A36E;#HV]N%%1
M2A$P'%:./6#0//?7'NAQX:-?\+BG2[V@O4#KK+XB^G3X.[8OA7E3'?,VM<EO
MDE,<]O09[SBW.Z)V01>&=;ZU:HM"K%-2')WAK5MH%JN2_LK%9I-C[&B);ME'
M]<H<FY'5%!<G)^6$;2C:DZ;4!A/2T)A:G5*LBH*=ZTE.E9L,.8D!_9)5QZE3
MT@9LBKK8SE;@PI/5&>O4XAA"J8>#V&`4$QU?WV8360XQ)=UTT,1CZ%@?>E(S
M2B_QWS"588=#UX)/BVXV"!)KV`U$+9Z.G9"LG<GXC%)0!6$VF-2(JY4_";'E
ML-+250=;,L;6Y$LY#\>=;F2H]#S<H/A+?D4/",KQYC<O#CA#J\[E3P<7=<M;
M#K6^%M%!7X>Z'$O+5N]YX7'F/7F9-%EF:9)Z40"C#055%=*R#<2DE@-00T\=
MK(G9.I9:;>Q?9@8^`05C&^U<@I=<*QW(,+D9S-):@119\D$ZNYYA*L%HQD`]
M,=#I$5(;4OGM&0AWN5"%E#O+LV))L$NF5$/K[KE2<26.I114\G!<$'8KK)$S
MG2U0>UFF.W1UJ[4FK\&9=K8>GC[.7[B8U"E2VENMR*SPU\$*W5&G5IDU*0[S
M0W\N&,5$C`G`;`&GI&F/]4L.>\?2%+4T8:5Q/5W(S\R*J-NI63;UK/"FIWMW
MX$GK<2RC(3J%3:-/2GE$GH!R9JA3U;D/X@1U.)85>02[/8J]^%"8H3H#M=B1
M4>PB36/XE*7$SQ[1RF/TKYW+EZW4H?RL\-K7/MU1W*%F@\D<&["MO!-3><>A
ME;LMN\"RXQY+'?SI[ZS\.%>@D0X#1;G"S`.\G,^USKGY><*-NZI]L$`?>ENN
MK*MMLG)LI]DB"&"AR\J#P6U4/@5-I_'$5%6^CD=E.5[4M-.!#9>C8[GA*_`,
M0I0?ZGM(O0VXCK!8^QB2^_O6T(?IPO>S71:2JXBOLAAW[W2)UJ*%*8;'I8W^
M#"V'KW&;Z2#=1.7.O7S7-IET0"<=R%D/0ZE..K!B,7/L(E#96)6_^B\D5SR%
M93V<-/75`9><M<&D<0MJ=MS35DRIMP!38`W/E[;9D^+"+;.,<Y&#?,JQ`G&^
M9"9.;,E*L=-9_%*S.9O9S0[=CF8JU^78))'2.U<R663I%L7PCU,H8B.31\U&
M9)MZKDB4Z&T$@>TZ')M@,O4E3X>HH:Y)*4)<13EOM#'U-8BTBK\UNX(&1!E_
M_[\JN0AO=IP#,`(ZU5,!O9"G<$9@MAN%*(7O(/XKR(VVRI4!>-`NAJ"P"!N&
MG")SA:**!8S`D5.1<]N,CNL>BO,1C1+M=24'YB'Z^G>#HU(]#FXY*G66S#T4
M*-OHF_&<0UW?WFA3G6O,=JM12U?F/$-"Q4/7[.87:GH:0I5X7C';#3XM/?ES
M"A52'K;F.9?0T-@0RA3F$&:V^-CP<%)]6:-<BITLS7^2BKSVNB.WC.>:WX-\
M7?@2)6F2-]&3EX!@53Z.S%D`,,.LVA[0D]ET.R]4!;^H"\Y[S,D0-UVC\KA-
M%L,,80N9MF@S`/:3,M^UT5<Z-Q^RJD7/["D!OV>XDNMGHOIT*Z24(+Q540E9
MM1+*)9MNKPPE$B]$2>DX*MH05J2M@]3UH\9"',[Y'AH^1T?=%_D9"51XB'<=
M87,=;J,UBG=Y/1T<F'/BN*IEP:B%-V31*%+UH4I%>GIM`OP?-^CY30!@X;#X
M'[2?XI]^+22X!QM(*H[2S]Z.3O^)2*I#U$R2Z?IZG49!2AI2W;1"!?GA:"9C
MD8N.VNR76(78"V^Q4W[_!Z"WI0EI&@W?HIE9RXMU[-/T+<ZB1?R1VK[2X!&S
MY42S^B<J:A6?9M/``HVZM6N3H6BU?.3F7%4//5_AKHS3KDP:JH$IFMFUM$C'
M?DU.<18M58_4]@LL5D!$NPD].NW(_%8=YVE^FTT;BW3JUK841]%:[]AM>@42
M/X:Y++RF99#0+=P@F5]#\S7LV=X-QJ)%U9&:O;S6[@8FOA?^"W@Q.Y++R*J%
M!"[9;""@J&DW&/"9BU8^1QV<?P5A^(\(?8L>@)>@"`3Y2EI,X4&)MC%8Y]+.
M!ADZ.O<9O'-K$*UECHJ17U"88>7BPPT,04Q?TB*D:6"B13,S+(AU[(.!%F?1
MXN*XD_<BA-V#/8K)+3%D[31C0T!,VIS*<TAG!@@EC7M-[#D5\'([X^,C!^PE
M[M,V*&:G=I@4#310%#,#@4B_/FU/\>4T^03YO%7V%$+_)D1>ZV),WO=&<S>^
MSZRQ^;KU:>H&5TY#CYJ\*Z./^NXC]0+-?L#.G4@=>X.N^Y$T^X0.NY+>39(K
M/,U[;O`O]*!!0D7E"UM4LP&'FI[]<H8MWAP8C)HV;`I7I#7E0&#0,:'0H)LI
M&/BZFH!#@SL'$/6<(W_=O?Q"_B`[@O`O_Q]02P,$%`````@`88%M0S&&E)E3
M"P```'$``!$`'`!F871E+3(P,3,P.3,P+GAS9%54"0`#Y>J#4N7J@U)U>`L`
M`00E#@``!#D!``#M7=USXC@2?[^J^Q]\O-Q<U1$"F9G;24UFBY!DBJTD4$GF
MXVU+V`*T(TN,)"=A__IKR3;8^!,P&V?+>3)V=ZN[?ZU62Y:<C[\^N]1ZQ$(2
MSLY:W:/CEH69S1W"9F<M3[:1M`EI_?KIG__X^*]VVQH(C!1VK,G2NL%"$$JM
M`1<++I`"`5:['1)^Q@R+D/3*^X,HZ5E#IJ`EA6;8^OX-,<<Z/^[^\F'-%6,:
MW@WOK>_G=]>A+-W`)9L1AGV&9^F<2GN.760I)&98W2(7RP6R\5EKKM3BM--Y
M>GHZFH)`-0<!"^PI8LLCF[N=WG'WY/C#"5B+E!)DXBE\Q85[@:?(HPHL9S\]
M1,F48`<<0K&+F8H11!Z#!YD\!6UBS3Z=''$Q@X:.NYWO-]?W1M&06.NTC9(^
M%R7L1XSK>2)HV,I)1S^>((E#<H&GF=3O._`T)&2>FT[H*-%1RP7N``46Q%XQ
M<%:"A[/V!I\F<M2*+ZK0NX[_<-4$GNE`R#3@0T=P"HWX9"$7!.P,H<6*:XKD
MQ'`$#XQ+V\?=]DEWI1/-<>GW:_#I&F%2C'";,`AP9N.HS22GB4UZ!Y.X@R2V
MCV;\L0,/4M7?#(I`K>Z'#Q\ZYFD+.HMEF>Z"&./*]"1S+[R[6!`VY<$MN*FY
M3L-PNL-3R\@YU;">M21Q%U2K:^[-393I\&V'X?K[0N`CT"XDT4#E.,#@""P2
MNIA1[7K=<"@""3LA)6$G".$++!3!,M(7.I6992.ZK5G`8GNTUE8Y>+JM5<!"
M&*FS411-MC4*6#`]K#U:S@-88.F++W?#XA'`:';!;4^//S!@7C)%U'((G56X
M)JI:%H$<F4NQ4B)48PW?IV/XL]I6R!^]U,.S+\R*2/O8V12Q*=V3V!FQ3^9Z
MLU<'W`%)'N=&QRG/&(_-=+[@;@A'-2B=(ZK3^/T<8^6C$KN3CT)7HW`/CL(!
M#`/.',Q`;7TE.26.*8L"D9:1*1LPRH`Q1@+,GF.@0#2)3/QQ`4SO=H')>A-K
MXS\-;%FPK5P[F@YA$N)B'Z[D[7R8>B5[TXI$6GQJC1;!)$.:W#?@+KA^#FSD
M$5O77#;=+1.W`9+S*\J?I(_7^F<^3B<[X:2E6T9\`TAFR4"D3;GT!!Z)&6+D
M3Z-\GSGWGNLBL1Q-[\F,P?S51DSU;9M[,-*SV1A<;D,-$U05>PK)`[_K#WGK
M)N!'M!73!8-V-.B1EJQU4U;85A,)Q9'0EQ(#3#\](HTBH^E7F)OSAP@;9-=-
MZ$MRY6/=2V!MQ%H1N1ID(]F*BH;2TSYJP"T&]PH1\151#]]@I'^;;+F)93I1
M/G0G">BT%,N(L:)R&I2*4;KF;/:`]2KB1$%]X1)E7`<I%<8[G=`P2TN_9=GR
MD7R;0%++;6O!EI;\7RLB.RB!(M(;?(OQO5?<_C'GU,%"7H`Z-E&;6*:1Y./V
M+H%;5,:_K4!*@T\)?+R)Q#\],/SR,2U!)I[G(_,^B<Q*@.5+:%`Y4(E:::E:
MJF3M55NR6F_"JV9!X%!!\H`FM*(0"43E!<A)U0'BM]F$1V63F_1XV(HW/P#V
MF^@TB.\[XTD'.(\T'\_2LY\&NNJG0>E@;L><#^^>4Z(&]/WF1ND`9Q/F@UER
MGM2`ML>$*0.Q=*I\N$I,GAJH#ET@7V"%"*VF0@YEY<'^MNH2.6BTB9`#1TBO
MRA#I%<5(]Q`Q8O6:**EL)I61.+9CSH^"?>=236K8<S*5@7$N;3ZD6TRG&O2J
M02^1N/.)"_!+).8B_)JD6^6,.*-';LF=C_'><^*FYQX*]T1?WI:]`/E$[]X-
M^:;/'P#[`5BZ)_Z^B((8Z%74^ZTWNKDF%'9=&\M(]3F4^<"67AUKTO?NRV-9
MH&60Y2-6:H&L06MOM!)9-9.N`*_$\)F-U]\[+W[L;)XJ#.[$3Q^:LX?$77"A
M+)8XNIM[=-,_]GO-;2,M?EXRE;&#J9+AG?9:U!'H$![4RM>GZ`!JADHQ-BI$
MC*NMY;2[O7;W_8Z*)$_HEM%CDZM*/:*G?K?3A;/;/=3)/2N;%R^;//JBD@B)
MGNTMXPG#HG^MSA!K1YQH1Z2H$1Q*-WJ<M2ZE(JX.J5NL]`&)H0NJF?,RT(,1
M'7L32NS1=`KN93.H#^\PU=0/`C$)A*!3,&KI1/I[)=+\LYKF^/.IRQDD/K$<
M*NSJ1`$.@=RHB/(T\6?!O45(2H"D92%X*D"45HCJLY2,4*I?!IVUE/#TV4]#
M//$/6IVU'#S1>RW]NPN]).@\F/8=3P0')3-]=S]'`I\CR&SZS`\&$\RBM@!K
M9H;N?+DF&:.EOM5_0L)Y@&Q&/P.9N@#S5PLK$4=6+_K5>+5O*P]1"(ZQX.;X
M:/30'1B%^H$R$7=MP1/U`]R#.-S!"[[1Z4[8TMS+9WNN0=6"#*37!$T()6IY
MRYGM"7T`,-K#2I'_I6#;`COI:/OI2.58OPK0OO.')Y5_5B]A8S3%E.9X-0$/
M@]<$B]%T#+E0!Z]\X)=LKN5&7DZ,N0(.R*&C:=_QJ+H'-0>8TJAK]A44]1AA
M"L^PJ-IANV18V0^^M*+%/?!DWEMG10F!0#T'.U>"N]\PF<UA=.D_@O$S''K'
MESGRE(Y-_;F:S;1[^/9B.<@\?F$_9V>5&ZRM*)6`0E+?.O]3+Z<.=Q%A+YMB
M]0=6(-3Q:#HPJLLA\T$92NEAY\N"L]"JM%0"PTI0OZQRC]E>\H"?U3GE]H]H
M`!V\J9AW57C_A>,G[65M(G+RB&H7,V.!H4J%D<VL=GU#NL^K[%Y1CKQV5IY[
MDC`L9>35^"5<Z>^`*`SQJ.1JN`"P!(8L.&3QQ-:WYP0_!J?L!U@H,$HO]6)A
M`U>P]>*&4!`&@W!TN'J)QFN7>0_E!$J8_F;$7^KXE#9KY^^Q(8?:9R$(U2=S
MDETYBZ)VO3?4]`8)>PZ:=C-M25#4V)9E@27+5V%'&#V]POCJU=:66'VBQS6_
MB+GP]*S9-R/,!JM$(K-*Q?+\M<L9*?DR4=1?<='W%-<?N[+OL(/=1;#!<5WN
M)::R%<M]#7ZK8IR!6LM^@>$MH]G7X/759&(T_<(<+.@2(DO721!P*CZ!V8D[
MR%R0MD!7X\$7]H'><3!D(-E\DDZ_6].[>V\Y&R06U(I)Z[&05+R6%MW4`9I(
MF30VF^35K!BFXU46UU<':IBY;)VP'O$8)/:.C_^77);)IZM=;6$RQR@<S#;T
M[IXD["M)7S\[=WV1`_61MA'I$;[O."83(QH,3YZ:<T'^U*^/]W]E5+:E6);7
M'(=,\L4]PXQ%3X+H361A]_9WL+DND7*C%BU%78^D4&IUBML8._(.VY@\ZD;T
M`K0NK[7LU+>ML<6J';CKX9L2"3.QJ*K+9J!(F7?D+6OGLM6NZ!M0).5H&BP\
MCL2=?A41_`K6GA_XV!-@I`SL@\*6LT?][6%H/+Y^&3R(I9>#M?!W\>6J'AXQ
MWSI)PL\L[^/`#+'U\UH4:JYS*A?+6YAHR0N8.;#>V]\\AF&H?IL8VK?FK-T@
M7V#!+WUOYDD%)KS?UO@4UMI9'W[YNY_R$?&4O1KER.NV3>,.+X*NN7JK<\7%
M%P!/0A;SJV]33:7,NG;@?373,9@H7[H+RI<81TKT1)CGD]4NI$-=(49+&EB:
MHW:V?H4HA.YEI@4C!G6.Z8T0&"DO<`LH7X]MYLYZ&0]0NT'B!U;Z0]+^.G1Y
MZ\O+JIU_PG<1OWETF3KMSB*HG277>AE7+VU=/BL,<[UHZ9KR+)I?0^DO7$#I
M_7M(S@=S_2^IPHVQO.1V-[/U,6\+0CP7'[2A>LP4R^PTW?CH0-K&TDR2NA4H
MFYJF[4[*H=ES6U$E)HST01RCH_]AS6C0ICRK@\KK_5[Y6Y#-Z9W4?6*E^.I@
M:LJ;H<V]:@5;=W>6L%=&V;GXC?O$/XGD'\>`G_\'4$L!`AX#%`````@`88%M
M0VNK+F!3I```=/@*`!$`&````````0```*2!`````&9A=&4M,C`Q,S`Y,S`N
M>&UL550%``/EZH-2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`88%M0]X_
M7A$.#```':```!4`&````````0```*2!GJ0``&9A=&4M,C`Q,S`Y,S!?8V%L
M+GAM;%54!0`#Y>J#4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&&!;4/B
MUX"G/B```$@H`@`5`!@```````$```"D@?NP``!F871E+3(P,3,P.3,P7V1E
M9BYX;6Q55`4``^7J@U)U>`L``00E#@``!#D!``!02P$"'@,4````"`!A@6U#
M]\=*57!_``#*]0<`%0`8```````!````I(&(T0``9F%T92TR,#$S,#DS,%]L
M86(N>&UL550%``/EZH-2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`88%M
M0QT']66"-@``+MD#`!4`&````````0```*2!1U$!`&9A=&4M,C`Q,S`Y,S!?
M<')E+GAM;%54!0`#Y>J#4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&&!
M;4,QAI294PL```!Q```1`!@```````$```"D@1B(`0!F871E+3(P,3,P.3,P
M+GAS9%54!0`#Y>J#4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``"V
%DP$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities not included in the calculation of diluted net loss per share</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 646px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="646">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;and&#160;Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock outstanding</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,229,590</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,065,934</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants for convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">480,763</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">403,841</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,710,517</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">721,539</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,456,944</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,227,388</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Long-Term Debt, Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Long-Term Debt, Commitments and Contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term debt and unamortized discount balances (excluding convertible debt)</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt and unamortized discount balances (excluding convertible debt) are as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 796px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="796">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December<br />
31,&#160;2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,750</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Less debt discount, net of current portion</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(18</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt, net of debt discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Less current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,000</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(2,000</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term debt, net of current portion</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">250</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,732</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,000</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of debt discount</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(29</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(59</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Current portion of long-term debt, net</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,971</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,941</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(e),(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDebtInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Principles of Consolidation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Therapeutics (Canada) Inc. (&#8220;Fate Canada&#8221;), Fate Therapeutics Ltd., incorporated in the United Kingdom, and Destin Therapeutics Inc., incorporated in Canada. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Reverse Stock Split</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On September&#160;12, 2013, the Company filed an amendment to its amended and restated certificate of incorporation, effecting a one-for-6.5 reverse stock split of the Company&#8217;s issued and outstanding shares of common stock. All issued and outstanding common stock and per share amounts contained in the Company&#8217;s consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.</font></p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_OtherAssetsPolicy', window );">Other Assets</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Other Assets</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other assets consist of the Company&#8217;s deferred IPO costs. These costs represent legal, accounting and other direct costs related to the Company&#8217;s efforts to raise capital through a public sale of its common stock. Future costs will be deferred until the completion of the IPO, at which time they will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.</font></p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Preferred Stock Warrant Liability</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Preferred Stock Warrant Liability</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has issued freestanding warrants to purchase shares of its convertible preferred stock. The fair value of these warrants is classified as a current liability in the accompanying consolidated balance sheets since the underlying convertible preferred stock has been classified as temporary equity in the accompanying consolidated balance sheets instead of in stockholders&#8217; deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities. Upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock can cause its redemption. The warrants are recorded at fair value using the Black-Scholes option pricing model with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations and comprehensive loss. The warrant liability will continue to be remeasured at fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Revenue Recognition</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company recognizes revenues when all four of the following criteria are met: (i)&#160;persuasive evidence that an agreement exists; (ii)&#160;delivery of the products and/or services has occurred; (iii)&#160;the selling price is fixed or determinable; and (iv)&#160;collectibility is reasonably assured.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#8217;s control.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Beginning in 2011, revenue is allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#8220;VSOE&#8221;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#8220;TPE&#8221;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&#160;the consideration being earned should be commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&#8217;s performance to achieve the milestone; (ii)&#160;the consideration being earned should relate solely to past performance; (iii)&#160;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&#160;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#8217;s revenue recognition criteria are recorded as deferred revenue on the Company&#8217;s consolidated balance sheets.</font></p>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award. The receivable for reimbursable amounts that have not been collected is reflected in prepaid and other current assets.</font></p>
</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Stock-Based Compensation</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice based model.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition has been achieved.</font></p>
</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Loss Per Share</font></b></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 102,998 shares and 166,252 shares for the three months ended September&#160;30, 2013 and 2012, respectively, and 111,614 shares and 184,517 shares for the nine months ended September&#160;30, 2013 and 2012, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of convertible preferred stock, warrants for the purchase of convertible preferred stock, exchangeable shares and common stock options outstanding under the Company&#8217;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 66.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.25in;" border="0" cellspacing="0" cellpadding="0" width="66%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 39.78%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="39%" colspan="3">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;and&#160;Nine&#160;Months&#160;Ended<br />
September&#160;30,</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock outstanding</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,229,590</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,065,934</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrants for convertible preferred stock</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">36,074</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">480,763</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">403,841</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock options</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,710,517</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">721,539</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">9,456,944</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.74%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="18%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,227,388</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table>
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p>
<p style="TEXT-INDENT: 23.05pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In addition to the potentially dilutive securities noted above, the Company has an aggregate of approximately $23.7 million of outstanding principal as of September&#160;30, 2013 under convertible promissory notes, issued in June&#160;2013, July&#160;2013 and August&#160;2013, that are convertible into convertible preferred stock or common stock upon the occurrence of various future events at prices that are not determinable until the occurrence of those future events. As such, the Company has excluded these convertible notes payable from the table above.&#160; A portion of the convertible notes were repaid in cash and the balance of the notes converted into common stock in connection with the closing of the Company&#8217;s IPO in October&#160;2013 (see Note 6).</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_OtherAssetsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accounting policy relating to other assets which can consist of the Company's deferred IPO costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_OtherAssetsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Acquisition of Verio Therapeutics Inc.<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition of Verio Therapeutics Inc.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AssetAcquisitionTextBlock', window );">Asset Acquisition of Verio Therapeutics Inc.</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;">
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Asset Acquisition of Verio Therapeutics Inc.</font></b></p>
<p style="TEXT-INDENT: -22.5pt; MARGIN: 0in 0in 0pt 22.5pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On April&#160;7, 2010, the Company acquired Verio Therapeutics Inc. (&#8220;Verio&#8221;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &#8220;Exchangeable Shares&#8221;) that were initially exchangeable into 138,462 shares of our common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, may be exchangeable for up to 884,605 shares of our common stock.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Exchangeable Shares will be automatically redeemed and exchanged for shares of the Company&#8217;s common stock upon the earliest of: (i)&#160;April&#160;13, 2017, (ii)&#160;the date immediately prior to an IPO of the Company&#8217;s common stock pursuant to a registration statement filed with and declared effective by the SEC, (iii)&#160;the effective date of certain change of control events, (iv)&#160;the date upon which holders of at least a majority of the then outstanding Exchangeable Shares approve the redemption and exchange of all of the outstanding Exchangeable Shares, (v)&#160;the date upon which there are less than 450,000 Exchangeable Shares outstanding or (vi)&#160;the date that the holders of the Exchangeable Shares can exchange for shares of the Company&#8217;s common stock on a tax-deferred basis.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013 and December&#160;31, 2012, the Exchangeable Shares were exchangeable into 480,763 shares and 403,841 shares, respectively, of the Company&#8217;s common stock. As of September&#160;30, 2013, the number of shares of the Company&#8217;s common stock to be issued upon exchange of the Exchangeable Shares is subject to further increase as follows: (i)&#160;76,922 shares for the achievement of certain pre-clinical milestones, (ii)&#160;211,539 shares for the achievement of certain clinical milestones and (iii)&#160;115,381 shares for the achievement of certain commercialization milestones.</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At the date of an increase in the number of shares of the Company&#8217;s common stock issuable upon any exchange of the Exchangeable Shares due to the achievement of a milestone as described above, the fair value of these additional shares of common stock is charged to research and development expense. At the end of each reporting period, any changes in the fair value of Exchangeable Shares resulting from changes in the fair value of the underlying common stock of the Company are recorded as a component of other income (expense).</font></p>
<p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013, the changes in the number of shares of the Company&#8217;s common stock issuable upon the exchange of the Exchangeable Shares and the initial fair value of the shares are summarized as follows (in thousands, except share and per share amounts):</font></p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;WIDTH: 86.68%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%">

<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exchangeable<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Per<br />
Share&#160;of<br />
Underlying<br />
Common&#160;Stock</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Initial&#160;Fair<br />
Value&#160;of<br />
Exchangeable<br />
Shares</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;2010</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">138,462</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">234</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">March&#160;2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">92,308</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">156</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">May&#160;2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">115,380</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.69</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">195</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">57,691</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.37</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">July&#160;2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">76,922</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4.49</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">346</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 48.66%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="48%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.9%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">480,763</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,009</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;">
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="316"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="90"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AssetAcquisitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_AssetAcquisitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AssetAcquisitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for an asset acquisition completed during the period, including background, timing, and recognized assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_AssetAcquisitionTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 12, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>item</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells', window );">Number of platforms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Reverse stock split</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
        <td class="nump">0.154<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue recognition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodFactors', window );">Four criteria needed for Company to recognize revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of platforms that optimize the activity and enhance the therapeutic potential of adult stem cells.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodFactors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the factors that the entity considered in determining whether the milestone or milestones are substantive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodFactors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of liabilities measured at fair value on a recurring basis</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Liabilities measured at fair value on a recurring basis are as follows (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 856px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.25in;" border="0" cellspacing="0" cellpadding="0" width="856">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.92%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="43%" colspan="8">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Fair&#160;Value&#160;Measurements&#160;at<br />
Reporting&#160;Date&#160;Using</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Total</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Quoted&#160;Prices<br />
in&#160;Active<br />
Markets&#160;for<br />
Identical<br />
Assets<br />
(Level&#160;1)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant<br />
Other<br />
Observable<br />
Inputs<br />
(Level&#160;2)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Significant<br />
Unobservable<br />
Inputs<br />
(Level&#160;3)</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of September&#160;30, 2013:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,048</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,048</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of December&#160;31, 2012:</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Warrant liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.86%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 37.04%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="37%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total liabilities</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">735</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.68%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">735</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.8%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock', window );">Schedule of assumptions used to determine fair value of preferred stock warrant liability</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<p style="MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 682px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="682">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br />
30,&#160;2013</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">December<br />
31,&#160;2012</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Risk-free interest rate</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2.1</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1.2</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected volatility</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">85.9</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">93.5</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Remaining contractual term (in years)</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7.56</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8.31</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Expected dividend yield</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0.0</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">%</font></p></td></tr></table></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs</a></td>
        <td class="text"><div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):</font></p>
<p style="TEXT-INDENT: 23pt; MARGIN: 0in 0in 0pt;">&#160;</p>
<table style="text-align:left;TEXT-ALIGN: left; WIDTH: 715px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1in;" border="0" cellspacing="0" cellpadding="0" width="715">

<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Warrant<br />
Liability</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Exchangeable<br />
Share<br />
Liability</font></b></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2011</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">221</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">563</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance of exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(37</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(90</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at December&#160;31, 2012</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">184</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">551</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Issuance of exchangeable shares</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">346</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Change in fair value</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(21</font></p></td>
<td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 16.36%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="16%" colspan="2">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,988</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr>
<tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;">
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 59.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="59%">
<p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Balance at September&#160;30, 2013</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td>
<td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.06%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%">
<p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td>
<td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.34%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of all information related to the key inputs and assumptions (including, at a minimum, but not limited to, and if applicable, quantitative information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses) used in measuring the fair value of assets or liabilities that relate to the transferor's continuing involvement with transferred financial assets, as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=13989330&amp;loc=d3e107314-111719<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYRBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfer of assets from level 1 to level 2</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfer of assets from level 2 to level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfer of liabilities from level 1 to level 2</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfer of liabilities from level 2 to level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Assumptions used to determine the fair value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump">2.10%<span></span></td>
        <td class="nump">1.20%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="nump">85.90%<span></span></td>
        <td class="nump">93.50%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Remaining contractual term</a></td>
        <td class="text">7 years 6 months 22 days<span></span></td>
        <td class="text">8 years 3 months 22 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Total</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">3,048,000<span></span></td>
        <td class="nump">735,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Total | Warrant liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">163,000<span></span></td>
        <td class="nump">184,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Total | Exchangeable share liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">2,885,000<span></span></td>
        <td class="nump">551,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Significant Unobservable Inputs (Level 3)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">3,048,000<span></span></td>
        <td class="nump">735,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">163,000<span></span></td>
        <td class="nump">184,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Recurring | Significant Unobservable Inputs (Level 3) | Exchangeable share liability</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump">2,885,000<span></span></td>
        <td class="nump">551,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non-recurring</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureNonrecurring', window );">Non-financial assets</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Non-financial liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Carrying amount | Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
        <td class="nump">$ 300,000<span></span></td>
        <td class="nump">$ 1,300,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureNonrecurring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a nonrecurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureNonrecurring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancialLiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonfinancialLiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPRAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 2) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding', window );">Shares excluded from weighted average number of shares attributable to share based payments</a></td>
        <td class="nump">102,998<span></span></td>
        <td class="nump">166,252<span></span></td>
        <td class="nump">111,614<span></span></td>
        <td class="nump">184,517<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
        <td class="nump">9,456,944<span></span></td>
        <td class="nump">7,227,388<span></span></td>
        <td class="nump">9,456,944<span></span></td>
        <td class="nump">7,227,388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Outstanding principal under convertible promissory notes (in dollars)</a></td>
        <td class="nump">$ 23.7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 23.7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible preferred stock outstanding</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
        <td class="nump">7,229,590<span></span></td>
        <td class="nump">6,065,934<span></span></td>
        <td class="nump">7,229,590<span></span></td>
        <td class="nump">6,065,934<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants for convertible preferred stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
        <td class="nump">36,074<span></span></td>
        <td class="nump">36,074<span></span></td>
        <td class="nump">36,074<span></span></td>
        <td class="nump">36,074<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchangeable shares</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
        <td class="nump">480,763<span></span></td>
        <td class="nump">403,841<span></span></td>
        <td class="nump">480,763<span></span></td>
        <td class="nump">403,841<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
        <td class="nump">1,710,517<span></span></td>
        <td class="nump">721,539<span></span></td>
        <td class="nump">1,710,517<span></span></td>
        <td class="nump">721,539<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the shares excluded from the weighted-average number of shares outstanding attributable to share based payment arrangements including shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 11, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">FATE THERAPEUTICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001434316<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Non-accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,357,158<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXHAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Acquisition of Verio Therapeutics Inc. (Details) (Verio, USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 07, 2010</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions', window );">Exchangeable Shares issued</a></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="nump">138,462<span></span></td>
        <td class="nump">480,763<span></span></td>
        <td class="nump">403,841<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain preclinical milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">76,922<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain clinical milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">211,539<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain commercialization milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">115,381<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,009<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">884,605<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares', window );">Shares outstanding for automatic redemption and exchange of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">450,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">April 2010</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">138,462<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock', window );">Fair value per share of underlying common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.69<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">234<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">March 2011</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">92,308<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock', window );">Fair value per share of underlying common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.69<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">156<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">May 2011</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">115,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock', window );">Fair value per share of underlying common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.69<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">195<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">April 2012</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,691<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock', window );">Fair value per share of underlying common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.37<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">July 2013</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">76,922<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock', window );">Fair value per share of underlying common stock (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.49<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares', window );">Initial fair value of exchangeable shares (in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 346<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain clinical milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain commercialization milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the Company's common stock to be issued upon exchange of the Exchangeable shares based on the achievement of certain preclinical milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the fair value per share of underlying common stock in a business acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionFairValueOfUnderlyingCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionInitialFairValueOfExchangeableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the initial fair value amount of exchangeable shares (in dollars).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionInitialFairValueOfExchangeableShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the shares outstanding, as a condition for automatic redemption and exchange of shares in a business acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_BusinessAcquisitionSharesOutstandingForAutomaticRedemptionAndExchangeOfShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of exchangeable stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
